{"after": {"end": 25, "start": 0, "text": "Lamia, Schimatari, 32009,", "truncated": false}, "after_length": 25, "after_sha256": "731caa8982d6c36ded24b2c0ae7f96bbe4b52b5f2fe4fdabe022c9e027a41c9e", "annex": "II", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 25, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 25}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-002012aa4027e9cc21f36bbc", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/003984", "medicine_name": "Bortezomib Accord", "medicine_slug": "bortezomib-accord", "observed_at": "2026-10-12T13:47:12Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "conditions", "section_type": "conditions", "source_provider": "European Medicines Agency", "source_sha256": "e4aac937241121e8ad1e32b40b1007fb58398035928568a7e60a65074b0efb36", "source_snapshot_id": "source-b1eaab6445cfa827e3b1481b", "source_updated_at": "2026-03-25", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/bortezomib-accord-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 3285}
{"after": {"end": 21, "start": 0, "text": "Tel: +31 35 528 39 57", "truncated": false}, "after_length": 21, "after_sha256": "7baf6601f41e49e470f803fdd4e755a86efa38be423317c000ed79963ebdd213", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 21, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 21}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-002294d9a2dd7ceb339a0577", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:19Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "77586d0bea0858214b43b86e91abc2d2711733b96959ead5ed0b5ecbd8ed888a", "source_snapshot_id": "source-85d476f9ad959cc117ca8f1f", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1927}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 13, "start": 0, "text": "Lucane Pharma", "truncated": false}, "before_length": 13, "before_sha256": "e338afdb64acf1a6e2083a50318853589248451dd3aa707181ba02641a8521e8", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 13, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 13, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-0034c94e9c80cd07a97b91ce", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:19Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "77586d0bea0858214b43b86e91abc2d2711733b96959ead5ed0b5ecbd8ed888a", "source_snapshot_id": "source-85d476f9ad959cc117ca8f1f", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1503}
{"after": {"end": 24, "start": 0, "text": "Tel.: +49 (0) 69 15 03 0", "truncated": false}, "after_length": 24, "after_sha256": "8946964007fee6067df3ceb486bef1ddd3122eb52726a03a5d4fdde280ca2f1c", "annex": "IIIA", "before": {"end": 24, "start": 0, "text": "Tel.: +353 (0)1 231 4609", "truncated": false}, "before_length": 24, "before_sha256": "46e1c7e37b938a7e0c3f9a071d43f9eb30bbe802826026f6c280be3cb250cd4d", "change_kind": "content", "change_operations": [{"after_end": 9, "after_start": 7, "before_end": 10, "before_start": 7, "kind": "replace"}, {"after_end": 17, "after_start": 13, "before_end": 14, "before_start": 14, "kind": "insert"}, {"after_end": 19, "after_start": 18, "before_end": 15, "before_start": 15, "kind": "insert"}, {"after_end": 21, "after_start": 20, "before_end": 17, "before_start": 16, "kind": "replace"}, {"after_end": 22, "after_start": 22, "before_end": 19, "before_start": 18, "kind": "delete"}, {"after_end": 23, "after_start": 23, "before_end": 22, "before_start": 20, "kind": "delete"}, {"after_end": 24, "after_start": 24, "before_end": 24, "before_start": 23, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 8, "chars_inserted": 8}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-006cb86ec1f45b9d423dac71", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002097", "medicine_name": "Fampyra", "medicine_slug": "fampyra", "observed_at": "2026-10-12T19:15:51Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "d9fe8aaaa611a84801d6308b13685258b5248df9022536697939afdf66fc1719", "source_snapshot_id": "source-ff8e0599077f0d01044dc867", "source_updated_at": "2025-08-21", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/fampyra-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1425}
{"after": {"end": 21, "start": 0, "text": "Tel: +31 35 528 39 57", "truncated": false}, "after_length": 21, "after_sha256": "7baf6601f41e49e470f803fdd4e755a86efa38be423317c000ed79963ebdd213", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 21, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 21}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-00ac3176c6558f7b09858b35", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:19Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "77586d0bea0858214b43b86e91abc2d2711733b96959ead5ed0b5ecbd8ed888a", "source_snapshot_id": "source-85d476f9ad959cc117ca8f1f", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1468}
{"after": {"end": 11, "start": 0, "text": "Netherlands", "truncated": false}, "after_length": 11, "after_sha256": "3a386c13d283dc2ebbe2aeffc1ab3930d086b28956930d913d8dc58f34c013b7", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 11, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 11}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-00bf3437b3a9bc430ea26f66", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/000980", "medicine_name": "Samsca", "medicine_slug": "samsca", "observed_at": "2026-10-12T13:28:23Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "b92d73a758b8976c4438a072d544f0d6c603112c90dfc9c084d362ce62419257", "source_snapshot_id": "source-15b8b5681aba542ec1668c0b", "source_updated_at": "2026-08-20", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/samsca-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1269}
{"after": {"end": 21, "start": 0, "text": "Tel: +31 35 528 39 57", "truncated": false}, "after_length": 21, "after_sha256": "7baf6601f41e49e470f803fdd4e755a86efa38be423317c000ed79963ebdd213", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 21, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 21}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-00e981942f1d37063842c113", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:14Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "8b8c4cc8e6f1a21fedee4bf0743c9c03e454b50f5eaba0e3760416d7fe0a74ec", "source_snapshot_id": "source-4efe4ecf3ebf08d338a763a5", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 2056}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "II", "before": {"end": 12, "start": 0, "text": "52078 Aachen", "truncated": false}, "before_length": 12, "before_sha256": "1475580660011b5e5dfa9a59bc8bd0d29441e95b38b37c8e74cd2bb2e32158de", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 12, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 12, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-0114d9262f333f965e59f1a1", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/005246", "medicine_name": "Byfavo", "medicine_slug": "byfavo", "observed_at": "2026-10-12T13:28:14Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "conditions", "section_type": "conditions", "source_provider": "European Medicines Agency", "source_sha256": "92a178ceb705631219efa40b1d0da73ebe6dfa866bc1b24d7e4dab9ded8a6861", "source_snapshot_id": "source-d485be5d9060fd557be910b2", "source_updated_at": "2026-08-26", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/byfavo-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1744}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 16, "start": 0, "text": "Extrovis EU Ltd.", "truncated": false}, "before_length": 16, "before_sha256": "f462ad48e7aef0bc82148ce088af1897d99ed86993128f30d506b27d3108a929", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 16, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 16, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-0127e126bd24ee8b5226161a", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/006047", "medicine_name": "Lacosamide Adroiq", "medicine_slug": "lacosamide-adroiq", "observed_at": "2026-10-12T19:07:59Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "cc83d966059d42856d0211a4f256b29b20d43593865704d6a9315aeb694f3c76", "source_snapshot_id": "source-896abba1d8391c918345d46b", "source_updated_at": "2025-09-25", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/lacosamide-adroiq-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1114}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 21, "start": 0, "text": "Τηλ: + 33 153 868 750", "truncated": false}, "before_length": 21, "before_sha256": "e4516e3adf69ae4bf8e517fd63976d7665183bba6c244e35e8cd4567dd8fb0e5", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 21, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 21, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-01330b9d715d17683f42c6bc", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:14Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "8b8c4cc8e6f1a21fedee4bf0743c9c03e454b50f5eaba0e3760416d7fe0a74ec", "source_snapshot_id": "source-4efe4ecf3ebf08d338a763a5", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1608}
{"after": {"end": 25, "start": 0, "text": "Eurocept International BV", "truncated": false}, "after_length": 25, "after_sha256": "b17bd89b3cf285c986a6070d0d67f5326dd5c1f08a70834c296c6c820f9e7505", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 25, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 25}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-0133a6581446d230f4c5e674", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:14Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "8b8c4cc8e6f1a21fedee4bf0743c9c03e454b50f5eaba0e3760416d7fe0a74ec", "source_snapshot_id": "source-4efe4ecf3ebf08d338a763a5", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 2055}
{"after": {"end": 9, "start": 0, "text": "Not known", "truncated": false}, "after_length": 9, "after_sha256": "117adf013b8521b57cc432f1d680aa8ca8ffe7ac83edfa7e0a5867794a6429cc", "annex": "I", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 9, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": true, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 9}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-013606fb08ecaa9098e55211", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/000554", "medicine_name": "Emselex", "medicine_slug": "emselex", "observed_at": "2026-10-12T19:12:04Z", "pipeline_version": "2.0.0", "presentation_label": "Emselex 7.5 mg prolonged-release tablets", "presentation_occurrence": 1, "presentation_status": "heading_extracted_unverified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "4.8", "section_type": "adverse_reactions", "source_provider": "European Medicines Agency", "source_sha256": "4f2565612bc728ec67b7f9c0cd5799ef2c594911c76f323aef8bf6a85adde245", "source_snapshot_id": "source-1fda25b331eb198b8b93feb3", "source_updated_at": "2025-09-15", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/emselex-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 214}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 18, "start": 0, "text": "Dublin 2, D02 T380", "truncated": false}, "before_length": 18, "before_sha256": "23e6871e7960b0dadc753bc127bbea230cc8308c88b2d33704eb275a3ec1a70d", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 18, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 18, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-015d157a225e4be0f0388765", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002097", "medicine_name": "Fampyra", "medicine_slug": "fampyra", "observed_at": "2026-10-12T19:16:07Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "a0c3ba8d58d6a43a809ecc3d142a78b10c2bd7f0b9f3a3553df2617d87daec1f", "source_snapshot_id": "source-c7a810dd21f94cd2d273f0da", "source_updated_at": "2025-08-21", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/fampyra-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1541}
{"after": {"end": 21, "start": 0, "text": "Tel: +31 35 528 39 57", "truncated": false}, "after_length": 21, "after_sha256": "7baf6601f41e49e470f803fdd4e755a86efa38be423317c000ed79963ebdd213", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 21, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 21}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-017fa3df3b8a3318fee4c608", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:14Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "8b8c4cc8e6f1a21fedee4bf0743c9c03e454b50f5eaba0e3760416d7fe0a74ec", "source_snapshot_id": "source-4efe4ecf3ebf08d338a763a5", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1610}
{"after": {"end": 25, "start": 0, "text": "Eurocept International BV", "truncated": false}, "after_length": 25, "after_sha256": "b17bd89b3cf285c986a6070d0d67f5326dd5c1f08a70834c296c6c820f9e7505", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 25, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 25}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-019fd440c1a5762a3a4e7a62", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:19Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "77586d0bea0858214b43b86e91abc2d2711733b96959ead5ed0b5ecbd8ed888a", "source_snapshot_id": "source-85d476f9ad959cc117ca8f1f", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1467}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 27, "start": 0, "text": "(Eurocept International BV)", "truncated": false}, "before_length": 27, "before_sha256": "e6cf9b20aaa466e53ad0d393512ca75931e13e488321e3be6f3e4f8b600970c8", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 27, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 27, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-01dd40678afdaab958c4653d", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:19Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "77586d0bea0858214b43b86e91abc2d2711733b96959ead5ed0b5ecbd8ed888a", "source_snapshot_id": "source-85d476f9ad959cc117ca8f1f", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1882}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 25, "start": 0, "text": "Tél/Tel: + 33 153 868 750", "truncated": false}, "before_length": 25, "before_sha256": "e5f8e4aadc105f123b1cb253b9afe1e362181b7777e0b94626adda3e9db7ed2e", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 25, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 25, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-02440b9f422533faecb4cc4d", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:19Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "77586d0bea0858214b43b86e91abc2d2711733b96959ead5ed0b5ecbd8ed888a", "source_snapshot_id": "source-85d476f9ad959cc117ca8f1f", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1409}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 22, "start": 0, "text": "Teл.: + 33 153 868 750", "truncated": false}, "before_length": 22, "before_sha256": "120524751a9a5afbd671d2280e37714c4f0f7472b699b4fcfa1461decd998217", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 22, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 22, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-0273d1035e55cf1764793070", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:19Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "77586d0bea0858214b43b86e91abc2d2711733b96959ead5ed0b5ecbd8ed888a", "source_snapshot_id": "source-85d476f9ad959cc117ca8f1f", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1395}
{"after": {"end": 14, "start": 0, "text": "Muscle spasms*", "truncated": false}, "after_length": 14, "after_sha256": "6a7a307975e8e02016754aaa7939a9e3d59a324c73c90f722f9ece2975ef0eaa", "annex": "I", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 14, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": true, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 14}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-027f5f2b674aadf1a1461ac4", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/000554", "medicine_name": "Emselex", "medicine_slug": "emselex", "observed_at": "2026-10-12T19:12:04Z", "pipeline_version": "2.0.0", "presentation_label": "Emselex 7.5 mg prolonged-release tablets", "presentation_occurrence": 1, "presentation_status": "heading_extracted_unverified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "4.8", "section_type": "adverse_reactions", "source_provider": "European Medicines Agency", "source_sha256": "4f2565612bc728ec67b7f9c0cd5799ef2c594911c76f323aef8bf6a85adde245", "source_snapshot_id": "source-1fda25b331eb198b8b93feb3", "source_updated_at": "2025-09-15", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/emselex-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 215}
{"after": {"end": 28, "start": 0, "text": "InfoDeutschland@dipharma.com", "truncated": false}, "after_length": 28, "after_sha256": "f5ed16f98f15b7236207edade83fdde3fb32cec02f927aaba23223b9f6077f21", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 28, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 28}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-028bb4f2ac44b7ba6fbdf764", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:19Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "77586d0bea0858214b43b86e91abc2d2711733b96959ead5ed0b5ecbd8ed888a", "source_snapshot_id": "source-85d476f9ad959cc117ca8f1f", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1853}
{"after": {"end": 26, "start": 0, "text": "Eckenheimer Landstraße 100", "truncated": false}, "after_length": 26, "after_sha256": "fdce1a9bd200c5ddd476c1ea5676b9ffbbea723f7353ad6fbc1fe019dcb86c07", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 26, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 26}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-03695ae321e27d64e3e29f74", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002097", "medicine_name": "Fampyra", "medicine_slug": "fampyra", "observed_at": "2026-10-12T19:16:07Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "a0c3ba8d58d6a43a809ecc3d142a78b10c2bd7f0b9f3a3553df2617d87daec1f", "source_snapshot_id": "source-c7a810dd21f94cd2d273f0da", "source_updated_at": "2025-08-21", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/fampyra-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1543}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 38, "start": 0, "text": "sanofi-aventis Ireland Ltd. T/A SANOFI", "truncated": false}, "before_length": 38, "before_sha256": "dad9251ce581d41bcfcb8818c11a57a8d3490b978d09cf04cfd9162a081c8d28", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 38, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 38, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-038c306df83617c341c83883", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002514", "medicine_name": "Aubagio", "medicine_slug": "aubagio", "observed_at": "2026-10-12T17:28:37Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "2583b2915ecedeb3bccc3ac6bea691e65d05f5e437bf8aa7970917b6fdeb700c", "source_snapshot_id": "source-15791f384b9e49792c9776dd", "source_updated_at": "2025-12-09", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/aubagio-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 2081}
{"after": {"end": 16, "start": 0, "text": "Extrovis EU Kft.", "truncated": false}, "after_length": 16, "after_sha256": "b9216ef80e71e17798dce313e4318f03f37328f225d30ab508b7413813a908e5", "annex": "IIIB", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "unassigned", "change_operations": [{"after_end": 16, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 16}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-0411a38dfc6c0d02c55ed04a", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/006047", "medicine_name": "Lacosamide Adroiq", "medicine_slug": "lacosamide-adroiq", "observed_at": "2026-10-12T19:07:56Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "", "section_type": "unassigned", "source_provider": "European Medicines Agency", "source_sha256": "0578c53a5e1c785c4d9d4dc0dabae49dbfa89e237aa571556bee548c3f9cf4d5", "source_snapshot_id": "source-64831dec5ebf55535e19d91b", "source_updated_at": "2025-09-25", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/lacosamide-adroiq-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1903}
{"after": {"end": 26, "start": 0, "text": "Eckenheimer Landstraße 100", "truncated": false}, "after_length": 26, "after_sha256": "fdce1a9bd200c5ddd476c1ea5676b9ffbbea723f7353ad6fbc1fe019dcb86c07", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 26, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 26}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-043e075ed42ab9dfee8cb3fc", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002097", "medicine_name": "Fampyra", "medicine_slug": "fampyra", "observed_at": "2026-10-12T19:15:51Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "d9fe8aaaa611a84801d6308b13685258b5248df9022536697939afdf66fc1719", "source_snapshot_id": "source-ff8e0599077f0d01044dc867", "source_updated_at": "2025-08-21", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/fampyra-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1422}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 13, "start": 0, "text": "Lucane Pharma", "truncated": false}, "before_length": 13, "before_sha256": "e338afdb64acf1a6e2083a50318853589248451dd3aa707181ba02641a8521e8", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 13, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 13, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-04818a9ffb5b5712cc2a26e5", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:14Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "8b8c4cc8e6f1a21fedee4bf0743c9c03e454b50f5eaba0e3760416d7fe0a74ec", "source_snapshot_id": "source-4efe4ecf3ebf08d338a763a5", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1438}
{"after": {"end": 25, "start": 0, "text": "Eurocept International BV", "truncated": false}, "after_length": 25, "after_sha256": "b17bd89b3cf285c986a6070d0d67f5326dd5c1f08a70834c296c6c820f9e7505", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 25, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 25}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-0483d3b34e1795f59e63e795", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:19Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "77586d0bea0858214b43b86e91abc2d2711733b96959ead5ed0b5ecbd8ed888a", "source_snapshot_id": "source-85d476f9ad959cc117ca8f1f", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1492}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 8, "start": 0, "text": "Írország", "truncated": false}, "before_length": 8, "before_sha256": "17626bbbdd692796fd93bdfc39a5853f3960883d102671585b9599a86d5b229b", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 8, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 8, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-0486cfbaf208468a50153d44", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002097", "medicine_name": "Fampyra", "medicine_slug": "fampyra", "observed_at": "2026-10-12T19:15:51Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "d9fe8aaaa611a84801d6308b13685258b5248df9022536697939afdf66fc1719", "source_snapshot_id": "source-ff8e0599077f0d01044dc867", "source_updated_at": "2025-08-21", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/fampyra-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1421}
{"after": {"end": 23, "start": 0, "text": "60318 Frankfurt am Main", "truncated": false}, "after_length": 23, "after_sha256": "24c3191b5088b20c209c4387a8127297e54c776e161d305c9e57956a13b7cbbe", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 23, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 23}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-04c8c44d053b3db02be1a9d4", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002097", "medicine_name": "Fampyra", "medicine_slug": "fampyra", "observed_at": "2026-10-12T19:16:07Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "a0c3ba8d58d6a43a809ecc3d142a78b10c2bd7f0b9f3a3553df2617d87daec1f", "source_snapshot_id": "source-c7a810dd21f94cd2d273f0da", "source_updated_at": "2025-08-21", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/fampyra-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1389}
{"after": {"end": 21, "start": 0, "text": "Teл.: +40 21 528 0290", "truncated": false}, "after_length": 21, "after_sha256": "ec107d1625029392f60daf4b58132a83529ea43f1b9ebdf646436a843f24ad5b", "annex": "IIIA", "before": {"end": 26, "start": 0, "text": "Teл.: +359 (0) 888 755 393", "truncated": false}, "before_length": 26, "before_sha256": "25d34bfa98e800128c16111612beebc119b20f0c6456910d298344a0c0ffe050", "change_kind": "content", "change_operations": [{"after_end": 13, "after_start": 7, "before_end": 8, "before_start": 7, "kind": "replace"}, {"after_end": 15, "after_start": 14, "before_end": 17, "before_start": 9, "kind": "replace"}, {"after_end": 19, "after_start": 17, "before_end": 24, "before_start": 19, "kind": "replace"}, {"after_end": 21, "after_start": 20, "before_end": 26, "before_start": 25, "kind": "replace"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 15, "chars_inserted": 10}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-04f715b00aa690d94c01402c", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002066", "medicine_name": "Ikervis", "medicine_slug": "ikervis", "observed_at": "2026-10-12T13:34:16Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "ab05f9fab48768c68482390488c5b90c577e852974d4448da6ea8fe5a4eda856", "source_snapshot_id": "source-324751bde2e11edc76c2dbfe", "source_updated_at": "2026-06-23", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/ikervis-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1760}
{"after": {"end": 246, "start": 0, "text": "Contactez immédiatement votre médecin ou votre pharmacien si vous ressentez l'un des symptômes suivants pendant votre traitement par Arava : douleurs musculaires inexpliquées, sensibilité (douleur à la pression du muscle) ou faiblesse musculaire.", "truncated": false}, "after_length": 246, "after_sha256": "46d67b9fd5b140e533e3a7770bea1ef3e421bd3a192d785a859402c0b3ca1fc6", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 246, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 246}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-0510c0eb1650833d09561beb", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/000235", "medicine_name": "Arava", "medicine_slug": "arava", "observed_at": "2026-10-12T13:28:00Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": null, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "98b73c5c6b1e5009c9d048f8f11257f3a8407759fd25a4c8d5ef5c611519e916", "source_snapshot_id": "source-4b7ea3b78addea82376b3432", "source_updated_at": "2026-09-07", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/arava-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 3084}
{"after": {"end": 25, "start": 0, "text": "Eurocept International BV", "truncated": false}, "after_length": 25, "after_sha256": "b17bd89b3cf285c986a6070d0d67f5326dd5c1f08a70834c296c6c820f9e7505", "annex": "IIIA", "before": {"end": 27, "start": 0, "text": "(Eurocept International BV)", "truncated": false}, "before_length": 27, "before_sha256": "e6cf9b20aaa466e53ad0d393512ca75931e13e488321e3be6f3e4f8b600970c8", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 1, "before_start": 0, "kind": "delete"}, {"after_end": 25, "after_start": 25, "before_end": 27, "before_start": 26, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 2, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-053ab43edd059f568e36fd8f", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:19Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "77586d0bea0858214b43b86e91abc2d2711733b96959ead5ed0b5ecbd8ed888a", "source_snapshot_id": "source-85d476f9ad959cc117ca8f1f", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1861}
{"after": {"end": 29, "start": 0, "text": "64th Km National Road Athens,", "truncated": false}, "after_length": 29, "after_sha256": "13ea56883a0ab9bffcaa1dd41d9bf3581890cd7cfc6830634cd50feb121599ea", "annex": "II", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 29, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 29}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-0547cddfd6c84d264cfa0c6d", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/003984", "medicine_name": "Bortezomib Accord", "medicine_slug": "bortezomib-accord", "observed_at": "2026-10-12T13:47:12Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "conditions", "section_type": "conditions", "source_provider": "European Medicines Agency", "source_sha256": "e4aac937241121e8ad1e32b40b1007fb58398035928568a7e60a65074b0efb36", "source_snapshot_id": "source-b1eaab6445cfa827e3b1481b", "source_updated_at": "2026-03-25", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/bortezomib-accord-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 3284}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 27, "start": 0, "text": "(Eurocept International BV)", "truncated": false}, "before_length": 27, "before_sha256": "e6cf9b20aaa466e53ad0d393512ca75931e13e488321e3be6f3e4f8b600970c8", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 27, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 27, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-05775bd75512b2088f83146e", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:14Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "8b8c4cc8e6f1a21fedee4bf0743c9c03e454b50f5eaba0e3760416d7fe0a74ec", "source_snapshot_id": "source-4efe4ecf3ebf08d338a763a5", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1880}
{"after": {"end": 23, "start": 0, "text": "60318 Frankfurt am Main", "truncated": false}, "after_length": 23, "after_sha256": "24c3191b5088b20c209c4387a8127297e54c776e161d305c9e57956a13b7cbbe", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 23, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 23}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-05b7ca26505024a2ab808333", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002097", "medicine_name": "Fampyra", "medicine_slug": "fampyra", "observed_at": "2026-10-12T19:16:07Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "a0c3ba8d58d6a43a809ecc3d142a78b10c2bd7f0b9f3a3553df2617d87daec1f", "source_snapshot_id": "source-c7a810dd21f94cd2d273f0da", "source_updated_at": "2025-08-21", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/fampyra-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1419}
{"after": {"end": 20, "start": 0, "text": "Τηλ: +30 210 8009111", "truncated": false}, "after_length": 20, "after_sha256": "4be2eb2931a7797b144651aebec87029f222cbdda35f539f6c814b9013ffc042", "annex": "IIIA", "before": {"end": 9, "start": 0, "text": "Santen Oy", "truncated": false}, "before_length": 9, "before_sha256": "b8d3bb307d9e8fe0e3311ac213bd7de3f9df0c142a11ebd9fb9b8ec5c7ed12b6", "change_kind": "content", "change_operations": [{"after_end": 4, "after_start": 0, "before_end": 6, "before_start": 0, "kind": "replace"}, {"after_end": 20, "after_start": 5, "before_end": 9, "before_start": 7, "kind": "replace"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 8, "chars_inserted": 19}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-063bc3001dd7e7a4e8c874c7", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002066", "medicine_name": "Ikervis", "medicine_slug": "ikervis", "observed_at": "2026-10-12T13:34:10Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "7995ffe3d4b9c2e870327b45fae2f1d35ae1ab0e1e9e22b434fd9805b58a174e", "source_snapshot_id": "source-5ff0e792002ee89d9eb06e5d", "source_updated_at": "2026-06-23", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/ikervis-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1850}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 16, "start": 0, "text": "Extrovis EU Ltd.", "truncated": false}, "before_length": 16, "before_sha256": "f462ad48e7aef0bc82148ce088af1897d99ed86993128f30d506b27d3108a929", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 16, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 16, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-0697a390e466a7a468d091c4", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/006047", "medicine_name": "Lacosamide Adroiq", "medicine_slug": "lacosamide-adroiq", "observed_at": "2026-10-12T19:07:59Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "cc83d966059d42856d0211a4f256b29b20d43593865704d6a9315aeb694f3c76", "source_snapshot_id": "source-896abba1d8391c918345d46b", "source_updated_at": "2025-09-25", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/lacosamide-adroiq-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1860}
{"after": {"end": 25, "start": 0, "text": "Eurocept International BV", "truncated": false}, "after_length": 25, "after_sha256": "b17bd89b3cf285c986a6070d0d67f5326dd5c1f08a70834c296c6c820f9e7505", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 25, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 25}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-06d1bfa8f9bc6c1594d2f7d7", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:19Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "77586d0bea0858214b43b86e91abc2d2711733b96959ead5ed0b5ecbd8ed888a", "source_snapshot_id": "source-85d476f9ad959cc117ca8f1f", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1799}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 21, "start": 0, "text": "Tel: + 33 153 868 750", "truncated": false}, "before_length": 21, "before_sha256": "efffe29324e968019e6e2b111904182ba06d83e76b1f29b933bed9dd8779c114", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 21, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 21, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-06f7894284ff326a1052c149", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:14Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "8b8c4cc8e6f1a21fedee4bf0743c9c03e454b50f5eaba0e3760416d7fe0a74ec", "source_snapshot_id": "source-4efe4ecf3ebf08d338a763a5", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1578}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 20, "start": 0, "text": "10 Earlsfort Terrace", "truncated": false}, "before_length": 20, "before_sha256": "22951bbf6ee77815d0c07b3af5f0a66e17d277636971c4eaff372dea65dcb193", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 20, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 20, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-07267c292d2d19b724489366", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002097", "medicine_name": "Fampyra", "medicine_slug": "fampyra", "observed_at": "2026-10-12T19:15:51Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "d9fe8aaaa611a84801d6308b13685258b5248df9022536697939afdf66fc1719", "source_snapshot_id": "source-ff8e0599077f0d01044dc867", "source_updated_at": "2025-08-21", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/fampyra-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 893}
{"after": {"end": 23, "start": 0, "text": "info@euroceptpharma.com", "truncated": false}, "after_length": 23, "after_sha256": "9297cc5acdcc837f054116992765943f7907937507b2564a99ea1327a00ac0e6", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 23, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 23}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-072883d695b9ad35b4fd5a20", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:14Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "8b8c4cc8e6f1a21fedee4bf0743c9c03e454b50f5eaba0e3760416d7fe0a74ec", "source_snapshot_id": "source-4efe4ecf3ebf08d338a763a5", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 2005}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 16, "start": 0, "text": "Biochemiestr. 10", "truncated": false}, "before_length": 16, "before_sha256": "81f5fd80fa6d15bedf7da13d3cb3de66938eb7c6943ab1798dd881ede2bc4804", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 16, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 16, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-077512d4ad64d640e8dbc682", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/000725", "medicine_name": "Binocrit", "medicine_slug": "binocrit", "observed_at": "2026-10-12T19:29:33Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "2110517cc45ca102ca5957f2578ba74090631cf709d5be3e5f6e34712f237bdb", "source_snapshot_id": "source-63ba5976f2b2d4350a9afd16", "source_updated_at": "2025-07-11", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/binocrit-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 3385}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 27, "start": 0, "text": "(Eurocept International BV)", "truncated": false}, "before_length": 27, "before_sha256": "e6cf9b20aaa466e53ad0d393512ca75931e13e488321e3be6f3e4f8b600970c8", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 27, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 27, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-07c7c562e2f62dcdf57f4bb8", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:19Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "77586d0bea0858214b43b86e91abc2d2711733b96959ead5ed0b5ecbd8ed888a", "source_snapshot_id": "source-85d476f9ad959cc117ca8f1f", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1980}
{"after": {"end": 20, "start": 0, "text": "Τηλ: +30 210 8009111", "truncated": false}, "after_length": 20, "after_sha256": "4be2eb2931a7797b144651aebec87029f222cbdda35f539f6c814b9013ffc042", "annex": "IIIA", "before": {"end": 9, "start": 0, "text": "Santen Oy", "truncated": false}, "before_length": 9, "before_sha256": "b8d3bb307d9e8fe0e3311ac213bd7de3f9df0c142a11ebd9fb9b8ec5c7ed12b6", "change_kind": "content", "change_operations": [{"after_end": 4, "after_start": 0, "before_end": 6, "before_start": 0, "kind": "replace"}, {"after_end": 20, "after_start": 5, "before_end": 9, "before_start": 7, "kind": "replace"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 8, "chars_inserted": 19}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-07f5cd49b1f3bee9a073741b", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002066", "medicine_name": "Ikervis", "medicine_slug": "ikervis", "observed_at": "2026-10-12T13:34:10Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "7995ffe3d4b9c2e870327b45fae2f1d35ae1ab0e1e9e22b434fd9805b58a174e", "source_snapshot_id": "source-5ff0e792002ee89d9eb06e5d", "source_updated_at": "2026-06-23", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/ikervis-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1793}
{"after": {"end": 11, "start": 0, "text": "Vistor ehf.", "truncated": false}, "after_length": 11, "after_sha256": "7b79f0f888fc32453606a29b908677d0b6c13a510070ab26fe31e12b995d77fe", "annex": "IIIA", "before": {"end": 6, "start": 0, "text": "Vistor", "truncated": false}, "before_length": 6, "before_sha256": "880db25626eb8b4d5d7d9cc13a3d8eb1ceea5578e74cf4680a38ffc73e92fe11", "change_kind": "content", "change_operations": [{"after_end": 11, "after_start": 6, "before_end": 6, "before_start": 6, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 5}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-0803a3789aa8a56754ac893e", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002702", "medicine_name": "Hexacima", "medicine_slug": "hexacima", "observed_at": "2026-10-12T19:07:06Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "b990725709f885f3f868e5da444393a40a54f89ba2f2d9b232d9c053493d1b03", "source_snapshot_id": "source-87ea40f95d82cdfb5ba074b0", "source_updated_at": "2025-09-29", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/hexacima-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 2063}
{"after": {"end": 137, "start": 0, "text": "UNE TECHNIQUE ASEPTIQUE DOIT ETRE STRICTEMENT OBSERVÉE PENDANT LA MANIPULATION DE BORTEZOMIB ACCORD CAR AUCUN CONSERVATEUR N’EST PRÉSENT.", "truncated": false}, "after_length": 137, "after_sha256": "5820a4a56ba1b9ea43b44dba1c42bae989813dd5c5efd6ee9a6b28f36851962c", "annex": "IIIA", "before": {"end": 137, "start": 0, "text": "UNE TECHNIQUE ASEPTIQUE DOIT ETRE STRICTEMENT OBSERVÉE PENDANT LA MANIPULATION DE BORTEZOMID ACCORD CAR AUCUN CONSERVATEUR N’EST PRÉSENT.", "truncated": false}, "before_length": 137, "before_sha256": "581dfbb1cdd5acffde75a0f8332b74f21628a9efdd0a21b43a4cb7c4f74e5af8", "change_kind": "content", "change_operations": [{"after_end": 92, "after_start": 91, "before_end": 92, "before_start": 91, "kind": "replace"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 1, "chars_inserted": 1}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-0819f1e6a25ed75b46c2b3ec", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/003984", "medicine_name": "Bortezomib Accord", "medicine_slug": "bortezomib-accord", "observed_at": "2026-10-12T13:47:15Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "150a191aaf0a1e169e9d5fa2530f0eccb4e3d46509faf5ec5ee975a2e67788c4", "source_snapshot_id": "source-cba4680b7fbd2c536884abd8", "source_updated_at": "2026-03-25", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/bortezomib-accord-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 4323}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 15, "start": 0, "text": "2000 Szentendre", "truncated": false}, "before_length": 15, "before_sha256": "6541cfa43ac22d35453442b205116e312f60338169ddc5a705a8fe3ff3f4fcd9", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 15, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 15, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-084746a6209a5c1de9c9fc42", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/006047", "medicine_name": "Lacosamide Adroiq", "medicine_slug": "lacosamide-adroiq", "observed_at": "2026-10-12T19:07:59Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "cc83d966059d42856d0211a4f256b29b20d43593865704d6a9315aeb694f3c76", "source_snapshot_id": "source-896abba1d8391c918345d46b", "source_updated_at": "2025-09-25", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/lacosamide-adroiq-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1681}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 5, "start": 0, "text": "Írsko", "truncated": false}, "before_length": 5, "before_sha256": "f94349a2269c5b8a87adcdc639846023eb0a54b3cd323637a78d9c7d5a8feb5e", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 5, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 5, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-0893e9f3dbfb0f0da74f4ddd", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002097", "medicine_name": "Fampyra", "medicine_slug": "fampyra", "observed_at": "2026-10-12T19:15:51Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "d9fe8aaaa611a84801d6308b13685258b5248df9022536697939afdf66fc1719", "source_snapshot_id": "source-ff8e0599077f0d01044dc867", "source_updated_at": "2025-08-21", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/fampyra-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1574}
{"after": {"end": 149, "start": 0, "text": "Des informations détaillées sur ce médicament sont disponibles sur le site internet de l’Agence européenne des médicaments https://www.ema.europa.eu.", "truncated": false}, "after_length": 149, "after_sha256": "0e6b9f35caaf0258b468a6e9a53665f0ec5536787f68eefee5f242bf64add02e", "annex": "I", "before": {"end": 149, "start": 0, "text": "Des informations détaillées sur ce médicament sont disponibles sur le site internet de l’Agence européenne des médicaments http://www.ema.europa.eu/.", "truncated": false}, "before_length": 149, "before_sha256": "16e6f5615757ceabad4641121cdcfa0a0ce3e97da03a8f65c0b7b47a6899d4ba", "change_kind": "technical", "change_operations": [{"after_end": 128, "after_start": 127, "before_end": 127, "before_start": 127, "kind": "insert"}, {"after_end": 148, "after_start": 148, "before_end": 148, "before_start": 147, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 1, "chars_inserted": 1}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-0945d32bb699ec3f560300de", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/001021", "medicine_name": "Adcirca (previously Tadalafil Lilly)", "medicine_slug": "adcirca-previously-tadalafil-lilly", "observed_at": "2026-10-12T19:02:45Z", "pipeline_version": "2.0.0", "presentation_label": "ADCIRCA 2 mg/mL suspension buvable", "presentation_occurrence": 2, "presentation_status": "heading_extracted_unverified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "10", "section_type": "administrative", "source_provider": "European Medicines Agency", "source_sha256": "cdbefcd6143c93e81f3c826bea8d3d01bffc55652e0f792243097df75c452721", "source_snapshot_id": "source-a1e85476de17f5a8664f7766", "source_updated_at": "2026-01-28", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/adcirca-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1239}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 20, "start": 0, "text": "10 Earlsfort Terrace", "truncated": false}, "before_length": 20, "before_sha256": "22951bbf6ee77815d0c07b3af5f0a66e17d277636971c4eaff372dea65dcb193", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 20, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 20, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-0975f26ded75bc4229702cfb", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002097", "medicine_name": "Fampyra", "medicine_slug": "fampyra", "observed_at": "2026-10-12T19:16:07Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "a0c3ba8d58d6a43a809ecc3d142a78b10c2bd7f0b9f3a3553df2617d87daec1f", "source_snapshot_id": "source-c7a810dd21f94cd2d273f0da", "source_updated_at": "2025-08-21", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/fampyra-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 898}
{"after": {"end": 17, "start": 0, "text": "Torokbalint, 2045", "truncated": false}, "after_length": 17, "after_sha256": "d6dbae334e70b70d590689409d24e6c0cda7d30fd5104550892da04a039d1276", "annex": "I", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "administrative", "change_operations": [{"after_end": 17, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 17}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-0a11c2583dd895e15ab89ffa", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/006047", "medicine_name": "Lacosamide Adroiq", "medicine_slug": "lacosamide-adroiq", "observed_at": "2026-10-12T19:07:59Z", "pipeline_version": "2.0.0", "presentation_label": "Lacosamide Adroiq 10 mg/ml solution pour perfusion", "presentation_occurrence": 1, "presentation_status": "heading_extracted_unverified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "7", "section_type": "administrative", "source_provider": "European Medicines Agency", "source_sha256": "cc83d966059d42856d0211a4f256b29b20d43593865704d6a9315aeb694f3c76", "source_snapshot_id": "source-896abba1d8391c918345d46b", "source_updated_at": "2025-09-25", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/lacosamide-adroiq-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 912}
{"after": {"end": 21, "start": 0, "text": "Tel: +31 35 528 39 57", "truncated": false}, "after_length": 21, "after_sha256": "7baf6601f41e49e470f803fdd4e755a86efa38be423317c000ed79963ebdd213", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 21, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 21}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-0a2d74bb01206af0b015dac8", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:19Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "77586d0bea0858214b43b86e91abc2d2711733b96959ead5ed0b5ecbd8ed888a", "source_snapshot_id": "source-85d476f9ad959cc117ca8f1f", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1544}
{"after": {"end": 21, "start": 0, "text": "Tel: +31 35 528 39 57", "truncated": false}, "after_length": 21, "after_sha256": "7baf6601f41e49e470f803fdd4e755a86efa38be423317c000ed79963ebdd213", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 21, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 21}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-0a701e945e9684fdfbf641ff", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:14Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "8b8c4cc8e6f1a21fedee4bf0743c9c03e454b50f5eaba0e3760416d7fe0a74ec", "source_snapshot_id": "source-4efe4ecf3ebf08d338a763a5", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1580}
{"after": {"end": 7, "start": 0, "text": "Nemecko", "truncated": false}, "after_length": 7, "after_sha256": "24d0126e5a26515542704a0c598527890b61fd4046ad4d533f1d262406306618", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 7, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 7}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-0bc6cd5934a40cf91fd9982e", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002097", "medicine_name": "Fampyra", "medicine_slug": "fampyra", "observed_at": "2026-10-12T19:15:51Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "d9fe8aaaa611a84801d6308b13685258b5248df9022536697939afdf66fc1719", "source_snapshot_id": "source-ff8e0599077f0d01044dc867", "source_updated_at": "2025-08-21", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/fampyra-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1577}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 13, "start": 0, "text": "Lucane Pharma", "truncated": false}, "before_length": 13, "before_sha256": "e338afdb64acf1a6e2083a50318853589248451dd3aa707181ba02641a8521e8", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 13, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 13, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-0c655f67e5889fc6dbb2be43", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:14Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "8b8c4cc8e6f1a21fedee4bf0743c9c03e454b50f5eaba0e3760416d7fe0a74ec", "source_snapshot_id": "source-4efe4ecf3ebf08d338a763a5", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 2000}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 33, "start": 0, "text": "United Kingdom (Northern Ireland)", "truncated": false}, "before_length": 33, "before_sha256": "9379d82927cdb505cfb186e912177065e56a1314de3a2b914ebbb8b5fe21525a", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 33, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 33, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-0c724a0c291121a16ecd6584", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/000619", "medicine_name": "Fosavance", "medicine_slug": "fosavance", "observed_at": "2026-10-12T19:01:49Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "97e93ccf75e837b32026ca36c34d5c78008211a75d5ef225c47e7b94a0027ab2", "source_snapshot_id": "source-1ef57638e1a307f1e5437651", "source_updated_at": "2026-02-12", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/fosavance-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1329}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 13, "start": 0, "text": "Lucane Pharma", "truncated": false}, "before_length": 13, "before_sha256": "e338afdb64acf1a6e2083a50318853589248451dd3aa707181ba02641a8521e8", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 13, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 13, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-0c7f2221d483bc5b67ae3eb2", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:14Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "8b8c4cc8e6f1a21fedee4bf0743c9c03e454b50f5eaba0e3760416d7fe0a74ec", "source_snapshot_id": "source-4efe4ecf3ebf08d338a763a5", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1545}
{"after": {"end": 8, "start": 0, "text": "Saksamaa", "truncated": false}, "after_length": 8, "after_sha256": "cc19dad198aa5593de7f67d07bcbd0bbe1dfa0b63733ef6d581860c2c5f16706", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 8, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 8}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-0cf83db3533bc3539a1bf416", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002097", "medicine_name": "Fampyra", "medicine_slug": "fampyra", "observed_at": "2026-10-12T19:16:07Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "a0c3ba8d58d6a43a809ecc3d142a78b10c2bd7f0b9f3a3553df2617d87daec1f", "source_snapshot_id": "source-c7a810dd21f94cd2d273f0da", "source_updated_at": "2025-08-21", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/fampyra-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1473}
{"after": {"end": 134, "start": 0, "text": "Detailed information on this medicinal product is available on the website of the European Medicines Agency https://www.ema.europa.eu.", "truncated": false}, "after_length": 134, "after_sha256": "9f2a855337f11701b0cd4191c51820fa5a70b201b2e0721ba6acd34544486f89", "annex": "I", "before": {"end": 133, "start": 0, "text": "Detailed information on this medicinal product is available on the website of the European Medicines Agency http://www.ema.europa.eu.", "truncated": false}, "before_length": 133, "before_sha256": "eabdb61a543e11ee016c5c43ada549964199ddf9e287a2eb3256e15d4a87fe4a", "change_kind": "technical", "change_operations": [{"after_end": 113, "after_start": 112, "before_end": 112, "before_start": 112, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 1}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-0cf95d8315125707b6ae9cbd", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/001021", "medicine_name": "Adcirca (previously Tadalafil Lilly)", "medicine_slug": "adcirca-previously-tadalafil-lilly", "observed_at": "2026-10-12T19:02:42Z", "pipeline_version": "2.0.0", "presentation_label": "ADCIRCA 2 mg/mL oral suspension", "presentation_occurrence": 2, "presentation_status": "heading_extracted_unverified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "10", "section_type": "administrative", "source_provider": "European Medicines Agency", "source_sha256": "43438c8e53504a78747a8ff36049250fee294557f3a8b0e3acb80f71ad43ebc0", "source_snapshot_id": "source-2305a67bd1e393ee340bb8e4", "source_updated_at": "2026-01-28", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/adcirca-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1246}
{"after": {"end": 25, "start": 0, "text": "Eurocept International BV", "truncated": false}, "after_length": 25, "after_sha256": "b17bd89b3cf285c986a6070d0d67f5326dd5c1f08a70834c296c6c820f9e7505", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 25, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 25}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-0d3613084b154ab36ab389f3", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:19Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "77586d0bea0858214b43b86e91abc2d2711733b96959ead5ed0b5ecbd8ed888a", "source_snapshot_id": "source-85d476f9ad959cc117ca8f1f", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1437}
{"after": {"end": 84, "start": 0, "text": "Motifs de la modification des termes de la/des autorisation(s) de mise sur le marché", "truncated": false}, "after_length": 84, "after_sha256": "4ae2391ae7d822fcc157b2047bb5fc98dea0742b977efc28a87cde01dda2e02a", "annex": "IV", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 84, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 84}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-0d69753d40b45b8c4c51215a", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/000554", "medicine_name": "Emselex", "medicine_slug": "emselex", "observed_at": "2026-10-12T19:12:07Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": null, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "conditions", "section_type": "conditions", "source_provider": "European Medicines Agency", "source_sha256": "9a4f1d7e260c7b80eaf397503623b63302e5945b579e9612177835e07c4ab888", "source_snapshot_id": "source-3aac7bf42b99529f25ac013b", "source_updated_at": "2025-09-15", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/emselex-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 2074}
{"after": {"end": 25, "start": 0, "text": "Eurocept International BV", "truncated": false}, "after_length": 25, "after_sha256": "b17bd89b3cf285c986a6070d0d67f5326dd5c1f08a70834c296c6c820f9e7505", "annex": "IIIA", "before": {"end": 21, "start": 0, "text": "info@lucanepharma.com", "truncated": false}, "before_length": 21, "before_sha256": "44fd39e5fb919cb3d680fa630da23b49238fec29159c509f3622f272bb41c7c6", "change_kind": "content", "change_operations": [{"after_end": 3, "after_start": 0, "before_end": 3, "before_start": 0, "kind": "replace"}, {"after_end": 4, "after_start": 4, "before_end": 7, "before_start": 4, "kind": "delete"}, {"after_end": 5, "after_start": 5, "before_end": 10, "before_start": 8, "kind": "delete"}, {"after_end": 15, "after_start": 7, "before_end": 13, "before_start": 12, "kind": "replace"}, {"after_end": 20, "after_start": 16, "before_end": 16, "before_start": 14, "kind": "replace"}, {"after_end": 25, "after_start": 21, "before_end": 21, "before_start": 17, "kind": "replace"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 15, "chars_inserted": 19}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-0dbbc79c6f5b6279d520cfb1", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:14Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "8b8c4cc8e6f1a21fedee4bf0743c9c03e454b50f5eaba0e3760416d7fe0a74ec", "source_snapshot_id": "source-4efe4ecf3ebf08d338a763a5", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1473}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 25, "start": 0, "text": "Tél/Tel: + 33 153 868 750", "truncated": false}, "before_length": 25, "before_sha256": "e5f8e4aadc105f123b1cb253b9afe1e362181b7777e0b94626adda3e9db7ed2e", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 25, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 25, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-0dc2227b0a3e9feff18660d5", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:19Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "77586d0bea0858214b43b86e91abc2d2711733b96959ead5ed0b5ecbd8ed888a", "source_snapshot_id": "source-85d476f9ad959cc117ca8f1f", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1382}
{"after": {"end": 22, "start": 0, "text": "Merz Therapeutics GmbH", "truncated": false}, "after_length": 22, "after_sha256": "059f049c7d0846aaadcf2573280d52110f302d4ecc7b38debd004571cd1e9d5e", "annex": "IIIA", "before": {"end": 35, "start": 0, "text": "Acorda Therapeutics Ireland Limited", "truncated": false}, "before_length": 35, "before_sha256": "d94d3153d193ed26567f2b4ed48df016d81c534e7c0cb1a6655a63f0083383ff", "change_kind": "content", "change_operations": [{"after_end": 2, "after_start": 0, "before_end": 3, "before_start": 0, "kind": "replace"}, {"after_end": 4, "after_start": 3, "before_end": 6, "before_start": 4, "kind": "replace"}, {"after_end": 19, "after_start": 18, "before_end": 30, "before_start": 20, "kind": "replace"}, {"after_end": 22, "after_start": 20, "before_end": 35, "before_start": 31, "kind": "replace"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 19, "chars_inserted": 6}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-0dd5574461af0287c2eeb91d", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002097", "medicine_name": "Fampyra", "medicine_slug": "fampyra", "observed_at": "2026-10-12T19:15:51Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "d9fe8aaaa611a84801d6308b13685258b5248df9022536697939afdf66fc1719", "source_snapshot_id": "source-ff8e0599077f0d01044dc867", "source_updated_at": "2025-08-21", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/fampyra-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1500}
{"after": {"end": 25, "start": 0, "text": "Eurocept International BV", "truncated": false}, "after_length": 25, "after_sha256": "b17bd89b3cf285c986a6070d0d67f5326dd5c1f08a70834c296c6c820f9e7505", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 25, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 25}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-0df5910b5b1f808c33a5cc4b", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:19Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "77586d0bea0858214b43b86e91abc2d2711733b96959ead5ed0b5ecbd8ed888a", "source_snapshot_id": "source-85d476f9ad959cc117ca8f1f", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1500}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 27, "start": 0, "text": "Tél/Tel. : +31 35 528 39 57", "truncated": false}, "before_length": 27, "before_sha256": "eddad606e05a9455dde7d268d2b9f8b333c53e1b7fe89a456795afc087881b80", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 27, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 27, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-0e23f83134ff2eeacd0968b3", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:19Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "77586d0bea0858214b43b86e91abc2d2711733b96959ead5ed0b5ecbd8ed888a", "source_snapshot_id": "source-85d476f9ad959cc117ca8f1f", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1790}
{"after": {"end": 30, "start": 0, "text": "Nederland/Pays-Bas/Niederlande", "truncated": false}, "after_length": 30, "after_sha256": "531c576490cac7295a5202182f4a0efb0dc7a4acfd97f71ab0f5a345dd36c11a", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 30, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 30}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-0e6168d9a761d80de71b846a", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002097", "medicine_name": "Fampyra", "medicine_slug": "fampyra", "observed_at": "2026-10-12T19:15:51Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "d9fe8aaaa611a84801d6308b13685258b5248df9022536697939afdf66fc1719", "source_snapshot_id": "source-ff8e0599077f0d01044dc867", "source_updated_at": "2025-08-21", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/fampyra-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1374}
{"after": {"end": 23, "start": 0, "text": "info@euroceptpharma.com", "truncated": false}, "after_length": 23, "after_sha256": "9297cc5acdcc837f054116992765943f7907937507b2564a99ea1327a00ac0e6", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 23, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 23}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-0e94818795635869266aea11", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:19Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "77586d0bea0858214b43b86e91abc2d2711733b96959ead5ed0b5ecbd8ed888a", "source_snapshot_id": "source-85d476f9ad959cc117ca8f1f", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1787}
{"after": {"end": 13, "start": 0, "text": "Hermeslaan 11", "truncated": false}, "after_length": 13, "after_sha256": "6426889eacea87c88f1e0405aad54515d8a889ca0f1b2ab39e2039040651e7d3", "annex": "II", "before": {"end": 11, "start": 0, "text": "Hoge Wei 10", "truncated": false}, "before_length": 11, "before_sha256": "ba5c0cab58e83e9dc6ec41e55e6acc00077e1be63c8a1ed970723221f2f12ba4", "change_kind": "content", "change_operations": [{"after_end": 1, "after_start": 1, "before_end": 3, "before_start": 1, "kind": "delete"}, {"after_end": 4, "after_start": 2, "before_end": 6, "before_start": 4, "kind": "replace"}, {"after_end": 10, "after_start": 5, "before_end": 8, "before_start": 7, "kind": "replace"}, {"after_end": 13, "after_start": 12, "before_end": 11, "before_start": 10, "kind": "replace"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 6, "chars_inserted": 8}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-0e9b92e4c4e090f3d1927a96", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/004697", "medicine_name": "Zirabev", "medicine_slug": "zirabev", "observed_at": "2026-10-12T19:08:39Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "conditions", "section_type": "conditions", "source_provider": "European Medicines Agency", "source_sha256": "ef33f1350f1fcae139a251926014b13e3e973646fc918d603307fbce8dac4777", "source_snapshot_id": "source-7ce336750684e46ba3e4e54c", "source_updated_at": "2025-09-17", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/zirabev-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 2508}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 13, "start": 0, "text": "Lucane Pharma", "truncated": false}, "before_length": 13, "before_sha256": "e338afdb64acf1a6e2083a50318853589248451dd3aa707181ba02641a8521e8", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 13, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 13, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-0eb016403526ea3647abbf74", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:19Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "77586d0bea0858214b43b86e91abc2d2711733b96959ead5ed0b5ecbd8ed888a", "source_snapshot_id": "source-85d476f9ad959cc117ca8f1f", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1394}
{"after": {"end": 16, "start": 0, "text": "Extrovis EU Kft.", "truncated": false}, "after_length": 16, "after_sha256": "b9216ef80e71e17798dce313e4318f03f37328f225d30ab508b7413813a908e5", "annex": "IIIB", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "unassigned", "change_operations": [{"after_end": 16, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 16}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-0f0474d2d973d0c9e3f54e9a", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/006047", "medicine_name": "Lacosamide Adroiq", "medicine_slug": "lacosamide-adroiq", "observed_at": "2026-10-12T19:07:56Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "", "section_type": "unassigned", "source_provider": "European Medicines Agency", "source_sha256": "0578c53a5e1c785c4d9d4dc0dabae49dbfa89e237aa571556bee548c3f9cf4d5", "source_snapshot_id": "source-64831dec5ebf55535e19d91b", "source_updated_at": "2025-09-25", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/lacosamide-adroiq-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1974}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "II", "before": {"end": 7, "start": 0, "text": "Irlande", "truncated": false}, "before_length": 7, "before_sha256": "a8cdfff5dbbda1b070a2acb339b6f0aa20b6230d9b5500c9ce066eaa89bc9a64", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 7, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 7, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-0f0506957a4032cfede7c42d", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/004025", "medicine_name": "Lopinavir/Ritonavir Viatris (previously Ritonavir Mylan)", "medicine_slug": "lopinavir-ritonavir-viatris-previously-ritonavir-mylan", "observed_at": "2026-10-12T19:14:59Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "conditions", "section_type": "conditions", "source_provider": "European Medicines Agency", "source_sha256": "d782e33ec97bc43bb54f942c83f07f89482c9a433e3846beaffe05b4a52b4b36", "source_snapshot_id": "source-ff48b23a80b98be4c15aa440", "source_updated_at": "2025-09-08", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/lopinavir-ritonavir-viatris-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1464}
{"after": {"end": 25, "start": 0, "text": "Eurocept International BV", "truncated": false}, "after_length": 25, "after_sha256": "b17bd89b3cf285c986a6070d0d67f5326dd5c1f08a70834c296c6c820f9e7505", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 25, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 25}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-0f69b38bc3893a3c586578a5", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:19Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "77586d0bea0858214b43b86e91abc2d2711733b96959ead5ed0b5ecbd8ed888a", "source_snapshot_id": "source-85d476f9ad959cc117ca8f1f", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1531}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "II", "before": {"end": 56, "start": 0, "text": "35/36 Baldoyle Industrial Estate, Grange Road, Dublin 13", "truncated": false}, "before_length": 56, "before_sha256": "f0fa66e07d117c6c91c11210809d32b098e6ea28fc318be9df3a372f6c002a1a", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 56, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 56, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-0f8153117a7e9afb2fdf0c37", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/004025", "medicine_name": "Lopinavir/Ritonavir Viatris (previously Ritonavir Mylan)", "medicine_slug": "lopinavir-ritonavir-viatris-previously-ritonavir-mylan", "observed_at": "2026-10-12T19:14:59Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "conditions", "section_type": "conditions", "source_provider": "European Medicines Agency", "source_sha256": "d782e33ec97bc43bb54f942c83f07f89482c9a433e3846beaffe05b4a52b4b36", "source_snapshot_id": "source-ff48b23a80b98be4c15aa440", "source_updated_at": "2025-09-08", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/lopinavir-ritonavir-viatris-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1463}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 16, "start": 0, "text": "Extrovis EU Ltd.", "truncated": false}, "before_length": 16, "before_sha256": "f462ad48e7aef0bc82148ce088af1897d99ed86993128f30d506b27d3108a929", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 16, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 16, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-0f90a4e3d6545df79c386209", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/006047", "medicine_name": "Lacosamide Adroiq", "medicine_slug": "lacosamide-adroiq", "observed_at": "2026-10-12T19:07:59Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "cc83d966059d42856d0211a4f256b29b20d43593865704d6a9315aeb694f3c76", "source_snapshot_id": "source-896abba1d8391c918345d46b", "source_updated_at": "2025-09-25", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/lacosamide-adroiq-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1810}
{"after": {"end": 205, "start": 0, "text": "If your baby is less than 4 weeks old, talk to your doctor or pharmacist before giving them this flavour topping in particular if the baby is given other medicines that contain propylene glycol or alcohol.", "truncated": false}, "after_length": 205, "after_sha256": "3f04cdf4be5696e7a89c05d7d76e6aec341afc9e8aa6f161af680c59846bb476", "annex": "I", "before": {"end": 199, "start": 0, "text": "If your baby is less than 4 weeks old, talk to your doctor or pharmacist before giving them this medicine, in particular if the baby is given other medicines that contain propylene glycol or alcohol.", "truncated": false}, "before_length": 199, "before_sha256": "b62170b5b3b036ea9b5cd69f0b30f5a76fb9c34977bff99fea9049c7075d499a", "change_kind": "content", "change_operations": [{"after_end": 109, "after_start": 97, "before_end": 102, "before_start": 97, "kind": "replace"}, {"after_end": 112, "after_start": 111, "before_end": 106, "before_start": 104, "kind": "replace"}], "classification_method": "documentary_rules_v2", "clinical_candidate": true, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 7, "chars_inserted": 13}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-0f96db8e6f6a313144afa0f5", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:14Z", "pipeline_version": "2.0.0", "presentation_label": "PHEBURANE 350 mg/mL oral solution", "presentation_occurrence": 2, "presentation_status": "heading_extracted_unverified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "4.4", "section_type": "warning", "source_provider": "European Medicines Agency", "source_sha256": "8b8c4cc8e6f1a21fedee4bf0743c9c03e454b50f5eaba0e3760416d7fe0a74ec", "source_snapshot_id": "source-4efe4ecf3ebf08d338a763a5", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 461}
{"after": {"end": 23, "start": 0, "text": "info@euroceptpharma.com", "truncated": false}, "after_length": 23, "after_sha256": "9297cc5acdcc837f054116992765943f7907937507b2564a99ea1327a00ac0e6", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 23, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 23}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-0fc394591375d7245ac7d433", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:19Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "77586d0bea0858214b43b86e91abc2d2711733b96959ead5ed0b5ecbd8ed888a", "source_snapshot_id": "source-85d476f9ad959cc117ca8f1f", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1545}
{"after": {"end": 26, "start": 0, "text": "Eckenheimer Landstraße 100", "truncated": false}, "after_length": 26, "after_sha256": "fdce1a9bd200c5ddd476c1ea5676b9ffbbea723f7353ad6fbc1fe019dcb86c07", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 26, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 26}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-0fd933cb096c9a1f4c94ea27", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002097", "medicine_name": "Fampyra", "medicine_slug": "fampyra", "observed_at": "2026-10-12T19:16:07Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "a0c3ba8d58d6a43a809ecc3d142a78b10c2bd7f0b9f3a3553df2617d87daec1f", "source_snapshot_id": "source-c7a810dd21f94cd2d273f0da", "source_updated_at": "2025-08-21", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/fampyra-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1625}
{"after": {"end": 18, "start": 0, "text": "dpoccyprus@msd.com", "truncated": false}, "after_length": 18, "after_sha256": "492fae7e6db021703bcb80e4b139bc2be78a7e6cf4c6056a9314c70cfe643716", "annex": "IIIA", "before": {"end": 20, "start": 0, "text": "malta_info@merck.com", "truncated": false}, "before_length": 20, "before_sha256": "d0529053ac5f753b95c76e02b64d46efbc0d61183bea7de30faa0abc218a9e1c", "change_kind": "content", "change_operations": [{"after_end": 2, "after_start": 0, "before_end": 9, "before_start": 0, "kind": "replace"}, {"after_end": 10, "after_start": 3, "before_end": 10, "before_start": 10, "kind": "insert"}, {"after_end": 14, "after_start": 12, "before_end": 16, "before_start": 12, "kind": "replace"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 13, "chars_inserted": 11}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-0ff2d068b90139d06a7596fc", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/000389", "medicine_name": "Invanz", "medicine_slug": "invanz", "observed_at": "2026-10-12T17:30:44Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "a9208c117495d2d6c465ba196e4dbbb3d498b27d747df3b2d0145b0549743e4b", "source_snapshot_id": "source-e56383168f778128e02c2b2e", "source_updated_at": "2025-11-21", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/invanz-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1131}
{"after": {"end": 21, "start": 0, "text": "Tel: +31 35 528 39 57", "truncated": false}, "after_length": 21, "after_sha256": "7baf6601f41e49e470f803fdd4e755a86efa38be423317c000ed79963ebdd213", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 21, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 21}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-0ff47376e257c5d7ad7e5916", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:14Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "8b8c4cc8e6f1a21fedee4bf0743c9c03e454b50f5eaba0e3760416d7fe0a74ec", "source_snapshot_id": "source-4efe4ecf3ebf08d338a763a5", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1527}
{"after": {"end": 26, "start": 0, "text": "Eckenheimer Landstraße 100", "truncated": false}, "after_length": 26, "after_sha256": "fdce1a9bd200c5ddd476c1ea5676b9ffbbea723f7353ad6fbc1fe019dcb86c07", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 26, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 26}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-0fff8a804f3c426708051fa8", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002097", "medicine_name": "Fampyra", "medicine_slug": "fampyra", "observed_at": "2026-10-12T19:15:51Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "d9fe8aaaa611a84801d6308b13685258b5248df9022536697939afdf66fc1719", "source_snapshot_id": "source-ff8e0599077f0d01044dc867", "source_updated_at": "2025-08-21", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/fampyra-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1537}
{"after": {"end": 23, "start": 0, "text": "info@euroceptpharma.com", "truncated": false}, "after_length": 23, "after_sha256": "9297cc5acdcc837f054116992765943f7907937507b2564a99ea1327a00ac0e6", "annex": "IIIA", "before": {"end": 13, "start": 0, "text": "Lucane Pharma", "truncated": false}, "before_length": 13, "before_sha256": "e338afdb64acf1a6e2083a50318853589248451dd3aa707181ba02641a8521e8", "change_kind": "content", "change_operations": [{"after_end": 6, "after_start": 0, "before_end": 1, "before_start": 0, "kind": "replace"}, {"after_end": 9, "after_start": 7, "before_end": 2, "before_start": 2, "kind": "insert"}, {"after_end": 10, "after_start": 10, "before_end": 5, "before_start": 3, "kind": "delete"}, {"after_end": 14, "after_start": 11, "before_end": 8, "before_start": 6, "kind": "replace"}, {"after_end": 23, "after_start": 19, "before_end": 13, "before_start": 13, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 5, "chars_inserted": 15}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-1008586b235a53ae159900ea", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:19Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "77586d0bea0858214b43b86e91abc2d2711733b96959ead5ed0b5ecbd8ed888a", "source_snapshot_id": "source-85d476f9ad959cc117ca8f1f", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1414}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 30, "start": 0, "text": "Tel/ Tél: +31 (0) 20 85 46 555", "truncated": false}, "before_length": 30, "before_sha256": "50ad21637c6beff5820972d6906c54fc86fedd58d52e82746152053b5c9b6ea8", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 30, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 30, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-1017cc1e11bb452aee897010", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/000980", "medicine_name": "Samsca", "medicine_slug": "samsca", "observed_at": "2026-10-12T13:28:23Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "b92d73a758b8976c4438a072d544f0d6c603112c90dfc9c084d362ce62419257", "source_snapshot_id": "source-15b8b5681aba542ec1668c0b", "source_updated_at": "2026-08-20", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/samsca-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1290}
{"after": {"end": 26, "start": 0, "text": "Dipharma Arzneimittel GmbH", "truncated": false}, "after_length": 26, "after_sha256": "d8cb257047b7439a3be44a22f3227e45df27054340bbfa9cd6525bbf1d237add", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 26, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 26}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-1042edc9492c4734e30f2eff", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:19Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "77586d0bea0858214b43b86e91abc2d2711733b96959ead5ed0b5ecbd8ed888a", "source_snapshot_id": "source-85d476f9ad959cc117ca8f1f", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1887}
{"after": {"end": 23, "start": 0, "text": "info@euroceptpharma.com", "truncated": false}, "after_length": 23, "after_sha256": "9297cc5acdcc837f054116992765943f7907937507b2564a99ea1327a00ac0e6", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 23, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 23}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-104a3f3f842d1a94cf92030d", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:14Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "8b8c4cc8e6f1a21fedee4bf0743c9c03e454b50f5eaba0e3760416d7fe0a74ec", "source_snapshot_id": "source-4efe4ecf3ebf08d338a763a5", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1567}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 21, "start": 0, "text": "Tel: + 33 153 868 750", "truncated": false}, "before_length": 21, "before_sha256": "efffe29324e968019e6e2b111904182ba06d83e76b1f29b933bed9dd8779c114", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 21, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 21, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-107fefc81bdb428ddf22f84b", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:19Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "77586d0bea0858214b43b86e91abc2d2711733b96959ead5ed0b5ecbd8ed888a", "source_snapshot_id": "source-85d476f9ad959cc117ca8f1f", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1426}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 27, "start": 0, "text": "(Eurocept International BV)", "truncated": false}, "before_length": 27, "before_sha256": "e6cf9b20aaa466e53ad0d393512ca75931e13e488321e3be6f3e4f8b600970c8", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 27, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 27, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-108d1e4a3b5063e965e773be", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:14Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "8b8c4cc8e6f1a21fedee4bf0743c9c03e454b50f5eaba0e3760416d7fe0a74ec", "source_snapshot_id": "source-4efe4ecf3ebf08d338a763a5", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1968}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 21, "start": 0, "text": "Tel: + 33 153 868 750", "truncated": false}, "before_length": 21, "before_sha256": "efffe29324e968019e6e2b111904182ba06d83e76b1f29b933bed9dd8779c114", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 21, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 21, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-109f9a475cf45acd92d87820", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:14Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "8b8c4cc8e6f1a21fedee4bf0743c9c03e454b50f5eaba0e3760416d7fe0a74ec", "source_snapshot_id": "source-4efe4ecf3ebf08d338a763a5", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1596}
{"after": {"end": 18, "start": 0, "text": "Raktarvarosi Ut 9,", "truncated": false}, "after_length": 18, "after_sha256": "71dd279084ba9f87e79f1095d3565620050fda91d248303c2e19c46598fb0c2b", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 18, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 18}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-10f11c221b4951e3ca8e71a3", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/006047", "medicine_name": "Lacosamide Adroiq", "medicine_slug": "lacosamide-adroiq", "observed_at": "2026-10-12T19:07:59Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "cc83d966059d42856d0211a4f256b29b20d43593865704d6a9315aeb694f3c76", "source_snapshot_id": "source-896abba1d8391c918345d46b", "source_updated_at": "2025-09-25", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/lacosamide-adroiq-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1112}
{"after": {"end": 25, "start": 0, "text": "Eurocept International BV", "truncated": false}, "after_length": 25, "after_sha256": "b17bd89b3cf285c986a6070d0d67f5326dd5c1f08a70834c296c6c820f9e7505", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 25, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 25}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-10f446fe80648511a950953b", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:14Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "8b8c4cc8e6f1a21fedee4bf0743c9c03e454b50f5eaba0e3760416d7fe0a74ec", "source_snapshot_id": "source-4efe4ecf3ebf08d338a763a5", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1511}
{"after": {"end": 23, "start": 0, "text": "Tel: +49 (0) 69 15 03 0", "truncated": false}, "after_length": 23, "after_sha256": "09683b3f43171b2266a32d9f7d44e3d62d536522dc6f42d4b47f2dda48b31833", "annex": "IIIA", "before": {"end": 23, "start": 0, "text": "Tel: +353 (0)1 231 4609", "truncated": false}, "before_length": 23, "before_sha256": "a115f11f382ef18898b9d956e48603ae236fd1846ce41e8586af99b6dabbfc4d", "change_kind": "content", "change_operations": [{"after_end": 8, "after_start": 6, "before_end": 9, "before_start": 6, "kind": "replace"}, {"after_end": 16, "after_start": 12, "before_end": 13, "before_start": 13, "kind": "insert"}, {"after_end": 18, "after_start": 17, "before_end": 14, "before_start": 14, "kind": "insert"}, {"after_end": 20, "after_start": 19, "before_end": 16, "before_start": 15, "kind": "replace"}, {"after_end": 21, "after_start": 21, "before_end": 18, "before_start": 17, "kind": "delete"}, {"after_end": 22, "after_start": 22, "before_end": 21, "before_start": 19, "kind": "delete"}, {"after_end": 23, "after_start": 23, "before_end": 23, "before_start": 22, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 8, "chars_inserted": 8}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-1115ab2873a12ee0e1949650", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002097", "medicine_name": "Fampyra", "medicine_slug": "fampyra", "observed_at": "2026-10-12T19:16:07Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "a0c3ba8d58d6a43a809ecc3d142a78b10c2bd7f0b9f3a3553df2617d87daec1f", "source_snapshot_id": "source-c7a810dd21f94cd2d273f0da", "source_updated_at": "2025-08-21", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/fampyra-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1474}
{"after": {"end": 25, "start": 0, "text": "Musculoskeletal disorders", "truncated": false}, "after_length": 25, "after_sha256": "554fab09c18c12d65cee54d5caa96534b1925e5ff23a67e98a7c7c04e66bf714", "annex": "I", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 25, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": true, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 25}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-112885771bdc480cda748c66", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/000235", "medicine_name": "Arava", "medicine_slug": "arava", "observed_at": "2026-10-12T13:27:58Z", "pipeline_version": "2.0.0", "presentation_label": "Arava 10 mg film-coated tablets", "presentation_occurrence": 1, "presentation_status": "heading_extracted_unverified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "4.4", "section_type": "warning", "source_provider": "European Medicines Agency", "source_sha256": "2efff7967e2237bf8343431eef5e08b56c2441eb8a691a90c64b2635109fd697", "source_snapshot_id": "source-08b4eba1f67d2654148f41c4", "source_updated_at": "2026-09-07", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/arava-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 182}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 13, "start": 0, "text": "Lucane Pharma", "truncated": false}, "before_length": 13, "before_sha256": "e338afdb64acf1a6e2083a50318853589248451dd3aa707181ba02641a8521e8", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 13, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 13, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-113c242f4535a0fbce785f66", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:14Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "8b8c4cc8e6f1a21fedee4bf0743c9c03e454b50f5eaba0e3760416d7fe0a74ec", "source_snapshot_id": "source-4efe4ecf3ebf08d338a763a5", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1531}
{"after": {"end": 21, "start": 0, "text": "Tel: +31 35 528 39 57", "truncated": false}, "after_length": 21, "after_sha256": "7baf6601f41e49e470f803fdd4e755a86efa38be423317c000ed79963ebdd213", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 21, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 21}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-11abc034c3476e955ed55df1", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:14Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "8b8c4cc8e6f1a21fedee4bf0743c9c03e454b50f5eaba0e3760416d7fe0a74ec", "source_snapshot_id": "source-4efe4ecf3ebf08d338a763a5", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 2071}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 21, "start": 0, "text": "Tel: + 33 153 868 750", "truncated": false}, "before_length": 21, "before_sha256": "efffe29324e968019e6e2b111904182ba06d83e76b1f29b933bed9dd8779c114", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 21, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 21, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-11c1d135e08ecbc0a8c6c947", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:19Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "77586d0bea0858214b43b86e91abc2d2711733b96959ead5ed0b5ecbd8ed888a", "source_snapshot_id": "source-85d476f9ad959cc117ca8f1f", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1489}
{"after": {"end": 16, "start": 0, "text": "Extrovis EU Kft.", "truncated": false}, "after_length": 16, "after_sha256": "b9216ef80e71e17798dce313e4318f03f37328f225d30ab508b7413813a908e5", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 16, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 16}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-11e0e4b88416c1f6c8b30701", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/006047", "medicine_name": "Lacosamide Adroiq", "medicine_slug": "lacosamide-adroiq", "observed_at": "2026-10-12T19:07:59Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "cc83d966059d42856d0211a4f256b29b20d43593865704d6a9315aeb694f3c76", "source_snapshot_id": "source-896abba1d8391c918345d46b", "source_updated_at": "2025-09-25", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/lacosamide-adroiq-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1843}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 21, "start": 0, "text": "Τηλ: + 33 153 868 750", "truncated": false}, "before_length": 21, "before_sha256": "e4516e3adf69ae4bf8e517fd63976d7665183bba6c244e35e8cd4567dd8fb0e5", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 21, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 21, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-121bebd6e4df9a0d9d066474", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:14Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "8b8c4cc8e6f1a21fedee4bf0743c9c03e454b50f5eaba0e3760416d7fe0a74ec", "source_snapshot_id": "source-4efe4ecf3ebf08d338a763a5", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1510}
{"after": {"end": 22, "start": 0, "text": "Merz Therapeutics GmbH", "truncated": false}, "after_length": 22, "after_sha256": "059f049c7d0846aaadcf2573280d52110f302d4ecc7b38debd004571cd1e9d5e", "annex": "IIIA", "before": {"end": 35, "start": 0, "text": "Acorda Therapeutics Ireland Limited", "truncated": false}, "before_length": 35, "before_sha256": "d94d3153d193ed26567f2b4ed48df016d81c534e7c0cb1a6655a63f0083383ff", "change_kind": "content", "change_operations": [{"after_end": 2, "after_start": 0, "before_end": 3, "before_start": 0, "kind": "replace"}, {"after_end": 4, "after_start": 3, "before_end": 6, "before_start": 4, "kind": "replace"}, {"after_end": 19, "after_start": 18, "before_end": 30, "before_start": 20, "kind": "replace"}, {"after_end": 22, "after_start": 20, "before_end": 35, "before_start": 31, "kind": "replace"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 19, "chars_inserted": 6}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-121df666116c050b5851dd01", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002097", "medicine_name": "Fampyra", "medicine_slug": "fampyra", "observed_at": "2026-10-12T19:15:51Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "d9fe8aaaa611a84801d6308b13685258b5248df9022536697939afdf66fc1719", "source_snapshot_id": "source-ff8e0599077f0d01044dc867", "source_updated_at": "2025-08-21", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/fampyra-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 892}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 14, "start": 0, "text": "Irlande/Irland", "truncated": false}, "before_length": 14, "before_sha256": "b273d331b1c063fa0e68d467f1babcfdd0f9d8054c6ea3f570cdc268ea454e91", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 14, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 14, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-1263939c081013855f73ba10", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002097", "medicine_name": "Fampyra", "medicine_slug": "fampyra", "observed_at": "2026-10-12T19:16:07Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "a0c3ba8d58d6a43a809ecc3d142a78b10c2bd7f0b9f3a3553df2617d87daec1f", "source_snapshot_id": "source-c7a810dd21f94cd2d273f0da", "source_updated_at": "2025-08-21", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/fampyra-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1407}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 18, "start": 0, "text": "Dublin 2, D02 T380", "truncated": false}, "before_length": 18, "before_sha256": "23e6871e7960b0dadc753bc127bbea230cc8308c88b2d33704eb275a3ec1a70d", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 18, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 18, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-1290775a638489cf0ec43b00", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002097", "medicine_name": "Fampyra", "medicine_slug": "fampyra", "observed_at": "2026-10-12T19:15:51Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "d9fe8aaaa611a84801d6308b13685258b5248df9022536697939afdf66fc1719", "source_snapshot_id": "source-ff8e0599077f0d01044dc867", "source_updated_at": "2025-08-21", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/fampyra-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1600}
{"after": {"end": 23, "start": 0, "text": "info@euroceptpharma.com", "truncated": false}, "after_length": 23, "after_sha256": "9297cc5acdcc837f054116992765943f7907937507b2564a99ea1327a00ac0e6", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 23, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 23}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-12ef73ff26e66d244df5e80d", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:14Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "8b8c4cc8e6f1a21fedee4bf0743c9c03e454b50f5eaba0e3760416d7fe0a74ec", "source_snapshot_id": "source-4efe4ecf3ebf08d338a763a5", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1560}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 16, "start": 0, "text": "Extrovis EU Ltd.", "truncated": false}, "before_length": 16, "before_sha256": "f462ad48e7aef0bc82148ce088af1897d99ed86993128f30d506b27d3108a929", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 16, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 16, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-130366037b56ce284de98358", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/006047", "medicine_name": "Lacosamide Adroiq", "medicine_slug": "lacosamide-adroiq", "observed_at": "2026-10-12T19:07:59Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "cc83d966059d42856d0211a4f256b29b20d43593865704d6a9315aeb694f3c76", "source_snapshot_id": "source-896abba1d8391c918345d46b", "source_updated_at": "2025-09-25", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/lacosamide-adroiq-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1755}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 21, "start": 0, "text": "info@lucanepharma.com", "truncated": false}, "before_length": 21, "before_sha256": "44fd39e5fb919cb3d680fa630da23b49238fec29159c509f3622f272bb41c7c6", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 21, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 21, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-135b895f6079511e37e970aa", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:19Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "77586d0bea0858214b43b86e91abc2d2711733b96959ead5ed0b5ecbd8ed888a", "source_snapshot_id": "source-85d476f9ad959cc117ca8f1f", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1403}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIB", "before": {"end": 16, "start": 0, "text": "Extrovis EU Ltd.", "truncated": false}, "before_length": 16, "before_sha256": "f462ad48e7aef0bc82148ce088af1897d99ed86993128f30d506b27d3108a929", "change_kind": "unassigned", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 16, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 16, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-136a2eff54af7dcf6d225b3d", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/006047", "medicine_name": "Lacosamide Adroiq", "medicine_slug": "lacosamide-adroiq", "observed_at": "2026-10-12T19:07:56Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "", "section_type": "unassigned", "source_provider": "European Medicines Agency", "source_sha256": "0578c53a5e1c785c4d9d4dc0dabae49dbfa89e237aa571556bee548c3f9cf4d5", "source_snapshot_id": "source-64831dec5ebf55535e19d91b", "source_updated_at": "2025-09-25", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/lacosamide-adroiq-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1958}
{"after": {"end": 23, "start": 0, "text": "60318 Frankfurt am Main", "truncated": false}, "after_length": 23, "after_sha256": "24c3191b5088b20c209c4387a8127297e54c776e161d305c9e57956a13b7cbbe", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 23, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 23}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-13703dc20b08a837b83d29db", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002097", "medicine_name": "Fampyra", "medicine_slug": "fampyra", "observed_at": "2026-10-12T19:16:07Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "a0c3ba8d58d6a43a809ecc3d142a78b10c2bd7f0b9f3a3553df2617d87daec1f", "source_snapshot_id": "source-c7a810dd21f94cd2d273f0da", "source_updated_at": "2025-08-21", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/fampyra-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1490}
{"after": {"end": 26, "start": 0, "text": "Eckenheimer Landstraße 100", "truncated": false}, "after_length": 26, "after_sha256": "fdce1a9bd200c5ddd476c1ea5676b9ffbbea723f7353ad6fbc1fe019dcb86c07", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 26, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 26}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-13eb622a7d93ec0fe86fc2cc", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002097", "medicine_name": "Fampyra", "medicine_slug": "fampyra", "observed_at": "2026-10-12T19:15:51Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "d9fe8aaaa611a84801d6308b13685258b5248df9022536697939afdf66fc1719", "source_snapshot_id": "source-ff8e0599077f0d01044dc867", "source_updated_at": "2025-08-21", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/fampyra-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1412}
{"after": {"end": 25, "start": 0, "text": "Tjoapack Netherlands B.V.", "truncated": false}, "after_length": 25, "after_sha256": "d61d4c5e6087155ec7a92a5c2e9e15aa7274bf924f4aaff549001249105e3be2", "annex": "II", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 25, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 25}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-143d88403d6d9cae80e5da7a", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/000980", "medicine_name": "Samsca", "medicine_slug": "samsca", "observed_at": "2026-10-12T13:28:23Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "conditions", "section_type": "conditions", "source_provider": "European Medicines Agency", "source_sha256": "b92d73a758b8976c4438a072d544f0d6c603112c90dfc9c084d362ce62419257", "source_snapshot_id": "source-15b8b5681aba542ec1668c0b", "source_updated_at": "2026-08-20", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/samsca-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 552}
{"after": {"end": 22, "start": 0, "text": "Merz Therapeutics GmbH", "truncated": false}, "after_length": 22, "after_sha256": "059f049c7d0846aaadcf2573280d52110f302d4ecc7b38debd004571cd1e9d5e", "annex": "IIIA", "before": {"end": 35, "start": 0, "text": "Acorda Therapeutics Ireland Limited", "truncated": false}, "before_length": 35, "before_sha256": "d94d3153d193ed26567f2b4ed48df016d81c534e7c0cb1a6655a63f0083383ff", "change_kind": "content", "change_operations": [{"after_end": 2, "after_start": 0, "before_end": 3, "before_start": 0, "kind": "replace"}, {"after_end": 4, "after_start": 3, "before_end": 6, "before_start": 4, "kind": "replace"}, {"after_end": 19, "after_start": 18, "before_end": 30, "before_start": 20, "kind": "replace"}, {"after_end": 22, "after_start": 20, "before_end": 35, "before_start": 31, "kind": "replace"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 19, "chars_inserted": 6}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-143f5115e29d8505c5cfb1ff", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002097", "medicine_name": "Fampyra", "medicine_slug": "fampyra", "observed_at": "2026-10-12T19:15:51Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "d9fe8aaaa611a84801d6308b13685258b5248df9022536697939afdf66fc1719", "source_snapshot_id": "source-ff8e0599077f0d01044dc867", "source_updated_at": "2025-08-21", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/fampyra-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1615}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "I", "before": {"end": 22, "start": 0, "text": "PAION Deutschland GmbH", "truncated": false}, "before_length": 22, "before_sha256": "695a7a774aacd3b6e919ed980dbfb2ee37bbe6099af551312782cc722dbb2b31", "change_kind": "administrative", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 22, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 22, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-146f388f04403f521107634b", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/005246", "medicine_name": "Byfavo", "medicine_slug": "byfavo", "observed_at": "2026-10-12T13:28:14Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "7", "section_type": "administrative", "source_provider": "European Medicines Agency", "source_sha256": "92a178ceb705631219efa40b1d0da73ebe6dfa866bc1b24d7e4dab9ded8a6861", "source_snapshot_id": "source-d485be5d9060fd557be910b2", "source_updated_at": "2026-08-26", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/byfavo-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 2621}
{"after": {"end": 23, "start": 0, "text": "info@euroceptpharma.com", "truncated": false}, "after_length": 23, "after_sha256": "9297cc5acdcc837f054116992765943f7907937507b2564a99ea1327a00ac0e6", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 23, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 23}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-1485b0435bbc830491826c82", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:14Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "8b8c4cc8e6f1a21fedee4bf0743c9c03e454b50f5eaba0e3760416d7fe0a74ec", "source_snapshot_id": "source-4efe4ecf3ebf08d338a763a5", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1876}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 27, "start": 0, "text": "(Eurocept International BV)", "truncated": false}, "before_length": 27, "before_sha256": "e6cf9b20aaa466e53ad0d393512ca75931e13e488321e3be6f3e4f8b600970c8", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 27, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 27, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-14a283dfac69c8e8e4ee8ae3", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:14Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "8b8c4cc8e6f1a21fedee4bf0743c9c03e454b50f5eaba0e3760416d7fe0a74ec", "source_snapshot_id": "source-4efe4ecf3ebf08d338a763a5", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 2011}
{"after": {"end": 8, "start": 0, "text": "ANNEX IV", "truncated": false}, "after_length": 8, "after_sha256": "29972ab77d4b1358a0bdb16d438bcde59007e95356d1f5f9ee2f7045597f9574", "annex": "IV", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 8, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 8}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-14bb5d0f820c697fcd2da058", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/000554", "medicine_name": "Emselex", "medicine_slug": "emselex", "observed_at": "2026-10-12T19:12:04Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "conditions", "section_type": "conditions", "source_provider": "European Medicines Agency", "source_sha256": "4f2565612bc728ec67b7f9c0cd5799ef2c594911c76f323aef8bf6a85adde245", "source_snapshot_id": "source-1fda25b331eb198b8b93feb3", "source_updated_at": "2025-09-15", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/emselex-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 2061}
{"after": {"end": 25, "start": 0, "text": "Eurocept International BV", "truncated": false}, "after_length": 25, "after_sha256": "b17bd89b3cf285c986a6070d0d67f5326dd5c1f08a70834c296c6c820f9e7505", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 25, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 25}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-14ca6f10a05f7ff8543d45c4", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:19Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "77586d0bea0858214b43b86e91abc2d2711733b96959ead5ed0b5ecbd8ed888a", "source_snapshot_id": "source-85d476f9ad959cc117ca8f1f", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1935}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 22, "start": 0, "text": "Tel : +31 35 528 39 57", "truncated": false}, "before_length": 22, "before_sha256": "7bb8afadf5dee15b4f4e1219e333b993040f0848bccea58b1141990fffb82aa1", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 22, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 22, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-14fa130f4c60909890f36a32", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:19Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "77586d0bea0858214b43b86e91abc2d2711733b96959ead5ed0b5ecbd8ed888a", "source_snapshot_id": "source-85d476f9ad959cc117ca8f1f", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1981}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 18, "start": 0, "text": "Dublin 2, D02 T380", "truncated": false}, "before_length": 18, "before_sha256": "23e6871e7960b0dadc753bc127bbea230cc8308c88b2d33704eb275a3ec1a70d", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 18, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 18, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-151c3a58df752f28cb89f38b", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002097", "medicine_name": "Fampyra", "medicine_slug": "fampyra", "observed_at": "2026-10-12T19:15:51Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "d9fe8aaaa611a84801d6308b13685258b5248df9022536697939afdf66fc1719", "source_snapshot_id": "source-ff8e0599077f0d01044dc867", "source_updated_at": "2025-08-21", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/fampyra-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1563}
{"after": {"end": 23, "start": 0, "text": "info@euroceptpharma.com", "truncated": false}, "after_length": 23, "after_sha256": "9297cc5acdcc837f054116992765943f7907937507b2564a99ea1327a00ac0e6", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 23, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 23}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-1520b1248e1106b1e4a58137", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:19Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "77586d0bea0858214b43b86e91abc2d2711733b96959ead5ed0b5ecbd8ed888a", "source_snapshot_id": "source-85d476f9ad959cc117ca8f1f", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1526}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 21, "start": 0, "text": "Tel: +31 35 528 39 57", "truncated": false}, "before_length": 21, "before_sha256": "7baf6601f41e49e470f803fdd4e755a86efa38be423317c000ed79963ebdd213", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 21, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 21, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-1534f08b8ff869a49cf6cf09", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:14Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "8b8c4cc8e6f1a21fedee4bf0743c9c03e454b50f5eaba0e3760416d7fe0a74ec", "source_snapshot_id": "source-4efe4ecf3ebf08d338a763a5", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1913}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 38, "start": 0, "text": "Otsuka Pharmaceutical Netherlands B.V.", "truncated": false}, "before_length": 38, "before_sha256": "2891d7989f773ce0b34a3e835488071e6ffd7e94478e61a5899dcf87bd99c38c", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 38, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 38, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-1542fd5bc0b4ad63265338cb", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/000980", "medicine_name": "Samsca", "medicine_slug": "samsca", "observed_at": "2026-10-12T13:28:24Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "3080d919225c2a98f20aec84d5803b3fde6e1b64f323055c46d098625f4ad301", "source_snapshot_id": "source-e05739a15a0532954ee45dd4", "source_updated_at": "2026-08-20", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/samsca-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1281}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 25, "start": 0, "text": "Tél/Tel: + 33 153 868 750", "truncated": false}, "before_length": 25, "before_sha256": "e5f8e4aadc105f123b1cb253b9afe1e362181b7777e0b94626adda3e9db7ed2e", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 25, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 25, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-1547ee1ee833f412acfad194", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:14Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "8b8c4cc8e6f1a21fedee4bf0743c9c03e454b50f5eaba0e3760416d7fe0a74ec", "source_snapshot_id": "source-4efe4ecf3ebf08d338a763a5", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1439}
{"after": {"end": 10, "start": 0, "text": "Dux pharma", "truncated": false}, "after_length": 10, "after_sha256": "dc883eef1df083eb86278145e5f12f39a539e9c6480843f1755b844cc69019ee", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 10, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 10}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-15501da598ff9462b7f117eb", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:14Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "8b8c4cc8e6f1a21fedee4bf0743c9c03e454b50f5eaba0e3760416d7fe0a74ec", "source_snapshot_id": "source-4efe4ecf3ebf08d338a763a5", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1548}
{"after": {"end": 13, "start": 0, "text": "Bredaseweg 63", "truncated": false}, "after_length": 13, "after_sha256": "a37bbd239b649e23c8960a4ab83fa25cba872a2c2e743860ae8149ff61815928", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 13, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 13}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-1558d72e5643c43d7f6f4243", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002097", "medicine_name": "Fampyra", "medicine_slug": "fampyra", "observed_at": "2026-10-12T19:16:07Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "a0c3ba8d58d6a43a809ecc3d142a78b10c2bd7f0b9f3a3553df2617d87daec1f", "source_snapshot_id": "source-c7a810dd21f94cd2d273f0da", "source_updated_at": "2025-08-21", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/fampyra-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1461}
{"after": {"end": 207, "start": 0, "text": "Contact your doctor or pharmacist immediately if you experience any of the following symptoms while taking Arava: unexplained muscle pain, tenderness (soreness when the muscle is pressed) or muscle weakness.", "truncated": false}, "after_length": 207, "after_sha256": "e54adb526f1c998d8db84ee9ca0359d3dde4372f14416f24c515365e96d1c41c", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 207, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 207}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-157531137c4094a29c5c5863", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/000235", "medicine_name": "Arava", "medicine_slug": "arava", "observed_at": "2026-10-12T13:27:58Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 3, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "2efff7967e2237bf8343431eef5e08b56c2441eb8a691a90c64b2635109fd697", "source_snapshot_id": "source-08b4eba1f67d2654148f41c4", "source_updated_at": "2026-09-07", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/arava-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 3042}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 16, "start": 0, "text": "Extrovis EU Ltd.", "truncated": false}, "before_length": 16, "before_sha256": "f462ad48e7aef0bc82148ce088af1897d99ed86993128f30d506b27d3108a929", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 16, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 16, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-15760e6cbb3a9975e40b8cba", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/006047", "medicine_name": "Lacosamide Adroiq", "medicine_slug": "lacosamide-adroiq", "observed_at": "2026-10-12T19:07:59Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "cc83d966059d42856d0211a4f256b29b20d43593865704d6a9315aeb694f3c76", "source_snapshot_id": "source-896abba1d8391c918345d46b", "source_updated_at": "2025-09-25", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/lacosamide-adroiq-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1749}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 18, "start": 0, "text": "Dublin 2, D02 T380", "truncated": false}, "before_length": 18, "before_sha256": "23e6871e7960b0dadc753bc127bbea230cc8308c88b2d33704eb275a3ec1a70d", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 18, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 18, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-159d1df618a059e12a080868", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002097", "medicine_name": "Fampyra", "medicine_slug": "fampyra", "observed_at": "2026-10-12T19:16:07Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "a0c3ba8d58d6a43a809ecc3d142a78b10c2bd7f0b9f3a3553df2617d87daec1f", "source_snapshot_id": "source-c7a810dd21f94cd2d273f0da", "source_updated_at": "2025-08-21", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/fampyra-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1035}
{"after": {"end": 15, "start": 0, "text": "The Netherlands", "truncated": false}, "after_length": 15, "after_sha256": "91729ff7107ee698fe168dc62d5b2020678fcfcf55b4ea9065982ce1d071ba31", "annex": "I", "before": {"end": 50, "start": 0, "text": "Papendorpseweg 83, 3528 BJ Utrecht The Netherlands", "truncated": false}, "before_length": 50, "before_sha256": "5d621ef45df9c1911e6b63f15edb513d80fad3ee63f11fe58a733f65b67cd3cd", "change_kind": "administrative", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 35, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 35, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-159d56657e0b557dbddc4fba", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/001021", "medicine_name": "Adcirca (previously Tadalafil Lilly)", "medicine_slug": "adcirca-previously-tadalafil-lilly", "observed_at": "2026-10-12T19:02:42Z", "pipeline_version": "2.0.0", "presentation_label": "ADCIRCA 2 mg/mL oral suspension", "presentation_occurrence": 2, "presentation_status": "heading_extracted_unverified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "7", "section_type": "administrative", "source_provider": "European Medicines Agency", "source_sha256": "43438c8e53504a78747a8ff36049250fee294557f3a8b0e3acb80f71ad43ebc0", "source_snapshot_id": "source-2305a67bd1e393ee340bb8e4", "source_updated_at": "2026-01-28", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/adcirca-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1229}
{"after": {"end": 25, "start": 0, "text": "Gustav III:s Boulevard 32", "truncated": false}, "after_length": 25, "after_sha256": "bba3ec2bf3d09014ee723cdd39b8fa83a1dc3705ce0797ed375b3af7c8be027c", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 25, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 25}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-15ba2f323895d59533a3c779", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002097", "medicine_name": "Fampyra", "medicine_slug": "fampyra", "observed_at": "2026-10-12T19:15:51Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "d9fe8aaaa611a84801d6308b13685258b5248df9022536697939afdf66fc1719", "source_snapshot_id": "source-ff8e0599077f0d01044dc867", "source_updated_at": "2025-08-21", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/fampyra-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1592}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 5, "start": 0, "text": "Irska", "truncated": false}, "before_length": 5, "before_sha256": "cdf0cd77f332e6161d4630ec3fed3ecf30c6b67caf2a1d2468282a1045c12636", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 5, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 5, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-15f5c295d32fb7fa88860f15", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002097", "medicine_name": "Fampyra", "medicine_slug": "fampyra", "observed_at": "2026-10-12T19:16:07Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "a0c3ba8d58d6a43a809ecc3d142a78b10c2bd7f0b9f3a3553df2617d87daec1f", "source_snapshot_id": "source-c7a810dd21f94cd2d273f0da", "source_updated_at": "2025-08-21", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/fampyra-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1532}
{"after": {"end": 333, "start": 0, "text": "Le profil général de tolérance de SPRYCEL dans la population pédiatrique atteinte de LMC Ph+ PC était similaire à celui de la population adulte, indépendamment de la formulation. Parmi les 130 sujets pédiatriques atteints de LMC PC traités par SPRYCEL, 2 (1,5 %) ont présenté des effets indésirables entraînant l’arrêt du traitement.", "truncated": false}, "after_length": 333, "after_sha256": "68755e2845726297f06d0075f534ad99061e27d0e5fe90f22406927735b118d2", "annex": "I", "before": {"end": 505, "start": 0, "text": "Le profil général de tolérance de SPRYCEL dans la population pédiatrique atteinte de LMC Ph+ PC était similaire à celui de la population adulte, indépendamment de la formulation, à l’exception de l’absence de cas rapporté d’épanchement péricardique, d’épanchement pleural, d’œdème pulmonaire ou hypertension pulmonaire dans la population pédiatrique. Parmi les 130 sujets pédiatriques atteints de LMC PC traités par SPRYCEL, 2 (1,5 %) ont présenté des effets indésirables entraînant l’arrêt du traitement.", "truncated": false}, "before_length": 505, "before_sha256": "cebe88c4ef21c9d6fe12ec355784573c5e8d19d697b4eda5f3af2c815393eb2e", "change_kind": "content", "change_operations": [{"after_end": 177, "after_start": 177, "before_end": 349, "before_start": 177, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": true, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 172, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-160b0f683fa01303b4cccd01", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/000709", "medicine_name": "Sprycel", "medicine_slug": "sprycel", "observed_at": "2026-10-12T13:27:38Z", "pipeline_version": "2.0.0", "presentation_label": "SPRYCEL 10 mg/mL poudre pour suspension buvable", "presentation_occurrence": 2, "presentation_status": "heading_extracted_unverified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "4.8", "section_type": "adverse_reactions", "source_provider": "European Medicines Agency", "source_sha256": "f19afb6c99c9f6c4da575a1ec1ad2116d41e1ee33bed1a9a3406fd820f8970ff", "source_snapshot_id": "source-753ed8ea69e2a319805bb49a", "source_updated_at": "2026-10-02", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/sprycel-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 2176}
{"after": {"end": 236, "start": 0, "text": "Ce document constitue les informations sur le produit approuvées pour Sprycel, les modifications apportées depuis la procédure précédente qui ont une incidence sur les informations sur le produit (VR/0000320681) étant mises en évidence.", "truncated": false}, "after_length": 236, "after_sha256": "ac6c3e9719e39f4f8e121383aadd3d4261b15d9a03dd066fbd0f386ee01604dc", "annex": "", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "unassigned", "change_operations": [{"after_end": 236, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 236}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-160df145a68eaa652f59bea7", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/000709", "medicine_name": "Sprycel", "medicine_slug": "sprycel", "observed_at": "2026-10-12T13:27:38Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": null, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "", "section_type": "unassigned", "source_provider": "European Medicines Agency", "source_sha256": "f19afb6c99c9f6c4da575a1ec1ad2116d41e1ee33bed1a9a3406fd820f8970ff", "source_snapshot_id": "source-753ed8ea69e2a319805bb49a", "source_updated_at": "2026-10-02", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/sprycel-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 0}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 13, "start": 0, "text": "Lucane Pharma", "truncated": false}, "before_length": 13, "before_sha256": "e338afdb64acf1a6e2083a50318853589248451dd3aa707181ba02641a8521e8", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 13, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 13, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-1610217d67ef9a137fcd6c71", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:14Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "8b8c4cc8e6f1a21fedee4bf0743c9c03e454b50f5eaba0e3760416d7fe0a74ec", "source_snapshot_id": "source-4efe4ecf3ebf08d338a763a5", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1911}
{"after": {"end": 30, "start": 0, "text": "Troubles musculo-squelettiques", "truncated": false}, "after_length": 30, "after_sha256": "19f3f11cced96282f29a83fb37b4e112d045fd9d5612609940e426e03f7708ab", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 30, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 30}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-1624037f636b47559f6829b6", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/000235", "medicine_name": "Arava", "medicine_slug": "arava", "observed_at": "2026-10-12T13:28:00Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": null, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "98b73c5c6b1e5009c9d048f8f11257f3a8407759fd25a4c8d5ef5c611519e916", "source_snapshot_id": "source-4b7ea3b78addea82376b3432", "source_updated_at": "2026-09-07", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/arava-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 3463}
{"after": {"end": 153, "start": 0, "text": "Des cas de maladies musculaires inflammatoires et de dégradation musculaire (myosite et rhabdomyolyse) ont été rapportés chez des patients prenant Arava.", "truncated": false}, "after_length": 153, "after_sha256": "bf44af41f5e86d44b1efb868b810995f7e8139f5f6be57cd1a49b92c73815dce", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 153, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 153}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-164a8398ccd03e4f20246a7c", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/000235", "medicine_name": "Arava", "medicine_slug": "arava", "observed_at": "2026-10-12T13:28:00Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": null, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "98b73c5c6b1e5009c9d048f8f11257f3a8407759fd25a4c8d5ef5c611519e916", "source_snapshot_id": "source-4b7ea3b78addea82376b3432", "source_updated_at": "2026-09-07", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/arava-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 3464}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "II", "before": {"end": 16, "start": 0, "text": "6336 Langkampfen", "truncated": false}, "before_length": 16, "before_sha256": "b9f18afdf777127453e8278d60cb7f5e3f22a29760be53f0595ada54a24f6ad2", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 16, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 16, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-165eed4f89a8f1207f9b7c60", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/000725", "medicine_name": "Binocrit", "medicine_slug": "binocrit", "observed_at": "2026-10-12T19:28:20Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "conditions", "section_type": "conditions", "source_provider": "European Medicines Agency", "source_sha256": "b2bb40c100cab3babee14bbe20cc7718cb73ac1bbb3971dfd487c4f10a0e6478", "source_snapshot_id": "source-b97c331d23a7a0f19aebfb61", "source_updated_at": "2025-07-11", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/binocrit-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1199}
{"after": {"end": 28, "start": 0, "text": "InfoDeutschland@dipharma.com", "truncated": false}, "after_length": 28, "after_sha256": "f5ed16f98f15b7236207edade83fdde3fb32cec02f927aaba23223b9f6077f21", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 28, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 28}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-1668d1fcb901d471a87b0d2e", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:14Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "8b8c4cc8e6f1a21fedee4bf0743c9c03e454b50f5eaba0e3760416d7fe0a74ec", "source_snapshot_id": "source-4efe4ecf3ebf08d338a763a5", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1493}
{"after": {"end": 248, "start": 0, "text": "Ce document constitue les informations sur le produit approuvées pour Pheburane, les modifications apportées depuis la procédure précédente qui ont une incidence sur les informations sur le produit (EMEA/H/C/002500/IB/0041) étant mises en évidence.", "truncated": false}, "after_length": 248, "after_sha256": "52e4d83933a479a57f5bf98ec350ad9ac02ceb18b1af99214c02b5f4991aa851", "annex": "", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "unassigned", "change_operations": [{"after_end": 248, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 248}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-166b006d3ff0ebc95659dd64", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:19Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": null, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "", "section_type": "unassigned", "source_provider": "European Medicines Agency", "source_sha256": "77586d0bea0858214b43b86e91abc2d2711733b96959ead5ed0b5ecbd8ed888a", "source_snapshot_id": "source-85d476f9ad959cc117ca8f1f", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 0}
{"after": {"end": 26, "start": 0, "text": "Eckenheimer Landstraße 100", "truncated": false}, "after_length": 26, "after_sha256": "fdce1a9bd200c5ddd476c1ea5676b9ffbbea723f7353ad6fbc1fe019dcb86c07", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 26, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 26}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-16924158a5e49d9a750049c5", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002097", "medicine_name": "Fampyra", "medicine_slug": "fampyra", "observed_at": "2026-10-12T19:16:07Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "a0c3ba8d58d6a43a809ecc3d142a78b10c2bd7f0b9f3a3553df2617d87daec1f", "source_snapshot_id": "source-c7a810dd21f94cd2d273f0da", "source_updated_at": "2025-08-21", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/fampyra-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1388}
{"after": {"end": 23, "start": 0, "text": "60318 Frankfurt am Main", "truncated": false}, "after_length": 23, "after_sha256": "24c3191b5088b20c209c4387a8127297e54c776e161d305c9e57956a13b7cbbe", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 23, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 23}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-16bf2044669cb48c0884e7cf", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002097", "medicine_name": "Fampyra", "medicine_slug": "fampyra", "observed_at": "2026-10-12T19:16:07Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "a0c3ba8d58d6a43a809ecc3d142a78b10c2bd7f0b9f3a3553df2617d87daec1f", "source_snapshot_id": "source-c7a810dd21f94cd2d273f0da", "source_updated_at": "2025-08-21", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/fampyra-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1609}
{"after": {"end": 9, "start": 0, "text": "Allemagne", "truncated": false}, "after_length": 9, "after_sha256": "6b58dbd6a994339b48d8446597da22402857b3409613459c7e3a293788fbe66a", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 9, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 9}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-16ca7e229c65c7edb50f84ad", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002097", "medicine_name": "Fampyra", "medicine_slug": "fampyra", "observed_at": "2026-10-12T19:16:07Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "a0c3ba8d58d6a43a809ecc3d142a78b10c2bd7f0b9f3a3553df2617d87daec1f", "source_snapshot_id": "source-c7a810dd21f94cd2d273f0da", "source_updated_at": "2025-08-21", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/fampyra-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1039}
{"after": {"end": 11, "start": 0, "text": "Németország", "truncated": false}, "after_length": 11, "after_sha256": "b5bbb24c748b70690808a17e5285ee60570c7732e995787c311f673f9c79e808", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 11, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 11}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-176afe777635f9ff60b17772", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002097", "medicine_name": "Fampyra", "medicine_slug": "fampyra", "observed_at": "2026-10-12T19:15:51Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "d9fe8aaaa611a84801d6308b13685258b5248df9022536697939afdf66fc1719", "source_snapshot_id": "source-ff8e0599077f0d01044dc867", "source_updated_at": "2025-08-21", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/fampyra-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1424}
{"after": {"end": 26, "start": 0, "text": "Eckenheimer Landstraße 100", "truncated": false}, "after_length": 26, "after_sha256": "fdce1a9bd200c5ddd476c1ea5676b9ffbbea723f7353ad6fbc1fe019dcb86c07", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 26, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 26}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-1775152a9520385984f916d4", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002097", "medicine_name": "Fampyra", "medicine_slug": "fampyra", "observed_at": "2026-10-12T19:15:51Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "d9fe8aaaa611a84801d6308b13685258b5248df9022536697939afdf66fc1719", "source_snapshot_id": "source-ff8e0599077f0d01044dc867", "source_updated_at": "2025-08-21", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/fampyra-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1575}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 20, "start": 0, "text": "Tel: +41 41 740 1120", "truncated": false}, "before_length": 20, "before_sha256": "86dec7eb8f60d9684a01122d4eab78962ed99ccf72a86d621931a71c30177300", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 20, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 20, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-177b5be8e09c7651c24bc840", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/006047", "medicine_name": "Lacosamide Adroiq", "medicine_slug": "lacosamide-adroiq", "observed_at": "2026-10-12T19:07:59Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "cc83d966059d42856d0211a4f256b29b20d43593865704d6a9315aeb694f3c76", "source_snapshot_id": "source-896abba1d8391c918345d46b", "source_updated_at": "2025-09-25", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/lacosamide-adroiq-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1861}
{"after": {"end": 15, "start": 0, "text": "The Netherlands", "truncated": false}, "after_length": 15, "after_sha256": "91729ff7107ee698fe168dc62d5b2020678fcfcf55b4ea9065982ce1d071ba31", "annex": "IIIA", "before": {"end": 50, "start": 0, "text": "Papendorpseweg 83, 3528 BJ Utrecht The Netherlands", "truncated": false}, "before_length": 50, "before_sha256": "5d621ef45df9c1911e6b63f15edb513d80fad3ee63f11fe58a733f65b67cd3cd", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 35, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 35, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-178a8f9e723795d44443a8c9", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/001021", "medicine_name": "Adcirca (previously Tadalafil Lilly)", "medicine_slug": "adcirca-previously-tadalafil-lilly", "observed_at": "2026-10-12T19:02:42Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "43438c8e53504a78747a8ff36049250fee294557f3a8b0e3acb80f71ad43ebc0", "source_snapshot_id": "source-2305a67bd1e393ee340bb8e4", "source_updated_at": "2026-01-28", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/adcirca-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1683}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 21, "start": 0, "text": "info@lucanepharma.com", "truncated": false}, "before_length": 21, "before_sha256": "44fd39e5fb919cb3d680fa630da23b49238fec29159c509f3622f272bb41c7c6", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 21, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 21, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-17b5cecfd61aa980faf5a180", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:19Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "77586d0bea0858214b43b86e91abc2d2711733b96959ead5ed0b5ecbd8ed888a", "source_snapshot_id": "source-85d476f9ad959cc117ca8f1f", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1893}
{"after": {"end": 246, "start": 0, "text": "Contactez immédiatement votre médecin ou votre pharmacien si vous ressentez l'un des symptômes suivants pendant votre traitement par Arava : douleurs musculaires inexpliquées, sensibilité (douleur à la pression du muscle) ou faiblesse musculaire.", "truncated": false}, "after_length": 246, "after_sha256": "46d67b9fd5b140e533e3a7770bea1ef3e421bd3a192d785a859402c0b3ca1fc6", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 246, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 246}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-17f1dc453e5aa06521a5a3d0", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/000235", "medicine_name": "Arava", "medicine_slug": "arava", "observed_at": "2026-10-12T13:28:00Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": null, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "98b73c5c6b1e5009c9d048f8f11257f3a8407759fd25a4c8d5ef5c611519e916", "source_snapshot_id": "source-4b7ea3b78addea82376b3432", "source_updated_at": "2026-09-07", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/arava-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 2702}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 27, "start": 0, "text": "(Eurocept International BV)", "truncated": false}, "before_length": 27, "before_sha256": "e6cf9b20aaa466e53ad0d393512ca75931e13e488321e3be6f3e4f8b600970c8", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 27, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 27, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-1809250e75ff708ecbc9ca75", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:19Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "77586d0bea0858214b43b86e91abc2d2711733b96959ead5ed0b5ecbd8ed888a", "source_snapshot_id": "source-85d476f9ad959cc117ca8f1f", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1899}
{"after": {"end": 25, "start": 0, "text": "Eurocept International BV", "truncated": false}, "after_length": 25, "after_sha256": "b17bd89b3cf285c986a6070d0d67f5326dd5c1f08a70834c296c6c820f9e7505", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 25, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 25}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-18384f3b7e095bbcb8b2f2be", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:19Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "77586d0bea0858214b43b86e91abc2d2711733b96959ead5ed0b5ecbd8ed888a", "source_snapshot_id": "source-85d476f9ad959cc117ca8f1f", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1399}
{"after": {"end": 233, "start": 0, "text": "Les autres composants sont l’hydrogénophosphate de calcium (anhydre), l’hypromellose, le stéarate de magnésium, le polyéthylène glycol, le talc, le dioxyde de titane (E171), l’oxyde de fer rouge (E172) et l’oxyde de fer jaune (E172).", "truncated": false}, "after_length": 233, "after_sha256": "4bda9a23afb6d23f117a2654b18b9c302210f74a44f4f9dd47663b6f584b7a83", "annex": "IIIA", "before": {"end": 233, "start": 0, "text": "Les autres composants sont l'hydrogénophosphate de calcium (anhydre), l'hypromellose, le stéarate de magnésium, le polyéthylène glycol, le talc, le dioxyde de titane (E171), l’oxyde de fer rouge (E172) et l’oxyde de fer jaune (E172).", "truncated": false}, "before_length": 233, "before_sha256": "92ca7daf2d8ed7ad43bf73e3d6c8ede3fc19521ff45a6029a96c46340b68c74d", "change_kind": "content", "change_operations": [{"after_end": 29, "after_start": 28, "before_end": 29, "before_start": 28, "kind": "replace"}, {"after_end": 72, "after_start": 71, "before_end": 72, "before_start": 71, "kind": "replace"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 2, "chars_inserted": 2}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-1859187a5187e2842cd9cf88", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/000554", "medicine_name": "Emselex", "medicine_slug": "emselex", "observed_at": "2026-10-12T19:12:07Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": null, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "9a4f1d7e260c7b80eaf397503623b63302e5945b579e9612177835e07c4ab888", "source_snapshot_id": "source-3aac7bf42b99529f25ac013b", "source_updated_at": "2025-09-15", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/emselex-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 2005}
{"after": {"end": 22, "start": 0, "text": "Tel: +351 21 824 98 76", "truncated": false}, "after_length": 22, "after_sha256": "7c8ecb2e5f42841d3a036da23e786a84794928014737e604cb9ae0cc1a9be439", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 22, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 22}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-1885c7e2f611a6b633790f61", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:14Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "8b8c4cc8e6f1a21fedee4bf0743c9c03e454b50f5eaba0e3760416d7fe0a74ec", "source_snapshot_id": "source-4efe4ecf3ebf08d338a763a5", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1996}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 21, "start": 0, "text": "info@lucanepharma.com", "truncated": false}, "before_length": 21, "before_sha256": "44fd39e5fb919cb3d680fa630da23b49238fec29159c509f3622f272bb41c7c6", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 21, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 21, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-189a2297d8b3f3cf346e1417", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:19Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "77586d0bea0858214b43b86e91abc2d2711733b96959ead5ed0b5ecbd8ed888a", "source_snapshot_id": "source-85d476f9ad959cc117ca8f1f", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1458}
{"after": {"end": 22, "start": 0, "text": "Fréquence indéterminée", "truncated": false}, "after_length": 22, "after_sha256": "9dbca2ea64869864cf27be15cb397d59f7675843792a00e126385e734d3768e0", "annex": "I", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 22, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": true, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 22}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-18ccf21e885a0ba98d78a300", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/000554", "medicine_name": "Emselex", "medicine_slug": "emselex", "observed_at": "2026-10-12T19:12:07Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": null, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "4.8", "section_type": "adverse_reactions", "source_provider": "European Medicines Agency", "source_sha256": "9a4f1d7e260c7b80eaf397503623b63302e5945b579e9612177835e07c4ab888", "source_snapshot_id": "source-3aac7bf42b99529f25ac013b", "source_updated_at": "2025-09-15", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/emselex-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 599}
{"after": {"end": 153, "start": 0, "text": "Des cas de maladies musculaires inflammatoires et de dégradation musculaire (myosite et rhabdomyolyse) ont été rapportés chez des patients prenant Arava.", "truncated": false}, "after_length": 153, "after_sha256": "bf44af41f5e86d44b1efb868b810995f7e8139f5f6be57cd1a49b92c73815dce", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 153, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 153}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-1971ad121ec7fe7d0bcc7753", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/000235", "medicine_name": "Arava", "medicine_slug": "arava", "observed_at": "2026-10-12T13:28:00Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": null, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "98b73c5c6b1e5009c9d048f8f11257f3a8407759fd25a4c8d5ef5c611519e916", "source_snapshot_id": "source-4b7ea3b78addea82376b3432", "source_updated_at": "2026-09-07", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/arava-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 3083}
{"after": {"end": 24, "start": 0, "text": "Tel.: +49 (0) 69 15 03 0", "truncated": false}, "after_length": 24, "after_sha256": "8946964007fee6067df3ceb486bef1ddd3122eb52726a03a5d4fdde280ca2f1c", "annex": "IIIA", "before": {"end": 24, "start": 0, "text": "Tel.: +353 (0)1 231 4609", "truncated": false}, "before_length": 24, "before_sha256": "46e1c7e37b938a7e0c3f9a071d43f9eb30bbe802826026f6c280be3cb250cd4d", "change_kind": "content", "change_operations": [{"after_end": 9, "after_start": 7, "before_end": 10, "before_start": 7, "kind": "replace"}, {"after_end": 17, "after_start": 13, "before_end": 14, "before_start": 14, "kind": "insert"}, {"after_end": 19, "after_start": 18, "before_end": 15, "before_start": 15, "kind": "insert"}, {"after_end": 21, "after_start": 20, "before_end": 17, "before_start": 16, "kind": "replace"}, {"after_end": 22, "after_start": 22, "before_end": 19, "before_start": 18, "kind": "delete"}, {"after_end": 23, "after_start": 23, "before_end": 22, "before_start": 20, "kind": "delete"}, {"after_end": 24, "after_start": 24, "before_end": 24, "before_start": 23, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 8, "chars_inserted": 8}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-19a6496d463fc80e683be24b", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002097", "medicine_name": "Fampyra", "medicine_slug": "fampyra", "observed_at": "2026-10-12T19:16:07Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "a0c3ba8d58d6a43a809ecc3d142a78b10c2bd7f0b9f3a3553df2617d87daec1f", "source_snapshot_id": "source-c7a810dd21f94cd2d273f0da", "source_updated_at": "2025-08-21", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/fampyra-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1513}
{"after": {"end": 25, "start": 0, "text": "Lamia, Schimatari, 32009,", "truncated": false}, "after_length": 25, "after_sha256": "731caa8982d6c36ded24b2c0ae7f96bbe4b52b5f2fe4fdabe022c9e027a41c9e", "annex": "II", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 25, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 25}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-19aec71745dc2c382d1c3f33", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/003984", "medicine_name": "Bortezomib Accord", "medicine_slug": "bortezomib-accord", "observed_at": "2026-10-12T13:47:15Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "conditions", "section_type": "conditions", "source_provider": "European Medicines Agency", "source_sha256": "150a191aaf0a1e169e9d5fa2530f0eccb4e3d46509faf5ec5ee975a2e67788c4", "source_snapshot_id": "source-cba4680b7fbd2c536884abd8", "source_updated_at": "2026-03-25", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/bortezomib-accord-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 3350}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIB", "before": {"end": 15, "start": 0, "text": "pv@extrovis.com", "truncated": false}, "before_length": 15, "before_sha256": "7363f9dc0fbbc5fcd5a6354cf2eb8172b30b6489d496158b7513b9f1a84c3817", "change_kind": "unassigned", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 15, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 15, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-19bbda2859e5fd218e788c4f", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/006047", "medicine_name": "Lacosamide Adroiq", "medicine_slug": "lacosamide-adroiq", "observed_at": "2026-10-12T19:07:56Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "", "section_type": "unassigned", "source_provider": "European Medicines Agency", "source_sha256": "0578c53a5e1c785c4d9d4dc0dabae49dbfa89e237aa571556bee548c3f9cf4d5", "source_snapshot_id": "source-64831dec5ebf55535e19d91b", "source_updated_at": "2025-09-25", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/lacosamide-adroiq-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 2038}
{"after": {"end": 22, "start": 0, "text": "Tel: +31 (0) 762057088", "truncated": false}, "after_length": 22, "after_sha256": "c454b0c9bb138a63ac3390284b6a75f5d68e39351b0aff35e8f0847a98b3625d", "annex": "IIIA", "before": {"end": 23, "start": 0, "text": "Tel: +353 (0)1 231 4609", "truncated": false}, "before_length": 23, "before_sha256": "a115f11f382ef18898b9d956e48603ae236fd1846ce41e8586af99b6dabbfc4d", "change_kind": "content", "change_operations": [{"after_end": 8, "after_start": 7, "before_end": 9, "before_start": 7, "kind": "replace"}, {"after_end": 12, "after_start": 12, "before_end": 14, "before_start": 13, "kind": "delete"}, {"after_end": 15, "after_start": 13, "before_end": 15, "before_start": 15, "kind": "insert"}, {"after_end": 16, "after_start": 16, "before_end": 21, "before_start": 16, "kind": "delete"}, {"after_end": 22, "after_start": 17, "before_end": 23, "before_start": 22, "kind": "replace"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 9, "chars_inserted": 8}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-19f82e2b3ff1af9f7247e5b2", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002097", "medicine_name": "Fampyra", "medicine_slug": "fampyra", "observed_at": "2026-10-12T19:15:51Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "d9fe8aaaa611a84801d6308b13685258b5248df9022536697939afdf66fc1719", "source_snapshot_id": "source-ff8e0599077f0d01044dc867", "source_updated_at": "2025-08-21", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/fampyra-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1458}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "I", "before": {"end": 14, "start": 0, "text": "Heussstraße 25", "truncated": false}, "before_length": 14, "before_sha256": "805584102a210d40b5c8e0e7014cb2d6f4194a7c2ef94da3309e0707eed85073", "change_kind": "administrative", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 14, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 14, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-1b2c3088e6bbfd0f5ddf8123", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/005246", "medicine_name": "Byfavo", "medicine_slug": "byfavo", "observed_at": "2026-10-12T13:28:16Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "7", "section_type": "administrative", "source_provider": "European Medicines Agency", "source_sha256": "61243a969f979f690fe718e414ceaeb66438c1faa31101ba25187d2f9ea662fd", "source_snapshot_id": "source-dd26eb8615d8c18bd80c1f6a", "source_updated_at": "2026-08-26", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/byfavo-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 2710}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 25, "start": 0, "text": "Tél/Tel: + 33 153 868 750", "truncated": false}, "before_length": 25, "before_sha256": "e5f8e4aadc105f123b1cb253b9afe1e362181b7777e0b94626adda3e9db7ed2e", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 25, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 25, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-1b47287f105ba7d24b4d003f", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:14Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "8b8c4cc8e6f1a21fedee4bf0743c9c03e454b50f5eaba0e3760416d7fe0a74ec", "source_snapshot_id": "source-4efe4ecf3ebf08d338a763a5", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1465}
{"after": {"end": 16, "start": 0, "text": "Extrovis EU Kft.", "truncated": false}, "after_length": 16, "after_sha256": "b9216ef80e71e17798dce313e4318f03f37328f225d30ab508b7413813a908e5", "annex": "IIIB", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "unassigned", "change_operations": [{"after_end": 16, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 16}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-1ba06668adf72890943db2f6", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/006047", "medicine_name": "Lacosamide Adroiq", "medicine_slug": "lacosamide-adroiq", "observed_at": "2026-10-12T19:07:56Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "", "section_type": "unassigned", "source_provider": "European Medicines Agency", "source_sha256": "0578c53a5e1c785c4d9d4dc0dabae49dbfa89e237aa571556bee548c3f9cf4d5", "source_snapshot_id": "source-64831dec5ebf55535e19d91b", "source_updated_at": "2025-09-25", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/lacosamide-adroiq-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1887}
{"after": {"end": 18, "start": 0, "text": "Tel: +39 800081631", "truncated": false}, "after_length": 18, "after_sha256": "e9fce0d94f9041280e35646ab57e254fcbe728cc284affbb3960407773c3578b", "annex": "IIIB", "before": {"end": 20, "start": 0, "text": "Tel: +39-02-38598801", "truncated": false}, "before_length": 20, "before_sha256": "b6360c0dfd7fea5b5771d4a018fb270c0d84f69f9d874f189292e2bdbb54fd10", "change_kind": "unassigned", "change_operations": [{"after_end": 9, "after_start": 8, "before_end": 17, "before_start": 8, "kind": "replace"}, {"after_end": 17, "after_start": 11, "before_end": 19, "before_start": 19, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 9, "chars_inserted": 7}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-1c1a2458841af3e9448a6037", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/006047", "medicine_name": "Lacosamide Adroiq", "medicine_slug": "lacosamide-adroiq", "observed_at": "2026-10-12T19:07:56Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "", "section_type": "unassigned", "source_provider": "European Medicines Agency", "source_sha256": "0578c53a5e1c785c4d9d4dc0dabae49dbfa89e237aa571556bee548c3f9cf4d5", "source_snapshot_id": "source-64831dec5ebf55535e19d91b", "source_updated_at": "2025-09-25", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/lacosamide-adroiq-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 2010}
{"after": {"end": 62, "start": 0, "text": "Titulaire de l’Autorisation de mise sur le marché et fabricant", "truncated": false}, "after_length": 62, "after_sha256": "5eb30fa63ee39d5d0a9744c66dc0cac4f6a5cbcfe786b3057e9cfb022517a46f", "annex": "IIIA", "before": {"end": 49, "start": 0, "text": "Titulaire de l’Autorisation de mise sur le marché", "truncated": false}, "before_length": 49, "before_sha256": "e6862501ae974515f409229ac48889a881f5d48257cce71c9b21dd7551f5c918", "change_kind": "administrative", "change_operations": [{"after_end": 62, "after_start": 49, "before_end": 49, "before_start": 49, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 13}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-1c5601d23a0143639a5c2ae6", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/000725", "medicine_name": "Binocrit", "medicine_slug": "binocrit", "observed_at": "2026-10-12T19:29:33Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "2110517cc45ca102ca5957f2578ba74090631cf709d5be3e5f6e34712f237bdb", "source_snapshot_id": "source-63ba5976f2b2d4350a9afd16", "source_updated_at": "2025-07-11", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/binocrit-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 3375}
{"after": {"end": 297, "start": 0, "text": "Tell your doctor or pharmacist if you are taking or have recently taken any other medicines, including medicines obtained without a prescription. This is particularly important if you are taking any of the following as your doctor may need to adjust your dose of Emselex and/or the other medicine:", "truncated": false}, "after_length": 297, "after_sha256": "59e026ebd56e57e7194536b2c4df21018bc5089017d5ccd4619588d7eac54095", "annex": "IIIA", "before": {"end": 304, "start": 0, "text": "Please tell your doctor or pharmacist if you are taking or have recently taken any other medicines, including medicines obtained without a prescription. This is particularly important if you are taking any of the following as your doctor may need to adjust your dose of Emselex and/or the other medicine:", "truncated": false}, "before_length": 304, "before_sha256": "db07e42c750c060f9c53d9d9512b51b8928dd31ca8651715e9e132a9eadd6093", "change_kind": "content", "change_operations": [{"after_end": 1, "after_start": 0, "before_end": 8, "before_start": 0, "kind": "replace"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 8, "chars_inserted": 1}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-1c70015b2453ec2926103e0b", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/000554", "medicine_name": "Emselex", "medicine_slug": "emselex", "observed_at": "2026-10-12T19:12:04Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "4f2565612bc728ec67b7f9c0cd5799ef2c594911c76f323aef8bf6a85adde245", "source_snapshot_id": "source-1fda25b331eb198b8b93feb3", "source_updated_at": "2025-09-15", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/emselex-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1921}
{"after": {"end": 72, "start": 0, "text": "Grounds for the variation to the terms of the Marketing Authorisation(s)", "truncated": false}, "after_length": 72, "after_sha256": "59c5b7c6be2c1cdd2a3b5bd48ba2e514fce918d283a5223bfeb2942763bc962e", "annex": "IV", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 72, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 72}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-1c840e669bda399981612a84", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/000554", "medicine_name": "Emselex", "medicine_slug": "emselex", "observed_at": "2026-10-12T19:12:04Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "conditions", "section_type": "conditions", "source_provider": "European Medicines Agency", "source_sha256": "4f2565612bc728ec67b7f9c0cd5799ef2c594911c76f323aef8bf6a85adde245", "source_snapshot_id": "source-1fda25b331eb198b8b93feb3", "source_updated_at": "2025-09-15", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/emselex-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 2085}
{"after": {"end": 50, "start": 0, "text": "Orteliuslaan 1000, 3528 BD Utrecht The Netherlands", "truncated": false}, "after_length": 50, "after_sha256": "de386d3b3aeebba1dff0a070ffc767173cbc1fa354dbcd29dd86469dc23d8ff6", "annex": "IIIA", "before": {"end": 50, "start": 0, "text": "Papendorpseweg 83, 3528 BJ Utrecht The Netherlands", "truncated": false}, "before_length": 50, "before_sha256": "5d621ef45df9c1911e6b63f15edb513d80fad3ee63f11fe58a733f65b67cd3cd", "change_kind": "content", "change_operations": [{"after_end": 9, "after_start": 0, "before_end": 1, "before_start": 0, "kind": "replace"}, {"after_end": 11, "after_start": 10, "before_end": 4, "before_start": 2, "kind": "replace"}, {"after_end": 12, "after_start": 12, "before_end": 14, "before_start": 5, "kind": "delete"}, {"after_end": 17, "after_start": 13, "before_end": 17, "before_start": 15, "kind": "replace"}, {"after_end": 26, "after_start": 25, "before_end": 26, "before_start": 25, "kind": "replace"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 15, "chars_inserted": 15}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-1c8d0d119fdd68da04da155b", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/001021", "medicine_name": "Adcirca (previously Tadalafil Lilly)", "medicine_slug": "adcirca-previously-tadalafil-lilly", "observed_at": "2026-10-12T19:02:42Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "43438c8e53504a78747a8ff36049250fee294557f3a8b0e3acb80f71ad43ebc0", "source_snapshot_id": "source-2305a67bd1e393ee340bb8e4", "source_updated_at": "2026-01-28", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/adcirca-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1583}
{"after": {"end": 22, "start": 0, "text": "Merz Therapeutics GmbH", "truncated": false}, "after_length": 22, "after_sha256": "059f049c7d0846aaadcf2573280d52110f302d4ecc7b38debd004571cd1e9d5e", "annex": "IIIA", "before": {"end": 35, "start": 0, "text": "Acorda Therapeutics Ireland Limited", "truncated": false}, "before_length": 35, "before_sha256": "d94d3153d193ed26567f2b4ed48df016d81c534e7c0cb1a6655a63f0083383ff", "change_kind": "content", "change_operations": [{"after_end": 2, "after_start": 0, "before_end": 3, "before_start": 0, "kind": "replace"}, {"after_end": 4, "after_start": 3, "before_end": 6, "before_start": 4, "kind": "replace"}, {"after_end": 19, "after_start": 18, "before_end": 30, "before_start": 20, "kind": "replace"}, {"after_end": 22, "after_start": 20, "before_end": 35, "before_start": 31, "kind": "replace"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 19, "chars_inserted": 6}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-1c917f6e2f2675ba8531645f", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002097", "medicine_name": "Fampyra", "medicine_slug": "fampyra", "observed_at": "2026-10-12T19:16:07Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "a0c3ba8d58d6a43a809ecc3d142a78b10c2bd7f0b9f3a3553df2617d87daec1f", "source_snapshot_id": "source-c7a810dd21f94cd2d273f0da", "source_updated_at": "2025-08-21", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/fampyra-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1414}
{"after": {"end": 22, "start": 0, "text": "Tel: +351 21 824 98 76", "truncated": false}, "after_length": 22, "after_sha256": "7c8ecb2e5f42841d3a036da23e786a84794928014737e604cb9ae0cc1a9be439", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 22, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 22}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-1ca2cccbd52d9b5073cfcf61", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:19Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "77586d0bea0858214b43b86e91abc2d2711733b96959ead5ed0b5ecbd8ed888a", "source_snapshot_id": "source-85d476f9ad959cc117ca8f1f", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1919}
{"after": {"end": 25, "start": 0, "text": "Eurocept International BV", "truncated": false}, "after_length": 25, "after_sha256": "b17bd89b3cf285c986a6070d0d67f5326dd5c1f08a70834c296c6c820f9e7505", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 25, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 25}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-1cbde0d15669f2076343ef34", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:19Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "77586d0bea0858214b43b86e91abc2d2711733b96959ead5ed0b5ecbd8ed888a", "source_snapshot_id": "source-85d476f9ad959cc117ca8f1f", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1508}
{"after": {"end": 21, "start": 0, "text": "Tel: +31 35 528 39 57", "truncated": false}, "after_length": 21, "after_sha256": "7baf6601f41e49e470f803fdd4e755a86efa38be423317c000ed79963ebdd213", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 21, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 21}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-1cc716f6474e0f2987928f0f", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:14Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "8b8c4cc8e6f1a21fedee4bf0743c9c03e454b50f5eaba0e3760416d7fe0a74ec", "source_snapshot_id": "source-4efe4ecf3ebf08d338a763a5", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1453}
{"after": {"end": 23, "start": 0, "text": "info@euroceptpharma.com", "truncated": false}, "after_length": 23, "after_sha256": "9297cc5acdcc837f054116992765943f7907937507b2564a99ea1327a00ac0e6", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 23, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 23}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-1ce6242bf214f70dbfbf081a", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:19Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "77586d0bea0858214b43b86e91abc2d2711733b96959ead5ed0b5ecbd8ed888a", "source_snapshot_id": "source-85d476f9ad959cc117ca8f1f", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1494}
{"after": {"end": 26, "start": 0, "text": "Eckenheimer Landstraße 100", "truncated": false}, "after_length": 26, "after_sha256": "fdce1a9bd200c5ddd476c1ea5676b9ffbbea723f7353ad6fbc1fe019dcb86c07", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 26, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 26}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-1ceb08152869851790ac62ab", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002097", "medicine_name": "Fampyra", "medicine_slug": "fampyra", "observed_at": "2026-10-12T19:15:51Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "d9fe8aaaa611a84801d6308b13685258b5248df9022536697939afdf66fc1719", "source_snapshot_id": "source-ff8e0599077f0d01044dc867", "source_updated_at": "2025-08-21", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/fampyra-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1527}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 22, "start": 0, "text": "Tel : +31 35 528 39 57", "truncated": false}, "before_length": 22, "before_sha256": "7bb8afadf5dee15b4f4e1219e333b993040f0848bccea58b1141990fffb82aa1", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 22, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 22, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-1d1e51d10427f25e97c9651a", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:19Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "77586d0bea0858214b43b86e91abc2d2711733b96959ead5ed0b5ecbd8ed888a", "source_snapshot_id": "source-85d476f9ad959cc117ca8f1f", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1909}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "I", "before": {"end": 25, "start": 0, "text": "Tél. : +353 (0)1 231 4609", "truncated": false}, "before_length": 25, "before_sha256": "7559b60efac10cd9095a91d00c551b436a807ad1176cc4f0e8d980243453fbd9", "change_kind": "administrative", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 25, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 25, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-1d4d96becac3b23fd16ece9a", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002097", "medicine_name": "Fampyra", "medicine_slug": "fampyra", "observed_at": "2026-10-12T19:16:07Z", "pipeline_version": "2.0.0", "presentation_label": "Fampyra 10 mg, comprimés à libération prolongée", "presentation_occurrence": 1, "presentation_status": "heading_extracted_unverified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "7", "section_type": "administrative", "source_provider": "European Medicines Agency", "source_sha256": "a0c3ba8d58d6a43a809ecc3d142a78b10c2bd7f0b9f3a3553df2617d87daec1f", "source_snapshot_id": "source-c7a810dd21f94cd2d273f0da", "source_updated_at": "2025-08-21", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/fampyra-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 683}
{"after": {"end": 6, "start": 0, "text": "Vācija", "truncated": false}, "after_length": 6, "after_sha256": "48b6655a9b490b23ced767bcfdf9112b44b466d83f3970463fdb7c0e9750a6a8", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 6, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 6}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-1d64e9502c6279a3020cd2af", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002097", "medicine_name": "Fampyra", "medicine_slug": "fampyra", "observed_at": "2026-10-12T19:15:51Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "d9fe8aaaa611a84801d6308b13685258b5248df9022536697939afdf66fc1719", "source_snapshot_id": "source-ff8e0599077f0d01044dc867", "source_updated_at": "2025-08-21", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/fampyra-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1621}
{"after": {"end": 22, "start": 0, "text": "dpoc.dk.is@organon.com", "truncated": false}, "after_length": 22, "after_sha256": "2ec8bd15095c32c4b391933a74e129811cc83d541dfa8c638f73b1846b2feb92", "annex": "IIIA", "before": {"end": 24, "start": 0, "text": "info.denmark@organon.com", "truncated": false}, "before_length": 24, "before_sha256": "0bd40edc47b513070be7fb7bee249de4ce365bb0cf6d0ae214166f9d5286ddaf", "change_kind": "content", "change_operations": [{"after_end": 2, "after_start": 0, "before_end": 3, "before_start": 0, "kind": "replace"}, {"after_end": 4, "after_start": 3, "before_end": 4, "before_start": 4, "kind": "insert"}, {"after_end": 6, "after_start": 6, "before_end": 11, "before_start": 6, "kind": "delete"}, {"after_end": 10, "after_start": 7, "before_end": 12, "before_start": 12, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 8, "chars_inserted": 6}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-1dd658dcab9ec4ef887e1876", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/000619", "medicine_name": "Fosavance", "medicine_slug": "fosavance", "observed_at": "2026-10-12T19:01:48Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "37324165444dd93963c38ccfa569b0631b8d34d16c725b5a46b16dd7bb4cbbc2", "source_snapshot_id": "source-829e9ebd79c1d98e8a839547", "source_updated_at": "2026-02-12", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/fosavance-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1208}
{"after": {"end": 28, "start": 0, "text": "Merz Therapeutics Nordics AB", "truncated": false}, "after_length": 28, "after_sha256": "808a08c0a7c3cad28ee90c8a6dd0178d599000f64f11d4886b61abaee3d65c15", "annex": "IIIA", "before": {"end": 35, "start": 0, "text": "Acorda Therapeutics Ireland Limited", "truncated": false}, "before_length": 35, "before_sha256": "d94d3153d193ed26567f2b4ed48df016d81c534e7c0cb1a6655a63f0083383ff", "change_kind": "content", "change_operations": [{"after_end": 2, "after_start": 0, "before_end": 3, "before_start": 0, "kind": "replace"}, {"after_end": 4, "after_start": 3, "before_end": 6, "before_start": 4, "kind": "replace"}, {"after_end": 20, "after_start": 18, "before_end": 21, "before_start": 20, "kind": "replace"}, {"after_end": 21, "after_start": 21, "before_end": 26, "before_start": 22, "kind": "delete"}, {"after_end": 25, "after_start": 22, "before_end": 27, "before_start": 27, "kind": "insert"}, {"after_end": 28, "after_start": 26, "before_end": 35, "before_start": 28, "kind": "replace"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 17, "chars_inserted": 10}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-1e43a455bb4f9c5baf200923", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002097", "medicine_name": "Fampyra", "medicine_slug": "fampyra", "observed_at": "2026-10-12T19:15:51Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "d9fe8aaaa611a84801d6308b13685258b5248df9022536697939afdf66fc1719", "source_snapshot_id": "source-ff8e0599077f0d01044dc867", "source_updated_at": "2025-08-21", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/fampyra-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1587}
{"after": {"end": 13, "start": 0, "text": "1932 Zaventem", "truncated": false}, "after_length": 13, "after_sha256": "cffe4475a5de91da7a3a6363a4d41ccfd1405766d95ae182d89bf39b29686221", "annex": "II", "before": {"end": 8, "start": 0, "text": "Zaventem", "truncated": false}, "before_length": 8, "before_sha256": "c4b5ae40e486a4f873f1e130ba599e7937f63dfb26a98371397efc8b5c430f14", "change_kind": "content", "change_operations": [{"after_end": 5, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 5}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-1ec3613e60b79399e8df38ea", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/004697", "medicine_name": "Zirabev", "medicine_slug": "zirabev", "observed_at": "2026-10-12T19:08:39Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "conditions", "section_type": "conditions", "source_provider": "European Medicines Agency", "source_sha256": "ef33f1350f1fcae139a251926014b13e3e973646fc918d603307fbce8dac4777", "source_snapshot_id": "source-7ce336750684e46ba3e4e54c", "source_updated_at": "2025-09-17", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/zirabev-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 2509}
{"after": {"end": 26, "start": 0, "text": "Eckenheimer Landstraße 100", "truncated": false}, "after_length": 26, "after_sha256": "fdce1a9bd200c5ddd476c1ea5676b9ffbbea723f7353ad6fbc1fe019dcb86c07", "annex": "I", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "administrative", "change_operations": [{"after_end": 26, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 26}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-1eefccb075ea592c1e8a7a97", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002097", "medicine_name": "Fampyra", "medicine_slug": "fampyra", "observed_at": "2026-10-12T19:16:07Z", "pipeline_version": "2.0.0", "presentation_label": "Fampyra 10 mg, comprimés à libération prolongée", "presentation_occurrence": 1, "presentation_status": "heading_extracted_unverified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "7", "section_type": "administrative", "source_provider": "European Medicines Agency", "source_sha256": "a0c3ba8d58d6a43a809ecc3d142a78b10c2bd7f0b9f3a3553df2617d87daec1f", "source_snapshot_id": "source-c7a810dd21f94cd2d273f0da", "source_updated_at": "2025-08-21", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/fampyra-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 684}
{"after": {"end": 16, "start": 0, "text": "Extrovis EU Kft.", "truncated": false}, "after_length": 16, "after_sha256": "b9216ef80e71e17798dce313e4318f03f37328f225d30ab508b7413813a908e5", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 16, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 16}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-1f20358c361d46887bb5d2f4", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/006047", "medicine_name": "Lacosamide Adroiq", "medicine_slug": "lacosamide-adroiq", "observed_at": "2026-10-12T19:07:59Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "cc83d966059d42856d0211a4f256b29b20d43593865704d6a9315aeb694f3c76", "source_snapshot_id": "source-896abba1d8391c918345d46b", "source_updated_at": "2025-09-25", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/lacosamide-adroiq-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1809}
{"after": {"end": 16, "start": 0, "text": "Extrovis EU Kft.", "truncated": false}, "after_length": 16, "after_sha256": "b9216ef80e71e17798dce313e4318f03f37328f225d30ab508b7413813a908e5", "annex": "IIIB", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "unassigned", "change_operations": [{"after_end": 16, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 16}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-1f26dd6ab6b78fd95ca98c22", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/006047", "medicine_name": "Lacosamide Adroiq", "medicine_slug": "lacosamide-adroiq", "observed_at": "2026-10-12T19:07:56Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "", "section_type": "unassigned", "source_provider": "European Medicines Agency", "source_sha256": "0578c53a5e1c785c4d9d4dc0dabae49dbfa89e237aa571556bee548c3f9cf4d5", "source_snapshot_id": "source-64831dec5ebf55535e19d91b", "source_updated_at": "2025-09-25", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/lacosamide-adroiq-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1997}
{"after": {"end": 14, "start": 0, "text": "Muscle spasms*", "truncated": false}, "after_length": 14, "after_sha256": "6a7a307975e8e02016754aaa7939a9e3d59a324c73c90f722f9ece2975ef0eaa", "annex": "I", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 14, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": true, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 14}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-1f77fdb1e8fc5d5ab753b4e5", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/000554", "medicine_name": "Emselex", "medicine_slug": "emselex", "observed_at": "2026-10-12T19:12:04Z", "pipeline_version": "2.0.0", "presentation_label": "Emselex 15 mg prolonged-release tablets", "presentation_occurrence": 2, "presentation_status": "heading_extracted_unverified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "4.8", "section_type": "adverse_reactions", "source_provider": "European Medicines Agency", "source_sha256": "4f2565612bc728ec67b7f9c0cd5799ef2c594911c76f323aef8bf6a85adde245", "source_snapshot_id": "source-1fda25b331eb198b8b93feb3", "source_updated_at": "2025-09-15", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/emselex-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 639}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 21, "start": 0, "text": "info@lucanepharma.com", "truncated": false}, "before_length": 21, "before_sha256": "44fd39e5fb919cb3d680fa630da23b49238fec29159c509f3622f272bb41c7c6", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 21, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 21, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-1fba077c65b023ddf9622053", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:19Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "77586d0bea0858214b43b86e91abc2d2711733b96959ead5ed0b5ecbd8ed888a", "source_snapshot_id": "source-85d476f9ad959cc117ca8f1f", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1950}
{"after": {"end": 22, "start": 0, "text": "Fréquence indéterminée", "truncated": false}, "after_length": 22, "after_sha256": "9dbca2ea64869864cf27be15cb397d59f7675843792a00e126385e734d3768e0", "annex": "I", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 22, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": true, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 22}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-1fc3a4db7a5aaa7e28b91302", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/000554", "medicine_name": "Emselex", "medicine_slug": "emselex", "observed_at": "2026-10-12T19:12:07Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": null, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "4.8", "section_type": "adverse_reactions", "source_provider": "European Medicines Agency", "source_sha256": "9a4f1d7e260c7b80eaf397503623b63302e5945b579e9612177835e07c4ab888", "source_snapshot_id": "source-3aac7bf42b99529f25ac013b", "source_updated_at": "2025-09-15", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/emselex-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 597}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 27, "start": 0, "text": "(Eurocept International BV)", "truncated": false}, "before_length": 27, "before_sha256": "e6cf9b20aaa466e53ad0d393512ca75931e13e488321e3be6f3e4f8b600970c8", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 27, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 27, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-1fe0bba8f7e5ad7d0822af35", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:14Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "8b8c4cc8e6f1a21fedee4bf0743c9c03e454b50f5eaba0e3760416d7fe0a74ec", "source_snapshot_id": "source-4efe4ecf3ebf08d338a763a5", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 2020}
{"after": {"end": 28, "start": 0, "text": "InfoDeutschland@dipharma.com", "truncated": false}, "after_length": 28, "after_sha256": "f5ed16f98f15b7236207edade83fdde3fb32cec02f927aaba23223b9f6077f21", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 28, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 28}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-1ff0c044f92aed52edcd4bec", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:19Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "77586d0bea0858214b43b86e91abc2d2711733b96959ead5ed0b5ecbd8ed888a", "source_snapshot_id": "source-85d476f9ad959cc117ca8f1f", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1889}
{"after": {"end": 79, "start": 0, "text": "Viatris Germany GmbH, Zweigniederlassung Bad Homburg v. d. Höhe, Benzstrasse 1,", "truncated": false}, "after_length": 79, "after_sha256": "ec5d8b467f097b5f6e626a2a056336fab8904b07ad533e62379b09597067a87b", "annex": "IIIA", "before": {"end": 77, "start": 0, "text": "Mylan Germany GmbH, Zweigniederlassung Bad Homburg v. d. Höhe, Benzstrasse 1,", "truncated": false}, "before_length": 77, "before_sha256": "592354ac8c07b62540d767b349e438cbf42cff382f1d83c4853733a8264bcf56", "change_kind": "content", "change_operations": [{"after_end": 2, "after_start": 0, "before_end": 3, "before_start": 0, "kind": "replace"}, {"after_end": 7, "after_start": 3, "before_end": 5, "before_start": 4, "kind": "replace"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 4, "chars_inserted": 6}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-20293d73f19fccc8effe2a3c", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/000403", "medicine_name": "Arixtra", "medicine_slug": "arixtra", "observed_at": "2026-10-12T13:38:45Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 5, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "d627c7ab3c0e2e04ec110e8a99901c16a8eb257c9c55138e1bd3875249a20bde", "source_snapshot_id": "source-1eab2dd77b34f4c6fe6e82df", "source_updated_at": "2026-05-07", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/arixtra-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 4170}
{"after": {"end": 54, "start": 0, "text": "Affections musculosquelettiques et du tissu conjonctif", "truncated": false}, "after_length": 54, "after_sha256": "526c3d2dffcdbc9eb5630a88bd92106a3f1a8db2503eba17353690907ac1cdc7", "annex": "I", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 54, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": true, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 54}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-2029e32cffc5bf46291e31b5", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/000554", "medicine_name": "Emselex", "medicine_slug": "emselex", "observed_at": "2026-10-12T19:12:07Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": null, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "4.8", "section_type": "adverse_reactions", "source_provider": "European Medicines Agency", "source_sha256": "9a4f1d7e260c7b80eaf397503623b63302e5945b579e9612177835e07c4ab888", "source_snapshot_id": "source-3aac7bf42b99529f25ac013b", "source_updated_at": "2025-09-15", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/emselex-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 212}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 27, "start": 0, "text": "(Eurocept International BV)", "truncated": false}, "before_length": 27, "before_sha256": "e6cf9b20aaa466e53ad0d393512ca75931e13e488321e3be6f3e4f8b600970c8", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 27, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 27, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-20be74966afebc112ddb0e03", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:19Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "77586d0bea0858214b43b86e91abc2d2711733b96959ead5ed0b5ecbd8ed888a", "source_snapshot_id": "source-85d476f9ad959cc117ca8f1f", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1948}
{"after": {"end": 16, "start": 0, "text": "Extrovis EU Kft.", "truncated": false}, "after_length": 16, "after_sha256": "b9216ef80e71e17798dce313e4318f03f37328f225d30ab508b7413813a908e5", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 16, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 16}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-21120da3de7efa468fc5e0b0", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/006047", "medicine_name": "Lacosamide Adroiq", "medicine_slug": "lacosamide-adroiq", "observed_at": "2026-10-12T19:07:59Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "cc83d966059d42856d0211a4f256b29b20d43593865704d6a9315aeb694f3c76", "source_snapshot_id": "source-896abba1d8391c918345d46b", "source_updated_at": "2025-09-25", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/lacosamide-adroiq-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1748}
{"after": {"end": 23, "start": 0, "text": "info@euroceptpharma.com", "truncated": false}, "after_length": 23, "after_sha256": "9297cc5acdcc837f054116992765943f7907937507b2564a99ea1327a00ac0e6", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 23, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 23}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-211e0ca66c1cfd8f012e11d6", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:14Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "8b8c4cc8e6f1a21fedee4bf0743c9c03e454b50f5eaba0e3760416d7fe0a74ec", "source_snapshot_id": "source-4efe4ecf3ebf08d338a763a5", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1574}
{"after": {"end": 21, "start": 0, "text": "Tlf.: +45 45 26 60 00", "truncated": false}, "after_length": 21, "after_sha256": "6bdd3c845f6a6e520023cbb8b3726e2eefc4bc4ac00ae57245f3055e31d53895", "annex": "IIIA", "before": {"end": 20, "start": 0, "text": "Tlf: +45 45 26 60 00", "truncated": false}, "before_length": 20, "before_sha256": "7932ef9452966b997a4a22618abb01fb644277c9ab041214e6264730772b2d64", "change_kind": "content", "change_operations": [{"after_end": 4, "after_start": 3, "before_end": 3, "before_start": 3, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 1}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-212dcfe85c48c027a25a7170", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/001021", "medicine_name": "Adcirca (previously Tadalafil Lilly)", "medicine_slug": "adcirca-previously-tadalafil-lilly", "observed_at": "2026-10-12T19:02:42Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "43438c8e53504a78747a8ff36049250fee294557f3a8b0e3acb80f71ad43ebc0", "source_snapshot_id": "source-2305a67bd1e393ee340bb8e4", "source_updated_at": "2026-01-28", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/adcirca-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1948}
{"after": {"end": 20, "start": 0, "text": "Τηλ: +30 210 8009111", "truncated": false}, "after_length": 20, "after_sha256": "4be2eb2931a7797b144651aebec87029f222cbdda35f539f6c814b9013ffc042", "annex": "IIIA", "before": {"end": 9, "start": 0, "text": "Santen Oy", "truncated": false}, "before_length": 9, "before_sha256": "b8d3bb307d9e8fe0e3311ac213bd7de3f9df0c142a11ebd9fb9b8ec5c7ed12b6", "change_kind": "content", "change_operations": [{"after_end": 4, "after_start": 0, "before_end": 6, "before_start": 0, "kind": "replace"}, {"after_end": 20, "after_start": 5, "before_end": 9, "before_start": 7, "kind": "replace"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 8, "chars_inserted": 19}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-2161651a4d7c4ed76a835c19", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002066", "medicine_name": "Ikervis", "medicine_slug": "ikervis", "observed_at": "2026-10-12T13:34:16Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "ab05f9fab48768c68482390488c5b90c577e852974d4448da6ea8fe5a4eda856", "source_snapshot_id": "source-324751bde2e11edc76c2dbfe", "source_updated_at": "2026-06-23", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/ikervis-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1482}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 13, "start": 0, "text": "Lucane Pharma", "truncated": false}, "before_length": 13, "before_sha256": "e338afdb64acf1a6e2083a50318853589248451dd3aa707181ba02641a8521e8", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 13, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 13, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-2237e6f648300f7ca8674c7f", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:19Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "77586d0bea0858214b43b86e91abc2d2711733b96959ead5ed0b5ecbd8ed888a", "source_snapshot_id": "source-85d476f9ad959cc117ca8f1f", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1929}
{"after": {"end": 25, "start": 0, "text": "Eurocept International BV", "truncated": false}, "after_length": 25, "after_sha256": "b17bd89b3cf285c986a6070d0d67f5326dd5c1f08a70834c296c6c820f9e7505", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 25, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 25}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-22723e9e5260986ef7e114be", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:19Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "77586d0bea0858214b43b86e91abc2d2711733b96959ead5ed0b5ecbd8ed888a", "source_snapshot_id": "source-85d476f9ad959cc117ca8f1f", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1826}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 27, "start": 0, "text": "(Eurocept International BV)", "truncated": false}, "before_length": 27, "before_sha256": "e6cf9b20aaa466e53ad0d393512ca75931e13e488321e3be6f3e4f8b600970c8", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 27, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 27, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-227e60b734b5a3f10a3cb913", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:14Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "8b8c4cc8e6f1a21fedee4bf0743c9c03e454b50f5eaba0e3760416d7fe0a74ec", "source_snapshot_id": "source-4efe4ecf3ebf08d338a763a5", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1872}
{"after": {"end": 25, "start": 0, "text": "Eurocept International BV", "truncated": false}, "after_length": 25, "after_sha256": "b17bd89b3cf285c986a6070d0d67f5326dd5c1f08a70834c296c6c820f9e7505", "annex": "IIIA", "before": {"end": 21, "start": 0, "text": "info@lucanepharma.com", "truncated": false}, "before_length": 21, "before_sha256": "44fd39e5fb919cb3d680fa630da23b49238fec29159c509f3622f272bb41c7c6", "change_kind": "content", "change_operations": [{"after_end": 3, "after_start": 0, "before_end": 3, "before_start": 0, "kind": "replace"}, {"after_end": 4, "after_start": 4, "before_end": 7, "before_start": 4, "kind": "delete"}, {"after_end": 5, "after_start": 5, "before_end": 10, "before_start": 8, "kind": "delete"}, {"after_end": 15, "after_start": 7, "before_end": 13, "before_start": 12, "kind": "replace"}, {"after_end": 20, "after_start": 16, "before_end": 16, "before_start": 14, "kind": "replace"}, {"after_end": 25, "after_start": 21, "before_end": 21, "before_start": 17, "kind": "replace"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 15, "chars_inserted": 19}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-2309fcbf8c5472e0b7d1fbd3", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:14Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "8b8c4cc8e6f1a21fedee4bf0743c9c03e454b50f5eaba0e3760416d7fe0a74ec", "source_snapshot_id": "source-4efe4ecf3ebf08d338a763a5", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1609}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 13, "start": 0, "text": "Lucane Pharma", "truncated": false}, "before_length": 13, "before_sha256": "e338afdb64acf1a6e2083a50318853589248451dd3aa707181ba02641a8521e8", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 13, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 13, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-230da48c0c57df02faa1fd90", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:14Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "8b8c4cc8e6f1a21fedee4bf0743c9c03e454b50f5eaba0e3760416d7fe0a74ec", "source_snapshot_id": "source-4efe4ecf3ebf08d338a763a5", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1516}
{"after": {"end": 20, "start": 0, "text": "Τηλ: +30 210 8009111", "truncated": false}, "after_length": 20, "after_sha256": "4be2eb2931a7797b144651aebec87029f222cbdda35f539f6c814b9013ffc042", "annex": "IIIA", "before": {"end": 9, "start": 0, "text": "Santen Oy", "truncated": false}, "before_length": 9, "before_sha256": "b8d3bb307d9e8fe0e3311ac213bd7de3f9df0c142a11ebd9fb9b8ec5c7ed12b6", "change_kind": "content", "change_operations": [{"after_end": 4, "after_start": 0, "before_end": 6, "before_start": 0, "kind": "replace"}, {"after_end": 20, "after_start": 5, "before_end": 9, "before_start": 7, "kind": "replace"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 8, "chars_inserted": 19}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-2312327fadafa724683e3b0a", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002066", "medicine_name": "Ikervis", "medicine_slug": "ikervis", "observed_at": "2026-10-12T13:34:10Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "7995ffe3d4b9c2e870327b45fae2f1d35ae1ab0e1e9e22b434fd9805b58a174e", "source_snapshot_id": "source-5ff0e792002ee89d9eb06e5d", "source_updated_at": "2026-06-23", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/ikervis-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1471}
{"after": {"end": 25, "start": 0, "text": "Eurocept International BV", "truncated": false}, "after_length": 25, "after_sha256": "b17bd89b3cf285c986a6070d0d67f5326dd5c1f08a70834c296c6c820f9e7505", "annex": "IIIA", "before": {"end": 21, "start": 0, "text": "info@lucanepharma.com", "truncated": false}, "before_length": 21, "before_sha256": "44fd39e5fb919cb3d680fa630da23b49238fec29159c509f3622f272bb41c7c6", "change_kind": "content", "change_operations": [{"after_end": 3, "after_start": 0, "before_end": 3, "before_start": 0, "kind": "replace"}, {"after_end": 4, "after_start": 4, "before_end": 7, "before_start": 4, "kind": "delete"}, {"after_end": 5, "after_start": 5, "before_end": 10, "before_start": 8, "kind": "delete"}, {"after_end": 15, "after_start": 7, "before_end": 13, "before_start": 12, "kind": "replace"}, {"after_end": 20, "after_start": 16, "before_end": 16, "before_start": 14, "kind": "replace"}, {"after_end": 25, "after_start": 21, "before_end": 21, "before_start": 17, "kind": "replace"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 15, "chars_inserted": 19}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-2324c8775aac5b1126458f3f", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:14Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "8b8c4cc8e6f1a21fedee4bf0743c9c03e454b50f5eaba0e3760416d7fe0a74ec", "source_snapshot_id": "source-4efe4ecf3ebf08d338a763a5", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 2022}
{"after": {"end": 81, "start": 0, "text": "Fréquence indéterminée (ne peut être estimée sur la base des données disponibles)", "truncated": false}, "after_length": 81, "after_sha256": "75ccbf7d675659d67f64d5a6b8b0887c0ca93da4861103bffd6fcb14ad37692c", "annex": "IIIA", "before": {"end": 94, "start": 0, "text": "Fréquence indéterminée (la fréquence ne peut être estimée sur la base des données disponibles)", "truncated": false}, "before_length": 94, "before_sha256": "db812e821bc4e2e2e193f4836d6898bf7d2562688ff1b90f19dcc697e86316dd", "change_kind": "content", "change_operations": [{"after_end": 24, "after_start": 24, "before_end": 37, "before_start": 24, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 13, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-23564db8e86e15a8cdcda36d", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/000554", "medicine_name": "Emselex", "medicine_slug": "emselex", "observed_at": "2026-10-12T19:12:07Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": null, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "9a4f1d7e260c7b80eaf397503623b63302e5945b579e9612177835e07c4ab888", "source_snapshot_id": "source-3aac7bf42b99529f25ac013b", "source_updated_at": "2025-09-15", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/emselex-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1972}
{"after": {"end": 29, "start": 0, "text": "64th Km National Road Athens,", "truncated": false}, "after_length": 29, "after_sha256": "13ea56883a0ab9bffcaa1dd41d9bf3581890cd7cfc6830634cd50feb121599ea", "annex": "II", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 29, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 29}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-2366cded25767e33a860fff8", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/003984", "medicine_name": "Bortezomib Accord", "medicine_slug": "bortezomib-accord", "observed_at": "2026-10-12T13:47:15Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "conditions", "section_type": "conditions", "source_provider": "European Medicines Agency", "source_sha256": "150a191aaf0a1e169e9d5fa2530f0eccb4e3d46509faf5ec5ee975a2e67788c4", "source_snapshot_id": "source-cba4680b7fbd2c536884abd8", "source_updated_at": "2026-03-25", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/bortezomib-accord-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 3349}
{"after": {"end": 23, "start": 0, "text": "info@euroceptpharma.com", "truncated": false}, "after_length": 23, "after_sha256": "9297cc5acdcc837f054116992765943f7907937507b2564a99ea1327a00ac0e6", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 23, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 23}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-237dde0876b0b98a46404500", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:19Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "77586d0bea0858214b43b86e91abc2d2711733b96959ead5ed0b5ecbd8ed888a", "source_snapshot_id": "source-85d476f9ad959cc117ca8f1f", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1407}
{"after": {"end": 22, "start": 0, "text": "Tel.: +48 22 306 57 64", "truncated": false}, "after_length": 22, "after_sha256": "f42743e78ffc8e7a70adfcfc9783dfbd7722e379db4da3de5fa3b4482b24ed3e", "annex": "IIIA", "before": {"end": 23, "start": 0, "text": "Tel.: + 48 22 105 50 01", "truncated": false}, "before_length": 23, "before_sha256": "5784fe8e45652a031b0eef0ea81fb192635fead85c3f1580420e76143dc1ef3c", "change_kind": "content", "change_operations": [{"after_end": 7, "after_start": 7, "before_end": 8, "before_start": 7, "kind": "delete"}, {"after_end": 14, "after_start": 13, "before_end": 15, "before_start": 14, "kind": "replace"}, {"after_end": 16, "after_start": 15, "before_end": 17, "before_start": 16, "kind": "replace"}, {"after_end": 19, "after_start": 18, "before_end": 20, "before_start": 19, "kind": "replace"}, {"after_end": 22, "after_start": 20, "before_end": 23, "before_start": 21, "kind": "replace"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 6, "chars_inserted": 5}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-23949a1b8423b6b3e8f43113", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/000619", "medicine_name": "Fosavance", "medicine_slug": "fosavance", "observed_at": "2026-10-12T19:01:49Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "97e93ccf75e837b32026ca36c34d5c78008211a75d5ef225c47e7b94a0027ab2", "source_snapshot_id": "source-1ef57638e1a307f1e5437651", "source_updated_at": "2026-02-12", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/fosavance-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1264}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 22, "start": 0, "text": "Tel : +31 35 528 39 57", "truncated": false}, "before_length": 22, "before_sha256": "7bb8afadf5dee15b4f4e1219e333b993040f0848bccea58b1141990fffb82aa1", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 22, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 22, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-23b874ef59f7ae40ddc256b1", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:19Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "77586d0bea0858214b43b86e91abc2d2711733b96959ead5ed0b5ecbd8ed888a", "source_snapshot_id": "source-85d476f9ad959cc117ca8f1f", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1846}
{"after": {"end": 15, "start": 0, "text": "Hallucinations*", "truncated": false}, "after_length": 15, "after_sha256": "e03d7497659f0976d952b2cf81a1f0c187edccdbb092664ea8649d30f7c62311", "annex": "I", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 15, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": true, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 15}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-23df4e1002060b8ec81f9858", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/000554", "medicine_name": "Emselex", "medicine_slug": "emselex", "observed_at": "2026-10-12T19:12:07Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": null, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "4.8", "section_type": "adverse_reactions", "source_provider": "European Medicines Agency", "source_sha256": "9a4f1d7e260c7b80eaf397503623b63302e5945b579e9612177835e07c4ab888", "source_snapshot_id": "source-3aac7bf42b99529f25ac013b", "source_updated_at": "2025-09-15", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/emselex-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 181}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIB", "before": {"end": 16, "start": 0, "text": "Extrovis EU Ltd.", "truncated": false}, "before_length": 16, "before_sha256": "f462ad48e7aef0bc82148ce088af1897d99ed86993128f30d506b27d3108a929", "change_kind": "unassigned", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 16, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 16, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-24535d66c8b571b67e9a8f74", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/006047", "medicine_name": "Lacosamide Adroiq", "medicine_slug": "lacosamide-adroiq", "observed_at": "2026-10-12T19:07:56Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "", "section_type": "unassigned", "source_provider": "European Medicines Agency", "source_sha256": "0578c53a5e1c785c4d9d4dc0dabae49dbfa89e237aa571556bee548c3f9cf4d5", "source_snapshot_id": "source-64831dec5ebf55535e19d91b", "source_updated_at": "2025-09-25", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/lacosamide-adroiq-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1998}
{"after": {"end": 18, "start": 0, "text": "4844 CK Terheijden", "truncated": false}, "after_length": 18, "after_sha256": "e7ea1ad04b1071e360b652726acc9e8a22118603b55f58e0bd782476a7e47649", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 18, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 18}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-2458f5edd1fd779adfcc2794", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002097", "medicine_name": "Fampyra", "medicine_slug": "fampyra", "observed_at": "2026-10-12T19:15:51Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "d9fe8aaaa611a84801d6308b13685258b5248df9022536697939afdf66fc1719", "source_snapshot_id": "source-ff8e0599077f0d01044dc867", "source_updated_at": "2025-08-21", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/fampyra-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1373}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 20, "start": 0, "text": "10 Earlsfort Terrace", "truncated": false}, "before_length": 20, "before_sha256": "22951bbf6ee77815d0c07b3af5f0a66e17d277636971c4eaff372dea65dcb193", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 20, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 20, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-245bcfc5319d451fcb609a21", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002097", "medicine_name": "Fampyra", "medicine_slug": "fampyra", "observed_at": "2026-10-12T19:15:51Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "d9fe8aaaa611a84801d6308b13685258b5248df9022536697939afdf66fc1719", "source_snapshot_id": "source-ff8e0599077f0d01044dc867", "source_updated_at": "2025-08-21", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/fampyra-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1399}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 18, "start": 0, "text": "Pátriárka utca 14.", "truncated": false}, "before_length": 18, "before_sha256": "488a80d25b682a58591b4751c4687d5b516ccd6a004748e40d4e8f1454217b07", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 18, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 18, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-2485ef6d48f1c921857cbfcc", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/006047", "medicine_name": "Lacosamide Adroiq", "medicine_slug": "lacosamide-adroiq", "observed_at": "2026-10-12T19:07:59Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "cc83d966059d42856d0211a4f256b29b20d43593865704d6a9315aeb694f3c76", "source_snapshot_id": "source-896abba1d8391c918345d46b", "source_updated_at": "2025-09-25", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/lacosamide-adroiq-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1680}
{"after": {"end": 16, "start": 0, "text": "Extrovis EU Kft.", "truncated": false}, "after_length": 16, "after_sha256": "b9216ef80e71e17798dce313e4318f03f37328f225d30ab508b7413813a908e5", "annex": "IIIB", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "unassigned", "change_operations": [{"after_end": 16, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 16}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-250811a4b9fb935c44dd1cc9", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/006047", "medicine_name": "Lacosamide Adroiq", "medicine_slug": "lacosamide-adroiq", "observed_at": "2026-10-12T19:07:56Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "", "section_type": "unassigned", "source_provider": "European Medicines Agency", "source_sha256": "0578c53a5e1c785c4d9d4dc0dabae49dbfa89e237aa571556bee548c3f9cf4d5", "source_snapshot_id": "source-64831dec5ebf55535e19d91b", "source_updated_at": "2025-09-25", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/lacosamide-adroiq-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1985}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 15, "start": 0, "text": "2000 Szentendre", "truncated": false}, "before_length": 15, "before_sha256": "6541cfa43ac22d35453442b205116e312f60338169ddc5a705a8fe3ff3f4fcd9", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 15, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 15, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-25366b4927a64239b3221b58", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/006047", "medicine_name": "Lacosamide Adroiq", "medicine_slug": "lacosamide-adroiq", "observed_at": "2026-10-12T19:07:59Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "cc83d966059d42856d0211a4f256b29b20d43593865704d6a9315aeb694f3c76", "source_snapshot_id": "source-896abba1d8391c918345d46b", "source_updated_at": "2025-09-25", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/lacosamide-adroiq-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1116}
{"after": {"end": 11, "start": 0, "text": "Vistor ehf.", "truncated": false}, "after_length": 11, "after_sha256": "7b79f0f888fc32453606a29b908677d0b6c13a510070ab26fe31e12b995d77fe", "annex": "IIIA", "before": {"end": 6, "start": 0, "text": "Vistor", "truncated": false}, "before_length": 6, "before_sha256": "880db25626eb8b4d5d7d9cc13a3d8eb1ceea5578e74cf4680a38ffc73e92fe11", "change_kind": "content", "change_operations": [{"after_end": 11, "after_start": 6, "before_end": 6, "before_start": 6, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 5}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-2591bb9946fa6d6b6d08c399", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002702", "medicine_name": "Hexacima", "medicine_slug": "hexacima", "observed_at": "2026-10-12T19:07:06Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "b990725709f885f3f868e5da444393a40a54f89ba2f2d9b232d9c053493d1b03", "source_snapshot_id": "source-87ea40f95d82cdfb5ba074b0", "source_updated_at": "2025-09-29", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/hexacima-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1661}
{"after": {"end": 30, "start": 0, "text": "Merz Therapeutics Benelux B.V.", "truncated": false}, "after_length": 30, "after_sha256": "7c5530f091b2eaff46486c1452be442d4a9c6f4c46924db34e94c6cdb089882e", "annex": "IIIA", "before": {"end": 35, "start": 0, "text": "Acorda Therapeutics Ireland Limited", "truncated": false}, "before_length": 35, "before_sha256": "d94d3153d193ed26567f2b4ed48df016d81c534e7c0cb1a6655a63f0083383ff", "change_kind": "content", "change_operations": [{"after_end": 2, "after_start": 0, "before_end": 3, "before_start": 0, "kind": "replace"}, {"after_end": 4, "after_start": 3, "before_end": 6, "before_start": 4, "kind": "replace"}, {"after_end": 21, "after_start": 18, "before_end": 22, "before_start": 20, "kind": "replace"}, {"after_end": 25, "after_start": 23, "before_end": 27, "before_start": 24, "kind": "replace"}, {"after_end": 30, "after_start": 26, "before_end": 35, "before_start": 28, "kind": "replace"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 17, "chars_inserted": 12}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-25951096e5fbb1f67ef4bce7", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002097", "medicine_name": "Fampyra", "medicine_slug": "fampyra", "observed_at": "2026-10-12T19:16:07Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "a0c3ba8d58d6a43a809ecc3d142a78b10c2bd7f0b9f3a3553df2617d87daec1f", "source_snapshot_id": "source-c7a810dd21f94cd2d273f0da", "source_updated_at": "2025-08-21", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/fampyra-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1404}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 20, "start": 0, "text": "10 Earlsfort Terrace", "truncated": false}, "before_length": 20, "before_sha256": "22951bbf6ee77815d0c07b3af5f0a66e17d277636971c4eaff372dea65dcb193", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 20, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 20, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-25eddebb6082e4266b5d8b27", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002097", "medicine_name": "Fampyra", "medicine_slug": "fampyra", "observed_at": "2026-10-12T19:16:07Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "a0c3ba8d58d6a43a809ecc3d142a78b10c2bd7f0b9f3a3553df2617d87daec1f", "source_snapshot_id": "source-c7a810dd21f94cd2d273f0da", "source_updated_at": "2025-08-21", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/fampyra-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1486}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 18, "start": 0, "text": "Dublin 2, D02 T380", "truncated": false}, "before_length": 18, "before_sha256": "23e6871e7960b0dadc753bc127bbea230cc8308c88b2d33704eb275a3ec1a70d", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 18, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 18, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-25f56a94ac1c50b94024dc76", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002097", "medicine_name": "Fampyra", "medicine_slug": "fampyra", "observed_at": "2026-10-12T19:16:07Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "a0c3ba8d58d6a43a809ecc3d142a78b10c2bd7f0b9f3a3553df2617d87daec1f", "source_snapshot_id": "source-c7a810dd21f94cd2d273f0da", "source_updated_at": "2025-08-21", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/fampyra-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1508}
{"after": {"end": 79, "start": 0, "text": "Viatris Germany GmbH, Zweigniederlassung Bad Homburg v. d. Höhe, Benzstrasse 1,", "truncated": false}, "after_length": 79, "after_sha256": "ec5d8b467f097b5f6e626a2a056336fab8904b07ad533e62379b09597067a87b", "annex": "IIIA", "before": {"end": 77, "start": 0, "text": "Mylan Germany GmbH, Zweigniederlassung Bad Homburg v. d. Höhe, Benzstrasse 1,", "truncated": false}, "before_length": 77, "before_sha256": "592354ac8c07b62540d767b349e438cbf42cff382f1d83c4853733a8264bcf56", "change_kind": "content", "change_operations": [{"after_end": 2, "after_start": 0, "before_end": 3, "before_start": 0, "kind": "replace"}, {"after_end": 7, "after_start": 3, "before_end": 5, "before_start": 4, "kind": "replace"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 4, "chars_inserted": 6}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-260f59041c4ed0a0cef49606", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/000403", "medicine_name": "Arixtra", "medicine_slug": "arixtra", "observed_at": "2026-10-12T13:38:45Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 5, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "d627c7ab3c0e2e04ec110e8a99901c16a8eb257c9c55138e1bd3875249a20bde", "source_snapshot_id": "source-1eab2dd77b34f4c6fe6e82df", "source_updated_at": "2026-05-07", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/arixtra-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 3750}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "II", "before": {"end": 12, "start": 0, "text": "52078 Aachen", "truncated": false}, "before_length": 12, "before_sha256": "1475580660011b5e5dfa9a59bc8bd0d29441e95b38b37c8e74cd2bb2e32158de", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 12, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 12, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-26779fb319a339fe5a6c4d49", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/005246", "medicine_name": "Byfavo", "medicine_slug": "byfavo", "observed_at": "2026-10-12T13:28:16Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "conditions", "section_type": "conditions", "source_provider": "European Medicines Agency", "source_sha256": "61243a969f979f690fe718e414ceaeb66438c1faa31101ba25187d2f9ea662fd", "source_snapshot_id": "source-dd26eb8615d8c18bd80c1f6a", "source_updated_at": "2026-08-26", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/byfavo-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1831}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 38, "start": 0, "text": "sanofi-aventis Ireland Ltd. T/A SANOFI", "truncated": false}, "before_length": 38, "before_sha256": "dad9251ce581d41bcfcb8818c11a57a8d3490b978d09cf04cfd9162a081c8d28", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 38, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 38, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-2695645b1a22a77b58fa6440", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002702", "medicine_name": "Hexacima", "medicine_slug": "hexacima", "observed_at": "2026-10-12T19:07:04Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "44c8996457a718019c75b8322ba07a5ae7af36377b1a6f1cf4ca5a30f9b72c23", "source_snapshot_id": "source-fa766d966dea704c333b9969", "source_updated_at": "2025-09-29", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/hexacima-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1702}
{"after": {"end": 23, "start": 0, "text": "Tel: +49 (0) 69 15 03 0", "truncated": false}, "after_length": 23, "after_sha256": "09683b3f43171b2266a32d9f7d44e3d62d536522dc6f42d4b47f2dda48b31833", "annex": "IIIA", "before": {"end": 23, "start": 0, "text": "Tel: +353 (0)1 231 4609", "truncated": false}, "before_length": 23, "before_sha256": "a115f11f382ef18898b9d956e48603ae236fd1846ce41e8586af99b6dabbfc4d", "change_kind": "content", "change_operations": [{"after_end": 8, "after_start": 6, "before_end": 9, "before_start": 6, "kind": "replace"}, {"after_end": 16, "after_start": 12, "before_end": 13, "before_start": 13, "kind": "insert"}, {"after_end": 18, "after_start": 17, "before_end": 14, "before_start": 14, "kind": "insert"}, {"after_end": 20, "after_start": 19, "before_end": 16, "before_start": 15, "kind": "replace"}, {"after_end": 21, "after_start": 21, "before_end": 18, "before_start": 17, "kind": "delete"}, {"after_end": 22, "after_start": 22, "before_end": 21, "before_start": 19, "kind": "delete"}, {"after_end": 23, "after_start": 23, "before_end": 23, "before_start": 22, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 8, "chars_inserted": 8}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-26c2356470871c0aa2efa370", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002097", "medicine_name": "Fampyra", "medicine_slug": "fampyra", "observed_at": "2026-10-12T19:16:07Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "a0c3ba8d58d6a43a809ecc3d142a78b10c2bd7f0b9f3a3553df2617d87daec1f", "source_snapshot_id": "source-c7a810dd21f94cd2d273f0da", "source_updated_at": "2025-08-21", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/fampyra-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1536}
{"after": {"end": 12, "start": 0, "text": "Виатрис ЕООД", "truncated": false}, "after_length": 12, "after_sha256": "92f9a32247d19bdb1e65df1219954c43f6ad757cc355e8022e7566c35de78f1a", "annex": "IIIA", "before": {"end": 11, "start": 0, "text": "Майлан ЕООД", "truncated": false}, "before_length": 11, "before_sha256": "5770366f858d91109bdad7a5551dc97b9878455f55713851de8277df30093b62", "change_kind": "content", "change_operations": [{"after_end": 2, "after_start": 0, "before_end": 1, "before_start": 0, "kind": "replace"}, {"after_end": 7, "after_start": 3, "before_end": 6, "before_start": 2, "kind": "replace"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 5, "chars_inserted": 6}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-2727c9a5fafa48c380f5d9fd", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/000403", "medicine_name": "Arixtra", "medicine_slug": "arixtra", "observed_at": "2026-10-12T13:38:50Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": null, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "123deb3dbdc841a7adc2b8046138993b8a6a1c228bde13a95278b14d17c5cefd", "source_snapshot_id": "source-79bede7a4a9cd1c040f622e0", "source_updated_at": "2026-05-07", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/arixtra-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 3374}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 13, "start": 0, "text": "Lucane Pharma", "truncated": false}, "before_length": 13, "before_sha256": "e338afdb64acf1a6e2083a50318853589248451dd3aa707181ba02641a8521e8", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 13, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 13, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-2764b6d2dcbac2045432b8e5", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:19Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "77586d0bea0858214b43b86e91abc2d2711733b96959ead5ed0b5ecbd8ed888a", "source_snapshot_id": "source-85d476f9ad959cc117ca8f1f", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1979}
{"after": {"end": 27, "start": 0, "text": "CPO Pharmaceuticals Limited", "truncated": false}, "after_length": 27, "after_sha256": "94b644443752e2cb52916b23f8141fbd44c47055b3416af333e12ac18e101b87", "annex": "IIIA", "before": {"end": 23, "start": 0, "text": "GPA Pharmaceuticals Ltd", "truncated": false}, "before_length": 23, "before_sha256": "ece7127e303c91e9501d2cedd822476265aae86acb9f96ef1553ab3a6954afe1", "change_kind": "content", "change_operations": [{"after_end": 1, "after_start": 0, "before_end": 1, "before_start": 0, "kind": "replace"}, {"after_end": 3, "after_start": 2, "before_end": 3, "before_start": 2, "kind": "replace"}, {"after_end": 24, "after_start": 21, "before_end": 21, "before_start": 21, "kind": "insert"}, {"after_end": 26, "after_start": 25, "before_end": 22, "before_start": 22, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 2, "chars_inserted": 6}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-27886cc8a714fff57b93293e", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/004025", "medicine_name": "Lopinavir/Ritonavir Viatris (previously Ritonavir Mylan)", "medicine_slug": "lopinavir-ritonavir-viatris-previously-ritonavir-mylan", "observed_at": "2026-10-12T19:14:59Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "d782e33ec97bc43bb54f942c83f07f89482c9a433e3846beaffe05b4a52b4b36", "source_snapshot_id": "source-ff48b23a80b98be4c15aa440", "source_updated_at": "2025-09-08", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/lopinavir-ritonavir-viatris-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 2988}
{"after": {"end": 25, "start": 0, "text": "Eurocept International BV", "truncated": false}, "after_length": 25, "after_sha256": "b17bd89b3cf285c986a6070d0d67f5326dd5c1f08a70834c296c6c820f9e7505", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 25, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 25}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-27acd72c0fd5812e695186d6", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:19Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "77586d0bea0858214b43b86e91abc2d2711733b96959ead5ed0b5ecbd8ed888a", "source_snapshot_id": "source-85d476f9ad959cc117ca8f1f", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1992}
{"after": {"end": 24, "start": 0, "text": "Tel.: +49 (0) 69 15 03 0", "truncated": false}, "after_length": 24, "after_sha256": "8946964007fee6067df3ceb486bef1ddd3122eb52726a03a5d4fdde280ca2f1c", "annex": "IIIA", "before": {"end": 24, "start": 0, "text": "Tel.: +353 (0)1 231 4609", "truncated": false}, "before_length": 24, "before_sha256": "46e1c7e37b938a7e0c3f9a071d43f9eb30bbe802826026f6c280be3cb250cd4d", "change_kind": "content", "change_operations": [{"after_end": 9, "after_start": 7, "before_end": 10, "before_start": 7, "kind": "replace"}, {"after_end": 17, "after_start": 13, "before_end": 14, "before_start": 14, "kind": "insert"}, {"after_end": 19, "after_start": 18, "before_end": 15, "before_start": 15, "kind": "insert"}, {"after_end": 21, "after_start": 20, "before_end": 17, "before_start": 16, "kind": "replace"}, {"after_end": 22, "after_start": 22, "before_end": 19, "before_start": 18, "kind": "delete"}, {"after_end": 23, "after_start": 23, "before_end": 22, "before_start": 20, "kind": "delete"}, {"after_end": 24, "after_start": 24, "before_end": 24, "before_start": 23, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 8, "chars_inserted": 8}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-27bf95c0f2f6855a6f7f3876", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002097", "medicine_name": "Fampyra", "medicine_slug": "fampyra", "observed_at": "2026-10-12T19:15:51Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "d9fe8aaaa611a84801d6308b13685258b5248df9022536697939afdf66fc1719", "source_snapshot_id": "source-ff8e0599077f0d01044dc867", "source_updated_at": "2025-08-21", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/fampyra-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1507}
{"after": {"end": 13, "start": 0, "text": "Bredaseweg 63", "truncated": false}, "after_length": 13, "after_sha256": "a37bbd239b649e23c8960a4ab83fa25cba872a2c2e743860ae8149ff61815928", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 13, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 13}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-27cbb5c530d234332db2dcae", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002097", "medicine_name": "Fampyra", "medicine_slug": "fampyra", "observed_at": "2026-10-12T19:16:07Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "a0c3ba8d58d6a43a809ecc3d142a78b10c2bd7f0b9f3a3553df2617d87daec1f", "source_snapshot_id": "source-c7a810dd21f94cd2d273f0da", "source_updated_at": "2025-08-21", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/fampyra-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1378}
{"after": {"end": 34, "start": 0, "text": "Orteliuslaan 1000, 3528 BD Utrecht", "truncated": false}, "after_length": 34, "after_sha256": "46a90fc46ae308c2beeb35ead613fcf3ade5a51e2217a834de3fa5972dab9eec", "annex": "I", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "administrative", "change_operations": [{"after_end": 34, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 34}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-27dc7a664cce91ef516d659b", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/001021", "medicine_name": "Adcirca (previously Tadalafil Lilly)", "medicine_slug": "adcirca-previously-tadalafil-lilly", "observed_at": "2026-10-12T19:02:42Z", "pipeline_version": "2.0.0", "presentation_label": "ADCIRCA 20 mg film-coated tablets", "presentation_occurrence": 1, "presentation_status": "heading_extracted_unverified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "7", "section_type": "administrative", "source_provider": "European Medicines Agency", "source_sha256": "43438c8e53504a78747a8ff36049250fee294557f3a8b0e3acb80f71ad43ebc0", "source_snapshot_id": "source-2305a67bd1e393ee340bb8e4", "source_updated_at": "2026-01-28", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/adcirca-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 614}
{"after": {"end": 22, "start": 0, "text": "Merz Therapeutics GmbH", "truncated": false}, "after_length": 22, "after_sha256": "059f049c7d0846aaadcf2573280d52110f302d4ecc7b38debd004571cd1e9d5e", "annex": "IIIA", "before": {"end": 35, "start": 0, "text": "Acorda Therapeutics Ireland Limited", "truncated": false}, "before_length": 35, "before_sha256": "d94d3153d193ed26567f2b4ed48df016d81c534e7c0cb1a6655a63f0083383ff", "change_kind": "content", "change_operations": [{"after_end": 2, "after_start": 0, "before_end": 3, "before_start": 0, "kind": "replace"}, {"after_end": 4, "after_start": 3, "before_end": 6, "before_start": 4, "kind": "replace"}, {"after_end": 19, "after_start": 18, "before_end": 30, "before_start": 20, "kind": "replace"}, {"after_end": 22, "after_start": 20, "before_end": 35, "before_start": 31, "kind": "replace"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 19, "chars_inserted": 6}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-27f8b213d4ddee5fadc50e57", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002097", "medicine_name": "Fampyra", "medicine_slug": "fampyra", "observed_at": "2026-10-12T19:16:07Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "a0c3ba8d58d6a43a809ecc3d142a78b10c2bd7f0b9f3a3553df2617d87daec1f", "source_snapshot_id": "source-c7a810dd21f94cd2d273f0da", "source_updated_at": "2025-08-21", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/fampyra-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1604}
{"after": {"end": 20, "start": 0, "text": "Viatris Germany GmbH", "truncated": false}, "after_length": 20, "after_sha256": "4c2f2a211c5c41870eee98c700979da5e888736aac1a795ab787143446de83ca", "annex": "II", "before": {"end": 18, "start": 0, "text": "Mylan Germany GmbH", "truncated": false}, "before_length": 18, "before_sha256": "d7a3f7e30e2672617d153ba93a8cf1c2908da6e7dcfe6d206314ed71d4e5405a", "change_kind": "content", "change_operations": [{"after_end": 2, "after_start": 0, "before_end": 3, "before_start": 0, "kind": "replace"}, {"after_end": 7, "after_start": 3, "before_end": 5, "before_start": 4, "kind": "replace"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 4, "chars_inserted": 6}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-28b9823b664bec380d7b8734", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/000403", "medicine_name": "Arixtra", "medicine_slug": "arixtra", "observed_at": "2026-10-12T13:38:50Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": null, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "conditions", "section_type": "conditions", "source_provider": "European Medicines Agency", "source_sha256": "123deb3dbdc841a7adc2b8046138993b8a6a1c228bde13a95278b14d17c5cefd", "source_snapshot_id": "source-79bede7a4a9cd1c040f622e0", "source_updated_at": "2026-05-07", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/arixtra-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 2317}
{"after": {"end": 21, "start": 0, "text": "Tlf.: +45 45 26 60 00", "truncated": false}, "after_length": 21, "after_sha256": "6bdd3c845f6a6e520023cbb8b3726e2eefc4bc4ac00ae57245f3055e31d53895", "annex": "IIIA", "before": {"end": 20, "start": 0, "text": "Tlf: +45 45 26 60 00", "truncated": false}, "before_length": 20, "before_sha256": "7932ef9452966b997a4a22618abb01fb644277c9ab041214e6264730772b2d64", "change_kind": "content", "change_operations": [{"after_end": 4, "after_start": 3, "before_end": 3, "before_start": 3, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 1}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-28d72c79ee74699d17b9eb24", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/001021", "medicine_name": "Adcirca (previously Tadalafil Lilly)", "medicine_slug": "adcirca-previously-tadalafil-lilly", "observed_at": "2026-10-12T19:02:42Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "43438c8e53504a78747a8ff36049250fee294557f3a8b0e3acb80f71ad43ebc0", "source_snapshot_id": "source-2305a67bd1e393ee340bb8e4", "source_updated_at": "2026-01-28", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/adcirca-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 2252}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 7, "start": 0, "text": "Ierland", "truncated": false}, "before_length": 7, "before_sha256": "5b6fef9c9233c2abd17af97e464b5721beead5db2103a11b72e69f4e32067ae4", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 7, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 7, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-28f48d85551e2a5dc3fe08f3", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002097", "medicine_name": "Fampyra", "medicine_slug": "fampyra", "observed_at": "2026-10-12T19:16:07Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "a0c3ba8d58d6a43a809ecc3d142a78b10c2bd7f0b9f3a3553df2617d87daec1f", "source_snapshot_id": "source-c7a810dd21f94cd2d273f0da", "source_updated_at": "2025-08-21", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/fampyra-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1460}
{"after": {"end": 21, "start": 0, "text": "Tel: +31 35 528 39 57", "truncated": false}, "after_length": 21, "after_sha256": "7baf6601f41e49e470f803fdd4e755a86efa38be423317c000ed79963ebdd213", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 21, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 21}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-2907efc0802c47b0eddd6b95", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:14Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "8b8c4cc8e6f1a21fedee4bf0743c9c03e454b50f5eaba0e3760416d7fe0a74ec", "source_snapshot_id": "source-4efe4ecf3ebf08d338a763a5", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1512}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 5, "start": 0, "text": "Regus", "truncated": false}, "before_length": 5, "before_sha256": "69ef2ca82e0f736644001207ab7589688f2ada81eedc4859209d50896d65b095", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 5, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 5, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-29e3eedfade9d5fa698f72c1", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002097", "medicine_name": "Fampyra", "medicine_slug": "fampyra", "observed_at": "2026-10-12T19:15:51Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "d9fe8aaaa611a84801d6308b13685258b5248df9022536697939afdf66fc1719", "source_snapshot_id": "source-ff8e0599077f0d01044dc867", "source_updated_at": "2025-08-21", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/fampyra-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1610}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "II", "before": {"end": 56, "start": 0, "text": "35/36 Baldoyle Industrial Estate, Grange Road, Dublin 13", "truncated": false}, "before_length": 56, "before_sha256": "f0fa66e07d117c6c91c11210809d32b098e6ea28fc318be9df3a372f6c002a1a", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 56, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 56, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-29e4453c7a57027d6dbbbe9d", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/004025", "medicine_name": "Lopinavir/Ritonavir Viatris (previously Ritonavir Mylan)", "medicine_slug": "lopinavir-ritonavir-viatris-previously-ritonavir-mylan", "observed_at": "2026-10-12T19:12:46Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "conditions", "section_type": "conditions", "source_provider": "European Medicines Agency", "source_sha256": "3e30663f02732816ed8779d7a929d500c824ae15aeaee9144ca6eef11900e273", "source_snapshot_id": "source-c58e019b5bec1fb24569e83e", "source_updated_at": "2025-09-08", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/lopinavir-ritonavir-viatris-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1469}
{"after": {"end": 16, "start": 0, "text": "Extrovis EU Kft.", "truncated": false}, "after_length": 16, "after_sha256": "b9216ef80e71e17798dce313e4318f03f37328f225d30ab508b7413813a908e5", "annex": "I", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "administrative", "change_operations": [{"after_end": 16, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 16}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-2a2c58d559b346df3154137b", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/006047", "medicine_name": "Lacosamide Adroiq", "medicine_slug": "lacosamide-adroiq", "observed_at": "2026-10-12T19:07:56Z", "pipeline_version": "2.0.0", "presentation_label": "Lacosamide Adroiq 10 mg/ml solution for infusion", "presentation_occurrence": 1, "presentation_status": "heading_extracted_unverified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "7", "section_type": "administrative", "source_provider": "European Medicines Agency", "source_sha256": "0578c53a5e1c785c4d9d4dc0dabae49dbfa89e237aa571556bee548c3f9cf4d5", "source_snapshot_id": "source-64831dec5ebf55535e19d91b", "source_updated_at": "2025-09-25", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/lacosamide-adroiq-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 919}
{"after": {"end": 21, "start": 0, "text": "Tel: +31 35 528 39 57", "truncated": false}, "after_length": 21, "after_sha256": "7baf6601f41e49e470f803fdd4e755a86efa38be423317c000ed79963ebdd213", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 21, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 21}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-2a302b8700c81d49610c7f96", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:19Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "77586d0bea0858214b43b86e91abc2d2711733b96959ead5ed0b5ecbd8ed888a", "source_snapshot_id": "source-85d476f9ad959cc117ca8f1f", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1532}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 20, "start": 0, "text": "10 Earlsfort Terrace", "truncated": false}, "before_length": 20, "before_sha256": "22951bbf6ee77815d0c07b3af5f0a66e17d277636971c4eaff372dea65dcb193", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 20, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 20, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-2a698b177ff3875779d67375", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002097", "medicine_name": "Fampyra", "medicine_slug": "fampyra", "observed_at": "2026-10-12T19:15:51Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "d9fe8aaaa611a84801d6308b13685258b5248df9022536697939afdf66fc1719", "source_snapshot_id": "source-ff8e0599077f0d01044dc867", "source_updated_at": "2025-08-21", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/fampyra-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1462}
{"after": {"end": 16, "start": 0, "text": "Extrovis EU Kft.", "truncated": false}, "after_length": 16, "after_sha256": "b9216ef80e71e17798dce313e4318f03f37328f225d30ab508b7413813a908e5", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 16, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 16}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-2a97251ad860893f13f93634", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/006047", "medicine_name": "Lacosamide Adroiq", "medicine_slug": "lacosamide-adroiq", "observed_at": "2026-10-12T19:07:59Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "cc83d966059d42856d0211a4f256b29b20d43593865704d6a9315aeb694f3c76", "source_snapshot_id": "source-896abba1d8391c918345d46b", "source_updated_at": "2025-09-25", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/lacosamide-adroiq-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1792}
{"after": {"end": 23, "start": 0, "text": "Tel: +49 (0) 69 15 03 0", "truncated": false}, "after_length": 23, "after_sha256": "09683b3f43171b2266a32d9f7d44e3d62d536522dc6f42d4b47f2dda48b31833", "annex": "IIIA", "before": {"end": 23, "start": 0, "text": "Tel: +353 (0)1 231 4609", "truncated": false}, "before_length": 23, "before_sha256": "a115f11f382ef18898b9d956e48603ae236fd1846ce41e8586af99b6dabbfc4d", "change_kind": "content", "change_operations": [{"after_end": 8, "after_start": 6, "before_end": 9, "before_start": 6, "kind": "replace"}, {"after_end": 16, "after_start": 12, "before_end": 13, "before_start": 13, "kind": "insert"}, {"after_end": 18, "after_start": 17, "before_end": 14, "before_start": 14, "kind": "insert"}, {"after_end": 20, "after_start": 19, "before_end": 16, "before_start": 15, "kind": "replace"}, {"after_end": 21, "after_start": 21, "before_end": 18, "before_start": 17, "kind": "delete"}, {"after_end": 22, "after_start": 22, "before_end": 21, "before_start": 19, "kind": "delete"}, {"after_end": 23, "after_start": 23, "before_end": 23, "before_start": 22, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 8, "chars_inserted": 8}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-2b18dcf00446a56a5004d0c7", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002097", "medicine_name": "Fampyra", "medicine_slug": "fampyra", "observed_at": "2026-10-12T19:15:51Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "d9fe8aaaa611a84801d6308b13685258b5248df9022536697939afdf66fc1719", "source_snapshot_id": "source-ff8e0599077f0d01044dc867", "source_updated_at": "2025-08-21", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/fampyra-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1385}
{"after": {"end": 122, "start": 0, "text": "Le nom et l’adresse du fabricant responsable de la libération du lot concerné doivent figurer sur la notice du médicament.", "truncated": false}, "after_length": 122, "after_sha256": "44e4cc51606bb9922ea370b5516225ebfc697081d5430983987dbbb788932154", "annex": "II", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 122, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 122}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-2b5c7b7a7920c60816331305", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/000980", "medicine_name": "Samsca", "medicine_slug": "samsca", "observed_at": "2026-10-12T13:28:24Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "conditions", "section_type": "conditions", "source_provider": "European Medicines Agency", "source_sha256": "3080d919225c2a98f20aec84d5803b3fde6e1b64f323055c46d098625f4ad301", "source_snapshot_id": "source-e05739a15a0532954ee45dd4", "source_updated_at": "2026-08-20", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/samsca-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 555}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 21, "start": 0, "text": "Tel: + 33 153 868 750", "truncated": false}, "before_length": 21, "before_sha256": "efffe29324e968019e6e2b111904182ba06d83e76b1f29b933bed9dd8779c114", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 21, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 21, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-2b7268191d98a362517bdeaa", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:19Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "77586d0bea0858214b43b86e91abc2d2711733b96959ead5ed0b5ecbd8ed888a", "source_snapshot_id": "source-85d476f9ad959cc117ca8f1f", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1478}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 21, "start": 0, "text": "Tel: +31 35 528 39 57", "truncated": false}, "before_length": 21, "before_sha256": "7baf6601f41e49e470f803fdd4e755a86efa38be423317c000ed79963ebdd213", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 21, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 21, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-2b76b79475efc0c69a863766", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:14Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "8b8c4cc8e6f1a21fedee4bf0743c9c03e454b50f5eaba0e3760416d7fe0a74ec", "source_snapshot_id": "source-4efe4ecf3ebf08d338a763a5", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 2044}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 27, "start": 0, "text": "(Eurocept International BV)", "truncated": false}, "before_length": 27, "before_sha256": "e6cf9b20aaa466e53ad0d393512ca75931e13e488321e3be6f3e4f8b600970c8", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 27, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 27, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-2b85b62da12b1dbae73ad093", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:19Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "77586d0bea0858214b43b86e91abc2d2711733b96959ead5ed0b5ecbd8ed888a", "source_snapshot_id": "source-85d476f9ad959cc117ca8f1f", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1830}
{"after": {"end": 29, "start": 0, "text": "customerservice@duxpharma.com", "truncated": false}, "after_length": 29, "after_sha256": "1864aab5df6d0c2e876c4cb522626eb01a745686a1fcb9fd4a2f9278c82aa1cb", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 29, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 29}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-2b8b40b1e4591e3e73ead862", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:14Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "8b8c4cc8e6f1a21fedee4bf0743c9c03e454b50f5eaba0e3760416d7fe0a74ec", "source_snapshot_id": "source-4efe4ecf3ebf08d338a763a5", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1997}
{"after": {"end": 25, "start": 0, "text": "Eurocept International BV", "truncated": false}, "after_length": 25, "after_sha256": "b17bd89b3cf285c986a6070d0d67f5326dd5c1f08a70834c296c6c820f9e7505", "annex": "IIIA", "before": {"end": 21, "start": 0, "text": "info@lucanepharma.com", "truncated": false}, "before_length": 21, "before_sha256": "44fd39e5fb919cb3d680fa630da23b49238fec29159c509f3622f272bb41c7c6", "change_kind": "content", "change_operations": [{"after_end": 3, "after_start": 0, "before_end": 3, "before_start": 0, "kind": "replace"}, {"after_end": 4, "after_start": 4, "before_end": 7, "before_start": 4, "kind": "delete"}, {"after_end": 5, "after_start": 5, "before_end": 10, "before_start": 8, "kind": "delete"}, {"after_end": 15, "after_start": 7, "before_end": 13, "before_start": 12, "kind": "replace"}, {"after_end": 20, "after_start": 16, "before_end": 16, "before_start": 14, "kind": "replace"}, {"after_end": 25, "after_start": 21, "before_end": 21, "before_start": 17, "kind": "replace"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 15, "chars_inserted": 19}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-2b94265f4faa33678ccf44be", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:14Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "8b8c4cc8e6f1a21fedee4bf0743c9c03e454b50f5eaba0e3760416d7fe0a74ec", "source_snapshot_id": "source-4efe4ecf3ebf08d338a763a5", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 2031}
{"after": {"end": 26, "start": 0, "text": "Eckenheimer Landstraße 100", "truncated": false}, "after_length": 26, "after_sha256": "fdce1a9bd200c5ddd476c1ea5676b9ffbbea723f7353ad6fbc1fe019dcb86c07", "annex": "I", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "administrative", "change_operations": [{"after_end": 26, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 26}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-2baad051416a97db45b5882f", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002097", "medicine_name": "Fampyra", "medicine_slug": "fampyra", "observed_at": "2026-10-12T19:15:51Z", "pipeline_version": "2.0.0", "presentation_label": "Fampyra 10 mg prolonged-release tablets", "presentation_occurrence": 1, "presentation_status": "heading_extracted_unverified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "7", "section_type": "administrative", "source_provider": "European Medicines Agency", "source_sha256": "d9fe8aaaa611a84801d6308b13685258b5248df9022536697939afdf66fc1719", "source_snapshot_id": "source-ff8e0599077f0d01044dc867", "source_updated_at": "2025-08-21", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/fampyra-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 687}
{"after": {"end": 132, "start": 0, "text": "There have been reports of inflammatory muscle disease and muscle breakdown (myositis and rhabdomyolysis), in patients taking Arava.", "truncated": false}, "after_length": 132, "after_sha256": "90becdd7bbf0bbe5f45ccf0044881cb69a6ac220fdad551e9ef9e14f245ee008", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 132, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 132}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-2bca3b51a440cbe41dc85103", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/000235", "medicine_name": "Arava", "medicine_slug": "arava", "observed_at": "2026-10-12T13:27:58Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 3, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "2efff7967e2237bf8343431eef5e08b56c2441eb8a691a90c64b2635109fd697", "source_snapshot_id": "source-08b4eba1f67d2654148f41c4", "source_updated_at": "2026-09-07", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/arava-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 3418}
{"after": {"end": 21, "start": 0, "text": "Tel: +31 35 528 39 57", "truncated": false}, "after_length": 21, "after_sha256": "7baf6601f41e49e470f803fdd4e755a86efa38be423317c000ed79963ebdd213", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 21, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 21}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-2bde942b0d139e1e03c6a6cd", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:14Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "8b8c4cc8e6f1a21fedee4bf0743c9c03e454b50f5eaba0e3760416d7fe0a74ec", "source_snapshot_id": "source-4efe4ecf3ebf08d338a763a5", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1460}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIB", "before": {"end": 16, "start": 0, "text": "Extrovis EU Ltd.", "truncated": false}, "before_length": 16, "before_sha256": "f462ad48e7aef0bc82148ce088af1897d99ed86993128f30d506b27d3108a929", "change_kind": "unassigned", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 16, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 16, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-2c476aebf2edbf7823eeaace", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/006047", "medicine_name": "Lacosamide Adroiq", "medicine_slug": "lacosamide-adroiq", "observed_at": "2026-10-12T19:07:56Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "", "section_type": "unassigned", "source_provider": "European Medicines Agency", "source_sha256": "0578c53a5e1c785c4d9d4dc0dabae49dbfa89e237aa571556bee548c3f9cf4d5", "source_snapshot_id": "source-64831dec5ebf55535e19d91b", "source_updated_at": "2025-09-25", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/lacosamide-adroiq-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1899}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 13, "start": 0, "text": "Lucane Pharma", "truncated": false}, "before_length": 13, "before_sha256": "e338afdb64acf1a6e2083a50318853589248451dd3aa707181ba02641a8521e8", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 13, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 13, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-2c7245ade6feb867f88baacc", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:14Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "8b8c4cc8e6f1a21fedee4bf0743c9c03e454b50f5eaba0e3760416d7fe0a74ec", "source_snapshot_id": "source-4efe4ecf3ebf08d338a763a5", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1607}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 13, "start": 0, "text": "Lucane Pharma", "truncated": false}, "before_length": 13, "before_sha256": "e338afdb64acf1a6e2083a50318853589248451dd3aa707181ba02641a8521e8", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 13, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 13, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-2cf4b4edd13d1eabd1ec19ee", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:19Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "77586d0bea0858214b43b86e91abc2d2711733b96959ead5ed0b5ecbd8ed888a", "source_snapshot_id": "source-85d476f9ad959cc117ca8f1f", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1470}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 25, "start": 0, "text": "Tel: +44 (0) 800 035 2525", "truncated": false}, "before_length": 25, "before_sha256": "84fbcd82ef02323a82bdadb0119979f04bfbc916f52f9d1dc35ed28128dd714d", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 25, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 25, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-2d4d02adf7a1e8460c0f677b", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002514", "medicine_name": "Aubagio", "medicine_slug": "aubagio", "observed_at": "2026-10-12T17:28:37Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "2583b2915ecedeb3bccc3ac6bea691e65d05f5e437bf8aa7970917b6fdeb700c", "source_snapshot_id": "source-15791f384b9e49792c9776dd", "source_updated_at": "2025-12-09", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/aubagio-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 2082}
{"after": {"end": 6, "start": 0, "text": "Niemcy", "truncated": false}, "after_length": 6, "after_sha256": "82a151e1ce6f9049025aa2bbeea8e0498f4f1f876417914affb5e23f00b2e42d", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 6, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 6}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-2da288c75400b1107eaf0ada", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002097", "medicine_name": "Fampyra", "medicine_slug": "fampyra", "observed_at": "2026-10-12T19:16:07Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "a0c3ba8d58d6a43a809ecc3d142a78b10c2bd7f0b9f3a3553df2617d87daec1f", "source_snapshot_id": "source-c7a810dd21f94cd2d273f0da", "source_updated_at": "2025-08-21", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/fampyra-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1512}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 20, "start": 0, "text": "10 Earlsfort Terrace", "truncated": false}, "before_length": 20, "before_sha256": "22951bbf6ee77815d0c07b3af5f0a66e17d277636971c4eaff372dea65dcb193", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 20, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 20, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-2df1431d53d135e4afee6b1d", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002097", "medicine_name": "Fampyra", "medicine_slug": "fampyra", "observed_at": "2026-10-12T19:16:07Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "a0c3ba8d58d6a43a809ecc3d142a78b10c2bd7f0b9f3a3553df2617d87daec1f", "source_snapshot_id": "source-c7a810dd21f94cd2d273f0da", "source_updated_at": "2025-08-21", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/fampyra-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1530}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 18, "start": 0, "text": "Dublin 2, D02 T380", "truncated": false}, "before_length": 18, "before_sha256": "23e6871e7960b0dadc753bc127bbea230cc8308c88b2d33704eb275a3ec1a70d", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 18, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 18, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-2df2ebfdc423207c7876ceda", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002097", "medicine_name": "Fampyra", "medicine_slug": "fampyra", "observed_at": "2026-10-12T19:16:07Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "a0c3ba8d58d6a43a809ecc3d142a78b10c2bd7f0b9f3a3553df2617d87daec1f", "source_snapshot_id": "source-c7a810dd21f94cd2d273f0da", "source_updated_at": "2025-08-21", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/fampyra-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1595}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 8, "start": 0, "text": "Irlandia", "truncated": false}, "before_length": 8, "before_sha256": "6bff01f45c592880e92a15c13630eb9cc0b59aacad2c2ad60a9e91435d5a022c", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 8, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 8, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-2df3675335ea250075c54b71", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002097", "medicine_name": "Fampyra", "medicine_slug": "fampyra", "observed_at": "2026-10-12T19:16:07Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "a0c3ba8d58d6a43a809ecc3d142a78b10c2bd7f0b9f3a3553df2617d87daec1f", "source_snapshot_id": "source-c7a810dd21f94cd2d273f0da", "source_updated_at": "2025-08-21", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/fampyra-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1509}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 21, "start": 0, "text": "info@lucanepharma.com", "truncated": false}, "before_length": 21, "before_sha256": "44fd39e5fb919cb3d680fa630da23b49238fec29159c509f3622f272bb41c7c6", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 21, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 21, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-2df86b301615f4fbc2444ba2", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:19Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "77586d0bea0858214b43b86e91abc2d2711733b96959ead5ed0b5ecbd8ed888a", "source_snapshot_id": "source-85d476f9ad959cc117ca8f1f", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1529}
{"after": {"end": 26, "start": 0, "text": "Eckenheimer Landstraße 100", "truncated": false}, "after_length": 26, "after_sha256": "fdce1a9bd200c5ddd476c1ea5676b9ffbbea723f7353ad6fbc1fe019dcb86c07", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 26, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 26}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-2e0f5e5e81baea1fc3f90312", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002097", "medicine_name": "Fampyra", "medicine_slug": "fampyra", "observed_at": "2026-10-12T19:16:07Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "a0c3ba8d58d6a43a809ecc3d142a78b10c2bd7f0b9f3a3553df2617d87daec1f", "source_snapshot_id": "source-c7a810dd21f94cd2d273f0da", "source_updated_at": "2025-08-21", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/fampyra-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1608}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 13, "start": 0, "text": "Lucane Pharma", "truncated": false}, "before_length": 13, "before_sha256": "e338afdb64acf1a6e2083a50318853589248451dd3aa707181ba02641a8521e8", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 13, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 13, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-2e5c2ac52bbb027b86e46363", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:14Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "8b8c4cc8e6f1a21fedee4bf0743c9c03e454b50f5eaba0e3760416d7fe0a74ec", "source_snapshot_id": "source-4efe4ecf3ebf08d338a763a5", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1888}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 20, "start": 0, "text": "10 Earlsfort Terrace", "truncated": false}, "before_length": 20, "before_sha256": "22951bbf6ee77815d0c07b3af5f0a66e17d277636971c4eaff372dea65dcb193", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 20, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 20, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-2e672ab1dfef5ca179cc6cb0", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002097", "medicine_name": "Fampyra", "medicine_slug": "fampyra", "observed_at": "2026-10-12T19:16:07Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "a0c3ba8d58d6a43a809ecc3d142a78b10c2bd7f0b9f3a3553df2617d87daec1f", "source_snapshot_id": "source-c7a810dd21f94cd2d273f0da", "source_updated_at": "2025-08-21", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/fampyra-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1605}
{"after": {"end": 25, "start": 0, "text": "Eurocept International BV", "truncated": false}, "after_length": 25, "after_sha256": "b17bd89b3cf285c986a6070d0d67f5326dd5c1f08a70834c296c6c820f9e7505", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 25, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 25}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-2e8cf57d71db678266ca6725", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:19Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "77586d0bea0858214b43b86e91abc2d2711733b96959ead5ed0b5ecbd8ed888a", "source_snapshot_id": "source-85d476f9ad959cc117ca8f1f", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1543}
{"after": {"end": 25, "start": 0, "text": "Eurocept International BV", "truncated": false}, "after_length": 25, "after_sha256": "b17bd89b3cf285c986a6070d0d67f5326dd5c1f08a70834c296c6c820f9e7505", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 25, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 25}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-2ea3a87487755acafed50285", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:19Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "77586d0bea0858214b43b86e91abc2d2711733b96959ead5ed0b5ecbd8ed888a", "source_snapshot_id": "source-85d476f9ad959cc117ca8f1f", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1976}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 20, "start": 0, "text": "10 Earlsfort Terrace", "truncated": false}, "before_length": 20, "before_sha256": "22951bbf6ee77815d0c07b3af5f0a66e17d277636971c4eaff372dea65dcb193", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 20, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 20, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-2ed0015ae64c300e5cc2675f", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002097", "medicine_name": "Fampyra", "medicine_slug": "fampyra", "observed_at": "2026-10-12T19:16:07Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "a0c3ba8d58d6a43a809ecc3d142a78b10c2bd7f0b9f3a3553df2617d87daec1f", "source_snapshot_id": "source-c7a810dd21f94cd2d273f0da", "source_updated_at": "2025-08-21", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/fampyra-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1458}
{"after": {"end": 11, "start": 0, "text": "Vistor ehf.", "truncated": false}, "after_length": 11, "after_sha256": "7b79f0f888fc32453606a29b908677d0b6c13a510070ab26fe31e12b995d77fe", "annex": "IIIA", "before": {"end": 10, "start": 0, "text": "Vistor hf.", "truncated": false}, "before_length": 10, "before_sha256": "4b40dfc2a19551f982dad779994a624f3432207c4666bbd66f0ec59c2f229b32", "change_kind": "content", "change_operations": [{"after_end": 8, "after_start": 7, "before_end": 7, "before_start": 7, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 1}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-2ee2e574b6aa40c3bc9cd692", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/000619", "medicine_name": "Fosavance", "medicine_slug": "fosavance", "observed_at": "2026-10-12T19:01:48Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "37324165444dd93963c38ccfa569b0631b8d34d16c725b5a46b16dd7bb4cbbc2", "source_snapshot_id": "source-829e9ebd79c1d98e8a839547", "source_updated_at": "2026-02-12", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/fosavance-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1282}
{"after": {"end": 23, "start": 0, "text": "info@euroceptpharma.com", "truncated": false}, "after_length": 23, "after_sha256": "9297cc5acdcc837f054116992765943f7907937507b2564a99ea1327a00ac0e6", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 23, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 23}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-2f760a4d6d4da9a76b57cb32", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:14Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "8b8c4cc8e6f1a21fedee4bf0743c9c03e454b50f5eaba0e3760416d7fe0a74ec", "source_snapshot_id": "source-4efe4ecf3ebf08d338a763a5", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1916}
{"after": {"end": 19, "start": 0, "text": "Etten-Leur, 4879 AC", "truncated": false}, "after_length": 19, "after_sha256": "8657c9b8722b346a71bad5816f5fba16b632ee27b0357aceb7406439602743c9", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 19, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 19}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-2f7b377a0ff0dfc0bb4f4221", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/000980", "medicine_name": "Samsca", "medicine_slug": "samsca", "observed_at": "2026-10-12T13:28:23Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "b92d73a758b8976c4438a072d544f0d6c603112c90dfc9c084d362ce62419257", "source_snapshot_id": "source-15b8b5681aba542ec1668c0b", "source_updated_at": "2026-08-20", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/samsca-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1268}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 23, "start": 0, "text": "Teл. : +31 35 528 39 57", "truncated": false}, "before_length": 23, "before_sha256": "70dd1f2749423ebadd6cea66401d7e40e1650b7afc94c9b3c226845b69f998cc", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 23, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 23, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-2f847b1498151f07652e6eba", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:19Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "77586d0bea0858214b43b86e91abc2d2711733b96959ead5ed0b5ecbd8ed888a", "source_snapshot_id": "source-85d476f9ad959cc117ca8f1f", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1804}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 39, "start": 0, "text": "Eli Lilly and Company (Ireland) Limited", "truncated": false}, "before_length": 39, "before_sha256": "0555e8a06c0ef36afd955d945d4997f04834690c546541adf74802bac524a0e4", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 39, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 39, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-2f85577119f1d5542f621e65", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/001021", "medicine_name": "Adcirca (previously Tadalafil Lilly)", "medicine_slug": "adcirca-previously-tadalafil-lilly", "observed_at": "2026-10-12T19:02:42Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "43438c8e53504a78747a8ff36049250fee294557f3a8b0e3acb80f71ad43ebc0", "source_snapshot_id": "source-2305a67bd1e393ee340bb8e4", "source_updated_at": "2026-01-28", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/adcirca-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 2331}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 20, "start": 0, "text": "10 Earlsfort Terrace", "truncated": false}, "before_length": 20, "before_sha256": "22951bbf6ee77815d0c07b3af5f0a66e17d277636971c4eaff372dea65dcb193", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 20, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 20, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-2f9546d14ba33bf3e6d472b4", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002097", "medicine_name": "Fampyra", "medicine_slug": "fampyra", "observed_at": "2026-10-12T19:16:07Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "a0c3ba8d58d6a43a809ecc3d142a78b10c2bd7f0b9f3a3553df2617d87daec1f", "source_snapshot_id": "source-c7a810dd21f94cd2d273f0da", "source_updated_at": "2025-08-21", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/fampyra-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1568}
{"after": {"end": 18, "start": 0, "text": "Raktarvarosi Ut 9,", "truncated": false}, "after_length": 18, "after_sha256": "71dd279084ba9f87e79f1095d3565620050fda91d248303c2e19c46598fb0c2b", "annex": "III", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "unassigned", "change_operations": [{"after_end": 18, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 18}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-30406056a554d7218c0ede45", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/006047", "medicine_name": "Lacosamide Adroiq", "medicine_slug": "lacosamide-adroiq", "observed_at": "2026-10-12T19:07:56Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "", "section_type": "unassigned", "source_provider": "European Medicines Agency", "source_sha256": "0578c53a5e1c785c4d9d4dc0dabae49dbfa89e237aa571556bee548c3f9cf4d5", "source_snapshot_id": "source-64831dec5ebf55535e19d91b", "source_updated_at": "2025-09-25", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/lacosamide-adroiq-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1202}
{"after": {"end": 34, "start": 0, "text": "Orteliuslaan 1000, 3528 BD Utrecht", "truncated": false}, "after_length": 34, "after_sha256": "46a90fc46ae308c2beeb35ead613fcf3ade5a51e2217a834de3fa5972dab9eec", "annex": "III", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "unassigned", "change_operations": [{"after_end": 34, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 34}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-3073b70fcc8fd32181b79872", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/001021", "medicine_name": "Adcirca (previously Tadalafil Lilly)", "medicine_slug": "adcirca-previously-tadalafil-lilly", "observed_at": "2026-10-12T19:02:45Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "", "section_type": "unassigned", "source_provider": "European Medicines Agency", "source_sha256": "cdbefcd6143c93e81f3c826bea8d3d01bffc55652e0f792243097df75c452721", "source_snapshot_id": "source-a1e85476de17f5a8664f7766", "source_updated_at": "2026-01-28", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/adcirca-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1679}
{"after": {"end": 25, "start": 0, "text": "Eurocept International BV", "truncated": false}, "after_length": 25, "after_sha256": "b17bd89b3cf285c986a6070d0d67f5326dd5c1f08a70834c296c6c820f9e7505", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 25, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 25}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-307b6a6c2a367bc53cbc5f03", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:19Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "77586d0bea0858214b43b86e91abc2d2711733b96959ead5ed0b5ecbd8ed888a", "source_snapshot_id": "source-85d476f9ad959cc117ca8f1f", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1953}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 22, "start": 0, "text": "PAION Deutschland GmbH", "truncated": false}, "before_length": 22, "before_sha256": "695a7a774aacd3b6e919ed980dbfb2ee37bbe6099af551312782cc722dbb2b31", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 22, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 22, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-30a990b13de64077916fc93c", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/005246", "medicine_name": "Byfavo", "medicine_slug": "byfavo", "observed_at": "2026-10-12T13:28:16Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "61243a969f979f690fe718e414ceaeb66438c1faa31101ba25187d2f9ea662fd", "source_snapshot_id": "source-dd26eb8615d8c18bd80c1f6a", "source_updated_at": "2026-08-26", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/byfavo-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 2378}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 56, "start": 0, "text": "35/36 Baldoyle Industrial Estate, Grange Road, Dublin 13", "truncated": false}, "before_length": 56, "before_sha256": "f0fa66e07d117c6c91c11210809d32b098e6ea28fc318be9df3a372f6c002a1a", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 56, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 56, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-30e8a340e273bcc6fa27f285", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/004025", "medicine_name": "Lopinavir/Ritonavir Viatris (previously Ritonavir Mylan)", "medicine_slug": "lopinavir-ritonavir-viatris-previously-ritonavir-mylan", "observed_at": "2026-10-12T19:12:46Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "3e30663f02732816ed8779d7a929d500c824ae15aeaee9144ca6eef11900e273", "source_snapshot_id": "source-c58e019b5bec1fb24569e83e", "source_updated_at": "2025-09-08", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/lopinavir-ritonavir-viatris-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 2967}
{"after": {"end": 21, "start": 0, "text": "Tel: +31 35 528 39 57", "truncated": false}, "after_length": 21, "after_sha256": "7baf6601f41e49e470f803fdd4e755a86efa38be423317c000ed79963ebdd213", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 21, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 21}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-30f1f89c6cb15757060183d8", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:14Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "8b8c4cc8e6f1a21fedee4bf0743c9c03e454b50f5eaba0e3760416d7fe0a74ec", "source_snapshot_id": "source-4efe4ecf3ebf08d338a763a5", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 2046}
{"after": {"end": 12, "start": 0, "text": "Виатрис ЕООД", "truncated": false}, "after_length": 12, "after_sha256": "92f9a32247d19bdb1e65df1219954c43f6ad757cc355e8022e7566c35de78f1a", "annex": "IIIA", "before": {"end": 11, "start": 0, "text": "Майлан ЕООД", "truncated": false}, "before_length": 11, "before_sha256": "5770366f858d91109bdad7a5551dc97b9878455f55713851de8277df30093b62", "change_kind": "content", "change_operations": [{"after_end": 2, "after_start": 0, "before_end": 1, "before_start": 0, "kind": "replace"}, {"after_end": 7, "after_start": 3, "before_end": 6, "before_start": 2, "kind": "replace"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 5, "chars_inserted": 6}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-30fa298d30f9a384e9e03cba", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/000403", "medicine_name": "Arixtra", "medicine_slug": "arixtra", "observed_at": "2026-10-12T13:38:50Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": null, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "123deb3dbdc841a7adc2b8046138993b8a6a1c228bde13a95278b14d17c5cefd", "source_snapshot_id": "source-79bede7a4a9cd1c040f622e0", "source_updated_at": "2026-05-07", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/arixtra-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 3786}
{"after": {"end": 22, "start": 0, "text": "Merz Therapeutics GmbH", "truncated": false}, "after_length": 22, "after_sha256": "059f049c7d0846aaadcf2573280d52110f302d4ecc7b38debd004571cd1e9d5e", "annex": "IIIA", "before": {"end": 35, "start": 0, "text": "Acorda Therapeutics Ireland Limited", "truncated": false}, "before_length": 35, "before_sha256": "d94d3153d193ed26567f2b4ed48df016d81c534e7c0cb1a6655a63f0083383ff", "change_kind": "content", "change_operations": [{"after_end": 2, "after_start": 0, "before_end": 3, "before_start": 0, "kind": "replace"}, {"after_end": 4, "after_start": 3, "before_end": 6, "before_start": 4, "kind": "replace"}, {"after_end": 19, "after_start": 18, "before_end": 30, "before_start": 20, "kind": "replace"}, {"after_end": 22, "after_start": 20, "before_end": 35, "before_start": 31, "kind": "replace"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 19, "chars_inserted": 6}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-3117702967c279b04eb0b75c", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002097", "medicine_name": "Fampyra", "medicine_slug": "fampyra", "observed_at": "2026-10-12T19:16:07Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "a0c3ba8d58d6a43a809ecc3d142a78b10c2bd7f0b9f3a3553df2617d87daec1f", "source_snapshot_id": "source-c7a810dd21f94cd2d273f0da", "source_updated_at": "2025-08-21", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/fampyra-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1090}
{"after": {"end": 26, "start": 0, "text": "Eckenheimer Landstraße 100", "truncated": false}, "after_length": 26, "after_sha256": "fdce1a9bd200c5ddd476c1ea5676b9ffbbea723f7353ad6fbc1fe019dcb86c07", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 26, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 26}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-31f169aa09d42d6d8e02a766", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002097", "medicine_name": "Fampyra", "medicine_slug": "fampyra", "observed_at": "2026-10-12T19:16:07Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "a0c3ba8d58d6a43a809ecc3d142a78b10c2bd7f0b9f3a3553df2617d87daec1f", "source_snapshot_id": "source-c7a810dd21f94cd2d273f0da", "source_updated_at": "2025-08-21", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/fampyra-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1489}
{"after": {"end": 19, "start": 0, "text": "Etten-Leur, 4879 AC", "truncated": false}, "after_length": 19, "after_sha256": "8657c9b8722b346a71bad5816f5fba16b632ee27b0357aceb7406439602743c9", "annex": "II", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 19, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 19}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-31ff762ef37f3bafb25bb026", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/000980", "medicine_name": "Samsca", "medicine_slug": "samsca", "observed_at": "2026-10-12T13:28:23Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "conditions", "section_type": "conditions", "source_provider": "European Medicines Agency", "source_sha256": "b92d73a758b8976c4438a072d544f0d6c603112c90dfc9c084d362ce62419257", "source_snapshot_id": "source-15b8b5681aba542ec1668c0b", "source_updated_at": "2026-08-20", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/samsca-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 554}
{"after": {"end": 23, "start": 0, "text": "Tel: +49 (0) 69 15 03 0", "truncated": false}, "after_length": 23, "after_sha256": "09683b3f43171b2266a32d9f7d44e3d62d536522dc6f42d4b47f2dda48b31833", "annex": "IIIA", "before": {"end": 23, "start": 0, "text": "Tel: +353 (0)1 231 4609", "truncated": false}, "before_length": 23, "before_sha256": "a115f11f382ef18898b9d956e48603ae236fd1846ce41e8586af99b6dabbfc4d", "change_kind": "content", "change_operations": [{"after_end": 8, "after_start": 6, "before_end": 9, "before_start": 6, "kind": "replace"}, {"after_end": 16, "after_start": 12, "before_end": 13, "before_start": 13, "kind": "insert"}, {"after_end": 18, "after_start": 17, "before_end": 14, "before_start": 14, "kind": "insert"}, {"after_end": 20, "after_start": 19, "before_end": 16, "before_start": 15, "kind": "replace"}, {"after_end": 21, "after_start": 21, "before_end": 18, "before_start": 17, "kind": "delete"}, {"after_end": 22, "after_start": 22, "before_end": 21, "before_start": 19, "kind": "delete"}, {"after_end": 23, "after_start": 23, "before_end": 23, "before_start": 22, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 8, "chars_inserted": 8}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-3228f391e07d07b411b5fc97", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002097", "medicine_name": "Fampyra", "medicine_slug": "fampyra", "observed_at": "2026-10-12T19:16:07Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "a0c3ba8d58d6a43a809ecc3d142a78b10c2bd7f0b9f3a3553df2617d87daec1f", "source_snapshot_id": "source-c7a810dd21f94cd2d273f0da", "source_updated_at": "2025-08-21", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/fampyra-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1584}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 18, "start": 0, "text": "Dublin 2, D02 T380", "truncated": false}, "before_length": 18, "before_sha256": "23e6871e7960b0dadc753bc127bbea230cc8308c88b2d33704eb275a3ec1a70d", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 18, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 18, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-32b68754c4d1fe575ee6b643", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002097", "medicine_name": "Fampyra", "medicine_slug": "fampyra", "observed_at": "2026-10-12T19:16:07Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "a0c3ba8d58d6a43a809ecc3d142a78b10c2bd7f0b9f3a3553df2617d87daec1f", "source_snapshot_id": "source-c7a810dd21f94cd2d273f0da", "source_updated_at": "2025-08-21", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/fampyra-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1569}
{"after": {"end": 23, "start": 0, "text": "info@euroceptpharma.com", "truncated": false}, "after_length": 23, "after_sha256": "9297cc5acdcc837f054116992765943f7907937507b2564a99ea1327a00ac0e6", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 23, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 23}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-32d427ae5d9c0e1941ecbc62", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:19Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "77586d0bea0858214b43b86e91abc2d2711733b96959ead5ed0b5ecbd8ed888a", "source_snapshot_id": "source-85d476f9ad959cc117ca8f1f", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1955}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 13, "start": 0, "text": "Lucane Pharma", "truncated": false}, "before_length": 13, "before_sha256": "e338afdb64acf1a6e2083a50318853589248451dd3aa707181ba02641a8521e8", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 13, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 13, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-32dff06824eadd292bfc2389", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:19Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "77586d0bea0858214b43b86e91abc2d2711733b96959ead5ed0b5ecbd8ed888a", "source_snapshot_id": "source-85d476f9ad959cc117ca8f1f", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1432}
{"after": {"end": 6, "start": 0, "text": "Greece", "truncated": false}, "after_length": 6, "after_sha256": "9c93ad439373b4ee35e70ba1318055a14d2ed222f69f9e2d069689e83829833d", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 6, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 6}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-33078499b48ac2865827a340", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/003984", "medicine_name": "Bortezomib Accord", "medicine_slug": "bortezomib-accord", "observed_at": "2026-10-12T13:47:12Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "e4aac937241121e8ad1e32b40b1007fb58398035928568a7e60a65074b0efb36", "source_snapshot_id": "source-b1eaab6445cfa827e3b1481b", "source_updated_at": "2026-03-25", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/bortezomib-accord-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 4240}
{"after": {"end": 25, "start": 0, "text": "Eurocept International BV", "truncated": false}, "after_length": 25, "after_sha256": "b17bd89b3cf285c986a6070d0d67f5326dd5c1f08a70834c296c6c820f9e7505", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 25, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 25}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-3328dc179a07e5a74d587453", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:14Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "8b8c4cc8e6f1a21fedee4bf0743c9c03e454b50f5eaba0e3760416d7fe0a74ec", "source_snapshot_id": "source-4efe4ecf3ebf08d338a763a5", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1970}
{"after": {"end": 23, "start": 0, "text": "Tel: +49 (0) 69 15 03 0", "truncated": false}, "after_length": 23, "after_sha256": "09683b3f43171b2266a32d9f7d44e3d62d536522dc6f42d4b47f2dda48b31833", "annex": "IIIA", "before": {"end": 23, "start": 0, "text": "Tel: +353 (0)1 231 4609", "truncated": false}, "before_length": 23, "before_sha256": "a115f11f382ef18898b9d956e48603ae236fd1846ce41e8586af99b6dabbfc4d", "change_kind": "content", "change_operations": [{"after_end": 8, "after_start": 6, "before_end": 9, "before_start": 6, "kind": "replace"}, {"after_end": 16, "after_start": 12, "before_end": 13, "before_start": 13, "kind": "insert"}, {"after_end": 18, "after_start": 17, "before_end": 14, "before_start": 14, "kind": "insert"}, {"after_end": 20, "after_start": 19, "before_end": 16, "before_start": 15, "kind": "replace"}, {"after_end": 21, "after_start": 21, "before_end": 18, "before_start": 17, "kind": "delete"}, {"after_end": 22, "after_start": 22, "before_end": 21, "before_start": 19, "kind": "delete"}, {"after_end": 23, "after_start": 23, "before_end": 23, "before_start": 22, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 8, "chars_inserted": 8}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-3337c094e10f904dad6f5a41", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002097", "medicine_name": "Fampyra", "medicine_slug": "fampyra", "observed_at": "2026-10-12T19:16:07Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "a0c3ba8d58d6a43a809ecc3d142a78b10c2bd7f0b9f3a3553df2617d87daec1f", "source_snapshot_id": "source-c7a810dd21f94cd2d273f0da", "source_updated_at": "2025-08-21", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/fampyra-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1449}
{"after": {"end": 23, "start": 0, "text": "Tel: +49 6431 285 88 30", "truncated": false}, "after_length": 23, "after_sha256": "ef2d8f53356e21d9673844a7ef23ea7b054ff18cc0092c86a4e97d96486b24a7", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 23, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 23}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-3383735410c9c3d5bb10e4fe", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:19Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "77586d0bea0858214b43b86e91abc2d2711733b96959ead5ed0b5ecbd8ed888a", "source_snapshot_id": "source-85d476f9ad959cc117ca8f1f", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1430}
{"after": {"end": 18, "start": 0, "text": "Confusional state*", "truncated": false}, "after_length": 18, "after_sha256": "be42c48a234274a52a872c07a6a1715a7231fe08b61d94e630180217453881c2", "annex": "I", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 18, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": true, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 18}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-33d66c032d1d1fa49827505e", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/000554", "medicine_name": "Emselex", "medicine_slug": "emselex", "observed_at": "2026-10-12T19:12:04Z", "pipeline_version": "2.0.0", "presentation_label": "Emselex 15 mg prolonged-release tablets", "presentation_occurrence": 2, "presentation_status": "heading_extracted_unverified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "4.8", "section_type": "adverse_reactions", "source_provider": "European Medicines Agency", "source_sha256": "4f2565612bc728ec67b7f9c0cd5799ef2c594911c76f323aef8bf6a85adde245", "source_snapshot_id": "source-1fda25b331eb198b8b93feb3", "source_updated_at": "2025-09-15", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/emselex-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 602}
{"after": {"end": 8, "start": 0, "text": "Germania", "truncated": false}, "after_length": 8, "after_sha256": "3d4b90e9744633e91a37fa52c3eb60fc25cd5b2c9ebd2ddbd39d876291f1d695", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 8, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 8}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-33e99671d98d9e58a89d2459", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002097", "medicine_name": "Fampyra", "medicine_slug": "fampyra", "observed_at": "2026-10-12T19:16:07Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "a0c3ba8d58d6a43a809ecc3d142a78b10c2bd7f0b9f3a3553df2617d87daec1f", "source_snapshot_id": "source-c7a810dd21f94cd2d273f0da", "source_updated_at": "2025-08-21", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/fampyra-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1545}
{"after": {"end": 29, "start": 0, "text": "customerservice@duxpharma.com", "truncated": false}, "after_length": 29, "after_sha256": "1864aab5df6d0c2e876c4cb522626eb01a745686a1fcb9fd4a2f9278c82aa1cb", "annex": "IIIA", "before": {"end": 13, "start": 0, "text": "Lucane Pharma", "truncated": false}, "before_length": 13, "before_sha256": "e338afdb64acf1a6e2083a50318853589248451dd3aa707181ba02641a8521e8", "change_kind": "content", "change_operations": [{"after_end": 1, "after_start": 0, "before_end": 1, "before_start": 0, "kind": "replace"}, {"after_end": 13, "after_start": 2, "before_end": 2, "before_start": 2, "kind": "insert"}, {"after_end": 14, "after_start": 14, "before_end": 5, "before_start": 3, "kind": "delete"}, {"after_end": 20, "after_start": 15, "before_end": 8, "before_start": 6, "kind": "replace"}, {"after_end": 29, "after_start": 25, "before_end": 13, "before_start": 13, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 5, "chars_inserted": 21}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-34065822c5b2b40aa3958a82", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:19Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "77586d0bea0858214b43b86e91abc2d2711733b96959ead5ed0b5ecbd8ed888a", "source_snapshot_id": "source-85d476f9ad959cc117ca8f1f", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1920}
{"after": {"end": 8, "start": 0, "text": "Pays-Bas", "truncated": false}, "after_length": 8, "after_sha256": "2f1d512c96e61c1e31319fc9326840a0ea9ab221bba6bbdca327b162ac12fa51", "annex": "II", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 8, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 8}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-344a39b1ae7fcfa6d5ec1d39", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/000980", "medicine_name": "Samsca", "medicine_slug": "samsca", "observed_at": "2026-10-12T13:28:24Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "conditions", "section_type": "conditions", "source_provider": "European Medicines Agency", "source_sha256": "3080d919225c2a98f20aec84d5803b3fde6e1b64f323055c46d098625f4ad301", "source_snapshot_id": "source-e05739a15a0532954ee45dd4", "source_updated_at": "2026-08-20", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/samsca-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 553}
{"after": {"end": 8, "start": 0, "text": "Германия", "truncated": false}, "after_length": 8, "after_sha256": "c2574453e3d10cfd248ec6f7ce0fcc01944f6ead4ff06b6617d5e8621ad4660f", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 8, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 8}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-345947a2529be32636bf5203", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002097", "medicine_name": "Fampyra", "medicine_slug": "fampyra", "observed_at": "2026-10-12T19:15:51Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "d9fe8aaaa611a84801d6308b13685258b5248df9022536697939afdf66fc1719", "source_snapshot_id": "source-ff8e0599077f0d01044dc867", "source_updated_at": "2025-08-21", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/fampyra-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1394}
{"after": {"end": 566, "start": 0, "text": "PHEBURANE oral solution tastes neutral. In order to improve the taste, one drop of the preferred flavour topping can be added to the content of the glass of water; swirled gently, and then consumed (If one drop of flavour topping would not provide the taste intensity, patient could use 2 drops). The solution with the lemon-mint flavour topping is less viscous than the one with blackcurrant flavour topping and may lead to adding of more than 2 drops. Therefore, it is recommended to carefully measure the lemon-mint topping and ensure that only one drop is added.", "truncated": false}, "after_length": 566, "after_sha256": "44935375444b2715d5b43a26ac9911ea454100fe80686b96336117ed743b4158", "annex": "I", "before": {"end": 296, "start": 0, "text": "PHEBURANE oral solution tastes neutral. In order to improve the taste, one drop of the preferred flavour topping can be added to the content of the glass of water; swirled gently, and then consumed (If one drop of flavour topping would not provide the taste intensity, patient could use 2 drops);", "truncated": false}, "before_length": 296, "before_sha256": "183e2e0aa62cc9cbec72e0064f1c44b2f27ab5d6ab0408035ae560cd43e240b8", "change_kind": "content", "change_operations": [{"after_end": 566, "after_start": 295, "before_end": 296, "before_start": 295, "kind": "replace"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 1, "chars_inserted": 271}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-3465d6179e6687ddd7fb45ce", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:14Z", "pipeline_version": "2.0.0", "presentation_label": "PHEBURANE 350 mg/mL oral solution", "presentation_occurrence": 2, "presentation_status": "heading_extracted_unverified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "6.6", "section_type": "quality_presentation", "source_provider": "European Medicines Agency", "source_sha256": "8b8c4cc8e6f1a21fedee4bf0743c9c03e454b50f5eaba0e3760416d7fe0a74ec", "source_snapshot_id": "source-4efe4ecf3ebf08d338a763a5", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 685}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 27, "start": 0, "text": "(Eurocept International BV)", "truncated": false}, "before_length": 27, "before_sha256": "e6cf9b20aaa466e53ad0d393512ca75931e13e488321e3be6f3e4f8b600970c8", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 27, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 27, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-347b7d9a575ce19cc70814e7", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:14Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "8b8c4cc8e6f1a21fedee4bf0743c9c03e454b50f5eaba0e3760416d7fe0a74ec", "source_snapshot_id": "source-4efe4ecf3ebf08d338a763a5", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1898}
{"after": {"end": 68, "start": 0, "text": "Nom et adresse des fabricants responsables de la libération des lots", "truncated": false}, "after_length": 68, "after_sha256": "41810f2adc1978abadf46688dfdd27a1472acf74761582e5aff9bb999049abc8", "annex": "II", "before": {"end": 65, "start": 0, "text": "Nom et adresse du fabricant responsable de la libération des lots", "truncated": false}, "before_length": 65, "before_sha256": "8201957d81696f960fcdb668063a8d0eff7ab3248eb5dafa2009701c0733f6ac", "change_kind": "content", "change_operations": [{"after_end": 18, "after_start": 16, "before_end": 17, "before_start": 16, "kind": "replace"}, {"after_end": 29, "after_start": 28, "before_end": 27, "before_start": 27, "kind": "insert"}, {"after_end": 42, "after_start": 41, "before_end": 39, "before_start": 39, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 1, "chars_inserted": 4}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-34b1bd1460055ecce80b3b18", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/003984", "medicine_name": "Bortezomib Accord", "medicine_slug": "bortezomib-accord", "observed_at": "2026-10-12T13:47:15Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "conditions", "section_type": "conditions", "source_provider": "European Medicines Agency", "source_sha256": "150a191aaf0a1e169e9d5fa2530f0eccb4e3d46509faf5ec5ee975a2e67788c4", "source_snapshot_id": "source-cba4680b7fbd2c536884abd8", "source_updated_at": "2026-03-25", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/bortezomib-accord-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 3343}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 18, "start": 0, "text": "Dublin 2, D02 T380", "truncated": false}, "before_length": 18, "before_sha256": "23e6871e7960b0dadc753bc127bbea230cc8308c88b2d33704eb275a3ec1a70d", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 18, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 18, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-34cb1e239ea06c1511c847fb", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002097", "medicine_name": "Fampyra", "medicine_slug": "fampyra", "observed_at": "2026-10-12T19:15:51Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "d9fe8aaaa611a84801d6308b13685258b5248df9022536697939afdf66fc1719", "source_snapshot_id": "source-ff8e0599077f0d01044dc867", "source_updated_at": "2025-08-21", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/fampyra-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1350}
{"after": {"end": 97, "start": 0, "text": "if you develop skin ulcers or experience impaired wound healing while being treated with AUBAGIO.", "truncated": false}, "after_length": 97, "after_sha256": "33190f3bfaf81fb92e95f1a1d5d2934c37fc5b293db7d3b2b0248fa4fe94c93e", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 97, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 97}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-34d6a22065a6a639b93bac7c", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002514", "medicine_name": "Aubagio", "medicine_slug": "aubagio", "observed_at": "2026-10-12T17:28:37Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "2583b2915ecedeb3bccc3ac6bea691e65d05f5e437bf8aa7970917b6fdeb700c", "source_snapshot_id": "source-15791f384b9e49792c9776dd", "source_updated_at": "2025-12-09", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/aubagio-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1733}
{"after": {"end": 22, "start": 0, "text": "Merz Therapeutics GmbH", "truncated": false}, "after_length": 22, "after_sha256": "059f049c7d0846aaadcf2573280d52110f302d4ecc7b38debd004571cd1e9d5e", "annex": "I", "before": {"end": 35, "start": 0, "text": "Acorda Therapeutics Ireland Limited", "truncated": false}, "before_length": 35, "before_sha256": "d94d3153d193ed26567f2b4ed48df016d81c534e7c0cb1a6655a63f0083383ff", "change_kind": "administrative", "change_operations": [{"after_end": 2, "after_start": 0, "before_end": 3, "before_start": 0, "kind": "replace"}, {"after_end": 4, "after_start": 3, "before_end": 6, "before_start": 4, "kind": "replace"}, {"after_end": 19, "after_start": 18, "before_end": 30, "before_start": 20, "kind": "replace"}, {"after_end": 22, "after_start": 20, "before_end": 35, "before_start": 31, "kind": "replace"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 19, "chars_inserted": 6}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-34d7e45ed0f7d845b32cb0b1", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002097", "medicine_name": "Fampyra", "medicine_slug": "fampyra", "observed_at": "2026-10-12T19:15:51Z", "pipeline_version": "2.0.0", "presentation_label": "Fampyra 10 mg prolonged-release tablets", "presentation_occurrence": 1, "presentation_status": "heading_extracted_unverified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "7", "section_type": "administrative", "source_provider": "European Medicines Agency", "source_sha256": "d9fe8aaaa611a84801d6308b13685258b5248df9022536697939afdf66fc1719", "source_snapshot_id": "source-ff8e0599077f0d01044dc867", "source_updated_at": "2025-08-21", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/fampyra-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 682}
{"after": {"end": 8, "start": 0, "text": "Ġermanja", "truncated": false}, "after_length": 8, "after_sha256": "777374490a90bf7933fa93e8dff699f1180358fdd68182f9a146eb475e78a3b7", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 8, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 8}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-3567146e1133edc667724211", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002097", "medicine_name": "Fampyra", "medicine_slug": "fampyra", "observed_at": "2026-10-12T19:16:07Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "a0c3ba8d58d6a43a809ecc3d142a78b10c2bd7f0b9f3a3553df2617d87daec1f", "source_snapshot_id": "source-c7a810dd21f94cd2d273f0da", "source_updated_at": "2025-08-21", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/fampyra-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1448}
{"after": {"end": 16, "start": 0, "text": "Extrovis EU Kft.", "truncated": false}, "after_length": 16, "after_sha256": "b9216ef80e71e17798dce313e4318f03f37328f225d30ab508b7413813a908e5", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 16, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 16}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-35d73b952b35aa725a057c15", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/006047", "medicine_name": "Lacosamide Adroiq", "medicine_slug": "lacosamide-adroiq", "observed_at": "2026-10-12T19:07:59Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "cc83d966059d42856d0211a4f256b29b20d43593865704d6a9315aeb694f3c76", "source_snapshot_id": "source-896abba1d8391c918345d46b", "source_updated_at": "2025-09-25", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/lacosamide-adroiq-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1711}
{"after": {"end": 23, "start": 0, "text": "info@euroceptpharma.com", "truncated": false}, "after_length": 23, "after_sha256": "9297cc5acdcc837f054116992765943f7907937507b2564a99ea1327a00ac0e6", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 23, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 23}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-35e546cb5b9d30fb90e7a8f5", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:19Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "77586d0bea0858214b43b86e91abc2d2711733b96959ead5ed0b5ecbd8ed888a", "source_snapshot_id": "source-85d476f9ad959cc117ca8f1f", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1969}
{"after": {"end": 21, "start": 0, "text": "Teл.: +40 21 528 0290", "truncated": false}, "after_length": 21, "after_sha256": "ec107d1625029392f60daf4b58132a83529ea43f1b9ebdf646436a843f24ad5b", "annex": "IIIA", "before": {"end": 26, "start": 0, "text": "Teл.: +359 (0) 888 755 393", "truncated": false}, "before_length": 26, "before_sha256": "25d34bfa98e800128c16111612beebc119b20f0c6456910d298344a0c0ffe050", "change_kind": "content", "change_operations": [{"after_end": 13, "after_start": 7, "before_end": 8, "before_start": 7, "kind": "replace"}, {"after_end": 15, "after_start": 14, "before_end": 17, "before_start": 9, "kind": "replace"}, {"after_end": 19, "after_start": 17, "before_end": 24, "before_start": 19, "kind": "replace"}, {"after_end": 21, "after_start": 20, "before_end": 26, "before_start": 25, "kind": "replace"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 15, "chars_inserted": 10}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-35f6883c4788bb8c1bec784d", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002066", "medicine_name": "Ikervis", "medicine_slug": "ikervis", "observed_at": "2026-10-12T13:34:16Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "ab05f9fab48768c68482390488c5b90c577e852974d4448da6ea8fe5a4eda856", "source_snapshot_id": "source-324751bde2e11edc76c2dbfe", "source_updated_at": "2026-06-23", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/ikervis-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1387}
{"after": {"end": 19, "start": 0, "text": "Do not take Emselex", "truncated": false}, "after_length": 19, "after_sha256": "929637f13e1fc092b772c24a2f8d8ad87f6e73bf64a35b8a6a6f787e48623476", "annex": "IIIA", "before": {"end": 20, "start": 0, "text": "Do not take Emselex:", "truncated": false}, "before_length": 20, "before_sha256": "111d08474f59e5a8e20440c2fc663f7f7c6614414c4ae42aa9c1c528ccc28731", "change_kind": "content", "change_operations": [{"after_end": 19, "after_start": 19, "before_end": 20, "before_start": 19, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 1, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-36541235b2bde2927430f8d5", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/000554", "medicine_name": "Emselex", "medicine_slug": "emselex", "observed_at": "2026-10-12T19:12:04Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "4f2565612bc728ec67b7f9c0cd5799ef2c594911c76f323aef8bf6a85adde245", "source_snapshot_id": "source-1fda25b331eb198b8b93feb3", "source_updated_at": "2025-09-15", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/emselex-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1709}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 9, "start": 0, "text": "Allemagne", "truncated": false}, "before_length": 9, "before_sha256": "6b58dbd6a994339b48d8446597da22402857b3409613459c7e3a293788fbe66a", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 9, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 9, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-366ef5dc24100fdc78773078", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/005246", "medicine_name": "Byfavo", "medicine_slug": "byfavo", "observed_at": "2026-10-12T13:28:16Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "61243a969f979f690fe718e414ceaeb66438c1faa31101ba25187d2f9ea662fd", "source_snapshot_id": "source-dd26eb8615d8c18bd80c1f6a", "source_updated_at": "2026-08-26", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/byfavo-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 2381}
{"after": {"end": 25, "start": 0, "text": "Eurocept International BV", "truncated": false}, "after_length": 25, "after_sha256": "b17bd89b3cf285c986a6070d0d67f5326dd5c1f08a70834c296c6c820f9e7505", "annex": "IIIA", "before": {"end": 21, "start": 0, "text": "info@lucanepharma.com", "truncated": false}, "before_length": 21, "before_sha256": "44fd39e5fb919cb3d680fa630da23b49238fec29159c509f3622f272bb41c7c6", "change_kind": "content", "change_operations": [{"after_end": 3, "after_start": 0, "before_end": 3, "before_start": 0, "kind": "replace"}, {"after_end": 4, "after_start": 4, "before_end": 7, "before_start": 4, "kind": "delete"}, {"after_end": 5, "after_start": 5, "before_end": 10, "before_start": 8, "kind": "delete"}, {"after_end": 15, "after_start": 7, "before_end": 13, "before_start": 12, "kind": "replace"}, {"after_end": 20, "after_start": 16, "before_end": 16, "before_start": 14, "kind": "replace"}, {"after_end": 25, "after_start": 21, "before_end": 21, "before_start": 17, "kind": "replace"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 15, "chars_inserted": 19}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-36cab6f9584b7fd865a0a4cd", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:14Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "8b8c4cc8e6f1a21fedee4bf0743c9c03e454b50f5eaba0e3760416d7fe0a74ec", "source_snapshot_id": "source-4efe4ecf3ebf08d338a763a5", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 2013}
{"after": {"end": 25, "start": 0, "text": "Gustav III:s Boulevard 32", "truncated": false}, "after_length": 25, "after_sha256": "bba3ec2bf3d09014ee723cdd39b8fa83a1dc3705ce0797ed375b3af7c8be027c", "annex": "IIIA", "before": {"end": 25, "start": 0, "text": "Gustav III S Boulevard 32", "truncated": false}, "before_length": 25, "before_sha256": "6117fe99f25fb7a4848fea16fe447d9ead174e8fb74f0ec2aaad6366c885562b", "change_kind": "content", "change_operations": [{"after_end": 12, "after_start": 10, "before_end": 12, "before_start": 10, "kind": "replace"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 2, "chars_inserted": 2}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-372fbab356ff14f8e68bb45e", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002097", "medicine_name": "Fampyra", "medicine_slug": "fampyra", "observed_at": "2026-10-12T19:16:07Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "a0c3ba8d58d6a43a809ecc3d142a78b10c2bd7f0b9f3a3553df2617d87daec1f", "source_snapshot_id": "source-c7a810dd21f94cd2d273f0da", "source_updated_at": "2025-08-21", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/fampyra-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1615}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 21, "start": 0, "text": "info@lucanepharma.com", "truncated": false}, "before_length": 21, "before_sha256": "44fd39e5fb919cb3d680fa630da23b49238fec29159c509f3622f272bb41c7c6", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 21, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 21, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-37f49c69a4db58864c5f0c08", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:19Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "77586d0bea0858214b43b86e91abc2d2711733b96959ead5ed0b5ecbd8ed888a", "source_snapshot_id": "source-85d476f9ad959cc117ca8f1f", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1857}
{"after": {"end": 16, "start": 0, "text": "Extrovis EU Kft.", "truncated": false}, "after_length": 16, "after_sha256": "b9216ef80e71e17798dce313e4318f03f37328f225d30ab508b7413813a908e5", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 16, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 16}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-38397f7087372842a76817d7", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/006047", "medicine_name": "Lacosamide Adroiq", "medicine_slug": "lacosamide-adroiq", "observed_at": "2026-10-12T19:07:59Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "cc83d966059d42856d0211a4f256b29b20d43593865704d6a9315aeb694f3c76", "source_snapshot_id": "source-896abba1d8391c918345d46b", "source_updated_at": "2025-09-25", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/lacosamide-adroiq-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1676}
{"after": {"end": 23, "start": 0, "text": "dpoc.norway@organon.com", "truncated": false}, "after_length": 23, "after_sha256": "b025b980392cdf94670dfebee5fbeff5ae19976bb91bc0d9205d54680e7c8926", "annex": "IIIA", "before": {"end": 23, "start": 0, "text": "info.norway@organon.com", "truncated": false}, "before_length": 23, "before_sha256": "64ba567dbdce02f4d0d01e13e8c2b99068a9ce6962d0f52339f81a5bb3f5999b", "change_kind": "content", "change_operations": [{"after_end": 2, "after_start": 0, "before_end": 3, "before_start": 0, "kind": "replace"}, {"after_end": 4, "after_start": 3, "before_end": 4, "before_start": 4, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 3, "chars_inserted": 3}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-384bcfc6c3744d15c9a98594", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/000619", "medicine_name": "Fosavance", "medicine_slug": "fosavance", "observed_at": "2026-10-12T19:01:49Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "97e93ccf75e837b32026ca36c34d5c78008211a75d5ef225c47e7b94a0027ab2", "source_snapshot_id": "source-1ef57638e1a307f1e5437651", "source_updated_at": "2026-02-12", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/fosavance-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1247}
{"after": {"end": 23, "start": 0, "text": "info@euroceptpharma.com", "truncated": false}, "after_length": 23, "after_sha256": "9297cc5acdcc837f054116992765943f7907937507b2564a99ea1327a00ac0e6", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 23, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 23}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-3898cb2216882a88bdfa2dc1", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:19Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "77586d0bea0858214b43b86e91abc2d2711733b96959ead5ed0b5ecbd8ed888a", "source_snapshot_id": "source-85d476f9ad959cc117ca8f1f", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1880}
{"after": {"end": 232, "start": 0, "text": "Chaque plaquette thermoformée contient 7, 14, 28, 49, 56 ou 98 comprimés par boîte ou dans des conditionnements multiples contenant 140 (10x14) comprimés. Toutes les présentations peuvent ne pas être commercialisées dans votre pays.", "truncated": false}, "after_length": 232, "after_sha256": "7770b0671372fe171453744ce3014d560a208202156d2bdfbacfc1a94dd3a321", "annex": "IIIA", "before": {"end": 234, "start": 0, "text": "Chaque plaquette thermoformée contient 7, 14, 28, 49, 56 ou 98 comprimés par boîte ou dans des conditionnements multiples composés de 140 (10x14) comprimés. Toutes les présentations peuvent ne pas être commercialisées dans votre pays.", "truncated": false}, "before_length": 234, "before_sha256": "2c89f09af1dfcfdfdc3926ce374fa47efe5d9a74f524c81fdffea8b906dfed81", "change_kind": "content", "change_operations": [{"after_end": 126, "after_start": 124, "before_end": 132, "before_start": 124, "kind": "replace"}, {"after_end": 131, "after_start": 127, "before_end": 133, "before_start": 133, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 8, "chars_inserted": 6}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-38afe43e27f3ea7d68ee84ec", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/000554", "medicine_name": "Emselex", "medicine_slug": "emselex", "observed_at": "2026-10-12T19:12:07Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": null, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "9a4f1d7e260c7b80eaf397503623b63302e5945b579e9612177835e07c4ab888", "source_snapshot_id": "source-3aac7bf42b99529f25ac013b", "source_updated_at": "2025-09-15", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/emselex-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 2010}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 27, "start": 0, "text": "Tél/Tel. : +31 35 528 39 57", "truncated": false}, "before_length": 27, "before_sha256": "eddad606e05a9455dde7d268d2b9f8b333c53e1b7fe89a456795afc087881b80", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 27, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 27, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-38f18f425305d7d165699e57", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:19Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "77586d0bea0858214b43b86e91abc2d2711733b96959ead5ed0b5ecbd8ed888a", "source_snapshot_id": "source-85d476f9ad959cc117ca8f1f", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1822}
{"after": {"end": 21, "start": 0, "text": "Tel: +31 35 528 39 57", "truncated": false}, "after_length": 21, "after_sha256": "7baf6601f41e49e470f803fdd4e755a86efa38be423317c000ed79963ebdd213", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 21, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 21}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-3907c8dbffc2644a276b9e93", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:14Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "8b8c4cc8e6f1a21fedee4bf0743c9c03e454b50f5eaba0e3760416d7fe0a74ec", "source_snapshot_id": "source-4efe4ecf3ebf08d338a763a5", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1971}
{"after": {"end": 10, "start": 0, "text": "6250 Kundl", "truncated": false}, "after_length": 10, "after_sha256": "67790cb68c49594409628724e5999d8cf300f8fd141207fdc89beccc8be3592d", "annex": "II", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 10, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 10}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-394841672fc762bfdb5de28f", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/000725", "medicine_name": "Binocrit", "medicine_slug": "binocrit", "observed_at": "2026-10-12T19:28:20Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "conditions", "section_type": "conditions", "source_provider": "European Medicines Agency", "source_sha256": "b2bb40c100cab3babee14bbe20cc7718cb73ac1bbb3971dfd487c4f10a0e6478", "source_snapshot_id": "source-b97c331d23a7a0f19aebfb61", "source_updated_at": "2025-07-11", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/binocrit-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1198}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 18, "start": 0, "text": "Dublin 2, D02 T380", "truncated": false}, "before_length": 18, "before_sha256": "23e6871e7960b0dadc753bc127bbea230cc8308c88b2d33704eb275a3ec1a70d", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 18, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 18, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-3949130bea77201cffe422be", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002097", "medicine_name": "Fampyra", "medicine_slug": "fampyra", "observed_at": "2026-10-12T19:16:07Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "a0c3ba8d58d6a43a809ecc3d142a78b10c2bd7f0b9f3a3553df2617d87daec1f", "source_snapshot_id": "source-c7a810dd21f94cd2d273f0da", "source_updated_at": "2025-08-21", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/fampyra-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1459}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 21, "start": 0, "text": "info@lucanepharma.com", "truncated": false}, "before_length": 21, "before_sha256": "44fd39e5fb919cb3d680fa630da23b49238fec29159c509f3622f272bb41c7c6", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 21, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 21, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-395a4f7deb40561c2c11e3e2", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:19Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "77586d0bea0858214b43b86e91abc2d2711733b96959ead5ed0b5ecbd8ed888a", "source_snapshot_id": "source-85d476f9ad959cc117ca8f1f", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1941}
{"after": {"end": 239, "start": 0, "text": "On the basis of the scientific conclusions for darifenacin the CHMP is of the opinion that the benefit-risk balance of the medicinal product(s) containing darifenacin is unchanged subject to the proposed changes to the product information.", "truncated": false}, "after_length": 239, "after_sha256": "8f99ef0fec27ea911789b1f580f1cf8d92273a64b9e1c893945a4b0b23974e5d", "annex": "IV", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 239, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 239}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-399957e2fcdf6a7848640e9a", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/000554", "medicine_name": "Emselex", "medicine_slug": "emselex", "observed_at": "2026-10-12T19:12:04Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "conditions", "section_type": "conditions", "source_provider": "European Medicines Agency", "source_sha256": "4f2565612bc728ec67b7f9c0cd5799ef2c594911c76f323aef8bf6a85adde245", "source_snapshot_id": "source-1fda25b331eb198b8b93feb3", "source_updated_at": "2025-09-15", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/emselex-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 2087}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 16, "start": 0, "text": "Extrovis EU Ltd.", "truncated": false}, "before_length": 16, "before_sha256": "f462ad48e7aef0bc82148ce088af1897d99ed86993128f30d506b27d3108a929", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 16, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 16, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-39dabbd4b76078148151800e", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/006047", "medicine_name": "Lacosamide Adroiq", "medicine_slug": "lacosamide-adroiq", "observed_at": "2026-10-12T19:07:59Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "cc83d966059d42856d0211a4f256b29b20d43593865704d6a9315aeb694f3c76", "source_snapshot_id": "source-896abba1d8391c918345d46b", "source_updated_at": "2025-09-25", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/lacosamide-adroiq-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1738}
{"after": {"end": 36, "start": 0, "text": "Accord Healthcare Single Member S.A.", "truncated": false}, "after_length": 36, "after_sha256": "b46201b7d0efe1b953d755aa025769e26c5374f0fb886ee6f67efa377121db82", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 36, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 36}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-3a0fb74e83030999db460a65", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/003984", "medicine_name": "Bortezomib Accord", "medicine_slug": "bortezomib-accord", "observed_at": "2026-10-12T13:47:15Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "150a191aaf0a1e169e9d5fa2530f0eccb4e3d46509faf5ec5ee975a2e67788c4", "source_snapshot_id": "source-cba4680b7fbd2c536884abd8", "source_updated_at": "2026-03-25", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/bortezomib-accord-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 4788}
{"after": {"end": 26, "start": 0, "text": "Dipharma Arzneimittel GmbH", "truncated": false}, "after_length": 26, "after_sha256": "d8cb257047b7439a3be44a22f3227e45df27054340bbfa9cd6525bbf1d237add", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 26, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 26}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-3a40a397070fe0feb289b7e4", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:14Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "8b8c4cc8e6f1a21fedee4bf0743c9c03e454b50f5eaba0e3760416d7fe0a74ec", "source_snapshot_id": "source-4efe4ecf3ebf08d338a763a5", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1491}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 21, "start": 0, "text": "Tel: + 33 153 868 750", "truncated": false}, "before_length": 21, "before_sha256": "efffe29324e968019e6e2b111904182ba06d83e76b1f29b933bed9dd8779c114", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 21, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 21, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-3a83c86dbe467d6b52ebde74", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:14Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "8b8c4cc8e6f1a21fedee4bf0743c9c03e454b50f5eaba0e3760416d7fe0a74ec", "source_snapshot_id": "source-4efe4ecf3ebf08d338a763a5", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1489}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 13, "start": 0, "text": "Lucane Pharma", "truncated": false}, "before_length": 13, "before_sha256": "e338afdb64acf1a6e2083a50318853589248451dd3aa707181ba02641a8521e8", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 13, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 13, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-3a8d82a2417b4cfc201a6b2a", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:14Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "8b8c4cc8e6f1a21fedee4bf0743c9c03e454b50f5eaba0e3760416d7fe0a74ec", "source_snapshot_id": "source-4efe4ecf3ebf08d338a763a5", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1976}
{"after": {"end": 22, "start": 0, "text": "IMED Poland Sp. z o.o.", "truncated": false}, "after_length": 22, "after_sha256": "b3265866c253edae29f5501eb68307d984be0f139bc8dba8b343d9b3ff61e415", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 22, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 22}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-3aa36414c319cf53841b6884", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:14Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "8b8c4cc8e6f1a21fedee4bf0743c9c03e454b50f5eaba0e3760416d7fe0a74ec", "source_snapshot_id": "source-4efe4ecf3ebf08d338a763a5", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1534}
{"after": {"end": 26, "start": 0, "text": "Eckenheimer Landstraße 100", "truncated": false}, "after_length": 26, "after_sha256": "fdce1a9bd200c5ddd476c1ea5676b9ffbbea723f7353ad6fbc1fe019dcb86c07", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 26, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 26}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-3aa91756204de614ecc16069", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002097", "medicine_name": "Fampyra", "medicine_slug": "fampyra", "observed_at": "2026-10-12T19:15:51Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "d9fe8aaaa611a84801d6308b13685258b5248df9022536697939afdf66fc1719", "source_snapshot_id": "source-ff8e0599077f0d01044dc867", "source_updated_at": "2025-08-21", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/fampyra-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1565}
{"after": {"end": 18, "start": 0, "text": "Raktarvarosi Ut 9,", "truncated": false}, "after_length": 18, "after_sha256": "71dd279084ba9f87e79f1095d3565620050fda91d248303c2e19c46598fb0c2b", "annex": "I", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "administrative", "change_operations": [{"after_end": 18, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 18}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-3adb8eb4c0e1e7ca74937abb", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/006047", "medicine_name": "Lacosamide Adroiq", "medicine_slug": "lacosamide-adroiq", "observed_at": "2026-10-12T19:07:56Z", "pipeline_version": "2.0.0", "presentation_label": "Lacosamide Adroiq 10 mg/ml solution for infusion", "presentation_occurrence": 1, "presentation_status": "heading_extracted_unverified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "7", "section_type": "administrative", "source_provider": "European Medicines Agency", "source_sha256": "0578c53a5e1c785c4d9d4dc0dabae49dbfa89e237aa571556bee548c3f9cf4d5", "source_snapshot_id": "source-64831dec5ebf55535e19d91b", "source_updated_at": "2025-09-25", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/lacosamide-adroiq-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 920}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 56, "start": 0, "text": "35/36 Baldoyle Industrial Estate, Grange Road, Dublin 13", "truncated": false}, "before_length": 56, "before_sha256": "f0fa66e07d117c6c91c11210809d32b098e6ea28fc318be9df3a372f6c002a1a", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 56, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 56, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-3ae6189065ddccaf760de5d4", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/004025", "medicine_name": "Lopinavir/Ritonavir Viatris (previously Ritonavir Mylan)", "medicine_slug": "lopinavir-ritonavir-viatris-previously-ritonavir-mylan", "observed_at": "2026-10-12T19:14:59Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "d782e33ec97bc43bb54f942c83f07f89482c9a433e3846beaffe05b4a52b4b36", "source_snapshot_id": "source-ff48b23a80b98be4c15aa440", "source_updated_at": "2025-09-08", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/lopinavir-ritonavir-viatris-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 2880}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 6, "start": 0, "text": "Airija", "truncated": false}, "before_length": 6, "before_sha256": "122e7e88d23518b941923b1d4da61e395a23dfecce5fed29aab991102acd4623", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 6, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 6, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-3ae680813ad0bac04af78e94", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002097", "medicine_name": "Fampyra", "medicine_slug": "fampyra", "observed_at": "2026-10-12T19:16:07Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "a0c3ba8d58d6a43a809ecc3d142a78b10c2bd7f0b9f3a3553df2617d87daec1f", "source_snapshot_id": "source-c7a810dd21f94cd2d273f0da", "source_updated_at": "2025-08-21", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/fampyra-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1387}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "I", "before": {"end": 16, "start": 0, "text": "2000, Szentendre", "truncated": false}, "before_length": 16, "before_sha256": "e7eec80782064f78f9518825c15b4c5b91e88a8bf75f429cef005c9630048901", "change_kind": "administrative", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 16, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 16, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-3b10acdc679f2488672a4cde", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/006047", "medicine_name": "Lacosamide Adroiq", "medicine_slug": "lacosamide-adroiq", "observed_at": "2026-10-12T19:07:59Z", "pipeline_version": "2.0.0", "presentation_label": "Lacosamide Adroiq 10 mg/ml solution pour perfusion", "presentation_occurrence": 1, "presentation_status": "heading_extracted_unverified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "7", "section_type": "administrative", "source_provider": "European Medicines Agency", "source_sha256": "cc83d966059d42856d0211a4f256b29b20d43593865704d6a9315aeb694f3c76", "source_snapshot_id": "source-896abba1d8391c918345d46b", "source_updated_at": "2025-09-25", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/lacosamide-adroiq-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 915}
{"after": {"end": 220, "start": 0, "text": "Si votre bébé est âgé de moins de 4 semaines, consultez votre médecin ou votre pharmacien avant de lui donner cet arôme, en particulier si le bébé reçoit d’autres médicaments contenant du propylène glycol ou de l’alcool.", "truncated": false}, "after_length": 220, "after_sha256": "82d965d7f3933904d2d63d21dea860afc36b53ccacc19115813b6d341af8ee25", "annex": "IIIA", "before": {"end": 224, "start": 0, "text": "Si votre bébé est âgé de moins de 4 semaines, consultez votre médecin ou votre pharmacien avant de lui donner ce médicament, en particulier si le bébé reçoit d’autres médicaments contenant du propylène glycol ou de l’alcool.", "truncated": false}, "before_length": 224, "before_sha256": "4da4000b63141de5814a102ec1a2df16618663fa4660b111ee9514bcbe2003b7", "change_kind": "content", "change_operations": [{"after_end": 113, "after_start": 112, "before_end": 112, "before_start": 112, "kind": "insert"}, {"after_end": 114, "after_start": 114, "before_end": 118, "before_start": 113, "kind": "delete"}, {"after_end": 117, "after_start": 115, "before_end": 119, "before_start": 119, "kind": "insert"}, {"after_end": 119, "after_start": 119, "before_end": 123, "before_start": 121, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 7, "chars_inserted": 3}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-3b2b5736ef5479074ad1e399", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:19Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "77586d0bea0858214b43b86e91abc2d2711733b96959ead5ed0b5ecbd8ed888a", "source_snapshot_id": "source-85d476f9ad959cc117ca8f1f", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1646}
{"after": {"end": 24, "start": 0, "text": "Warnings and precautions", "truncated": false}, "after_length": 24, "after_sha256": "7c50a9f032d2bc78cb5840e24dc5db22ab4301d6230e27ee968e39233617a1c4", "annex": "IIIA", "before": {"end": 25, "start": 0, "text": "Warnings and precautions:", "truncated": false}, "before_length": 25, "before_sha256": "8c649ad72edb8eac6b88e557f841e48a7a6e3defb316768cd8b5ec441df9028a", "change_kind": "content", "change_operations": [{"after_end": 24, "after_start": 24, "before_end": 25, "before_start": 24, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 1, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-3b4817c652c9f21ff1785247", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/000554", "medicine_name": "Emselex", "medicine_slug": "emselex", "observed_at": "2026-10-12T19:12:04Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "4f2565612bc728ec67b7f9c0cd5799ef2c594911c76f323aef8bf6a85adde245", "source_snapshot_id": "source-1fda25b331eb198b8b93feb3", "source_updated_at": "2025-09-15", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/emselex-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1899}
{"after": {"end": 29, "start": 0, "text": "Tél/Tel: +46 (0) 8 545 286 60", "truncated": false}, "after_length": 29, "after_sha256": "672d350e486dbb33717dc4c2744825e72dd0b3f703f12d852ec53e65d676b58d", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 29, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 29}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-3b6c6c9c15f6845af62a7804", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/000980", "medicine_name": "Samsca", "medicine_slug": "samsca", "observed_at": "2026-10-12T13:28:23Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "b92d73a758b8976c4438a072d544f0d6c603112c90dfc9c084d362ce62419257", "source_snapshot_id": "source-15b8b5681aba542ec1668c0b", "source_updated_at": "2026-08-20", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/samsca-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1275}
{"after": {"end": 28, "start": 0, "text": "InfoDeutschland@dipharma.com", "truncated": false}, "after_length": 28, "after_sha256": "f5ed16f98f15b7236207edade83fdde3fb32cec02f927aaba23223b9f6077f21", "annex": "IIIA", "before": {"end": 13, "start": 0, "text": "Lucane Pharma", "truncated": false}, "before_length": 13, "before_sha256": "e338afdb64acf1a6e2083a50318853589248451dd3aa707181ba02641a8521e8", "change_kind": "content", "change_operations": [{"after_end": 6, "after_start": 0, "before_end": 1, "before_start": 0, "kind": "replace"}, {"after_end": 9, "after_start": 7, "before_end": 2, "before_start": 2, "kind": "insert"}, {"after_end": 12, "after_start": 10, "before_end": 3, "before_start": 3, "kind": "insert"}, {"after_end": 19, "after_start": 14, "before_end": 8, "before_start": 5, "kind": "replace"}, {"after_end": 28, "after_start": 24, "before_end": 13, "before_start": 13, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 4, "chars_inserted": 19}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-3b93dac30ad95792356ad583", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:19Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "77586d0bea0858214b43b86e91abc2d2711733b96959ead5ed0b5ecbd8ed888a", "source_snapshot_id": "source-85d476f9ad959cc117ca8f1f", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1463}
{"after": {"end": 34, "start": 0, "text": "Orteliuslaan 1000, 3528 BD Utrecht", "truncated": false}, "after_length": 34, "after_sha256": "46a90fc46ae308c2beeb35ead613fcf3ade5a51e2217a834de3fa5972dab9eec", "annex": "I", "before": {"end": 34, "start": 0, "text": "Papendorpseweg 83, 3528 BJ Utrecht", "truncated": false}, "before_length": 34, "before_sha256": "60888004fee306d543204a2a97b5d75a5110dd00a9886110b9dbc8d4fba5db60", "change_kind": "administrative", "change_operations": [{"after_end": 9, "after_start": 0, "before_end": 1, "before_start": 0, "kind": "replace"}, {"after_end": 11, "after_start": 10, "before_end": 4, "before_start": 2, "kind": "replace"}, {"after_end": 12, "after_start": 12, "before_end": 14, "before_start": 5, "kind": "delete"}, {"after_end": 17, "after_start": 13, "before_end": 17, "before_start": 15, "kind": "replace"}, {"after_end": 26, "after_start": 25, "before_end": 26, "before_start": 25, "kind": "replace"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 15, "chars_inserted": 15}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-3ba53284d68dc16891a47952", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/001021", "medicine_name": "Adcirca (previously Tadalafil Lilly)", "medicine_slug": "adcirca-previously-tadalafil-lilly", "observed_at": "2026-10-12T19:02:45Z", "pipeline_version": "2.0.0", "presentation_label": "ADCIRCA 2 mg/mL suspension buvable", "presentation_occurrence": 2, "presentation_status": "heading_extracted_unverified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "7", "section_type": "administrative", "source_provider": "European Medicines Agency", "source_sha256": "cdbefcd6143c93e81f3c826bea8d3d01bffc55652e0f792243097df75c452721", "source_snapshot_id": "source-a1e85476de17f5a8664f7766", "source_updated_at": "2026-01-28", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/adcirca-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1221}
{"after": {"end": 25, "start": 0, "text": "Musculoskeletal disorders", "truncated": false}, "after_length": 25, "after_sha256": "554fab09c18c12d65cee54d5caa96534b1925e5ff23a67e98a7c7c04e66bf714", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 25, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 25}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-3bc14625716e6c6ba13e6a34", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/000235", "medicine_name": "Arava", "medicine_slug": "arava", "observed_at": "2026-10-12T13:27:58Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 3, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "2efff7967e2237bf8343431eef5e08b56c2441eb8a691a90c64b2635109fd697", "source_snapshot_id": "source-08b4eba1f67d2654148f41c4", "source_updated_at": "2026-09-07", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/arava-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 3039}
{"after": {"end": 81, "start": 0, "text": "Fréquence indéterminée (ne peut être estimée sur la base des données disponibles)", "truncated": false}, "after_length": 81, "after_sha256": "75ccbf7d675659d67f64d5a6b8b0887c0ca93da4861103bffd6fcb14ad37692c", "annex": "IIIA", "before": {"end": 94, "start": 0, "text": "Fréquence indéterminée (la fréquence ne peut être estimée sur la base des données disponibles)", "truncated": false}, "before_length": 94, "before_sha256": "db812e821bc4e2e2e193f4836d6898bf7d2562688ff1b90f19dcc697e86316dd", "change_kind": "content", "change_operations": [{"after_end": 24, "after_start": 24, "before_end": 37, "before_start": 24, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 13, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-3c3e7a00a0cbd75b9690acda", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/000554", "medicine_name": "Emselex", "medicine_slug": "emselex", "observed_at": "2026-10-12T19:12:07Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": null, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "9a4f1d7e260c7b80eaf397503623b63302e5945b579e9612177835e07c4ab888", "source_snapshot_id": "source-3aac7bf42b99529f25ac013b", "source_updated_at": "2025-09-15", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/emselex-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1791}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 29, "start": 0, "text": "Tél/Tel: +31 (0) 20 85 46 555", "truncated": false}, "before_length": 29, "before_sha256": "c6fd2acd87a106185334bd33a7213eb7d433542e847a90de387d56c3c2992a3f", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 29, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 29, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-3c57ece358389fa106c67b94", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/000980", "medicine_name": "Samsca", "medicine_slug": "samsca", "observed_at": "2026-10-12T13:28:23Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "b92d73a758b8976c4438a072d544f0d6c603112c90dfc9c084d362ce62419257", "source_snapshot_id": "source-15b8b5681aba542ec1668c0b", "source_updated_at": "2026-08-20", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/samsca-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1277}
{"after": {"end": 22, "start": 0, "text": "Merz Therapeutics GmbH", "truncated": false}, "after_length": 22, "after_sha256": "059f049c7d0846aaadcf2573280d52110f302d4ecc7b38debd004571cd1e9d5e", "annex": "IIIA", "before": {"end": 35, "start": 0, "text": "Acorda Therapeutics Ireland Limited", "truncated": false}, "before_length": 35, "before_sha256": "d94d3153d193ed26567f2b4ed48df016d81c534e7c0cb1a6655a63f0083383ff", "change_kind": "content", "change_operations": [{"after_end": 2, "after_start": 0, "before_end": 3, "before_start": 0, "kind": "replace"}, {"after_end": 4, "after_start": 3, "before_end": 6, "before_start": 4, "kind": "replace"}, {"after_end": 19, "after_start": 18, "before_end": 30, "before_start": 20, "kind": "replace"}, {"after_end": 22, "after_start": 20, "before_end": 35, "before_start": 31, "kind": "replace"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 19, "chars_inserted": 6}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-3c6c0f0439fbde1a07fa938e", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002097", "medicine_name": "Fampyra", "medicine_slug": "fampyra", "observed_at": "2026-10-12T19:15:51Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "d9fe8aaaa611a84801d6308b13685258b5248df9022536697939afdf66fc1719", "source_snapshot_id": "source-ff8e0599077f0d01044dc867", "source_updated_at": "2025-08-21", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/fampyra-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1436}
{"after": {"end": 9, "start": 0, "text": "Not known", "truncated": false}, "after_length": 9, "after_sha256": "117adf013b8521b57cc432f1d680aa8ca8ffe7ac83edfa7e0a5867794a6429cc", "annex": "I", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 9, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": true, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 9}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-3c7d847e5f16c429cdb6ddae", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/000554", "medicine_name": "Emselex", "medicine_slug": "emselex", "observed_at": "2026-10-12T19:12:04Z", "pipeline_version": "2.0.0", "presentation_label": "Emselex 7.5 mg prolonged-release tablets", "presentation_occurrence": 1, "presentation_status": "heading_extracted_unverified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "4.8", "section_type": "adverse_reactions", "source_provider": "European Medicines Agency", "source_sha256": "4f2565612bc728ec67b7f9c0cd5799ef2c594911c76f323aef8bf6a85adde245", "source_snapshot_id": "source-1fda25b331eb198b8b93feb3", "source_updated_at": "2025-09-15", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/emselex-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 181}
{"after": {"end": 17, "start": 0, "text": "Torokbalint, 2045", "truncated": false}, "after_length": 17, "after_sha256": "d6dbae334e70b70d590689409d24e6c0cda7d30fd5104550892da04a039d1276", "annex": "III", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "unassigned", "change_operations": [{"after_end": 17, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 17}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-3cbbe3bf65ad3423744309b4", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/006047", "medicine_name": "Lacosamide Adroiq", "medicine_slug": "lacosamide-adroiq", "observed_at": "2026-10-12T19:07:56Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "", "section_type": "unassigned", "source_provider": "European Medicines Agency", "source_sha256": "0578c53a5e1c785c4d9d4dc0dabae49dbfa89e237aa571556bee548c3f9cf4d5", "source_snapshot_id": "source-64831dec5ebf55535e19d91b", "source_updated_at": "2025-09-25", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/lacosamide-adroiq-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1348}
{"after": {"end": 48, "start": 0, "text": "Little Connell, Newbridge, Co. Kildare, W12 HX57", "truncated": false}, "after_length": 48, "after_sha256": "e24ae6f19ff1387cb1129051f52d1144ea2d1dd8a59cbed0f1f16a9c19777dba", "annex": "II", "before": {"end": 38, "start": 0, "text": "Little Connell, Newbridge, Co. Kildare", "truncated": false}, "before_length": 38, "before_sha256": "29c5d08dec823cc45f23c459d73a960a08283dd9f284ea5b10840876e8d522a6", "change_kind": "content", "change_operations": [{"after_end": 48, "after_start": 38, "before_end": 38, "before_start": 38, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 10}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-3d3003acaf99fd8c7dbdbb0b", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/000273", "medicine_name": "Rapamune", "medicine_slug": "rapamune", "observed_at": "2026-10-12T13:39:00Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "conditions", "section_type": "conditions", "source_provider": "European Medicines Agency", "source_sha256": "5ec17411e4c1a81999ea8a4a3fb0ca56fd42f205f10b55b04218801cee6c6cfa", "source_snapshot_id": "source-dda7a9536e6e3b6e820a6139", "source_updated_at": "2026-05-04", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/rapamune-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1475}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 18, "start": 0, "text": "Dublin 2, D02 T380", "truncated": false}, "before_length": 18, "before_sha256": "23e6871e7960b0dadc753bc127bbea230cc8308c88b2d33704eb275a3ec1a70d", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 18, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 18, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-3d42950d2be967276f7b604c", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002097", "medicine_name": "Fampyra", "medicine_slug": "fampyra", "observed_at": "2026-10-12T19:16:07Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "a0c3ba8d58d6a43a809ecc3d142a78b10c2bd7f0b9f3a3553df2617d87daec1f", "source_snapshot_id": "source-c7a810dd21f94cd2d273f0da", "source_updated_at": "2025-08-21", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/fampyra-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1469}
{"after": {"end": 23, "start": 0, "text": "60318 Frankfurt am Main", "truncated": false}, "after_length": 23, "after_sha256": "24c3191b5088b20c209c4387a8127297e54c776e161d305c9e57956a13b7cbbe", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 23, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 23}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-3d467507e68482886e412433", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002097", "medicine_name": "Fampyra", "medicine_slug": "fampyra", "observed_at": "2026-10-12T19:16:07Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "a0c3ba8d58d6a43a809ecc3d142a78b10c2bd7f0b9f3a3553df2617d87daec1f", "source_snapshot_id": "source-c7a810dd21f94cd2d273f0da", "source_updated_at": "2025-08-21", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/fampyra-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1582}
{"after": {"end": 23, "start": 0, "text": "info@euroceptpharma.com", "truncated": false}, "after_length": 23, "after_sha256": "9297cc5acdcc837f054116992765943f7907937507b2564a99ea1327a00ac0e6", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 23, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 23}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-3e28bbdfa8337d28c2d861e5", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:14Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "8b8c4cc8e6f1a21fedee4bf0743c9c03e454b50f5eaba0e3760416d7fe0a74ec", "source_snapshot_id": "source-4efe4ecf3ebf08d338a763a5", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 2047}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "I", "before": {"end": 387, "start": 0, "text": "The following events have been reported in association with darifenacin use in worldwide post-marketing experience: generalised hypersensitivity reactions including angioedema, depressed mood/mood alterations, hallucination. Because these spontaneously reported events are from the worldwide post-marketing experience, the frequency of events cannot be estimated from the available data.", "truncated": false}, "before_length": 387, "before_sha256": "d00f072d246c0b54154e0c2d4cd81b024833b5d70f3e815410be3c4474cf89dd", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 387, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": true, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 387, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-3e2d7d7efeac0b36c298d11b", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/000554", "medicine_name": "Emselex", "medicine_slug": "emselex", "observed_at": "2026-10-12T19:12:04Z", "pipeline_version": "2.0.0", "presentation_label": "Emselex 7.5 mg prolonged-release tablets", "presentation_occurrence": 1, "presentation_status": "heading_extracted_unverified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "4.8", "section_type": "adverse_reactions", "source_provider": "European Medicines Agency", "source_sha256": "4f2565612bc728ec67b7f9c0cd5799ef2c594911c76f323aef8bf6a85adde245", "source_snapshot_id": "source-1fda25b331eb198b8b93feb3", "source_updated_at": "2025-09-15", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/emselex-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 241}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 162, "start": 0, "text": "- if you experience unexplained muscle pain, tenderness (soreness when the muscle is pressed) or muscle weakness with or without fever while taking this medicine.", "truncated": false}, "before_length": 162, "before_sha256": "f890cf5f6db7b3cdd8b8f8c398dbb8619759e91d8e962d3a402397305c598127", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 162, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 162, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-3e3ad0df10d402649e9a56a5", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/000235", "medicine_name": "Arava", "medicine_slug": "arava", "observed_at": "2026-10-12T13:27:58Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 3, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "2efff7967e2237bf8343431eef5e08b56c2441eb8a691a90c64b2635109fd697", "source_snapshot_id": "source-08b4eba1f67d2654148f41c4", "source_updated_at": "2026-09-07", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/arava-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 3037}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "I", "before": {"end": 18, "start": 0, "text": "Pátriárka utca 14.", "truncated": false}, "before_length": 18, "before_sha256": "488a80d25b682a58591b4751c4687d5b516ccd6a004748e40d4e8f1454217b07", "change_kind": "administrative", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 18, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 18, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-3e72a675a8a91c72564ab562", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/006047", "medicine_name": "Lacosamide Adroiq", "medicine_slug": "lacosamide-adroiq", "observed_at": "2026-10-12T19:07:59Z", "pipeline_version": "2.0.0", "presentation_label": "Lacosamide Adroiq 10 mg/ml solution pour perfusion", "presentation_occurrence": 1, "presentation_status": "heading_extracted_unverified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "7", "section_type": "administrative", "source_provider": "European Medicines Agency", "source_sha256": "cc83d966059d42856d0211a4f256b29b20d43593865704d6a9315aeb694f3c76", "source_snapshot_id": "source-896abba1d8391c918345d46b", "source_updated_at": "2025-09-25", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/lacosamide-adroiq-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 914}
{"after": {"end": 69, "start": 0, "text": "Confusion, depressed mood/mood altered, hallucination, muscle spasms.", "truncated": false}, "after_length": 69, "after_sha256": "5a77dca70cd9eeafa3e30ec4a922e6d3fec869393ba43ec4a2af4169726d70d1", "annex": "IIIA", "before": {"end": 47, "start": 0, "text": "Depressed mood/mood alterations, hallucination.", "truncated": false}, "before_length": 47, "before_sha256": "5a84bee65df7fc0dc0346e4f215076e2e9bac102a607e0355ab0621fcc17874e", "change_kind": "content", "change_operations": [{"after_end": 12, "after_start": 0, "before_end": 1, "before_start": 0, "kind": "replace"}, {"after_end": 38, "after_start": 36, "before_end": 31, "before_start": 25, "kind": "replace"}, {"after_end": 68, "after_start": 53, "before_end": 46, "before_start": 46, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 7, "chars_inserted": 29}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-3ee382ce4d9a15521d5be517", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/000554", "medicine_name": "Emselex", "medicine_slug": "emselex", "observed_at": "2026-10-12T19:12:04Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "4f2565612bc728ec67b7f9c0cd5799ef2c594911c76f323aef8bf6a85adde245", "source_snapshot_id": "source-1fda25b331eb198b8b93feb3", "source_updated_at": "2025-09-15", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/emselex-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1990}
{"after": {"end": 16, "start": 0, "text": "Extrovis EU Kft.", "truncated": false}, "after_length": 16, "after_sha256": "b9216ef80e71e17798dce313e4318f03f37328f225d30ab508b7413813a908e5", "annex": "IIIB", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "unassigned", "change_operations": [{"after_end": 16, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 16}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-3ee3999845497605e1e669c9", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/006047", "medicine_name": "Lacosamide Adroiq", "medicine_slug": "lacosamide-adroiq", "observed_at": "2026-10-12T19:07:56Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "", "section_type": "unassigned", "source_provider": "European Medicines Agency", "source_sha256": "0578c53a5e1c785c4d9d4dc0dabae49dbfa89e237aa571556bee548c3f9cf4d5", "source_snapshot_id": "source-64831dec5ebf55535e19d91b", "source_updated_at": "2025-09-25", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/lacosamide-adroiq-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 2003}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 21, "start": 0, "text": "info@lucanepharma.com", "truncated": false}, "before_length": 21, "before_sha256": "44fd39e5fb919cb3d680fa630da23b49238fec29159c509f3622f272bb41c7c6", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 21, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 21, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-3f2d1cf20e0b0d26295eec63", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:19Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "77586d0bea0858214b43b86e91abc2d2711733b96959ead5ed0b5ecbd8ed888a", "source_snapshot_id": "source-85d476f9ad959cc117ca8f1f", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1791}
{"after": {"end": 16, "start": 0, "text": "Extrovis EU Kft.", "truncated": false}, "after_length": 16, "after_sha256": "b9216ef80e71e17798dce313e4318f03f37328f225d30ab508b7413813a908e5", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 16, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 16}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-3f5a1b38114bd2e84bfeff91", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/006047", "medicine_name": "Lacosamide Adroiq", "medicine_slug": "lacosamide-adroiq", "observed_at": "2026-10-12T19:07:59Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "cc83d966059d42856d0211a4f256b29b20d43593865704d6a9315aeb694f3c76", "source_snapshot_id": "source-896abba1d8391c918345d46b", "source_updated_at": "2025-09-25", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/lacosamide-adroiq-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1208}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 61, "start": 0, "text": "McDermott Laboratories Limited trading as Gerard Laboratories", "truncated": false}, "before_length": 61, "before_sha256": "f28bee890ae72cccea9b87c3be57809b0afb7f64e286de2c77b2c05b413da700", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 61, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 61, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-3f72a054ed5556bccc01f6f6", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/004025", "medicine_name": "Lopinavir/Ritonavir Viatris (previously Ritonavir Mylan)", "medicine_slug": "lopinavir-ritonavir-viatris-previously-ritonavir-mylan", "observed_at": "2026-10-12T19:12:46Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "3e30663f02732816ed8779d7a929d500c824ae15aeaee9144ca6eef11900e273", "source_snapshot_id": "source-c58e019b5bec1fb24569e83e", "source_updated_at": "2025-09-08", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/lopinavir-ritonavir-viatris-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 2966}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 22, "start": 0, "text": "PAION Deutschland GmbH", "truncated": false}, "before_length": 22, "before_sha256": "695a7a774aacd3b6e919ed980dbfb2ee37bbe6099af551312782cc722dbb2b31", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 22, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 22, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-3f7a52375f08111fb33fb654", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/005246", "medicine_name": "Byfavo", "medicine_slug": "byfavo", "observed_at": "2026-10-12T13:28:14Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "92a178ceb705631219efa40b1d0da73ebe6dfa866bc1b24d7e4dab9ded8a6861", "source_snapshot_id": "source-d485be5d9060fd557be910b2", "source_updated_at": "2026-08-26", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/byfavo-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 2291}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 23, "start": 0, "text": "info@euroceptpharma.com", "truncated": false}, "before_length": 23, "before_sha256": "9297cc5acdcc837f054116992765943f7907937507b2564a99ea1327a00ac0e6", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 23, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 23, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-3fa8fc941ccc2725c1f40438", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:19Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "77586d0bea0858214b43b86e91abc2d2711733b96959ead5ed0b5ecbd8ed888a", "source_snapshot_id": "source-85d476f9ad959cc117ca8f1f", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1441}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "I", "before": {"end": 20, "start": 0, "text": "10 Earlsfort Terrace", "truncated": false}, "before_length": 20, "before_sha256": "22951bbf6ee77815d0c07b3af5f0a66e17d277636971c4eaff372dea65dcb193", "change_kind": "administrative", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 20, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 20, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-3fd29a32f6e954a0f3f4f3ba", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002097", "medicine_name": "Fampyra", "medicine_slug": "fampyra", "observed_at": "2026-10-12T19:15:51Z", "pipeline_version": "2.0.0", "presentation_label": "Fampyra 10 mg prolonged-release tablets", "presentation_occurrence": 1, "presentation_status": "heading_extracted_unverified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "7", "section_type": "administrative", "source_provider": "European Medicines Agency", "source_sha256": "d9fe8aaaa611a84801d6308b13685258b5248df9022536697939afdf66fc1719", "source_snapshot_id": "source-ff8e0599077f0d01044dc867", "source_updated_at": "2025-08-21", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/fampyra-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 683}
{"after": {"end": 171, "start": 0, "text": "This document is the approved product information for Sprycel, with the changes since the previous procedure affecting the product information (EMA/VR/0000320681) tracked.", "truncated": false}, "after_length": 171, "after_sha256": "3a6eec26e52919aea3a8051412ba2289d8ba8a7036c100b46c50b81e3931f746", "annex": "", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "unassigned", "change_operations": [{"after_end": 171, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 171}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-3fd8cc7fc15625e9bc7a2de6", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/000709", "medicine_name": "Sprycel", "medicine_slug": "sprycel", "observed_at": "2026-10-12T13:27:33Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": null, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "", "section_type": "unassigned", "source_provider": "European Medicines Agency", "source_sha256": "7b2a270ca60f948a69940b5bd26552042c4c20cae01b420ad781477ba43b0fe9", "source_snapshot_id": "source-c03fb6f08190e30934edc22f", "source_updated_at": "2026-10-02", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/sprycel-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 0}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 21, "start": 0, "text": "Tel: + 33 153 868 750", "truncated": false}, "before_length": 21, "before_sha256": "efffe29324e968019e6e2b111904182ba06d83e76b1f29b933bed9dd8779c114", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 21, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 21, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-4002bd3baa7d0a6d8d50100d", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:19Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "77586d0bea0858214b43b86e91abc2d2711733b96959ead5ed0b5ecbd8ed888a", "source_snapshot_id": "source-85d476f9ad959cc117ca8f1f", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1433}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 162, "start": 0, "text": "- if you experience unexplained muscle pain, tenderness (soreness when the muscle is pressed) or muscle weakness with or without fever while taking this medicine.", "truncated": false}, "before_length": 162, "before_sha256": "f890cf5f6db7b3cdd8b8f8c398dbb8619759e91d8e962d3a402397305c598127", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 162, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 162, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-402f88cc18b0112bd5ef6e97", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/000235", "medicine_name": "Arava", "medicine_slug": "arava", "observed_at": "2026-10-12T13:27:58Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 3, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "2efff7967e2237bf8343431eef5e08b56c2441eb8a691a90c64b2635109fd697", "source_snapshot_id": "source-08b4eba1f67d2654148f41c4", "source_updated_at": "2026-09-07", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/arava-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 3415}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 13, "start": 0, "text": "Lucane Pharma", "truncated": false}, "before_length": 13, "before_sha256": "e338afdb64acf1a6e2083a50318853589248451dd3aa707181ba02641a8521e8", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 13, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 13, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-4062884e22c41db4562a15f3", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:14Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "8b8c4cc8e6f1a21fedee4bf0743c9c03e454b50f5eaba0e3760416d7fe0a74ec", "source_snapshot_id": "source-4efe4ecf3ebf08d338a763a5", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1588}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 18, "start": 0, "text": "Pátriárka utca 14.", "truncated": false}, "before_length": 18, "before_sha256": "488a80d25b682a58591b4751c4687d5b516ccd6a004748e40d4e8f1454217b07", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 18, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 18, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-40af659e53300179ea622855", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/006047", "medicine_name": "Lacosamide Adroiq", "medicine_slug": "lacosamide-adroiq", "observed_at": "2026-10-12T19:07:59Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "cc83d966059d42856d0211a4f256b29b20d43593865704d6a9315aeb694f3c76", "source_snapshot_id": "source-896abba1d8391c918345d46b", "source_updated_at": "2025-09-25", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/lacosamide-adroiq-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1115}
{"after": {"end": 546, "start": 0, "text": "La dose quotidienne totale doit être répartie en plusieurs prises équivalentes administrées au moment de chaque repas ou prise alimentaire (par exemple 4 à 6 fois par jour chez le petit enfant). Les granulés peuvent être directement avalés à l’aide d’une boisson (par exemple, eau, jus de fruit, ou préparations infantiles sans protéines) ou saupoudrés sur une cuillerée d'aliments solides (par exemple, purée de pomme de terre, compote de pommes) ; dans ce cas, il est important que la prise soit immédiate afin de préserver le masquage du goût.", "truncated": false}, "after_length": 546, "after_sha256": "9e8ce824c03baf69bf91cdd19c4eedcbb17e532e47fe0f5e5b442e60c41302e2", "annex": "I", "before": {"end": 520, "start": 0, "text": "La dose quotidienne totale doit être répartie en plusieurs prises équivalentes administrées au moment de chaque repas ou prise alimentaire (par exemple 4 à 6 fois par jour chez le petit enfant). Les granulés peuvent être directement avalés à l’aide d’une boisson (eau, jus de fruit, ou préparations infantiles sans protéines) ou saupoudrés sur une cuillerée d'aliments solides (purée de pomme de terre, compote de pommes) ; dans ce cas, il est important que la prise soit immédiate afin de préserver le masquage du goût.", "truncated": false}, "before_length": 520, "before_sha256": "921ea22bb14e43e07ab46c8ad8fe9279ee1dcb26a67dceadf5059a148a431f7e", "change_kind": "content", "change_operations": [{"after_end": 277, "after_start": 264, "before_end": 264, "before_start": 264, "kind": "insert"}, {"after_end": 404, "after_start": 391, "before_end": 378, "before_start": 378, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": true, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 26}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-40d2eeb2f6d1a8222cbbf9c5", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:19Z", "pipeline_version": "2.0.0", "presentation_label": "PHEBURANE 483 mg/g granulés", "presentation_occurrence": 1, "presentation_status": "heading_extracted_unverified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "4.2", "section_type": "posology", "source_provider": "European Medicines Agency", "source_sha256": "77586d0bea0858214b43b86e91abc2d2711733b96959ead5ed0b5ecbd8ed888a", "source_snapshot_id": "source-85d476f9ad959cc117ca8f1f", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 88}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 21, "start": 0, "text": "info@lucanepharma.com", "truncated": false}, "before_length": 21, "before_sha256": "44fd39e5fb919cb3d680fa630da23b49238fec29159c509f3622f272bb41c7c6", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 21, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 21, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-413f43c7071d2ab8db888223", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:14Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "8b8c4cc8e6f1a21fedee4bf0743c9c03e454b50f5eaba0e3760416d7fe0a74ec", "source_snapshot_id": "source-4efe4ecf3ebf08d338a763a5", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1994}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIB", "before": {"end": 16, "start": 0, "text": "2000, Szentendre", "truncated": false}, "before_length": 16, "before_sha256": "e7eec80782064f78f9518825c15b4c5b91e88a8bf75f429cef005c9630048901", "change_kind": "unassigned", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 16, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 16, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-414d9cc6285c6be19f02d50f", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/006047", "medicine_name": "Lacosamide Adroiq", "medicine_slug": "lacosamide-adroiq", "observed_at": "2026-10-12T19:07:56Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "", "section_type": "unassigned", "source_provider": "European Medicines Agency", "source_sha256": "0578c53a5e1c785c4d9d4dc0dabae49dbfa89e237aa571556bee548c3f9cf4d5", "source_snapshot_id": "source-64831dec5ebf55535e19d91b", "source_updated_at": "2025-09-25", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/lacosamide-adroiq-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1859}
{"after": {"end": 25, "start": 0, "text": "Eurocept International BV", "truncated": false}, "after_length": 25, "after_sha256": "b17bd89b3cf285c986a6070d0d67f5326dd5c1f08a70834c296c6c820f9e7505", "annex": "IIIA", "before": {"end": 21, "start": 0, "text": "info@lucanepharma.com", "truncated": false}, "before_length": 21, "before_sha256": "44fd39e5fb919cb3d680fa630da23b49238fec29159c509f3622f272bb41c7c6", "change_kind": "content", "change_operations": [{"after_end": 3, "after_start": 0, "before_end": 3, "before_start": 0, "kind": "replace"}, {"after_end": 4, "after_start": 4, "before_end": 7, "before_start": 4, "kind": "delete"}, {"after_end": 5, "after_start": 5, "before_end": 10, "before_start": 8, "kind": "delete"}, {"after_end": 15, "after_start": 7, "before_end": 13, "before_start": 12, "kind": "replace"}, {"after_end": 20, "after_start": 16, "before_end": 16, "before_start": 14, "kind": "replace"}, {"after_end": 25, "after_start": 21, "before_end": 21, "before_start": 17, "kind": "replace"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 15, "chars_inserted": 19}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-415020d9b7fe28171ef2c342", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:14Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "8b8c4cc8e6f1a21fedee4bf0743c9c03e454b50f5eaba0e3760416d7fe0a74ec", "source_snapshot_id": "source-4efe4ecf3ebf08d338a763a5", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1914}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "II", "before": {"end": 14, "start": 0, "text": "Heussstraße 25", "truncated": false}, "before_length": 14, "before_sha256": "805584102a210d40b5c8e0e7014cb2d6f4194a7c2ef94da3309e0707eed85073", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 14, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 14, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-416398976f3c3d5e48a1acaf", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/005246", "medicine_name": "Byfavo", "medicine_slug": "byfavo", "observed_at": "2026-10-12T13:28:14Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "conditions", "section_type": "conditions", "source_provider": "European Medicines Agency", "source_sha256": "92a178ceb705631219efa40b1d0da73ebe6dfa866bc1b24d7e4dab9ded8a6861", "source_snapshot_id": "source-d485be5d9060fd557be910b2", "source_updated_at": "2026-08-26", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/byfavo-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1743}
{"after": {"end": 11, "start": 0, "text": "Vistor ehf.", "truncated": false}, "after_length": 11, "after_sha256": "7b79f0f888fc32453606a29b908677d0b6c13a510070ab26fe31e12b995d77fe", "annex": "IIIA", "before": {"end": 10, "start": 0, "text": "Vistor hf.", "truncated": false}, "before_length": 10, "before_sha256": "4b40dfc2a19551f982dad779994a624f3432207c4666bbd66f0ec59c2f229b32", "change_kind": "content", "change_operations": [{"after_end": 8, "after_start": 7, "before_end": 7, "before_start": 7, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 1}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-416fd26ec7c3e698ea4bfdbc", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002514", "medicine_name": "Aubagio", "medicine_slug": "aubagio", "observed_at": "2026-10-12T17:28:37Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "2583b2915ecedeb3bccc3ac6bea691e65d05f5e437bf8aa7970917b6fdeb700c", "source_snapshot_id": "source-15791f384b9e49792c9776dd", "source_updated_at": "2025-12-09", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/aubagio-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 2053}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 16, "start": 0, "text": "Extrovis EU Ltd.", "truncated": false}, "before_length": 16, "before_sha256": "f462ad48e7aef0bc82148ce088af1897d99ed86993128f30d506b27d3108a929", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 16, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 16, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-416fdcf5d6a4773ae5137ac9", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/006047", "medicine_name": "Lacosamide Adroiq", "medicine_slug": "lacosamide-adroiq", "observed_at": "2026-10-12T19:07:59Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "cc83d966059d42856d0211a4f256b29b20d43593865704d6a9315aeb694f3c76", "source_snapshot_id": "source-896abba1d8391c918345d46b", "source_updated_at": "2025-09-25", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/lacosamide-adroiq-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1856}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 7, "start": 0, "text": "Germany", "truncated": false}, "before_length": 7, "before_sha256": "80db4ccdca106d37b920206331fcfe3e9e50a9e763d89b54ce3ad5ac8cf30f03", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 7, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 7, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-4183bca67d3518431a78bbdb", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/005246", "medicine_name": "Byfavo", "medicine_slug": "byfavo", "observed_at": "2026-10-12T13:28:14Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "92a178ceb705631219efa40b1d0da73ebe6dfa866bc1b24d7e4dab9ded8a6861", "source_snapshot_id": "source-d485be5d9060fd557be910b2", "source_updated_at": "2026-08-26", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/byfavo-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 2294}
{"after": {"end": 21, "start": 0, "text": "Tel: +31 35 528 39 57", "truncated": false}, "after_length": 21, "after_sha256": "7baf6601f41e49e470f803fdd4e755a86efa38be423317c000ed79963ebdd213", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 21, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 21}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-41a2c1d074828f29d569e23e", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:19Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "77586d0bea0858214b43b86e91abc2d2711733b96959ead5ed0b5ecbd8ed888a", "source_snapshot_id": "source-85d476f9ad959cc117ca8f1f", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1993}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 20, "start": 0, "text": "10 Earlsfort Terrace", "truncated": false}, "before_length": 20, "before_sha256": "22951bbf6ee77815d0c07b3af5f0a66e17d277636971c4eaff372dea65dcb193", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 20, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 20, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-41eb90a7aabc0e4444add96d", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002097", "medicine_name": "Fampyra", "medicine_slug": "fampyra", "observed_at": "2026-10-12T19:16:07Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "a0c3ba8d58d6a43a809ecc3d142a78b10c2bd7f0b9f3a3553df2617d87daec1f", "source_snapshot_id": "source-c7a810dd21f94cd2d273f0da", "source_updated_at": "2025-08-21", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/fampyra-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1034}
{"after": {"end": 11, "start": 0, "text": "Vianex S.A.", "truncated": false}, "after_length": 11, "after_sha256": "5aa05543f23c771ae6d358a0283a8ebc791ceaed5f1fb141cf038e2e49a6ac7b", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 11, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 11}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-421697c6c79c7747093f680e", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002066", "medicine_name": "Ikervis", "medicine_slug": "ikervis", "observed_at": "2026-10-12T13:34:16Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "ab05f9fab48768c68482390488c5b90c577e852974d4448da6ea8fe5a4eda856", "source_snapshot_id": "source-324751bde2e11edc76c2dbfe", "source_updated_at": "2026-06-23", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/ikervis-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1854}
{"after": {"end": 248, "start": 0, "text": "Ce document constitue les informations sur le produit approuvées pour Adcirca, les modifications apportées depuis la procédure précédente qui ont une incidence sur les informations sur le produit (EMEA/H/C/001021/IB/0038/G) étant mises en évidence.", "truncated": false}, "after_length": 248, "after_sha256": "43b86693691b146d2ed59f07d60cf1a35809be3228f88f847720c615d9e27e5b", "annex": "", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "unassigned", "change_operations": [{"after_end": 248, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 248}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-42aa5aca6c607f5466f79ace", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/001021", "medicine_name": "Adcirca (previously Tadalafil Lilly)", "medicine_slug": "adcirca-previously-tadalafil-lilly", "observed_at": "2026-10-12T19:02:45Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": null, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "", "section_type": "unassigned", "source_provider": "European Medicines Agency", "source_sha256": "cdbefcd6143c93e81f3c826bea8d3d01bffc55652e0f792243097df75c452721", "source_snapshot_id": "source-a1e85476de17f5a8664f7766", "source_updated_at": "2026-01-28", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/adcirca-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 0}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 61, "start": 0, "text": "McDermott Laboratories Limited trading as Gerard Laboratories", "truncated": false}, "before_length": 61, "before_sha256": "f28bee890ae72cccea9b87c3be57809b0afb7f64e286de2c77b2c05b413da700", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 61, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 61, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-42f22bb5e126b3bdcd603899", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/004025", "medicine_name": "Lopinavir/Ritonavir Viatris (previously Ritonavir Mylan)", "medicine_slug": "lopinavir-ritonavir-viatris-previously-ritonavir-mylan", "observed_at": "2026-10-12T19:14:59Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "d782e33ec97bc43bb54f942c83f07f89482c9a433e3846beaffe05b4a52b4b36", "source_snapshot_id": "source-ff48b23a80b98be4c15aa440", "source_updated_at": "2025-09-08", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/lopinavir-ritonavir-viatris-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 2879}
{"after": {"end": 25, "start": 0, "text": "Eurocept International BV", "truncated": false}, "after_length": 25, "after_sha256": "b17bd89b3cf285c986a6070d0d67f5326dd5c1f08a70834c296c6c820f9e7505", "annex": "IIIA", "before": {"end": 21, "start": 0, "text": "info@lucanepharma.com", "truncated": false}, "before_length": 21, "before_sha256": "44fd39e5fb919cb3d680fa630da23b49238fec29159c509f3622f272bb41c7c6", "change_kind": "content", "change_operations": [{"after_end": 3, "after_start": 0, "before_end": 3, "before_start": 0, "kind": "replace"}, {"after_end": 4, "after_start": 4, "before_end": 7, "before_start": 4, "kind": "delete"}, {"after_end": 5, "after_start": 5, "before_end": 10, "before_start": 8, "kind": "delete"}, {"after_end": 15, "after_start": 7, "before_end": 13, "before_start": 12, "kind": "replace"}, {"after_end": 20, "after_start": 16, "before_end": 16, "before_start": 14, "kind": "replace"}, {"after_end": 25, "after_start": 21, "before_end": 21, "before_start": 17, "kind": "replace"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 15, "chars_inserted": 19}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-42fc733129bd441c887ea1b9", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:14Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "8b8c4cc8e6f1a21fedee4bf0743c9c03e454b50f5eaba0e3760416d7fe0a74ec", "source_snapshot_id": "source-4efe4ecf3ebf08d338a763a5", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1452}
{"after": {"end": 22, "start": 0, "text": "Tel: +351 21 824 98 76", "truncated": false}, "after_length": 22, "after_sha256": "7c8ecb2e5f42841d3a036da23e786a84794928014737e604cb9ae0cc1a9be439", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 22, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 22}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-42feb89c4809b13b45f54ab0", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:14Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "8b8c4cc8e6f1a21fedee4bf0743c9c03e454b50f5eaba0e3760416d7fe0a74ec", "source_snapshot_id": "source-4efe4ecf3ebf08d338a763a5", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1549}
{"after": {"end": 124, "start": 0, "text": "For more information, see the European Medicines Agency’s website: https://www.ema.europa.eu/en/medicines/human/EPAR/sprycel", "truncated": false}, "after_length": 124, "after_sha256": "245bfd97c7ce16987825249ed0932702333ff514ef8c6aab97b1aa13bc3e62b3", "annex": "", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "unassigned", "change_operations": [{"after_end": 124, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 124}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-4342a8b32a2c53a981474557", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/000709", "medicine_name": "Sprycel", "medicine_slug": "sprycel", "observed_at": "2026-10-12T13:27:33Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": null, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "", "section_type": "unassigned", "source_provider": "European Medicines Agency", "source_sha256": "7b2a270ca60f948a69940b5bd26552042c4c20cae01b420ad781477ba43b0fe9", "source_snapshot_id": "source-c03fb6f08190e30934edc22f", "source_updated_at": "2026-10-02", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/sprycel-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 2}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 11, "start": 0, "text": "Sandoz GmbH", "truncated": false}, "before_length": 11, "before_sha256": "503d20ac6cfe17be906a08dea4551c3c95b04eb3306e0f2392e0ef4f74d9fb03", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 11, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 11, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-43cf2da04dde822860795beb", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/000725", "medicine_name": "Binocrit", "medicine_slug": "binocrit", "observed_at": "2026-10-12T19:29:33Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "2110517cc45ca102ca5957f2578ba74090631cf709d5be3e5f6e34712f237bdb", "source_snapshot_id": "source-63ba5976f2b2d4350a9afd16", "source_updated_at": "2025-07-11", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/binocrit-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 3384}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 18, "start": 0, "text": "Dublin 2, D02 T380", "truncated": false}, "before_length": 18, "before_sha256": "23e6871e7960b0dadc753bc127bbea230cc8308c88b2d33704eb275a3ec1a70d", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 18, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 18, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-44929a458c2f821155d6d97e", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002097", "medicine_name": "Fampyra", "medicine_slug": "fampyra", "observed_at": "2026-10-12T19:16:07Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "a0c3ba8d58d6a43a809ecc3d142a78b10c2bd7f0b9f3a3553df2617d87daec1f", "source_snapshot_id": "source-c7a810dd21f94cd2d273f0da", "source_updated_at": "2025-08-21", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/fampyra-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1487}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 20, "start": 0, "text": "10 Earlsfort Terrace", "truncated": false}, "before_length": 20, "before_sha256": "22951bbf6ee77815d0c07b3af5f0a66e17d277636971c4eaff372dea65dcb193", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 20, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 20, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-44a5735c21cd5219adf87df8", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002097", "medicine_name": "Fampyra", "medicine_slug": "fampyra", "observed_at": "2026-10-12T19:15:51Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "d9fe8aaaa611a84801d6308b13685258b5248df9022536697939afdf66fc1719", "source_snapshot_id": "source-ff8e0599077f0d01044dc867", "source_updated_at": "2025-08-21", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/fampyra-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1524}
{"after": {"end": 25, "start": 0, "text": "Eurocept International BV", "truncated": false}, "after_length": 25, "after_sha256": "b17bd89b3cf285c986a6070d0d67f5326dd5c1f08a70834c296c6c820f9e7505", "annex": "IIIA", "before": {"end": 21, "start": 0, "text": "info@lucanepharma.com", "truncated": false}, "before_length": 21, "before_sha256": "44fd39e5fb919cb3d680fa630da23b49238fec29159c509f3622f272bb41c7c6", "change_kind": "content", "change_operations": [{"after_end": 3, "after_start": 0, "before_end": 3, "before_start": 0, "kind": "replace"}, {"after_end": 4, "after_start": 4, "before_end": 7, "before_start": 4, "kind": "delete"}, {"after_end": 5, "after_start": 5, "before_end": 10, "before_start": 8, "kind": "delete"}, {"after_end": 15, "after_start": 7, "before_end": 13, "before_start": 12, "kind": "replace"}, {"after_end": 20, "after_start": 16, "before_end": 16, "before_start": 14, "kind": "replace"}, {"after_end": 25, "after_start": 21, "before_end": 21, "before_start": 17, "kind": "replace"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 15, "chars_inserted": 19}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-44c2e64e5420fade80343228", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:14Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "8b8c4cc8e6f1a21fedee4bf0743c9c03e454b50f5eaba0e3760416d7fe0a74ec", "source_snapshot_id": "source-4efe4ecf3ebf08d338a763a5", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1900}
{"after": {"end": 25, "start": 0, "text": "Eurocept International BV", "truncated": false}, "after_length": 25, "after_sha256": "b17bd89b3cf285c986a6070d0d67f5326dd5c1f08a70834c296c6c820f9e7505", "annex": "IIIA", "before": {"end": 41, "start": 0, "text": "Eurocept International BV (Lucane Pharma)", "truncated": false}, "before_length": 41, "before_sha256": "d1cf3f14927b7038ed47975d2f7feb981f2ee8e6e304b86c1eb0fdc0b2419528", "change_kind": "content", "change_operations": [{"after_end": 25, "after_start": 25, "before_end": 41, "before_start": 25, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 16, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-450ae6b2719bed6d53a2d37c", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:14Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "8b8c4cc8e6f1a21fedee4bf0743c9c03e454b50f5eaba0e3760416d7fe0a74ec", "source_snapshot_id": "source-4efe4ecf3ebf08d338a763a5", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1016}
{"after": {"end": 8, "start": 0, "text": "Γερμανία", "truncated": false}, "after_length": 8, "after_sha256": "bfec9f93122249c327451f277e22c198da0ea7dab804bbd84f5bf35170f7eb40", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 8, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 8}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-45578116cd6232852d53eef9", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002097", "medicine_name": "Fampyra", "medicine_slug": "fampyra", "observed_at": "2026-10-12T19:15:51Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "d9fe8aaaa611a84801d6308b13685258b5248df9022536697939afdf66fc1719", "source_snapshot_id": "source-ff8e0599077f0d01044dc867", "source_updated_at": "2025-08-21", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/fampyra-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1485}
{"after": {"end": 21, "start": 0, "text": "Tel: +31 35 528 39 57", "truncated": false}, "after_length": 21, "after_sha256": "7baf6601f41e49e470f803fdd4e755a86efa38be423317c000ed79963ebdd213", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 21, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 21}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-456654b5ffef2c3cdb2c9506", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:19Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "77586d0bea0858214b43b86e91abc2d2711733b96959ead5ed0b5ecbd8ed888a", "source_snapshot_id": "source-85d476f9ad959cc117ca8f1f", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1392}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "III", "before": {"end": 16, "start": 0, "text": "Extrovis EU Ltd.", "truncated": false}, "before_length": 16, "before_sha256": "f462ad48e7aef0bc82148ce088af1897d99ed86993128f30d506b27d3108a929", "change_kind": "unassigned", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 16, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 16, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-45a76c7a76efa4fd6172a3ac", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/006047", "medicine_name": "Lacosamide Adroiq", "medicine_slug": "lacosamide-adroiq", "observed_at": "2026-10-12T19:07:56Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "", "section_type": "unassigned", "source_provider": "European Medicines Agency", "source_sha256": "0578c53a5e1c785c4d9d4dc0dabae49dbfa89e237aa571556bee548c3f9cf4d5", "source_snapshot_id": "source-64831dec5ebf55535e19d91b", "source_updated_at": "2025-09-25", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/lacosamide-adroiq-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1349}
{"after": {"end": 79, "start": 0, "text": "Viatris Germany GmbH, Zweigniederlassung Bad Homburg v. d. Höhe, Benzstrasse 1,", "truncated": false}, "after_length": 79, "after_sha256": "ec5d8b467f097b5f6e626a2a056336fab8904b07ad533e62379b09597067a87b", "annex": "IIIA", "before": {"end": 77, "start": 0, "text": "Mylan Germany GmbH, Zweigniederlassung Bad Homburg v. d. Höhe, Benzstrasse 1,", "truncated": false}, "before_length": 77, "before_sha256": "592354ac8c07b62540d767b349e438cbf42cff382f1d83c4853733a8264bcf56", "change_kind": "content", "change_operations": [{"after_end": 2, "after_start": 0, "before_end": 3, "before_start": 0, "kind": "replace"}, {"after_end": 7, "after_start": 3, "before_end": 5, "before_start": 4, "kind": "replace"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 4, "chars_inserted": 6}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-45c5849cf9fc209d40310cf3", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/000403", "medicine_name": "Arixtra", "medicine_slug": "arixtra", "observed_at": "2026-10-12T13:38:50Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": null, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "123deb3dbdc841a7adc2b8046138993b8a6a1c228bde13a95278b14d17c5cefd", "source_snapshot_id": "source-79bede7a4a9cd1c040f622e0", "source_updated_at": "2026-05-07", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/arixtra-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 4188}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 22, "start": 0, "text": "Tel : +31 35 528 39 57", "truncated": false}, "before_length": 22, "before_sha256": "7bb8afadf5dee15b4f4e1219e333b993040f0848bccea58b1141990fffb82aa1", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 22, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 22, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-46b4a24153af9b4a1e61ad34", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:19Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "77586d0bea0858214b43b86e91abc2d2711733b96959ead5ed0b5ecbd8ed888a", "source_snapshot_id": "source-85d476f9ad959cc117ca8f1f", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1856}
{"after": {"end": 23, "start": 0, "text": "60318 Frankfurt am Main", "truncated": false}, "after_length": 23, "after_sha256": "24c3191b5088b20c209c4387a8127297e54c776e161d305c9e57956a13b7cbbe", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 23, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 23}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-46c9ac8ee67716576d337c47", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002097", "medicine_name": "Fampyra", "medicine_slug": "fampyra", "observed_at": "2026-10-12T19:15:51Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "d9fe8aaaa611a84801d6308b13685258b5248df9022536697939afdf66fc1719", "source_snapshot_id": "source-ff8e0599077f0d01044dc867", "source_updated_at": "2025-08-21", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/fampyra-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1566}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 20, "start": 0, "text": "10 Earlsfort Terrace", "truncated": false}, "before_length": 20, "before_sha256": "22951bbf6ee77815d0c07b3af5f0a66e17d277636971c4eaff372dea65dcb193", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 20, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 20, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-46dfe9a934eafcf6756b9c29", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002097", "medicine_name": "Fampyra", "medicine_slug": "fampyra", "observed_at": "2026-10-12T19:16:07Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "a0c3ba8d58d6a43a809ecc3d142a78b10c2bd7f0b9f3a3553df2617d87daec1f", "source_snapshot_id": "source-c7a810dd21f94cd2d273f0da", "source_updated_at": "2025-08-21", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/fampyra-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1578}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 20, "start": 0, "text": "10 Earlsfort Terrace", "truncated": false}, "before_length": 20, "before_sha256": "22951bbf6ee77815d0c07b3af5f0a66e17d277636971c4eaff372dea65dcb193", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 20, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 20, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-4730871b9ef16372307f619c", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002097", "medicine_name": "Fampyra", "medicine_slug": "fampyra", "observed_at": "2026-10-12T19:15:51Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "d9fe8aaaa611a84801d6308b13685258b5248df9022536697939afdf66fc1719", "source_snapshot_id": "source-ff8e0599077f0d01044dc867", "source_updated_at": "2025-08-21", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/fampyra-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1369}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 25, "start": 0, "text": "Tel: + 353-(0) 1 661 4377", "truncated": false}, "before_length": 25, "before_sha256": "48fde288146f4033a2172164570180a8f875f4e361fcf85a8e43ff77834511cc", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 25, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 25, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-478de61b24a21e4c0b3153c7", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/001021", "medicine_name": "Adcirca (previously Tadalafil Lilly)", "medicine_slug": "adcirca-previously-tadalafil-lilly", "observed_at": "2026-10-12T19:02:42Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "43438c8e53504a78747a8ff36049250fee294557f3a8b0e3acb80f71ad43ebc0", "source_snapshot_id": "source-2305a67bd1e393ee340bb8e4", "source_updated_at": "2026-01-28", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/adcirca-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 2028}
{"after": {"end": 20, "start": 0, "text": "Τηλ: +30 210 8009111", "truncated": false}, "after_length": 20, "after_sha256": "4be2eb2931a7797b144651aebec87029f222cbdda35f539f6c814b9013ffc042", "annex": "IIIA", "before": {"end": 9, "start": 0, "text": "Santen Oy", "truncated": false}, "before_length": 9, "before_sha256": "b8d3bb307d9e8fe0e3311ac213bd7de3f9df0c142a11ebd9fb9b8ec5c7ed12b6", "change_kind": "content", "change_operations": [{"after_end": 4, "after_start": 0, "before_end": 6, "before_start": 0, "kind": "replace"}, {"after_end": 20, "after_start": 5, "before_end": 9, "before_start": 7, "kind": "replace"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 8, "chars_inserted": 19}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-47a442ab775495aaeb75db6a", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002066", "medicine_name": "Ikervis", "medicine_slug": "ikervis", "observed_at": "2026-10-12T13:34:16Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "ab05f9fab48768c68482390488c5b90c577e852974d4448da6ea8fe5a4eda856", "source_snapshot_id": "source-324751bde2e11edc76c2dbfe", "source_updated_at": "2026-06-23", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/ikervis-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1855}
{"after": {"end": 22, "start": 0, "text": "dpoc.dk.is@organon.com", "truncated": false}, "after_length": 22, "after_sha256": "2ec8bd15095c32c4b391933a74e129811cc83d541dfa8c638f73b1846b2feb92", "annex": "IIIA", "before": {"end": 24, "start": 0, "text": "info.denmark@organon.com", "truncated": false}, "before_length": 24, "before_sha256": "0bd40edc47b513070be7fb7bee249de4ce365bb0cf6d0ae214166f9d5286ddaf", "change_kind": "content", "change_operations": [{"after_end": 2, "after_start": 0, "before_end": 3, "before_start": 0, "kind": "replace"}, {"after_end": 4, "after_start": 3, "before_end": 4, "before_start": 4, "kind": "insert"}, {"after_end": 6, "after_start": 6, "before_end": 11, "before_start": 6, "kind": "delete"}, {"after_end": 10, "after_start": 7, "before_end": 12, "before_start": 12, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 8, "chars_inserted": 6}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-47aef6e80d6a671942dd4a05", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/000619", "medicine_name": "Fosavance", "medicine_slug": "fosavance", "observed_at": "2026-10-12T19:01:49Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "97e93ccf75e837b32026ca36c34d5c78008211a75d5ef225c47e7b94a0027ab2", "source_snapshot_id": "source-1ef57638e1a307f1e5437651", "source_updated_at": "2026-02-12", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/fosavance-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1223}
{"after": {"end": 21, "start": 0, "text": "notice du médicament.", "truncated": false}, "after_length": 21, "after_sha256": "68e71dd2cf970f24e37c9264f0e8faff94999eb833b6e31af6b7160de667eb26", "annex": "II", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 21, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 21}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-47d208021fa05c907eb85140", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/003984", "medicine_name": "Bortezomib Accord", "medicine_slug": "bortezomib-accord", "observed_at": "2026-10-12T13:47:15Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "conditions", "section_type": "conditions", "source_provider": "European Medicines Agency", "source_sha256": "150a191aaf0a1e169e9d5fa2530f0eccb4e3d46509faf5ec5ee975a2e67788c4", "source_snapshot_id": "source-cba4680b7fbd2c536884abd8", "source_updated_at": "2026-03-25", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/bortezomib-accord-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 3354}
{"after": {"end": 28, "start": 0, "text": "Depressed mood/mood altered*", "truncated": false}, "after_length": 28, "after_sha256": "66ff665807886829d149b66603b562aed7d6aa63dff022ea162b00999956ff23", "annex": "I", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 28, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": true, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 28}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-47fd327c7359fb888868097b", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/000554", "medicine_name": "Emselex", "medicine_slug": "emselex", "observed_at": "2026-10-12T19:12:04Z", "pipeline_version": "2.0.0", "presentation_label": "Emselex 15 mg prolonged-release tablets", "presentation_occurrence": 2, "presentation_status": "heading_extracted_unverified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "4.8", "section_type": "adverse_reactions", "source_provider": "European Medicines Agency", "source_sha256": "4f2565612bc728ec67b7f9c0cd5799ef2c594911c76f323aef8bf6a85adde245", "source_snapshot_id": "source-1fda25b331eb198b8b93feb3", "source_updated_at": "2025-09-15", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/emselex-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 604}
{"after": {"end": 23, "start": 0, "text": "info@euroceptpharma.com", "truncated": false}, "after_length": 23, "after_sha256": "9297cc5acdcc837f054116992765943f7907937507b2564a99ea1327a00ac0e6", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 23, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 23}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-49576ad3bcabe873e7d45048", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:14Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "8b8c4cc8e6f1a21fedee4bf0743c9c03e454b50f5eaba0e3760416d7fe0a74ec", "source_snapshot_id": "source-4efe4ecf3ebf08d338a763a5", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1592}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 20, "start": 0, "text": "10 Earlsfort Terrace", "truncated": false}, "before_length": 20, "before_sha256": "22951bbf6ee77815d0c07b3af5f0a66e17d277636971c4eaff372dea65dcb193", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 20, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 20, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-4983b36c419a7489bc39d7d6", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002097", "medicine_name": "Fampyra", "medicine_slug": "fampyra", "observed_at": "2026-10-12T19:16:07Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "a0c3ba8d58d6a43a809ecc3d142a78b10c2bd7f0b9f3a3553df2617d87daec1f", "source_snapshot_id": "source-c7a810dd21f94cd2d273f0da", "source_updated_at": "2025-08-21", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/fampyra-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1395}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 38, "start": 0, "text": "sanofi-aventis Ireland Ltd. T/A SANOFI", "truncated": false}, "before_length": 38, "before_sha256": "dad9251ce581d41bcfcb8818c11a57a8d3490b978d09cf04cfd9162a081c8d28", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 38, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 38, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-49f9f1a7e029d68331d70d5a", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002702", "medicine_name": "Hexacima", "medicine_slug": "hexacima", "observed_at": "2026-10-12T19:07:04Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "44c8996457a718019c75b8322ba07a5ae7af36377b1a6f1cf4ca5a30f9b72c23", "source_snapshot_id": "source-fa766d966dea704c333b9969", "source_updated_at": "2025-09-29", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/hexacima-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 2120}
{"after": {"end": 23, "start": 0, "text": "info@euroceptpharma.com", "truncated": false}, "after_length": 23, "after_sha256": "9297cc5acdcc837f054116992765943f7907937507b2564a99ea1327a00ac0e6", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 23, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 23}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-4a11f2b29cdb04f5d2f99fd9", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:14Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "8b8c4cc8e6f1a21fedee4bf0743c9c03e454b50f5eaba0e3760416d7fe0a74ec", "source_snapshot_id": "source-4efe4ecf3ebf08d338a763a5", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1611}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 13, "start": 0, "text": "Lucane Pharma", "truncated": false}, "before_length": 13, "before_sha256": "e338afdb64acf1a6e2083a50318853589248451dd3aa707181ba02641a8521e8", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 13, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 13, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-4a37e04143ff17c01830afa7", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:14Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "8b8c4cc8e6f1a21fedee4bf0743c9c03e454b50f5eaba0e3760416d7fe0a74ec", "source_snapshot_id": "source-4efe4ecf3ebf08d338a763a5", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1879}
{"after": {"end": 17, "start": 0, "text": "Torokbalint, 2045", "truncated": false}, "after_length": 17, "after_sha256": "d6dbae334e70b70d590689409d24e6c0cda7d30fd5104550892da04a039d1276", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 17, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 17}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-4a592bcea53bf93021505678", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/006047", "medicine_name": "Lacosamide Adroiq", "medicine_slug": "lacosamide-adroiq", "observed_at": "2026-10-12T19:07:59Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "cc83d966059d42856d0211a4f256b29b20d43593865704d6a9315aeb694f3c76", "source_snapshot_id": "source-896abba1d8391c918345d46b", "source_updated_at": "2025-09-25", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/lacosamide-adroiq-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1210}
{"after": {"end": 21, "start": 0, "text": "Tel: +420 277 051 010", "truncated": false}, "after_length": 21, "after_sha256": "50d60e49161099285c4e19a446177466795e2c022df75a1c35dff2fb7dc41435", "annex": "IIIA", "before": {"end": 21, "start": 0, "text": "Tel: +420 233 010 300", "truncated": false}, "before_length": 21, "before_sha256": "746918552274379bd7e6869467f464a71268035ce8f31deabc258dfbe6696cda", "change_kind": "content", "change_operations": [{"after_end": 17, "after_start": 11, "before_end": 13, "before_start": 11, "kind": "replace"}, {"after_end": 20, "after_start": 20, "before_end": 20, "before_start": 16, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 6, "chars_inserted": 6}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-4a74022f291d2c1076338f94", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/000619", "medicine_name": "Fosavance", "medicine_slug": "fosavance", "observed_at": "2026-10-12T19:01:49Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "97e93ccf75e837b32026ca36c34d5c78008211a75d5ef225c47e7b94a0027ab2", "source_snapshot_id": "source-1ef57638e1a307f1e5437651", "source_updated_at": "2026-02-12", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/fosavance-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1212}
{"after": {"end": 142, "start": 0, "text": "Pour plus d’informations, voir le site web de l’Agence européenne des médicaments: https://www.ema.europa.eu/en/medicines/human/EPAR/pheburane", "truncated": false}, "after_length": 142, "after_sha256": "4eaebe043077e34d7d1eaa840a4a53ad180ce184728a849c558337187be12820", "annex": "", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "unassigned", "change_operations": [{"after_end": 142, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 142}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-4adba2669112ef824518db17", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:19Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": null, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "", "section_type": "unassigned", "source_provider": "European Medicines Agency", "source_sha256": "77586d0bea0858214b43b86e91abc2d2711733b96959ead5ed0b5ecbd8ed888a", "source_snapshot_id": "source-85d476f9ad959cc117ca8f1f", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 2}
{"after": {"end": 175, "start": 0, "text": "Les autres composants sont l’hydrogénophosphate de calcium (anhydre), l’hypromellose, le stéarate de magnésium, le polyéthylène glycol, le dioxyde de titane (E171) et le talc.", "truncated": false}, "after_length": 175, "after_sha256": "da606a14010020abb0a5a556009275e7ff9c7f6c43ca7d5acc43e979c3ceb18b", "annex": "IIIA", "before": {"end": 175, "start": 0, "text": "Les autres composants sont l'hydrogénophosphate de calcium (anhydre), l'hypromellose, le stéarate de magnésium, le polyéthylène glycol, le dioxyde de titane (E171) et le talc.", "truncated": false}, "before_length": 175, "before_sha256": "bd215a158319553b6595e2bc676d7b4106f6d1486393ad436a15347b061212b2", "change_kind": "content", "change_operations": [{"after_end": 29, "after_start": 28, "before_end": 29, "before_start": 28, "kind": "replace"}, {"after_end": 72, "after_start": 71, "before_end": 72, "before_start": 71, "kind": "replace"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 2, "chars_inserted": 2}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-4afd9b7ac38877923020a6e4", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/000554", "medicine_name": "Emselex", "medicine_slug": "emselex", "observed_at": "2026-10-12T19:12:07Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": null, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "9a4f1d7e260c7b80eaf397503623b63302e5945b579e9612177835e07c4ab888", "source_snapshot_id": "source-3aac7bf42b99529f25ac013b", "source_updated_at": "2025-09-15", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/emselex-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1824}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 13, "start": 0, "text": "Lucane Pharma", "truncated": false}, "before_length": 13, "before_sha256": "e338afdb64acf1a6e2083a50318853589248451dd3aa707181ba02641a8521e8", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 13, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 13, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-4b18a66e0b542ca823f59a9f", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:19Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "77586d0bea0858214b43b86e91abc2d2711733b96959ead5ed0b5ecbd8ed888a", "source_snapshot_id": "source-85d476f9ad959cc117ca8f1f", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1788}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "II", "before": {"end": 22, "start": 0, "text": "PAION Deutschland GmbH", "truncated": false}, "before_length": 22, "before_sha256": "695a7a774aacd3b6e919ed980dbfb2ee37bbe6099af551312782cc722dbb2b31", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 22, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 22, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-4b291785cbe522b04b8e8ffe", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/005246", "medicine_name": "Byfavo", "medicine_slug": "byfavo", "observed_at": "2026-10-12T13:28:14Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "conditions", "section_type": "conditions", "source_provider": "European Medicines Agency", "source_sha256": "92a178ceb705631219efa40b1d0da73ebe6dfa866bc1b24d7e4dab9ded8a6861", "source_snapshot_id": "source-d485be5d9060fd557be910b2", "source_updated_at": "2026-08-26", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/byfavo-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1742}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 27, "start": 0, "text": "Organon Pharma (UK) Limited", "truncated": false}, "before_length": 27, "before_sha256": "c8c04efa9dcf216d0ea3d041a3d87291ade3325e118bd7735bab989bbb69d521", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 27, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 27, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-4b3306d64d50423e324b7a39", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/000619", "medicine_name": "Fosavance", "medicine_slug": "fosavance", "observed_at": "2026-10-12T19:01:48Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "37324165444dd93963c38ccfa569b0631b8d34d16c725b5a46b16dd7bb4cbbc2", "source_snapshot_id": "source-829e9ebd79c1d98e8a839547", "source_updated_at": "2026-02-12", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/fosavance-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1316}
{"after": {"end": 23, "start": 0, "text": "60318 Frankfurt am Main", "truncated": false}, "after_length": 23, "after_sha256": "24c3191b5088b20c209c4387a8127297e54c776e161d305c9e57956a13b7cbbe", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 23, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 23}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-4b47ab105e114eed7a187163", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002097", "medicine_name": "Fampyra", "medicine_slug": "fampyra", "observed_at": "2026-10-12T19:15:51Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "d9fe8aaaa611a84801d6308b13685258b5248df9022536697939afdf66fc1719", "source_snapshot_id": "source-ff8e0599077f0d01044dc867", "source_updated_at": "2025-08-21", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/fampyra-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1441}
{"after": {"end": 18, "start": 0, "text": "4844 CK Terheijden", "truncated": false}, "after_length": 18, "after_sha256": "e7ea1ad04b1071e360b652726acc9e8a22118603b55f58e0bd782476a7e47649", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 18, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 18}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-4b49a2b5d1d03f12e2d5c6e6", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002097", "medicine_name": "Fampyra", "medicine_slug": "fampyra", "observed_at": "2026-10-12T19:15:51Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "d9fe8aaaa611a84801d6308b13685258b5248df9022536697939afdf66fc1719", "source_snapshot_id": "source-ff8e0599077f0d01044dc867", "source_updated_at": "2025-08-21", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/fampyra-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1403}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIB", "before": {"end": 16, "start": 0, "text": "Extrovis EU Ltd.", "truncated": false}, "before_length": 16, "before_sha256": "f462ad48e7aef0bc82148ce088af1897d99ed86993128f30d506b27d3108a929", "change_kind": "unassigned", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 16, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 16, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-4b4b8d5220d328bc374b8d62", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/006047", "medicine_name": "Lacosamide Adroiq", "medicine_slug": "lacosamide-adroiq", "observed_at": "2026-10-12T19:07:56Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "", "section_type": "unassigned", "source_provider": "European Medicines Agency", "source_sha256": "0578c53a5e1c785c4d9d4dc0dabae49dbfa89e237aa571556bee548c3f9cf4d5", "source_snapshot_id": "source-64831dec5ebf55535e19d91b", "source_updated_at": "2025-09-25", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/lacosamide-adroiq-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1925}
{"after": {"end": 16, "start": 0, "text": "Extrovis EU Kft.", "truncated": false}, "after_length": 16, "after_sha256": "b9216ef80e71e17798dce313e4318f03f37328f225d30ab508b7413813a908e5", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 16, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 16}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-4b7608e6357596a53d434117", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/006047", "medicine_name": "Lacosamide Adroiq", "medicine_slug": "lacosamide-adroiq", "observed_at": "2026-10-12T19:07:59Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "cc83d966059d42856d0211a4f256b29b20d43593865704d6a9315aeb694f3c76", "source_snapshot_id": "source-896abba1d8391c918345d46b", "source_updated_at": "2025-09-25", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/lacosamide-adroiq-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1827}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 13, "start": 0, "text": "Lucane Pharma", "truncated": false}, "before_length": 13, "before_sha256": "e338afdb64acf1a6e2083a50318853589248451dd3aa707181ba02641a8521e8", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 13, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 13, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-4b7624fe417a1d48b213adf2", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:19Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "77586d0bea0858214b43b86e91abc2d2711733b96959ead5ed0b5ecbd8ed888a", "source_snapshot_id": "source-85d476f9ad959cc117ca8f1f", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1495}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "I", "before": {"end": 38, "start": 0, "text": "Expérience depuis la commercialisation", "truncated": false}, "before_length": 38, "before_sha256": "c4ab722defc01fa56c27aa24fbc973ae8f80fdf66b8b9bbb2409e75cb1616f6f", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 38, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": true, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 38, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-4b95ad2abd0f15183d109ea5", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/000554", "medicine_name": "Emselex", "medicine_slug": "emselex", "observed_at": "2026-10-12T19:12:07Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": null, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "4.8", "section_type": "adverse_reactions", "source_provider": "European Medicines Agency", "source_sha256": "9a4f1d7e260c7b80eaf397503623b63302e5945b579e9612177835e07c4ab888", "source_snapshot_id": "source-3aac7bf42b99529f25ac013b", "source_updated_at": "2025-09-15", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/emselex-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 659}
{"after": {"end": 810, "start": 0, "text": "Des cas de myosite et/ou de rhabdomyolyse ont été rapportés chez des patients traités par le léflunomide, souvent en association avec d'autres médicaments immunosuppresseurs. Les symptômes cliniques peuvent inclure des douleurs musculaires inexpliquées, une sensibilité ou une faiblesse musculaire. Les patients doivent être informés des signes et des symptômes associés à la myosite et à la rhabdomyolyse et ils doivent consulter immédiatement un médecin si de tels symptômes surviennent au cours du traitement par le léflunomide. L’élévation des taux de créatine kinase doit être surveillée chez les patients selon leur situation clinique. Si les patients développent l'une de ces manifestations, le léflunomide doit être arrêté et une procédure d'élimination accélérée doit être initiée (voir rubrique 4.4).", "truncated": false}, "after_length": 810, "after_sha256": "cc10a5be2b707546b777c939543f700115911fa1a843b097c61bccdf668a3cf8", "annex": "I", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 810, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": true, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 810}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-4b9f13f0f60653e3d1e9faa2", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/000235", "medicine_name": "Arava", "medicine_slug": "arava", "observed_at": "2026-10-12T13:28:00Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": null, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "4.4", "section_type": "warning", "source_provider": "European Medicines Agency", "source_sha256": "98b73c5c6b1e5009c9d048f8f11257f3a8407759fd25a4c8d5ef5c611519e916", "source_snapshot_id": "source-4b7ea3b78addea82376b3432", "source_updated_at": "2026-09-07", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/arava-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1328}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 5, "start": 0, "text": "Regus", "truncated": false}, "before_length": 5, "before_sha256": "69ef2ca82e0f736644001207ab7589688f2ada81eedc4859209d50896d65b095", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 5, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 5, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-4bc4a28c7979fae92545754f", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002097", "medicine_name": "Fampyra", "medicine_slug": "fampyra", "observed_at": "2026-10-12T19:15:51Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "d9fe8aaaa611a84801d6308b13685258b5248df9022536697939afdf66fc1719", "source_snapshot_id": "source-ff8e0599077f0d01044dc867", "source_updated_at": "2025-08-21", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/fampyra-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1430}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 21, "start": 0, "text": "info@lucanepharma.com", "truncated": false}, "before_length": 21, "before_sha256": "44fd39e5fb919cb3d680fa630da23b49238fec29159c509f3622f272bb41c7c6", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 21, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 21, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-4bdcf3b4835c6d52bdac2456", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:19Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "77586d0bea0858214b43b86e91abc2d2711733b96959ead5ed0b5ecbd8ed888a", "source_snapshot_id": "source-85d476f9ad959cc117ca8f1f", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1465}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 20, "start": 0, "text": "10 Earlsfort Terrace", "truncated": false}, "before_length": 20, "before_sha256": "22951bbf6ee77815d0c07b3af5f0a66e17d277636971c4eaff372dea65dcb193", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 20, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 20, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-4c1bda7fceea0c15983b1661", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002097", "medicine_name": "Fampyra", "medicine_slug": "fampyra", "observed_at": "2026-10-12T19:16:07Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "a0c3ba8d58d6a43a809ecc3d142a78b10c2bd7f0b9f3a3553df2617d87daec1f", "source_snapshot_id": "source-c7a810dd21f94cd2d273f0da", "source_updated_at": "2025-08-21", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/fampyra-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1415}
{"after": {"end": 23, "start": 0, "text": "info@euroceptpharma.com", "truncated": false}, "after_length": 23, "after_sha256": "9297cc5acdcc837f054116992765943f7907937507b2564a99ea1327a00ac0e6", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 23, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 23}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-4c23aba9bdf5fe48107458ff", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:14Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "8b8c4cc8e6f1a21fedee4bf0743c9c03e454b50f5eaba0e3760416d7fe0a74ec", "source_snapshot_id": "source-4efe4ecf3ebf08d338a763a5", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1884}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "II", "before": {"end": 4, "start": 0, "text": "1930", "truncated": false}, "before_length": 4, "before_sha256": "70fa656aa0391eb9ef7bbc9c7e6771ec09e7d5d7ab1fcbbde2480d21263ee79a", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 4, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 4, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-4c6a6df9b281d77adb2f9724", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/004697", "medicine_name": "Zirabev", "medicine_slug": "zirabev", "observed_at": "2026-10-12T19:08:39Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "conditions", "section_type": "conditions", "source_provider": "European Medicines Agency", "source_sha256": "ef33f1350f1fcae139a251926014b13e3e973646fc918d603307fbce8dac4777", "source_snapshot_id": "source-7ce336750684e46ba3e4e54c", "source_updated_at": "2025-09-17", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/zirabev-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 2510}
{"after": {"end": 16, "start": 0, "text": "Extrovis EU Kft.", "truncated": false}, "after_length": 16, "after_sha256": "b9216ef80e71e17798dce313e4318f03f37328f225d30ab508b7413813a908e5", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 16, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 16}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-4ce8ecd98ba202445b5bfa53", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/006047", "medicine_name": "Lacosamide Adroiq", "medicine_slug": "lacosamide-adroiq", "observed_at": "2026-10-12T19:07:59Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "cc83d966059d42856d0211a4f256b29b20d43593865704d6a9315aeb694f3c76", "source_snapshot_id": "source-896abba1d8391c918345d46b", "source_updated_at": "2025-09-25", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/lacosamide-adroiq-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1754}
{"after": {"end": 23, "start": 0, "text": "60318 Frankfurt am Main", "truncated": false}, "after_length": 23, "after_sha256": "24c3191b5088b20c209c4387a8127297e54c776e161d305c9e57956a13b7cbbe", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 23, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 23}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-4d489c3107bc2ecf6e7109eb", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002097", "medicine_name": "Fampyra", "medicine_slug": "fampyra", "observed_at": "2026-10-12T19:15:51Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "d9fe8aaaa611a84801d6308b13685258b5248df9022536697939afdf66fc1719", "source_snapshot_id": "source-ff8e0599077f0d01044dc867", "source_updated_at": "2025-08-21", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/fampyra-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 897}
{"after": {"end": 119, "start": 0, "text": "Detailed information on this medicine is available on the European Medicines Agency web site: https://www.ema.europa.eu", "truncated": false}, "after_length": 119, "after_sha256": "0f2b81ab8009e1a279ca008eb6e21bdb2e532de63aef52b62bdac980c49555d4", "annex": "IIIA", "before": {"end": 118, "start": 0, "text": "Detailed information on this medicine is available on the European Medicines Agency web site: http://www.ema.europa.eu", "truncated": false}, "before_length": 118, "before_sha256": "d114210a3c6f4b6710e22609ee80410ff17f5efd93b30ab72728a60b65635068", "change_kind": "technical", "change_operations": [{"after_end": 99, "after_start": 98, "before_end": 98, "before_start": 98, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 1}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-4e422b1299cc41a46fa86895", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/001021", "medicine_name": "Adcirca (previously Tadalafil Lilly)", "medicine_slug": "adcirca-previously-tadalafil-lilly", "observed_at": "2026-10-12T19:02:42Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "43438c8e53504a78747a8ff36049250fee294557f3a8b0e3acb80f71ad43ebc0", "source_snapshot_id": "source-2305a67bd1e393ee340bb8e4", "source_updated_at": "2026-01-28", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/adcirca-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 2336}
{"after": {"end": 23, "start": 0, "text": "60318 Frankfurt am Main", "truncated": false}, "after_length": 23, "after_sha256": "24c3191b5088b20c209c4387a8127297e54c776e161d305c9e57956a13b7cbbe", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 23, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 23}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-4e6c8abb7c38e6f79d592da2", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002097", "medicine_name": "Fampyra", "medicine_slug": "fampyra", "observed_at": "2026-10-12T19:16:07Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "a0c3ba8d58d6a43a809ecc3d142a78b10c2bd7f0b9f3a3553df2617d87daec1f", "source_snapshot_id": "source-c7a810dd21f94cd2d273f0da", "source_updated_at": "2025-08-21", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/fampyra-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1429}
{"after": {"end": 26, "start": 0, "text": "Eckenheimer Landstraße 100", "truncated": false}, "after_length": 26, "after_sha256": "fdce1a9bd200c5ddd476c1ea5676b9ffbbea723f7353ad6fbc1fe019dcb86c07", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 26, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 26}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-4ead04391ffe5654eda76c27", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002097", "medicine_name": "Fampyra", "medicine_slug": "fampyra", "observed_at": "2026-10-12T19:16:07Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "a0c3ba8d58d6a43a809ecc3d142a78b10c2bd7f0b9f3a3553df2617d87daec1f", "source_snapshot_id": "source-c7a810dd21f94cd2d273f0da", "source_updated_at": "2025-08-21", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/fampyra-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 901}
{"after": {"end": 22, "start": 0, "text": "Merz Therapeutics GmbH", "truncated": false}, "after_length": 22, "after_sha256": "059f049c7d0846aaadcf2573280d52110f302d4ecc7b38debd004571cd1e9d5e", "annex": "IIIA", "before": {"end": 35, "start": 0, "text": "Acorda Therapeutics Ireland Limited", "truncated": false}, "before_length": 35, "before_sha256": "d94d3153d193ed26567f2b4ed48df016d81c534e7c0cb1a6655a63f0083383ff", "change_kind": "content", "change_operations": [{"after_end": 2, "after_start": 0, "before_end": 3, "before_start": 0, "kind": "replace"}, {"after_end": 4, "after_start": 3, "before_end": 6, "before_start": 4, "kind": "replace"}, {"after_end": 19, "after_start": 18, "before_end": 30, "before_start": 20, "kind": "replace"}, {"after_end": 22, "after_start": 20, "before_end": 35, "before_start": 31, "kind": "replace"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 19, "chars_inserted": 6}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-4ebe540e0f563b2cc8b9eac1", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002097", "medicine_name": "Fampyra", "medicine_slug": "fampyra", "observed_at": "2026-10-12T19:15:51Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "d9fe8aaaa611a84801d6308b13685258b5248df9022536697939afdf66fc1719", "source_snapshot_id": "source-ff8e0599077f0d01044dc867", "source_updated_at": "2025-08-21", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/fampyra-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1523}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 21, "start": 0, "text": "Tel: +31 35 528 39 57", "truncated": false}, "before_length": 21, "before_sha256": "7baf6601f41e49e470f803fdd4e755a86efa38be423317c000ed79963ebdd213", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 21, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 21, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-4ecb083f873a0cf73429a134", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:14Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "8b8c4cc8e6f1a21fedee4bf0743c9c03e454b50f5eaba0e3760416d7fe0a74ec", "source_snapshot_id": "source-4efe4ecf3ebf08d338a763a5", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1993}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 18, "start": 0, "text": "Dublin 2, D02 T380", "truncated": false}, "before_length": 18, "before_sha256": "23e6871e7960b0dadc753bc127bbea230cc8308c88b2d33704eb275a3ec1a70d", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 18, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 18, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-4ecd492f2498519c53f58954", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002097", "medicine_name": "Fampyra", "medicine_slug": "fampyra", "observed_at": "2026-10-12T19:16:07Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "a0c3ba8d58d6a43a809ecc3d142a78b10c2bd7f0b9f3a3553df2617d87daec1f", "source_snapshot_id": "source-c7a810dd21f94cd2d273f0da", "source_updated_at": "2025-08-21", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/fampyra-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1406}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 20, "start": 0, "text": "10 Earlsfort Terrace", "truncated": false}, "before_length": 20, "before_sha256": "22951bbf6ee77815d0c07b3af5f0a66e17d277636971c4eaff372dea65dcb193", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 20, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 20, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-4ee360ea9bd77e3d8d478b84", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002097", "medicine_name": "Fampyra", "medicine_slug": "fampyra", "observed_at": "2026-10-12T19:16:07Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "a0c3ba8d58d6a43a809ecc3d142a78b10c2bd7f0b9f3a3553df2617d87daec1f", "source_snapshot_id": "source-c7a810dd21f94cd2d273f0da", "source_updated_at": "2025-08-21", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/fampyra-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1594}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 24, "start": 0, "text": "Τηλ: +358 (0) 3 284 8111", "truncated": false}, "before_length": 24, "before_sha256": "d6067cd3f2a7a2e958ac076aba456632e50c80f365a8e35948e7f408fe8f5396", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 24, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 24, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-4f0fe53f32c53f47259663f6", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002066", "medicine_name": "Ikervis", "medicine_slug": "ikervis", "observed_at": "2026-10-12T13:34:16Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "ab05f9fab48768c68482390488c5b90c577e852974d4448da6ea8fe5a4eda856", "source_snapshot_id": "source-324751bde2e11edc76c2dbfe", "source_updated_at": "2026-06-23", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/ikervis-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1799}
{"after": {"end": 30, "start": 0, "text": "Merz Therapeutics Benelux B.V.", "truncated": false}, "after_length": 30, "after_sha256": "7c5530f091b2eaff46486c1452be442d4a9c6f4c46924db34e94c6cdb089882e", "annex": "IIIA", "before": {"end": 35, "start": 0, "text": "Acorda Therapeutics Ireland Limited", "truncated": false}, "before_length": 35, "before_sha256": "d94d3153d193ed26567f2b4ed48df016d81c534e7c0cb1a6655a63f0083383ff", "change_kind": "content", "change_operations": [{"after_end": 2, "after_start": 0, "before_end": 3, "before_start": 0, "kind": "replace"}, {"after_end": 4, "after_start": 3, "before_end": 6, "before_start": 4, "kind": "replace"}, {"after_end": 21, "after_start": 18, "before_end": 22, "before_start": 20, "kind": "replace"}, {"after_end": 25, "after_start": 23, "before_end": 27, "before_start": 24, "kind": "replace"}, {"after_end": 30, "after_start": 26, "before_end": 35, "before_start": 28, "kind": "replace"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 17, "chars_inserted": 12}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-4f4e90f524445ef03ba86436", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002097", "medicine_name": "Fampyra", "medicine_slug": "fampyra", "observed_at": "2026-10-12T19:16:07Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "a0c3ba8d58d6a43a809ecc3d142a78b10c2bd7f0b9f3a3553df2617d87daec1f", "source_snapshot_id": "source-c7a810dd21f94cd2d273f0da", "source_updated_at": "2025-08-21", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/fampyra-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1457}
{"after": {"end": 22, "start": 0, "text": "Tel: +351 21 824 98 76", "truncated": false}, "after_length": 22, "after_sha256": "7c8ecb2e5f42841d3a036da23e786a84794928014737e604cb9ae0cc1a9be439", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 22, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 22}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-4f5f13f4425b916e6d8bc309", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:19Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "77586d0bea0858214b43b86e91abc2d2711733b96959ead5ed0b5ecbd8ed888a", "source_snapshot_id": "source-85d476f9ad959cc117ca8f1f", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1487}
{"after": {"end": 43, "start": 0, "text": "Orteliuslaan 1000, 3528 BD Utrecht Pays-Bas", "truncated": false}, "after_length": 43, "after_sha256": "5ad64eea087c05f92e591c89db00e99e8b23fd93d759d787c9fa4ac6829e7502", "annex": "III", "before": {"end": 43, "start": 0, "text": "Papendorpseweg 83, 3528 BJ Utrecht Pays-Bas", "truncated": false}, "before_length": 43, "before_sha256": "2ff8bcc9830507f63dba8a77d1aaeef88302446a200f1fe6ecefbad29b5ae46f", "change_kind": "unassigned", "change_operations": [{"after_end": 9, "after_start": 0, "before_end": 1, "before_start": 0, "kind": "replace"}, {"after_end": 11, "after_start": 10, "before_end": 4, "before_start": 2, "kind": "replace"}, {"after_end": 12, "after_start": 12, "before_end": 14, "before_start": 5, "kind": "delete"}, {"after_end": 17, "after_start": 13, "before_end": 17, "before_start": 15, "kind": "replace"}, {"after_end": 26, "after_start": 25, "before_end": 26, "before_start": 25, "kind": "replace"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 15, "chars_inserted": 15}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-4f8957fada94577bb512a107", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/001021", "medicine_name": "Adcirca (previously Tadalafil Lilly)", "medicine_slug": "adcirca-previously-tadalafil-lilly", "observed_at": "2026-10-12T19:02:45Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "", "section_type": "unassigned", "source_provider": "European Medicines Agency", "source_sha256": "cdbefcd6143c93e81f3c826bea8d3d01bffc55652e0f792243097df75c452721", "source_snapshot_id": "source-a1e85476de17f5a8664f7766", "source_updated_at": "2026-01-28", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/adcirca-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1584}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 14, "start": 0, "text": "Heussstraße 25", "truncated": false}, "before_length": 14, "before_sha256": "805584102a210d40b5c8e0e7014cb2d6f4194a7c2ef94da3309e0707eed85073", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 14, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 14, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-5039f091a6dcf50aeeeeff5c", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/005246", "medicine_name": "Byfavo", "medicine_slug": "byfavo", "observed_at": "2026-10-12T13:28:14Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "92a178ceb705631219efa40b1d0da73ebe6dfa866bc1b24d7e4dab9ded8a6861", "source_snapshot_id": "source-d485be5d9060fd557be910b2", "source_updated_at": "2026-08-26", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/byfavo-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 2292}
{"after": {"end": 13, "start": 0, "text": "Nieuwe Donk 9", "truncated": false}, "after_length": 13, "after_sha256": "9b03d8cf912ad0cf483871c4e8c85fde0243688b3a66c83ca9b8961156374e51", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 13, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 13}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-503f7323c7cc465b2ec39af0", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/000980", "medicine_name": "Samsca", "medicine_slug": "samsca", "observed_at": "2026-10-12T13:28:23Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "b92d73a758b8976c4438a072d544f0d6c603112c90dfc9c084d362ce62419257", "source_snapshot_id": "source-15b8b5681aba542ec1668c0b", "source_updated_at": "2026-08-20", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/samsca-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1267}
{"after": {"end": 23, "start": 0, "text": "Tel: +49 6431 285 88 30", "truncated": false}, "after_length": 23, "after_sha256": "ef2d8f53356e21d9673844a7ef23ea7b054ff18cc0092c86a4e97d96486b24a7", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 23, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 23}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-50463cd0b60602ae5c79b9d6", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:19Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "77586d0bea0858214b43b86e91abc2d2711733b96959ead5ed0b5ecbd8ed888a", "source_snapshot_id": "source-85d476f9ad959cc117ca8f1f", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1462}
{"after": {"end": 12, "start": 0, "text": "169 73 Solna", "truncated": false}, "after_length": 12, "after_sha256": "396199e813d8f79edb20275a432ef3c356a2964b18c41134b918894de8dcbb3d", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 12, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 12}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-50535e7bd0b71227ea796b38", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002097", "medicine_name": "Fampyra", "medicine_slug": "fampyra", "observed_at": "2026-10-12T19:15:51Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "d9fe8aaaa611a84801d6308b13685258b5248df9022536697939afdf66fc1719", "source_snapshot_id": "source-ff8e0599077f0d01044dc867", "source_updated_at": "2025-08-21", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/fampyra-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1593}
{"after": {"end": 22, "start": 0, "text": "Merz Therapeutics GmbH", "truncated": false}, "after_length": 22, "after_sha256": "059f049c7d0846aaadcf2573280d52110f302d4ecc7b38debd004571cd1e9d5e", "annex": "IIIA", "before": {"end": 35, "start": 0, "text": "Acorda Therapeutics Ireland Limited", "truncated": false}, "before_length": 35, "before_sha256": "d94d3153d193ed26567f2b4ed48df016d81c534e7c0cb1a6655a63f0083383ff", "change_kind": "content", "change_operations": [{"after_end": 2, "after_start": 0, "before_end": 3, "before_start": 0, "kind": "replace"}, {"after_end": 4, "after_start": 3, "before_end": 6, "before_start": 4, "kind": "replace"}, {"after_end": 19, "after_start": 18, "before_end": 30, "before_start": 20, "kind": "replace"}, {"after_end": 22, "after_start": 20, "before_end": 35, "before_start": 31, "kind": "replace"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 19, "chars_inserted": 6}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-50627434020f7583ff127f75", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002097", "medicine_name": "Fampyra", "medicine_slug": "fampyra", "observed_at": "2026-10-12T19:15:51Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "d9fe8aaaa611a84801d6308b13685258b5248df9022536697939afdf66fc1719", "source_snapshot_id": "source-ff8e0599077f0d01044dc867", "source_updated_at": "2025-08-21", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/fampyra-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1598}
{"after": {"end": 23, "start": 0, "text": "60318 Frankfurt am Main", "truncated": false}, "after_length": 23, "after_sha256": "24c3191b5088b20c209c4387a8127297e54c776e161d305c9e57956a13b7cbbe", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 23, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 23}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-507bcc812c0f727d4910c998", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002097", "medicine_name": "Fampyra", "medicine_slug": "fampyra", "observed_at": "2026-10-12T19:15:51Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "d9fe8aaaa611a84801d6308b13685258b5248df9022536697939afdf66fc1719", "source_snapshot_id": "source-ff8e0599077f0d01044dc867", "source_updated_at": "2025-08-21", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/fampyra-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1603}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 21, "start": 0, "text": "info@lucanepharma.com", "truncated": false}, "before_length": 21, "before_sha256": "44fd39e5fb919cb3d680fa630da23b49238fec29159c509f3622f272bb41c7c6", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 21, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 21, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-5094a0cfb816a4a7cbde9210", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:19Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "77586d0bea0858214b43b86e91abc2d2711733b96959ead5ed0b5ecbd8ed888a", "source_snapshot_id": "source-85d476f9ad959cc117ca8f1f", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1923}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "I", "before": {"end": 7, "start": 0, "text": "Irlande", "truncated": false}, "before_length": 7, "before_sha256": "a8cdfff5dbbda1b070a2acb339b6f0aa20b6230d9b5500c9ce066eaa89bc9a64", "change_kind": "administrative", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 7, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 7, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-50a4bb541c4dd1106f7351f3", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002097", "medicine_name": "Fampyra", "medicine_slug": "fampyra", "observed_at": "2026-10-12T19:16:07Z", "pipeline_version": "2.0.0", "presentation_label": "Fampyra 10 mg, comprimés à libération prolongée", "presentation_occurrence": 1, "presentation_status": "heading_extracted_unverified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "7", "section_type": "administrative", "source_provider": "European Medicines Agency", "source_sha256": "a0c3ba8d58d6a43a809ecc3d142a78b10c2bd7f0b9f3a3553df2617d87daec1f", "source_snapshot_id": "source-c7a810dd21f94cd2d273f0da", "source_updated_at": "2025-08-21", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/fampyra-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 682}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 13, "start": 0, "text": "Lucane Pharma", "truncated": false}, "before_length": 13, "before_sha256": "e338afdb64acf1a6e2083a50318853589248451dd3aa707181ba02641a8521e8", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 13, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 13, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-50d28d0d5c197e8f3df8394a", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:19Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "77586d0bea0858214b43b86e91abc2d2711733b96959ead5ed0b5ecbd8ed888a", "source_snapshot_id": "source-85d476f9ad959cc117ca8f1f", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1890}
{"after": {"end": 18, "start": 0, "text": "4844 CK Terheijden", "truncated": false}, "after_length": 18, "after_sha256": "e7ea1ad04b1071e360b652726acc9e8a22118603b55f58e0bd782476a7e47649", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 18, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 18}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-50d346c05bf637e76520fac1", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002097", "medicine_name": "Fampyra", "medicine_slug": "fampyra", "observed_at": "2026-10-12T19:16:07Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "a0c3ba8d58d6a43a809ecc3d142a78b10c2bd7f0b9f3a3553df2617d87daec1f", "source_snapshot_id": "source-c7a810dd21f94cd2d273f0da", "source_updated_at": "2025-08-21", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/fampyra-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1409}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 20, "start": 0, "text": "10 Earlsfort Terrace", "truncated": false}, "before_length": 20, "before_sha256": "22951bbf6ee77815d0c07b3af5f0a66e17d277636971c4eaff372dea65dcb193", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 20, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 20, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-50ec63b1b17142b6cfe43ae3", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002097", "medicine_name": "Fampyra", "medicine_slug": "fampyra", "observed_at": "2026-10-12T19:16:07Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "a0c3ba8d58d6a43a809ecc3d142a78b10c2bd7f0b9f3a3553df2617d87daec1f", "source_snapshot_id": "source-c7a810dd21f94cd2d273f0da", "source_updated_at": "2025-08-21", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/fampyra-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1540}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 21, "start": 0, "text": "info@lucanepharma.com", "truncated": false}, "before_length": 21, "before_sha256": "44fd39e5fb919cb3d680fa630da23b49238fec29159c509f3622f272bb41c7c6", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 21, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 21, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-510c1a989b40f202153f830e", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:19Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "77586d0bea0858214b43b86e91abc2d2711733b96959ead5ed0b5ecbd8ed888a", "source_snapshot_id": "source-85d476f9ad959cc117ca8f1f", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1427}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 13, "start": 0, "text": "Lucane Pharma", "truncated": false}, "before_length": 13, "before_sha256": "e338afdb64acf1a6e2083a50318853589248451dd3aa707181ba02641a8521e8", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 13, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 13, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-5126fb9705744fc41bb60879", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:19Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "77586d0bea0858214b43b86e91abc2d2711733b96959ead5ed0b5ecbd8ed888a", "source_snapshot_id": "source-85d476f9ad959cc117ca8f1f", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1970}
{"after": {"end": 9, "start": 0, "text": "Not known", "truncated": false}, "after_length": 9, "after_sha256": "117adf013b8521b57cc432f1d680aa8ca8ffe7ac83edfa7e0a5867794a6429cc", "annex": "I", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 9, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": true, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 9}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-512935cc70b6748e7b1dde75", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/000554", "medicine_name": "Emselex", "medicine_slug": "emselex", "observed_at": "2026-10-12T19:12:04Z", "pipeline_version": "2.0.0", "presentation_label": "Emselex 15 mg prolonged-release tablets", "presentation_occurrence": 2, "presentation_status": "heading_extracted_unverified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "4.8", "section_type": "adverse_reactions", "source_provider": "European Medicines Agency", "source_sha256": "4f2565612bc728ec67b7f9c0cd5799ef2c594911c76f323aef8bf6a85adde245", "source_snapshot_id": "source-1fda25b331eb198b8b93feb3", "source_updated_at": "2025-09-15", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/emselex-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 601}
{"after": {"end": 13, "start": 0, "text": "Bredaseweg 63", "truncated": false}, "after_length": 13, "after_sha256": "a37bbd239b649e23c8960a4ab83fa25cba872a2c2e743860ae8149ff61815928", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 13, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 13}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-51321ed5e1f767ddb51d24ec", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002097", "medicine_name": "Fampyra", "medicine_slug": "fampyra", "observed_at": "2026-10-12T19:16:07Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "a0c3ba8d58d6a43a809ecc3d142a78b10c2bd7f0b9f3a3553df2617d87daec1f", "source_snapshot_id": "source-c7a810dd21f94cd2d273f0da", "source_updated_at": "2025-08-21", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/fampyra-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1408}
{"after": {"end": 26, "start": 0, "text": "Eckenheimer Landstraße 100", "truncated": false}, "after_length": 26, "after_sha256": "fdce1a9bd200c5ddd476c1ea5676b9ffbbea723f7353ad6fbc1fe019dcb86c07", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 26, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 26}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-513e8c1bb6b8cc747b7fed8b", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002097", "medicine_name": "Fampyra", "medicine_slug": "fampyra", "observed_at": "2026-10-12T19:16:07Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "a0c3ba8d58d6a43a809ecc3d142a78b10c2bd7f0b9f3a3553df2617d87daec1f", "source_snapshot_id": "source-c7a810dd21f94cd2d273f0da", "source_updated_at": "2025-08-21", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/fampyra-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1533}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 16, "start": 0, "text": "Extrovis EU Ltd.", "truncated": false}, "before_length": 16, "before_sha256": "f462ad48e7aef0bc82148ce088af1897d99ed86993128f30d506b27d3108a929", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 16, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 16, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-5146570f4889eeb55fad9e02", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/006047", "medicine_name": "Lacosamide Adroiq", "medicine_slug": "lacosamide-adroiq", "observed_at": "2026-10-12T19:07:59Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "cc83d966059d42856d0211a4f256b29b20d43593865704d6a9315aeb694f3c76", "source_snapshot_id": "source-896abba1d8391c918345d46b", "source_updated_at": "2025-09-25", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/lacosamide-adroiq-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1782}
{"after": {"end": 255, "start": 0, "text": "The solution with the lemon-mint flavour topping is slightly less thick than the one with blackcurrant flavour topping and may lead to adding of more than 2 drops. You should carefully measure the lemon-mint topping to be sure that only one drop is added.", "truncated": false}, "after_length": 255, "after_sha256": "e476a8c530815fd301a14f019711ccda0d5cea436372a183776744731e235d20", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 255, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 255}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-5165e98559ce5282b2e67342", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:14Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "8b8c4cc8e6f1a21fedee4bf0743c9c03e454b50f5eaba0e3760416d7fe0a74ec", "source_snapshot_id": "source-4efe4ecf3ebf08d338a763a5", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1746}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 21, "start": 0, "text": "info@lucanepharma.com", "truncated": false}, "before_length": 21, "before_sha256": "44fd39e5fb919cb3d680fa630da23b49238fec29159c509f3622f272bb41c7c6", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 21, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 21, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-51849506f173d45eb82df8c8", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:19Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "77586d0bea0858214b43b86e91abc2d2711733b96959ead5ed0b5ecbd8ed888a", "source_snapshot_id": "source-85d476f9ad959cc117ca8f1f", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1434}
{"after": {"end": 54, "start": 0, "text": "Affections musculosquelettiques et du tissu conjonctif", "truncated": false}, "after_length": 54, "after_sha256": "526c3d2dffcdbc9eb5630a88bd92106a3f1a8db2503eba17353690907ac1cdc7", "annex": "I", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 54, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": true, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 54}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-5189e1931565c2fab80206d4", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/000554", "medicine_name": "Emselex", "medicine_slug": "emselex", "observed_at": "2026-10-12T19:12:07Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": null, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "4.8", "section_type": "adverse_reactions", "source_provider": "European Medicines Agency", "source_sha256": "9a4f1d7e260c7b80eaf397503623b63302e5945b579e9612177835e07c4ab888", "source_snapshot_id": "source-3aac7bf42b99529f25ac013b", "source_updated_at": "2025-09-15", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/emselex-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 633}
{"after": {"end": 16, "start": 0, "text": "Extrovis EU Kft.", "truncated": false}, "after_length": 16, "after_sha256": "b9216ef80e71e17798dce313e4318f03f37328f225d30ab508b7413813a908e5", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 16, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 16}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-52184f62940525153850e1a2", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/006047", "medicine_name": "Lacosamide Adroiq", "medicine_slug": "lacosamide-adroiq", "observed_at": "2026-10-12T19:07:59Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "cc83d966059d42856d0211a4f256b29b20d43593865704d6a9315aeb694f3c76", "source_snapshot_id": "source-896abba1d8391c918345d46b", "source_updated_at": "2025-09-25", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/lacosamide-adroiq-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1111}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 18, "start": 0, "text": "Pátriárka utca 14.", "truncated": false}, "before_length": 18, "before_sha256": "488a80d25b682a58591b4751c4687d5b516ccd6a004748e40d4e8f1454217b07", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 18, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 18, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-52201283903c68b3301c34a9", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/006047", "medicine_name": "Lacosamide Adroiq", "medicine_slug": "lacosamide-adroiq", "observed_at": "2026-10-12T19:07:59Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "cc83d966059d42856d0211a4f256b29b20d43593865704d6a9315aeb694f3c76", "source_snapshot_id": "source-896abba1d8391c918345d46b", "source_updated_at": "2025-09-25", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/lacosamide-adroiq-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1212}
{"after": {"end": 7, "start": 0, "text": "Germany", "truncated": false}, "after_length": 7, "after_sha256": "80db4ccdca106d37b920206331fcfe3e9e50a9e763d89b54ce3ad5ac8cf30f03", "annex": "I", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "administrative", "change_operations": [{"after_end": 7, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 7}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-5268a13cb559c76669f8cbc0", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002097", "medicine_name": "Fampyra", "medicine_slug": "fampyra", "observed_at": "2026-10-12T19:15:51Z", "pipeline_version": "2.0.0", "presentation_label": "Fampyra 10 mg prolonged-release tablets", "presentation_occurrence": 1, "presentation_status": "heading_extracted_unverified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "7", "section_type": "administrative", "source_provider": "European Medicines Agency", "source_sha256": "d9fe8aaaa611a84801d6308b13685258b5248df9022536697939afdf66fc1719", "source_snapshot_id": "source-ff8e0599077f0d01044dc867", "source_updated_at": "2025-08-21", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/fampyra-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 689}
{"after": {"end": 27, "start": 0, "text": "CPO Pharmaceuticals Limited", "truncated": false}, "after_length": 27, "after_sha256": "94b644443752e2cb52916b23f8141fbd44c47055b3416af333e12ac18e101b87", "annex": "IIIA", "before": {"end": 23, "start": 0, "text": "GPA Pharmaceuticals Ltd", "truncated": false}, "before_length": 23, "before_sha256": "ece7127e303c91e9501d2cedd822476265aae86acb9f96ef1553ab3a6954afe1", "change_kind": "content", "change_operations": [{"after_end": 1, "after_start": 0, "before_end": 1, "before_start": 0, "kind": "replace"}, {"after_end": 3, "after_start": 2, "before_end": 3, "before_start": 2, "kind": "replace"}, {"after_end": 24, "after_start": 21, "before_end": 21, "before_start": 21, "kind": "insert"}, {"after_end": 26, "after_start": 25, "before_end": 22, "before_start": 22, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 2, "chars_inserted": 6}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-527b508a2d686bf650e0ca71", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/004025", "medicine_name": "Lopinavir/Ritonavir Viatris (previously Ritonavir Mylan)", "medicine_slug": "lopinavir-ritonavir-viatris-previously-ritonavir-mylan", "observed_at": "2026-10-12T19:12:46Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "3e30663f02732816ed8779d7a929d500c824ae15aeaee9144ca6eef11900e273", "source_snapshot_id": "source-c58e019b5bec1fb24569e83e", "source_updated_at": "2025-09-08", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/lopinavir-ritonavir-viatris-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 3526}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 20, "start": 0, "text": "10 Earlsfort Terrace", "truncated": false}, "before_length": 20, "before_sha256": "22951bbf6ee77815d0c07b3af5f0a66e17d277636971c4eaff372dea65dcb193", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 20, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 20, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-528b97d71023466e25e32246", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002097", "medicine_name": "Fampyra", "medicine_slug": "fampyra", "observed_at": "2026-10-12T19:16:07Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "a0c3ba8d58d6a43a809ecc3d142a78b10c2bd7f0b9f3a3553df2617d87daec1f", "source_snapshot_id": "source-c7a810dd21f94cd2d273f0da", "source_updated_at": "2025-08-21", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/fampyra-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1425}
{"after": {"end": 23, "start": 0, "text": "dpoc.poland@organon.com", "truncated": false}, "after_length": 23, "after_sha256": "64a2356c9c563e1d59ad602a49d34aa457ffdf163dfa15c37c91becde91165f3", "annex": "IIIA", "before": {"end": 25, "start": 0, "text": "organonpolska@organon.com", "truncated": false}, "before_length": 25, "before_sha256": "25d407302ccedc28a9421e77900513d332e9ab19a438b83d152bf1baab000ba3", "change_kind": "content", "change_operations": [{"after_end": 2, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}, {"after_end": 5, "after_start": 3, "before_end": 7, "before_start": 1, "kind": "replace"}, {"after_end": 8, "after_start": 8, "before_end": 12, "before_start": 10, "kind": "delete"}, {"after_end": 11, "after_start": 9, "before_end": 13, "before_start": 13, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 8, "chars_inserted": 6}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-52997ea554f51f99070bb915", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/000619", "medicine_name": "Fosavance", "medicine_slug": "fosavance", "observed_at": "2026-10-12T19:01:48Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "37324165444dd93963c38ccfa569b0631b8d34d16c725b5a46b16dd7bb4cbbc2", "source_snapshot_id": "source-829e9ebd79c1d98e8a839547", "source_updated_at": "2026-02-12", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/fosavance-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1251}
{"after": {"end": 16, "start": 0, "text": "Extrovis EU Kft.", "truncated": false}, "after_length": 16, "after_sha256": "b9216ef80e71e17798dce313e4318f03f37328f225d30ab508b7413813a908e5", "annex": "IIIB", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "unassigned", "change_operations": [{"after_end": 16, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 16}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-52c279ddbe1bcd1b67c54c81", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/006047", "medicine_name": "Lacosamide Adroiq", "medicine_slug": "lacosamide-adroiq", "observed_at": "2026-10-12T19:07:56Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "", "section_type": "unassigned", "source_provider": "European Medicines Agency", "source_sha256": "0578c53a5e1c785c4d9d4dc0dabae49dbfa89e237aa571556bee548c3f9cf4d5", "source_snapshot_id": "source-64831dec5ebf55535e19d91b", "source_updated_at": "2025-09-25", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/lacosamide-adroiq-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1991}
{"after": {"end": 23, "start": 0, "text": "60318 Frankfurt am Main", "truncated": false}, "after_length": 23, "after_sha256": "24c3191b5088b20c209c4387a8127297e54c776e161d305c9e57956a13b7cbbe", "annex": "I", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "administrative", "change_operations": [{"after_end": 23, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 23}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-52c36084727922ba8205c108", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002097", "medicine_name": "Fampyra", "medicine_slug": "fampyra", "observed_at": "2026-10-12T19:16:07Z", "pipeline_version": "2.0.0", "presentation_label": "Fampyra 10 mg, comprimés à libération prolongée", "presentation_occurrence": 1, "presentation_status": "heading_extracted_unverified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "7", "section_type": "administrative", "source_provider": "European Medicines Agency", "source_sha256": "a0c3ba8d58d6a43a809ecc3d142a78b10c2bd7f0b9f3a3553df2617d87daec1f", "source_snapshot_id": "source-c7a810dd21f94cd2d273f0da", "source_updated_at": "2025-08-21", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/fampyra-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 685}
{"after": {"end": 20, "start": 0, "text": "Viatris Germany GmbH", "truncated": false}, "after_length": 20, "after_sha256": "4c2f2a211c5c41870eee98c700979da5e888736aac1a795ab787143446de83ca", "annex": "II", "before": {"end": 18, "start": 0, "text": "Mylan Germany GmbH", "truncated": false}, "before_length": 18, "before_sha256": "d7a3f7e30e2672617d153ba93a8cf1c2908da6e7dcfe6d206314ed71d4e5405a", "change_kind": "content", "change_operations": [{"after_end": 2, "after_start": 0, "before_end": 3, "before_start": 0, "kind": "replace"}, {"after_end": 7, "after_start": 3, "before_end": 5, "before_start": 4, "kind": "replace"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 4, "chars_inserted": 6}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-52ca7c646ee79991f09910a9", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/000403", "medicine_name": "Arixtra", "medicine_slug": "arixtra", "observed_at": "2026-10-12T13:38:45Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 5, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "conditions", "section_type": "conditions", "source_provider": "European Medicines Agency", "source_sha256": "d627c7ab3c0e2e04ec110e8a99901c16a8eb257c9c55138e1bd3875249a20bde", "source_snapshot_id": "source-1eab2dd77b34f4c6fe6e82df", "source_updated_at": "2026-05-07", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/arixtra-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 2300}
{"after": {"end": 22, "start": 0, "text": "Fréquence indéterminée", "truncated": false}, "after_length": 22, "after_sha256": "9dbca2ea64869864cf27be15cb397d59f7675843792a00e126385e734d3768e0", "annex": "I", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 22, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": true, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 22}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-5305fe4a0f3d02ac96f27b47", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/000554", "medicine_name": "Emselex", "medicine_slug": "emselex", "observed_at": "2026-10-12T19:12:07Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": null, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "4.8", "section_type": "adverse_reactions", "source_provider": "European Medicines Agency", "source_sha256": "9a4f1d7e260c7b80eaf397503623b63302e5945b579e9612177835e07c4ab888", "source_snapshot_id": "source-3aac7bf42b99529f25ac013b", "source_updated_at": "2025-09-15", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/emselex-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 634}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 13, "start": 0, "text": "Lucane Pharma", "truncated": false}, "before_length": 13, "before_sha256": "e338afdb64acf1a6e2083a50318853589248451dd3aa707181ba02641a8521e8", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 13, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 13, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-533b84b02548c23d19a7f22a", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:19Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "77586d0bea0858214b43b86e91abc2d2711733b96959ead5ed0b5ecbd8ed888a", "source_snapshot_id": "source-85d476f9ad959cc117ca8f1f", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1811}
{"after": {"end": 18, "start": 0, "text": "Confusional state*", "truncated": false}, "after_length": 18, "after_sha256": "be42c48a234274a52a872c07a6a1715a7231fe08b61d94e630180217453881c2", "annex": "I", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 18, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": true, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 18}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-533ec6d280e83f6d8ff0fd4a", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/000554", "medicine_name": "Emselex", "medicine_slug": "emselex", "observed_at": "2026-10-12T19:12:04Z", "pipeline_version": "2.0.0", "presentation_label": "Emselex 7.5 mg prolonged-release tablets", "presentation_occurrence": 1, "presentation_status": "heading_extracted_unverified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "4.8", "section_type": "adverse_reactions", "source_provider": "European Medicines Agency", "source_sha256": "4f2565612bc728ec67b7f9c0cd5799ef2c594911c76f323aef8bf6a85adde245", "source_snapshot_id": "source-1fda25b331eb198b8b93feb3", "source_updated_at": "2025-09-15", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/emselex-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 178}
{"after": {"end": 23, "start": 0, "text": "60318 Frankfurt am Main", "truncated": false}, "after_length": 23, "after_sha256": "24c3191b5088b20c209c4387a8127297e54c776e161d305c9e57956a13b7cbbe", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 23, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 23}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-534833e797405437626c242c", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002097", "medicine_name": "Fampyra", "medicine_slug": "fampyra", "observed_at": "2026-10-12T19:15:51Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "d9fe8aaaa611a84801d6308b13685258b5248df9022536697939afdf66fc1719", "source_snapshot_id": "source-ff8e0599077f0d01044dc867", "source_updated_at": "2025-08-21", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/fampyra-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1383}
{"after": {"end": 38, "start": 0, "text": "*observed in post-marketing experience", "truncated": false}, "after_length": 38, "after_sha256": "02e765dfaf4417c8e0b4f8e92452cff6a42cf8088dacac2dfe6aa971aeb970b5", "annex": "I", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 38, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": true, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 38}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-5360570cdbbb5e02500f64bb", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/000554", "medicine_name": "Emselex", "medicine_slug": "emselex", "observed_at": "2026-10-12T19:12:04Z", "pipeline_version": "2.0.0", "presentation_label": "Emselex 7.5 mg prolonged-release tablets", "presentation_occurrence": 1, "presentation_status": "heading_extracted_unverified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "4.8", "section_type": "adverse_reactions", "source_provider": "European Medicines Agency", "source_sha256": "4f2565612bc728ec67b7f9c0cd5799ef2c594911c76f323aef8bf6a85adde245", "source_snapshot_id": "source-1fda25b331eb198b8b93feb3", "source_updated_at": "2025-09-15", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/emselex-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 231}
{"after": {"end": 21, "start": 0, "text": "Tel: +420 277 051 010", "truncated": false}, "after_length": 21, "after_sha256": "50d60e49161099285c4e19a446177466795e2c022df75a1c35dff2fb7dc41435", "annex": "IIIA", "before": {"end": 21, "start": 0, "text": "Tel: +420 233 010 300", "truncated": false}, "before_length": 21, "before_sha256": "746918552274379bd7e6869467f464a71268035ce8f31deabc258dfbe6696cda", "change_kind": "content", "change_operations": [{"after_end": 17, "after_start": 11, "before_end": 13, "before_start": 11, "kind": "replace"}, {"after_end": 20, "after_start": 20, "before_end": 20, "before_start": 16, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 6, "chars_inserted": 6}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-5378438f789b3f6d67d59ea0", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/000619", "medicine_name": "Fosavance", "medicine_slug": "fosavance", "observed_at": "2026-10-12T19:01:48Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "37324165444dd93963c38ccfa569b0631b8d34d16c725b5a46b16dd7bb4cbbc2", "source_snapshot_id": "source-829e9ebd79c1d98e8a839547", "source_updated_at": "2026-02-12", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/fosavance-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1197}
{"after": {"end": 8, "start": 0, "text": "Njemačka", "truncated": false}, "after_length": 8, "after_sha256": "d86d75a0350345bd2fc6c8bca77b927decba49ece60e02b51c592d8d5cd55dd8", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 8, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 8}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-53832a3e27b154dd5f9ca4af", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002097", "medicine_name": "Fampyra", "medicine_slug": "fampyra", "observed_at": "2026-10-12T19:15:51Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "d9fe8aaaa611a84801d6308b13685258b5248df9022536697939afdf66fc1719", "source_snapshot_id": "source-ff8e0599077f0d01044dc867", "source_updated_at": "2025-08-21", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/fampyra-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1529}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 5, "start": 0, "text": "Regus", "truncated": false}, "before_length": 5, "before_sha256": "69ef2ca82e0f736644001207ab7589688f2ada81eedc4859209d50896d65b095", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 5, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 5, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-53d340cd6d09c957870df9b8", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002097", "medicine_name": "Fampyra", "medicine_slug": "fampyra", "observed_at": "2026-10-12T19:16:07Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "a0c3ba8d58d6a43a809ecc3d142a78b10c2bd7f0b9f3a3553df2617d87daec1f", "source_snapshot_id": "source-c7a810dd21f94cd2d273f0da", "source_updated_at": "2025-08-21", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/fampyra-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1436}
{"after": {"end": 79, "start": 0, "text": "Viatris Germany GmbH, Zweigniederlassung Bad Homburg v. d. Höhe, Benzstrasse 1,", "truncated": false}, "after_length": 79, "after_sha256": "ec5d8b467f097b5f6e626a2a056336fab8904b07ad533e62379b09597067a87b", "annex": "IIIA", "before": {"end": 77, "start": 0, "text": "Mylan Germany GmbH, Zweigniederlassung Bad Homburg v. d. Höhe, Benzstrasse 1,", "truncated": false}, "before_length": 77, "before_sha256": "592354ac8c07b62540d767b349e438cbf42cff382f1d83c4853733a8264bcf56", "change_kind": "content", "change_operations": [{"after_end": 2, "after_start": 0, "before_end": 3, "before_start": 0, "kind": "replace"}, {"after_end": 7, "after_start": 3, "before_end": 5, "before_start": 4, "kind": "replace"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 4, "chars_inserted": 6}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-53e940239c8b5ceb31d71b07", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/000403", "medicine_name": "Arixtra", "medicine_slug": "arixtra", "observed_at": "2026-10-12T13:38:50Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": null, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "123deb3dbdc841a7adc2b8046138993b8a6a1c228bde13a95278b14d17c5cefd", "source_snapshot_id": "source-79bede7a4a9cd1c040f622e0", "source_updated_at": "2026-05-07", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/arixtra-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 3361}
{"after": {"end": 23, "start": 0, "text": "60318 Frankfurt am Main", "truncated": false}, "after_length": 23, "after_sha256": "24c3191b5088b20c209c4387a8127297e54c776e161d305c9e57956a13b7cbbe", "annex": "IIIA", "before": {"end": 15, "start": 0, "text": "60318 Frankfurt", "truncated": false}, "before_length": 15, "before_sha256": "e51a2d4338d09f9fbc6ab0ad5d0a6dc6efd90f583e365f4764dd86681442d5b4", "change_kind": "content", "change_operations": [{"after_end": 23, "after_start": 15, "before_end": 15, "before_start": 15, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 8}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-541ce7b4414f0d8beaa1a6bd", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002097", "medicine_name": "Fampyra", "medicine_slug": "fampyra", "observed_at": "2026-10-12T19:15:51Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "d9fe8aaaa611a84801d6308b13685258b5248df9022536697939afdf66fc1719", "source_snapshot_id": "source-ff8e0599077f0d01044dc867", "source_updated_at": "2025-08-21", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/fampyra-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1448}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 18, "start": 0, "text": "Dublin 2, D02 T380", "truncated": false}, "before_length": 18, "before_sha256": "23e6871e7960b0dadc753bc127bbea230cc8308c88b2d33704eb275a3ec1a70d", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 18, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 18, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-54349bb296731d4a8311ac91", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002097", "medicine_name": "Fampyra", "medicine_slug": "fampyra", "observed_at": "2026-10-12T19:15:51Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "d9fe8aaaa611a84801d6308b13685258b5248df9022536697939afdf66fc1719", "source_snapshot_id": "source-ff8e0599077f0d01044dc867", "source_updated_at": "2025-08-21", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/fampyra-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1400}
{"after": {"end": 23, "start": 0, "text": "info@euroceptpharma.com", "truncated": false}, "after_length": 23, "after_sha256": "9297cc5acdcc837f054116992765943f7907937507b2564a99ea1327a00ac0e6", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 23, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 23}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-545761fe9fbbf2e294174938", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:14Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "8b8c4cc8e6f1a21fedee4bf0743c9c03e454b50f5eaba0e3760416d7fe0a74ec", "source_snapshot_id": "source-4efe4ecf3ebf08d338a763a5", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 2015}
{"after": {"end": 26, "start": 0, "text": "Tél/Tel: +31 (0) 762057088", "truncated": false}, "after_length": 26, "after_sha256": "3bc75506c55c8b7cd4fff8d2140ba08d71ae9e9c73edbd7c8810587852e9e7f9", "annex": "IIIA", "before": {"end": 27, "start": 0, "text": "Tél/Tel: +353 (0)1 231 4609", "truncated": false}, "before_length": 27, "before_sha256": "87104ca41090d27d4255b5464c46bf8c8c6fca2440bf6dae9e31ce28d2ad406a", "change_kind": "content", "change_operations": [{"after_end": 12, "after_start": 11, "before_end": 13, "before_start": 11, "kind": "replace"}, {"after_end": 16, "after_start": 16, "before_end": 18, "before_start": 17, "kind": "delete"}, {"after_end": 19, "after_start": 17, "before_end": 19, "before_start": 19, "kind": "insert"}, {"after_end": 20, "after_start": 20, "before_end": 25, "before_start": 20, "kind": "delete"}, {"after_end": 26, "after_start": 21, "before_end": 27, "before_start": 26, "kind": "replace"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 9, "chars_inserted": 8}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-54628723dca8e311c445520a", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002097", "medicine_name": "Fampyra", "medicine_slug": "fampyra", "observed_at": "2026-10-12T19:16:07Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "a0c3ba8d58d6a43a809ecc3d142a78b10c2bd7f0b9f3a3553df2617d87daec1f", "source_snapshot_id": "source-c7a810dd21f94cd2d273f0da", "source_updated_at": "2025-08-21", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/fampyra-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1381}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "III", "before": {"end": 39, "start": 0, "text": "Eli Lilly and Company (Ireland) Limited", "truncated": false}, "before_length": 39, "before_sha256": "0555e8a06c0ef36afd955d945d4997f04834690c546541adf74802bac524a0e4", "change_kind": "unassigned", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 39, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 39, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-54db7b475f1f095d94019d7a", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/001021", "medicine_name": "Adcirca (previously Tadalafil Lilly)", "medicine_slug": "adcirca-previously-tadalafil-lilly", "observed_at": "2026-10-12T19:02:45Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "", "section_type": "unassigned", "source_provider": "European Medicines Agency", "source_sha256": "cdbefcd6143c93e81f3c826bea8d3d01bffc55652e0f792243097df75c452721", "source_snapshot_id": "source-a1e85476de17f5a8664f7766", "source_updated_at": "2026-01-28", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/adcirca-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 2014}
{"after": {"end": 86, "start": 0, "text": "The CHMP recommends that the terms of the Marketing Authorisation(s) should be varied.", "truncated": false}, "after_length": 86, "after_sha256": "cbb4f69529a9be6de0d2c00965408c358c7d6304c2a0f7852653b1180bb73b09", "annex": "IV", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 86, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 86}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-54ea80cc7e609754b0bfc533", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/000554", "medicine_name": "Emselex", "medicine_slug": "emselex", "observed_at": "2026-10-12T19:12:04Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "conditions", "section_type": "conditions", "source_provider": "European Medicines Agency", "source_sha256": "4f2565612bc728ec67b7f9c0cd5799ef2c594911c76f323aef8bf6a85adde245", "source_snapshot_id": "source-1fda25b331eb198b8b93feb3", "source_updated_at": "2025-09-15", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/emselex-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 2089}
{"after": {"end": 11, "start": 0, "text": "Vianex S.A.", "truncated": false}, "after_length": 11, "after_sha256": "5aa05543f23c771ae6d358a0283a8ebc791ceaed5f1fb141cf038e2e49a6ac7b", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 11, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 11}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-5514c4522b959ce9a5ce15ad", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002066", "medicine_name": "Ikervis", "medicine_slug": "ikervis", "observed_at": "2026-10-12T13:34:16Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "ab05f9fab48768c68482390488c5b90c577e852974d4448da6ea8fe5a4eda856", "source_snapshot_id": "source-324751bde2e11edc76c2dbfe", "source_updated_at": "2026-06-23", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/ikervis-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1797}
{"after": {"end": 444, "start": 0, "text": "Skin ulcers and impaired wound healing may potentially occur in patients during therapy with AUBAGIO. If AUBAGIO-associated skin ulcer is suspected, if skin ulcers persist despite appropriate therapy, or if there is a high risk for impaired wound healing after surgery, consider AUBAGIO discontinuation and an accelerated drug elimination procedure. The decision to resume AUBAGIO should be based on clinical judgment of adequate wound healing.", "truncated": false}, "after_length": 444, "after_sha256": "4ef9e9998671c687ea75601e130471a623452869832d0f4bc3b4cf8967346234", "annex": "I", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 444, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": true, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 444}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-554a8314c0f2c4d80000b1c8", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002514", "medicine_name": "Aubagio", "medicine_slug": "aubagio", "observed_at": "2026-10-12T17:28:37Z", "pipeline_version": "2.0.0", "presentation_label": "AUBAGIO 7 mg film-coated tablets AUBAGIO 14 mg film-coated tablets", "presentation_occurrence": 1, "presentation_status": "heading_extracted_unverified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "4.4", "section_type": "warning", "source_provider": "European Medicines Agency", "source_sha256": "2583b2915ecedeb3bccc3ac6bea691e65d05f5e437bf8aa7970917b6fdeb700c", "source_snapshot_id": "source-15791f384b9e49792c9776dd", "source_updated_at": "2025-12-09", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/aubagio-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 215}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 13, "start": 0, "text": "Lucane Pharma", "truncated": false}, "before_length": 13, "before_sha256": "e338afdb64acf1a6e2083a50318853589248451dd3aa707181ba02641a8521e8", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 13, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 13, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-558a66095358ba8faeceea99", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:19Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "77586d0bea0858214b43b86e91abc2d2711733b96959ead5ed0b5ecbd8ed888a", "source_snapshot_id": "source-85d476f9ad959cc117ca8f1f", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1881}
{"after": {"end": 644, "start": 0, "text": "Myositis and /or rhabdomyolysis have been reported in patients treated with leflunomide, frequently in combination with other immunosuppressive drugs. Clinical symptoms may include unexplained muscle pain, tenderness or muscle weakness. Patients should be informed about the signs and symptoms associated with myositis and rhabdomyolysis and advised to seek medical attention immediately if such symptoms occur during leflunomide treatment. Monitor the patients for elevation of CK levels if clinically indicated. If patients develop any of these conditions, leflunomide must be discontinued and a washout procedure initiated (see section 4.4).", "truncated": false}, "after_length": 644, "after_sha256": "54416fa80b2720b6142b9cb375a3b6e04c26b8a363a88b57c6bfcd4d9d1e672b", "annex": "I", "before": {"end": 135, "start": 0, "text": "Myopathy muscle injury has with leflunomide treatment. Follow-up with patients periodically for muscle pain and weakness. as necessary.", "truncated": false}, "before_length": 135, "before_sha256": "a9c5aa43249002e83964883b90965cb0316721089889783990eedc99707d282f", "change_kind": "content", "change_operations": [{"after_end": 54, "after_start": 3, "before_end": 3, "before_start": 3, "kind": "insert"}, {"after_end": 74, "after_start": 57, "before_end": 6, "before_start": 6, "kind": "insert"}, {"after_end": 98, "after_start": 75, "before_end": 7, "before_start": 7, "kind": "insert"}, {"after_end": 192, "after_start": 99, "before_end": 8, "before_start": 8, "kind": "insert"}, {"after_end": 202, "after_start": 200, "before_end": 16, "before_start": 16, "kind": "insert"}, {"after_end": 221, "after_start": 204, "before_end": 19, "before_start": 18, "kind": "replace"}, {"after_end": 260, "after_start": 222, "before_end": 20, "before_start": 20, "kind": "insert"}, {"after_end": 286, "after_start": 261, "before_end": 21, "before_start": 21, "kind": "insert"}, {"after_end": 293, "after_start": 287, "before_end": 22, "before_start": 22, "kind": "insert"}, {"after_end": 294, "after_start": 294, "before_end": 24, "before_start": 23, "kind": "delete"}, {"after_end": 304, "after_start": 296, "before_end": 26, "before_start": 26, "kind": "insert"}, {"after_end": 417, "after_start": 309, "before_end": 31, "before_start": 31, "kind": "insert"}, {"after_end": 442, "after_start": 441, "before_end": 56, "before_start": 55, "kind": "replace"}, {"after_end": 444, "after_start": 443, "before_end": 66, "before_start": 57, "kind": "replace"}, {"after_end": 450, "after_start": 446, "before_end": 68, "before_start": 68, "kind": "insert"}, {"after_end": 452, "after_start": 451, "before_end": 69, "before_start": 69, "kind": "insert"}, {"after_end": 466, "after_start": 462, "before_end": 80, "before_start": 79, "kind": "replace"}, {"after_end": 472, "after_start": 467, "before_end": 82, "before_start": 81, "kind": "replace"}, {"after_end": 496, "after_start": 474, "before_end": 85, "before_start": 84, "kind": "replace"}, {"after_end": 515, "after_start": 503, "before_end": 92, "before_start": 92, "kind": "insert"}, {"after_end": 531, "after_start": 516, "before_end": 93, "before_start": 93, "kind": "insert"}, {"after_end": 570, "after_start": 532, "before_end": 95, "before_start": 94, "kind": "replace"}, {"after_end": 577, "after_start": 574, "before_end": 101, "before_start": 99, "kind": "replace"}, {"after_end": 586, "after_start": 579, "before_end": 105, "before_start": 103, "kind": "replace"}, {"after_end": 591, "after_start": 588, "before_end": 107, "before_start": 107, "kind": "insert"}, {"after_end": 598, "after_start": 596, "before_end": 112, "before_start": 112, "kind": "insert"}, {"after_end": 599, "after_start": 599, "before_end": 122, "before_start": 113, "kind": "delete"}, {"after_end": 605, "after_start": 601, "before_end": 124, "before_start": 124, "kind": "insert"}, {"after_end": 617, "after_start": 606, "before_end": 125, "before_start": 125, "kind": "insert"}, {"after_end": 632, "after_start": 618, "before_end": 126, "before_start": 126, "kind": "insert"}, {"after_end": 643, "after_start": 634, "before_end": 134, "before_start": 128, "kind": "replace"}], "classification_method": "documentary_rules_v2", "clinical_candidate": true, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 35, "chars_inserted": 544}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-55bd9b1b000445d466cdba53", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/000235", "medicine_name": "Arava", "medicine_slug": "arava", "observed_at": "2026-10-12T13:27:58Z", "pipeline_version": "2.0.0", "presentation_label": "Arava 100 mg film-coated tablets", "presentation_occurrence": 3, "presentation_status": "heading_extracted_unverified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "4.4", "section_type": "warning", "source_provider": "European Medicines Agency", "source_sha256": "2efff7967e2237bf8343431eef5e08b56c2441eb8a691a90c64b2635109fd697", "source_snapshot_id": "source-08b4eba1f67d2654148f41c4", "source_updated_at": "2026-09-07", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/arava-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1310}
{"after": {"end": 141, "start": 0, "text": "Pour plus d’informations, voir le site web de l’Agence européenne des médicaments : https://www.ema.europa.eu/en/medicines/human/EPAR/adcirca", "truncated": false}, "after_length": 141, "after_sha256": "97750fa962c6889396bb2a7232b9e91140e743f35b8f76ae2c30944d48a50ef0", "annex": "", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "unassigned", "change_operations": [{"after_end": 141, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 141}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-568f82939f813c4b35257d41", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/001021", "medicine_name": "Adcirca (previously Tadalafil Lilly)", "medicine_slug": "adcirca-previously-tadalafil-lilly", "observed_at": "2026-10-12T19:02:45Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": null, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "", "section_type": "unassigned", "source_provider": "European Medicines Agency", "source_sha256": "cdbefcd6143c93e81f3c826bea8d3d01bffc55652e0f792243097df75c452721", "source_snapshot_id": "source-a1e85476de17f5a8664f7766", "source_updated_at": "2026-01-28", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/adcirca-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 2}
{"after": {"end": 23, "start": 0, "text": "60318 Frankfurt am Main", "truncated": false}, "after_length": 23, "after_sha256": "24c3191b5088b20c209c4387a8127297e54c776e161d305c9e57956a13b7cbbe", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 23, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 23}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-56a306d834839c888f386ba9", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002097", "medicine_name": "Fampyra", "medicine_slug": "fampyra", "observed_at": "2026-10-12T19:15:51Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "d9fe8aaaa611a84801d6308b13685258b5248df9022536697939afdf66fc1719", "source_snapshot_id": "source-ff8e0599077f0d01044dc867", "source_updated_at": "2025-08-21", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/fampyra-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1620}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 18, "start": 0, "text": "Dublin 2, D02 T380", "truncated": false}, "before_length": 18, "before_sha256": "23e6871e7960b0dadc753bc127bbea230cc8308c88b2d33704eb275a3ec1a70d", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 18, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 18, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-56f50494f97be2bd76dcdca5", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002097", "medicine_name": "Fampyra", "medicine_slug": "fampyra", "observed_at": "2026-10-12T19:15:51Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "d9fe8aaaa611a84801d6308b13685258b5248df9022536697939afdf66fc1719", "source_snapshot_id": "source-ff8e0599077f0d01044dc867", "source_updated_at": "2025-08-21", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/fampyra-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1502}
{"after": {"end": 16, "start": 0, "text": "Extrovis EU Kft.", "truncated": false}, "after_length": 16, "after_sha256": "b9216ef80e71e17798dce313e4318f03f37328f225d30ab508b7413813a908e5", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 16, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 16}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-573af6d786d84572d9bf386a", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/006047", "medicine_name": "Lacosamide Adroiq", "medicine_slug": "lacosamide-adroiq", "observed_at": "2026-10-12T19:07:59Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "cc83d966059d42856d0211a4f256b29b20d43593865704d6a9315aeb694f3c76", "source_snapshot_id": "source-896abba1d8391c918345d46b", "source_updated_at": "2025-09-25", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/lacosamide-adroiq-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1727}
{"after": {"end": 79, "start": 0, "text": "Viatris Germany GmbH, Zweigniederlassung Bad Homburg v. d. Höhe, Benzstrasse 1,", "truncated": false}, "after_length": 79, "after_sha256": "ec5d8b467f097b5f6e626a2a056336fab8904b07ad533e62379b09597067a87b", "annex": "IIIA", "before": {"end": 77, "start": 0, "text": "Mylan Germany GmbH, Zweigniederlassung Bad Homburg v. d. Höhe, Benzstrasse 1,", "truncated": false}, "before_length": 77, "before_sha256": "592354ac8c07b62540d767b349e438cbf42cff382f1d83c4853733a8264bcf56", "change_kind": "content", "change_operations": [{"after_end": 2, "after_start": 0, "before_end": 3, "before_start": 0, "kind": "replace"}, {"after_end": 7, "after_start": 3, "before_end": 5, "before_start": 4, "kind": "replace"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 4, "chars_inserted": 6}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-574f99107a811c770bbd8c1b", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/000403", "medicine_name": "Arixtra", "medicine_slug": "arixtra", "observed_at": "2026-10-12T13:38:50Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": null, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "123deb3dbdc841a7adc2b8046138993b8a6a1c228bde13a95278b14d17c5cefd", "source_snapshot_id": "source-79bede7a4a9cd1c040f622e0", "source_updated_at": "2026-05-07", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/arixtra-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 3772}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 6, "start": 0, "text": "Airija", "truncated": false}, "before_length": 6, "before_sha256": "122e7e88d23518b941923b1d4da61e395a23dfecce5fed29aab991102acd4623", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 6, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 6, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-575f6cc06fbebbe7739d8076", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002097", "medicine_name": "Fampyra", "medicine_slug": "fampyra", "observed_at": "2026-10-12T19:15:51Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "d9fe8aaaa611a84801d6308b13685258b5248df9022536697939afdf66fc1719", "source_snapshot_id": "source-ff8e0599077f0d01044dc867", "source_updated_at": "2025-08-21", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/fampyra-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1381}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 33, "start": 0, "text": "United Kingdom (Northern Ireland)", "truncated": false}, "before_length": 33, "before_sha256": "9379d82927cdb505cfb186e912177065e56a1314de3a2b914ebbb8b5fe21525a", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 33, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 33, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-57dc9559eaf9184830d546d7", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/006047", "medicine_name": "Lacosamide Adroiq", "medicine_slug": "lacosamide-adroiq", "observed_at": "2026-10-12T19:07:59Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "cc83d966059d42856d0211a4f256b29b20d43593865704d6a9315aeb694f3c76", "source_snapshot_id": "source-896abba1d8391c918345d46b", "source_updated_at": "2025-09-25", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/lacosamide-adroiq-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1859}
{"after": {"end": 23, "start": 0, "text": "Tel: +49 (0) 69 15 03 0", "truncated": false}, "after_length": 23, "after_sha256": "09683b3f43171b2266a32d9f7d44e3d62d536522dc6f42d4b47f2dda48b31833", "annex": "IIIA", "before": {"end": 23, "start": 0, "text": "Tel: +353 (0)1 231 4609", "truncated": false}, "before_length": 23, "before_sha256": "a115f11f382ef18898b9d956e48603ae236fd1846ce41e8586af99b6dabbfc4d", "change_kind": "content", "change_operations": [{"after_end": 8, "after_start": 6, "before_end": 9, "before_start": 6, "kind": "replace"}, {"after_end": 16, "after_start": 12, "before_end": 13, "before_start": 13, "kind": "insert"}, {"after_end": 18, "after_start": 17, "before_end": 14, "before_start": 14, "kind": "insert"}, {"after_end": 20, "after_start": 19, "before_end": 16, "before_start": 15, "kind": "replace"}, {"after_end": 21, "after_start": 21, "before_end": 18, "before_start": 17, "kind": "delete"}, {"after_end": 22, "after_start": 22, "before_end": 21, "before_start": 19, "kind": "delete"}, {"after_end": 23, "after_start": 23, "before_end": 23, "before_start": 22, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 8, "chars_inserted": 8}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-582810158c17ea4e4a9de95d", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002097", "medicine_name": "Fampyra", "medicine_slug": "fampyra", "observed_at": "2026-10-12T19:16:07Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "a0c3ba8d58d6a43a809ecc3d142a78b10c2bd7f0b9f3a3553df2617d87daec1f", "source_snapshot_id": "source-c7a810dd21f94cd2d273f0da", "source_updated_at": "2025-08-21", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/fampyra-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1628}
{"after": {"end": 25, "start": 0, "text": "Gustav III:s Boulevard 32", "truncated": false}, "after_length": 25, "after_sha256": "bba3ec2bf3d09014ee723cdd39b8fa83a1dc3705ce0797ed375b3af7c8be027c", "annex": "IIIA", "before": {"end": 25, "start": 0, "text": "Gustav III S Boulevard 32", "truncated": false}, "before_length": 25, "before_sha256": "6117fe99f25fb7a4848fea16fe447d9ead174e8fb74f0ec2aaad6366c885562b", "change_kind": "content", "change_operations": [{"after_end": 12, "after_start": 10, "before_end": 12, "before_start": 10, "kind": "replace"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 2, "chars_inserted": 2}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-582a410778d16457e7fbf163", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002097", "medicine_name": "Fampyra", "medicine_slug": "fampyra", "observed_at": "2026-10-12T19:15:51Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "d9fe8aaaa611a84801d6308b13685258b5248df9022536697939afdf66fc1719", "source_snapshot_id": "source-ff8e0599077f0d01044dc867", "source_updated_at": "2025-08-21", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/fampyra-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1609}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 20, "start": 0, "text": "10 Earlsfort Terrace", "truncated": false}, "before_length": 20, "before_sha256": "22951bbf6ee77815d0c07b3af5f0a66e17d277636971c4eaff372dea65dcb193", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 20, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 20, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-58506c9e69cc0a0d27d779b8", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002097", "medicine_name": "Fampyra", "medicine_slug": "fampyra", "observed_at": "2026-10-12T19:15:51Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "d9fe8aaaa611a84801d6308b13685258b5248df9022536697939afdf66fc1719", "source_snapshot_id": "source-ff8e0599077f0d01044dc867", "source_updated_at": "2025-08-21", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/fampyra-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1501}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 13, "start": 0, "text": "Lucane Pharma", "truncated": false}, "before_length": 13, "before_sha256": "e338afdb64acf1a6e2083a50318853589248451dd3aa707181ba02641a8521e8", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 13, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 13, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-58b017c4d496238c8f141be5", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:14Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "8b8c4cc8e6f1a21fedee4bf0743c9c03e454b50f5eaba0e3760416d7fe0a74ec", "source_snapshot_id": "source-4efe4ecf3ebf08d338a763a5", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 2028}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 7, "start": 0, "text": "Ireland", "truncated": false}, "before_length": 7, "before_sha256": "02bf1dfa9a0365a86223f0e4ac9eaa0517b06b2e9273790f719feda656a247ae", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 7, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 7, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-58bc971acc94660254ece4e3", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/004025", "medicine_name": "Lopinavir/Ritonavir Viatris (previously Ritonavir Mylan)", "medicine_slug": "lopinavir-ritonavir-viatris-previously-ritonavir-mylan", "observed_at": "2026-10-12T19:12:46Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "3e30663f02732816ed8779d7a929d500c824ae15aeaee9144ca6eef11900e273", "source_snapshot_id": "source-c58e019b5bec1fb24569e83e", "source_updated_at": "2025-09-08", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/lopinavir-ritonavir-viatris-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 3418}
{"after": {"end": 23, "start": 0, "text": "info@euroceptpharma.com", "truncated": false}, "after_length": 23, "after_sha256": "9297cc5acdcc837f054116992765943f7907937507b2564a99ea1327a00ac0e6", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 23, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 23}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-58ddaf968e3a7ffe78f3a9cd", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:14Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "8b8c4cc8e6f1a21fedee4bf0743c9c03e454b50f5eaba0e3760416d7fe0a74ec", "source_snapshot_id": "source-4efe4ecf3ebf08d338a763a5", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 2024}
{"after": {"end": 23, "start": 0, "text": "60318 Frankfurt am Main", "truncated": false}, "after_length": 23, "after_sha256": "24c3191b5088b20c209c4387a8127297e54c776e161d305c9e57956a13b7cbbe", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 23, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 23}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-59631d08ed19f1fa521c1138", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002097", "medicine_name": "Fampyra", "medicine_slug": "fampyra", "observed_at": "2026-10-12T19:16:07Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "a0c3ba8d58d6a43a809ecc3d142a78b10c2bd7f0b9f3a3553df2617d87daec1f", "source_snapshot_id": "source-c7a810dd21f94cd2d273f0da", "source_updated_at": "2025-08-21", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/fampyra-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1544}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 13, "start": 0, "text": "Lucane Pharma", "truncated": false}, "before_length": 13, "before_sha256": "e338afdb64acf1a6e2083a50318853589248451dd3aa707181ba02641a8521e8", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 13, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 13, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-5967774b080fb65c0209242a", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:19Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "77586d0bea0858214b43b86e91abc2d2711733b96959ead5ed0b5ecbd8ed888a", "source_snapshot_id": "source-85d476f9ad959cc117ca8f1f", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1947}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 13, "start": 0, "text": "Lucane Pharma", "truncated": false}, "before_length": 13, "before_sha256": "e338afdb64acf1a6e2083a50318853589248451dd3aa707181ba02641a8521e8", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 13, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 13, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-597ac36aa32f8f80185e3653", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:14Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "8b8c4cc8e6f1a21fedee4bf0743c9c03e454b50f5eaba0e3760416d7fe0a74ec", "source_snapshot_id": "source-4efe4ecf3ebf08d338a763a5", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 2042}
{"after": {"end": 29, "start": 0, "text": "customerservice@duxpharma.com", "truncated": false}, "after_length": 29, "after_sha256": "1864aab5df6d0c2e876c4cb522626eb01a745686a1fcb9fd4a2f9278c82aa1cb", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 29, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 29}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-59d70a8df37345573af888bb", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:14Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "8b8c4cc8e6f1a21fedee4bf0743c9c03e454b50f5eaba0e3760416d7fe0a74ec", "source_snapshot_id": "source-4efe4ecf3ebf08d338a763a5", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1552}
{"after": {"end": 34, "start": 0, "text": "Orteliuslaan 1000, 3528 BD Utrecht", "truncated": false}, "after_length": 34, "after_sha256": "46a90fc46ae308c2beeb35ead613fcf3ade5a51e2217a834de3fa5972dab9eec", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 34, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 34}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-59e419ded1df206cbd8e5f1b", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/001021", "medicine_name": "Adcirca (previously Tadalafil Lilly)", "medicine_slug": "adcirca-previously-tadalafil-lilly", "observed_at": "2026-10-12T19:02:42Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "43438c8e53504a78747a8ff36049250fee294557f3a8b0e3acb80f71ad43ebc0", "source_snapshot_id": "source-2305a67bd1e393ee340bb8e4", "source_updated_at": "2026-01-28", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/adcirca-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1682}
{"after": {"end": 556, "start": 0, "text": "PHEBURANE solution buvable a un goût neutre. Pour améliorer le goût, il est possible d’ajouter une goutte de l’arôme souhaité au contenu du verre d’eau : remuer doucement puis consommer (si une goutte d’arôme ne suffit pas à obtenir un goût suffisamment intense, le patient peut prendre 2 gouttes). La solution avec l’arôme citron-menthe est moins visqueuse que celle avec l’arôme cassis et peut conduire à l’ajout de plus de 2 gouttes. Il est donc recommandé de mesurer soigneusement l’arôme citron-menthe et de s’assurer qu’une seule goutte est ajoutée ;", "truncated": false}, "after_length": 556, "after_sha256": "b71af590a482a88dfba04a60a939ac284940a523d0b4dfcb07d41b45aea33bcf", "annex": "I", "before": {"end": 299, "start": 0, "text": "PHEBURANE solution buvable a un goût neutre. Pour améliorer le goût, il est possible d’ajouter une goutte de l’arôme souhaité au contenu du verre d’eau : remuer doucement puis consommer (si une goutte d’arôme ne suffit pas à obtenir un goût suffisamment intense, le patient peut prendre 2 gouttes) ;", "truncated": false}, "before_length": 299, "before_sha256": "a8a87d1a16fee892c1ef6898acd099357e69806de685573d8e7738b756546c50", "change_kind": "content", "change_operations": [{"after_end": 554, "after_start": 297, "before_end": 297, "before_start": 297, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 257}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-59e5ac13f069da6b67ae1e18", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:19Z", "pipeline_version": "2.0.0", "presentation_label": "PHEBURANE 350 mg/ml solution buvable", "presentation_occurrence": 2, "presentation_status": "heading_extracted_unverified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "6.6", "section_type": "quality_presentation", "source_provider": "European Medicines Agency", "source_sha256": "77586d0bea0858214b43b86e91abc2d2711733b96959ead5ed0b5ecbd8ed888a", "source_snapshot_id": "source-85d476f9ad959cc117ca8f1f", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 656}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 13, "start": 0, "text": "Lucane Pharma", "truncated": false}, "before_length": 13, "before_sha256": "e338afdb64acf1a6e2083a50318853589248451dd3aa707181ba02641a8521e8", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 13, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 13, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-59ee44ee98fe0ff44dc3f76d", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:19Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "77586d0bea0858214b43b86e91abc2d2711733b96959ead5ed0b5ecbd8ed888a", "source_snapshot_id": "source-85d476f9ad959cc117ca8f1f", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1956}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 13, "start": 0, "text": "Lucane Pharma", "truncated": false}, "before_length": 13, "before_sha256": "e338afdb64acf1a6e2083a50318853589248451dd3aa707181ba02641a8521e8", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 13, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 13, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-5a07e472c491539b4c601265", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:14Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "8b8c4cc8e6f1a21fedee4bf0743c9c03e454b50f5eaba0e3760416d7fe0a74ec", "source_snapshot_id": "source-4efe4ecf3ebf08d338a763a5", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1471}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 21, "start": 0, "text": "info@lucanepharma.com", "truncated": false}, "before_length": 21, "before_sha256": "44fd39e5fb919cb3d680fa630da23b49238fec29159c509f3622f272bb41c7c6", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 21, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 21, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-5a1db30939c832012cb02bff", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:19Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "77586d0bea0858214b43b86e91abc2d2711733b96959ead5ed0b5ecbd8ed888a", "source_snapshot_id": "source-85d476f9ad959cc117ca8f1f", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1901}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 21, "start": 0, "text": "info@lucanepharma.com", "truncated": false}, "before_length": 21, "before_sha256": "44fd39e5fb919cb3d680fa630da23b49238fec29159c509f3622f272bb41c7c6", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 21, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 21, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-5b54912c56bb1044595f0a2b", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:14Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "8b8c4cc8e6f1a21fedee4bf0743c9c03e454b50f5eaba0e3760416d7fe0a74ec", "source_snapshot_id": "source-4efe4ecf3ebf08d338a763a5", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 2069}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 27, "start": 0, "text": "(Eurocept International BV)", "truncated": false}, "before_length": 27, "before_sha256": "e6cf9b20aaa466e53ad0d393512ca75931e13e488321e3be6f3e4f8b600970c8", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 27, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 27, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-5b5787690a1f638d8d645ac0", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:14Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "8b8c4cc8e6f1a21fedee4bf0743c9c03e454b50f5eaba0e3760416d7fe0a74ec", "source_snapshot_id": "source-4efe4ecf3ebf08d338a763a5", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 2001}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 27, "start": 0, "text": "(Eurocept International BV)", "truncated": false}, "before_length": 27, "before_sha256": "e6cf9b20aaa466e53ad0d393512ca75931e13e488321e3be6f3e4f8b600970c8", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 27, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 27, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-5b5ec85be81d3e4ee89d2325", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:14Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "8b8c4cc8e6f1a21fedee4bf0743c9c03e454b50f5eaba0e3760416d7fe0a74ec", "source_snapshot_id": "source-4efe4ecf3ebf08d338a763a5", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1889}
{"after": {"end": 23, "start": 0, "text": "60318 Frankfurt am Main", "truncated": false}, "after_length": 23, "after_sha256": "24c3191b5088b20c209c4387a8127297e54c776e161d305c9e57956a13b7cbbe", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 23, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 23}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-5b626de21541a27bf589f4b4", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002097", "medicine_name": "Fampyra", "medicine_slug": "fampyra", "observed_at": "2026-10-12T19:16:07Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "a0c3ba8d58d6a43a809ecc3d142a78b10c2bd7f0b9f3a3553df2617d87daec1f", "source_snapshot_id": "source-c7a810dd21f94cd2d273f0da", "source_updated_at": "2025-08-21", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/fampyra-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1534}
{"after": {"end": 22, "start": 0, "text": "Merz Therapeutics GmbH", "truncated": false}, "after_length": 22, "after_sha256": "059f049c7d0846aaadcf2573280d52110f302d4ecc7b38debd004571cd1e9d5e", "annex": "IIIA", "before": {"end": 35, "start": 0, "text": "Acorda Therapeutics Ireland Limited", "truncated": false}, "before_length": 35, "before_sha256": "d94d3153d193ed26567f2b4ed48df016d81c534e7c0cb1a6655a63f0083383ff", "change_kind": "content", "change_operations": [{"after_end": 2, "after_start": 0, "before_end": 3, "before_start": 0, "kind": "replace"}, {"after_end": 4, "after_start": 3, "before_end": 6, "before_start": 4, "kind": "replace"}, {"after_end": 19, "after_start": 18, "before_end": 30, "before_start": 20, "kind": "replace"}, {"after_end": 22, "after_start": 20, "before_end": 35, "before_start": 31, "kind": "replace"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 19, "chars_inserted": 6}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-5b63e2d06430a759f8a6693f", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002097", "medicine_name": "Fampyra", "medicine_slug": "fampyra", "observed_at": "2026-10-12T19:15:51Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "d9fe8aaaa611a84801d6308b13685258b5248df9022536697939afdf66fc1719", "source_snapshot_id": "source-ff8e0599077f0d01044dc867", "source_updated_at": "2025-08-21", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/fampyra-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1461}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "I", "before": {"end": 23, "start": 0, "text": "Tel: +353 (0)1 231 4609", "truncated": false}, "before_length": 23, "before_sha256": "a115f11f382ef18898b9d956e48603ae236fd1846ce41e8586af99b6dabbfc4d", "change_kind": "administrative", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 23, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 23, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-5b66c33d07556f1372080d8f", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002097", "medicine_name": "Fampyra", "medicine_slug": "fampyra", "observed_at": "2026-10-12T19:15:51Z", "pipeline_version": "2.0.0", "presentation_label": "Fampyra 10 mg prolonged-release tablets", "presentation_occurrence": 1, "presentation_status": "heading_extracted_unverified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "7", "section_type": "administrative", "source_provider": "European Medicines Agency", "source_sha256": "d9fe8aaaa611a84801d6308b13685258b5248df9022536697939afdf66fc1719", "source_snapshot_id": "source-ff8e0599077f0d01044dc867", "source_updated_at": "2025-08-21", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/fampyra-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 686}
{"after": {"end": 12, "start": 0, "text": "169 73 Solna", "truncated": false}, "after_length": 12, "after_sha256": "396199e813d8f79edb20275a432ef3c356a2964b18c41134b918894de8dcbb3d", "annex": "IIIA", "before": {"end": 12, "start": 0, "text": "Solna 169 73", "truncated": false}, "before_length": 12, "before_sha256": "48d3b71370d55743d8f6af2ff4ab7a798818c3958ea6d6d44d45c3a952fd50d5", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 6, "before_start": 0, "kind": "delete"}, {"after_end": 12, "after_start": 6, "before_end": 12, "before_start": 12, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 6, "chars_inserted": 6}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-5bfa47977540abef7c9fa764", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002097", "medicine_name": "Fampyra", "medicine_slug": "fampyra", "observed_at": "2026-10-12T19:16:07Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "a0c3ba8d58d6a43a809ecc3d142a78b10c2bd7f0b9f3a3553df2617d87daec1f", "source_snapshot_id": "source-c7a810dd21f94cd2d273f0da", "source_updated_at": "2025-08-21", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/fampyra-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1437}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 21, "start": 0, "text": "info@lucanepharma.com", "truncated": false}, "before_length": 21, "before_sha256": "44fd39e5fb919cb3d680fa630da23b49238fec29159c509f3622f272bb41c7c6", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 21, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 21, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-5c445f87b6e2b48ee19ef265", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:19Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "77586d0bea0858214b43b86e91abc2d2711733b96959ead5ed0b5ecbd8ed888a", "source_snapshot_id": "source-85d476f9ad959cc117ca8f1f", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1847}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 16, "start": 0, "text": "Extrovis EU Ltd.", "truncated": false}, "before_length": 16, "before_sha256": "f462ad48e7aef0bc82148ce088af1897d99ed86993128f30d506b27d3108a929", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 16, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 16, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-5c703cfbe0f73570816d3a11", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/006047", "medicine_name": "Lacosamide Adroiq", "medicine_slug": "lacosamide-adroiq", "observed_at": "2026-10-12T19:07:59Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "cc83d966059d42856d0211a4f256b29b20d43593865704d6a9315aeb694f3c76", "source_snapshot_id": "source-896abba1d8391c918345d46b", "source_updated_at": "2025-09-25", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/lacosamide-adroiq-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1822}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 27, "start": 0, "text": "(Eurocept International BV)", "truncated": false}, "before_length": 27, "before_sha256": "e6cf9b20aaa466e53ad0d393512ca75931e13e488321e3be6f3e4f8b600970c8", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 27, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 27, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-5c7f22a39c2f082052620263", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:19Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "77586d0bea0858214b43b86e91abc2d2711733b96959ead5ed0b5ecbd8ed888a", "source_snapshot_id": "source-85d476f9ad959cc117ca8f1f", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1908}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 27, "start": 0, "text": "(Eurocept International BV)", "truncated": false}, "before_length": 27, "before_sha256": "e6cf9b20aaa466e53ad0d393512ca75931e13e488321e3be6f3e4f8b600970c8", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 27, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 27, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-5ca847dc53ab9ddcae547711", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:14Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "8b8c4cc8e6f1a21fedee4bf0743c9c03e454b50f5eaba0e3760416d7fe0a74ec", "source_snapshot_id": "source-4efe4ecf3ebf08d338a763a5", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 2043}
{"after": {"end": 30, "start": 0, "text": "Merz Therapeutics Benelux B.V.", "truncated": false}, "after_length": 30, "after_sha256": "7c5530f091b2eaff46486c1452be442d4a9c6f4c46924db34e94c6cdb089882e", "annex": "IIIA", "before": {"end": 35, "start": 0, "text": "Acorda Therapeutics Ireland Limited", "truncated": false}, "before_length": 35, "before_sha256": "d94d3153d193ed26567f2b4ed48df016d81c534e7c0cb1a6655a63f0083383ff", "change_kind": "content", "change_operations": [{"after_end": 2, "after_start": 0, "before_end": 3, "before_start": 0, "kind": "replace"}, {"after_end": 4, "after_start": 3, "before_end": 6, "before_start": 4, "kind": "replace"}, {"after_end": 21, "after_start": 18, "before_end": 22, "before_start": 20, "kind": "replace"}, {"after_end": 25, "after_start": 23, "before_end": 27, "before_start": 24, "kind": "replace"}, {"after_end": 30, "after_start": 26, "before_end": 35, "before_start": 28, "kind": "replace"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 17, "chars_inserted": 12}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-5cc73dd962e4b88bf0c2da0d", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002097", "medicine_name": "Fampyra", "medicine_slug": "fampyra", "observed_at": "2026-10-12T19:15:51Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "d9fe8aaaa611a84801d6308b13685258b5248df9022536697939afdf66fc1719", "source_snapshot_id": "source-ff8e0599077f0d01044dc867", "source_updated_at": "2025-08-21", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/fampyra-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1451}
{"after": {"end": 23, "start": 0, "text": "Tel: +49 6431 285 88 30", "truncated": false}, "after_length": 23, "after_sha256": "ef2d8f53356e21d9673844a7ef23ea7b054ff18cc0092c86a4e97d96486b24a7", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 23, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 23}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-5cd0acf319cc31ea31a7da6b", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:14Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "8b8c4cc8e6f1a21fedee4bf0743c9c03e454b50f5eaba0e3760416d7fe0a74ec", "source_snapshot_id": "source-4efe4ecf3ebf08d338a763a5", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1492}
{"after": {"end": 810, "start": 0, "text": "Des cas de myosite et/ou de rhabdomyolyse ont été rapportés chez des patients traités par le léflunomide, souvent en association avec d'autres médicaments immunosuppresseurs. Les symptômes cliniques peuvent inclure des douleurs musculaires inexpliquées, une sensibilité ou une faiblesse musculaire. Les patients doivent être informés des signes et des symptômes associés à la myosite et à la rhabdomyolyse et ils doivent consulter immédiatement un médecin si de tels symptômes surviennent au cours du traitement par le léflunomide. L’élévation des taux de créatine kinase doit être surveillée chez les patients selon leur situation clinique. Si les patients développent l'une de ces manifestations, le léflunomide doit être arrêté et une procédure d'élimination accélérée doit être initiée (voir rubrique 4.4).", "truncated": false}, "after_length": 810, "after_sha256": "cc10a5be2b707546b777c939543f700115911fa1a843b097c61bccdf668a3cf8", "annex": "I", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 810, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": true, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 810}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-5d4c452bb98c4309ae53ea94", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/000235", "medicine_name": "Arava", "medicine_slug": "arava", "observed_at": "2026-10-12T13:28:00Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": null, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "4.4", "section_type": "warning", "source_provider": "European Medicines Agency", "source_sha256": "98b73c5c6b1e5009c9d048f8f11257f3a8407759fd25a4c8d5ef5c611519e916", "source_snapshot_id": "source-4b7ea3b78addea82376b3432", "source_updated_at": "2026-09-07", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/arava-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 753}
{"after": {"end": 22, "start": 0, "text": "Tel: + 48 22 663 43 03", "truncated": false}, "after_length": 22, "after_sha256": "5345f797275d32abdc54039c15f0a4f05223d8f5424eaa63545f2efe682185e2", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 22, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 22}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-5d4c8ab2f6da5faa021d32ac", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:14Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "8b8c4cc8e6f1a21fedee4bf0743c9c03e454b50f5eaba0e3760416d7fe0a74ec", "source_snapshot_id": "source-4efe4ecf3ebf08d338a763a5", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1981}
{"after": {"end": 129, "start": 0, "text": "Après examen de la recommandation du PRAC, le CHMP approuve les conclusions générales du PRAC et les motifs de sa recommandation.", "truncated": false}, "after_length": 129, "after_sha256": "7f742dd4d84dfcd3eaee344b865d2447706c76828f7b7aeaa1db7fa5791f3aec", "annex": "IV", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 129, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 129}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-5dd9a7856cb25377f4bb04d2", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/000554", "medicine_name": "Emselex", "medicine_slug": "emselex", "observed_at": "2026-10-12T19:12:07Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": null, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "conditions", "section_type": "conditions", "source_provider": "European Medicines Agency", "source_sha256": "9a4f1d7e260c7b80eaf397503623b63302e5945b579e9612177835e07c4ab888", "source_snapshot_id": "source-3aac7bf42b99529f25ac013b", "source_updated_at": "2025-09-15", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/emselex-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 2072}
{"after": {"end": 19, "start": 0, "text": "Etten-Leur, 4879 AC", "truncated": false}, "after_length": 19, "after_sha256": "8657c9b8722b346a71bad5816f5fba16b632ee27b0357aceb7406439602743c9", "annex": "II", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 19, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 19}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-5de019ce89355b3aeb322e79", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/000980", "medicine_name": "Samsca", "medicine_slug": "samsca", "observed_at": "2026-10-12T13:28:24Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "conditions", "section_type": "conditions", "source_provider": "European Medicines Agency", "source_sha256": "3080d919225c2a98f20aec84d5803b3fde6e1b64f323055c46d098625f4ad301", "source_snapshot_id": "source-e05739a15a0532954ee45dd4", "source_updated_at": "2026-08-20", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/samsca-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 552}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIB", "before": {"end": 16, "start": 0, "text": "Extrovis EU Ltd.", "truncated": false}, "before_length": 16, "before_sha256": "f462ad48e7aef0bc82148ce088af1897d99ed86993128f30d506b27d3108a929", "change_kind": "unassigned", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 16, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 16, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-5df310094b822430d93aa093", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/006047", "medicine_name": "Lacosamide Adroiq", "medicine_slug": "lacosamide-adroiq", "observed_at": "2026-10-12T19:07:56Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "", "section_type": "unassigned", "source_provider": "European Medicines Agency", "source_sha256": "0578c53a5e1c785c4d9d4dc0dabae49dbfa89e237aa571556bee548c3f9cf4d5", "source_snapshot_id": "source-64831dec5ebf55535e19d91b", "source_updated_at": "2025-09-25", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/lacosamide-adroiq-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1893}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 25, "start": 0, "text": "Tél/Tel: + 33 153 868 750", "truncated": false}, "before_length": 25, "before_sha256": "e5f8e4aadc105f123b1cb253b9afe1e362181b7777e0b94626adda3e9db7ed2e", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 25, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 25, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-5dfe696bb9cf5230b2cffb59", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:14Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "8b8c4cc8e6f1a21fedee4bf0743c9c03e454b50f5eaba0e3760416d7fe0a74ec", "source_snapshot_id": "source-4efe4ecf3ebf08d338a763a5", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1458}
{"after": {"end": 25, "start": 0, "text": "Eurocept International BV", "truncated": false}, "after_length": 25, "after_sha256": "b17bd89b3cf285c986a6070d0d67f5326dd5c1f08a70834c296c6c820f9e7505", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 25, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 25}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-5e3bbc55a5f2282352337eee", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:19Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "77586d0bea0858214b43b86e91abc2d2711733b96959ead5ed0b5ecbd8ed888a", "source_snapshot_id": "source-85d476f9ad959cc117ca8f1f", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1808}
{"after": {"end": 21, "start": 0, "text": "Tel: +31 35 528 39 57", "truncated": false}, "after_length": 21, "after_sha256": "7baf6601f41e49e470f803fdd4e755a86efa38be423317c000ed79963ebdd213", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 21, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 21}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-5e6d865f116907ad2c83d07f", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:14Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "8b8c4cc8e6f1a21fedee4bf0743c9c03e454b50f5eaba0e3760416d7fe0a74ec", "source_snapshot_id": "source-4efe4ecf3ebf08d338a763a5", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1953}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 21, "start": 0, "text": "Tel: + 33 153 868 750", "truncated": false}, "before_length": 21, "before_sha256": "efffe29324e968019e6e2b111904182ba06d83e76b1f29b933bed9dd8779c114", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 21, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 21, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-5e74ef6aaeb20ea1909d7a2f", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:19Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "77586d0bea0858214b43b86e91abc2d2711733b96959ead5ed0b5ecbd8ed888a", "source_snapshot_id": "source-85d476f9ad959cc117ca8f1f", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1504}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 13, "start": 0, "text": "Lucane Pharma", "truncated": false}, "before_length": 13, "before_sha256": "e338afdb64acf1a6e2083a50318853589248451dd3aa707181ba02641a8521e8", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 13, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 13, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-5eaef0143a9eb1957fc8d190", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:19Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "77586d0bea0858214b43b86e91abc2d2711733b96959ead5ed0b5ecbd8ed888a", "source_snapshot_id": "source-85d476f9ad959cc117ca8f1f", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1829}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 20, "start": 0, "text": "10 Earlsfort Terrace", "truncated": false}, "before_length": 20, "before_sha256": "22951bbf6ee77815d0c07b3af5f0a66e17d277636971c4eaff372dea65dcb193", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 20, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 20, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-5ecad720c38781ee02ee7f5c", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002097", "medicine_name": "Fampyra", "medicine_slug": "fampyra", "observed_at": "2026-10-12T19:16:07Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "a0c3ba8d58d6a43a809ecc3d142a78b10c2bd7f0b9f3a3553df2617d87daec1f", "source_snapshot_id": "source-c7a810dd21f94cd2d273f0da", "source_updated_at": "2025-08-21", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/fampyra-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1443}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 5, "start": 0, "text": "Īrija", "truncated": false}, "before_length": 5, "before_sha256": "8a6adc0410f24796a13031ae3d8e883a6939ac968000d59f9b32d97fce8d68be", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 5, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 5, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-5ed3f93e301fdb6de81cd254", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002097", "medicine_name": "Fampyra", "medicine_slug": "fampyra", "observed_at": "2026-10-12T19:16:07Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "a0c3ba8d58d6a43a809ecc3d142a78b10c2bd7f0b9f3a3553df2617d87daec1f", "source_snapshot_id": "source-c7a810dd21f94cd2d273f0da", "source_updated_at": "2025-08-21", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/fampyra-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1624}
{"after": {"end": 23, "start": 0, "text": "info@euroceptpharma.com", "truncated": false}, "after_length": 23, "after_sha256": "9297cc5acdcc837f054116992765943f7907937507b2564a99ea1327a00ac0e6", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 23, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 23}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-5ed71dca4f77a1a2bc5ac50a", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:14Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "8b8c4cc8e6f1a21fedee4bf0743c9c03e454b50f5eaba0e3760416d7fe0a74ec", "source_snapshot_id": "source-4efe4ecf3ebf08d338a763a5", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1486}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 7, "start": 0, "text": "Irlande", "truncated": false}, "before_length": 7, "before_sha256": "a8cdfff5dbbda1b070a2acb339b6f0aa20b6230d9b5500c9ce066eaa89bc9a64", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 7, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 7, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-5eeded8c37ea0a88fb84a7f4", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002097", "medicine_name": "Fampyra", "medicine_slug": "fampyra", "observed_at": "2026-10-12T19:16:07Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "a0c3ba8d58d6a43a809ecc3d142a78b10c2bd7f0b9f3a3553df2617d87daec1f", "source_snapshot_id": "source-c7a810dd21f94cd2d273f0da", "source_updated_at": "2025-08-21", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/fampyra-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 900}
{"after": {"end": 596, "start": 0, "text": "This document is the approved product information for Hexacima, with the changes since the previous procedure affecting the product information (EMA/VR/0000246654) tracked. For more information, see the European Medicines Agency’s website: https://www.ema.europa.eu/en/medicines/human/EPAR/hexacimaThis document is the approved product information for Hexacima, with the changes since the previous procedure affecting the product information (EMA/VR/0000246654) tracked. For more information, see the European Medicines Agency’s website: https://www.ema.europa.eu/en/medicines/human/EPAR/hexacima", "truncated": false}, "after_length": 596, "after_sha256": "663ab2a8aa39c04978b8689564b5087d9faeaee5aba91b2e551f447961a2f545", "annex": "", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "unassigned", "change_operations": [{"after_end": 596, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 596}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-5eee9acfc52b6623cf193b94", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002702", "medicine_name": "Hexacima", "medicine_slug": "hexacima", "observed_at": "2026-10-12T19:07:04Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": null, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "", "section_type": "unassigned", "source_provider": "European Medicines Agency", "source_sha256": "44c8996457a718019c75b8322ba07a5ae7af36377b1a6f1cf4ca5a30f9b72c23", "source_snapshot_id": "source-fa766d966dea704c333b9969", "source_updated_at": "2025-09-29", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/hexacima-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 0}
{"after": {"end": 9, "start": 0, "text": "Duxpharma", "truncated": false}, "after_length": 9, "after_sha256": "0734aea3ec8a00bf23f9b3325a0a1bec5b56c7749f8de2ffe58ef6a80bbef1ab", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 9, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 9}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-5f07ee56d9c4ed3b3ddd866d", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:19Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "77586d0bea0858214b43b86e91abc2d2711733b96959ead5ed0b5ecbd8ed888a", "source_snapshot_id": "source-85d476f9ad959cc117ca8f1f", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1918}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 13, "start": 0, "text": "Lucane Pharma", "truncated": false}, "before_length": 13, "before_sha256": "e338afdb64acf1a6e2083a50318853589248451dd3aa707181ba02641a8521e8", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 13, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 13, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-5f363fdc7ffc7c0aead52561", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:19Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "77586d0bea0858214b43b86e91abc2d2711733b96959ead5ed0b5ecbd8ed888a", "source_snapshot_id": "source-85d476f9ad959cc117ca8f1f", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1820}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 21, "start": 0, "text": "Tel: +31 35 528 39 57", "truncated": false}, "before_length": 21, "before_sha256": "7baf6601f41e49e470f803fdd4e755a86efa38be423317c000ed79963ebdd213", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 21, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 21, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-5f4c0b4feb8cd73100bfed5e", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:14Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "8b8c4cc8e6f1a21fedee4bf0743c9c03e454b50f5eaba0e3760416d7fe0a74ec", "source_snapshot_id": "source-4efe4ecf3ebf08d338a763a5", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1960}
{"after": {"end": 16, "start": 0, "text": "Extrovis EU Kft.", "truncated": false}, "after_length": 16, "after_sha256": "b9216ef80e71e17798dce313e4318f03f37328f225d30ab508b7413813a908e5", "annex": "III", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "unassigned", "change_operations": [{"after_end": 16, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 16}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-5f5fbb15cc94243dc98c4395", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/006047", "medicine_name": "Lacosamide Adroiq", "medicine_slug": "lacosamide-adroiq", "observed_at": "2026-10-12T19:07:56Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "", "section_type": "unassigned", "source_provider": "European Medicines Agency", "source_sha256": "0578c53a5e1c785c4d9d4dc0dabae49dbfa89e237aa571556bee548c3f9cf4d5", "source_snapshot_id": "source-64831dec5ebf55535e19d91b", "source_updated_at": "2025-09-25", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/lacosamide-adroiq-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1201}
{"after": {"end": 22, "start": 0, "text": "Merz Therapeutics GmbH", "truncated": false}, "after_length": 22, "after_sha256": "059f049c7d0846aaadcf2573280d52110f302d4ecc7b38debd004571cd1e9d5e", "annex": "IIIA", "before": {"end": 35, "start": 0, "text": "Acorda Therapeutics Ireland Limited", "truncated": false}, "before_length": 35, "before_sha256": "d94d3153d193ed26567f2b4ed48df016d81c534e7c0cb1a6655a63f0083383ff", "change_kind": "content", "change_operations": [{"after_end": 2, "after_start": 0, "before_end": 3, "before_start": 0, "kind": "replace"}, {"after_end": 4, "after_start": 3, "before_end": 6, "before_start": 4, "kind": "replace"}, {"after_end": 19, "after_start": 18, "before_end": 30, "before_start": 20, "kind": "replace"}, {"after_end": 22, "after_start": 20, "before_end": 35, "before_start": 31, "kind": "replace"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 19, "chars_inserted": 6}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-5f603e7d2c1a7c68bb6effd3", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002097", "medicine_name": "Fampyra", "medicine_slug": "fampyra", "observed_at": "2026-10-12T19:15:51Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "d9fe8aaaa611a84801d6308b13685258b5248df9022536697939afdf66fc1719", "source_snapshot_id": "source-ff8e0599077f0d01044dc867", "source_updated_at": "2025-08-21", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/fampyra-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1348}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "I", "before": {"end": 12, "start": 0, "text": "52078 Aachen", "truncated": false}, "before_length": 12, "before_sha256": "1475580660011b5e5dfa9a59bc8bd0d29441e95b38b37c8e74cd2bb2e32158de", "change_kind": "administrative", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 12, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 12, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-5f702a1312e58b6e18d23791", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/005246", "medicine_name": "Byfavo", "medicine_slug": "byfavo", "observed_at": "2026-10-12T13:28:14Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "7", "section_type": "administrative", "source_provider": "European Medicines Agency", "source_sha256": "92a178ceb705631219efa40b1d0da73ebe6dfa866bc1b24d7e4dab9ded8a6861", "source_snapshot_id": "source-d485be5d9060fd557be910b2", "source_updated_at": "2026-08-26", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/byfavo-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 2623}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 21, "start": 0, "text": "Τηλ: +31 35 528 39 57", "truncated": false}, "before_length": 21, "before_sha256": "7b92e5311969e99f5dab8cb972fdbf42abc15ad173a746b3593ccbf111119114", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 21, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 21, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-5fee221052a34cf4f2b4c2e7", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:14Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "8b8c4cc8e6f1a21fedee4bf0743c9c03e454b50f5eaba0e3760416d7fe0a74ec", "source_snapshot_id": "source-4efe4ecf3ebf08d338a763a5", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 2068}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "II", "before": {"end": 9, "start": 0, "text": "Allemagne", "truncated": false}, "before_length": 9, "before_sha256": "6b58dbd6a994339b48d8446597da22402857b3409613459c7e3a293788fbe66a", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 9, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 9, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-5fef2f3a3b11b17fb1c3f79b", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/005246", "medicine_name": "Byfavo", "medicine_slug": "byfavo", "observed_at": "2026-10-12T13:28:16Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "conditions", "section_type": "conditions", "source_provider": "European Medicines Agency", "source_sha256": "61243a969f979f690fe718e414ceaeb66438c1faa31101ba25187d2f9ea662fd", "source_snapshot_id": "source-dd26eb8615d8c18bd80c1f6a", "source_updated_at": "2026-08-26", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/byfavo-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1832}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 13, "start": 0, "text": "Lucane Pharma", "truncated": false}, "before_length": 13, "before_sha256": "e338afdb64acf1a6e2083a50318853589248451dd3aa707181ba02641a8521e8", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 13, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 13, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-60119cc09690f731dd26b58c", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:19Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "77586d0bea0858214b43b86e91abc2d2711733b96959ead5ed0b5ecbd8ed888a", "source_snapshot_id": "source-85d476f9ad959cc117ca8f1f", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1408}
{"after": {"end": 8, "start": 0, "text": "Saksamaa", "truncated": false}, "after_length": 8, "after_sha256": "cc19dad198aa5593de7f67d07bcbd0bbe1dfa0b63733ef6d581860c2c5f16706", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 8, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 8}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-6060ca3f9940e1e39ceaa1cf", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002097", "medicine_name": "Fampyra", "medicine_slug": "fampyra", "observed_at": "2026-10-12T19:15:51Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "d9fe8aaaa611a84801d6308b13685258b5248df9022536697939afdf66fc1719", "source_snapshot_id": "source-ff8e0599077f0d01044dc867", "source_updated_at": "2025-08-21", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/fampyra-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1467}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 21, "start": 0, "text": "info@lucanepharma.com", "truncated": false}, "before_length": 21, "before_sha256": "44fd39e5fb919cb3d680fa630da23b49238fec29159c509f3622f272bb41c7c6", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 21, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 21, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-6063b9b629a71ba47eb56c51", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:19Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "77586d0bea0858214b43b86e91abc2d2711733b96959ead5ed0b5ecbd8ed888a", "source_snapshot_id": "source-85d476f9ad959cc117ca8f1f", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1832}
{"after": {"end": 8, "start": 0, "text": "Pays-Bas", "truncated": false}, "after_length": 8, "after_sha256": "2f1d512c96e61c1e31319fc9326840a0ea9ab221bba6bbdca327b162ac12fa51", "annex": "III", "before": {"end": 43, "start": 0, "text": "Papendorpseweg 83, 3528 BJ Utrecht Pays-Bas", "truncated": false}, "before_length": 43, "before_sha256": "2ff8bcc9830507f63dba8a77d1aaeef88302446a200f1fe6ecefbad29b5ae46f", "change_kind": "unassigned", "change_operations": [{"after_end": 2, "after_start": 2, "before_end": 37, "before_start": 2, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 35, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-60c87d0a8e49d06fee9c0dd1", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/001021", "medicine_name": "Adcirca (previously Tadalafil Lilly)", "medicine_slug": "adcirca-previously-tadalafil-lilly", "observed_at": "2026-10-12T19:02:45Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "", "section_type": "unassigned", "source_provider": "European Medicines Agency", "source_sha256": "cdbefcd6143c93e81f3c826bea8d3d01bffc55652e0f792243097df75c452721", "source_snapshot_id": "source-a1e85476de17f5a8664f7766", "source_updated_at": "2026-01-28", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/adcirca-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1680}
{"after": {"end": 22, "start": 0, "text": "Merz Therapeutics GmbH", "truncated": false}, "after_length": 22, "after_sha256": "059f049c7d0846aaadcf2573280d52110f302d4ecc7b38debd004571cd1e9d5e", "annex": "IIIA", "before": {"end": 35, "start": 0, "text": "Acorda Therapeutics Ireland Limited", "truncated": false}, "before_length": 35, "before_sha256": "d94d3153d193ed26567f2b4ed48df016d81c534e7c0cb1a6655a63f0083383ff", "change_kind": "content", "change_operations": [{"after_end": 2, "after_start": 0, "before_end": 3, "before_start": 0, "kind": "replace"}, {"after_end": 4, "after_start": 3, "before_end": 6, "before_start": 4, "kind": "replace"}, {"after_end": 19, "after_start": 18, "before_end": 30, "before_start": 20, "kind": "replace"}, {"after_end": 22, "after_start": 20, "before_end": 35, "before_start": 31, "kind": "replace"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 19, "chars_inserted": 6}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-60ccf5a4ecbee2ed103b75d9", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002097", "medicine_name": "Fampyra", "medicine_slug": "fampyra", "observed_at": "2026-10-12T19:16:07Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "a0c3ba8d58d6a43a809ecc3d142a78b10c2bd7f0b9f3a3553df2617d87daec1f", "source_snapshot_id": "source-c7a810dd21f94cd2d273f0da", "source_updated_at": "2025-08-21", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/fampyra-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1485}
{"after": {"end": 23, "start": 0, "text": "info@euroceptpharma.com", "truncated": false}, "after_length": 23, "after_sha256": "9297cc5acdcc837f054116992765943f7907937507b2564a99ea1327a00ac0e6", "annex": "IIIA", "before": {"end": 13, "start": 0, "text": "Lucane Pharma", "truncated": false}, "before_length": 13, "before_sha256": "e338afdb64acf1a6e2083a50318853589248451dd3aa707181ba02641a8521e8", "change_kind": "content", "change_operations": [{"after_end": 6, "after_start": 0, "before_end": 1, "before_start": 0, "kind": "replace"}, {"after_end": 9, "after_start": 7, "before_end": 2, "before_start": 2, "kind": "insert"}, {"after_end": 10, "after_start": 10, "before_end": 5, "before_start": 3, "kind": "delete"}, {"after_end": 14, "after_start": 11, "before_end": 8, "before_start": 6, "kind": "replace"}, {"after_end": 23, "after_start": 19, "before_end": 13, "before_start": 13, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 5, "chars_inserted": 15}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-61425732a348cd2dbc1f182f", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:19Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "77586d0bea0858214b43b86e91abc2d2711733b96959ead5ed0b5ecbd8ed888a", "source_snapshot_id": "source-85d476f9ad959cc117ca8f1f", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1401}
{"after": {"end": 139, "start": 0, "text": "Pour plus d’informations, voir le site web de l’Agence européenne des médicaments: https://www.ema.europa.eu/en/medicines/human/EPAR/Byfavo", "truncated": false}, "after_length": 139, "after_sha256": "b27cc73dbad9dd207d1d96511ab14c8f82d2acae9bbbe06336be124a99f7b990", "annex": "", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "unassigned", "change_operations": [{"after_end": 139, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 139}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-614e1152a07e2f074809ddd0", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/005246", "medicine_name": "Byfavo", "medicine_slug": "byfavo", "observed_at": "2026-10-12T13:28:16Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": null, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "", "section_type": "unassigned", "source_provider": "European Medicines Agency", "source_sha256": "61243a969f979f690fe718e414ceaeb66438c1faa31101ba25187d2f9ea662fd", "source_snapshot_id": "source-dd26eb8615d8c18bd80c1f6a", "source_updated_at": "2026-08-26", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/byfavo-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 2}
{"after": {"end": 13, "start": 0, "text": "Bredaseweg 63", "truncated": false}, "after_length": 13, "after_sha256": "a37bbd239b649e23c8960a4ab83fa25cba872a2c2e743860ae8149ff61815928", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 13, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 13}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-61a8f79acd0de53143eef495", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002097", "medicine_name": "Fampyra", "medicine_slug": "fampyra", "observed_at": "2026-10-12T19:15:51Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "d9fe8aaaa611a84801d6308b13685258b5248df9022536697939afdf66fc1719", "source_snapshot_id": "source-ff8e0599077f0d01044dc867", "source_updated_at": "2025-08-21", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/fampyra-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1455}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 7, "start": 0, "text": "Irlanda", "truncated": false}, "before_length": 7, "before_sha256": "b62093ae50b42c09bf9083f92f576b6b687195082e19705b63f1aed7277898a5", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 7, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 7, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-61dcc3fb0775b3ff4dbdda07", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002097", "medicine_name": "Fampyra", "medicine_slug": "fampyra", "observed_at": "2026-10-12T19:16:07Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "a0c3ba8d58d6a43a809ecc3d142a78b10c2bd7f0b9f3a3553df2617d87daec1f", "source_snapshot_id": "source-c7a810dd21f94cd2d273f0da", "source_updated_at": "2025-08-21", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/fampyra-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1542}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 16, "start": 0, "text": "Extrovis EU Ltd.", "truncated": false}, "before_length": 16, "before_sha256": "f462ad48e7aef0bc82148ce088af1897d99ed86993128f30d506b27d3108a929", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 16, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 16, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-62144cb5e32ce03c7bf9904c", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/006047", "medicine_name": "Lacosamide Adroiq", "medicine_slug": "lacosamide-adroiq", "observed_at": "2026-10-12T19:07:59Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "cc83d966059d42856d0211a4f256b29b20d43593865704d6a9315aeb694f3c76", "source_snapshot_id": "source-896abba1d8391c918345d46b", "source_updated_at": "2025-09-25", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/lacosamide-adroiq-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1828}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIB", "before": {"end": 16, "start": 0, "text": "Extrovis EU Ltd.", "truncated": false}, "before_length": 16, "before_sha256": "f462ad48e7aef0bc82148ce088af1897d99ed86993128f30d506b27d3108a929", "change_kind": "unassigned", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 16, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 16, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-6225fa523bff6c179248356d", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/006047", "medicine_name": "Lacosamide Adroiq", "medicine_slug": "lacosamide-adroiq", "observed_at": "2026-10-12T19:07:56Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "", "section_type": "unassigned", "source_provider": "European Medicines Agency", "source_sha256": "0578c53a5e1c785c4d9d4dc0dabae49dbfa89e237aa571556bee548c3f9cf4d5", "source_snapshot_id": "source-64831dec5ebf55535e19d91b", "source_updated_at": "2025-09-25", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/lacosamide-adroiq-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1942}
{"after": {"end": 8, "start": 0, "text": "Pays-Bas", "truncated": false}, "after_length": 8, "after_sha256": "2f1d512c96e61c1e31319fc9326840a0ea9ab221bba6bbdca327b162ac12fa51", "annex": "III", "before": {"end": 43, "start": 0, "text": "Papendorpseweg 83, 3528 BJ Utrecht Pays-Bas", "truncated": false}, "before_length": 43, "before_sha256": "2ff8bcc9830507f63dba8a77d1aaeef88302446a200f1fe6ecefbad29b5ae46f", "change_kind": "unassigned", "change_operations": [{"after_end": 2, "after_start": 2, "before_end": 37, "before_start": 2, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 35, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-628f688ecadefc59d9475dc2", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/001021", "medicine_name": "Adcirca (previously Tadalafil Lilly)", "medicine_slug": "adcirca-previously-tadalafil-lilly", "observed_at": "2026-10-12T19:02:45Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "", "section_type": "unassigned", "source_provider": "European Medicines Agency", "source_sha256": "cdbefcd6143c93e81f3c826bea8d3d01bffc55652e0f792243097df75c452721", "source_snapshot_id": "source-a1e85476de17f5a8664f7766", "source_updated_at": "2026-01-28", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/adcirca-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1446}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 25, "start": 0, "text": "Tel: +44 (0) 800 035 2525", "truncated": false}, "before_length": 25, "before_sha256": "84fbcd82ef02323a82bdadb0119979f04bfbc916f52f9d1dc35ed28128dd714d", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 25, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 25, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-62f5c6b9c5d47b67e976714b", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002702", "medicine_name": "Hexacima", "medicine_slug": "hexacima", "observed_at": "2026-10-12T19:07:06Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "b990725709f885f3f868e5da444393a40a54f89ba2f2d9b232d9c053493d1b03", "source_snapshot_id": "source-87ea40f95d82cdfb5ba074b0", "source_updated_at": "2025-09-29", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/hexacima-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1687}
{"after": {"end": 21, "start": 0, "text": "Tel: +31 35 528 39 57", "truncated": false}, "after_length": 21, "after_sha256": "7baf6601f41e49e470f803fdd4e755a86efa38be423317c000ed79963ebdd213", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 21, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 21}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-6340692e86c4c38200d62fe0", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:19Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "77586d0bea0858214b43b86e91abc2d2711733b96959ead5ed0b5ecbd8ed888a", "source_snapshot_id": "source-85d476f9ad959cc117ca8f1f", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1827}
{"after": {"end": 21, "start": 0, "text": "Tel: +31 35 528 39 57", "truncated": false}, "after_length": 21, "after_sha256": "7baf6601f41e49e470f803fdd4e755a86efa38be423317c000ed79963ebdd213", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 21, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 21}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-636a19d6812d1a06e303249c", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:14Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "8b8c4cc8e6f1a21fedee4bf0743c9c03e454b50f5eaba0e3760416d7fe0a74ec", "source_snapshot_id": "source-4efe4ecf3ebf08d338a763a5", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1573}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 27, "start": 0, "text": "(Eurocept International BV)", "truncated": false}, "before_length": 27, "before_sha256": "e6cf9b20aaa466e53ad0d393512ca75931e13e488321e3be6f3e4f8b600970c8", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 27, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 27, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-644638a5b99a1123c41cc8a0", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:19Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "77586d0bea0858214b43b86e91abc2d2711733b96959ead5ed0b5ecbd8ed888a", "source_snapshot_id": "source-85d476f9ad959cc117ca8f1f", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1921}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 13, "start": 0, "text": "Lucane Pharma", "truncated": false}, "before_length": 13, "before_sha256": "e338afdb64acf1a6e2083a50318853589248451dd3aa707181ba02641a8521e8", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 13, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 13, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-644de8098dc606afdec43c60", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:14Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "8b8c4cc8e6f1a21fedee4bf0743c9c03e454b50f5eaba0e3760416d7fe0a74ec", "source_snapshot_id": "source-4efe4ecf3ebf08d338a763a5", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1509}
{"after": {"end": 20, "start": 0, "text": "Spasmes musculaires*", "truncated": false}, "after_length": 20, "after_sha256": "df3c70c1bf6b966f7e1b4bdc2e747b88e6c6df93b1806d5cf65081ea5205d790", "annex": "I", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 20, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": true, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 20}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-6457d4cbca029ed841c08a28", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/000554", "medicine_name": "Emselex", "medicine_slug": "emselex", "observed_at": "2026-10-12T19:12:07Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": null, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "4.8", "section_type": "adverse_reactions", "source_provider": "European Medicines Agency", "source_sha256": "9a4f1d7e260c7b80eaf397503623b63302e5945b579e9612177835e07c4ab888", "source_snapshot_id": "source-3aac7bf42b99529f25ac013b", "source_updated_at": "2025-09-15", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/emselex-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 635}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 21, "start": 0, "text": "Τηλ: +31 35 528 39 57", "truncated": false}, "before_length": 21, "before_sha256": "7b92e5311969e99f5dab8cb972fdbf42abc15ad173a746b3593ccbf111119114", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 21, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 21, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-646188bb72a2b38b39d11513", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:14Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "8b8c4cc8e6f1a21fedee4bf0743c9c03e454b50f5eaba0e3760416d7fe0a74ec", "source_snapshot_id": "source-4efe4ecf3ebf08d338a763a5", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1951}
{"after": {"end": 21, "start": 0, "text": "Tel: +31 35 528 39 57", "truncated": false}, "after_length": 21, "after_sha256": "7baf6601f41e49e470f803fdd4e755a86efa38be423317c000ed79963ebdd213", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 21, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 21}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-646eb59b518d9ee95713c254", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:14Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "8b8c4cc8e6f1a21fedee4bf0743c9c03e454b50f5eaba0e3760416d7fe0a74ec", "source_snapshot_id": "source-4efe4ecf3ebf08d338a763a5", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1474}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIB", "before": {"end": 16, "start": 0, "text": "Extrovis EU Ltd.", "truncated": false}, "before_length": 16, "before_sha256": "f462ad48e7aef0bc82148ce088af1897d99ed86993128f30d506b27d3108a929", "change_kind": "unassigned", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 16, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 16, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-6480503bde997950902475b3", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/006047", "medicine_name": "Lacosamide Adroiq", "medicine_slug": "lacosamide-adroiq", "observed_at": "2026-10-12T19:07:56Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "", "section_type": "unassigned", "source_provider": "European Medicines Agency", "source_sha256": "0578c53a5e1c785c4d9d4dc0dabae49dbfa89e237aa571556bee548c3f9cf4d5", "source_snapshot_id": "source-64831dec5ebf55535e19d91b", "source_updated_at": "2025-09-25", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/lacosamide-adroiq-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1883}
{"after": {"end": 20, "start": 0, "text": "Tel: +386 1 2355 100", "truncated": false}, "after_length": 20, "after_sha256": "08d49fea809e3878122f78a398ef6a77d2a4cf472eb2cf3d9f1450515a1ced0f", "annex": "IIIA", "before": {"end": 19, "start": 0, "text": "Tel: +386 235 51 00", "truncated": false}, "before_length": 19, "before_sha256": "fd65023f7b15127a4e3fb22b56c0b3c2e844610946d4b104bb5a61e296f3bb32", "change_kind": "content", "change_operations": [{"after_end": 12, "after_start": 10, "before_end": 10, "before_start": 10, "kind": "insert"}, {"after_end": 16, "after_start": 15, "before_end": 13, "before_start": 13, "kind": "insert"}, {"after_end": 17, "after_start": 17, "before_end": 15, "before_start": 14, "kind": "delete"}, {"after_end": 18, "after_start": 18, "before_end": 17, "before_start": 16, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 2, "chars_inserted": 3}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-64b746a8fc4e565f249522d1", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002702", "medicine_name": "Hexacima", "medicine_slug": "hexacima", "observed_at": "2026-10-12T19:07:04Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "44c8996457a718019c75b8322ba07a5ae7af36377b1a6f1cf4ca5a30f9b72c23", "source_snapshot_id": "source-fa766d966dea704c333b9969", "source_updated_at": "2025-09-29", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/hexacima-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1672}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 13, "start": 0, "text": "Lucane Pharma", "truncated": false}, "before_length": 13, "before_sha256": "e338afdb64acf1a6e2083a50318853589248451dd3aa707181ba02641a8521e8", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 13, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 13, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-64e435673ab4aa2b71628684", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:14Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "8b8c4cc8e6f1a21fedee4bf0743c9c03e454b50f5eaba0e3760416d7fe0a74ec", "source_snapshot_id": "source-4efe4ecf3ebf08d338a763a5", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1577}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 21, "start": 0, "text": "Τηλ: + 33 153 868 750", "truncated": false}, "before_length": 21, "before_sha256": "e4516e3adf69ae4bf8e517fd63976d7665183bba6c244e35e8cd4567dd8fb0e5", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 21, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 21, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-64fb333bacfe6820025933c0", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:19Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "77586d0bea0858214b43b86e91abc2d2711733b96959ead5ed0b5ecbd8ed888a", "source_snapshot_id": "source-85d476f9ad959cc117ca8f1f", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1457}
{"after": {"end": 25, "start": 0, "text": "Tjoapack Netherlands B.V.", "truncated": false}, "after_length": 25, "after_sha256": "d61d4c5e6087155ec7a92a5c2e9e15aa7274bf924f4aaff549001249105e3be2", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 25, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 25}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-655b276a89c3a76302cd58a1", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/000980", "medicine_name": "Samsca", "medicine_slug": "samsca", "observed_at": "2026-10-12T13:28:23Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "b92d73a758b8976c4438a072d544f0d6c603112c90dfc9c084d362ce62419257", "source_snapshot_id": "source-15b8b5681aba542ec1668c0b", "source_updated_at": "2026-08-20", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/samsca-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1266}
{"after": {"end": 7, "start": 0, "text": "Nemecko", "truncated": false}, "after_length": 7, "after_sha256": "24d0126e5a26515542704a0c598527890b61fd4046ad4d533f1d262406306618", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 7, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 7}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-65ad5e52cd22367b3f32f29f", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002097", "medicine_name": "Fampyra", "medicine_slug": "fampyra", "observed_at": "2026-10-12T19:16:07Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "a0c3ba8d58d6a43a809ecc3d142a78b10c2bd7f0b9f3a3553df2617d87daec1f", "source_snapshot_id": "source-c7a810dd21f94cd2d273f0da", "source_updated_at": "2025-08-21", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/fampyra-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1583}
{"after": {"end": 23, "start": 0, "text": "dpoc.norway@organon.com", "truncated": false}, "after_length": 23, "after_sha256": "b025b980392cdf94670dfebee5fbeff5ae19976bb91bc0d9205d54680e7c8926", "annex": "IIIA", "before": {"end": 23, "start": 0, "text": "info.norway@organon.com", "truncated": false}, "before_length": 23, "before_sha256": "64ba567dbdce02f4d0d01e13e8c2b99068a9ce6962d0f52339f81a5bb3f5999b", "change_kind": "content", "change_operations": [{"after_end": 2, "after_start": 0, "before_end": 3, "before_start": 0, "kind": "replace"}, {"after_end": 4, "after_start": 3, "before_end": 4, "before_start": 4, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 3, "chars_inserted": 3}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-65b05aa5bd9af392c8ade5e8", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/000619", "medicine_name": "Fosavance", "medicine_slug": "fosavance", "observed_at": "2026-10-12T19:01:48Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "37324165444dd93963c38ccfa569b0631b8d34d16c725b5a46b16dd7bb4cbbc2", "source_snapshot_id": "source-829e9ebd79c1d98e8a839547", "source_updated_at": "2026-02-12", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/fosavance-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1233}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 13, "start": 0, "text": "Lucane Pharma", "truncated": false}, "before_length": 13, "before_sha256": "e338afdb64acf1a6e2083a50318853589248451dd3aa707181ba02641a8521e8", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 13, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 13, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-65cd1f0b30ccce28af37659b", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:14Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "8b8c4cc8e6f1a21fedee4bf0743c9c03e454b50f5eaba0e3760416d7fe0a74ec", "source_snapshot_id": "source-4efe4ecf3ebf08d338a763a5", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1931}
{"after": {"end": 26, "start": 0, "text": "Dipharma Arzneimittel GmbH", "truncated": false}, "after_length": 26, "after_sha256": "d8cb257047b7439a3be44a22f3227e45df27054340bbfa9cd6525bbf1d237add", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 26, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 26}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-661491e1dd330aca95f08cee", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:14Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "8b8c4cc8e6f1a21fedee4bf0743c9c03e454b50f5eaba0e3760416d7fe0a74ec", "source_snapshot_id": "source-4efe4ecf3ebf08d338a763a5", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1924}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 18, "start": 0, "text": "Dublin 2, D02 T380", "truncated": false}, "before_length": 18, "before_sha256": "23e6871e7960b0dadc753bc127bbea230cc8308c88b2d33704eb275a3ec1a70d", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 18, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 18, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-669a09bd896a18ab7c9cad4d", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002097", "medicine_name": "Fampyra", "medicine_slug": "fampyra", "observed_at": "2026-10-12T19:15:51Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "d9fe8aaaa611a84801d6308b13685258b5248df9022536697939afdf66fc1719", "source_snapshot_id": "source-ff8e0599077f0d01044dc867", "source_updated_at": "2025-08-21", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/fampyra-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1390}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 21, "start": 0, "text": "Tel: + 33 153 868 750", "truncated": false}, "before_length": 21, "before_sha256": "efffe29324e968019e6e2b111904182ba06d83e76b1f29b933bed9dd8779c114", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 21, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 21, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-672f2c36ac026d362e6003fe", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:19Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "77586d0bea0858214b43b86e91abc2d2711733b96959ead5ed0b5ecbd8ed888a", "source_snapshot_id": "source-85d476f9ad959cc117ca8f1f", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1528}
{"after": {"end": 29, "start": 0, "text": "64th Km National Road Athens,", "truncated": false}, "after_length": 29, "after_sha256": "13ea56883a0ab9bffcaa1dd41d9bf3581890cd7cfc6830634cd50feb121599ea", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 29, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 29}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-67c93673e75a3e0a48eb85d1", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/003984", "medicine_name": "Bortezomib Accord", "medicine_slug": "bortezomib-accord", "observed_at": "2026-10-12T13:47:12Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "e4aac937241121e8ad1e32b40b1007fb58398035928568a7e60a65074b0efb36", "source_snapshot_id": "source-b1eaab6445cfa827e3b1481b", "source_updated_at": "2026-03-25", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/bortezomib-accord-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 4746}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 7, "start": 0, "text": "Iirimaa", "truncated": false}, "before_length": 7, "before_sha256": "d2823304b98ff33bc049d03ecb5f62b2d904970e9af20cabc6d9cd21fa70e6b5", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 7, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 7, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-67d4a3c86dc9a1293072cf88", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002097", "medicine_name": "Fampyra", "medicine_slug": "fampyra", "observed_at": "2026-10-12T19:15:51Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "d9fe8aaaa611a84801d6308b13685258b5248df9022536697939afdf66fc1719", "source_snapshot_id": "source-ff8e0599077f0d01044dc867", "source_updated_at": "2025-08-21", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/fampyra-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1464}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "I", "before": {"end": 437, "start": 0, "text": "Les événements suivants ont été rapportés en association avec la darifénacine depuis sa commercialisation mondiale : réactions d’hypersensibilité généralisées incluant des oedèmes de Quincke, dépression/altération de l’humeur, hallucinations. Du fait que ces événements indésirables ont été rapportés spontanément depuis la commercialisation mondiale, la fréquence de ces événements ne peut être estimée à partir des données disponibles.", "truncated": false}, "before_length": 437, "before_sha256": "910956457aa25f620772a2dfe040318739a13956ea672ab17ff6d8ce656c0e79", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 437, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": true, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 437, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-680a79f7207b7f1b0f5ce580", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/000554", "medicine_name": "Emselex", "medicine_slug": "emselex", "observed_at": "2026-10-12T19:12:07Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": null, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "4.8", "section_type": "adverse_reactions", "source_provider": "European Medicines Agency", "source_sha256": "9a4f1d7e260c7b80eaf397503623b63302e5945b579e9612177835e07c4ab888", "source_snapshot_id": "source-3aac7bf42b99529f25ac013b", "source_updated_at": "2025-09-15", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/emselex-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 240}
{"after": {"end": 129, "start": 0, "text": "Taking into account the PRAC Assessment Report on the PSUR(s) for darifenacin, the scientific conclusions of PRAC are as follows:", "truncated": false}, "after_length": 129, "after_sha256": "0aae2442a5ea81dd54e8efc7a43f97745a822a85a5641a409a20129974b4b86b", "annex": "IV", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 129, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 129}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-680dc95dd16d218de6dbd286", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/000554", "medicine_name": "Emselex", "medicine_slug": "emselex", "observed_at": "2026-10-12T19:12:04Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "conditions", "section_type": "conditions", "source_provider": "European Medicines Agency", "source_sha256": "4f2565612bc728ec67b7f9c0cd5799ef2c594911c76f323aef8bf6a85adde245", "source_snapshot_id": "source-1fda25b331eb198b8b93feb3", "source_updated_at": "2025-09-15", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/emselex-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 2075}
{"after": {"end": 23, "start": 0, "text": "info@euroceptpharma.com", "truncated": false}, "after_length": 23, "after_sha256": "9297cc5acdcc837f054116992765943f7907937507b2564a99ea1327a00ac0e6", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 23, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 23}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-6833591510e10e5576b0a6b0", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:19Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "77586d0bea0858214b43b86e91abc2d2711733b96959ead5ed0b5ecbd8ed888a", "source_snapshot_id": "source-85d476f9ad959cc117ca8f1f", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1533}
{"after": {"end": 100, "start": 0, "text": "Le nom et l’adresse du fabricant responsable de la libération du lot concerné doivent figurer sur la", "truncated": false}, "after_length": 100, "after_sha256": "3b61619dfb3139317ef576ac39d8809e0d6eb4fc13483513bb0413d4003376b6", "annex": "II", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 100, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 100}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-689f43c696c03956601d64c4", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/003984", "medicine_name": "Bortezomib Accord", "medicine_slug": "bortezomib-accord", "observed_at": "2026-10-12T13:47:15Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "conditions", "section_type": "conditions", "source_provider": "European Medicines Agency", "source_sha256": "150a191aaf0a1e169e9d5fa2530f0eccb4e3d46509faf5ec5ee975a2e67788c4", "source_snapshot_id": "source-cba4680b7fbd2c536884abd8", "source_updated_at": "2026-03-25", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/bortezomib-accord-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 3353}
{"after": {"end": 26, "start": 0, "text": "Eckenheimer Landstraße 100", "truncated": false}, "after_length": 26, "after_sha256": "fdce1a9bd200c5ddd476c1ea5676b9ffbbea723f7353ad6fbc1fe019dcb86c07", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 26, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 26}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-68aafa8d36e8114af781d49b", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002097", "medicine_name": "Fampyra", "medicine_slug": "fampyra", "observed_at": "2026-10-12T19:15:51Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "d9fe8aaaa611a84801d6308b13685258b5248df9022536697939afdf66fc1719", "source_snapshot_id": "source-ff8e0599077f0d01044dc867", "source_updated_at": "2025-08-21", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/fampyra-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1602}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 21, "start": 0, "text": "info@lucanepharma.com", "truncated": false}, "before_length": 21, "before_sha256": "44fd39e5fb919cb3d680fa630da23b49238fec29159c509f3622f272bb41c7c6", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 21, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 21, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-68ad8291b251d6f0a0d5c05e", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:19Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "77586d0bea0858214b43b86e91abc2d2711733b96959ead5ed0b5ecbd8ed888a", "source_snapshot_id": "source-85d476f9ad959cc117ca8f1f", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1932}
{"after": {"end": 25, "start": 0, "text": "Eurocept International BV", "truncated": false}, "after_length": 25, "after_sha256": "b17bd89b3cf285c986a6070d0d67f5326dd5c1f08a70834c296c6c820f9e7505", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 25, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 25}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-68b1c07aeba00a4b8300510b", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:19Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "77586d0bea0858214b43b86e91abc2d2711733b96959ead5ed0b5ecbd8ed888a", "source_snapshot_id": "source-85d476f9ad959cc117ca8f1f", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1423}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 27, "start": 0, "text": "(Eurocept International BV)", "truncated": false}, "before_length": 27, "before_sha256": "e6cf9b20aaa466e53ad0d393512ca75931e13e488321e3be6f3e4f8b600970c8", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 27, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 27, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-69149e80a13ee109c8c0a025", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:14Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "8b8c4cc8e6f1a21fedee4bf0743c9c03e454b50f5eaba0e3760416d7fe0a74ec", "source_snapshot_id": "source-4efe4ecf3ebf08d338a763a5", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1959}
{"after": {"end": 23, "start": 0, "text": "60318 Frankfurt am Main", "truncated": false}, "after_length": 23, "after_sha256": "24c3191b5088b20c209c4387a8127297e54c776e161d305c9e57956a13b7cbbe", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 23, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 23}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-6930d3c1d36eac68224ae19f", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002097", "medicine_name": "Fampyra", "medicine_slug": "fampyra", "observed_at": "2026-10-12T19:16:07Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "a0c3ba8d58d6a43a809ecc3d142a78b10c2bd7f0b9f3a3553df2617d87daec1f", "source_snapshot_id": "source-c7a810dd21f94cd2d273f0da", "source_updated_at": "2025-08-21", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/fampyra-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1360}
{"after": {"end": 29, "start": 0, "text": "Tél/Tel: +46 (0) 8 545 286 60", "truncated": false}, "after_length": 29, "after_sha256": "672d350e486dbb33717dc4c2744825e72dd0b3f703f12d852ec53e65d676b58d", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 29, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 29}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-69477b0ecbf5d3b5ac948c2d", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/000980", "medicine_name": "Samsca", "medicine_slug": "samsca", "observed_at": "2026-10-12T13:28:24Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "3080d919225c2a98f20aec84d5803b3fde6e1b64f323055c46d098625f4ad301", "source_snapshot_id": "source-e05739a15a0532954ee45dd4", "source_updated_at": "2026-08-20", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/samsca-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1280}
{"after": {"end": 16, "start": 0, "text": "Extrovis EU Kft.", "truncated": false}, "after_length": 16, "after_sha256": "b9216ef80e71e17798dce313e4318f03f37328f225d30ab508b7413813a908e5", "annex": "IIIB", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "unassigned", "change_operations": [{"after_end": 16, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 16}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-696ad8fe9a330025ca5b5e8a", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/006047", "medicine_name": "Lacosamide Adroiq", "medicine_slug": "lacosamide-adroiq", "observed_at": "2026-10-12T19:07:56Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "", "section_type": "unassigned", "source_provider": "European Medicines Agency", "source_sha256": "0578c53a5e1c785c4d9d4dc0dabae49dbfa89e237aa571556bee548c3f9cf4d5", "source_snapshot_id": "source-64831dec5ebf55535e19d91b", "source_updated_at": "2025-09-25", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/lacosamide-adroiq-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1898}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 7, "start": 0, "text": "Irlande", "truncated": false}, "before_length": 7, "before_sha256": "a8cdfff5dbbda1b070a2acb339b6f0aa20b6230d9b5500c9ce066eaa89bc9a64", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 7, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 7, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-69856df2de82ae2955d78a92", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002097", "medicine_name": "Fampyra", "medicine_slug": "fampyra", "observed_at": "2026-10-12T19:16:07Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "a0c3ba8d58d6a43a809ecc3d142a78b10c2bd7f0b9f3a3553df2617d87daec1f", "source_snapshot_id": "source-c7a810dd21f94cd2d273f0da", "source_updated_at": "2025-08-21", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/fampyra-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1358}
{"after": {"end": 19, "start": 0, "text": "Do not take Emselex", "truncated": false}, "after_length": 19, "after_sha256": "929637f13e1fc092b772c24a2f8d8ad87f6e73bf64a35b8a6a6f787e48623476", "annex": "IIIA", "before": {"end": 20, "start": 0, "text": "Do not take Emselex:", "truncated": false}, "before_length": 20, "before_sha256": "111d08474f59e5a8e20440c2fc663f7f7c6614414c4ae42aa9c1c528ccc28731", "change_kind": "content", "change_operations": [{"after_end": 19, "after_start": 19, "before_end": 20, "before_start": 19, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 1, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-69a48a1822c0e53444ae5d69", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/000554", "medicine_name": "Emselex", "medicine_slug": "emselex", "observed_at": "2026-10-12T19:12:04Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "4f2565612bc728ec67b7f9c0cd5799ef2c594911c76f323aef8bf6a85adde245", "source_snapshot_id": "source-1fda25b331eb198b8b93feb3", "source_updated_at": "2025-09-15", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/emselex-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1889}
{"after": {"end": 48, "start": 0, "text": "Little Connell, Newbridge, Co. Kildare, W12 HX57", "truncated": false}, "after_length": 48, "after_sha256": "e24ae6f19ff1387cb1129051f52d1144ea2d1dd8a59cbed0f1f16a9c19777dba", "annex": "II", "before": {"end": 38, "start": 0, "text": "Little Connell, Newbridge, Co. Kildare", "truncated": false}, "before_length": 38, "before_sha256": "29c5d08dec823cc45f23c459d73a960a08283dd9f284ea5b10840876e8d522a6", "change_kind": "content", "change_operations": [{"after_end": 48, "after_start": 38, "before_end": 38, "before_start": 38, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 10}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-69ab59d9b4d117b304e8d895", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/000273", "medicine_name": "Rapamune", "medicine_slug": "rapamune", "observed_at": "2026-10-12T13:39:02Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": null, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "conditions", "section_type": "conditions", "source_provider": "European Medicines Agency", "source_sha256": "1bc6ada5e7d1ea7efaa7d7335dea3defceb38c76db5469ed0119010981160699", "source_snapshot_id": "source-2864bce7b25be5450f0e0ac7", "source_updated_at": "2026-05-04", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/rapamune-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1495}
{"after": {"end": 29, "start": 0, "text": "Tél/Tel: +46 (0) 8 545 286 60", "truncated": false}, "after_length": 29, "after_sha256": "672d350e486dbb33717dc4c2744825e72dd0b3f703f12d852ec53e65d676b58d", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 29, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 29}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-69b986404f2c8837ff1fd0f2", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/000980", "medicine_name": "Samsca", "medicine_slug": "samsca", "observed_at": "2026-10-12T13:28:24Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "3080d919225c2a98f20aec84d5803b3fde6e1b64f323055c46d098625f4ad301", "source_snapshot_id": "source-e05739a15a0532954ee45dd4", "source_updated_at": "2026-08-20", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/samsca-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1267}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 21, "start": 0, "text": "info@lucanepharma.com", "truncated": false}, "before_length": 21, "before_sha256": "44fd39e5fb919cb3d680fa630da23b49238fec29159c509f3622f272bb41c7c6", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 21, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 21, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-69cef085e1a57618cb7f7828", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:19Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "77586d0bea0858214b43b86e91abc2d2711733b96959ead5ed0b5ecbd8ed888a", "source_snapshot_id": "source-85d476f9ad959cc117ca8f1f", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1472}
{"after": {"end": 11, "start": 0, "text": "Vianex S.A.", "truncated": false}, "after_length": 11, "after_sha256": "5aa05543f23c771ae6d358a0283a8ebc791ceaed5f1fb141cf038e2e49a6ac7b", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 11, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 11}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-6a41be7e8b9f58d97e6d99ac", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002066", "medicine_name": "Ikervis", "medicine_slug": "ikervis", "observed_at": "2026-10-12T13:34:10Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "7995ffe3d4b9c2e870327b45fae2f1d35ae1ab0e1e9e22b434fd9805b58a174e", "source_snapshot_id": "source-5ff0e792002ee89d9eb06e5d", "source_updated_at": "2026-06-23", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/ikervis-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1849}
{"after": {"end": 68, "start": 0, "text": "* observés dans le cadre de l’expérience depuis la commercialisation", "truncated": false}, "after_length": 68, "after_sha256": "6a66df38643e7ee27efd700b8bd1783e4a4f6005b15265de84f0e10132cfcb4d", "annex": "I", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 68, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": true, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 68}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-6a67fd4a4b8eeb071921a252", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/000554", "medicine_name": "Emselex", "medicine_slug": "emselex", "observed_at": "2026-10-12T19:12:07Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": null, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "4.8", "section_type": "adverse_reactions", "source_provider": "European Medicines Agency", "source_sha256": "9a4f1d7e260c7b80eaf397503623b63302e5945b579e9612177835e07c4ab888", "source_snapshot_id": "source-3aac7bf42b99529f25ac013b", "source_updated_at": "2025-09-15", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/emselex-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 651}
{"after": {"end": 16, "start": 0, "text": "Extrovis EU Kft.", "truncated": false}, "after_length": 16, "after_sha256": "b9216ef80e71e17798dce313e4318f03f37328f225d30ab508b7413813a908e5", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 16, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 16}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-6ad5ee6c4c124e4ca02ee6ed", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/006047", "medicine_name": "Lacosamide Adroiq", "medicine_slug": "lacosamide-adroiq", "observed_at": "2026-10-12T19:07:59Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "cc83d966059d42856d0211a4f256b29b20d43593865704d6a9315aeb694f3c76", "source_snapshot_id": "source-896abba1d8391c918345d46b", "source_updated_at": "2025-09-25", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/lacosamide-adroiq-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1804}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIB", "before": {"end": 16, "start": 0, "text": "Extrovis EU Ltd.", "truncated": false}, "before_length": 16, "before_sha256": "f462ad48e7aef0bc82148ce088af1897d99ed86993128f30d506b27d3108a929", "change_kind": "unassigned", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 16, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 16, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-6aecb8efe2518398ea939a03", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/006047", "medicine_name": "Lacosamide Adroiq", "medicine_slug": "lacosamide-adroiq", "observed_at": "2026-10-12T19:07:56Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "", "section_type": "unassigned", "source_provider": "European Medicines Agency", "source_sha256": "0578c53a5e1c785c4d9d4dc0dabae49dbfa89e237aa571556bee548c3f9cf4d5", "source_snapshot_id": "source-64831dec5ebf55535e19d91b", "source_updated_at": "2025-09-25", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/lacosamide-adroiq-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 2032}
{"after": {"end": 13, "start": 0, "text": "Bredaseweg 63", "truncated": false}, "after_length": 13, "after_sha256": "a37bbd239b649e23c8960a4ab83fa25cba872a2c2e743860ae8149ff61815928", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 13, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 13}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-6b1915c36c8acb8665e4b604", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002097", "medicine_name": "Fampyra", "medicine_slug": "fampyra", "observed_at": "2026-10-12T19:15:51Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "d9fe8aaaa611a84801d6308b13685258b5248df9022536697939afdf66fc1719", "source_snapshot_id": "source-ff8e0599077f0d01044dc867", "source_updated_at": "2025-08-21", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/fampyra-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1402}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 22, "start": 0, "text": "Tel : +31 35 528 39 57", "truncated": false}, "before_length": 22, "before_sha256": "7bb8afadf5dee15b4f4e1219e333b993040f0848bccea58b1141990fffb82aa1", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 22, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 22, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-6b25321974ec288aedec28a0", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:19Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "77586d0bea0858214b43b86e91abc2d2711733b96959ead5ed0b5ecbd8ed888a", "source_snapshot_id": "source-85d476f9ad959cc117ca8f1f", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1931}
{"after": {"end": 47, "start": 0, "text": "Marketing Authorisation Holder and Manufacturer", "truncated": false}, "after_length": 47, "after_sha256": "4542f9bb3095abea29e124e5e4ba8ada603cefe01cb57b9ddc98b99054dc2887", "annex": "IIIA", "before": {"end": 30, "start": 0, "text": "Marketing Authorisation Holder", "truncated": false}, "before_length": 30, "before_sha256": "49b1d8044839391ca09e6bef9f9460184c586c4da018732ac3a7e596cf20e965", "change_kind": "administrative", "change_operations": [{"after_end": 47, "after_start": 30, "before_end": 30, "before_start": 30, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 17}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-6b58963932375c5cf444d074", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/000725", "medicine_name": "Binocrit", "medicine_slug": "binocrit", "observed_at": "2026-10-12T19:28:20Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "b2bb40c100cab3babee14bbe20cc7718cb73ac1bbb3971dfd487c4f10a0e6478", "source_snapshot_id": "source-b97c331d23a7a0f19aebfb61", "source_updated_at": "2025-07-11", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/binocrit-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 3437}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "III", "before": {"end": 25, "start": 0, "text": "Tel: + 353-(0) 1 661 4377", "truncated": false}, "before_length": 25, "before_sha256": "48fde288146f4033a2172164570180a8f875f4e361fcf85a8e43ff77834511cc", "change_kind": "unassigned", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 25, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 25, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-6b5f11a2bf5398ca764a516b", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/001021", "medicine_name": "Adcirca (previously Tadalafil Lilly)", "medicine_slug": "adcirca-previously-tadalafil-lilly", "observed_at": "2026-10-12T19:02:45Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "", "section_type": "unassigned", "source_provider": "European Medicines Agency", "source_sha256": "cdbefcd6143c93e81f3c826bea8d3d01bffc55652e0f792243097df75c452721", "source_snapshot_id": "source-a1e85476de17f5a8664f7766", "source_updated_at": "2026-01-28", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/adcirca-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 2015}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 21, "start": 0, "text": "Tel: + 33 153 868 750", "truncated": false}, "before_length": 21, "before_sha256": "efffe29324e968019e6e2b111904182ba06d83e76b1f29b933bed9dd8779c114", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 21, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 21, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-6b631ae43236888d59375eaa", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:19Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "77586d0bea0858214b43b86e91abc2d2711733b96959ead5ed0b5ecbd8ed888a", "source_snapshot_id": "source-85d476f9ad959cc117ca8f1f", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1471}
{"after": {"end": 25, "start": 0, "text": "Gustav III:s Boulevard 32", "truncated": false}, "after_length": 25, "after_sha256": "bba3ec2bf3d09014ee723cdd39b8fa83a1dc3705ce0797ed375b3af7c8be027c", "annex": "IIIA", "before": {"end": 25, "start": 0, "text": "Gustav III S Boulevard 32", "truncated": false}, "before_length": 25, "before_sha256": "6117fe99f25fb7a4848fea16fe447d9ead174e8fb74f0ec2aaad6366c885562b", "change_kind": "content", "change_operations": [{"after_end": 12, "after_start": 10, "before_end": 12, "before_start": 10, "kind": "replace"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 2, "chars_inserted": 2}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-6b88c4db19312965915f6898", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002097", "medicine_name": "Fampyra", "medicine_slug": "fampyra", "observed_at": "2026-10-12T19:16:07Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "a0c3ba8d58d6a43a809ecc3d142a78b10c2bd7f0b9f3a3553df2617d87daec1f", "source_snapshot_id": "source-c7a810dd21f94cd2d273f0da", "source_updated_at": "2025-08-21", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/fampyra-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1478}
{"after": {"end": 23, "start": 0, "text": "60318 Frankfurt am Main", "truncated": false}, "after_length": 23, "after_sha256": "24c3191b5088b20c209c4387a8127297e54c776e161d305c9e57956a13b7cbbe", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 23, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 23}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-6ba15d0c82b8a7f82b3cd3ed", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002097", "medicine_name": "Fampyra", "medicine_slug": "fampyra", "observed_at": "2026-10-12T19:15:51Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "d9fe8aaaa611a84801d6308b13685258b5248df9022536697939afdf66fc1719", "source_snapshot_id": "source-ff8e0599077f0d01044dc867", "source_updated_at": "2025-08-21", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/fampyra-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1466}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 16, "start": 0, "text": "Extrovis EU Ltd.", "truncated": false}, "before_length": 16, "before_sha256": "f462ad48e7aef0bc82148ce088af1897d99ed86993128f30d506b27d3108a929", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 16, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 16, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-6c976fb0d7e4ccd2c89ae83e", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/006047", "medicine_name": "Lacosamide Adroiq", "medicine_slug": "lacosamide-adroiq", "observed_at": "2026-10-12T19:07:59Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "cc83d966059d42856d0211a4f256b29b20d43593865704d6a9315aeb694f3c76", "source_snapshot_id": "source-896abba1d8391c918345d46b", "source_updated_at": "2025-09-25", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/lacosamide-adroiq-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1805}
{"after": {"end": 30, "start": 0, "text": "Merz Therapeutics Benelux B.V.", "truncated": false}, "after_length": 30, "after_sha256": "7c5530f091b2eaff46486c1452be442d4a9c6f4c46924db34e94c6cdb089882e", "annex": "IIIA", "before": {"end": 35, "start": 0, "text": "Acorda Therapeutics Ireland Limited", "truncated": false}, "before_length": 35, "before_sha256": "d94d3153d193ed26567f2b4ed48df016d81c534e7c0cb1a6655a63f0083383ff", "change_kind": "content", "change_operations": [{"after_end": 2, "after_start": 0, "before_end": 3, "before_start": 0, "kind": "replace"}, {"after_end": 4, "after_start": 3, "before_end": 6, "before_start": 4, "kind": "replace"}, {"after_end": 21, "after_start": 18, "before_end": 22, "before_start": 20, "kind": "replace"}, {"after_end": 25, "after_start": 23, "before_end": 27, "before_start": 24, "kind": "replace"}, {"after_end": 30, "after_start": 26, "before_end": 35, "before_start": 28, "kind": "replace"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 17, "chars_inserted": 12}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-6ca1e3656d0451afdd57851f", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002097", "medicine_name": "Fampyra", "medicine_slug": "fampyra", "observed_at": "2026-10-12T19:16:07Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "a0c3ba8d58d6a43a809ecc3d142a78b10c2bd7f0b9f3a3553df2617d87daec1f", "source_snapshot_id": "source-c7a810dd21f94cd2d273f0da", "source_updated_at": "2025-08-21", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/fampyra-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1374}
{"after": {"end": 12, "start": 0, "text": "169 73 Solna", "truncated": false}, "after_length": 12, "after_sha256": "396199e813d8f79edb20275a432ef3c356a2964b18c41134b918894de8dcbb3d", "annex": "IIIA", "before": {"end": 12, "start": 0, "text": "Solna 169 73", "truncated": false}, "before_length": 12, "before_sha256": "48d3b71370d55743d8f6af2ff4ab7a798818c3958ea6d6d44d45c3a952fd50d5", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 6, "before_start": 0, "kind": "delete"}, {"after_end": 12, "after_start": 6, "before_end": 12, "before_start": 12, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 6, "chars_inserted": 6}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-6cbca5dc564c32a55a4d0ab6", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002097", "medicine_name": "Fampyra", "medicine_slug": "fampyra", "observed_at": "2026-10-12T19:16:07Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "a0c3ba8d58d6a43a809ecc3d142a78b10c2bd7f0b9f3a3553df2617d87daec1f", "source_snapshot_id": "source-c7a810dd21f94cd2d273f0da", "source_updated_at": "2025-08-21", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/fampyra-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1617}
{"after": {"end": 15, "start": 0, "text": "The Netherlands", "truncated": false}, "after_length": 15, "after_sha256": "91729ff7107ee698fe168dc62d5b2020678fcfcf55b4ea9065982ce1d071ba31", "annex": "I", "before": {"end": 50, "start": 0, "text": "Papendorpseweg 83, 3528 BJ Utrecht The Netherlands", "truncated": false}, "before_length": 50, "before_sha256": "5d621ef45df9c1911e6b63f15edb513d80fad3ee63f11fe58a733f65b67cd3cd", "change_kind": "administrative", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 35, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 35, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-6cd35885b05cbf011f10e796", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/001021", "medicine_name": "Adcirca (previously Tadalafil Lilly)", "medicine_slug": "adcirca-previously-tadalafil-lilly", "observed_at": "2026-10-12T19:02:42Z", "pipeline_version": "2.0.0", "presentation_label": "ADCIRCA 20 mg film-coated tablets", "presentation_occurrence": 1, "presentation_status": "heading_extracted_unverified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "7", "section_type": "administrative", "source_provider": "European Medicines Agency", "source_sha256": "43438c8e53504a78747a8ff36049250fee294557f3a8b0e3acb80f71ad43ebc0", "source_snapshot_id": "source-2305a67bd1e393ee340bb8e4", "source_updated_at": "2026-01-28", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/adcirca-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 615}
{"after": {"end": 16, "start": 0, "text": "Extrovis EU Kft.", "truncated": false}, "after_length": 16, "after_sha256": "b9216ef80e71e17798dce313e4318f03f37328f225d30ab508b7413813a908e5", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 16, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 16}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-6ce47c5233ef062e99ba0f7e", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/006047", "medicine_name": "Lacosamide Adroiq", "medicine_slug": "lacosamide-adroiq", "observed_at": "2026-10-12T19:07:59Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "cc83d966059d42856d0211a4f256b29b20d43593865704d6a9315aeb694f3c76", "source_snapshot_id": "source-896abba1d8391c918345d46b", "source_updated_at": "2025-09-25", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/lacosamide-adroiq-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1798}
{"after": {"end": 25, "start": 0, "text": "Lamia, Schimatari, 32009,", "truncated": false}, "after_length": 25, "after_sha256": "731caa8982d6c36ded24b2c0ae7f96bbe4b52b5f2fe4fdabe022c9e027a41c9e", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 25, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 25}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-6d137ba8ddb9e54e546e8921", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/003984", "medicine_name": "Bortezomib Accord", "medicine_slug": "bortezomib-accord", "observed_at": "2026-10-12T13:47:15Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "150a191aaf0a1e169e9d5fa2530f0eccb4e3d46509faf5ec5ee975a2e67788c4", "source_snapshot_id": "source-cba4680b7fbd2c536884abd8", "source_updated_at": "2026-03-25", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/bortezomib-accord-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 4298}
{"after": {"end": 23, "start": 0, "text": "Tel: +49 6431 285 88 30", "truncated": false}, "after_length": 23, "after_sha256": "ef2d8f53356e21d9673844a7ef23ea7b054ff18cc0092c86a4e97d96486b24a7", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 23, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 23}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-6d28755f626522fdd2d84853", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:19Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "77586d0bea0858214b43b86e91abc2d2711733b96959ead5ed0b5ecbd8ed888a", "source_snapshot_id": "source-85d476f9ad959cc117ca8f1f", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1851}
{"after": {"end": 25, "start": 0, "text": "Eurocept International BV", "truncated": false}, "after_length": 25, "after_sha256": "b17bd89b3cf285c986a6070d0d67f5326dd5c1f08a70834c296c6c820f9e7505", "annex": "IIIA", "before": {"end": 21, "start": 0, "text": "info@lucanepharma.com", "truncated": false}, "before_length": 21, "before_sha256": "44fd39e5fb919cb3d680fa630da23b49238fec29159c509f3622f272bb41c7c6", "change_kind": "content", "change_operations": [{"after_end": 3, "after_start": 0, "before_end": 3, "before_start": 0, "kind": "replace"}, {"after_end": 4, "after_start": 4, "before_end": 7, "before_start": 4, "kind": "delete"}, {"after_end": 5, "after_start": 5, "before_end": 10, "before_start": 8, "kind": "delete"}, {"after_end": 15, "after_start": 7, "before_end": 13, "before_start": 12, "kind": "replace"}, {"after_end": 20, "after_start": 16, "before_end": 16, "before_start": 14, "kind": "replace"}, {"after_end": 25, "after_start": 21, "before_end": 21, "before_start": 17, "kind": "replace"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 15, "chars_inserted": 19}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-6d441a23b03e5a7dcf0c1f2e", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:14Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "8b8c4cc8e6f1a21fedee4bf0743c9c03e454b50f5eaba0e3760416d7fe0a74ec", "source_snapshot_id": "source-4efe4ecf3ebf08d338a763a5", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1590}
{"after": {"end": 30, "start": 0, "text": "Troubles musculo-squelettiques", "truncated": false}, "after_length": 30, "after_sha256": "19f3f11cced96282f29a83fb37b4e112d045fd9d5612609940e426e03f7708ab", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 30, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 30}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-6d6b34f4e6b6675e7cd729f7", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/000235", "medicine_name": "Arava", "medicine_slug": "arava", "observed_at": "2026-10-12T13:28:00Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": null, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "98b73c5c6b1e5009c9d048f8f11257f3a8407759fd25a4c8d5ef5c611519e916", "source_snapshot_id": "source-4b7ea3b78addea82376b3432", "source_updated_at": "2026-09-07", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/arava-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 3082}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 7, "start": 0, "text": "Austria", "truncated": false}, "before_length": 7, "before_sha256": "c9cab0238debc6e55498e2c0963a1d8e25bd29c95ddd53a3fff841ee636b6bc5", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 7, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 7, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-6d728406c4d49331b19c78d5", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/000725", "medicine_name": "Binocrit", "medicine_slug": "binocrit", "observed_at": "2026-10-12T19:28:20Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "b2bb40c100cab3babee14bbe20cc7718cb73ac1bbb3971dfd487c4f10a0e6478", "source_snapshot_id": "source-b97c331d23a7a0f19aebfb61", "source_updated_at": "2025-07-11", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/binocrit-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 3450}
{"after": {"end": 166, "start": 0, "text": "PHEBURANE est administré par voie orale. En raison de sa lente dissolution, PHEBURANE granulés ne doit pas être administré par sonde nasogastrique ou de gastrostomie.", "truncated": false}, "after_length": 166, "after_sha256": "50a7f577f4316a35cb2e268474cb9a51f04298745abb55f78f3283ea019b94bf", "annex": "I", "before": {"end": 157, "start": 0, "text": "PHEBURANE est administré par voie orale. En raison de sa lente dissolution, PHEBURANE ne doit pas être administré par sonde nasogastrique ou de gastrostomie.", "truncated": false}, "before_length": 157, "before_sha256": "09c0782a2893a75791dd4bab8c528ead3125a3699377f8d1cfbcd28fed60bb92", "change_kind": "content", "change_operations": [{"after_end": 95, "after_start": 86, "before_end": 86, "before_start": 86, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": true, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 9}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-6dab58be432f1dfb84832b6e", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:19Z", "pipeline_version": "2.0.0", "presentation_label": "PHEBURANE 483 mg/g granulés", "presentation_occurrence": 1, "presentation_status": "heading_extracted_unverified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "4.2", "section_type": "posology", "source_provider": "European Medicines Agency", "source_sha256": "77586d0bea0858214b43b86e91abc2d2711733b96959ead5ed0b5ecbd8ed888a", "source_snapshot_id": "source-85d476f9ad959cc117ca8f1f", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 86}
{"after": {"end": 18, "start": 0, "text": "Etat confusionnel*", "truncated": false}, "after_length": 18, "after_sha256": "9c517ef7eba58e2c4cf7657316241b7240ba53a6fe9f18c6caab6e7a21f32ccb", "annex": "I", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 18, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": true, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 18}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-6dccbd477b1f288d7565ab81", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/000554", "medicine_name": "Emselex", "medicine_slug": "emselex", "observed_at": "2026-10-12T19:12:07Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": null, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "4.8", "section_type": "adverse_reactions", "source_provider": "European Medicines Agency", "source_sha256": "9a4f1d7e260c7b80eaf397503623b63302e5945b579e9612177835e07c4ab888", "source_snapshot_id": "source-3aac7bf42b99529f25ac013b", "source_updated_at": "2025-09-15", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/emselex-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 598}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 18, "start": 0, "text": "Dublin 2, D02 T380", "truncated": false}, "before_length": 18, "before_sha256": "23e6871e7960b0dadc753bc127bbea230cc8308c88b2d33704eb275a3ec1a70d", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 18, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 18, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-6de0ea0518e5e4f3c04ba17b", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002097", "medicine_name": "Fampyra", "medicine_slug": "fampyra", "observed_at": "2026-10-12T19:15:51Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "d9fe8aaaa611a84801d6308b13685258b5248df9022536697939afdf66fc1719", "source_snapshot_id": "source-ff8e0599077f0d01044dc867", "source_updated_at": "2025-08-21", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/fampyra-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1438}
{"after": {"end": 499, "start": 0, "text": "if you are taking medicines that strongly decrease the activity of some liver enzymes such as ciclosporin (a medicine used in transplantation to prevent organ rejection or for other conditions, e.g. rheumatoid arthritis or atopic dermatitis), verapamil (a medicine used to lower blood pressure, to correct heart rhythm or to treat angina pectoris), antifungal medicines (e.g. ketoconazole and itraconazole) and some antiviral medicines (e.g. ritonavir) – see paragraph “Other medicines and Emselex”.", "truncated": false}, "after_length": 499, "after_sha256": "10ef34598d39153c23a6459dfdc1095cd1be00e82fdde7d6077b324a39fa5fef", "annex": "IIIA", "before": {"end": 499, "start": 0, "text": "If you are taking medicines that strongly decrease the activity of some liver enzymes such as ciclosporin (a medicine used in transplantation to prevent organ rejection or for other conditions, e.g. rheumatoid arthritis or atopic dermatitis), verapamil (a medicine used to lower blood pressure, to correct heart rhythm or to treat angina pectoris), antifungal medicines (e.g. ketoconazole and itraconazole) and some antiviral medicines (e.g. ritonavir) – see paragraph “Other medicines and Emselex”.", "truncated": false}, "before_length": 499, "before_sha256": "7ae5aee85455c335cea5627cae14beea62ea01a82d2f210ede8459ec9e1f58d7", "change_kind": "content", "change_operations": [{"after_end": 1, "after_start": 0, "before_end": 1, "before_start": 0, "kind": "replace"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 1, "chars_inserted": 1}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-6df0a90fb4da08ff453bbed6", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/000554", "medicine_name": "Emselex", "medicine_slug": "emselex", "observed_at": "2026-10-12T19:12:04Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "4f2565612bc728ec67b7f9c0cd5799ef2c594911c76f323aef8bf6a85adde245", "source_snapshot_id": "source-1fda25b331eb198b8b93feb3", "source_updated_at": "2025-09-15", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/emselex-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1897}
{"after": {"end": 25, "start": 0, "text": "Eurocept International BV", "truncated": false}, "after_length": 25, "after_sha256": "b17bd89b3cf285c986a6070d0d67f5326dd5c1f08a70834c296c6c820f9e7505", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 25, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 25}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-6e95e3b39e9690efbab63411", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:19Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "77586d0bea0858214b43b86e91abc2d2711733b96959ead5ed0b5ecbd8ed888a", "source_snapshot_id": "source-85d476f9ad959cc117ca8f1f", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1878}
{"after": {"end": 9, "start": 0, "text": "Not known", "truncated": false}, "after_length": 9, "after_sha256": "117adf013b8521b57cc432f1d680aa8ca8ffe7ac83edfa7e0a5867794a6429cc", "annex": "I", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 9, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": true, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 9}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-6ec0a5c4e558ad543494e910", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/000554", "medicine_name": "Emselex", "medicine_slug": "emselex", "observed_at": "2026-10-12T19:12:04Z", "pipeline_version": "2.0.0", "presentation_label": "Emselex 7.5 mg prolonged-release tablets", "presentation_occurrence": 1, "presentation_status": "heading_extracted_unverified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "4.8", "section_type": "adverse_reactions", "source_provider": "European Medicines Agency", "source_sha256": "4f2565612bc728ec67b7f9c0cd5799ef2c594911c76f323aef8bf6a85adde245", "source_snapshot_id": "source-1fda25b331eb198b8b93feb3", "source_updated_at": "2025-09-15", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/emselex-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 179}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 20, "start": 0, "text": "10 Earlsfort Terrace", "truncated": false}, "before_length": 20, "before_sha256": "22951bbf6ee77815d0c07b3af5f0a66e17d277636971c4eaff372dea65dcb193", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 20, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 20, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-6eca1bb220402db4abefcbbc", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002097", "medicine_name": "Fampyra", "medicine_slug": "fampyra", "observed_at": "2026-10-12T19:15:51Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "d9fe8aaaa611a84801d6308b13685258b5248df9022536697939afdf66fc1719", "source_snapshot_id": "source-ff8e0599077f0d01044dc867", "source_updated_at": "2025-08-21", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/fampyra-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1379}
{"after": {"end": 69, "start": 0, "text": "Confusion, depressed mood/mood altered, hallucination, muscle spasms.", "truncated": false}, "after_length": 69, "after_sha256": "5a77dca70cd9eeafa3e30ec4a922e6d3fec869393ba43ec4a2af4169726d70d1", "annex": "IIIA", "before": {"end": 47, "start": 0, "text": "Depressed mood/mood alterations, hallucination.", "truncated": false}, "before_length": 47, "before_sha256": "5a84bee65df7fc0dc0346e4f215076e2e9bac102a607e0355ab0621fcc17874e", "change_kind": "content", "change_operations": [{"after_end": 12, "after_start": 0, "before_end": 1, "before_start": 0, "kind": "replace"}, {"after_end": 38, "after_start": 36, "before_end": 31, "before_start": 25, "kind": "replace"}, {"after_end": 68, "after_start": 53, "before_end": 46, "before_start": 46, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 7, "chars_inserted": 29}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-6ef71a1b8d1093561f3f4e21", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/000554", "medicine_name": "Emselex", "medicine_slug": "emselex", "observed_at": "2026-10-12T19:12:04Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "4f2565612bc728ec67b7f9c0cd5799ef2c594911c76f323aef8bf6a85adde245", "source_snapshot_id": "source-1fda25b331eb198b8b93feb3", "source_updated_at": "2025-09-15", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/emselex-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1810}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 7, "start": 0, "text": "Irlande", "truncated": false}, "before_length": 7, "before_sha256": "a8cdfff5dbbda1b070a2acb339b6f0aa20b6230d9b5500c9ce066eaa89bc9a64", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 7, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 7, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-6efef6ae00a9334d75176c96", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/004025", "medicine_name": "Lopinavir/Ritonavir Viatris (previously Ritonavir Mylan)", "medicine_slug": "lopinavir-ritonavir-viatris-previously-ritonavir-mylan", "observed_at": "2026-10-12T19:14:59Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "d782e33ec97bc43bb54f942c83f07f89482c9a433e3846beaffe05b4a52b4b36", "source_snapshot_id": "source-ff48b23a80b98be4c15aa440", "source_updated_at": "2025-09-08", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/lopinavir-ritonavir-viatris-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 3332}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "I", "before": {"end": 7, "start": 0, "text": "Germany", "truncated": false}, "before_length": 7, "before_sha256": "80db4ccdca106d37b920206331fcfe3e9e50a9e763d89b54ce3ad5ac8cf30f03", "change_kind": "administrative", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 7, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 7, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-6f59890a2a4492b2599ade74", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/005246", "medicine_name": "Byfavo", "medicine_slug": "byfavo", "observed_at": "2026-10-12T13:28:14Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "7", "section_type": "administrative", "source_provider": "European Medicines Agency", "source_sha256": "92a178ceb705631219efa40b1d0da73ebe6dfa866bc1b24d7e4dab9ded8a6861", "source_snapshot_id": "source-d485be5d9060fd557be910b2", "source_updated_at": "2026-08-26", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/byfavo-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 2624}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 31, "start": 0, "text": "Tel/ Tél : +31 (0) 20 85 46 555", "truncated": false}, "before_length": 31, "before_sha256": "44178fa5e84f821ca53309312e3df9631f685111f77982bf80a2abb7c33c25bb", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 31, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 31, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-6fd1667199a4978478a736dc", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/000980", "medicine_name": "Samsca", "medicine_slug": "samsca", "observed_at": "2026-10-12T13:28:24Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "3080d919225c2a98f20aec84d5803b3fde6e1b64f323055c46d098625f4ad301", "source_snapshot_id": "source-e05739a15a0532954ee45dd4", "source_updated_at": "2026-08-20", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/samsca-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1282}
{"after": {"end": 8, "start": 0, "text": "Γερμανία", "truncated": false}, "after_length": 8, "after_sha256": "bfec9f93122249c327451f277e22c198da0ea7dab804bbd84f5bf35170f7eb40", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 8, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 8}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-700198d55390d155f883f35d", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002097", "medicine_name": "Fampyra", "medicine_slug": "fampyra", "observed_at": "2026-10-12T19:16:07Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "a0c3ba8d58d6a43a809ecc3d142a78b10c2bd7f0b9f3a3553df2617d87daec1f", "source_snapshot_id": "source-c7a810dd21f94cd2d273f0da", "source_updated_at": "2025-08-21", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/fampyra-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1610}
{"after": {"end": 23, "start": 0, "text": "info@euroceptpharma.com", "truncated": false}, "after_length": 23, "after_sha256": "9297cc5acdcc837f054116992765943f7907937507b2564a99ea1327a00ac0e6", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 23, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 23}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-700a7bb015f7a19cb0fa5240", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:19Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "77586d0bea0858214b43b86e91abc2d2711733b96959ead5ed0b5ecbd8ed888a", "source_snapshot_id": "source-85d476f9ad959cc117ca8f1f", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1946}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 21, "start": 0, "text": "info@lucanepharma.com", "truncated": false}, "before_length": 21, "before_sha256": "44fd39e5fb919cb3d680fa630da23b49238fec29159c509f3622f272bb41c7c6", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 21, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 21, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-7016836c19a03409f698d765", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:19Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "77586d0bea0858214b43b86e91abc2d2711733b96959ead5ed0b5ecbd8ed888a", "source_snapshot_id": "source-85d476f9ad959cc117ca8f1f", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1505}
{"after": {"end": 21, "start": 0, "text": "Tel: +31 35 528 39 57", "truncated": false}, "after_length": 21, "after_sha256": "7baf6601f41e49e470f803fdd4e755a86efa38be423317c000ed79963ebdd213", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 21, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 21}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-7025fb40a834ed57031d42de", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:19Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "77586d0bea0858214b43b86e91abc2d2711733b96959ead5ed0b5ecbd8ed888a", "source_snapshot_id": "source-85d476f9ad959cc117ca8f1f", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1809}
{"after": {"end": 22, "start": 0, "text": "Merz Therapeutics GmbH", "truncated": false}, "after_length": 22, "after_sha256": "059f049c7d0846aaadcf2573280d52110f302d4ecc7b38debd004571cd1e9d5e", "annex": "IIIA", "before": {"end": 35, "start": 0, "text": "Acorda Therapeutics Ireland Limited", "truncated": false}, "before_length": 35, "before_sha256": "d94d3153d193ed26567f2b4ed48df016d81c534e7c0cb1a6655a63f0083383ff", "change_kind": "content", "change_operations": [{"after_end": 2, "after_start": 0, "before_end": 3, "before_start": 0, "kind": "replace"}, {"after_end": 4, "after_start": 3, "before_end": 6, "before_start": 4, "kind": "replace"}, {"after_end": 19, "after_start": 18, "before_end": 30, "before_start": 20, "kind": "replace"}, {"after_end": 22, "after_start": 20, "before_end": 35, "before_start": 31, "kind": "replace"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 19, "chars_inserted": 6}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-703c10419f60582a2c0be6fa", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002097", "medicine_name": "Fampyra", "medicine_slug": "fampyra", "observed_at": "2026-10-12T19:15:51Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "d9fe8aaaa611a84801d6308b13685258b5248df9022536697939afdf66fc1719", "source_snapshot_id": "source-ff8e0599077f0d01044dc867", "source_updated_at": "2025-08-21", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/fampyra-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1378}
{"after": {"end": 22, "start": 0, "text": "Fréquence indéterminée", "truncated": false}, "after_length": 22, "after_sha256": "9dbca2ea64869864cf27be15cb397d59f7675843792a00e126385e734d3768e0", "annex": "I", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 22, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": true, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 22}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-7049b57c4787004425c50334", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/000554", "medicine_name": "Emselex", "medicine_slug": "emselex", "observed_at": "2026-10-12T19:12:07Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": null, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "4.8", "section_type": "adverse_reactions", "source_provider": "European Medicines Agency", "source_sha256": "9a4f1d7e260c7b80eaf397503623b63302e5945b579e9612177835e07c4ab888", "source_snapshot_id": "source-3aac7bf42b99529f25ac013b", "source_updated_at": "2025-09-15", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/emselex-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 178}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 9, "start": 0, "text": "Fabricant", "truncated": false}, "before_length": 9, "before_sha256": "169067cf6ab90924cd5082a7a6d0aac85081d5b4f04e0d28ba8141fab5cbbda6", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 9, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 9, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-7078de0368565a1f60ae28bd", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/000725", "medicine_name": "Binocrit", "medicine_slug": "binocrit", "observed_at": "2026-10-12T19:29:33Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "2110517cc45ca102ca5957f2578ba74090631cf709d5be3e5f6e34712f237bdb", "source_snapshot_id": "source-63ba5976f2b2d4350a9afd16", "source_updated_at": "2025-07-11", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/binocrit-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 3382}
{"after": {"end": 9, "start": 0, "text": "Not known", "truncated": false}, "after_length": 9, "after_sha256": "117adf013b8521b57cc432f1d680aa8ca8ffe7ac83edfa7e0a5867794a6429cc", "annex": "I", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 9, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": true, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 9}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-707a9d7a9a1730322e520312", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/000554", "medicine_name": "Emselex", "medicine_slug": "emselex", "observed_at": "2026-10-12T19:12:04Z", "pipeline_version": "2.0.0", "presentation_label": "Emselex 7.5 mg prolonged-release tablets", "presentation_occurrence": 1, "presentation_status": "heading_extracted_unverified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "4.8", "section_type": "adverse_reactions", "source_provider": "European Medicines Agency", "source_sha256": "4f2565612bc728ec67b7f9c0cd5799ef2c594911c76f323aef8bf6a85adde245", "source_snapshot_id": "source-1fda25b331eb198b8b93feb3", "source_updated_at": "2025-09-15", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/emselex-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 177}
{"after": {"end": 22, "start": 0, "text": "Tel.: +48 22 306 57 64", "truncated": false}, "after_length": 22, "after_sha256": "f42743e78ffc8e7a70adfcfc9783dfbd7722e379db4da3de5fa3b4482b24ed3e", "annex": "IIIA", "before": {"end": 22, "start": 0, "text": "Tel.: +48 22 105 50 01", "truncated": false}, "before_length": 22, "before_sha256": "4b6e5da3666f5b91284ff36e8999b7b08cee19f82bea6c085934d8b49db435c7", "change_kind": "content", "change_operations": [{"after_end": 14, "after_start": 13, "before_end": 14, "before_start": 13, "kind": "replace"}, {"after_end": 16, "after_start": 15, "before_end": 16, "before_start": 15, "kind": "replace"}, {"after_end": 19, "after_start": 18, "before_end": 19, "before_start": 18, "kind": "replace"}, {"after_end": 22, "after_start": 20, "before_end": 22, "before_start": 20, "kind": "replace"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 5, "chars_inserted": 5}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-70e5181ae5fca028c8ca2da6", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/000619", "medicine_name": "Fosavance", "medicine_slug": "fosavance", "observed_at": "2026-10-12T19:01:48Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "37324165444dd93963c38ccfa569b0631b8d34d16c725b5a46b16dd7bb4cbbc2", "source_snapshot_id": "source-829e9ebd79c1d98e8a839547", "source_updated_at": "2026-02-12", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/fosavance-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1250}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 27, "start": 0, "text": "(Eurocept International BV)", "truncated": false}, "before_length": 27, "before_sha256": "e6cf9b20aaa466e53ad0d393512ca75931e13e488321e3be6f3e4f8b600970c8", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 27, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 27, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-70e8c929852ac08951d9c706", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:19Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "77586d0bea0858214b43b86e91abc2d2711733b96959ead5ed0b5ecbd8ed888a", "source_snapshot_id": "source-85d476f9ad959cc117ca8f1f", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1971}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 18, "start": 0, "text": "Dublin 2, D02 T380", "truncated": false}, "before_length": 18, "before_sha256": "23e6871e7960b0dadc753bc127bbea230cc8308c88b2d33704eb275a3ec1a70d", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 18, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 18, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-70ef96c003e82fe79f79e386", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002097", "medicine_name": "Fampyra", "medicine_slug": "fampyra", "observed_at": "2026-10-12T19:15:51Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "d9fe8aaaa611a84801d6308b13685258b5248df9022536697939afdf66fc1719", "source_snapshot_id": "source-ff8e0599077f0d01044dc867", "source_updated_at": "2025-08-21", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/fampyra-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1573}
{"after": {"end": 7, "start": 0, "text": "Germany", "truncated": false}, "after_length": 7, "after_sha256": "80db4ccdca106d37b920206331fcfe3e9e50a9e763d89b54ce3ad5ac8cf30f03", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 7, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 7}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-7149263e0a6de029f5116975", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002097", "medicine_name": "Fampyra", "medicine_slug": "fampyra", "observed_at": "2026-10-12T19:15:51Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "d9fe8aaaa611a84801d6308b13685258b5248df9022536697939afdf66fc1719", "source_snapshot_id": "source-ff8e0599077f0d01044dc867", "source_updated_at": "2025-08-21", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/fampyra-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1355}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 20, "start": 0, "text": "10 Earlsfort Terrace", "truncated": false}, "before_length": 20, "before_sha256": "22951bbf6ee77815d0c07b3af5f0a66e17d277636971c4eaff372dea65dcb193", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 20, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 20, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-7151e5fac1d225b988a91cd4", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002097", "medicine_name": "Fampyra", "medicine_slug": "fampyra", "observed_at": "2026-10-12T19:16:07Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "a0c3ba8d58d6a43a809ecc3d142a78b10c2bd7f0b9f3a3553df2617d87daec1f", "source_snapshot_id": "source-c7a810dd21f94cd2d273f0da", "source_updated_at": "2025-08-21", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/fampyra-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1375}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "II", "before": {"end": 61, "start": 0, "text": "McDermott Laboratories Limited trading as Gerard Laboratories", "truncated": false}, "before_length": 61, "before_sha256": "f28bee890ae72cccea9b87c3be57809b0afb7f64e286de2c77b2c05b413da700", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 61, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 61, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-71cd2c211b729ca9d8e5265f", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/004025", "medicine_name": "Lopinavir/Ritonavir Viatris (previously Ritonavir Mylan)", "medicine_slug": "lopinavir-ritonavir-viatris-previously-ritonavir-mylan", "observed_at": "2026-10-12T19:12:46Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "conditions", "section_type": "conditions", "source_provider": "European Medicines Agency", "source_sha256": "3e30663f02732816ed8779d7a929d500c824ae15aeaee9144ca6eef11900e273", "source_snapshot_id": "source-c58e019b5bec1fb24569e83e", "source_updated_at": "2025-09-08", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/lopinavir-ritonavir-viatris-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1468}
{"after": {"end": 179, "start": 0, "text": "This document is the approved product information for Adcirca, with the changes since the previous procedure affecting the product information (EMEA/H/C/001021/IB/0038/G) tracked.", "truncated": false}, "after_length": 179, "after_sha256": "fd732d25267df5af597b7b99e7edb047d075b051740933d3a645803d06a8dfc4", "annex": "", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "unassigned", "change_operations": [{"after_end": 179, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 179}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-71dbb8245a59d9ffe3194b53", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/001021", "medicine_name": "Adcirca (previously Tadalafil Lilly)", "medicine_slug": "adcirca-previously-tadalafil-lilly", "observed_at": "2026-10-12T19:02:42Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": null, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "", "section_type": "unassigned", "source_provider": "European Medicines Agency", "source_sha256": "43438c8e53504a78747a8ff36049250fee294557f3a8b0e3acb80f71ad43ebc0", "source_snapshot_id": "source-2305a67bd1e393ee340bb8e4", "source_updated_at": "2026-01-28", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/adcirca-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 0}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 5, "start": 0, "text": "Irska", "truncated": false}, "before_length": 5, "before_sha256": "cdf0cd77f332e6161d4630ec3fed3ecf30c6b67caf2a1d2468282a1045c12636", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 5, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 5, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-720cd3386435ed3c4bddf50f", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002097", "medicine_name": "Fampyra", "medicine_slug": "fampyra", "observed_at": "2026-10-12T19:15:51Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "d9fe8aaaa611a84801d6308b13685258b5248df9022536697939afdf66fc1719", "source_snapshot_id": "source-ff8e0599077f0d01044dc867", "source_updated_at": "2025-08-21", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/fampyra-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1526}
{"after": {"end": 6, "start": 0, "text": "Greece", "truncated": false}, "after_length": 6, "after_sha256": "9c93ad439373b4ee35e70ba1318055a14d2ed222f69f9e2d069689e83829833d", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 6, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 6}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-723ac4c7990432cf8d61c977", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/003984", "medicine_name": "Bortezomib Accord", "medicine_slug": "bortezomib-accord", "observed_at": "2026-10-12T13:47:12Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "e4aac937241121e8ad1e32b40b1007fb58398035928568a7e60a65074b0efb36", "source_snapshot_id": "source-b1eaab6445cfa827e3b1481b", "source_updated_at": "2026-03-25", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/bortezomib-accord-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 4748}
{"after": {"end": 207, "start": 0, "text": "Contact your doctor or pharmacist immediately if you experience any of the following symptoms while taking Arava: unexplained muscle pain, tenderness (soreness when the muscle is pressed) or muscle weakness.", "truncated": false}, "after_length": 207, "after_sha256": "e54adb526f1c998d8db84ee9ca0359d3dde4372f14416f24c515365e96d1c41c", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 207, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 207}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-723b570d3138a23f89b552bd", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/000235", "medicine_name": "Arava", "medicine_slug": "arava", "observed_at": "2026-10-12T13:27:58Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 3, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "2efff7967e2237bf8343431eef5e08b56c2441eb8a691a90c64b2635109fd697", "source_snapshot_id": "source-08b4eba1f67d2654148f41c4", "source_updated_at": "2026-09-07", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/arava-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 2661}
{"after": {"end": 25, "start": 0, "text": "Eurocept International BV", "truncated": false}, "after_length": 25, "after_sha256": "b17bd89b3cf285c986a6070d0d67f5326dd5c1f08a70834c296c6c820f9e7505", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 25, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 25}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-723cec3f2eb3d2d8efe26b7e", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:19Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "77586d0bea0858214b43b86e91abc2d2711733b96959ead5ed0b5ecbd8ed888a", "source_snapshot_id": "source-85d476f9ad959cc117ca8f1f", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1379}
{"after": {"end": 342, "start": 0, "text": "In view of available data on risk(s) from the literature, spontaneous reports including in 8 cases a close temporal relationship, a positive de-challenge and/or re-challenge and in view of a plausible mechanism of action, the PRAC considers a causal relationship between darifenacin and confusional state is at least a reasonable possibility.", "truncated": false}, "after_length": 342, "after_sha256": "5ae3512fec870802fbead893ad198ab246d02aff59fd97e86ab01edf8cdd6ae5", "annex": "IV", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 342, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 342}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-7240b128d3300072a6e331e4", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/000554", "medicine_name": "Emselex", "medicine_slug": "emselex", "observed_at": "2026-10-12T19:12:04Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "conditions", "section_type": "conditions", "source_provider": "European Medicines Agency", "source_sha256": "4f2565612bc728ec67b7f9c0cd5799ef2c594911c76f323aef8bf6a85adde245", "source_snapshot_id": "source-1fda25b331eb198b8b93feb3", "source_updated_at": "2025-09-15", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/emselex-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 2077}
{"after": {"end": 9, "start": 0, "text": "ANNEXE IV", "truncated": false}, "after_length": 9, "after_sha256": "5623d2bfc35b28c1d982ab389e6c5fa37f50e40d0b9b737593e164d081c1191d", "annex": "IV", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 9, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 9}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-724a21dff24369f3db474f84", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/000554", "medicine_name": "Emselex", "medicine_slug": "emselex", "observed_at": "2026-10-12T19:12:07Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": null, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "conditions", "section_type": "conditions", "source_provider": "European Medicines Agency", "source_sha256": "9a4f1d7e260c7b80eaf397503623b63302e5945b579e9612177835e07c4ab888", "source_snapshot_id": "source-3aac7bf42b99529f25ac013b", "source_updated_at": "2025-09-15", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/emselex-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 2058}
{"after": {"end": 41, "start": 0, "text": "Package leaflet: Information for the user", "truncated": false}, "after_length": 41, "after_sha256": "b6986acd5fcd0810c8e128d8e30a00ceaf146ccc2ef4d6c0280b65c1ab484727", "annex": "IIIA", "before": {"end": 41, "start": 0, "text": "Package leaflet: information for the user", "truncated": false}, "before_length": 41, "before_sha256": "bd238bab71c1d974c4876c803463ae885bc99a38c5b41be1899f98b4fa0c80e7", "change_kind": "content", "change_operations": [{"after_end": 18, "after_start": 17, "before_end": 18, "before_start": 17, "kind": "replace"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 1, "chars_inserted": 1}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-72699563f9e3f9e9824cc98f", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/000554", "medicine_name": "Emselex", "medicine_slug": "emselex", "observed_at": "2026-10-12T19:12:04Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "4f2565612bc728ec67b7f9c0cd5799ef2c594911c76f323aef8bf6a85adde245", "source_snapshot_id": "source-1fda25b331eb198b8b93feb3", "source_updated_at": "2025-09-15", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/emselex-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1858}
{"after": {"end": 25, "start": 0, "text": "Eurocept International BV", "truncated": false}, "after_length": 25, "after_sha256": "b17bd89b3cf285c986a6070d0d67f5326dd5c1f08a70834c296c6c820f9e7505", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 25, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 25}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-72c78ca3df3f0896233f1664", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:19Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "77586d0bea0858214b43b86e91abc2d2711733b96959ead5ed0b5ecbd8ed888a", "source_snapshot_id": "source-85d476f9ad959cc117ca8f1f", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1817}
{"after": {"end": 21, "start": 0, "text": "Tel: +31 35 528 39 57", "truncated": false}, "after_length": 21, "after_sha256": "7baf6601f41e49e470f803fdd4e755a86efa38be423317c000ed79963ebdd213", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 21, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 21}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-72e4022d7f4c23e542114c7a", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:14Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "8b8c4cc8e6f1a21fedee4bf0743c9c03e454b50f5eaba0e3760416d7fe0a74ec", "source_snapshot_id": "source-4efe4ecf3ebf08d338a763a5", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1915}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 27, "start": 0, "text": "(Eurocept International BV)", "truncated": false}, "before_length": 27, "before_sha256": "e6cf9b20aaa466e53ad0d393512ca75931e13e488321e3be6f3e4f8b600970c8", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 27, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 27, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-73688c2c06357ef2d50be693", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:19Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "77586d0bea0858214b43b86e91abc2d2711733b96959ead5ed0b5ecbd8ed888a", "source_snapshot_id": "source-85d476f9ad959cc117ca8f1f", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1845}
{"after": {"end": 23, "start": 0, "text": "Tel: +49 6431 285 88 30", "truncated": false}, "after_length": 23, "after_sha256": "ef2d8f53356e21d9673844a7ef23ea7b054ff18cc0092c86a4e97d96486b24a7", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 23, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 23}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-73970df7237fcc68cd29a799", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:14Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "8b8c4cc8e6f1a21fedee4bf0743c9c03e454b50f5eaba0e3760416d7fe0a74ec", "source_snapshot_id": "source-4efe4ecf3ebf08d338a763a5", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1963}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIB", "before": {"end": 16, "start": 0, "text": "Extrovis EU Ltd.", "truncated": false}, "before_length": 16, "before_sha256": "f462ad48e7aef0bc82148ce088af1897d99ed86993128f30d506b27d3108a929", "change_kind": "unassigned", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 16, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 16, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-73c212749ebea502903af98f", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/006047", "medicine_name": "Lacosamide Adroiq", "medicine_slug": "lacosamide-adroiq", "observed_at": "2026-10-12T19:07:56Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "", "section_type": "unassigned", "source_provider": "European Medicines Agency", "source_sha256": "0578c53a5e1c785c4d9d4dc0dabae49dbfa89e237aa571556bee548c3f9cf4d5", "source_snapshot_id": "source-64831dec5ebf55535e19d91b", "source_updated_at": "2025-09-25", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/lacosamide-adroiq-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1986}
{"after": {"end": 38, "start": 0, "text": "*observed in post-marketing experience", "truncated": false}, "after_length": 38, "after_sha256": "02e765dfaf4417c8e0b4f8e92452cff6a42cf8088dacac2dfe6aa971aeb970b5", "annex": "I", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 38, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": true, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 38}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-73c227709427c47e166e5305", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/000554", "medicine_name": "Emselex", "medicine_slug": "emselex", "observed_at": "2026-10-12T19:12:04Z", "pipeline_version": "2.0.0", "presentation_label": "Emselex 15 mg prolonged-release tablets", "presentation_occurrence": 2, "presentation_status": "heading_extracted_unverified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "4.8", "section_type": "adverse_reactions", "source_provider": "European Medicines Agency", "source_sha256": "4f2565612bc728ec67b7f9c0cd5799ef2c594911c76f323aef8bf6a85adde245", "source_snapshot_id": "source-1fda25b331eb198b8b93feb3", "source_updated_at": "2025-09-15", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/emselex-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 655}
{"after": {"end": 23, "start": 0, "text": "info@euroceptpharma.com", "truncated": false}, "after_length": 23, "after_sha256": "9297cc5acdcc837f054116992765943f7907937507b2564a99ea1327a00ac0e6", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 23, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 23}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-73f8ab896bbd4e112b51f130", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:19Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "77586d0bea0858214b43b86e91abc2d2711733b96959ead5ed0b5ecbd8ed888a", "source_snapshot_id": "source-85d476f9ad959cc117ca8f1f", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1978}
{"after": {"end": 18, "start": 0, "text": "4844 CK Terheijden", "truncated": false}, "after_length": 18, "after_sha256": "e7ea1ad04b1071e360b652726acc9e8a22118603b55f58e0bd782476a7e47649", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 18, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 18}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-740ae63314d20d60bb475c5e", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002097", "medicine_name": "Fampyra", "medicine_slug": "fampyra", "observed_at": "2026-10-12T19:16:07Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "a0c3ba8d58d6a43a809ecc3d142a78b10c2bd7f0b9f3a3553df2617d87daec1f", "source_snapshot_id": "source-c7a810dd21f94cd2d273f0da", "source_updated_at": "2025-08-21", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/fampyra-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1379}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 13, "start": 0, "text": "Lucane Pharma", "truncated": false}, "before_length": 13, "before_sha256": "e338afdb64acf1a6e2083a50318853589248451dd3aa707181ba02641a8521e8", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 13, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 13, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-74357740f3d8f322042c3fa2", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:14Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "8b8c4cc8e6f1a21fedee4bf0743c9c03e454b50f5eaba0e3760416d7fe0a74ec", "source_snapshot_id": "source-4efe4ecf3ebf08d338a763a5", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1871}
{"after": {"end": 255, "start": 0, "text": "Sur la base des conclusions scientifiques relatives à la darifénacine, le CHMP estime que le rapport bénéfice-risque du/des médicament(s) contenant la darifénacine demeure inchangé, sous réserve des modifications proposées des informations sur le produit.", "truncated": false}, "after_length": 255, "after_sha256": "ddc530ee3742605a22c53b6b1cc83f383082f417662125f84fdcfea088006582", "annex": "IV", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 255, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 255}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-7474789836a1aa93d0edc290", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/000554", "medicine_name": "Emselex", "medicine_slug": "emselex", "observed_at": "2026-10-12T19:12:07Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": null, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "conditions", "section_type": "conditions", "source_provider": "European Medicines Agency", "source_sha256": "9a4f1d7e260c7b80eaf397503623b63302e5945b579e9612177835e07c4ab888", "source_snapshot_id": "source-3aac7bf42b99529f25ac013b", "source_updated_at": "2025-09-15", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/emselex-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 2076}
{"after": {"end": 19, "start": 0, "text": "dpoc.greece@msd.com", "truncated": false}, "after_length": 19, "after_sha256": "d96a401106c51f4f8693adaf45abc406ae4e520f06826181cac8e7fb34e045be", "annex": "IIIA", "before": {"end": 21, "start": 0, "text": "dpoc_greece@merck.com", "truncated": false}, "before_length": 21, "before_sha256": "9b56f5b84cf1285f2f89288b0c6eaf5971bf26de57aec36149b36f892216f048", "change_kind": "content", "change_operations": [{"after_end": 5, "after_start": 4, "before_end": 5, "before_start": 4, "kind": "replace"}, {"after_end": 15, "after_start": 13, "before_end": 17, "before_start": 13, "kind": "replace"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 5, "chars_inserted": 3}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-74e0b99f6b3eef991655b0a8", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/000389", "medicine_name": "Invanz", "medicine_slug": "invanz", "observed_at": "2026-10-12T17:30:44Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "a9208c117495d2d6c465ba196e4dbbb3d498b27d747df3b2d0145b0549743e4b", "source_snapshot_id": "source-e56383168f778128e02c2b2e", "source_updated_at": "2025-11-21", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/invanz-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1157}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 25, "start": 0, "text": "Τηλ: + 358 (0) 3 284 8111", "truncated": false}, "before_length": 25, "before_sha256": "d2ab4368a6c3c7f07a280429f635d511f63583d8ab426619ec80daa220d95537", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 25, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 25, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-74f716e9ff41f5dda10869da", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002066", "medicine_name": "Ikervis", "medicine_slug": "ikervis", "observed_at": "2026-10-12T13:34:10Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "7995ffe3d4b9c2e870327b45fae2f1d35ae1ab0e1e9e22b434fd9805b58a174e", "source_snapshot_id": "source-5ff0e792002ee89d9eb06e5d", "source_updated_at": "2026-06-23", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/ikervis-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1415}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 18, "start": 0, "text": "Dublin 2, D02 T380", "truncated": false}, "before_length": 18, "before_sha256": "23e6871e7960b0dadc753bc127bbea230cc8308c88b2d33704eb275a3ec1a70d", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 18, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 18, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-74fafdc2e5c8b4db2dbd9314", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002097", "medicine_name": "Fampyra", "medicine_slug": "fampyra", "observed_at": "2026-10-12T19:15:51Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "d9fe8aaaa611a84801d6308b13685258b5248df9022536697939afdf66fc1719", "source_snapshot_id": "source-ff8e0599077f0d01044dc867", "source_updated_at": "2025-08-21", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/fampyra-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1617}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 21, "start": 0, "text": "info@lucanepharma.com", "truncated": false}, "before_length": 21, "before_sha256": "44fd39e5fb919cb3d680fa630da23b49238fec29159c509f3622f272bb41c7c6", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 21, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 21, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-75181aca7a22f74e5c99b11e", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:14Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "8b8c4cc8e6f1a21fedee4bf0743c9c03e454b50f5eaba0e3760416d7fe0a74ec", "source_snapshot_id": "source-4efe4ecf3ebf08d338a763a5", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1923}
{"after": {"end": 7, "start": 0, "text": "Německo", "truncated": false}, "after_length": 7, "after_sha256": "c2aec41a3a1d19fef51d31f2834532dfd151a882b1d6a79e86c190fa19105372", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 7, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 7}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-752f712b82a4e89cb428dff5", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002097", "medicine_name": "Fampyra", "medicine_slug": "fampyra", "observed_at": "2026-10-12T19:16:07Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "a0c3ba8d58d6a43a809ecc3d142a78b10c2bd7f0b9f3a3553df2617d87daec1f", "source_snapshot_id": "source-c7a810dd21f94cd2d273f0da", "source_updated_at": "2025-08-21", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/fampyra-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1420}
{"after": {"end": 36, "start": 0, "text": "Accord Healthcare Single Member S.A.", "truncated": false}, "after_length": 36, "after_sha256": "b46201b7d0efe1b953d755aa025769e26c5374f0fb886ee6f67efa377121db82", "annex": "II", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 36, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 36}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-75c85bdb25bc1baf475f9cab", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/003984", "medicine_name": "Bortezomib Accord", "medicine_slug": "bortezomib-accord", "observed_at": "2026-10-12T13:47:15Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "conditions", "section_type": "conditions", "source_provider": "European Medicines Agency", "source_sha256": "150a191aaf0a1e169e9d5fa2530f0eccb4e3d46509faf5ec5ee975a2e67788c4", "source_snapshot_id": "source-cba4680b7fbd2c536884abd8", "source_updated_at": "2026-03-25", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/bortezomib-accord-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 3348}
{"after": {"end": 25, "start": 0, "text": "Eurocept International BV", "truncated": false}, "after_length": 25, "after_sha256": "b17bd89b3cf285c986a6070d0d67f5326dd5c1f08a70834c296c6c820f9e7505", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 25, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 25}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-75ff5856d41da1d427634f79", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:14Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "8b8c4cc8e6f1a21fedee4bf0743c9c03e454b50f5eaba0e3760416d7fe0a74ec", "source_snapshot_id": "source-4efe4ecf3ebf08d338a763a5", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1558}
{"after": {"end": 11, "start": 0, "text": "Vistor ehf.", "truncated": false}, "after_length": 11, "after_sha256": "7b79f0f888fc32453606a29b908677d0b6c13a510070ab26fe31e12b995d77fe", "annex": "IIIA", "before": {"end": 6, "start": 0, "text": "Vistor", "truncated": false}, "before_length": 6, "before_sha256": "880db25626eb8b4d5d7d9cc13a3d8eb1ceea5578e74cf4680a38ffc73e92fe11", "change_kind": "content", "change_operations": [{"after_end": 11, "after_start": 6, "before_end": 6, "before_start": 6, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 5}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-76586137487cfb1670bca413", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002702", "medicine_name": "Hexacima", "medicine_slug": "hexacima", "observed_at": "2026-10-12T19:07:04Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "44c8996457a718019c75b8322ba07a5ae7af36377b1a6f1cf4ca5a30f9b72c23", "source_snapshot_id": "source-fa766d966dea704c333b9969", "source_updated_at": "2025-09-29", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/hexacima-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1675}
{"after": {"end": 22, "start": 0, "text": "Merz Therapeutics GmbH", "truncated": false}, "after_length": 22, "after_sha256": "059f049c7d0846aaadcf2573280d52110f302d4ecc7b38debd004571cd1e9d5e", "annex": "IIIA", "before": {"end": 35, "start": 0, "text": "Acorda Therapeutics Ireland Limited", "truncated": false}, "before_length": 35, "before_sha256": "d94d3153d193ed26567f2b4ed48df016d81c534e7c0cb1a6655a63f0083383ff", "change_kind": "content", "change_operations": [{"after_end": 2, "after_start": 0, "before_end": 3, "before_start": 0, "kind": "replace"}, {"after_end": 4, "after_start": 3, "before_end": 6, "before_start": 4, "kind": "replace"}, {"after_end": 19, "after_start": 18, "before_end": 30, "before_start": 20, "kind": "replace"}, {"after_end": 22, "after_start": 20, "before_end": 35, "before_start": 31, "kind": "replace"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 19, "chars_inserted": 6}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-770c409eaabb0bdfe13cc257", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002097", "medicine_name": "Fampyra", "medicine_slug": "fampyra", "observed_at": "2026-10-12T19:16:07Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "a0c3ba8d58d6a43a809ecc3d142a78b10c2bd7f0b9f3a3553df2617d87daec1f", "source_snapshot_id": "source-c7a810dd21f94cd2d273f0da", "source_updated_at": "2025-08-21", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/fampyra-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1394}
{"after": {"end": 9, "start": 0, "text": "Duxpharma", "truncated": false}, "after_length": 9, "after_sha256": "0734aea3ec8a00bf23f9b3325a0a1bec5b56c7749f8de2ffe58ef6a80bbef1ab", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 9, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 9}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-778cc882c846377f009917cf", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:14Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "8b8c4cc8e6f1a21fedee4bf0743c9c03e454b50f5eaba0e3760416d7fe0a74ec", "source_snapshot_id": "source-4efe4ecf3ebf08d338a763a5", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1995}
{"after": {"end": 25, "start": 0, "text": "Eurocept International BV", "truncated": false}, "after_length": 25, "after_sha256": "b17bd89b3cf285c986a6070d0d67f5326dd5c1f08a70834c296c6c820f9e7505", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 25, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 25}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-77987000a45250a5b90b45ee", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:14Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "8b8c4cc8e6f1a21fedee4bf0743c9c03e454b50f5eaba0e3760416d7fe0a74ec", "source_snapshot_id": "source-4efe4ecf3ebf08d338a763a5", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1459}
{"after": {"end": 22, "start": 0, "text": "Merz Therapeutics GmbH", "truncated": false}, "after_length": 22, "after_sha256": "059f049c7d0846aaadcf2573280d52110f302d4ecc7b38debd004571cd1e9d5e", "annex": "IIIA", "before": {"end": 35, "start": 0, "text": "Acorda Therapeutics Ireland Limited", "truncated": false}, "before_length": 35, "before_sha256": "d94d3153d193ed26567f2b4ed48df016d81c534e7c0cb1a6655a63f0083383ff", "change_kind": "content", "change_operations": [{"after_end": 2, "after_start": 0, "before_end": 3, "before_start": 0, "kind": "replace"}, {"after_end": 4, "after_start": 3, "before_end": 6, "before_start": 4, "kind": "replace"}, {"after_end": 19, "after_start": 18, "before_end": 30, "before_start": 20, "kind": "replace"}, {"after_end": 22, "after_start": 20, "before_end": 35, "before_start": 31, "kind": "replace"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 19, "chars_inserted": 6}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-77b75acae87e5d6fb659c9e6", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002097", "medicine_name": "Fampyra", "medicine_slug": "fampyra", "observed_at": "2026-10-12T19:15:51Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "d9fe8aaaa611a84801d6308b13685258b5248df9022536697939afdf66fc1719", "source_snapshot_id": "source-ff8e0599077f0d01044dc867", "source_updated_at": "2025-08-21", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/fampyra-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1552}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 21, "start": 0, "text": "Tel: +31 35 528 39 57", "truncated": false}, "before_length": 21, "before_sha256": "7baf6601f41e49e470f803fdd4e755a86efa38be423317c000ed79963ebdd213", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 21, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 21, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-77c70d6766cb5165ebb227ff", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:19Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "77586d0bea0858214b43b86e91abc2d2711733b96959ead5ed0b5ecbd8ed888a", "source_snapshot_id": "source-85d476f9ad959cc117ca8f1f", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1440}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 21, "start": 0, "text": "info@lucanepharma.com", "truncated": false}, "before_length": 21, "before_sha256": "44fd39e5fb919cb3d680fa630da23b49238fec29159c509f3622f272bb41c7c6", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 21, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 21, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-77e6d01618d33919dbc26c58", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:19Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "77586d0bea0858214b43b86e91abc2d2711733b96959ead5ed0b5ecbd8ed888a", "source_snapshot_id": "source-85d476f9ad959cc117ca8f1f", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1383}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 33, "start": 0, "text": "United Kingdom (Northern Ireland)", "truncated": false}, "before_length": 33, "before_sha256": "9379d82927cdb505cfb186e912177065e56a1314de3a2b914ebbb8b5fe21525a", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 33, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 33, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-780a38e8a04dc7c469ac9a69", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/001021", "medicine_name": "Adcirca (previously Tadalafil Lilly)", "medicine_slug": "adcirca-previously-tadalafil-lilly", "observed_at": "2026-10-12T19:02:42Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "43438c8e53504a78747a8ff36049250fee294557f3a8b0e3acb80f71ad43ebc0", "source_snapshot_id": "source-2305a67bd1e393ee340bb8e4", "source_updated_at": "2026-01-28", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/adcirca-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 2026}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "III", "before": {"end": 33, "start": 0, "text": "United Kingdom (Northern Ireland)", "truncated": false}, "before_length": 33, "before_sha256": "9379d82927cdb505cfb186e912177065e56a1314de3a2b914ebbb8b5fe21525a", "change_kind": "unassigned", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 33, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 33, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-781d3a66901a53da6af6085b", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/001021", "medicine_name": "Adcirca (previously Tadalafil Lilly)", "medicine_slug": "adcirca-previously-tadalafil-lilly", "observed_at": "2026-10-12T19:02:45Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "", "section_type": "unassigned", "source_provider": "European Medicines Agency", "source_sha256": "cdbefcd6143c93e81f3c826bea8d3d01bffc55652e0f792243097df75c452721", "source_snapshot_id": "source-a1e85476de17f5a8664f7766", "source_updated_at": "2026-01-28", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/adcirca-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 2303}
{"after": {"end": 12, "start": 0, "text": "Виатрис ЕООД", "truncated": false}, "after_length": 12, "after_sha256": "92f9a32247d19bdb1e65df1219954c43f6ad757cc355e8022e7566c35de78f1a", "annex": "IIIA", "before": {"end": 11, "start": 0, "text": "Майлан ЕООД", "truncated": false}, "before_length": 11, "before_sha256": "5770366f858d91109bdad7a5551dc97b9878455f55713851de8277df30093b62", "change_kind": "content", "change_operations": [{"after_end": 2, "after_start": 0, "before_end": 1, "before_start": 0, "kind": "replace"}, {"after_end": 7, "after_start": 3, "before_end": 6, "before_start": 2, "kind": "replace"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 5, "chars_inserted": 6}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-7868a95d916f47ef600aed06", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/000403", "medicine_name": "Arixtra", "medicine_slug": "arixtra", "observed_at": "2026-10-12T13:38:45Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 5, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "d627c7ab3c0e2e04ec110e8a99901c16a8eb257c9c55138e1bd3875249a20bde", "source_snapshot_id": "source-1eab2dd77b34f4c6fe6e82df", "source_updated_at": "2026-05-07", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/arixtra-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 3345}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 21, "start": 0, "text": "Tel: + 33 153 868 750", "truncated": false}, "before_length": 21, "before_sha256": "efffe29324e968019e6e2b111904182ba06d83e76b1f29b933bed9dd8779c114", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 21, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 21, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-7874528732b0287adacf40cd", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:14Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "8b8c4cc8e6f1a21fedee4bf0743c9c03e454b50f5eaba0e3760416d7fe0a74ec", "source_snapshot_id": "source-4efe4ecf3ebf08d338a763a5", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1517}
{"after": {"end": 25, "start": 0, "text": "Eurocept International BV", "truncated": false}, "after_length": 25, "after_sha256": "b17bd89b3cf285c986a6070d0d67f5326dd5c1f08a70834c296c6c820f9e7505", "annex": "IIIA", "before": {"end": 21, "start": 0, "text": "info@lucanepharma.com", "truncated": false}, "before_length": 21, "before_sha256": "44fd39e5fb919cb3d680fa630da23b49238fec29159c509f3622f272bb41c7c6", "change_kind": "content", "change_operations": [{"after_end": 3, "after_start": 0, "before_end": 3, "before_start": 0, "kind": "replace"}, {"after_end": 4, "after_start": 4, "before_end": 7, "before_start": 4, "kind": "delete"}, {"after_end": 5, "after_start": 5, "before_end": 10, "before_start": 8, "kind": "delete"}, {"after_end": 15, "after_start": 7, "before_end": 13, "before_start": 12, "kind": "replace"}, {"after_end": 20, "after_start": 16, "before_end": 16, "before_start": 14, "kind": "replace"}, {"after_end": 25, "after_start": 21, "before_end": 21, "before_start": 17, "kind": "replace"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 15, "chars_inserted": 19}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-78bc65077975e4979398db14", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:14Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "8b8c4cc8e6f1a21fedee4bf0743c9c03e454b50f5eaba0e3760416d7fe0a74ec", "source_snapshot_id": "source-4efe4ecf3ebf08d338a763a5", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1860}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 14, "start": 0, "text": "Irlanti/Irland", "truncated": false}, "before_length": 14, "before_sha256": "f8843fba35e81866fa6c37940ee500a77f509d98b1c78410796638d567548f02", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 14, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 14, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-790413d7fa2472cb11bc37e3", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002097", "medicine_name": "Fampyra", "medicine_slug": "fampyra", "observed_at": "2026-10-12T19:16:07Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "a0c3ba8d58d6a43a809ecc3d142a78b10c2bd7f0b9f3a3553df2617d87daec1f", "source_snapshot_id": "source-c7a810dd21f94cd2d273f0da", "source_updated_at": "2025-08-21", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/fampyra-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1596}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 21, "start": 0, "text": "Tel: +31 35 528 39 57", "truncated": false}, "before_length": 21, "before_sha256": "7baf6601f41e49e470f803fdd4e755a86efa38be423317c000ed79963ebdd213", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 21, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 21, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-7912dfa5eaec72b21ff830d6", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:14Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "8b8c4cc8e6f1a21fedee4bf0743c9c03e454b50f5eaba0e3760416d7fe0a74ec", "source_snapshot_id": "source-4efe4ecf3ebf08d338a763a5", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1978}
{"after": {"end": 28, "start": 0, "text": "Otsuka Pharma Scandinavia AB", "truncated": false}, "after_length": 28, "after_sha256": "da6b14629ea48096b1862cba5aad936b5d470b29f653a1de638e5ea031c53c39", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 28, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 28}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-795e6d99884fca833ebad6dd", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/000980", "medicine_name": "Samsca", "medicine_slug": "samsca", "observed_at": "2026-10-12T13:28:23Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "b92d73a758b8976c4438a072d544f0d6c603112c90dfc9c084d362ce62419257", "source_snapshot_id": "source-15b8b5681aba542ec1668c0b", "source_updated_at": "2026-08-20", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/samsca-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1274}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 20, "start": 0, "text": "10 Earlsfort Terrace", "truncated": false}, "before_length": 20, "before_sha256": "22951bbf6ee77815d0c07b3af5f0a66e17d277636971c4eaff372dea65dcb193", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 20, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 20, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-7962fad13f94c58fff380e0e", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002097", "medicine_name": "Fampyra", "medicine_slug": "fampyra", "observed_at": "2026-10-12T19:15:51Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "d9fe8aaaa611a84801d6308b13685258b5248df9022536697939afdf66fc1719", "source_snapshot_id": "source-ff8e0599077f0d01044dc867", "source_updated_at": "2025-08-21", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/fampyra-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1409}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 8, "start": 0, "text": "Ιρλανδία", "truncated": false}, "before_length": 8, "before_sha256": "095fc3722309c3e2ff6ebfa3844425d8040e1db38d62071ba0f333f624dc0081", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 8, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 8, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-79646ed3e5a4960fb4a1599c", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002097", "medicine_name": "Fampyra", "medicine_slug": "fampyra", "observed_at": "2026-10-12T19:15:51Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "d9fe8aaaa611a84801d6308b13685258b5248df9022536697939afdf66fc1719", "source_snapshot_id": "source-ff8e0599077f0d01044dc867", "source_updated_at": "2025-08-21", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/fampyra-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1482}
{"after": {"end": 16, "start": 0, "text": "imed@imed.com.pl", "truncated": false}, "after_length": 16, "after_sha256": "ea84c1c4a48b3783f0be9b72cd284be4ace13bfe979d55d22fedbadbb0b4aff0", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 16, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 16}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-796687d4f2afd5f9146ae026", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:19Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "77586d0bea0858214b43b86e91abc2d2711733b96959ead5ed0b5ecbd8ed888a", "source_snapshot_id": "source-85d476f9ad959cc117ca8f1f", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1906}
{"after": {"end": 34, "start": 0, "text": "Talk to your doctor or pharmacist:", "truncated": false}, "after_length": 34, "after_sha256": "ad1c9d72f9b50c48631e2c11d688f82c8db348489ab22dc32bded6c634bdcb2c", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 34, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 34}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-798ccb374ad0b06f9c7bd2de", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002514", "medicine_name": "Aubagio", "medicine_slug": "aubagio", "observed_at": "2026-10-12T17:28:37Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "2583b2915ecedeb3bccc3ac6bea691e65d05f5e437bf8aa7970917b6fdeb700c", "source_snapshot_id": "source-15791f384b9e49792c9776dd", "source_updated_at": "2025-12-09", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/aubagio-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1732}
{"after": {"end": 47, "start": 0, "text": "Musculoskeletal and connective tissue disorders", "truncated": false}, "after_length": 47, "after_sha256": "69d772c782fa9697b873fb5f9f3414bb76b587f7b06356c4c8e2da44b36fd9ea", "annex": "I", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 47, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": true, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 47}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-7a2428e09030a7a43401108a", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/000554", "medicine_name": "Emselex", "medicine_slug": "emselex", "observed_at": "2026-10-12T19:12:04Z", "pipeline_version": "2.0.0", "presentation_label": "Emselex 15 mg prolonged-release tablets", "presentation_occurrence": 2, "presentation_status": "heading_extracted_unverified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "4.8", "section_type": "adverse_reactions", "source_provider": "European Medicines Agency", "source_sha256": "4f2565612bc728ec67b7f9c0cd5799ef2c594911c76f323aef8bf6a85adde245", "source_snapshot_id": "source-1fda25b331eb198b8b93feb3", "source_updated_at": "2025-09-15", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/emselex-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 637}
{"after": {"end": 23, "start": 0, "text": "Tel: +49 (0) 69 15 03 0", "truncated": false}, "after_length": 23, "after_sha256": "09683b3f43171b2266a32d9f7d44e3d62d536522dc6f42d4b47f2dda48b31833", "annex": "IIIA", "before": {"end": 23, "start": 0, "text": "Tel: +353 (0)1 231 4609", "truncated": false}, "before_length": 23, "before_sha256": "a115f11f382ef18898b9d956e48603ae236fd1846ce41e8586af99b6dabbfc4d", "change_kind": "content", "change_operations": [{"after_end": 8, "after_start": 6, "before_end": 9, "before_start": 6, "kind": "replace"}, {"after_end": 16, "after_start": 12, "before_end": 13, "before_start": 13, "kind": "insert"}, {"after_end": 18, "after_start": 17, "before_end": 14, "before_start": 14, "kind": "insert"}, {"after_end": 20, "after_start": 19, "before_end": 16, "before_start": 15, "kind": "replace"}, {"after_end": 21, "after_start": 21, "before_end": 18, "before_start": 17, "kind": "delete"}, {"after_end": 22, "after_start": 22, "before_end": 21, "before_start": 19, "kind": "delete"}, {"after_end": 23, "after_start": 23, "before_end": 23, "before_start": 22, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 8, "chars_inserted": 8}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-7a324b19c2da36ef3f779e57", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002097", "medicine_name": "Fampyra", "medicine_slug": "fampyra", "observed_at": "2026-10-12T19:15:51Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "d9fe8aaaa611a84801d6308b13685258b5248df9022536697939afdf66fc1719", "source_snapshot_id": "source-ff8e0599077f0d01044dc867", "source_updated_at": "2025-08-21", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/fampyra-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1530}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 13, "start": 0, "text": "Lucane Pharma", "truncated": false}, "before_length": 13, "before_sha256": "e338afdb64acf1a6e2083a50318853589248451dd3aa707181ba02641a8521e8", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 13, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 13, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-7abacd204834930a398123aa", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:14Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "8b8c4cc8e6f1a21fedee4bf0743c9c03e454b50f5eaba0e3760416d7fe0a74ec", "source_snapshot_id": "source-4efe4ecf3ebf08d338a763a5", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 2019}
{"after": {"end": 22, "start": 0, "text": "Merz Therapeutics GmbH", "truncated": false}, "after_length": 22, "after_sha256": "059f049c7d0846aaadcf2573280d52110f302d4ecc7b38debd004571cd1e9d5e", "annex": "IIIA", "before": {"end": 35, "start": 0, "text": "Acorda Therapeutics Ireland Limited", "truncated": false}, "before_length": 35, "before_sha256": "d94d3153d193ed26567f2b4ed48df016d81c534e7c0cb1a6655a63f0083383ff", "change_kind": "content", "change_operations": [{"after_end": 2, "after_start": 0, "before_end": 3, "before_start": 0, "kind": "replace"}, {"after_end": 4, "after_start": 3, "before_end": 6, "before_start": 4, "kind": "replace"}, {"after_end": 19, "after_start": 18, "before_end": 30, "before_start": 20, "kind": "replace"}, {"after_end": 22, "after_start": 20, "before_end": 35, "before_start": 31, "kind": "replace"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 19, "chars_inserted": 6}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-7abf8f28c7bcaf393d3ccf9c", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002097", "medicine_name": "Fampyra", "medicine_slug": "fampyra", "observed_at": "2026-10-12T19:16:07Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "a0c3ba8d58d6a43a809ecc3d142a78b10c2bd7f0b9f3a3553df2617d87daec1f", "source_snapshot_id": "source-c7a810dd21f94cd2d273f0da", "source_updated_at": "2025-08-21", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/fampyra-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1384}
{"after": {"end": 22, "start": 0, "text": "Merz Therapeutics GmbH", "truncated": false}, "after_length": 22, "after_sha256": "059f049c7d0846aaadcf2573280d52110f302d4ecc7b38debd004571cd1e9d5e", "annex": "IIIA", "before": {"end": 35, "start": 0, "text": "Acorda Therapeutics Ireland Limited", "truncated": false}, "before_length": 35, "before_sha256": "d94d3153d193ed26567f2b4ed48df016d81c534e7c0cb1a6655a63f0083383ff", "change_kind": "content", "change_operations": [{"after_end": 2, "after_start": 0, "before_end": 3, "before_start": 0, "kind": "replace"}, {"after_end": 4, "after_start": 3, "before_end": 6, "before_start": 4, "kind": "replace"}, {"after_end": 19, "after_start": 18, "before_end": 30, "before_start": 20, "kind": "replace"}, {"after_end": 22, "after_start": 20, "before_end": 35, "before_start": 31, "kind": "replace"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 19, "chars_inserted": 6}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-7aca4f1cddbb4b4f97ea6b33", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002097", "medicine_name": "Fampyra", "medicine_slug": "fampyra", "observed_at": "2026-10-12T19:16:07Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "a0c3ba8d58d6a43a809ecc3d142a78b10c2bd7f0b9f3a3553df2617d87daec1f", "source_snapshot_id": "source-c7a810dd21f94cd2d273f0da", "source_updated_at": "2025-08-21", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/fampyra-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1467}
{"after": {"end": 16, "start": 0, "text": "Extrovis EU Kft.", "truncated": false}, "after_length": 16, "after_sha256": "b9216ef80e71e17798dce313e4318f03f37328f225d30ab508b7413813a908e5", "annex": "IIIB", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "unassigned", "change_operations": [{"after_end": 16, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 16}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-7aed06fc6c17ddde01275c7d", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/006047", "medicine_name": "Lacosamide Adroiq", "medicine_slug": "lacosamide-adroiq", "observed_at": "2026-10-12T19:07:56Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "", "section_type": "unassigned", "source_provider": "European Medicines Agency", "source_sha256": "0578c53a5e1c785c4d9d4dc0dabae49dbfa89e237aa571556bee548c3f9cf4d5", "source_snapshot_id": "source-64831dec5ebf55535e19d91b", "source_updated_at": "2025-09-25", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/lacosamide-adroiq-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1854}
{"after": {"end": 25, "start": 0, "text": "Eurocept International BV", "truncated": false}, "after_length": 25, "after_sha256": "b17bd89b3cf285c986a6070d0d67f5326dd5c1f08a70834c296c6c820f9e7505", "annex": "IIIA", "before": {"end": 21, "start": 0, "text": "info@lucanepharma.com", "truncated": false}, "before_length": 21, "before_sha256": "44fd39e5fb919cb3d680fa630da23b49238fec29159c509f3622f272bb41c7c6", "change_kind": "content", "change_operations": [{"after_end": 3, "after_start": 0, "before_end": 3, "before_start": 0, "kind": "replace"}, {"after_end": 4, "after_start": 4, "before_end": 7, "before_start": 4, "kind": "delete"}, {"after_end": 5, "after_start": 5, "before_end": 10, "before_start": 8, "kind": "delete"}, {"after_end": 15, "after_start": 7, "before_end": 13, "before_start": 12, "kind": "replace"}, {"after_end": 20, "after_start": 16, "before_end": 16, "before_start": 14, "kind": "replace"}, {"after_end": 25, "after_start": 21, "before_end": 21, "before_start": 17, "kind": "replace"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 15, "chars_inserted": 19}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-7af05ead873d2913b944e074", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:14Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "8b8c4cc8e6f1a21fedee4bf0743c9c03e454b50f5eaba0e3760416d7fe0a74ec", "source_snapshot_id": "source-4efe4ecf3ebf08d338a763a5", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1952}
{"after": {"end": 26, "start": 0, "text": "Eckenheimer Landstraße 100", "truncated": false}, "after_length": 26, "after_sha256": "fdce1a9bd200c5ddd476c1ea5676b9ffbbea723f7353ad6fbc1fe019dcb86c07", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 26, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 26}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-7b08aeaa5b12a961404b1cc7", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002097", "medicine_name": "Fampyra", "medicine_slug": "fampyra", "observed_at": "2026-10-12T19:16:07Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "a0c3ba8d58d6a43a809ecc3d142a78b10c2bd7f0b9f3a3553df2617d87daec1f", "source_snapshot_id": "source-c7a810dd21f94cd2d273f0da", "source_updated_at": "2025-08-21", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/fampyra-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1398}
{"after": {"end": 25, "start": 0, "text": "Tjoapack Netherlands B.V.", "truncated": false}, "after_length": 25, "after_sha256": "d61d4c5e6087155ec7a92a5c2e9e15aa7274bf924f4aaff549001249105e3be2", "annex": "II", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 25, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 25}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-7b14a6dcc4a17cb69868dd0a", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/000980", "medicine_name": "Samsca", "medicine_slug": "samsca", "observed_at": "2026-10-12T13:28:24Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "conditions", "section_type": "conditions", "source_provider": "European Medicines Agency", "source_sha256": "3080d919225c2a98f20aec84d5803b3fde6e1b64f323055c46d098625f4ad301", "source_snapshot_id": "source-e05739a15a0532954ee45dd4", "source_updated_at": "2026-08-20", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/samsca-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 550}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 20, "start": 0, "text": "10 Earlsfort Terrace", "truncated": false}, "before_length": 20, "before_sha256": "22951bbf6ee77815d0c07b3af5f0a66e17d277636971c4eaff372dea65dcb193", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 20, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 20, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-7b4900ba12b92774bf5cb936", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002097", "medicine_name": "Fampyra", "medicine_slug": "fampyra", "observed_at": "2026-10-12T19:16:07Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "a0c3ba8d58d6a43a809ecc3d142a78b10c2bd7f0b9f3a3553df2617d87daec1f", "source_snapshot_id": "source-c7a810dd21f94cd2d273f0da", "source_updated_at": "2025-08-21", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/fampyra-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1385}
{"after": {"end": 12, "start": 0, "text": "Виатрис ЕООД", "truncated": false}, "after_length": 12, "after_sha256": "92f9a32247d19bdb1e65df1219954c43f6ad757cc355e8022e7566c35de78f1a", "annex": "IIIA", "before": {"end": 11, "start": 0, "text": "Майлан ЕООД", "truncated": false}, "before_length": 11, "before_sha256": "5770366f858d91109bdad7a5551dc97b9878455f55713851de8277df30093b62", "change_kind": "content", "change_operations": [{"after_end": 2, "after_start": 0, "before_end": 1, "before_start": 0, "kind": "replace"}, {"after_end": 7, "after_start": 3, "before_end": 6, "before_start": 2, "kind": "replace"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 5, "chars_inserted": 6}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-7b4c6cc94cf180574040844a", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/000403", "medicine_name": "Arixtra", "medicine_slug": "arixtra", "observed_at": "2026-10-12T13:38:45Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 5, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "d627c7ab3c0e2e04ec110e8a99901c16a8eb257c9c55138e1bd3875249a20bde", "source_snapshot_id": "source-1eab2dd77b34f4c6fe6e82df", "source_updated_at": "2026-05-07", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/arixtra-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 4180}
{"after": {"end": 25, "start": 0, "text": "Eurocept International BV", "truncated": false}, "after_length": 25, "after_sha256": "b17bd89b3cf285c986a6070d0d67f5326dd5c1f08a70834c296c6c820f9e7505", "annex": "IIIA", "before": {"end": 21, "start": 0, "text": "info@lucanepharma.com", "truncated": false}, "before_length": 21, "before_sha256": "44fd39e5fb919cb3d680fa630da23b49238fec29159c509f3622f272bb41c7c6", "change_kind": "content", "change_operations": [{"after_end": 3, "after_start": 0, "before_end": 3, "before_start": 0, "kind": "replace"}, {"after_end": 4, "after_start": 4, "before_end": 7, "before_start": 4, "kind": "delete"}, {"after_end": 5, "after_start": 5, "before_end": 10, "before_start": 8, "kind": "delete"}, {"after_end": 15, "after_start": 7, "before_end": 13, "before_start": 12, "kind": "replace"}, {"after_end": 20, "after_start": 16, "before_end": 16, "before_start": 14, "kind": "replace"}, {"after_end": 25, "after_start": 21, "before_end": 21, "before_start": 17, "kind": "replace"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 15, "chars_inserted": 19}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-7b500cffd213daef94ebf839", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:14Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "8b8c4cc8e6f1a21fedee4bf0743c9c03e454b50f5eaba0e3760416d7fe0a74ec", "source_snapshot_id": "source-4efe4ecf3ebf08d338a763a5", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1874}
{"after": {"end": 22, "start": 0, "text": "Fréquence indéterminée", "truncated": false}, "after_length": 22, "after_sha256": "9dbca2ea64869864cf27be15cb397d59f7675843792a00e126385e734d3768e0", "annex": "I", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 22, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": true, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 22}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-7b5154e566a93892ed0d0895", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/000554", "medicine_name": "Emselex", "medicine_slug": "emselex", "observed_at": "2026-10-12T19:12:07Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": null, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "4.8", "section_type": "adverse_reactions", "source_provider": "European Medicines Agency", "source_sha256": "9a4f1d7e260c7b80eaf397503623b63302e5945b579e9612177835e07c4ab888", "source_snapshot_id": "source-3aac7bf42b99529f25ac013b", "source_updated_at": "2025-09-15", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/emselex-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 180}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 24, "start": 0, "text": "Τηλ: +358 (0) 3 284 8111", "truncated": false}, "before_length": 24, "before_sha256": "d6067cd3f2a7a2e958ac076aba456632e50c80f365a8e35948e7f408fe8f5396", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 24, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 24, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-7b609365325d8c425dab4d46", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002066", "medicine_name": "Ikervis", "medicine_slug": "ikervis", "observed_at": "2026-10-12T13:34:16Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "ab05f9fab48768c68482390488c5b90c577e852974d4448da6ea8fe5a4eda856", "source_snapshot_id": "source-324751bde2e11edc76c2dbfe", "source_updated_at": "2026-06-23", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/ikervis-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1856}
{"after": {"end": 37, "start": 0, "text": "Accord Healthcare single member S.A.,", "truncated": false}, "after_length": 37, "after_sha256": "752db38ded53417be77ebcd9ac87192289314f53aaa486d956ca57b89edd2bea", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 37, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 37}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-7c19d2fd559b0c27479669d9", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/003984", "medicine_name": "Bortezomib Accord", "medicine_slug": "bortezomib-accord", "observed_at": "2026-10-12T13:47:12Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "e4aac937241121e8ad1e32b40b1007fb58398035928568a7e60a65074b0efb36", "source_snapshot_id": "source-b1eaab6445cfa827e3b1481b", "source_updated_at": "2026-03-25", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/bortezomib-accord-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 4745}
{"after": {"end": 22, "start": 0, "text": "medicalinfo.nl@msd.com", "truncated": false}, "after_length": 22, "after_sha256": "578550b051823e92654f0b1dd2f62a8da0f4aa2c1bad41b233b8e6951a41272c", "annex": "IIIA", "before": {"end": 24, "start": 0, "text": "medicalinfo.nl@merck.com", "truncated": false}, "before_length": 24, "before_sha256": "cc3a8af00f6f52af5b0956221d649740a16b082158e556d4b49a01bcba8e6a99", "change_kind": "content", "change_operations": [{"after_end": 18, "after_start": 16, "before_end": 20, "before_start": 16, "kind": "replace"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 4, "chars_inserted": 2}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-7c219949902bf8f430c5169b", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/000389", "medicine_name": "Invanz", "medicine_slug": "invanz", "observed_at": "2026-10-12T17:30:44Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "a9208c117495d2d6c465ba196e4dbbb3d498b27d747df3b2d0145b0549743e4b", "source_snapshot_id": "source-e56383168f778128e02c2b2e", "source_updated_at": "2025-11-21", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/invanz-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1142}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 21, "start": 0, "text": "Tel: + 33 153 868 750", "truncated": false}, "before_length": 21, "before_sha256": "efffe29324e968019e6e2b111904182ba06d83e76b1f29b933bed9dd8779c114", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 21, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 21, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-7c517b45ab6c285dac9c2288", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:19Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "77586d0bea0858214b43b86e91abc2d2711733b96959ead5ed0b5ecbd8ed888a", "source_snapshot_id": "source-85d476f9ad959cc117ca8f1f", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1415}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 18, "start": 0, "text": "Dublin 2, D02 T380", "truncated": false}, "before_length": 18, "before_sha256": "23e6871e7960b0dadc753bc127bbea230cc8308c88b2d33704eb275a3ec1a70d", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 18, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 18, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-7c5fd3ca9e72d66677f14357", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002097", "medicine_name": "Fampyra", "medicine_slug": "fampyra", "observed_at": "2026-10-12T19:16:07Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "a0c3ba8d58d6a43a809ecc3d142a78b10c2bd7f0b9f3a3553df2617d87daec1f", "source_snapshot_id": "source-c7a810dd21f94cd2d273f0da", "source_updated_at": "2025-08-21", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/fampyra-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1531}
{"after": {"end": 23, "start": 0, "text": "info@euroceptpharma.com", "truncated": false}, "after_length": 23, "after_sha256": "9297cc5acdcc837f054116992765943f7907937507b2564a99ea1327a00ac0e6", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 23, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 23}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-7c95516f93feb5db18312564", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:19Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "77586d0bea0858214b43b86e91abc2d2711733b96959ead5ed0b5ecbd8ed888a", "source_snapshot_id": "source-85d476f9ad959cc117ca8f1f", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1810}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 20, "start": 0, "text": "10 Earlsfort Terrace", "truncated": false}, "before_length": 20, "before_sha256": "22951bbf6ee77815d0c07b3af5f0a66e17d277636971c4eaff372dea65dcb193", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 20, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 20, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-7cadf70ad18e4b81e2cc3a14", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002097", "medicine_name": "Fampyra", "medicine_slug": "fampyra", "observed_at": "2026-10-12T19:16:07Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "a0c3ba8d58d6a43a809ecc3d142a78b10c2bd7f0b9f3a3553df2617d87daec1f", "source_snapshot_id": "source-c7a810dd21f94cd2d273f0da", "source_updated_at": "2025-08-21", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/fampyra-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1507}
{"after": {"end": 23, "start": 0, "text": "info@euroceptpharma.com", "truncated": false}, "after_length": 23, "after_sha256": "9297cc5acdcc837f054116992765943f7907937507b2564a99ea1327a00ac0e6", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 23, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 23}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-7cb2e12679c09c7cc2c87fbb", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:14Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "8b8c4cc8e6f1a21fedee4bf0743c9c03e454b50f5eaba0e3760416d7fe0a74ec", "source_snapshot_id": "source-4efe4ecf3ebf08d338a763a5", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1581}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 12, "start": 0, "text": "Manufacturer", "truncated": false}, "before_length": 12, "before_sha256": "1af384c577f294d4164a7ea49f3021259e2b92802eac577722d14066b2bbd5ce", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 12, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 12, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-7cb8bb1c6234ed346b184085", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/000725", "medicine_name": "Binocrit", "medicine_slug": "binocrit", "observed_at": "2026-10-12T19:28:20Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "b2bb40c100cab3babee14bbe20cc7718cb73ac1bbb3971dfd487c4f10a0e6478", "source_snapshot_id": "source-b97c331d23a7a0f19aebfb61", "source_updated_at": "2025-07-11", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/binocrit-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 3445}
{"after": {"end": 24, "start": 0, "text": "Tel.: +49 (0) 69 15 03 0", "truncated": false}, "after_length": 24, "after_sha256": "8946964007fee6067df3ceb486bef1ddd3122eb52726a03a5d4fdde280ca2f1c", "annex": "IIIA", "before": {"end": 24, "start": 0, "text": "Tel.: +353 (0)1 231 4609", "truncated": false}, "before_length": 24, "before_sha256": "46e1c7e37b938a7e0c3f9a071d43f9eb30bbe802826026f6c280be3cb250cd4d", "change_kind": "content", "change_operations": [{"after_end": 9, "after_start": 7, "before_end": 10, "before_start": 7, "kind": "replace"}, {"after_end": 17, "after_start": 13, "before_end": 14, "before_start": 14, "kind": "insert"}, {"after_end": 19, "after_start": 18, "before_end": 15, "before_start": 15, "kind": "insert"}, {"after_end": 21, "after_start": 20, "before_end": 17, "before_start": 16, "kind": "replace"}, {"after_end": 22, "after_start": 22, "before_end": 19, "before_start": 18, "kind": "delete"}, {"after_end": 23, "after_start": 23, "before_end": 22, "before_start": 20, "kind": "delete"}, {"after_end": 24, "after_start": 24, "before_end": 24, "before_start": 23, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 8, "chars_inserted": 8}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-7cbbac1abde146702420067c", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002097", "medicine_name": "Fampyra", "medicine_slug": "fampyra", "observed_at": "2026-10-12T19:16:07Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "a0c3ba8d58d6a43a809ecc3d142a78b10c2bd7f0b9f3a3553df2617d87daec1f", "source_snapshot_id": "source-c7a810dd21f94cd2d273f0da", "source_updated_at": "2025-08-21", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/fampyra-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1431}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 16, "start": 0, "text": "Extrovis EU Ltd.", "truncated": false}, "before_length": 16, "before_sha256": "f462ad48e7aef0bc82148ce088af1897d99ed86993128f30d506b27d3108a929", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 16, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 16, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-7cd5de8c0fa348abb1ff897c", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/006047", "medicine_name": "Lacosamide Adroiq", "medicine_slug": "lacosamide-adroiq", "observed_at": "2026-10-12T19:07:59Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "cc83d966059d42856d0211a4f256b29b20d43593865704d6a9315aeb694f3c76", "source_snapshot_id": "source-896abba1d8391c918345d46b", "source_updated_at": "2025-09-25", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/lacosamide-adroiq-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1844}
{"after": {"end": 19, "start": 0, "text": "Etten-Leur, 4879 AC", "truncated": false}, "after_length": 19, "after_sha256": "8657c9b8722b346a71bad5816f5fba16b632ee27b0357aceb7406439602743c9", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 19, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 19}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-7d1f5278de5b79e10f55a237", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/000980", "medicine_name": "Samsca", "medicine_slug": "samsca", "observed_at": "2026-10-12T13:28:24Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "3080d919225c2a98f20aec84d5803b3fde6e1b64f323055c46d098625f4ad301", "source_snapshot_id": "source-e05739a15a0532954ee45dd4", "source_updated_at": "2026-08-20", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/samsca-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1260}
{"after": {"end": 22, "start": 0, "text": "Tel: + 48 22 663 43 03", "truncated": false}, "after_length": 22, "after_sha256": "5345f797275d32abdc54039c15f0a4f05223d8f5424eaa63545f2efe682185e2", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 22, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 22}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-7d68a09751e22e17e7115098", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:19Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "77586d0bea0858214b43b86e91abc2d2711733b96959ead5ed0b5ecbd8ed888a", "source_snapshot_id": "source-85d476f9ad959cc117ca8f1f", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1476}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 5, "start": 0, "text": "Irska", "truncated": false}, "before_length": 5, "before_sha256": "cdf0cd77f332e6161d4630ec3fed3ecf30c6b67caf2a1d2468282a1045c12636", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 5, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 5, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-7d7b7dc546915da57f05990b", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002097", "medicine_name": "Fampyra", "medicine_slug": "fampyra", "observed_at": "2026-10-12T19:16:07Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "a0c3ba8d58d6a43a809ecc3d142a78b10c2bd7f0b9f3a3553df2617d87daec1f", "source_snapshot_id": "source-c7a810dd21f94cd2d273f0da", "source_updated_at": "2025-08-21", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/fampyra-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1561}
{"after": {"end": 8, "start": 0, "text": "Γερμανία", "truncated": false}, "after_length": 8, "after_sha256": "bfec9f93122249c327451f277e22c198da0ea7dab804bbd84f5bf35170f7eb40", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 8, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 8}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-7d8ff434e729423e4b9b16c2", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002097", "medicine_name": "Fampyra", "medicine_slug": "fampyra", "observed_at": "2026-10-12T19:15:51Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "d9fe8aaaa611a84801d6308b13685258b5248df9022536697939afdf66fc1719", "source_snapshot_id": "source-ff8e0599077f0d01044dc867", "source_updated_at": "2025-08-21", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/fampyra-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1604}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 21, "start": 0, "text": "info@lucanepharma.com", "truncated": false}, "before_length": 21, "before_sha256": "44fd39e5fb919cb3d680fa630da23b49238fec29159c509f3622f272bb41c7c6", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 21, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 21, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-7dc707793636d913bae841b2", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:19Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "77586d0bea0858214b43b86e91abc2d2711733b96959ead5ed0b5ecbd8ed888a", "source_snapshot_id": "source-85d476f9ad959cc117ca8f1f", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1479}
{"after": {"end": 26, "start": 0, "text": "Eckenheimer Landstraße 100", "truncated": false}, "after_length": 26, "after_sha256": "fdce1a9bd200c5ddd476c1ea5676b9ffbbea723f7353ad6fbc1fe019dcb86c07", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 26, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 26}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-7e32ce36feff1e9672080614", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002097", "medicine_name": "Fampyra", "medicine_slug": "fampyra", "observed_at": "2026-10-12T19:15:51Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "d9fe8aaaa611a84801d6308b13685258b5248df9022536697939afdf66fc1719", "source_snapshot_id": "source-ff8e0599077f0d01044dc867", "source_updated_at": "2025-08-21", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/fampyra-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 896}
{"after": {"end": 9, "start": 0, "text": "Þýskaland", "truncated": false}, "after_length": 9, "after_sha256": "d32adc70fe696c4501fd3fddf1b6e3d7928a44f722cbe3cb1cf07cfba49fb424", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 9, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 9}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-7e489119af08548421968736", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002097", "medicine_name": "Fampyra", "medicine_slug": "fampyra", "observed_at": "2026-10-12T19:16:07Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "a0c3ba8d58d6a43a809ecc3d142a78b10c2bd7f0b9f3a3553df2617d87daec1f", "source_snapshot_id": "source-c7a810dd21f94cd2d273f0da", "source_updated_at": "2025-08-21", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/fampyra-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1573}
{"after": {"end": 16, "start": 0, "text": "Extrovis EU Kft.", "truncated": false}, "after_length": 16, "after_sha256": "b9216ef80e71e17798dce313e4318f03f37328f225d30ab508b7413813a908e5", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 16, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 16}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-7f0bb5b168aaa39869aa2b81", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/006047", "medicine_name": "Lacosamide Adroiq", "medicine_slug": "lacosamide-adroiq", "observed_at": "2026-10-12T19:07:59Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "cc83d966059d42856d0211a4f256b29b20d43593865704d6a9315aeb694f3c76", "source_snapshot_id": "source-896abba1d8391c918345d46b", "source_updated_at": "2025-09-25", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/lacosamide-adroiq-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1765}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 27, "start": 0, "text": "(Eurocept International BV)", "truncated": false}, "before_length": 27, "before_sha256": "e6cf9b20aaa466e53ad0d393512ca75931e13e488321e3be6f3e4f8b600970c8", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 27, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 27, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-7f2e963091ef8cf8bad62a86", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:14Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "8b8c4cc8e6f1a21fedee4bf0743c9c03e454b50f5eaba0e3760416d7fe0a74ec", "source_snapshot_id": "source-4efe4ecf3ebf08d338a763a5", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 2029}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 22, "start": 0, "text": "Ierland/Irlande/Irland", "truncated": false}, "before_length": 22, "before_sha256": "f5b90d33b60e3ce9ce9b34aa380ddef8bb49ac31af7f3f716c0bee0b2c7e8497", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 22, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 22, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-7f86569842bd0e536335afb6", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002097", "medicine_name": "Fampyra", "medicine_slug": "fampyra", "observed_at": "2026-10-12T19:15:51Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "d9fe8aaaa611a84801d6308b13685258b5248df9022536697939afdf66fc1719", "source_snapshot_id": "source-ff8e0599077f0d01044dc867", "source_updated_at": "2025-08-21", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/fampyra-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1371}
{"after": {"end": 21, "start": 0, "text": "Tlf.: +45 45 26 60 00", "truncated": false}, "after_length": 21, "after_sha256": "6bdd3c845f6a6e520023cbb8b3726e2eefc4bc4ac00ae57245f3055e31d53895", "annex": "III", "before": {"end": 20, "start": 0, "text": "Tlf: +45 45 26 60 00", "truncated": false}, "before_length": 20, "before_sha256": "7932ef9452966b997a4a22618abb01fb644277c9ab041214e6264730772b2d64", "change_kind": "unassigned", "change_operations": [{"after_end": 4, "after_start": 3, "before_end": 3, "before_start": 3, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 1}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-7fa6822307124aee086acc65", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/001021", "medicine_name": "Adcirca (previously Tadalafil Lilly)", "medicine_slug": "adcirca-previously-tadalafil-lilly", "observed_at": "2026-10-12T19:02:45Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "", "section_type": "unassigned", "source_provider": "European Medicines Agency", "source_sha256": "cdbefcd6143c93e81f3c826bea8d3d01bffc55652e0f792243097df75c452721", "source_snapshot_id": "source-a1e85476de17f5a8664f7766", "source_updated_at": "2026-01-28", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/adcirca-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 2236}
{"after": {"end": 11, "start": 0, "text": "Vianex S.A.", "truncated": false}, "after_length": 11, "after_sha256": "5aa05543f23c771ae6d358a0283a8ebc791ceaed5f1fb141cf038e2e49a6ac7b", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 11, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 11}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-7fc298857c13b5c96d608c40", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002066", "medicine_name": "Ikervis", "medicine_slug": "ikervis", "observed_at": "2026-10-12T13:34:10Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "7995ffe3d4b9c2e870327b45fae2f1d35ae1ab0e1e9e22b434fd9805b58a174e", "source_snapshot_id": "source-5ff0e792002ee89d9eb06e5d", "source_updated_at": "2026-06-23", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/ikervis-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1413}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 13, "start": 0, "text": "Lucane Pharma", "truncated": false}, "before_length": 13, "before_sha256": "e338afdb64acf1a6e2083a50318853589248451dd3aa707181ba02641a8521e8", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 13, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 13, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-803146a7214a1cad4d226cd3", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:19Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "77586d0bea0858214b43b86e91abc2d2711733b96959ead5ed0b5ecbd8ed888a", "source_snapshot_id": "source-85d476f9ad959cc117ca8f1f", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1995}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 8, "start": 0, "text": "Ирландия", "truncated": false}, "before_length": 8, "before_sha256": "79d0d5d9793987bd8aa0f026623d4cd6143b424872656570820b1ca97cea0ba2", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 8, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 8, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-804806c8af76f8a70e5c988d", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002097", "medicine_name": "Fampyra", "medicine_slug": "fampyra", "observed_at": "2026-10-12T19:15:51Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "d9fe8aaaa611a84801d6308b13685258b5248df9022536697939afdf66fc1719", "source_snapshot_id": "source-ff8e0599077f0d01044dc867", "source_updated_at": "2025-08-21", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/fampyra-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1391}
{"after": {"end": 23, "start": 0, "text": "Tel: +49 (0) 69 15 03 0", "truncated": false}, "after_length": 23, "after_sha256": "09683b3f43171b2266a32d9f7d44e3d62d536522dc6f42d4b47f2dda48b31833", "annex": "IIIA", "before": {"end": 23, "start": 0, "text": "Tel: +353 (0)1 231 4609", "truncated": false}, "before_length": 23, "before_sha256": "a115f11f382ef18898b9d956e48603ae236fd1846ce41e8586af99b6dabbfc4d", "change_kind": "content", "change_operations": [{"after_end": 8, "after_start": 6, "before_end": 9, "before_start": 6, "kind": "replace"}, {"after_end": 16, "after_start": 12, "before_end": 13, "before_start": 13, "kind": "insert"}, {"after_end": 18, "after_start": 17, "before_end": 14, "before_start": 14, "kind": "insert"}, {"after_end": 20, "after_start": 19, "before_end": 16, "before_start": 15, "kind": "replace"}, {"after_end": 21, "after_start": 21, "before_end": 18, "before_start": 17, "kind": "delete"}, {"after_end": 22, "after_start": 22, "before_end": 21, "before_start": 19, "kind": "delete"}, {"after_end": 23, "after_start": 23, "before_end": 23, "before_start": 22, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 8, "chars_inserted": 8}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-80b60f00b1586dabf891dac3", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002097", "medicine_name": "Fampyra", "medicine_slug": "fampyra", "observed_at": "2026-10-12T19:16:07Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "a0c3ba8d58d6a43a809ecc3d142a78b10c2bd7f0b9f3a3553df2617d87daec1f", "source_snapshot_id": "source-c7a810dd21f94cd2d273f0da", "source_updated_at": "2025-08-21", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/fampyra-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1565}
{"after": {"end": 21, "start": 0, "text": "Tel: +31 35 528 39 57", "truncated": false}, "after_length": 21, "after_sha256": "7baf6601f41e49e470f803fdd4e755a86efa38be423317c000ed79963ebdd213", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 21, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 21}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-80f5099276f9283392d10993", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:14Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "8b8c4cc8e6f1a21fedee4bf0743c9c03e454b50f5eaba0e3760416d7fe0a74ec", "source_snapshot_id": "source-4efe4ecf3ebf08d338a763a5", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1485}
{"after": {"end": 41, "start": 0, "text": "Humeur dépressive/altération de l’humeur*", "truncated": false}, "after_length": 41, "after_sha256": "dd5c3e4accf22b1df1479bc3e64bb39bdc164eb5a426916bd455e1de8bd49ab4", "annex": "I", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 41, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": true, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 41}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-81064b9af1472bc9ad1e79b0", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/000554", "medicine_name": "Emselex", "medicine_slug": "emselex", "observed_at": "2026-10-12T19:12:07Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": null, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "4.8", "section_type": "adverse_reactions", "source_provider": "European Medicines Agency", "source_sha256": "9a4f1d7e260c7b80eaf397503623b63302e5945b579e9612177835e07c4ab888", "source_snapshot_id": "source-3aac7bf42b99529f25ac013b", "source_updated_at": "2025-09-15", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/emselex-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 600}
{"after": {"end": 23, "start": 0, "text": "Tel: +49 (0) 69 15 03 0", "truncated": false}, "after_length": 23, "after_sha256": "09683b3f43171b2266a32d9f7d44e3d62d536522dc6f42d4b47f2dda48b31833", "annex": "IIIA", "before": {"end": 23, "start": 0, "text": "Tel: +353 (0)1 231 4609", "truncated": false}, "before_length": 23, "before_sha256": "a115f11f382ef18898b9d956e48603ae236fd1846ce41e8586af99b6dabbfc4d", "change_kind": "content", "change_operations": [{"after_end": 8, "after_start": 6, "before_end": 9, "before_start": 6, "kind": "replace"}, {"after_end": 16, "after_start": 12, "before_end": 13, "before_start": 13, "kind": "insert"}, {"after_end": 18, "after_start": 17, "before_end": 14, "before_start": 14, "kind": "insert"}, {"after_end": 20, "after_start": 19, "before_end": 16, "before_start": 15, "kind": "replace"}, {"after_end": 21, "after_start": 21, "before_end": 18, "before_start": 17, "kind": "delete"}, {"after_end": 22, "after_start": 22, "before_end": 21, "before_start": 19, "kind": "delete"}, {"after_end": 23, "after_start": 23, "before_end": 23, "before_start": 22, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 8, "chars_inserted": 8}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-81719401ea5893e43df431c2", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002097", "medicine_name": "Fampyra", "medicine_slug": "fampyra", "observed_at": "2026-10-12T19:15:51Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "d9fe8aaaa611a84801d6308b13685258b5248df9022536697939afdf66fc1719", "source_snapshot_id": "source-ff8e0599077f0d01044dc867", "source_updated_at": "2025-08-21", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/fampyra-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1540}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 27, "start": 0, "text": "Puh/Tel: +353 (0)1 231 4609", "truncated": false}, "before_length": 27, "before_sha256": "f946a5d376a72faf3c642bb86119f2a062037954a86623b94a3726bfe30ae694", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 27, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 27, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-81726d79706ff162a77d8208", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002097", "medicine_name": "Fampyra", "medicine_slug": "fampyra", "observed_at": "2026-10-12T19:15:51Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "d9fe8aaaa611a84801d6308b13685258b5248df9022536697939afdf66fc1719", "source_snapshot_id": "source-ff8e0599077f0d01044dc867", "source_updated_at": "2025-08-21", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/fampyra-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1591}
{"after": {"end": 20, "start": 0, "text": "Spasmes musculaires*", "truncated": false}, "after_length": 20, "after_sha256": "df3c70c1bf6b966f7e1b4bdc2e747b88e6c6df93b1806d5cf65081ea5205d790", "annex": "I", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 20, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": true, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 20}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-82211015cef07d7d9fb7b7d7", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/000554", "medicine_name": "Emselex", "medicine_slug": "emselex", "observed_at": "2026-10-12T19:12:07Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": null, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "4.8", "section_type": "adverse_reactions", "source_provider": "European Medicines Agency", "source_sha256": "9a4f1d7e260c7b80eaf397503623b63302e5945b579e9612177835e07c4ab888", "source_snapshot_id": "source-3aac7bf42b99529f25ac013b", "source_updated_at": "2025-09-15", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/emselex-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 214}
{"after": {"end": 18, "start": 0, "text": "Raktarvarosi Ut 9,", "truncated": false}, "after_length": 18, "after_sha256": "71dd279084ba9f87e79f1095d3565620050fda91d248303c2e19c46598fb0c2b", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 18, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 18}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-826b8e3a2286b6bd598d1f61", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/006047", "medicine_name": "Lacosamide Adroiq", "medicine_slug": "lacosamide-adroiq", "observed_at": "2026-10-12T19:07:59Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "cc83d966059d42856d0211a4f256b29b20d43593865704d6a9315aeb694f3c76", "source_snapshot_id": "source-896abba1d8391c918345d46b", "source_updated_at": "2025-09-25", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/lacosamide-adroiq-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1677}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIB", "before": {"end": 16, "start": 0, "text": "Extrovis EU Ltd.", "truncated": false}, "before_length": 16, "before_sha256": "f462ad48e7aef0bc82148ce088af1897d99ed86993128f30d506b27d3108a929", "change_kind": "unassigned", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 16, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 16, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-82e063484b2dba7927eaf889", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/006047", "medicine_name": "Lacosamide Adroiq", "medicine_slug": "lacosamide-adroiq", "observed_at": "2026-10-12T19:07:56Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "", "section_type": "unassigned", "source_provider": "European Medicines Agency", "source_sha256": "0578c53a5e1c785c4d9d4dc0dabae49dbfa89e237aa571556bee548c3f9cf4d5", "source_snapshot_id": "source-64831dec5ebf55535e19d91b", "source_updated_at": "2025-09-25", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/lacosamide-adroiq-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1931}
{"after": {"end": 26, "start": 0, "text": "Eckenheimer Landstraße 100", "truncated": false}, "after_length": 26, "after_sha256": "fdce1a9bd200c5ddd476c1ea5676b9ffbbea723f7353ad6fbc1fe019dcb86c07", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 26, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 26}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-831633a83d81a2d5b39a6257", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002097", "medicine_name": "Fampyra", "medicine_slug": "fampyra", "observed_at": "2026-10-12T19:16:07Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "a0c3ba8d58d6a43a809ecc3d142a78b10c2bd7f0b9f3a3553df2617d87daec1f", "source_snapshot_id": "source-c7a810dd21f94cd2d273f0da", "source_updated_at": "2025-08-21", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/fampyra-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1581}
{"after": {"end": 22, "start": 0, "text": "Merz Therapeutics GmbH", "truncated": false}, "after_length": 22, "after_sha256": "059f049c7d0846aaadcf2573280d52110f302d4ecc7b38debd004571cd1e9d5e", "annex": "IIIA", "before": {"end": 35, "start": 0, "text": "Acorda Therapeutics Ireland Limited", "truncated": false}, "before_length": 35, "before_sha256": "d94d3153d193ed26567f2b4ed48df016d81c534e7c0cb1a6655a63f0083383ff", "change_kind": "content", "change_operations": [{"after_end": 2, "after_start": 0, "before_end": 3, "before_start": 0, "kind": "replace"}, {"after_end": 4, "after_start": 3, "before_end": 6, "before_start": 4, "kind": "replace"}, {"after_end": 19, "after_start": 18, "before_end": 30, "before_start": 20, "kind": "replace"}, {"after_end": 22, "after_start": 20, "before_end": 35, "before_start": 31, "kind": "replace"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 19, "chars_inserted": 6}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-832157a151a2360a6a150b57", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002097", "medicine_name": "Fampyra", "medicine_slug": "fampyra", "observed_at": "2026-10-12T19:16:07Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "a0c3ba8d58d6a43a809ecc3d142a78b10c2bd7f0b9f3a3553df2617d87daec1f", "source_snapshot_id": "source-c7a810dd21f94cd2d273f0da", "source_updated_at": "2025-08-21", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/fampyra-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1033}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 21, "start": 0, "text": "Tel: + 33 153 868 750", "truncated": false}, "before_length": 21, "before_sha256": "efffe29324e968019e6e2b111904182ba06d83e76b1f29b933bed9dd8779c114", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 21, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 21, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-8330d05f44691dc6a2aa24bc", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:14Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "8b8c4cc8e6f1a21fedee4bf0743c9c03e454b50f5eaba0e3760416d7fe0a74ec", "source_snapshot_id": "source-4efe4ecf3ebf08d338a763a5", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1571}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 21, "start": 0, "text": "info@lucanepharma.com", "truncated": false}, "before_length": 21, "before_sha256": "44fd39e5fb919cb3d680fa630da23b49238fec29159c509f3622f272bb41c7c6", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 21, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 21, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-834f38fb5ce9e3fe3ec50806", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:19Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "77586d0bea0858214b43b86e91abc2d2711733b96959ead5ed0b5ecbd8ed888a", "source_snapshot_id": "source-85d476f9ad959cc117ca8f1f", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1959}
{"after": {"end": 16, "start": 0, "text": "Extrovis EU Kft.", "truncated": false}, "after_length": 16, "after_sha256": "b9216ef80e71e17798dce313e4318f03f37328f225d30ab508b7413813a908e5", "annex": "IIIB", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "unassigned", "change_operations": [{"after_end": 16, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 16}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-835f1e4c20cae26a736a03c2", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/006047", "medicine_name": "Lacosamide Adroiq", "medicine_slug": "lacosamide-adroiq", "observed_at": "2026-10-12T19:07:56Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "", "section_type": "unassigned", "source_provider": "European Medicines Agency", "source_sha256": "0578c53a5e1c785c4d9d4dc0dabae49dbfa89e237aa571556bee548c3f9cf4d5", "source_snapshot_id": "source-64831dec5ebf55535e19d91b", "source_updated_at": "2025-09-25", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/lacosamide-adroiq-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1930}
{"after": {"end": 11, "start": 0, "text": "Netherlands", "truncated": false}, "after_length": 11, "after_sha256": "3a386c13d283dc2ebbe2aeffc1ab3930d086b28956930d913d8dc58f34c013b7", "annex": "II", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 11, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 11}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-8362f241939911e99eda2d8c", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/000980", "medicine_name": "Samsca", "medicine_slug": "samsca", "observed_at": "2026-10-12T13:28:23Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "conditions", "section_type": "conditions", "source_provider": "European Medicines Agency", "source_sha256": "b92d73a758b8976c4438a072d544f0d6c603112c90dfc9c084d362ce62419257", "source_snapshot_id": "source-15b8b5681aba542ec1668c0b", "source_updated_at": "2026-08-20", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/samsca-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 555}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 21, "start": 0, "text": "Tel: + 33 153 868 750", "truncated": false}, "before_length": 21, "before_sha256": "efffe29324e968019e6e2b111904182ba06d83e76b1f29b933bed9dd8779c114", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 21, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 21, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-8364efec5fcbc4cc2c53a59e", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:19Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "77586d0bea0858214b43b86e91abc2d2711733b96959ead5ed0b5ecbd8ed888a", "source_snapshot_id": "source-85d476f9ad959cc117ca8f1f", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1535}
{"after": {"end": 18, "start": 0, "text": "Etat confusionnel*", "truncated": false}, "after_length": 18, "after_sha256": "9c517ef7eba58e2c4cf7657316241b7240ba53a6fe9f18c6caab6e7a21f32ccb", "annex": "I", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 18, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": true, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 18}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-836c606a0f351402be7c5b26", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/000554", "medicine_name": "Emselex", "medicine_slug": "emselex", "observed_at": "2026-10-12T19:12:07Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": null, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "4.8", "section_type": "adverse_reactions", "source_provider": "European Medicines Agency", "source_sha256": "9a4f1d7e260c7b80eaf397503623b63302e5945b579e9612177835e07c4ab888", "source_snapshot_id": "source-3aac7bf42b99529f25ac013b", "source_updated_at": "2025-09-15", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/emselex-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 177}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 32, "start": 0, "text": "medicalinformationuk@organon.com", "truncated": false}, "before_length": 32, "before_sha256": "9a3c944e088e3b61b964a93081a954458dd24de64e54fc2a29ad4559ba69dfc6", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 32, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 32, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-83c6fedf9c5e9a8bd1eea0e3", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/000619", "medicine_name": "Fosavance", "medicine_slug": "fosavance", "observed_at": "2026-10-12T19:01:49Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "97e93ccf75e837b32026ca36c34d5c78008211a75d5ef225c47e7b94a0027ab2", "source_snapshot_id": "source-1ef57638e1a307f1e5437651", "source_updated_at": "2026-02-12", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/fosavance-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1332}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 33, "start": 0, "text": "United Kingdom (Northern Ireland)", "truncated": false}, "before_length": 33, "before_sha256": "9379d82927cdb505cfb186e912177065e56a1314de3a2b914ebbb8b5fe21525a", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 33, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 33, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-842efa89cf50825cdb18dadd", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002702", "medicine_name": "Hexacima", "medicine_slug": "hexacima", "observed_at": "2026-10-12T19:07:04Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "44c8996457a718019c75b8322ba07a5ae7af36377b1a6f1cf4ca5a30f9b72c23", "source_snapshot_id": "source-fa766d966dea704c333b9969", "source_updated_at": "2025-09-29", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/hexacima-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 2119}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 20, "start": 0, "text": "10 Earlsfort Terrace", "truncated": false}, "before_length": 20, "before_sha256": "22951bbf6ee77815d0c07b3af5f0a66e17d277636971c4eaff372dea65dcb193", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 20, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 20, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-8446636d594c32a654a304c2", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002097", "medicine_name": "Fampyra", "medicine_slug": "fampyra", "observed_at": "2026-10-12T19:15:51Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "d9fe8aaaa611a84801d6308b13685258b5248df9022536697939afdf66fc1719", "source_snapshot_id": "source-ff8e0599077f0d01044dc867", "source_updated_at": "2025-08-21", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/fampyra-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1616}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 20, "start": 0, "text": "10 Earlsfort Terrace", "truncated": false}, "before_length": 20, "before_sha256": "22951bbf6ee77815d0c07b3af5f0a66e17d277636971c4eaff372dea65dcb193", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 20, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 20, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-849262bdce7ea1343ddb3981", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002097", "medicine_name": "Fampyra", "medicine_slug": "fampyra", "observed_at": "2026-10-12T19:15:51Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "d9fe8aaaa611a84801d6308b13685258b5248df9022536697939afdf66fc1719", "source_snapshot_id": "source-ff8e0599077f0d01044dc867", "source_updated_at": "2025-08-21", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/fampyra-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1562}
{"after": {"end": 170, "start": 0, "text": "This document is the approved product information for Byfavo, with the changes since the previous procedure affecting the product information (EMA/VR/0000348950) tracked.", "truncated": false}, "after_length": 170, "after_sha256": "4aaa0ef53afc669ae7dbdf07e7c23ede9b7dffebe857e87b7d254f20b50080a6", "annex": "", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "unassigned", "change_operations": [{"after_end": 170, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 170}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-8498600c5088bbb3150dc351", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/005246", "medicine_name": "Byfavo", "medicine_slug": "byfavo", "observed_at": "2026-10-12T13:28:14Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": null, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "", "section_type": "unassigned", "source_provider": "European Medicines Agency", "source_sha256": "92a178ceb705631219efa40b1d0da73ebe6dfa866bc1b24d7e4dab9ded8a6861", "source_snapshot_id": "source-d485be5d9060fd557be910b2", "source_updated_at": "2026-08-26", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/byfavo-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 0}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 13, "start": 0, "text": "Lucane Pharma", "truncated": false}, "before_length": 13, "before_sha256": "e338afdb64acf1a6e2083a50318853589248451dd3aa707181ba02641a8521e8", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 13, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 13, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-84be2c537065c19e6c8f43bb", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:14Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "8b8c4cc8e6f1a21fedee4bf0743c9c03e454b50f5eaba0e3760416d7fe0a74ec", "source_snapshot_id": "source-4efe4ecf3ebf08d338a763a5", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1457}
{"after": {"end": 9, "start": 0, "text": "Þýskaland", "truncated": false}, "after_length": 9, "after_sha256": "d32adc70fe696c4501fd3fddf1b6e3d7928a44f722cbe3cb1cf07cfba49fb424", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 9, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 9}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-84d31d6bbe108f7eef979c48", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002097", "medicine_name": "Fampyra", "medicine_slug": "fampyra", "observed_at": "2026-10-12T19:15:51Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "d9fe8aaaa611a84801d6308b13685258b5248df9022536697939afdf66fc1719", "source_snapshot_id": "source-ff8e0599077f0d01044dc867", "source_updated_at": "2025-08-21", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/fampyra-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1567}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 13, "start": 0, "text": "Lucane Pharma", "truncated": false}, "before_length": 13, "before_sha256": "e338afdb64acf1a6e2083a50318853589248451dd3aa707181ba02641a8521e8", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 13, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 13, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-84e07b05cee4744c31b6a2b4", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:14Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "8b8c4cc8e6f1a21fedee4bf0743c9c03e454b50f5eaba0e3760416d7fe0a74ec", "source_snapshot_id": "source-4efe4ecf3ebf08d338a763a5", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1488}
{"after": {"end": 25, "start": 0, "text": "Eurocept International BV", "truncated": false}, "after_length": 25, "after_sha256": "b17bd89b3cf285c986a6070d0d67f5326dd5c1f08a70834c296c6c820f9e7505", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 25, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 25}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-853e7d2187f56c7badb04a2f", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:19Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "77586d0bea0858214b43b86e91abc2d2711733b96959ead5ed0b5ecbd8ed888a", "source_snapshot_id": "source-85d476f9ad959cc117ca8f1f", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1896}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIB", "before": {"end": 16, "start": 0, "text": "Extrovis EU Ltd.", "truncated": false}, "before_length": 16, "before_sha256": "f462ad48e7aef0bc82148ce088af1897d99ed86993128f30d506b27d3108a929", "change_kind": "unassigned", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 16, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 16, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-85c883a76663764c76959aab", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/006047", "medicine_name": "Lacosamide Adroiq", "medicine_slug": "lacosamide-adroiq", "observed_at": "2026-10-12T19:07:56Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "", "section_type": "unassigned", "source_provider": "European Medicines Agency", "source_sha256": "0578c53a5e1c785c4d9d4dc0dabae49dbfa89e237aa571556bee548c3f9cf4d5", "source_snapshot_id": "source-64831dec5ebf55535e19d91b", "source_updated_at": "2025-09-25", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/lacosamide-adroiq-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1914}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 21, "start": 0, "text": "Tel: +31 35 528 39 57", "truncated": false}, "before_length": 21, "before_sha256": "7baf6601f41e49e470f803fdd4e755a86efa38be423317c000ed79963ebdd213", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 21, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 21, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-85d76424648068f64b94c600", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:14Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "8b8c4cc8e6f1a21fedee4bf0743c9c03e454b50f5eaba0e3760416d7fe0a74ec", "source_snapshot_id": "source-4efe4ecf3ebf08d338a763a5", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1899}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 5, "start": 0, "text": "Irsko", "truncated": false}, "before_length": 5, "before_sha256": "9ec7bc95bee4f9b389ce7195514d6c61521a21ed76102c902803086caf1a3bc9", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 5, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 5, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-8618c9981edd173332b3da5b", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002097", "medicine_name": "Fampyra", "medicine_slug": "fampyra", "observed_at": "2026-10-12T19:15:51Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "d9fe8aaaa611a84801d6308b13685258b5248df9022536697939afdf66fc1719", "source_snapshot_id": "source-ff8e0599077f0d01044dc867", "source_updated_at": "2025-08-21", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/fampyra-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1411}
{"after": {"end": 26, "start": 0, "text": "Eckenheimer Landstraße 100", "truncated": false}, "after_length": 26, "after_sha256": "fdce1a9bd200c5ddd476c1ea5676b9ffbbea723f7353ad6fbc1fe019dcb86c07", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 26, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 26}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-86341a22b96bc29f97194475", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002097", "medicine_name": "Fampyra", "medicine_slug": "fampyra", "observed_at": "2026-10-12T19:15:51Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "d9fe8aaaa611a84801d6308b13685258b5248df9022536697939afdf66fc1719", "source_snapshot_id": "source-ff8e0599077f0d01044dc867", "source_updated_at": "2025-08-21", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/fampyra-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1353}
{"after": {"end": 23, "start": 0, "text": "Tel: +49 (0) 69 15 03 0", "truncated": false}, "after_length": 23, "after_sha256": "09683b3f43171b2266a32d9f7d44e3d62d536522dc6f42d4b47f2dda48b31833", "annex": "IIIA", "before": {"end": 23, "start": 0, "text": "Tel: +353 (0)1 231 4609", "truncated": false}, "before_length": 23, "before_sha256": "a115f11f382ef18898b9d956e48603ae236fd1846ce41e8586af99b6dabbfc4d", "change_kind": "content", "change_operations": [{"after_end": 8, "after_start": 6, "before_end": 9, "before_start": 6, "kind": "replace"}, {"after_end": 16, "after_start": 12, "before_end": 13, "before_start": 13, "kind": "insert"}, {"after_end": 18, "after_start": 17, "before_end": 14, "before_start": 14, "kind": "insert"}, {"after_end": 20, "after_start": 19, "before_end": 16, "before_start": 15, "kind": "replace"}, {"after_end": 21, "after_start": 21, "before_end": 18, "before_start": 17, "kind": "delete"}, {"after_end": 22, "after_start": 22, "before_end": 21, "before_start": 19, "kind": "delete"}, {"after_end": 23, "after_start": 23, "before_end": 23, "before_start": 22, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 8, "chars_inserted": 8}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-8674eefe9538f4f1efe4aa7f", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002097", "medicine_name": "Fampyra", "medicine_slug": "fampyra", "observed_at": "2026-10-12T19:15:51Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "d9fe8aaaa611a84801d6308b13685258b5248df9022536697939afdf66fc1719", "source_snapshot_id": "source-ff8e0599077f0d01044dc867", "source_updated_at": "2025-08-21", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/fampyra-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1415}
{"after": {"end": 70, "start": 0, "text": "Réactions d’hypersensibilité généralisées incluant l’œdème de Quincke*", "truncated": false}, "after_length": 70, "after_sha256": "6ea63e1e60e6f8b5de819f7146d11464728d9191d81ca8a6579aab54c47dd648", "annex": "I", "before": {"end": 16, "start": 0, "text": "Œdème de Quincke", "truncated": false}, "before_length": 16, "before_sha256": "b8d48c3260ed7fc1ddfe0761e62377846018ea8bfa63994517e465d1df19a27f", "change_kind": "content", "change_operations": [{"after_end": 54, "after_start": 0, "before_end": 1, "before_start": 0, "kind": "replace"}, {"after_end": 70, "after_start": 69, "before_end": 16, "before_start": 16, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": true, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 1, "chars_inserted": 55}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-86c6227a9b23b8d07b53de98", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/000554", "medicine_name": "Emselex", "medicine_slug": "emselex", "observed_at": "2026-10-12T19:12:07Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": null, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "4.8", "section_type": "adverse_reactions", "source_provider": "European Medicines Agency", "source_sha256": "9a4f1d7e260c7b80eaf397503623b63302e5945b579e9612177835e07c4ab888", "source_snapshot_id": "source-3aac7bf42b99529f25ac013b", "source_updated_at": "2025-09-15", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/emselex-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 632}
{"after": {"end": 27, "start": 0, "text": "CPO Pharmaceuticals Limited", "truncated": false}, "after_length": 27, "after_sha256": "94b644443752e2cb52916b23f8141fbd44c47055b3416af333e12ac18e101b87", "annex": "IIIA", "before": {"end": 23, "start": 0, "text": "GPA Pharmaceuticals Ltd", "truncated": false}, "before_length": 23, "before_sha256": "ece7127e303c91e9501d2cedd822476265aae86acb9f96ef1553ab3a6954afe1", "change_kind": "content", "change_operations": [{"after_end": 1, "after_start": 0, "before_end": 1, "before_start": 0, "kind": "replace"}, {"after_end": 3, "after_start": 2, "before_end": 3, "before_start": 2, "kind": "replace"}, {"after_end": 24, "after_start": 21, "before_end": 21, "before_start": 21, "kind": "insert"}, {"after_end": 26, "after_start": 25, "before_end": 22, "before_start": 22, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 2, "chars_inserted": 6}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-87154024eaeed2921f4f1f97", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/004025", "medicine_name": "Lopinavir/Ritonavir Viatris (previously Ritonavir Mylan)", "medicine_slug": "lopinavir-ritonavir-viatris-previously-ritonavir-mylan", "observed_at": "2026-10-12T19:12:46Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "3e30663f02732816ed8779d7a929d500c824ae15aeaee9144ca6eef11900e273", "source_snapshot_id": "source-c58e019b5bec1fb24569e83e", "source_updated_at": "2025-09-08", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/lopinavir-ritonavir-viatris-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 3079}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 23, "start": 0, "text": "Tel: +353 (0)1 231 4609", "truncated": false}, "before_length": 23, "before_sha256": "a115f11f382ef18898b9d956e48603ae236fd1846ce41e8586af99b6dabbfc4d", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 23, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 23, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-87228cf01cb192b5a23b1a09", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002097", "medicine_name": "Fampyra", "medicine_slug": "fampyra", "observed_at": "2026-10-12T19:15:51Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "d9fe8aaaa611a84801d6308b13685258b5248df9022536697939afdf66fc1719", "source_snapshot_id": "source-ff8e0599077f0d01044dc867", "source_updated_at": "2025-08-21", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/fampyra-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1352}
{"after": {"end": 25, "start": 0, "text": "Eurocept International BV", "truncated": false}, "after_length": 25, "after_sha256": "b17bd89b3cf285c986a6070d0d67f5326dd5c1f08a70834c296c6c820f9e7505", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 25, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 25}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-8727fa0f16c69c41ec03c73d", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:19Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "77586d0bea0858214b43b86e91abc2d2711733b96959ead5ed0b5ecbd8ed888a", "source_snapshot_id": "source-85d476f9ad959cc117ca8f1f", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1785}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIB", "before": {"end": 16, "start": 0, "text": "Extrovis EU Ltd.", "truncated": false}, "before_length": 16, "before_sha256": "f462ad48e7aef0bc82148ce088af1897d99ed86993128f30d506b27d3108a929", "change_kind": "unassigned", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 16, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 16, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-87363c3a999ce63fffd6be88", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/006047", "medicine_name": "Lacosamide Adroiq", "medicine_slug": "lacosamide-adroiq", "observed_at": "2026-10-12T19:07:56Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "", "section_type": "unassigned", "source_provider": "European Medicines Agency", "source_sha256": "0578c53a5e1c785c4d9d4dc0dabae49dbfa89e237aa571556bee548c3f9cf4d5", "source_snapshot_id": "source-64831dec5ebf55535e19d91b", "source_updated_at": "2025-09-25", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/lacosamide-adroiq-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1992}
{"after": {"end": 22, "start": 0, "text": "Merz Therapeutics GmbH", "truncated": false}, "after_length": 22, "after_sha256": "059f049c7d0846aaadcf2573280d52110f302d4ecc7b38debd004571cd1e9d5e", "annex": "IIIA", "before": {"end": 35, "start": 0, "text": "Acorda Therapeutics Ireland Limited", "truncated": false}, "before_length": 35, "before_sha256": "d94d3153d193ed26567f2b4ed48df016d81c534e7c0cb1a6655a63f0083383ff", "change_kind": "content", "change_operations": [{"after_end": 2, "after_start": 0, "before_end": 3, "before_start": 0, "kind": "replace"}, {"after_end": 4, "after_start": 3, "before_end": 6, "before_start": 4, "kind": "replace"}, {"after_end": 19, "after_start": 18, "before_end": 30, "before_start": 20, "kind": "replace"}, {"after_end": 22, "after_start": 20, "before_end": 35, "before_start": 31, "kind": "replace"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 19, "chars_inserted": 6}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-877be27fe93c32ffa74b7092", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002097", "medicine_name": "Fampyra", "medicine_slug": "fampyra", "observed_at": "2026-10-12T19:16:07Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "a0c3ba8d58d6a43a809ecc3d142a78b10c2bd7f0b9f3a3553df2617d87daec1f", "source_snapshot_id": "source-c7a810dd21f94cd2d273f0da", "source_updated_at": "2025-08-21", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/fampyra-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 897}
{"after": {"end": 23, "start": 0, "text": "60318 Frankfurt am Main", "truncated": false}, "after_length": 23, "after_sha256": "24c3191b5088b20c209c4387a8127297e54c776e161d305c9e57956a13b7cbbe", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 23, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 23}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-879f36dcaf8cdd5dfe0ce8e6", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002097", "medicine_name": "Fampyra", "medicine_slug": "fampyra", "observed_at": "2026-10-12T19:16:07Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "a0c3ba8d58d6a43a809ecc3d142a78b10c2bd7f0b9f3a3553df2617d87daec1f", "source_snapshot_id": "source-c7a810dd21f94cd2d273f0da", "source_updated_at": "2025-08-21", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/fampyra-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1511}
{"after": {"end": 8, "start": 0, "text": "Γερμανία", "truncated": false}, "after_length": 8, "after_sha256": "bfec9f93122249c327451f277e22c198da0ea7dab804bbd84f5bf35170f7eb40", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 8, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 8}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-87fccfd9ad9bbd08bd2aa9e4", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002097", "medicine_name": "Fampyra", "medicine_slug": "fampyra", "observed_at": "2026-10-12T19:16:07Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "a0c3ba8d58d6a43a809ecc3d142a78b10c2bd7f0b9f3a3553df2617d87daec1f", "source_snapshot_id": "source-c7a810dd21f94cd2d273f0da", "source_updated_at": "2025-08-21", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/fampyra-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1491}
{"after": {"end": 36, "start": 0, "text": "Accord Healthcare Single Member S.A.", "truncated": false}, "after_length": 36, "after_sha256": "b46201b7d0efe1b953d755aa025769e26c5374f0fb886ee6f67efa377121db82", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 36, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 36}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-8807fabe47b37ab4f5feed8b", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/003984", "medicine_name": "Bortezomib Accord", "medicine_slug": "bortezomib-accord", "observed_at": "2026-10-12T13:47:15Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "150a191aaf0a1e169e9d5fa2530f0eccb4e3d46509faf5ec5ee975a2e67788c4", "source_snapshot_id": "source-cba4680b7fbd2c536884abd8", "source_updated_at": "2026-03-25", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/bortezomib-accord-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 4296}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 21, "start": 0, "text": "info@lucanepharma.com", "truncated": false}, "before_length": 21, "before_sha256": "44fd39e5fb919cb3d680fa630da23b49238fec29159c509f3622f272bb41c7c6", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 21, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 21, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-882a06ce656c6c1c2218e21a", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:19Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "77586d0bea0858214b43b86e91abc2d2711733b96959ead5ed0b5ecbd8ed888a", "source_snapshot_id": "source-85d476f9ad959cc117ca8f1f", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1998}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 9, "start": 0, "text": "L-Irlanda", "truncated": false}, "before_length": 9, "before_sha256": "5eb0ac67738a7e0d70fbddb7744faafd60a4efdf5e93e46fca1bc519d14e757b", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 9, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 9, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-88f37ce78485200be6bbc432", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002097", "medicine_name": "Fampyra", "medicine_slug": "fampyra", "observed_at": "2026-10-12T19:15:51Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "d9fe8aaaa611a84801d6308b13685258b5248df9022536697939afdf66fc1719", "source_snapshot_id": "source-ff8e0599077f0d01044dc867", "source_updated_at": "2025-08-21", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/fampyra-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1439}
{"after": {"end": 16, "start": 0, "text": "imed@imed.com.pl", "truncated": false}, "after_length": 16, "after_sha256": "ea84c1c4a48b3783f0be9b72cd284be4ace13bfe979d55d22fedbadbb0b4aff0", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 16, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 16}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-89122df89e0052e31dd0b10c", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:14Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "8b8c4cc8e6f1a21fedee4bf0743c9c03e454b50f5eaba0e3760416d7fe0a74ec", "source_snapshot_id": "source-4efe4ecf3ebf08d338a763a5", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1536}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 18, "start": 0, "text": "Dublin 2, D02 T380", "truncated": false}, "before_length": 18, "before_sha256": "23e6871e7960b0dadc753bc127bbea230cc8308c88b2d33704eb275a3ec1a70d", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 18, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 18, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-891e73729f4603fc703074e7", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002097", "medicine_name": "Fampyra", "medicine_slug": "fampyra", "observed_at": "2026-10-12T19:15:51Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "d9fe8aaaa611a84801d6308b13685258b5248df9022536697939afdf66fc1719", "source_snapshot_id": "source-ff8e0599077f0d01044dc867", "source_updated_at": "2025-08-21", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/fampyra-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 894}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 21, "start": 0, "text": "info@lucanepharma.com", "truncated": false}, "before_length": 21, "before_sha256": "44fd39e5fb919cb3d680fa630da23b49238fec29159c509f3622f272bb41c7c6", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 21, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 21, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-898cf6cf79ed53c750badc9e", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:19Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "77586d0bea0858214b43b86e91abc2d2711733b96959ead5ed0b5ecbd8ed888a", "source_snapshot_id": "source-85d476f9ad959cc117ca8f1f", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1884}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIB", "before": {"end": 16, "start": 0, "text": "Extrovis EU Ltd.", "truncated": false}, "before_length": 16, "before_sha256": "f462ad48e7aef0bc82148ce088af1897d99ed86993128f30d506b27d3108a929", "change_kind": "unassigned", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 16, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 16, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-898f57a1f33b4a2b38ed08c9", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/006047", "medicine_name": "Lacosamide Adroiq", "medicine_slug": "lacosamide-adroiq", "observed_at": "2026-10-12T19:07:56Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "", "section_type": "unassigned", "source_provider": "European Medicines Agency", "source_sha256": "0578c53a5e1c785c4d9d4dc0dabae49dbfa89e237aa571556bee548c3f9cf4d5", "source_snapshot_id": "source-64831dec5ebf55535e19d91b", "source_updated_at": "2025-09-25", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/lacosamide-adroiq-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1877}
{"after": {"end": 122, "start": 0, "text": "Having reviewed the PRAC recommendation, the CHMP agrees with the PRAC overall conclusions and grounds for recommendation.", "truncated": false}, "after_length": 122, "after_sha256": "095a3b724a58255112d0ae23e9c65e77959b40571fcaaf1946c9da9f699beeda", "annex": "IV", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 122, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 122}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-899356c492779f3535716c3c", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/000554", "medicine_name": "Emselex", "medicine_slug": "emselex", "observed_at": "2026-10-12T19:12:04Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "conditions", "section_type": "conditions", "source_provider": "European Medicines Agency", "source_sha256": "4f2565612bc728ec67b7f9c0cd5799ef2c594911c76f323aef8bf6a85adde245", "source_snapshot_id": "source-1fda25b331eb198b8b93feb3", "source_updated_at": "2025-09-15", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/emselex-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 2083}
{"after": {"end": 37, "start": 0, "text": "Accord Healthcare single member S.A.,", "truncated": false}, "after_length": 37, "after_sha256": "752db38ded53417be77ebcd9ac87192289314f53aaa486d956ca57b89edd2bea", "annex": "II", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 37, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 37}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-8a09908c0e2bd329ae0b1671", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/003984", "medicine_name": "Bortezomib Accord", "medicine_slug": "bortezomib-accord", "observed_at": "2026-10-12T13:47:12Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "conditions", "section_type": "conditions", "source_provider": "European Medicines Agency", "source_sha256": "e4aac937241121e8ad1e32b40b1007fb58398035928568a7e60a65074b0efb36", "source_snapshot_id": "source-b1eaab6445cfa827e3b1481b", "source_updated_at": "2026-03-25", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/bortezomib-accord-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 3283}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 22, "start": 0, "text": "Tel : +31 35 528 39 57", "truncated": false}, "before_length": 22, "before_sha256": "7bb8afadf5dee15b4f4e1219e333b993040f0848bccea58b1141990fffb82aa1", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 22, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 22, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-8a11867ae27bc2c79e912df1", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:19Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "77586d0bea0858214b43b86e91abc2d2711733b96959ead5ed0b5ecbd8ed888a", "source_snapshot_id": "source-85d476f9ad959cc117ca8f1f", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1831}
{"after": {"end": 23, "start": 0, "text": "info@euroceptpharma.com", "truncated": false}, "after_length": 23, "after_sha256": "9297cc5acdcc837f054116992765943f7907937507b2564a99ea1327a00ac0e6", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 23, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 23}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-8a61c73fdd09314b1ca329ec", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:19Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "77586d0bea0858214b43b86e91abc2d2711733b96959ead5ed0b5ecbd8ed888a", "source_snapshot_id": "source-85d476f9ad959cc117ca8f1f", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1819}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 13, "start": 0, "text": "Lucane Pharma", "truncated": false}, "before_length": 13, "before_sha256": "e338afdb64acf1a6e2083a50318853589248451dd3aa707181ba02641a8521e8", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 13, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 13, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-8a64101f66199d90b39dd65d", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:19Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "77586d0bea0858214b43b86e91abc2d2711733b96959ead5ed0b5ecbd8ed888a", "source_snapshot_id": "source-85d476f9ad959cc117ca8f1f", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1488}
{"after": {"end": 21, "start": 0, "text": "Tel: +31 35 528 39 57", "truncated": false}, "after_length": 21, "after_sha256": "7baf6601f41e49e470f803fdd4e755a86efa38be423317c000ed79963ebdd213", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 21, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 21}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-8ab0cd07daae84ef1fe56a68", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:19Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "77586d0bea0858214b43b86e91abc2d2711733b96959ead5ed0b5ecbd8ed888a", "source_snapshot_id": "source-85d476f9ad959cc117ca8f1f", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1413}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 20, "start": 0, "text": "10 Earlsfort Terrace", "truncated": false}, "before_length": 20, "before_sha256": "22951bbf6ee77815d0c07b3af5f0a66e17d277636971c4eaff372dea65dcb193", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 20, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 20, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-8b52eea5a4b7154afa986f64", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002097", "medicine_name": "Fampyra", "medicine_slug": "fampyra", "observed_at": "2026-10-12T19:15:51Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "d9fe8aaaa611a84801d6308b13685258b5248df9022536697939afdf66fc1719", "source_snapshot_id": "source-ff8e0599077f0d01044dc867", "source_updated_at": "2025-08-21", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/fampyra-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1437}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 13, "start": 0, "text": "Lucane Pharma", "truncated": false}, "before_length": 13, "before_sha256": "e338afdb64acf1a6e2083a50318853589248451dd3aa707181ba02641a8521e8", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 13, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 13, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-8b611d70c1ebadc3b66748b3", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:14Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "8b8c4cc8e6f1a21fedee4bf0743c9c03e454b50f5eaba0e3760416d7fe0a74ec", "source_snapshot_id": "source-4efe4ecf3ebf08d338a763a5", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1991}
{"after": {"end": 21, "start": 0, "text": "Tel: +31 35 528 39 57", "truncated": false}, "after_length": 21, "after_sha256": "7baf6601f41e49e470f803fdd4e755a86efa38be423317c000ed79963ebdd213", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 21, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 21}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-8b6fb1e9a4436b1854a8ccce", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:14Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "8b8c4cc8e6f1a21fedee4bf0743c9c03e454b50f5eaba0e3760416d7fe0a74ec", "source_snapshot_id": "source-4efe4ecf3ebf08d338a763a5", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1591}
{"after": {"end": 21, "start": 0, "text": "Tel: +31 35 528 39 57", "truncated": false}, "after_length": 21, "after_sha256": "7baf6601f41e49e470f803fdd4e755a86efa38be423317c000ed79963ebdd213", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 21, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 21}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-8b72f49b2034e1a48c9b87f1", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:19Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "77586d0bea0858214b43b86e91abc2d2711733b96959ead5ed0b5ecbd8ed888a", "source_snapshot_id": "source-85d476f9ad959cc117ca8f1f", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1380}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "I", "before": {"end": 12, "start": 0, "text": "52078 Aachen", "truncated": false}, "before_length": 12, "before_sha256": "1475580660011b5e5dfa9a59bc8bd0d29441e95b38b37c8e74cd2bb2e32158de", "change_kind": "administrative", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 12, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 12, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-8ba7346f5c771178606257d1", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/005246", "medicine_name": "Byfavo", "medicine_slug": "byfavo", "observed_at": "2026-10-12T13:28:16Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "7", "section_type": "administrative", "source_provider": "European Medicines Agency", "source_sha256": "61243a969f979f690fe718e414ceaeb66438c1faa31101ba25187d2f9ea662fd", "source_snapshot_id": "source-dd26eb8615d8c18bd80c1f6a", "source_updated_at": "2026-08-26", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/byfavo-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 2711}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 7, "start": 0, "text": "Iirimaa", "truncated": false}, "before_length": 7, "before_sha256": "d2823304b98ff33bc049d03ecb5f62b2d904970e9af20cabc6d9cd21fa70e6b5", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 7, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 7, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-8bba352969ab7579b26252f9", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002097", "medicine_name": "Fampyra", "medicine_slug": "fampyra", "observed_at": "2026-10-12T19:16:07Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "a0c3ba8d58d6a43a809ecc3d142a78b10c2bd7f0b9f3a3553df2617d87daec1f", "source_snapshot_id": "source-c7a810dd21f94cd2d273f0da", "source_updated_at": "2025-08-21", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/fampyra-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1470}
{"after": {"end": 34, "start": 0, "text": "Orteliuslaan 1000, 3528 BD Utrecht", "truncated": false}, "after_length": 34, "after_sha256": "46a90fc46ae308c2beeb35ead613fcf3ade5a51e2217a834de3fa5972dab9eec", "annex": "I", "before": {"end": 34, "start": 0, "text": "Papendorpseweg 83, 3528 BJ Utrecht", "truncated": false}, "before_length": 34, "before_sha256": "60888004fee306d543204a2a97b5d75a5110dd00a9886110b9dbc8d4fba5db60", "change_kind": "administrative", "change_operations": [{"after_end": 9, "after_start": 0, "before_end": 1, "before_start": 0, "kind": "replace"}, {"after_end": 11, "after_start": 10, "before_end": 4, "before_start": 2, "kind": "replace"}, {"after_end": 12, "after_start": 12, "before_end": 14, "before_start": 5, "kind": "delete"}, {"after_end": 17, "after_start": 13, "before_end": 17, "before_start": 15, "kind": "replace"}, {"after_end": 26, "after_start": 25, "before_end": 26, "before_start": 25, "kind": "replace"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 15, "chars_inserted": 15}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-8bbe241d9a0b065113e72826", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/001021", "medicine_name": "Adcirca (previously Tadalafil Lilly)", "medicine_slug": "adcirca-previously-tadalafil-lilly", "observed_at": "2026-10-12T19:02:45Z", "pipeline_version": "2.0.0", "presentation_label": "ADCIRCA 20 mg comprimés pelliculés", "presentation_occurrence": 1, "presentation_status": "heading_extracted_unverified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "7", "section_type": "administrative", "source_provider": "European Medicines Agency", "source_sha256": "cdbefcd6143c93e81f3c826bea8d3d01bffc55652e0f792243097df75c452721", "source_snapshot_id": "source-a1e85476de17f5a8664f7766", "source_updated_at": "2026-01-28", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/adcirca-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 608}
{"after": {"end": 16, "start": 0, "text": "Extrovis EU Kft.", "truncated": false}, "after_length": 16, "after_sha256": "b9216ef80e71e17798dce313e4318f03f37328f225d30ab508b7413813a908e5", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 16, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 16}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-8bcd930ff31d258bafee3a50", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/006047", "medicine_name": "Lacosamide Adroiq", "medicine_slug": "lacosamide-adroiq", "observed_at": "2026-10-12T19:07:59Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "cc83d966059d42856d0211a4f256b29b20d43593865704d6a9315aeb694f3c76", "source_snapshot_id": "source-896abba1d8391c918345d46b", "source_updated_at": "2025-09-25", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/lacosamide-adroiq-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1815}
{"after": {"end": 25, "start": 0, "text": "Eurocept International BV", "truncated": false}, "after_length": 25, "after_sha256": "b17bd89b3cf285c986a6070d0d67f5326dd5c1f08a70834c296c6c820f9e7505", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 25, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 25}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-8bd9d327d24f1ea5d3f5d2a2", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:19Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "77586d0bea0858214b43b86e91abc2d2711733b96959ead5ed0b5ecbd8ed888a", "source_snapshot_id": "source-85d476f9ad959cc117ca8f1f", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1524}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 13, "start": 0, "text": "Lucane Pharma", "truncated": false}, "before_length": 13, "before_sha256": "e338afdb64acf1a6e2083a50318853589248451dd3aa707181ba02641a8521e8", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 13, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 13, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-8bde6ffbf82f4f5241d488d5", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:14Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "8b8c4cc8e6f1a21fedee4bf0743c9c03e454b50f5eaba0e3760416d7fe0a74ec", "source_snapshot_id": "source-4efe4ecf3ebf08d338a763a5", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1450}
{"after": {"end": 23, "start": 0, "text": "info@euroceptpharma.com", "truncated": false}, "after_length": 23, "after_sha256": "9297cc5acdcc837f054116992765943f7907937507b2564a99ea1327a00ac0e6", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 23, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 23}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-8c2047e13e20554a3b0e1a4b", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:19Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "77586d0bea0858214b43b86e91abc2d2711733b96959ead5ed0b5ecbd8ed888a", "source_snapshot_id": "source-85d476f9ad959cc117ca8f1f", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1994}
{"after": {"end": 109, "start": 0, "text": "Marketing Authorisation Holder: Eli Lilly Nederland B.V., Orteliuslaan 1000, 3528 BD Utrecht, The Netherlands", "truncated": false}, "after_length": 109, "after_sha256": "60a228fbf1ec2f19e615c9b676c9dff75b4935be8aadcdbe4902c014b861d939", "annex": "IIIA", "before": {"end": 109, "start": 0, "text": "Marketing Authorisation Holder: Eli Lilly Nederland B.V., Papendorpseweg 83, 3528 BJ Utrecht, The Netherlands", "truncated": false}, "before_length": 109, "before_sha256": "500ff14606beaa924e6e2a258711fcdf39978fdda94be513851db6b0a3356ccd", "change_kind": "administrative", "change_operations": [{"after_end": 67, "after_start": 58, "before_end": 59, "before_start": 58, "kind": "replace"}, {"after_end": 69, "after_start": 68, "before_end": 62, "before_start": 60, "kind": "replace"}, {"after_end": 70, "after_start": 70, "before_end": 72, "before_start": 63, "kind": "delete"}, {"after_end": 75, "after_start": 71, "before_end": 75, "before_start": 73, "kind": "replace"}, {"after_end": 84, "after_start": 83, "before_end": 84, "before_start": 83, "kind": "replace"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 15, "chars_inserted": 15}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-8c622685f9ef1a8b99af7e76", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/001021", "medicine_name": "Adcirca (previously Tadalafil Lilly)", "medicine_slug": "adcirca-previously-tadalafil-lilly", "observed_at": "2026-10-12T19:02:42Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "43438c8e53504a78747a8ff36049250fee294557f3a8b0e3acb80f71ad43ebc0", "source_snapshot_id": "source-2305a67bd1e393ee340bb8e4", "source_updated_at": "2026-01-28", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/adcirca-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1919}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 18, "start": 0, "text": "Dublin 2, D02 T380", "truncated": false}, "before_length": 18, "before_sha256": "23e6871e7960b0dadc753bc127bbea230cc8308c88b2d33704eb275a3ec1a70d", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 18, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 18, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-8caa02e0e6a175667630f0bf", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002097", "medicine_name": "Fampyra", "medicine_slug": "fampyra", "observed_at": "2026-10-12T19:15:51Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "d9fe8aaaa611a84801d6308b13685258b5248df9022536697939afdf66fc1719", "source_snapshot_id": "source-ff8e0599077f0d01044dc867", "source_updated_at": "2025-08-21", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/fampyra-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1525}
{"after": {"end": 122, "start": 0, "text": "Titulaire de l'Autorisation de mise sur le marché : Eli Lilly Nederland B.V., Orteliuslaan 1000, 3528 BD Utrecht, Pays-Bas", "truncated": false}, "after_length": 122, "after_sha256": "ade372096524673477bf185c16b219229849746d0f4e8be16cf963ceff153934", "annex": "III", "before": {"end": 122, "start": 0, "text": "Titulaire de l'Autorisation de mise sur le marché : Eli Lilly Nederland B.V., Papendorpseweg 83, 3528 BJ Utrecht, Pays-Bas", "truncated": false}, "before_length": 122, "before_sha256": "7d63b7a6b8d5b2c667555505f5fa293d8d6b61d71e39f5840690b997eb1f6fb5", "change_kind": "administrative", "change_operations": [{"after_end": 87, "after_start": 78, "before_end": 79, "before_start": 78, "kind": "replace"}, {"after_end": 89, "after_start": 88, "before_end": 82, "before_start": 80, "kind": "replace"}, {"after_end": 90, "after_start": 90, "before_end": 92, "before_start": 83, "kind": "delete"}, {"after_end": 95, "after_start": 91, "before_end": 95, "before_start": 93, "kind": "replace"}, {"after_end": 104, "after_start": 103, "before_end": 104, "before_start": 103, "kind": "replace"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 15, "chars_inserted": 15}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-8cd0042095e5300efa51dcc9", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/001021", "medicine_name": "Adcirca (previously Tadalafil Lilly)", "medicine_slug": "adcirca-previously-tadalafil-lilly", "observed_at": "2026-10-12T19:02:45Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "", "section_type": "unassigned", "source_provider": "European Medicines Agency", "source_sha256": "cdbefcd6143c93e81f3c826bea8d3d01bffc55652e0f792243097df75c452721", "source_snapshot_id": "source-a1e85476de17f5a8664f7766", "source_updated_at": "2026-01-28", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/adcirca-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 2208}
{"after": {"end": 22, "start": 0, "text": "Merz Therapeutics GmbH", "truncated": false}, "after_length": 22, "after_sha256": "059f049c7d0846aaadcf2573280d52110f302d4ecc7b38debd004571cd1e9d5e", "annex": "IIIA", "before": {"end": 35, "start": 0, "text": "Acorda Therapeutics Ireland Limited", "truncated": false}, "before_length": 35, "before_sha256": "d94d3153d193ed26567f2b4ed48df016d81c534e7c0cb1a6655a63f0083383ff", "change_kind": "content", "change_operations": [{"after_end": 2, "after_start": 0, "before_end": 3, "before_start": 0, "kind": "replace"}, {"after_end": 4, "after_start": 3, "before_end": 6, "before_start": 4, "kind": "replace"}, {"after_end": 19, "after_start": 18, "before_end": 30, "before_start": 20, "kind": "replace"}, {"after_end": 22, "after_start": 20, "before_end": 35, "before_start": 31, "kind": "replace"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 19, "chars_inserted": 6}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-8cf2565dc86ed3507034c370", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002097", "medicine_name": "Fampyra", "medicine_slug": "fampyra", "observed_at": "2026-10-12T19:15:51Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "d9fe8aaaa611a84801d6308b13685258b5248df9022536697939afdf66fc1719", "source_snapshot_id": "source-ff8e0599077f0d01044dc867", "source_updated_at": "2025-08-21", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/fampyra-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1533}
{"after": {"end": 23, "start": 0, "text": "60318 Frankfurt am Main", "truncated": false}, "after_length": 23, "after_sha256": "24c3191b5088b20c209c4387a8127297e54c776e161d305c9e57956a13b7cbbe", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 23, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 23}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-8d8eb3dc8c4992c9b8596f7d", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002097", "medicine_name": "Fampyra", "medicine_slug": "fampyra", "observed_at": "2026-10-12T19:16:07Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "a0c3ba8d58d6a43a809ecc3d142a78b10c2bd7f0b9f3a3553df2617d87daec1f", "source_snapshot_id": "source-c7a810dd21f94cd2d273f0da", "source_updated_at": "2025-08-21", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/fampyra-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1447}
{"after": {"end": 644, "start": 0, "text": "Myositis and /or rhabdomyolysis have been reported in patients treated with leflunomide, frequently in combination with other immunosuppressive drugs. Clinical symptoms may include unexplained muscle pain, tenderness or muscle weakness. Patients should be informed about the signs and symptoms associated with myositis and rhabdomyolysis and advised to seek medical attention immediately if such symptoms occur during leflunomide treatment. Monitor the patients for elevation of CK levels if clinically indicated. If patients develop any of these conditions, leflunomide must be discontinued and a washout procedure initiated (see section 4.4).", "truncated": false}, "after_length": 644, "after_sha256": "54416fa80b2720b6142b9cb375a3b6e04c26b8a363a88b57c6bfcd4d9d1e672b", "annex": "I", "before": {"end": 135, "start": 0, "text": "Myopathy muscle injury has with leflunomide treatment. Follow-up with patients periodically for muscle pain and weakness. as necessary.", "truncated": false}, "before_length": 135, "before_sha256": "a9c5aa43249002e83964883b90965cb0316721089889783990eedc99707d282f", "change_kind": "content", "change_operations": [{"after_end": 54, "after_start": 3, "before_end": 3, "before_start": 3, "kind": "insert"}, {"after_end": 74, "after_start": 57, "before_end": 6, "before_start": 6, "kind": "insert"}, {"after_end": 98, "after_start": 75, "before_end": 7, "before_start": 7, "kind": "insert"}, {"after_end": 192, "after_start": 99, "before_end": 8, "before_start": 8, "kind": "insert"}, {"after_end": 202, "after_start": 200, "before_end": 16, "before_start": 16, "kind": "insert"}, {"after_end": 221, "after_start": 204, "before_end": 19, "before_start": 18, "kind": "replace"}, {"after_end": 260, "after_start": 222, "before_end": 20, "before_start": 20, "kind": "insert"}, {"after_end": 286, "after_start": 261, "before_end": 21, "before_start": 21, "kind": "insert"}, {"after_end": 293, "after_start": 287, "before_end": 22, "before_start": 22, "kind": "insert"}, {"after_end": 294, "after_start": 294, "before_end": 24, "before_start": 23, "kind": "delete"}, {"after_end": 304, "after_start": 296, "before_end": 26, "before_start": 26, "kind": "insert"}, {"after_end": 417, "after_start": 309, "before_end": 31, "before_start": 31, "kind": "insert"}, {"after_end": 442, "after_start": 441, "before_end": 56, "before_start": 55, "kind": "replace"}, {"after_end": 444, "after_start": 443, "before_end": 66, "before_start": 57, "kind": "replace"}, {"after_end": 450, "after_start": 446, "before_end": 68, "before_start": 68, "kind": "insert"}, {"after_end": 452, "after_start": 451, "before_end": 69, "before_start": 69, "kind": "insert"}, {"after_end": 466, "after_start": 462, "before_end": 80, "before_start": 79, "kind": "replace"}, {"after_end": 472, "after_start": 467, "before_end": 82, "before_start": 81, "kind": "replace"}, {"after_end": 496, "after_start": 474, "before_end": 85, "before_start": 84, "kind": "replace"}, {"after_end": 515, "after_start": 503, "before_end": 92, "before_start": 92, "kind": "insert"}, {"after_end": 531, "after_start": 516, "before_end": 93, "before_start": 93, "kind": "insert"}, {"after_end": 570, "after_start": 532, "before_end": 95, "before_start": 94, "kind": "replace"}, {"after_end": 577, "after_start": 574, "before_end": 101, "before_start": 99, "kind": "replace"}, {"after_end": 586, "after_start": 579, "before_end": 105, "before_start": 103, "kind": "replace"}, {"after_end": 591, "after_start": 588, "before_end": 107, "before_start": 107, "kind": "insert"}, {"after_end": 598, "after_start": 596, "before_end": 112, "before_start": 112, "kind": "insert"}, {"after_end": 599, "after_start": 599, "before_end": 122, "before_start": 113, "kind": "delete"}, {"after_end": 605, "after_start": 601, "before_end": 124, "before_start": 124, "kind": "insert"}, {"after_end": 617, "after_start": 606, "before_end": 125, "before_start": 125, "kind": "insert"}, {"after_end": 632, "after_start": 618, "before_end": 126, "before_start": 126, "kind": "insert"}, {"after_end": 643, "after_start": 634, "before_end": 134, "before_start": 128, "kind": "replace"}], "classification_method": "documentary_rules_v2", "clinical_candidate": true, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 35, "chars_inserted": 544}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-8dc59932b5614372e476870b", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/000235", "medicine_name": "Arava", "medicine_slug": "arava", "observed_at": "2026-10-12T13:27:58Z", "pipeline_version": "2.0.0", "presentation_label": "Arava 20 mg film-coated tablets", "presentation_occurrence": 2, "presentation_status": "heading_extracted_unverified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "4.4", "section_type": "warning", "source_provider": "European Medicines Agency", "source_sha256": "2efff7967e2237bf8343431eef5e08b56c2441eb8a691a90c64b2635109fd697", "source_snapshot_id": "source-08b4eba1f67d2654148f41c4", "source_updated_at": "2026-09-07", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/arava-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 749}
{"after": {"end": 26, "start": 0, "text": "Eckenheimer Landstraße 100", "truncated": false}, "after_length": 26, "after_sha256": "fdce1a9bd200c5ddd476c1ea5676b9ffbbea723f7353ad6fbc1fe019dcb86c07", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 26, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 26}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-8dcedaa78c3d8b970e9a0187", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002097", "medicine_name": "Fampyra", "medicine_slug": "fampyra", "observed_at": "2026-10-12T19:16:07Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "a0c3ba8d58d6a43a809ecc3d142a78b10c2bd7f0b9f3a3553df2617d87daec1f", "source_snapshot_id": "source-c7a810dd21f94cd2d273f0da", "source_updated_at": "2025-08-21", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/fampyra-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1510}
{"after": {"end": 12, "start": 0, "text": "Виатрис ЕООД", "truncated": false}, "after_length": 12, "after_sha256": "92f9a32247d19bdb1e65df1219954c43f6ad757cc355e8022e7566c35de78f1a", "annex": "IIIA", "before": {"end": 11, "start": 0, "text": "Майлан ЕООД", "truncated": false}, "before_length": 11, "before_sha256": "5770366f858d91109bdad7a5551dc97b9878455f55713851de8277df30093b62", "change_kind": "content", "change_operations": [{"after_end": 2, "after_start": 0, "before_end": 1, "before_start": 0, "kind": "replace"}, {"after_end": 7, "after_start": 3, "before_end": 6, "before_start": 2, "kind": "replace"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 5, "chars_inserted": 6}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-8ddd77376013d74670491fc4", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/000403", "medicine_name": "Arixtra", "medicine_slug": "arixtra", "observed_at": "2026-10-12T13:38:50Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": null, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "123deb3dbdc841a7adc2b8046138993b8a6a1c228bde13a95278b14d17c5cefd", "source_snapshot_id": "source-79bede7a4a9cd1c040f622e0", "source_updated_at": "2026-05-07", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/arixtra-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 4202}
{"after": {"end": 16, "start": 0, "text": "Extrovis EU Kft.", "truncated": false}, "after_length": 16, "after_sha256": "b9216ef80e71e17798dce313e4318f03f37328f225d30ab508b7413813a908e5", "annex": "IIIB", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "unassigned", "change_operations": [{"after_end": 16, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 16}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-8de50ca1b398523a1ed957c7", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/006047", "medicine_name": "Lacosamide Adroiq", "medicine_slug": "lacosamide-adroiq", "observed_at": "2026-10-12T19:07:56Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "", "section_type": "unassigned", "source_provider": "European Medicines Agency", "source_sha256": "0578c53a5e1c785c4d9d4dc0dabae49dbfa89e237aa571556bee548c3f9cf4d5", "source_snapshot_id": "source-64831dec5ebf55535e19d91b", "source_updated_at": "2025-09-25", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/lacosamide-adroiq-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1941}
{"after": {"end": 26, "start": 0, "text": "Eckenheimer Landstraße 100", "truncated": false}, "after_length": 26, "after_sha256": "fdce1a9bd200c5ddd476c1ea5676b9ffbbea723f7353ad6fbc1fe019dcb86c07", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 26, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 26}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-8de78cafa35d22da68446142", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002097", "medicine_name": "Fampyra", "medicine_slug": "fampyra", "observed_at": "2026-10-12T19:16:07Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "a0c3ba8d58d6a43a809ecc3d142a78b10c2bd7f0b9f3a3553df2617d87daec1f", "source_snapshot_id": "source-c7a810dd21f94cd2d273f0da", "source_updated_at": "2025-08-21", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/fampyra-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1418}
{"after": {"end": 16, "start": 0, "text": "Extrovis EU Kft.", "truncated": false}, "after_length": 16, "after_sha256": "b9216ef80e71e17798dce313e4318f03f37328f225d30ab508b7413813a908e5", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 16, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 16}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-8df08013873797f4ff064da6", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/006047", "medicine_name": "Lacosamide Adroiq", "medicine_slug": "lacosamide-adroiq", "observed_at": "2026-10-12T19:07:59Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "cc83d966059d42856d0211a4f256b29b20d43593865704d6a9315aeb694f3c76", "source_snapshot_id": "source-896abba1d8391c918345d46b", "source_updated_at": "2025-09-25", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/lacosamide-adroiq-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1737}
{"after": {"end": 16, "start": 0, "text": "Extrovis EU Kft.", "truncated": false}, "after_length": 16, "after_sha256": "b9216ef80e71e17798dce313e4318f03f37328f225d30ab508b7413813a908e5", "annex": "IIIB", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "unassigned", "change_operations": [{"after_end": 16, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 16}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-8e001a83260d7763bcd3c45d", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/006047", "medicine_name": "Lacosamide Adroiq", "medicine_slug": "lacosamide-adroiq", "observed_at": "2026-10-12T19:07:56Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "", "section_type": "unassigned", "source_provider": "European Medicines Agency", "source_sha256": "0578c53a5e1c785c4d9d4dc0dabae49dbfa89e237aa571556bee548c3f9cf4d5", "source_snapshot_id": "source-64831dec5ebf55535e19d91b", "source_updated_at": "2025-09-25", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/lacosamide-adroiq-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 2019}
{"after": {"end": 25, "start": 0, "text": "Eurocept International BV", "truncated": false}, "after_length": 25, "after_sha256": "b17bd89b3cf285c986a6070d0d67f5326dd5c1f08a70834c296c6c820f9e7505", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 25, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 25}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-8e004f23a2f2bd41192f57fe", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:19Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "77586d0bea0858214b43b86e91abc2d2711733b96959ead5ed0b5ecbd8ed888a", "source_snapshot_id": "source-85d476f9ad959cc117ca8f1f", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1944}
{"after": {"end": 7, "start": 0, "text": "Sverige", "truncated": false}, "after_length": 7, "after_sha256": "3a7d70b4edb982a403e97d77681309e5fb1032b12d727aa1e92b145b069b9aa4", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 7, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 7}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-8e1cf4d1a17c24d4260c8550", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002097", "medicine_name": "Fampyra", "medicine_slug": "fampyra", "observed_at": "2026-10-12T19:15:51Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "d9fe8aaaa611a84801d6308b13685258b5248df9022536697939afdf66fc1719", "source_snapshot_id": "source-ff8e0599077f0d01044dc867", "source_updated_at": "2025-08-21", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/fampyra-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1594}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 33, "start": 0, "text": "United Kingdom (Northern Ireland)", "truncated": false}, "before_length": 33, "before_sha256": "9379d82927cdb505cfb186e912177065e56a1314de3a2b914ebbb8b5fe21525a", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 33, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 33, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-8e3f0fc390575135e9fca002", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/001021", "medicine_name": "Adcirca (previously Tadalafil Lilly)", "medicine_slug": "adcirca-previously-tadalafil-lilly", "observed_at": "2026-10-12T19:02:42Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "43438c8e53504a78747a8ff36049250fee294557f3a8b0e3acb80f71ad43ebc0", "source_snapshot_id": "source-2305a67bd1e393ee340bb8e4", "source_updated_at": "2026-01-28", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/adcirca-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 2330}
{"after": {"end": 23, "start": 0, "text": "info@euroceptpharma.com", "truncated": false}, "after_length": 23, "after_sha256": "9297cc5acdcc837f054116992765943f7907937507b2564a99ea1327a00ac0e6", "annex": "IIIA", "before": {"end": 13, "start": 0, "text": "Lucane Pharma", "truncated": false}, "before_length": 13, "before_sha256": "e338afdb64acf1a6e2083a50318853589248451dd3aa707181ba02641a8521e8", "change_kind": "content", "change_operations": [{"after_end": 6, "after_start": 0, "before_end": 1, "before_start": 0, "kind": "replace"}, {"after_end": 9, "after_start": 7, "before_end": 2, "before_start": 2, "kind": "insert"}, {"after_end": 10, "after_start": 10, "before_end": 5, "before_start": 3, "kind": "delete"}, {"after_end": 14, "after_start": 11, "before_end": 8, "before_start": 6, "kind": "replace"}, {"after_end": 23, "after_start": 19, "before_end": 13, "before_start": 13, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 5, "chars_inserted": 15}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-8e64713aa2a47ec17367ca26", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:19Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "77586d0bea0858214b43b86e91abc2d2711733b96959ead5ed0b5ecbd8ed888a", "source_snapshot_id": "source-85d476f9ad959cc117ca8f1f", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1898}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 18, "start": 0, "text": "Dublin 2, D02 T380", "truncated": false}, "before_length": 18, "before_sha256": "23e6871e7960b0dadc753bc127bbea230cc8308c88b2d33704eb275a3ec1a70d", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 18, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 18, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-8e67c0049bbd7b8d24aaf1b7", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002097", "medicine_name": "Fampyra", "medicine_slug": "fampyra", "observed_at": "2026-10-12T19:15:51Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "d9fe8aaaa611a84801d6308b13685258b5248df9022536697939afdf66fc1719", "source_snapshot_id": "source-ff8e0599077f0d01044dc867", "source_updated_at": "2025-08-21", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/fampyra-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1420}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 25, "start": 0, "text": "Tel: +44 (0) 800 035 2525", "truncated": false}, "before_length": 25, "before_sha256": "84fbcd82ef02323a82bdadb0119979f04bfbc916f52f9d1dc35ed28128dd714d", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 25, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 25, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-8e86f3d8850425df69134971", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002702", "medicine_name": "Hexacima", "medicine_slug": "hexacima", "observed_at": "2026-10-12T19:07:06Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "b990725709f885f3f868e5da444393a40a54f89ba2f2d9b232d9c053493d1b03", "source_snapshot_id": "source-87ea40f95d82cdfb5ba074b0", "source_updated_at": "2025-09-29", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/hexacima-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 2090}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 16, "start": 0, "text": "Extrovis EU Ltd.", "truncated": false}, "before_length": 16, "before_sha256": "f462ad48e7aef0bc82148ce088af1897d99ed86993128f30d506b27d3108a929", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 16, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 16, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-8edf5900f5535549401e1261", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/006047", "medicine_name": "Lacosamide Adroiq", "medicine_slug": "lacosamide-adroiq", "observed_at": "2026-10-12T19:07:59Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "cc83d966059d42856d0211a4f256b29b20d43593865704d6a9315aeb694f3c76", "source_snapshot_id": "source-896abba1d8391c918345d46b", "source_updated_at": "2025-09-25", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/lacosamide-adroiq-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1816}
{"after": {"end": 25, "start": 0, "text": "Tjoapack Netherlands B.V.", "truncated": false}, "after_length": 25, "after_sha256": "d61d4c5e6087155ec7a92a5c2e9e15aa7274bf924f4aaff549001249105e3be2", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 25, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 25}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-8ee3b51d9e94c6371c82d5da", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/000980", "medicine_name": "Samsca", "medicine_slug": "samsca", "observed_at": "2026-10-12T13:28:24Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "3080d919225c2a98f20aec84d5803b3fde6e1b64f323055c46d098625f4ad301", "source_snapshot_id": "source-e05739a15a0532954ee45dd4", "source_updated_at": "2026-08-20", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/samsca-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1258}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 27, "start": 0, "text": "(Eurocept International BV)", "truncated": false}, "before_length": 27, "before_sha256": "e6cf9b20aaa466e53ad0d393512ca75931e13e488321e3be6f3e4f8b600970c8", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 27, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 27, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-8ef136169877a8aa4c637aeb", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:14Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "8b8c4cc8e6f1a21fedee4bf0743c9c03e454b50f5eaba0e3760416d7fe0a74ec", "source_snapshot_id": "source-4efe4ecf3ebf08d338a763a5", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1912}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 21, "start": 0, "text": "info@lucanepharma.com", "truncated": false}, "before_length": 21, "before_sha256": "44fd39e5fb919cb3d680fa630da23b49238fec29159c509f3622f272bb41c7c6", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 21, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 21, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-8f04029ac45f68b2ff4d60cb", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:19Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "77586d0bea0858214b43b86e91abc2d2711733b96959ead5ed0b5ecbd8ed888a", "source_snapshot_id": "source-85d476f9ad959cc117ca8f1f", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1910}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 13, "start": 0, "text": "Lucane Pharma", "truncated": false}, "before_length": 13, "before_sha256": "e338afdb64acf1a6e2083a50318853589248451dd3aa707181ba02641a8521e8", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 13, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 13, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-8f0990bf25f6d8ead014cd5b", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:19Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "77586d0bea0858214b43b86e91abc2d2711733b96959ead5ed0b5ecbd8ed888a", "source_snapshot_id": "source-85d476f9ad959cc117ca8f1f", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1854}
{"after": {"end": 16, "start": 0, "text": "Extrovis EU Kft.", "truncated": false}, "after_length": 16, "after_sha256": "b9216ef80e71e17798dce313e4318f03f37328f225d30ab508b7413813a908e5", "annex": "IIIB", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "unassigned", "change_operations": [{"after_end": 16, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 16}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-8f11fbd78ea34b5eb0d84ac7", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/006047", "medicine_name": "Lacosamide Adroiq", "medicine_slug": "lacosamide-adroiq", "observed_at": "2026-10-12T19:07:56Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "", "section_type": "unassigned", "source_provider": "European Medicines Agency", "source_sha256": "0578c53a5e1c785c4d9d4dc0dabae49dbfa89e237aa571556bee548c3f9cf4d5", "source_snapshot_id": "source-64831dec5ebf55535e19d91b", "source_updated_at": "2025-09-25", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/lacosamide-adroiq-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1924}
{"after": {"end": 24, "start": 0, "text": "Sími: +49 (0) 69 15 03 0", "truncated": false}, "after_length": 24, "after_sha256": "24af20366ad81c2ae102bbb5532b3b16b7c41b0e4064781db9eed9cacd582723", "annex": "IIIA", "before": {"end": 24, "start": 0, "text": "Sími: +353 (0)1 231 4609", "truncated": false}, "before_length": 24, "before_sha256": "8572127f763bac954beb7dd6f8ef40964e7478c186731008b7840e2d0bb05099", "change_kind": "content", "change_operations": [{"after_end": 9, "after_start": 7, "before_end": 10, "before_start": 7, "kind": "replace"}, {"after_end": 17, "after_start": 13, "before_end": 14, "before_start": 14, "kind": "insert"}, {"after_end": 19, "after_start": 18, "before_end": 15, "before_start": 15, "kind": "insert"}, {"after_end": 21, "after_start": 20, "before_end": 17, "before_start": 16, "kind": "replace"}, {"after_end": 22, "after_start": 22, "before_end": 19, "before_start": 18, "kind": "delete"}, {"after_end": 23, "after_start": 23, "before_end": 22, "before_start": 20, "kind": "delete"}, {"after_end": 24, "after_start": 24, "before_end": 24, "before_start": 23, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 8, "chars_inserted": 8}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-8f233f788184e99844035b5e", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002097", "medicine_name": "Fampyra", "medicine_slug": "fampyra", "observed_at": "2026-10-12T19:16:07Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "a0c3ba8d58d6a43a809ecc3d142a78b10c2bd7f0b9f3a3553df2617d87daec1f", "source_snapshot_id": "source-c7a810dd21f94cd2d273f0da", "source_updated_at": "2025-08-21", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/fampyra-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1574}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 21, "start": 0, "text": "Tel: + 33 153 868 750", "truncated": false}, "before_length": 21, "before_sha256": "efffe29324e968019e6e2b111904182ba06d83e76b1f29b933bed9dd8779c114", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 21, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 21, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-8f37096642723995f790f071", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:14Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "8b8c4cc8e6f1a21fedee4bf0743c9c03e454b50f5eaba0e3760416d7fe0a74ec", "source_snapshot_id": "source-4efe4ecf3ebf08d338a763a5", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1557}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 25, "start": 0, "text": "Tel: +44 (0) 208 159 3593", "truncated": false}, "before_length": 25, "before_sha256": "414e64590804cce28e6009911f9bd5a23d726e7fc95e07972af37d503d5083c8", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 25, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 25, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-8f9cb65af28396cce6915a83", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/000619", "medicine_name": "Fosavance", "medicine_slug": "fosavance", "observed_at": "2026-10-12T19:01:49Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "97e93ccf75e837b32026ca36c34d5c78008211a75d5ef225c47e7b94a0027ab2", "source_snapshot_id": "source-1ef57638e1a307f1e5437651", "source_updated_at": "2026-02-12", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/fosavance-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1331}
{"after": {"end": 150, "start": 0, "text": "Des informations détaillées sur ce médicament sont disponibles sur le site internet de l'Agence européenne des médicaments : https://www.ema.europa.eu", "truncated": false}, "after_length": 150, "after_sha256": "7a57f3971964eb7bea4ed295986ca64649117ce6b1ea800c91cdf0ed4877b711", "annex": "III", "before": {"end": 150, "start": 0, "text": "Des informations détaillées sur ce médicament sont disponibles sur le site internet de l'Agence européenne des médicaments : http://www.ema.europa.eu.", "truncated": false}, "before_length": 150, "before_sha256": "6272fb3d1bf208f727e3ec8521cb6d15c24e42031d06a96b3c4d43ff5b48aa11", "change_kind": "technical", "change_operations": [{"after_end": 130, "after_start": 129, "before_end": 129, "before_start": 129, "kind": "insert"}, {"after_end": 150, "after_start": 150, "before_end": 150, "before_start": 149, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 1, "chars_inserted": 1}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-8fba9d7d4a519dc0468a6d23", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/001021", "medicine_name": "Adcirca (previously Tadalafil Lilly)", "medicine_slug": "adcirca-previously-tadalafil-lilly", "observed_at": "2026-10-12T19:02:45Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "", "section_type": "unassigned", "source_provider": "European Medicines Agency", "source_sha256": "cdbefcd6143c93e81f3c826bea8d3d01bffc55652e0f792243097df75c452721", "source_snapshot_id": "source-a1e85476de17f5a8664f7766", "source_updated_at": "2026-01-28", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/adcirca-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 2310}
{"after": {"end": 89, "start": 0, "text": "Confusion, humeur dépressive/altération de l’humeur, hallucinations, spasmes musculaires.", "truncated": false}, "after_length": 89, "after_sha256": "5304f2a1844257c299518ee93e48e17acc2ec82123701078c0bc6b89a57eb756", "annex": "IIIA", "before": {"end": 57, "start": 0, "text": "Humeur dépressive/altération de l’humeur, hallucinations.", "truncated": false}, "before_length": 57, "before_sha256": "542fe37d57d34ac2c05d3e25aeab6c112fb589a5da4e0cff3946e4cef96a4797", "change_kind": "content", "change_operations": [{"after_end": 12, "after_start": 0, "before_end": 1, "before_start": 0, "kind": "replace"}, {"after_end": 87, "after_start": 66, "before_end": 55, "before_start": 55, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 1, "chars_inserted": 33}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-8fd476dd4ace8bc88fae7e80", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/000554", "medicine_name": "Emselex", "medicine_slug": "emselex", "observed_at": "2026-10-12T19:12:07Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": null, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "9a4f1d7e260c7b80eaf397503623b63302e5945b579e9612177835e07c4ab888", "source_snapshot_id": "source-3aac7bf42b99529f25ac013b", "source_updated_at": "2025-09-15", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/emselex-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1805}
{"after": {"end": 21, "start": 0, "text": "Tel: +31 35 528 39 57", "truncated": false}, "after_length": 21, "after_sha256": "7baf6601f41e49e470f803fdd4e755a86efa38be423317c000ed79963ebdd213", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 21, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 21}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-9017734c982bef1e991f9bec", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:14Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "8b8c4cc8e6f1a21fedee4bf0743c9c03e454b50f5eaba0e3760416d7fe0a74ec", "source_snapshot_id": "source-4efe4ecf3ebf08d338a763a5", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1861}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 16, "start": 0, "text": "Extrovis EU Ltd.", "truncated": false}, "before_length": 16, "before_sha256": "f462ad48e7aef0bc82148ce088af1897d99ed86993128f30d506b27d3108a929", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 16, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 16, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-901a8dc86a7137cbe21cf76d", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/006047", "medicine_name": "Lacosamide Adroiq", "medicine_slug": "lacosamide-adroiq", "observed_at": "2026-10-12T19:07:59Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "cc83d966059d42856d0211a4f256b29b20d43593865704d6a9315aeb694f3c76", "source_snapshot_id": "source-896abba1d8391c918345d46b", "source_updated_at": "2025-09-25", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/lacosamide-adroiq-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1701}
{"after": {"end": 11, "start": 0, "text": "Vistor ehf.", "truncated": false}, "after_length": 11, "after_sha256": "7b79f0f888fc32453606a29b908677d0b6c13a510070ab26fe31e12b995d77fe", "annex": "IIIA", "before": {"end": 10, "start": 0, "text": "Vistor hf.", "truncated": false}, "before_length": 10, "before_sha256": "4b40dfc2a19551f982dad779994a624f3432207c4666bbd66f0ec59c2f229b32", "change_kind": "content", "change_operations": [{"after_end": 8, "after_start": 7, "before_end": 7, "before_start": 7, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 1}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-906a6fc2582218af9f7960ea", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/000619", "medicine_name": "Fosavance", "medicine_slug": "fosavance", "observed_at": "2026-10-12T19:01:49Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "97e93ccf75e837b32026ca36c34d5c78008211a75d5ef225c47e7b94a0027ab2", "source_snapshot_id": "source-1ef57638e1a307f1e5437651", "source_updated_at": "2026-02-12", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/fosavance-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1297}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 15, "start": 0, "text": "pv@extrovis.com", "truncated": false}, "before_length": 15, "before_sha256": "7363f9dc0fbbc5fcd5a6354cf2eb8172b30b6489d496158b7513b9f1a84c3817", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 15, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 15, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-906c5ed8c069c07e46750830", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/006047", "medicine_name": "Lacosamide Adroiq", "medicine_slug": "lacosamide-adroiq", "observed_at": "2026-10-12T19:07:59Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "cc83d966059d42856d0211a4f256b29b20d43593865704d6a9315aeb694f3c76", "source_snapshot_id": "source-896abba1d8391c918345d46b", "source_updated_at": "2025-09-25", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/lacosamide-adroiq-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1862}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 7, "start": 0, "text": "Ierland", "truncated": false}, "before_length": 7, "before_sha256": "5b6fef9c9233c2abd17af97e464b5721beead5db2103a11b72e69f4e32067ae4", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 7, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 7, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-90930932c3837cec8c8098e0", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002097", "medicine_name": "Fampyra", "medicine_slug": "fampyra", "observed_at": "2026-10-12T19:15:51Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "d9fe8aaaa611a84801d6308b13685258b5248df9022536697939afdf66fc1719", "source_snapshot_id": "source-ff8e0599077f0d01044dc867", "source_updated_at": "2025-08-21", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/fampyra-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1454}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 38, "start": 0, "text": "sanofi-aventis Ireland Ltd. T/A SANOFI", "truncated": false}, "before_length": 38, "before_sha256": "dad9251ce581d41bcfcb8818c11a57a8d3490b978d09cf04cfd9162a081c8d28", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 38, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 38, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-90c3c2392258fdfa243ecf0a", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002702", "medicine_name": "Hexacima", "medicine_slug": "hexacima", "observed_at": "2026-10-12T19:07:06Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "b990725709f885f3f868e5da444393a40a54f89ba2f2d9b232d9c053493d1b03", "source_snapshot_id": "source-87ea40f95d82cdfb5ba074b0", "source_updated_at": "2025-09-29", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/hexacima-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 2089}
{"after": {"end": 9, "start": 0, "text": "Allemagne", "truncated": false}, "after_length": 9, "after_sha256": "6b58dbd6a994339b48d8446597da22402857b3409613459c7e3a293788fbe66a", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 9, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 9}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-90fb90be49b4ce773e024eff", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002097", "medicine_name": "Fampyra", "medicine_slug": "fampyra", "observed_at": "2026-10-12T19:16:07Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "a0c3ba8d58d6a43a809ecc3d142a78b10c2bd7f0b9f3a3553df2617d87daec1f", "source_snapshot_id": "source-c7a810dd21f94cd2d273f0da", "source_updated_at": "2025-08-21", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/fampyra-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 903}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 16, "start": 0, "text": "Extrovis EU Ltd.", "truncated": false}, "before_length": 16, "before_sha256": "f462ad48e7aef0bc82148ce088af1897d99ed86993128f30d506b27d3108a929", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 16, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 16, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-910224ed13a80d75bb9b808c", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/006047", "medicine_name": "Lacosamide Adroiq", "medicine_slug": "lacosamide-adroiq", "observed_at": "2026-10-12T19:07:59Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "cc83d966059d42856d0211a4f256b29b20d43593865704d6a9315aeb694f3c76", "source_snapshot_id": "source-896abba1d8391c918345d46b", "source_updated_at": "2025-09-25", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/lacosamide-adroiq-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1679}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 13, "start": 0, "text": "Lucane Pharma", "truncated": false}, "before_length": 13, "before_sha256": "e338afdb64acf1a6e2083a50318853589248451dd3aa707181ba02641a8521e8", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 13, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 13, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-9114509a1075628fb164cd00", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:14Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "8b8c4cc8e6f1a21fedee4bf0743c9c03e454b50f5eaba0e3760416d7fe0a74ec", "source_snapshot_id": "source-4efe4ecf3ebf08d338a763a5", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1920}
{"after": {"end": 21, "start": 0, "text": "Tel: +31 35 528 39 57", "truncated": false}, "after_length": 21, "after_sha256": "7baf6601f41e49e470f803fdd4e755a86efa38be423317c000ed79963ebdd213", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 21, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 21}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-91195ba4555a93b366eb648f", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:19Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "77586d0bea0858214b43b86e91abc2d2711733b96959ead5ed0b5ecbd8ed888a", "source_snapshot_id": "source-85d476f9ad959cc117ca8f1f", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1525}
{"after": {"end": 23, "start": 0, "text": "60318 Frankfurt am Main", "truncated": false}, "after_length": 23, "after_sha256": "24c3191b5088b20c209c4387a8127297e54c776e161d305c9e57956a13b7cbbe", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 23, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 23}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-913c84034162ad6e180ef7ec", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002097", "medicine_name": "Fampyra", "medicine_slug": "fampyra", "observed_at": "2026-10-12T19:16:07Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "a0c3ba8d58d6a43a809ecc3d142a78b10c2bd7f0b9f3a3553df2617d87daec1f", "source_snapshot_id": "source-c7a810dd21f94cd2d273f0da", "source_updated_at": "2025-08-21", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/fampyra-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 902}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "III", "before": {"end": 16, "start": 0, "text": "2000, Szentendre", "truncated": false}, "before_length": 16, "before_sha256": "e7eec80782064f78f9518825c15b4c5b91e88a8bf75f429cef005c9630048901", "change_kind": "unassigned", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 16, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 16, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-913ce900fc765316fa3311ab", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/006047", "medicine_name": "Lacosamide Adroiq", "medicine_slug": "lacosamide-adroiq", "observed_at": "2026-10-12T19:07:56Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "", "section_type": "unassigned", "source_provider": "European Medicines Agency", "source_sha256": "0578c53a5e1c785c4d9d4dc0dabae49dbfa89e237aa571556bee548c3f9cf4d5", "source_snapshot_id": "source-64831dec5ebf55535e19d91b", "source_updated_at": "2025-09-25", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/lacosamide-adroiq-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1206}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 61, "start": 0, "text": "McDermott Laboratories Limited trading as Gerard Laboratories", "truncated": false}, "before_length": 61, "before_sha256": "f28bee890ae72cccea9b87c3be57809b0afb7f64e286de2c77b2c05b413da700", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 61, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 61, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-9159739da8fd0c3c3644568e", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/004025", "medicine_name": "Lopinavir/Ritonavir Viatris (previously Ritonavir Mylan)", "medicine_slug": "lopinavir-ritonavir-viatris-previously-ritonavir-mylan", "observed_at": "2026-10-12T19:12:46Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "3e30663f02732816ed8779d7a929d500c824ae15aeaee9144ca6eef11900e273", "source_snapshot_id": "source-c58e019b5bec1fb24569e83e", "source_updated_at": "2025-09-08", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/lopinavir-ritonavir-viatris-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 3416}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 6, "start": 0, "text": "Írland", "truncated": false}, "before_length": 6, "before_sha256": "79e1686a0077421a1a954c9396db299b5732be9336ce03f0071f7749fcd800a0", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 6, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 6, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-918f6c35710f3781b1aecc38", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002097", "medicine_name": "Fampyra", "medicine_slug": "fampyra", "observed_at": "2026-10-12T19:16:07Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "a0c3ba8d58d6a43a809ecc3d142a78b10c2bd7f0b9f3a3553df2617d87daec1f", "source_snapshot_id": "source-c7a810dd21f94cd2d273f0da", "source_updated_at": "2025-08-21", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/fampyra-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1570}
{"after": {"end": 23, "start": 0, "text": "info@euroceptpharma.com", "truncated": false}, "after_length": 23, "after_sha256": "9297cc5acdcc837f054116992765943f7907937507b2564a99ea1327a00ac0e6", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 23, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 23}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-9194e771dc9cbef7a97a82b0", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:19Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "77586d0bea0858214b43b86e91abc2d2711733b96959ead5ed0b5ecbd8ed888a", "source_snapshot_id": "source-85d476f9ad959cc117ca8f1f", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1928}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "I", "before": {"end": 7, "start": 0, "text": "Ireland", "truncated": false}, "before_length": 7, "before_sha256": "02bf1dfa9a0365a86223f0e4ac9eaa0517b06b2e9273790f719feda656a247ae", "change_kind": "administrative", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 7, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 7, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-91bc8300f356e722adf934e3", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002097", "medicine_name": "Fampyra", "medicine_slug": "fampyra", "observed_at": "2026-10-12T19:15:51Z", "pipeline_version": "2.0.0", "presentation_label": "Fampyra 10 mg prolonged-release tablets", "presentation_occurrence": 1, "presentation_status": "heading_extracted_unverified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "7", "section_type": "administrative", "source_provider": "European Medicines Agency", "source_sha256": "d9fe8aaaa611a84801d6308b13685258b5248df9022536697939afdf66fc1719", "source_snapshot_id": "source-ff8e0599077f0d01044dc867", "source_updated_at": "2025-08-21", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/fampyra-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 685}
{"after": {"end": 21, "start": 0, "text": "Tel: +31 35 528 39 57", "truncated": false}, "after_length": 21, "after_sha256": "7baf6601f41e49e470f803fdd4e755a86efa38be423317c000ed79963ebdd213", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 21, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 21}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-91dcfd1d803df6746a1f35ad", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:19Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "77586d0bea0858214b43b86e91abc2d2711733b96959ead5ed0b5ecbd8ed888a", "source_snapshot_id": "source-85d476f9ad959cc117ca8f1f", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1454}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "III", "before": {"end": 16, "start": 0, "text": "2000, Szentendre", "truncated": false}, "before_length": 16, "before_sha256": "e7eec80782064f78f9518825c15b4c5b91e88a8bf75f429cef005c9630048901", "change_kind": "unassigned", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 16, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 16, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-9201a3dd81192ab0ddd15c83", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/006047", "medicine_name": "Lacosamide Adroiq", "medicine_slug": "lacosamide-adroiq", "observed_at": "2026-10-12T19:07:56Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "", "section_type": "unassigned", "source_provider": "European Medicines Agency", "source_sha256": "0578c53a5e1c785c4d9d4dc0dabae49dbfa89e237aa571556bee548c3f9cf4d5", "source_snapshot_id": "source-64831dec5ebf55535e19d91b", "source_updated_at": "2025-09-25", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/lacosamide-adroiq-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1351}
{"after": {"end": 24, "start": 0, "text": "Teл.: +49 (0) 69 15 03 0", "truncated": false}, "after_length": 24, "after_sha256": "920fc0f7a659b3b50c2a6a85a5d47a1509a5f33c7f539f20a7fa2b0b956e96af", "annex": "IIIA", "before": {"end": 24, "start": 0, "text": "Teл.: +353 (0)1 231 4609", "truncated": false}, "before_length": 24, "before_sha256": "67b46938ef79870beff219e6d0952c45314aa461a4b12e308a32545acb979c47", "change_kind": "content", "change_operations": [{"after_end": 9, "after_start": 7, "before_end": 10, "before_start": 7, "kind": "replace"}, {"after_end": 17, "after_start": 13, "before_end": 14, "before_start": 14, "kind": "insert"}, {"after_end": 19, "after_start": 18, "before_end": 15, "before_start": 15, "kind": "insert"}, {"after_end": 21, "after_start": 20, "before_end": 17, "before_start": 16, "kind": "replace"}, {"after_end": 22, "after_start": 22, "before_end": 19, "before_start": 18, "kind": "delete"}, {"after_end": 23, "after_start": 23, "before_end": 22, "before_start": 20, "kind": "delete"}, {"after_end": 24, "after_start": 24, "before_end": 24, "before_start": 23, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 8, "chars_inserted": 8}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-923c5fabfb9a9da58be5ef89", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002097", "medicine_name": "Fampyra", "medicine_slug": "fampyra", "observed_at": "2026-10-12T19:16:07Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "a0c3ba8d58d6a43a809ecc3d142a78b10c2bd7f0b9f3a3553df2617d87daec1f", "source_snapshot_id": "source-c7a810dd21f94cd2d273f0da", "source_updated_at": "2025-08-21", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/fampyra-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1401}
{"after": {"end": 18, "start": 0, "text": "dpoccyprus@msd.com", "truncated": false}, "after_length": 18, "after_sha256": "492fae7e6db021703bcb80e4b139bc2be78a7e6cf4c6056a9314c70cfe643716", "annex": "IIIA", "before": {"end": 21, "start": 0, "text": "cyprus_info@merck.com", "truncated": false}, "before_length": 21, "before_sha256": "a6a31d0f7dc84283ce751c4e4d77e632a879da9a362680e26db9aa73403f7008", "change_kind": "content", "change_operations": [{"after_end": 4, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}, {"after_end": 10, "after_start": 10, "before_end": 11, "before_start": 6, "kind": "delete"}, {"after_end": 14, "after_start": 12, "before_end": 17, "before_start": 13, "kind": "replace"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 9, "chars_inserted": 6}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-92d2a94b6ff344325d7ecc7a", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/000389", "medicine_name": "Invanz", "medicine_slug": "invanz", "observed_at": "2026-10-12T17:30:44Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "a9208c117495d2d6c465ba196e4dbbb3d498b27d747df3b2d0145b0549743e4b", "source_snapshot_id": "source-e56383168f778128e02c2b2e", "source_updated_at": "2025-11-21", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/invanz-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1225}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "I", "before": {"end": 16, "start": 0, "text": "Extrovis EU Ltd.", "truncated": false}, "before_length": 16, "before_sha256": "f462ad48e7aef0bc82148ce088af1897d99ed86993128f30d506b27d3108a929", "change_kind": "administrative", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 16, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 16, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-92d64f271874e613bf55bb7b", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/006047", "medicine_name": "Lacosamide Adroiq", "medicine_slug": "lacosamide-adroiq", "observed_at": "2026-10-12T19:07:56Z", "pipeline_version": "2.0.0", "presentation_label": "Lacosamide Adroiq 10 mg/ml solution for infusion", "presentation_occurrence": 1, "presentation_status": "heading_extracted_unverified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "7", "section_type": "administrative", "source_provider": "European Medicines Agency", "source_sha256": "0578c53a5e1c785c4d9d4dc0dabae49dbfa89e237aa571556bee548c3f9cf4d5", "source_snapshot_id": "source-64831dec5ebf55535e19d91b", "source_updated_at": "2025-09-25", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/lacosamide-adroiq-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 922}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 25, "start": 0, "text": "Tel: +44 (0) 800 035 2525", "truncated": false}, "before_length": 25, "before_sha256": "84fbcd82ef02323a82bdadb0119979f04bfbc916f52f9d1dc35ed28128dd714d", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 25, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 25, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-93721db9fea7e60f72534bd4", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002702", "medicine_name": "Hexacima", "medicine_slug": "hexacima", "observed_at": "2026-10-12T19:07:04Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "44c8996457a718019c75b8322ba07a5ae7af36377b1a6f1cf4ca5a30f9b72c23", "source_snapshot_id": "source-fa766d966dea704c333b9969", "source_updated_at": "2025-09-29", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/hexacima-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 2121}
{"after": {"end": 25, "start": 0, "text": "Eurocept International BV", "truncated": false}, "after_length": 25, "after_sha256": "b17bd89b3cf285c986a6070d0d67f5326dd5c1f08a70834c296c6c820f9e7505", "annex": "IIIA", "before": {"end": 21, "start": 0, "text": "info@lucanepharma.com", "truncated": false}, "before_length": 21, "before_sha256": "44fd39e5fb919cb3d680fa630da23b49238fec29159c509f3622f272bb41c7c6", "change_kind": "content", "change_operations": [{"after_end": 3, "after_start": 0, "before_end": 3, "before_start": 0, "kind": "replace"}, {"after_end": 4, "after_start": 4, "before_end": 7, "before_start": 4, "kind": "delete"}, {"after_end": 5, "after_start": 5, "before_end": 10, "before_start": 8, "kind": "delete"}, {"after_end": 15, "after_start": 7, "before_end": 13, "before_start": 12, "kind": "replace"}, {"after_end": 20, "after_start": 16, "before_end": 16, "before_start": 14, "kind": "replace"}, {"after_end": 25, "after_start": 21, "before_end": 21, "before_start": 17, "kind": "replace"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 15, "chars_inserted": 19}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-9383ebc57504a8cffedf0ca6", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:14Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "8b8c4cc8e6f1a21fedee4bf0743c9c03e454b50f5eaba0e3760416d7fe0a74ec", "source_snapshot_id": "source-4efe4ecf3ebf08d338a763a5", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 2003}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 13, "start": 0, "text": "Lucane Pharma", "truncated": false}, "before_length": 13, "before_sha256": "e338afdb64acf1a6e2083a50318853589248451dd3aa707181ba02641a8521e8", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 13, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 13, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-94228fc357fb1f2dd082f205", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:19Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "77586d0bea0858214b43b86e91abc2d2711733b96959ead5ed0b5ecbd8ed888a", "source_snapshot_id": "source-85d476f9ad959cc117ca8f1f", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1860}
{"after": {"end": 22, "start": 0, "text": "Merz Therapeutics GmbH", "truncated": false}, "after_length": 22, "after_sha256": "059f049c7d0846aaadcf2573280d52110f302d4ecc7b38debd004571cd1e9d5e", "annex": "IIIA", "before": {"end": 35, "start": 0, "text": "Acorda Therapeutics Ireland Limited", "truncated": false}, "before_length": 35, "before_sha256": "d94d3153d193ed26567f2b4ed48df016d81c534e7c0cb1a6655a63f0083383ff", "change_kind": "content", "change_operations": [{"after_end": 2, "after_start": 0, "before_end": 3, "before_start": 0, "kind": "replace"}, {"after_end": 4, "after_start": 3, "before_end": 6, "before_start": 4, "kind": "replace"}, {"after_end": 19, "after_start": 18, "before_end": 30, "before_start": 20, "kind": "replace"}, {"after_end": 22, "after_start": 20, "before_end": 35, "before_start": 31, "kind": "replace"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 19, "chars_inserted": 6}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-94491ab1b3a6b8c9eb603cea", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002097", "medicine_name": "Fampyra", "medicine_slug": "fampyra", "observed_at": "2026-10-12T19:16:07Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "a0c3ba8d58d6a43a809ecc3d142a78b10c2bd7f0b9f3a3553df2617d87daec1f", "source_snapshot_id": "source-c7a810dd21f94cd2d273f0da", "source_updated_at": "2025-08-21", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/fampyra-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1529}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 32, "start": 0, "text": "medicalinformationuk@organon.com", "truncated": false}, "before_length": 32, "before_sha256": "9a3c944e088e3b61b964a93081a954458dd24de64e54fc2a29ad4559ba69dfc6", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 32, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 32, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-9475542c41bef1c0637faa87", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/000619", "medicine_name": "Fosavance", "medicine_slug": "fosavance", "observed_at": "2026-10-12T19:01:48Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "37324165444dd93963c38ccfa569b0631b8d34d16c725b5a46b16dd7bb4cbbc2", "source_snapshot_id": "source-829e9ebd79c1d98e8a839547", "source_updated_at": "2026-02-12", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/fosavance-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1318}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 8, "start": 0, "text": "Ирландия", "truncated": false}, "before_length": 8, "before_sha256": "79d0d5d9793987bd8aa0f026623d4cd6143b424872656570820b1ca97cea0ba2", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 8, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 8, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-9488722850d3618cb6d4ffcf", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002097", "medicine_name": "Fampyra", "medicine_slug": "fampyra", "observed_at": "2026-10-12T19:16:07Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "a0c3ba8d58d6a43a809ecc3d142a78b10c2bd7f0b9f3a3553df2617d87daec1f", "source_snapshot_id": "source-c7a810dd21f94cd2d273f0da", "source_updated_at": "2025-08-21", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/fampyra-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1397}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "I", "before": {"end": 38, "start": 0, "text": "Expérience depuis la commercialisation", "truncated": false}, "before_length": 38, "before_sha256": "c4ab722defc01fa56c27aa24fbc973ae8f80fdf66b8b9bbb2409e75cb1616f6f", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 38, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": true, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 38, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-94cc32866178a56f50b47b71", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/000554", "medicine_name": "Emselex", "medicine_slug": "emselex", "observed_at": "2026-10-12T19:12:07Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": null, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "4.8", "section_type": "adverse_reactions", "source_provider": "European Medicines Agency", "source_sha256": "9a4f1d7e260c7b80eaf397503623b63302e5945b579e9612177835e07c4ab888", "source_snapshot_id": "source-3aac7bf42b99529f25ac013b", "source_updated_at": "2025-09-15", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/emselex-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 239}
{"after": {"end": 25, "start": 0, "text": "Eurocept International BV", "truncated": false}, "after_length": 25, "after_sha256": "b17bd89b3cf285c986a6070d0d67f5326dd5c1f08a70834c296c6c820f9e7505", "annex": "IIIA", "before": {"end": 41, "start": 0, "text": "Lucane Pharma (Eurocept International BV)", "truncated": false}, "before_length": 41, "before_sha256": "87a4a04cbc41898e70563a8a6a0bc58aa2a16ee237e3d8f60b32d1bcb6c41583", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 15, "before_start": 0, "kind": "delete"}, {"after_end": 25, "after_start": 25, "before_end": 41, "before_start": 40, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 16, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-9503faf988f32a6db8a57dda", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:14Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "8b8c4cc8e6f1a21fedee4bf0743c9c03e454b50f5eaba0e3760416d7fe0a74ec", "source_snapshot_id": "source-4efe4ecf3ebf08d338a763a5", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1497}
{"after": {"end": 21, "start": 0, "text": "Tel: +31 35 528 39 57", "truncated": false}, "after_length": 21, "after_sha256": "7baf6601f41e49e470f803fdd4e755a86efa38be423317c000ed79963ebdd213", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 21, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 21}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-953b2ab7a9a8a8236b94e71c", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:14Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "8b8c4cc8e6f1a21fedee4bf0743c9c03e454b50f5eaba0e3760416d7fe0a74ec", "source_snapshot_id": "source-4efe4ecf3ebf08d338a763a5", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1901}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 27, "start": 0, "text": "(Eurocept International BV)", "truncated": false}, "before_length": 27, "before_sha256": "e6cf9b20aaa466e53ad0d393512ca75931e13e488321e3be6f3e4f8b600970c8", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 27, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 27, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-953fdd1e6413e8be1565e3b3", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:19Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "77586d0bea0858214b43b86e91abc2d2711733b96959ead5ed0b5ecbd8ed888a", "source_snapshot_id": "source-85d476f9ad959cc117ca8f1f", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1812}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "I", "before": {"end": 387, "start": 0, "text": "The following events have been reported in association with darifenacin use in worldwide post-marketing experience: generalised hypersensitivity reactions including angioedema, depressed mood/mood alterations, hallucination. Because these spontaneously reported events are from the worldwide post-marketing experience, the frequency of events cannot be estimated from the available data.", "truncated": false}, "before_length": 387, "before_sha256": "d00f072d246c0b54154e0c2d4cd81b024833b5d70f3e815410be3c4474cf89dd", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 387, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": true, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 387, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-9574a7e5e16c092e4fc98eb3", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/000554", "medicine_name": "Emselex", "medicine_slug": "emselex", "observed_at": "2026-10-12T19:12:04Z", "pipeline_version": "2.0.0", "presentation_label": "Emselex 15 mg prolonged-release tablets", "presentation_occurrence": 2, "presentation_status": "heading_extracted_unverified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "4.8", "section_type": "adverse_reactions", "source_provider": "European Medicines Agency", "source_sha256": "4f2565612bc728ec67b7f9c0cd5799ef2c594911c76f323aef8bf6a85adde245", "source_snapshot_id": "source-1fda25b331eb198b8b93feb3", "source_updated_at": "2025-09-15", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/emselex-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 665}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 13, "start": 0, "text": "Lucane Pharma", "truncated": false}, "before_length": 13, "before_sha256": "e338afdb64acf1a6e2083a50318853589248451dd3aa707181ba02641a8521e8", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 13, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 13, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-95f7c689405af44e06c22260", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:14Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "8b8c4cc8e6f1a21fedee4bf0743c9c03e454b50f5eaba0e3760416d7fe0a74ec", "source_snapshot_id": "source-4efe4ecf3ebf08d338a763a5", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 2066}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 25, "start": 0, "text": "Tél/Tel: + 33 153 868 750", "truncated": false}, "before_length": 25, "before_sha256": "e5f8e4aadc105f123b1cb253b9afe1e362181b7777e0b94626adda3e9db7ed2e", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 25, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 25, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-960b5355a3530653cc1fa651", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:19Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "77586d0bea0858214b43b86e91abc2d2711733b96959ead5ed0b5ecbd8ed888a", "source_snapshot_id": "source-85d476f9ad959cc117ca8f1f", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1402}
{"after": {"end": 221, "start": 0, "text": "Plaquettes thermoformées en PVC/CTFE/aluminium ou en PVC/PVDC/aluminium conditionnées dans des cartons de 7, 14, 28, 49, 56 ou 98 comprimés par boîte ou dans des conditionnements multiples contenant 140 (10x14) comprimés.", "truncated": false}, "after_length": 221, "after_sha256": "ae2a26205584afd43c5835fe4a5abda2086878ec7d2123020bec962d5c7d0b00", "annex": "I", "before": {"end": 223, "start": 0, "text": "Plaquettes thermoformées en PVC/CTFE/aluminium ou en PVC/PVDC/aluminium conditionnées dans des cartons de 7, 14, 28, 49, 56 ou 98 comprimés par boîte ou dans des conditionnements multiples composés de 140 (10x14) comprimés.", "truncated": false}, "before_length": 223, "before_sha256": "674b4bd0851564aae1b559f4bb6a12bd8c8428b01f8b0f76aafeac6a4308206d", "change_kind": "content", "change_operations": [{"after_end": 193, "after_start": 191, "before_end": 199, "before_start": 191, "kind": "replace"}, {"after_end": 198, "after_start": 194, "before_end": 200, "before_start": 200, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 8, "chars_inserted": 6}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-9622d146f89b68b1fa8855e4", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/000554", "medicine_name": "Emselex", "medicine_slug": "emselex", "observed_at": "2026-10-12T19:12:07Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": null, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "6.5", "section_type": "quality_presentation", "source_provider": "European Medicines Agency", "source_sha256": "9a4f1d7e260c7b80eaf397503623b63302e5945b579e9612177835e07c4ab888", "source_snapshot_id": "source-3aac7bf42b99529f25ac013b", "source_updated_at": "2025-09-15", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/emselex-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 836}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 13, "start": 0, "text": "Lucane Pharma", "truncated": false}, "before_length": 13, "before_sha256": "e338afdb64acf1a6e2083a50318853589248451dd3aa707181ba02641a8521e8", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 13, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 13, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-9652c68157457a1e584f4b95", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:14Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "8b8c4cc8e6f1a21fedee4bf0743c9c03e454b50f5eaba0e3760416d7fe0a74ec", "source_snapshot_id": "source-4efe4ecf3ebf08d338a763a5", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1556}
{"after": {"end": 8, "start": 0, "text": "Germania", "truncated": false}, "after_length": 8, "after_sha256": "3d4b90e9744633e91a37fa52c3eb60fc25cd5b2c9ebd2ddbd39d876291f1d695", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 8, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 8}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-9660cb46b919db583ce10405", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002097", "medicine_name": "Fampyra", "medicine_slug": "fampyra", "observed_at": "2026-10-12T19:15:51Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "d9fe8aaaa611a84801d6308b13685258b5248df9022536697939afdf66fc1719", "source_snapshot_id": "source-ff8e0599077f0d01044dc867", "source_updated_at": "2025-08-21", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/fampyra-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1539}
{"after": {"end": 149, "start": 0, "text": "Des informations détaillées sur ce médicament sont disponibles sur le site internet de l’Agence européenne des médicaments https://www.ema.europa.eu.", "truncated": false}, "after_length": 149, "after_sha256": "0e6b9f35caaf0258b468a6e9a53665f0ec5536787f68eefee5f242bf64add02e", "annex": "I", "before": {"end": 148, "start": 0, "text": "Des informations détaillées sur ce médicament sont disponibles sur le site internet de l’Agence européenne des médicaments http://www.ema.europa.eu.", "truncated": false}, "before_length": 148, "before_sha256": "8781a4dba25cf8cb978f0efd517b11bd29ec42e3e0fffadb61d4b9c2e7362806", "change_kind": "technical", "change_operations": [{"after_end": 128, "after_start": 127, "before_end": 127, "before_start": 127, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 1}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-96666d8c5bad3fc3b73f7d0d", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/001021", "medicine_name": "Adcirca (previously Tadalafil Lilly)", "medicine_slug": "adcirca-previously-tadalafil-lilly", "observed_at": "2026-10-12T19:02:45Z", "pipeline_version": "2.0.0", "presentation_label": "ADCIRCA 20 mg comprimés pelliculés", "presentation_occurrence": 1, "presentation_status": "heading_extracted_unverified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "10", "section_type": "administrative", "source_provider": "European Medicines Agency", "source_sha256": "cdbefcd6143c93e81f3c826bea8d3d01bffc55652e0f792243097df75c452721", "source_snapshot_id": "source-a1e85476de17f5a8664f7766", "source_updated_at": "2026-01-28", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/adcirca-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 625}
{"after": {"end": 16, "start": 0, "text": "Extrovis EU Kft.", "truncated": false}, "after_length": 16, "after_sha256": "b9216ef80e71e17798dce313e4318f03f37328f225d30ab508b7413813a908e5", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 16, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 16}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-968c0ac022d7e133314956b0", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/006047", "medicine_name": "Lacosamide Adroiq", "medicine_slug": "lacosamide-adroiq", "observed_at": "2026-10-12T19:07:59Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "cc83d966059d42856d0211a4f256b29b20d43593865704d6a9315aeb694f3c76", "source_snapshot_id": "source-896abba1d8391c918345d46b", "source_updated_at": "2025-09-25", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/lacosamide-adroiq-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1821}
{"after": {"end": 21, "start": 0, "text": "Tel: +31 35 528 39 57", "truncated": false}, "after_length": 21, "after_sha256": "7baf6601f41e49e470f803fdd4e755a86efa38be423317c000ed79963ebdd213", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 21, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 21}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-96b15d6a23502b4cef22955d", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:19Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "77586d0bea0858214b43b86e91abc2d2711733b96959ead5ed0b5ecbd8ed888a", "source_snapshot_id": "source-85d476f9ad959cc117ca8f1f", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1424}
{"after": {"end": 7, "start": 0, "text": "Německo", "truncated": false}, "after_length": 7, "after_sha256": "c2aec41a3a1d19fef51d31f2834532dfd151a882b1d6a79e86c190fa19105372", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 7, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 7}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-96e7fa9e7f39a040bc36281b", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002097", "medicine_name": "Fampyra", "medicine_slug": "fampyra", "observed_at": "2026-10-12T19:15:51Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "d9fe8aaaa611a84801d6308b13685258b5248df9022536697939afdf66fc1719", "source_snapshot_id": "source-ff8e0599077f0d01044dc867", "source_updated_at": "2025-08-21", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/fampyra-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1414}
{"after": {"end": 5, "start": 0, "text": "Grèce", "truncated": false}, "after_length": 5, "after_sha256": "9a953a79ebdbc073046b47e64c16f1b45fce0df4f6acef8c7c40ffb97cf8997c", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 5, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 5}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-97454005bdbba04ea720e4fb", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/003984", "medicine_name": "Bortezomib Accord", "medicine_slug": "bortezomib-accord", "observed_at": "2026-10-12T13:47:15Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "150a191aaf0a1e169e9d5fa2530f0eccb4e3d46509faf5ec5ee975a2e67788c4", "source_snapshot_id": "source-cba4680b7fbd2c536884abd8", "source_updated_at": "2026-03-25", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/bortezomib-accord-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 4299}
{"after": {"end": 391, "start": 0, "text": "In view of available data on risk(s) from the literature, spontaneous reports including 2 cases with positive de-challenge, positive rechallenge and compatible TTO, 5 cases with a compatible TTO and positive de-challenge and other 13 cases with a close temporal association, the PRAC considers a causal relationship between darifenacin, and muscle spasm is at least a reasonable possibility.", "truncated": false}, "after_length": 391, "after_sha256": "3a851b84fc3e33f818c56ce8aafde86703dab91a7539308982af584b50c98d57", "annex": "IV", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 391, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 391}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-97808f237182ace137880700", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/000554", "medicine_name": "Emselex", "medicine_slug": "emselex", "observed_at": "2026-10-12T19:12:04Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "conditions", "section_type": "conditions", "source_provider": "European Medicines Agency", "source_sha256": "4f2565612bc728ec67b7f9c0cd5799ef2c594911c76f323aef8bf6a85adde245", "source_snapshot_id": "source-1fda25b331eb198b8b93feb3", "source_updated_at": "2025-09-15", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/emselex-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 2079}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 5, "start": 0, "text": "Īrija", "truncated": false}, "before_length": 5, "before_sha256": "8a6adc0410f24796a13031ae3d8e883a6939ac968000d59f9b32d97fce8d68be", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 5, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 5, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-978ecde2f2502a2a6cba4c23", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002097", "medicine_name": "Fampyra", "medicine_slug": "fampyra", "observed_at": "2026-10-12T19:15:51Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "d9fe8aaaa611a84801d6308b13685258b5248df9022536697939afdf66fc1719", "source_snapshot_id": "source-ff8e0599077f0d01044dc867", "source_updated_at": "2025-08-21", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/fampyra-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1618}
{"after": {"end": 23, "start": 0, "text": "60318 Frankfurt am Main", "truncated": false}, "after_length": 23, "after_sha256": "24c3191b5088b20c209c4387a8127297e54c776e161d305c9e57956a13b7cbbe", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 23, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 23}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-97c998271f492cfda5fd4ebf", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002097", "medicine_name": "Fampyra", "medicine_slug": "fampyra", "observed_at": "2026-10-12T19:15:51Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "d9fe8aaaa611a84801d6308b13685258b5248df9022536697939afdf66fc1719", "source_snapshot_id": "source-ff8e0599077f0d01044dc867", "source_updated_at": "2025-08-21", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/fampyra-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1528}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 21, "start": 0, "text": "Tel: +31 35 528 39 57", "truncated": false}, "before_length": 21, "before_sha256": "7baf6601f41e49e470f803fdd4e755a86efa38be423317c000ed79963ebdd213", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 21, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 21, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-980d9753e84f266dadd99a9f", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:14Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "8b8c4cc8e6f1a21fedee4bf0743c9c03e454b50f5eaba0e3760416d7fe0a74ec", "source_snapshot_id": "source-4efe4ecf3ebf08d338a763a5", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 2012}
{"after": {"end": 25, "start": 0, "text": "Eurocept International BV", "truncated": false}, "after_length": 25, "after_sha256": "b17bd89b3cf285c986a6070d0d67f5326dd5c1f08a70834c296c6c820f9e7505", "annex": "IIIA", "before": {"end": 27, "start": 0, "text": "(Eurocept International BV)", "truncated": false}, "before_length": 27, "before_sha256": "e6cf9b20aaa466e53ad0d393512ca75931e13e488321e3be6f3e4f8b600970c8", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 1, "before_start": 0, "kind": "delete"}, {"after_end": 25, "after_start": 25, "before_end": 27, "before_start": 26, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 2, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-981000a5c137a72f15de18bf", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:14Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "8b8c4cc8e6f1a21fedee4bf0743c9c03e454b50f5eaba0e3760416d7fe0a74ec", "source_snapshot_id": "source-4efe4ecf3ebf08d338a763a5", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1932}
{"after": {"end": 18, "start": 0, "text": "Raktarvarosi Ut 9,", "truncated": false}, "after_length": 18, "after_sha256": "71dd279084ba9f87e79f1095d3565620050fda91d248303c2e19c46598fb0c2b", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 18, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 18}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-9834247c0bfd5375bdc05974", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/006047", "medicine_name": "Lacosamide Adroiq", "medicine_slug": "lacosamide-adroiq", "observed_at": "2026-10-12T19:07:59Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "cc83d966059d42856d0211a4f256b29b20d43593865704d6a9315aeb694f3c76", "source_snapshot_id": "source-896abba1d8391c918345d46b", "source_updated_at": "2025-09-25", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/lacosamide-adroiq-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1209}
{"after": {"end": 21, "start": 0, "text": "Tel: +31 35 528 39 57", "truncated": false}, "after_length": 21, "after_sha256": "7baf6601f41e49e470f803fdd4e755a86efa38be423317c000ed79963ebdd213", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 21, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 21}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-9850cb8b83225011c4654882", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:19Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "77586d0bea0858214b43b86e91abc2d2711733b96959ead5ed0b5ecbd8ed888a", "source_snapshot_id": "source-85d476f9ad959cc117ca8f1f", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1818}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "I", "before": {"end": 9, "start": 0, "text": "Allemagne", "truncated": false}, "before_length": 9, "before_sha256": "6b58dbd6a994339b48d8446597da22402857b3409613459c7e3a293788fbe66a", "change_kind": "administrative", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 9, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 9, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-98539537dd5963b064457204", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/005246", "medicine_name": "Byfavo", "medicine_slug": "byfavo", "observed_at": "2026-10-12T13:28:16Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "7", "section_type": "administrative", "source_provider": "European Medicines Agency", "source_sha256": "61243a969f979f690fe718e414ceaeb66438c1faa31101ba25187d2f9ea662fd", "source_snapshot_id": "source-dd26eb8615d8c18bd80c1f6a", "source_updated_at": "2026-08-26", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/byfavo-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 2712}
{"after": {"end": 37, "start": 0, "text": "Accord Healthcare single member S.A.,", "truncated": false}, "after_length": 37, "after_sha256": "752db38ded53417be77ebcd9ac87192289314f53aaa486d956ca57b89edd2bea", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 37, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 37}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-986aecc6e7a5de37d8371330", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/003984", "medicine_name": "Bortezomib Accord", "medicine_slug": "bortezomib-accord", "observed_at": "2026-10-12T13:47:12Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "e4aac937241121e8ad1e32b40b1007fb58398035928568a7e60a65074b0efb36", "source_snapshot_id": "source-b1eaab6445cfa827e3b1481b", "source_updated_at": "2026-03-25", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/bortezomib-accord-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 4237}
{"after": {"end": 26, "start": 0, "text": "Dipharma Arzneimittel GmbH", "truncated": false}, "after_length": 26, "after_sha256": "d8cb257047b7439a3be44a22f3227e45df27054340bbfa9cd6525bbf1d237add", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 26, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 26}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-989597e344d5086e4a7cce4c", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:19Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "77586d0bea0858214b43b86e91abc2d2711733b96959ead5ed0b5ecbd8ed888a", "source_snapshot_id": "source-85d476f9ad959cc117ca8f1f", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1429}
{"after": {"end": 21, "start": 0, "text": "Teл.: +40 21 528 0290", "truncated": false}, "after_length": 21, "after_sha256": "ec107d1625029392f60daf4b58132a83529ea43f1b9ebdf646436a843f24ad5b", "annex": "IIIA", "before": {"end": 26, "start": 0, "text": "Teл.: +359 (0) 888 755 393", "truncated": false}, "before_length": 26, "before_sha256": "25d34bfa98e800128c16111612beebc119b20f0c6456910d298344a0c0ffe050", "change_kind": "content", "change_operations": [{"after_end": 13, "after_start": 7, "before_end": 8, "before_start": 7, "kind": "replace"}, {"after_end": 15, "after_start": 14, "before_end": 17, "before_start": 9, "kind": "replace"}, {"after_end": 19, "after_start": 17, "before_end": 24, "before_start": 19, "kind": "replace"}, {"after_end": 21, "after_start": 20, "before_end": 26, "before_start": 25, "kind": "replace"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 15, "chars_inserted": 10}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-98a06519c0fd105f958cfcf3", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002066", "medicine_name": "Ikervis", "medicine_slug": "ikervis", "observed_at": "2026-10-12T13:34:10Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "7995ffe3d4b9c2e870327b45fae2f1d35ae1ab0e1e9e22b434fd9805b58a174e", "source_snapshot_id": "source-5ff0e792002ee89d9eb06e5d", "source_updated_at": "2026-06-23", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/ikervis-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1754}
{"after": {"end": 21, "start": 0, "text": "Tel: +31 35 528 39 57", "truncated": false}, "after_length": 21, "after_sha256": "7baf6601f41e49e470f803fdd4e755a86efa38be423317c000ed79963ebdd213", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 21, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 21}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-98b50716a6fb367541964683", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:14Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "8b8c4cc8e6f1a21fedee4bf0743c9c03e454b50f5eaba0e3760416d7fe0a74ec", "source_snapshot_id": "source-4efe4ecf3ebf08d338a763a5", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1883}
{"after": {"end": 25, "start": 0, "text": "Conclusions scientifiques", "truncated": false}, "after_length": 25, "after_sha256": "b9dba41fa3c9d3b642cfe755c989781c6765c2e1667b80c2d6fb1f02a6cb6463", "annex": "IV", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 25, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 25}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-98b767a5da123c7be5f4c141", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/000554", "medicine_name": "Emselex", "medicine_slug": "emselex", "observed_at": "2026-10-12T19:12:07Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": null, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "conditions", "section_type": "conditions", "source_provider": "European Medicines Agency", "source_sha256": "9a4f1d7e260c7b80eaf397503623b63302e5945b579e9612177835e07c4ab888", "source_snapshot_id": "source-3aac7bf42b99529f25ac013b", "source_updated_at": "2025-09-15", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/emselex-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 2062}
{"after": {"end": 26, "start": 0, "text": "Eckenheimer Landstraße 100", "truncated": false}, "after_length": 26, "after_sha256": "fdce1a9bd200c5ddd476c1ea5676b9ffbbea723f7353ad6fbc1fe019dcb86c07", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 26, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 26}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-98bc3cd6c904333f4b8b9287", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002097", "medicine_name": "Fampyra", "medicine_slug": "fampyra", "observed_at": "2026-10-12T19:15:51Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "d9fe8aaaa611a84801d6308b13685258b5248df9022536697939afdf66fc1719", "source_snapshot_id": "source-ff8e0599077f0d01044dc867", "source_updated_at": "2025-08-21", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/fampyra-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1619}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 56, "start": 0, "text": "35/36 Baldoyle Industrial Estate, Grange Road, Dublin 13", "truncated": false}, "before_length": 56, "before_sha256": "f0fa66e07d117c6c91c11210809d32b098e6ea28fc318be9df3a372f6c002a1a", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 56, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 56, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-9900833fc0b8f82cdcc14eb0", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/004025", "medicine_name": "Lopinavir/Ritonavir Viatris (previously Ritonavir Mylan)", "medicine_slug": "lopinavir-ritonavir-viatris-previously-ritonavir-mylan", "observed_at": "2026-10-12T19:12:46Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "3e30663f02732816ed8779d7a929d500c824ae15aeaee9144ca6eef11900e273", "source_snapshot_id": "source-c58e019b5bec1fb24569e83e", "source_updated_at": "2025-09-08", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/lopinavir-ritonavir-viatris-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 3417}
{"after": {"end": 9, "start": 0, "text": "Not known", "truncated": false}, "after_length": 9, "after_sha256": "117adf013b8521b57cc432f1d680aa8ca8ffe7ac83edfa7e0a5867794a6429cc", "annex": "I", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 9, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": true, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 9}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-99260a892180d7d3ef389335", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/000554", "medicine_name": "Emselex", "medicine_slug": "emselex", "observed_at": "2026-10-12T19:12:04Z", "pipeline_version": "2.0.0", "presentation_label": "Emselex 15 mg prolonged-release tablets", "presentation_occurrence": 2, "presentation_status": "heading_extracted_unverified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "4.8", "section_type": "adverse_reactions", "source_provider": "European Medicines Agency", "source_sha256": "4f2565612bc728ec67b7f9c0cd5799ef2c594911c76f323aef8bf6a85adde245", "source_snapshot_id": "source-1fda25b331eb198b8b93feb3", "source_updated_at": "2025-09-15", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/emselex-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 603}
{"after": {"end": 22, "start": 0, "text": "IMED Poland Sp. z o.o.", "truncated": false}, "after_length": 22, "after_sha256": "b3265866c253edae29f5501eb68307d984be0f139bc8dba8b343d9b3ff61e415", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 22, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 22}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-993ffb04dd2b361d00b32d1c", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:19Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "77586d0bea0858214b43b86e91abc2d2711733b96959ead5ed0b5ecbd8ed888a", "source_snapshot_id": "source-85d476f9ad959cc117ca8f1f", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1904}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 16, "start": 0, "text": "Extrovis EU Ltd.", "truncated": false}, "before_length": 16, "before_sha256": "f462ad48e7aef0bc82148ce088af1897d99ed86993128f30d506b27d3108a929", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 16, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 16, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-99413b8f11e6105f5b6a41e9", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/006047", "medicine_name": "Lacosamide Adroiq", "medicine_slug": "lacosamide-adroiq", "observed_at": "2026-10-12T19:07:59Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "cc83d966059d42856d0211a4f256b29b20d43593865704d6a9315aeb694f3c76", "source_snapshot_id": "source-896abba1d8391c918345d46b", "source_updated_at": "2025-09-25", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/lacosamide-adroiq-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1712}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 27, "start": 0, "text": "(Eurocept International BV)", "truncated": false}, "before_length": 27, "before_sha256": "e6cf9b20aaa466e53ad0d393512ca75931e13e488321e3be6f3e4f8b600970c8", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 27, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 27, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-996c9dc014a516949afc8de5", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:14Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "8b8c4cc8e6f1a21fedee4bf0743c9c03e454b50f5eaba0e3760416d7fe0a74ec", "source_snapshot_id": "source-4efe4ecf3ebf08d338a763a5", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1921}
{"after": {"end": 21, "start": 0, "text": "Tel: +31 35 528 39 57", "truncated": false}, "after_length": 21, "after_sha256": "7baf6601f41e49e470f803fdd4e755a86efa38be423317c000ed79963ebdd213", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 21, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 21}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-998e616754b868cca704f47b", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:14Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "8b8c4cc8e6f1a21fedee4bf0743c9c03e454b50f5eaba0e3760416d7fe0a74ec", "source_snapshot_id": "source-4efe4ecf3ebf08d338a763a5", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1467}
{"after": {"end": 20, "start": 0, "text": "dpoc.croatia@msd.com", "truncated": false}, "after_length": 20, "after_sha256": "e6060fe9f944bc26788eae6c6fde884372f9d1fb19a754bedfaa7c027a1b33e8", "annex": "IIIA", "before": {"end": 20, "start": 0, "text": "croatia_info@msd.com", "truncated": false}, "before_length": 20, "before_sha256": "e27d3e8b649fc3426307a99d89af2559641417eb6eb1e1e1eb89c992ad0abe97", "change_kind": "content", "change_operations": [{"after_end": 5, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}, {"after_end": 12, "after_start": 12, "before_end": 12, "before_start": 7, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 5, "chars_inserted": 5}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-99a50f220153c8cd4b5f5592", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/000389", "medicine_name": "Invanz", "medicine_slug": "invanz", "observed_at": "2026-10-12T17:30:44Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "a9208c117495d2d6c465ba196e4dbbb3d498b27d747df3b2d0145b0549743e4b", "source_snapshot_id": "source-e56383168f778128e02c2b2e", "source_updated_at": "2025-11-21", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/invanz-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1186}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 13, "start": 0, "text": "Lucane Pharma", "truncated": false}, "before_length": 13, "before_sha256": "e338afdb64acf1a6e2083a50318853589248451dd3aa707181ba02641a8521e8", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 13, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 13, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-99d7982f59c60663bb70b5e8", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:14Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "8b8c4cc8e6f1a21fedee4bf0743c9c03e454b50f5eaba0e3760416d7fe0a74ec", "source_snapshot_id": "source-4efe4ecf3ebf08d338a763a5", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1482}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 21, "start": 0, "text": "info@lucanepharma.com", "truncated": false}, "before_length": 21, "before_sha256": "44fd39e5fb919cb3d680fa630da23b49238fec29159c509f3622f272bb41c7c6", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 21, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 21, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-9a208216ded5e7cfe77ec812", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:19Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "77586d0bea0858214b43b86e91abc2d2711733b96959ead5ed0b5ecbd8ed888a", "source_snapshot_id": "source-85d476f9ad959cc117ca8f1f", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1805}
{"after": {"end": 26, "start": 0, "text": "Eckenheimer Landstraße 100", "truncated": false}, "after_length": 26, "after_sha256": "fdce1a9bd200c5ddd476c1ea5676b9ffbbea723f7353ad6fbc1fe019dcb86c07", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 26, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 26}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-9a5bdda0bfd958f6044f8cfe", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002097", "medicine_name": "Fampyra", "medicine_slug": "fampyra", "observed_at": "2026-10-12T19:16:07Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "a0c3ba8d58d6a43a809ecc3d142a78b10c2bd7f0b9f3a3553df2617d87daec1f", "source_snapshot_id": "source-c7a810dd21f94cd2d273f0da", "source_updated_at": "2025-08-21", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/fampyra-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1471}
{"after": {"end": 21, "start": 0, "text": "Tel: +31 35 528 39 57", "truncated": false}, "after_length": 21, "after_sha256": "7baf6601f41e49e470f803fdd4e755a86efa38be423317c000ed79963ebdd213", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 21, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 21}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-9a8630c7e45cfc391ecc8a2c", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:19Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "77586d0bea0858214b43b86e91abc2d2711733b96959ead5ed0b5ecbd8ed888a", "source_snapshot_id": "source-85d476f9ad959cc117ca8f1f", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1879}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 18, "start": 0, "text": "Dublin 2, D02 T380", "truncated": false}, "before_length": 18, "before_sha256": "23e6871e7960b0dadc753bc127bbea230cc8308c88b2d33704eb275a3ec1a70d", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 18, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 18, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-9a894c4fb62f98dadc6ae0d6", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002097", "medicine_name": "Fampyra", "medicine_slug": "fampyra", "observed_at": "2026-10-12T19:15:51Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "d9fe8aaaa611a84801d6308b13685258b5248df9022536697939afdf66fc1719", "source_snapshot_id": "source-ff8e0599077f0d01044dc867", "source_updated_at": "2025-08-21", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/fampyra-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1029}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 21, "start": 0, "text": "Tel: +31 35 528 39 57", "truncated": false}, "before_length": 21, "before_sha256": "7baf6601f41e49e470f803fdd4e755a86efa38be423317c000ed79963ebdd213", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 21, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 21, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-9ab4668f5e3133688bef7db0", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:14Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "8b8c4cc8e6f1a21fedee4bf0743c9c03e454b50f5eaba0e3760416d7fe0a74ec", "source_snapshot_id": "source-4efe4ecf3ebf08d338a763a5", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1922}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 16, "start": 0, "text": "Extrovis EU Ltd.", "truncated": false}, "before_length": 16, "before_sha256": "f462ad48e7aef0bc82148ce088af1897d99ed86993128f30d506b27d3108a929", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 16, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 16, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-9ac5c130a1013b9218068f9e", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/006047", "medicine_name": "Lacosamide Adroiq", "medicine_slug": "lacosamide-adroiq", "observed_at": "2026-10-12T19:07:59Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "cc83d966059d42856d0211a4f256b29b20d43593865704d6a9315aeb694f3c76", "source_snapshot_id": "source-896abba1d8391c918345d46b", "source_updated_at": "2025-09-25", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/lacosamide-adroiq-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1723}
{"after": {"end": 6, "start": 0, "text": "Niemcy", "truncated": false}, "after_length": 6, "after_sha256": "82a151e1ce6f9049025aa2bbeea8e0498f4f1f876417914affb5e23f00b2e42d", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 6, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 6}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-9b22f892d668ed5bdd20aaba", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002097", "medicine_name": "Fampyra", "medicine_slug": "fampyra", "observed_at": "2026-10-12T19:15:51Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "d9fe8aaaa611a84801d6308b13685258b5248df9022536697939afdf66fc1719", "source_snapshot_id": "source-ff8e0599077f0d01044dc867", "source_updated_at": "2025-08-21", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/fampyra-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1506}
{"after": {"end": 26, "start": 0, "text": "Eckenheimer Landstraße 100", "truncated": false}, "after_length": 26, "after_sha256": "fdce1a9bd200c5ddd476c1ea5676b9ffbbea723f7353ad6fbc1fe019dcb86c07", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 26, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 26}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-9b94b2849b6a0a0588ceef62", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002097", "medicine_name": "Fampyra", "medicine_slug": "fampyra", "observed_at": "2026-10-12T19:15:51Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "d9fe8aaaa611a84801d6308b13685258b5248df9022536697939afdf66fc1719", "source_snapshot_id": "source-ff8e0599077f0d01044dc867", "source_updated_at": "2025-08-21", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/fampyra-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1483}
{"after": {"end": 26, "start": 0, "text": "Dipharma Arzneimittel GmbH", "truncated": false}, "after_length": 26, "after_sha256": "d8cb257047b7439a3be44a22f3227e45df27054340bbfa9cd6525bbf1d237add", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 26, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 26}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-9bb75c1103386d497e3af58e", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:19Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "77586d0bea0858214b43b86e91abc2d2711733b96959ead5ed0b5ecbd8ed888a", "source_snapshot_id": "source-85d476f9ad959cc117ca8f1f", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1461}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIB", "before": {"end": 16, "start": 0, "text": "Extrovis EU Ltd.", "truncated": false}, "before_length": 16, "before_sha256": "f462ad48e7aef0bc82148ce088af1897d99ed86993128f30d506b27d3108a929", "change_kind": "unassigned", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 16, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 16, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-9bd0b20e2b31331bcfc5e476", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/006047", "medicine_name": "Lacosamide Adroiq", "medicine_slug": "lacosamide-adroiq", "observed_at": "2026-10-12T19:07:56Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "", "section_type": "unassigned", "source_provider": "European Medicines Agency", "source_sha256": "0578c53a5e1c785c4d9d4dc0dabae49dbfa89e237aa571556bee548c3f9cf4d5", "source_snapshot_id": "source-64831dec5ebf55535e19d91b", "source_updated_at": "2025-09-25", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/lacosamide-adroiq-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1969}
{"after": {"end": 23, "start": 0, "text": "info@euroceptpharma.com", "truncated": false}, "after_length": 23, "after_sha256": "9297cc5acdcc837f054116992765943f7907937507b2564a99ea1327a00ac0e6", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 23, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 23}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-9bf23a080fe0c2fe87054ebd", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:14Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "8b8c4cc8e6f1a21fedee4bf0743c9c03e454b50f5eaba0e3760416d7fe0a74ec", "source_snapshot_id": "source-4efe4ecf3ebf08d338a763a5", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1972}
{"after": {"end": 143, "start": 0, "text": "Compte tenu du rapport d’évaluation du PRAC sur les PSUR concernant la darifénacine, les conclusions scientifiques du PRAC sont les suivantes :", "truncated": false}, "after_length": 143, "after_sha256": "26e0dad50479bee84ea48404696e9ef592b5dc5f77b662c0833989175d2a3915", "annex": "IV", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 143, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 143}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-9bf613048195b1f25004d5da", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/000554", "medicine_name": "Emselex", "medicine_slug": "emselex", "observed_at": "2026-10-12T19:12:07Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": null, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "conditions", "section_type": "conditions", "source_provider": "European Medicines Agency", "source_sha256": "9a4f1d7e260c7b80eaf397503623b63302e5945b579e9612177835e07c4ab888", "source_snapshot_id": "source-3aac7bf42b99529f25ac013b", "source_updated_at": "2025-09-15", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/emselex-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 2064}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 13, "start": 0, "text": "Lucane Pharma", "truncated": false}, "before_length": 13, "before_sha256": "e338afdb64acf1a6e2083a50318853589248451dd3aa707181ba02641a8521e8", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 13, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 13, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-9c10c39583f8e594a65e470e", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:19Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "77586d0bea0858214b43b86e91abc2d2711733b96959ead5ed0b5ecbd8ed888a", "source_snapshot_id": "source-85d476f9ad959cc117ca8f1f", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1511}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 18, "start": 0, "text": "Dublin 2, D02 T380", "truncated": false}, "before_length": 18, "before_sha256": "23e6871e7960b0dadc753bc127bbea230cc8308c88b2d33704eb275a3ec1a70d", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 18, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 18, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-9c274a1a8aa09679fb6d8b18", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002097", "medicine_name": "Fampyra", "medicine_slug": "fampyra", "observed_at": "2026-10-12T19:16:07Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "a0c3ba8d58d6a43a809ecc3d142a78b10c2bd7f0b9f3a3553df2617d87daec1f", "source_snapshot_id": "source-c7a810dd21f94cd2d273f0da", "source_updated_at": "2025-08-21", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/fampyra-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1416}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 33, "start": 0, "text": "United Kingdom (Northern Ireland)", "truncated": false}, "before_length": 33, "before_sha256": "9379d82927cdb505cfb186e912177065e56a1314de3a2b914ebbb8b5fe21525a", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 33, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 33, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-9cc120f29e6b6e29a7a613b5", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002514", "medicine_name": "Aubagio", "medicine_slug": "aubagio", "observed_at": "2026-10-12T17:28:37Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "2583b2915ecedeb3bccc3ac6bea691e65d05f5e437bf8aa7970917b6fdeb700c", "source_snapshot_id": "source-15791f384b9e49792c9776dd", "source_updated_at": "2025-12-09", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/aubagio-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 2080}
{"after": {"end": 28, "start": 0, "text": "Otsuka Pharma Scandinavia AB", "truncated": false}, "after_length": 28, "after_sha256": "da6b14629ea48096b1862cba5aad936b5d470b29f653a1de638e5ea031c53c39", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 28, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 28}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-9cd89f4a5c7cd499eb7ffed2", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/000980", "medicine_name": "Samsca", "medicine_slug": "samsca", "observed_at": "2026-10-12T13:28:23Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "b92d73a758b8976c4438a072d544f0d6c603112c90dfc9c084d362ce62419257", "source_snapshot_id": "source-15b8b5681aba542ec1668c0b", "source_updated_at": "2026-08-20", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/samsca-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1287}
{"after": {"end": 21, "start": 0, "text": "Tel: +31 35 528 39 57", "truncated": false}, "after_length": 21, "after_sha256": "7baf6601f41e49e470f803fdd4e755a86efa38be423317c000ed79963ebdd213", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 21, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 21}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-9cdf0db2809ebdd8790b1a6a", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:19Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "77586d0bea0858214b43b86e91abc2d2711733b96959ead5ed0b5ecbd8ed888a", "source_snapshot_id": "source-85d476f9ad959cc117ca8f1f", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1954}
{"after": {"end": 23, "start": 0, "text": "info@euroceptpharma.com", "truncated": false}, "after_length": 23, "after_sha256": "9297cc5acdcc837f054116992765943f7907937507b2564a99ea1327a00ac0e6", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 23, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 23}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-9d96c30e786dcd540d51a515", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:14Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "8b8c4cc8e6f1a21fedee4bf0743c9c03e454b50f5eaba0e3760416d7fe0a74ec", "source_snapshot_id": "source-4efe4ecf3ebf08d338a763a5", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1528}
{"after": {"end": 22, "start": 0, "text": "IMED Poland Sp. z o.o.", "truncated": false}, "after_length": 22, "after_sha256": "b3265866c253edae29f5501eb68307d984be0f139bc8dba8b343d9b3ff61e415", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 22, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 22}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-9da24efb2fadea208a9c52b9", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:19Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "77586d0bea0858214b43b86e91abc2d2711733b96959ead5ed0b5ecbd8ed888a", "source_snapshot_id": "source-85d476f9ad959cc117ca8f1f", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1475}
{"after": {"end": 23, "start": 0, "text": "60318 Frankfurt am Main", "truncated": false}, "after_length": 23, "after_sha256": "24c3191b5088b20c209c4387a8127297e54c776e161d305c9e57956a13b7cbbe", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 23, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 23}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-9dcd62bbfcb6fa8bc0066d4c", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002097", "medicine_name": "Fampyra", "medicine_slug": "fampyra", "observed_at": "2026-10-12T19:15:51Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "d9fe8aaaa611a84801d6308b13685258b5248df9022536697939afdf66fc1719", "source_snapshot_id": "source-ff8e0599077f0d01044dc867", "source_updated_at": "2025-08-21", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/fampyra-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1557}
{"after": {"end": 22, "start": 0, "text": "Merz Therapeutics GmbH", "truncated": false}, "after_length": 22, "after_sha256": "059f049c7d0846aaadcf2573280d52110f302d4ecc7b38debd004571cd1e9d5e", "annex": "IIIA", "before": {"end": 35, "start": 0, "text": "Acorda Therapeutics Ireland Limited", "truncated": false}, "before_length": 35, "before_sha256": "d94d3153d193ed26567f2b4ed48df016d81c534e7c0cb1a6655a63f0083383ff", "change_kind": "content", "change_operations": [{"after_end": 2, "after_start": 0, "before_end": 3, "before_start": 0, "kind": "replace"}, {"after_end": 4, "after_start": 3, "before_end": 6, "before_start": 4, "kind": "replace"}, {"after_end": 19, "after_start": 18, "before_end": 30, "before_start": 20, "kind": "replace"}, {"after_end": 22, "after_start": 20, "before_end": 35, "before_start": 31, "kind": "replace"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 19, "chars_inserted": 6}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-9e3c68b40c2838e778de50f2", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002097", "medicine_name": "Fampyra", "medicine_slug": "fampyra", "observed_at": "2026-10-12T19:16:07Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "a0c3ba8d58d6a43a809ecc3d142a78b10c2bd7f0b9f3a3553df2617d87daec1f", "source_snapshot_id": "source-c7a810dd21f94cd2d273f0da", "source_updated_at": "2025-08-21", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/fampyra-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1567}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 22, "start": 0, "text": "Tel : +31 35 528 39 57", "truncated": false}, "before_length": 22, "before_sha256": "7bb8afadf5dee15b4f4e1219e333b993040f0848bccea58b1141990fffb82aa1", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 22, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 22, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-9e44a40703149c5b13993389", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:19Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "77586d0bea0858214b43b86e91abc2d2711733b96959ead5ed0b5ecbd8ed888a", "source_snapshot_id": "source-85d476f9ad959cc117ca8f1f", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1922}
{"after": {"end": 21, "start": 0, "text": "Tel: +31 35 528 39 57", "truncated": false}, "after_length": 21, "after_sha256": "7baf6601f41e49e470f803fdd4e755a86efa38be423317c000ed79963ebdd213", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 21, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 21}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-9e64cd5dfa25404b6cd02852", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:19Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "77586d0bea0858214b43b86e91abc2d2711733b96959ead5ed0b5ecbd8ed888a", "source_snapshot_id": "source-85d476f9ad959cc117ca8f1f", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1438}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 22, "start": 0, "text": "Tel : +31 35 528 39 57", "truncated": false}, "before_length": 22, "before_sha256": "7bb8afadf5dee15b4f4e1219e333b993040f0848bccea58b1141990fffb82aa1", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 22, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 22, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-9e7bd26ed50d4a8bd6ce4219", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:19Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "77586d0bea0858214b43b86e91abc2d2711733b96959ead5ed0b5ecbd8ed888a", "source_snapshot_id": "source-85d476f9ad959cc117ca8f1f", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1900}
{"after": {"end": 21, "start": 0, "text": "Tel: +31 35 528 39 57", "truncated": false}, "after_length": 21, "after_sha256": "7baf6601f41e49e470f803fdd4e755a86efa38be423317c000ed79963ebdd213", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 21, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 21}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-9ed3f31f6c6987fe7bc5549a", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:19Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "77586d0bea0858214b43b86e91abc2d2711733b96959ead5ed0b5ecbd8ed888a", "source_snapshot_id": "source-85d476f9ad959cc117ca8f1f", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1977}
{"after": {"end": 23, "start": 0, "text": "Tel: +49 (0) 69 15 03 0", "truncated": false}, "after_length": 23, "after_sha256": "09683b3f43171b2266a32d9f7d44e3d62d536522dc6f42d4b47f2dda48b31833", "annex": "IIIA", "before": {"end": 23, "start": 0, "text": "Tel: +353 (0)1 231 4609", "truncated": false}, "before_length": 23, "before_sha256": "a115f11f382ef18898b9d956e48603ae236fd1846ce41e8586af99b6dabbfc4d", "change_kind": "content", "change_operations": [{"after_end": 8, "after_start": 6, "before_end": 9, "before_start": 6, "kind": "replace"}, {"after_end": 16, "after_start": 12, "before_end": 13, "before_start": 13, "kind": "insert"}, {"after_end": 18, "after_start": 17, "before_end": 14, "before_start": 14, "kind": "insert"}, {"after_end": 20, "after_start": 19, "before_end": 16, "before_start": 15, "kind": "replace"}, {"after_end": 21, "after_start": 21, "before_end": 18, "before_start": 17, "kind": "delete"}, {"after_end": 22, "after_start": 22, "before_end": 21, "before_start": 19, "kind": "delete"}, {"after_end": 23, "after_start": 23, "before_end": 23, "before_start": 22, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 8, "chars_inserted": 8}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-9eeea1101f90ee53e432995d", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002097", "medicine_name": "Fampyra", "medicine_slug": "fampyra", "observed_at": "2026-10-12T19:16:07Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "a0c3ba8d58d6a43a809ecc3d142a78b10c2bd7f0b9f3a3553df2617d87daec1f", "source_snapshot_id": "source-c7a810dd21f94cd2d273f0da", "source_updated_at": "2025-08-21", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/fampyra-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1421}
{"after": {"end": 21, "start": 0, "text": "Tlf.: +45 45 26 60 00", "truncated": false}, "after_length": 21, "after_sha256": "6bdd3c845f6a6e520023cbb8b3726e2eefc4bc4ac00ae57245f3055e31d53895", "annex": "III", "before": {"end": 20, "start": 0, "text": "Tlf: +45 45 26 60 00", "truncated": false}, "before_length": 20, "before_sha256": "7932ef9452966b997a4a22618abb01fb644277c9ab041214e6264730772b2d64", "change_kind": "unassigned", "change_operations": [{"after_end": 4, "after_start": 3, "before_end": 3, "before_start": 3, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 1}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-9ef833ee6d84b0bf1409be5b", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/001021", "medicine_name": "Adcirca (previously Tadalafil Lilly)", "medicine_slug": "adcirca-previously-tadalafil-lilly", "observed_at": "2026-10-12T19:02:45Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "", "section_type": "unassigned", "source_provider": "European Medicines Agency", "source_sha256": "cdbefcd6143c93e81f3c826bea8d3d01bffc55652e0f792243097df75c452721", "source_snapshot_id": "source-a1e85476de17f5a8664f7766", "source_updated_at": "2026-01-28", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/adcirca-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1946}
{"after": {"end": 21, "start": 0, "text": "Tel: +31 35 528 39 57", "truncated": false}, "after_length": 21, "after_sha256": "7baf6601f41e49e470f803fdd4e755a86efa38be423317c000ed79963ebdd213", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 21, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 21}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-9f0fae464e5f82535d7ebfe6", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:14Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "8b8c4cc8e6f1a21fedee4bf0743c9c03e454b50f5eaba0e3760416d7fe0a74ec", "source_snapshot_id": "source-4efe4ecf3ebf08d338a763a5", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 2014}
{"after": {"end": 22, "start": 0, "text": "Merz Therapeutics GmbH", "truncated": false}, "after_length": 22, "after_sha256": "059f049c7d0846aaadcf2573280d52110f302d4ecc7b38debd004571cd1e9d5e", "annex": "IIIA", "before": {"end": 35, "start": 0, "text": "Acorda Therapeutics Ireland Limited", "truncated": false}, "before_length": 35, "before_sha256": "d94d3153d193ed26567f2b4ed48df016d81c534e7c0cb1a6655a63f0083383ff", "change_kind": "content", "change_operations": [{"after_end": 2, "after_start": 0, "before_end": 3, "before_start": 0, "kind": "replace"}, {"after_end": 4, "after_start": 3, "before_end": 6, "before_start": 4, "kind": "replace"}, {"after_end": 19, "after_start": 18, "before_end": 30, "before_start": 20, "kind": "replace"}, {"after_end": 22, "after_start": 20, "before_end": 35, "before_start": 31, "kind": "replace"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 19, "chars_inserted": 6}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-9f103911e6384cf9c9632870", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002097", "medicine_name": "Fampyra", "medicine_slug": "fampyra", "observed_at": "2026-10-12T19:16:07Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "a0c3ba8d58d6a43a809ecc3d142a78b10c2bd7f0b9f3a3553df2617d87daec1f", "source_snapshot_id": "source-c7a810dd21f94cd2d273f0da", "source_updated_at": "2025-08-21", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/fampyra-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1558}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "III", "before": {"end": 39, "start": 0, "text": "Eli Lilly and Company (Ireland) Limited", "truncated": false}, "before_length": 39, "before_sha256": "0555e8a06c0ef36afd955d945d4997f04834690c546541adf74802bac524a0e4", "change_kind": "unassigned", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 39, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 39, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-9f554a68c84eca6fbd1d7fb3", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/001021", "medicine_name": "Adcirca (previously Tadalafil Lilly)", "medicine_slug": "adcirca-previously-tadalafil-lilly", "observed_at": "2026-10-12T19:02:45Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "", "section_type": "unassigned", "source_provider": "European Medicines Agency", "source_sha256": "cdbefcd6143c93e81f3c826bea8d3d01bffc55652e0f792243097df75c452721", "source_snapshot_id": "source-a1e85476de17f5a8664f7766", "source_updated_at": "2026-01-28", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/adcirca-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 2304}
{"after": {"end": 16, "start": 0, "text": "Extrovis EU Kft.", "truncated": false}, "after_length": 16, "after_sha256": "b9216ef80e71e17798dce313e4318f03f37328f225d30ab508b7413813a908e5", "annex": "IIIB", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "unassigned", "change_operations": [{"after_end": 16, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 16}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-9f904d3f64d42452f255f27c", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/006047", "medicine_name": "Lacosamide Adroiq", "medicine_slug": "lacosamide-adroiq", "observed_at": "2026-10-12T19:07:56Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "", "section_type": "unassigned", "source_provider": "European Medicines Agency", "source_sha256": "0578c53a5e1c785c4d9d4dc0dabae49dbfa89e237aa571556bee548c3f9cf4d5", "source_snapshot_id": "source-64831dec5ebf55535e19d91b", "source_updated_at": "2025-09-25", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/lacosamide-adroiq-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1892}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "III", "before": {"end": 16, "start": 0, "text": "Extrovis EU Ltd.", "truncated": false}, "before_length": 16, "before_sha256": "f462ad48e7aef0bc82148ce088af1897d99ed86993128f30d506b27d3108a929", "change_kind": "unassigned", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 16, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 16, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-9fff4390970641cf7af9b1be", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/006047", "medicine_name": "Lacosamide Adroiq", "medicine_slug": "lacosamide-adroiq", "observed_at": "2026-10-12T19:07:56Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "", "section_type": "unassigned", "source_provider": "European Medicines Agency", "source_sha256": "0578c53a5e1c785c4d9d4dc0dabae49dbfa89e237aa571556bee548c3f9cf4d5", "source_snapshot_id": "source-64831dec5ebf55535e19d91b", "source_updated_at": "2025-09-25", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/lacosamide-adroiq-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1204}
{"after": {"end": 156, "start": 0, "text": "PHEBURANE should be administered orally. Because of its slow dissolution, PHEBURANE granules should not be administered by nasogastric or gastrostomy tubes.", "truncated": false}, "after_length": 156, "after_sha256": "becc37c9c3bf85fb72582155147c547a5523fe17c6c4868893056e82432d2ea3", "annex": "I", "before": {"end": 147, "start": 0, "text": "PHEBURANE should be administered orally. Because of its slow dissolution, PHEBURANE should not be administered by nasogastric or gastrostomy tubes.", "truncated": false}, "before_length": 147, "before_sha256": "250ce1afacf5f0b7b8787504fd8d9b20c3e54e12d3a14e662056082eca7c32cc", "change_kind": "content", "change_operations": [{"after_end": 93, "after_start": 84, "before_end": 84, "before_start": 84, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": true, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 9}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-a0005e5845b678789f76183d", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:14Z", "pipeline_version": "2.0.0", "presentation_label": "PHEBURANE 483 mg/g granules", "presentation_occurrence": 1, "presentation_status": "heading_extracted_unverified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "4.2", "section_type": "posology", "source_provider": "European Medicines Agency", "source_sha256": "8b8c4cc8e6f1a21fedee4bf0743c9c03e454b50f5eaba0e3760416d7fe0a74ec", "source_snapshot_id": "source-4efe4ecf3ebf08d338a763a5", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 93}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 13, "start": 0, "text": "Lucane Pharma", "truncated": false}, "before_length": 13, "before_sha256": "e338afdb64acf1a6e2083a50318853589248451dd3aa707181ba02641a8521e8", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 13, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 13, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-a0147f6f8e40ba47005c3e2a", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:19Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "77586d0bea0858214b43b86e91abc2d2711733b96959ead5ed0b5ecbd8ed888a", "source_snapshot_id": "source-85d476f9ad959cc117ca8f1f", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1546}
{"after": {"end": 25, "start": 0, "text": "Gustav III:s Boulevard 32", "truncated": false}, "after_length": 25, "after_sha256": "bba3ec2bf3d09014ee723cdd39b8fa83a1dc3705ce0797ed375b3af7c8be027c", "annex": "IIIA", "before": {"end": 25, "start": 0, "text": "Gustav III S Boulevard 32", "truncated": false}, "before_length": 25, "before_sha256": "6117fe99f25fb7a4848fea16fe447d9ead174e8fb74f0ec2aaad6366c885562b", "change_kind": "content", "change_operations": [{"after_end": 12, "after_start": 10, "before_end": 12, "before_start": 10, "kind": "replace"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 2, "chars_inserted": 2}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-a04cc3b627488062273e362e", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002097", "medicine_name": "Fampyra", "medicine_slug": "fampyra", "observed_at": "2026-10-12T19:15:51Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "d9fe8aaaa611a84801d6308b13685258b5248df9022536697939afdf66fc1719", "source_snapshot_id": "source-ff8e0599077f0d01044dc867", "source_updated_at": "2025-08-21", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/fampyra-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1429}
{"after": {"end": 26, "start": 0, "text": "Eckenheimer Landstraße 100", "truncated": false}, "after_length": 26, "after_sha256": "fdce1a9bd200c5ddd476c1ea5676b9ffbbea723f7353ad6fbc1fe019dcb86c07", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 26, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 26}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-a07c7273b5977f3181feb782", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002097", "medicine_name": "Fampyra", "medicine_slug": "fampyra", "observed_at": "2026-10-12T19:15:51Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "d9fe8aaaa611a84801d6308b13685258b5248df9022536697939afdf66fc1719", "source_snapshot_id": "source-ff8e0599077f0d01044dc867", "source_updated_at": "2025-08-21", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/fampyra-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1440}
{"after": {"end": 22, "start": 0, "text": "Merz Therapeutics GmbH", "truncated": false}, "after_length": 22, "after_sha256": "059f049c7d0846aaadcf2573280d52110f302d4ecc7b38debd004571cd1e9d5e", "annex": "IIIA", "before": {"end": 35, "start": 0, "text": "Acorda Therapeutics Ireland Limited", "truncated": false}, "before_length": 35, "before_sha256": "d94d3153d193ed26567f2b4ed48df016d81c534e7c0cb1a6655a63f0083383ff", "change_kind": "content", "change_operations": [{"after_end": 2, "after_start": 0, "before_end": 3, "before_start": 0, "kind": "replace"}, {"after_end": 4, "after_start": 3, "before_end": 6, "before_start": 4, "kind": "replace"}, {"after_end": 19, "after_start": 18, "before_end": 30, "before_start": 20, "kind": "replace"}, {"after_end": 22, "after_start": 20, "before_end": 35, "before_start": 31, "kind": "replace"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 19, "chars_inserted": 6}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-a0997ee244ad6ebaf118a8b5", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002097", "medicine_name": "Fampyra", "medicine_slug": "fampyra", "observed_at": "2026-10-12T19:16:07Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "a0c3ba8d58d6a43a809ecc3d142a78b10c2bd7f0b9f3a3553df2617d87daec1f", "source_snapshot_id": "source-c7a810dd21f94cd2d273f0da", "source_updated_at": "2025-08-21", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/fampyra-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1621}
{"after": {"end": 21, "start": 0, "text": "Tel: +31 35 528 39 57", "truncated": false}, "after_length": 21, "after_sha256": "7baf6601f41e49e470f803fdd4e755a86efa38be423317c000ed79963ebdd213", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 21, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 21}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-a09a2efb0fc5c75023b17c7e", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:14Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "8b8c4cc8e6f1a21fedee4bf0743c9c03e454b50f5eaba0e3760416d7fe0a74ec", "source_snapshot_id": "source-4efe4ecf3ebf08d338a763a5", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 2004}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 21, "start": 0, "text": "info@lucanepharma.com", "truncated": false}, "before_length": 21, "before_sha256": "44fd39e5fb919cb3d680fa630da23b49238fec29159c509f3622f272bb41c7c6", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 21, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 21, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-a0a51ca71d5528ed970aad69", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:19Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "77586d0bea0858214b43b86e91abc2d2711733b96959ead5ed0b5ecbd8ed888a", "source_snapshot_id": "source-85d476f9ad959cc117ca8f1f", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1548}
{"after": {"end": 16, "start": 0, "text": "Extrovis EU Kft.", "truncated": false}, "after_length": 16, "after_sha256": "b9216ef80e71e17798dce313e4318f03f37328f225d30ab508b7413813a908e5", "annex": "IIIB", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "unassigned", "change_operations": [{"after_end": 16, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 16}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-a0fbbb9649e92793683fad1a", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/006047", "medicine_name": "Lacosamide Adroiq", "medicine_slug": "lacosamide-adroiq", "observed_at": "2026-10-12T19:07:56Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "", "section_type": "unassigned", "source_provider": "European Medicines Agency", "source_sha256": "0578c53a5e1c785c4d9d4dc0dabae49dbfa89e237aa571556bee548c3f9cf4d5", "source_snapshot_id": "source-64831dec5ebf55535e19d91b", "source_updated_at": "2025-09-25", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/lacosamide-adroiq-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1876}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIB", "before": {"end": 16, "start": 0, "text": "Extrovis EU Ltd.", "truncated": false}, "before_length": 16, "before_sha256": "f462ad48e7aef0bc82148ce088af1897d99ed86993128f30d506b27d3108a929", "change_kind": "unassigned", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 16, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 16, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-a100936cf1cdb4fbaf5f92be", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/006047", "medicine_name": "Lacosamide Adroiq", "medicine_slug": "lacosamide-adroiq", "observed_at": "2026-10-12T19:07:56Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "", "section_type": "unassigned", "source_provider": "European Medicines Agency", "source_sha256": "0578c53a5e1c785c4d9d4dc0dabae49dbfa89e237aa571556bee548c3f9cf4d5", "source_snapshot_id": "source-64831dec5ebf55535e19d91b", "source_updated_at": "2025-09-25", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/lacosamide-adroiq-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1975}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 21, "start": 0, "text": "Tel: +31 35 528 39 57", "truncated": false}, "before_length": 21, "before_sha256": "7baf6601f41e49e470f803fdd4e755a86efa38be423317c000ed79963ebdd213", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 21, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 21, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-a1716a863a95e8424a0cfbd4", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:14Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "8b8c4cc8e6f1a21fedee4bf0743c9c03e454b50f5eaba0e3760416d7fe0a74ec", "source_snapshot_id": "source-4efe4ecf3ebf08d338a763a5", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 2030}
{"after": {"end": 65, "start": 0, "text": "Pfizer Service Company BV, Hermeslaan 11, 1932 Zaventem, Belgique", "truncated": false}, "after_length": 65, "after_sha256": "1e843ccc499bfe57d3aef99cecb4ccde7e4db9f73285a7b604970aa745f190dc", "annex": "IIIA", "before": {"end": 64, "start": 0, "text": "Pfizer Service Company BV, Hoge Wei 10, Zaventem, 1930, Belgique", "truncated": false}, "before_length": 64, "before_sha256": "49237e9435f16fd0f8c1a03120a2d68b2a2c2b90a650b5aa5268da2b3a7392f8", "change_kind": "content", "change_operations": [{"after_end": 28, "after_start": 28, "before_end": 30, "before_start": 28, "kind": "delete"}, {"after_end": 31, "after_start": 29, "before_end": 33, "before_start": 31, "kind": "replace"}, {"after_end": 37, "after_start": 32, "before_end": 35, "before_start": 34, "kind": "replace"}, {"after_end": 40, "after_start": 39, "before_end": 38, "before_start": 37, "kind": "replace"}, {"after_end": 46, "after_start": 41, "before_end": 39, "before_start": 39, "kind": "insert"}, {"after_end": 55, "after_start": 55, "before_end": 54, "before_start": 48, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 12, "chars_inserted": 13}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-a17942fe753b0a19c544c563", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/004697", "medicine_name": "Zirabev", "medicine_slug": "zirabev", "observed_at": "2026-10-12T19:08:42Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "845774ee3d135dcbab2d035e014eb75d076ae724c8a5ea323882196493b05d44", "source_snapshot_id": "source-58a9ecf053a0ab93bbcc0173", "source_updated_at": "2025-09-17", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/zirabev-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 3313}
{"after": {"end": 25, "start": 0, "text": "Lamia, Schimatari, 32009,", "truncated": false}, "after_length": 25, "after_sha256": "731caa8982d6c36ded24b2c0ae7f96bbe4b52b5f2fe4fdabe022c9e027a41c9e", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 25, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 25}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-a1c690b9a6042ec6835aae51", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/003984", "medicine_name": "Bortezomib Accord", "medicine_slug": "bortezomib-accord", "observed_at": "2026-10-12T13:47:12Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "e4aac937241121e8ad1e32b40b1007fb58398035928568a7e60a65074b0efb36", "source_snapshot_id": "source-b1eaab6445cfa827e3b1481b", "source_updated_at": "2026-03-25", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/bortezomib-accord-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 4239}
{"after": {"end": 30, "start": 0, "text": "Troubles musculo-squelettiques", "truncated": false}, "after_length": 30, "after_sha256": "19f3f11cced96282f29a83fb37b4e112d045fd9d5612609940e426e03f7708ab", "annex": "I", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 30, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": true, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 30}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-a1f44bd6cb1296d74dfcf9a1", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/000235", "medicine_name": "Arava", "medicine_slug": "arava", "observed_at": "2026-10-12T13:28:00Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": null, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "4.4", "section_type": "warning", "source_provider": "European Medicines Agency", "source_sha256": "98b73c5c6b1e5009c9d048f8f11257f3a8407759fd25a4c8d5ef5c611519e916", "source_snapshot_id": "source-4b7ea3b78addea82376b3432", "source_updated_at": "2026-09-07", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/arava-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 175}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIB", "before": {"end": 20, "start": 0, "text": "Tel: +41 41 740 1120", "truncated": false}, "before_length": 20, "before_sha256": "86dec7eb8f60d9684a01122d4eab78962ed99ccf72a86d621931a71c30177300", "change_kind": "unassigned", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 20, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 20, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-a23817288ed07c2a0e9561c4", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/006047", "medicine_name": "Lacosamide Adroiq", "medicine_slug": "lacosamide-adroiq", "observed_at": "2026-10-12T19:07:56Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "", "section_type": "unassigned", "source_provider": "European Medicines Agency", "source_sha256": "0578c53a5e1c785c4d9d4dc0dabae49dbfa89e237aa571556bee548c3f9cf4d5", "source_snapshot_id": "source-64831dec5ebf55535e19d91b", "source_updated_at": "2025-09-25", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/lacosamide-adroiq-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 2037}
{"after": {"end": 25, "start": 0, "text": "Eurocept International BV", "truncated": false}, "after_length": 25, "after_sha256": "b17bd89b3cf285c986a6070d0d67f5326dd5c1f08a70834c296c6c820f9e7505", "annex": "IIIA", "before": {"end": 21, "start": 0, "text": "info@lucanepharma.com", "truncated": false}, "before_length": 21, "before_sha256": "44fd39e5fb919cb3d680fa630da23b49238fec29159c509f3622f272bb41c7c6", "change_kind": "content", "change_operations": [{"after_end": 3, "after_start": 0, "before_end": 3, "before_start": 0, "kind": "replace"}, {"after_end": 4, "after_start": 4, "before_end": 7, "before_start": 4, "kind": "delete"}, {"after_end": 5, "after_start": 5, "before_end": 10, "before_start": 8, "kind": "delete"}, {"after_end": 15, "after_start": 7, "before_end": 13, "before_start": 12, "kind": "replace"}, {"after_end": 20, "after_start": 16, "before_end": 16, "before_start": 14, "kind": "replace"}, {"after_end": 25, "after_start": 21, "before_end": 21, "before_start": 17, "kind": "replace"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 15, "chars_inserted": 19}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-a297c8d1b9d45d1bba82b55b", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:14Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "8b8c4cc8e6f1a21fedee4bf0743c9c03e454b50f5eaba0e3760416d7fe0a74ec", "source_snapshot_id": "source-4efe4ecf3ebf08d338a763a5", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1579}
{"after": {"end": 60, "start": 0, "text": "Generalised hypersensitivity reactions including angioedema*", "truncated": false}, "after_length": 60, "after_sha256": "e3396d35bd3fb07037a8790b0cb7dfa0628aa99dd8644fbeca4326956de79649", "annex": "I", "before": {"end": 10, "start": 0, "text": "Angioedema", "truncated": false}, "before_length": 10, "before_sha256": "99d2f164d6af2bac1f3a337d3c06922d938ea4591240fe12d89d638459724b03", "change_kind": "content", "change_operations": [{"after_end": 50, "after_start": 0, "before_end": 1, "before_start": 0, "kind": "replace"}, {"after_end": 60, "after_start": 59, "before_end": 10, "before_start": 10, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": true, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 1, "chars_inserted": 51}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-a2ba7473047dbc34f41ab009", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/000554", "medicine_name": "Emselex", "medicine_slug": "emselex", "observed_at": "2026-10-12T19:12:04Z", "pipeline_version": "2.0.0", "presentation_label": "Emselex 7.5 mg prolonged-release tablets", "presentation_occurrence": 1, "presentation_status": "heading_extracted_unverified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "4.8", "section_type": "adverse_reactions", "source_provider": "European Medicines Agency", "source_sha256": "4f2565612bc728ec67b7f9c0cd5799ef2c594911c76f323aef8bf6a85adde245", "source_snapshot_id": "source-1fda25b331eb198b8b93feb3", "source_updated_at": "2025-09-15", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/emselex-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 212}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 7, "start": 0, "text": "Irlande", "truncated": false}, "before_length": 7, "before_sha256": "a8cdfff5dbbda1b070a2acb339b6f0aa20b6230d9b5500c9ce066eaa89bc9a64", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 7, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 7, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-a2c8621aba0a9798dad101a8", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/004025", "medicine_name": "Lopinavir/Ritonavir Viatris (previously Ritonavir Mylan)", "medicine_slug": "lopinavir-ritonavir-viatris-previously-ritonavir-mylan", "observed_at": "2026-10-12T19:14:59Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "d782e33ec97bc43bb54f942c83f07f89482c9a433e3846beaffe05b4a52b4b36", "source_snapshot_id": "source-ff48b23a80b98be4c15aa440", "source_updated_at": "2025-09-08", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/lopinavir-ritonavir-viatris-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 2881}
{"after": {"end": 26, "start": 0, "text": "Eckenheimer Landstraße 100", "truncated": false}, "after_length": 26, "after_sha256": "fdce1a9bd200c5ddd476c1ea5676b9ffbbea723f7353ad6fbc1fe019dcb86c07", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 26, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 26}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-a33a8867695f194d5fc6f3e1", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002097", "medicine_name": "Fampyra", "medicine_slug": "fampyra", "observed_at": "2026-10-12T19:15:51Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "d9fe8aaaa611a84801d6308b13685258b5248df9022536697939afdf66fc1719", "source_snapshot_id": "source-ff8e0599077f0d01044dc867", "source_updated_at": "2025-08-21", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/fampyra-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1465}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 18, "start": 0, "text": "Dublin 2, D02 T380", "truncated": false}, "before_length": 18, "before_sha256": "23e6871e7960b0dadc753bc127bbea230cc8308c88b2d33704eb275a3ec1a70d", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 18, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 18, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-a3607244bf6e81841c5bd167", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002097", "medicine_name": "Fampyra", "medicine_slug": "fampyra", "observed_at": "2026-10-12T19:16:07Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "a0c3ba8d58d6a43a809ecc3d142a78b10c2bd7f0b9f3a3553df2617d87daec1f", "source_snapshot_id": "source-c7a810dd21f94cd2d273f0da", "source_updated_at": "2025-08-21", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/fampyra-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1426}
{"after": {"end": 11, "start": 0, "text": "Vianex S.A.", "truncated": false}, "after_length": 11, "after_sha256": "5aa05543f23c771ae6d358a0283a8ebc791ceaed5f1fb141cf038e2e49a6ac7b", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 11, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 11}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-a362fed6c5ba7026e819f369", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002066", "medicine_name": "Ikervis", "medicine_slug": "ikervis", "observed_at": "2026-10-12T13:34:10Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "7995ffe3d4b9c2e870327b45fae2f1d35ae1ab0e1e9e22b434fd9805b58a174e", "source_snapshot_id": "source-5ff0e792002ee89d9eb06e5d", "source_updated_at": "2026-06-23", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/ikervis-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1792}
{"after": {"end": 22, "start": 0, "text": "Merz Therapeutics GmbH", "truncated": false}, "after_length": 22, "after_sha256": "059f049c7d0846aaadcf2573280d52110f302d4ecc7b38debd004571cd1e9d5e", "annex": "IIIA", "before": {"end": 35, "start": 0, "text": "Acorda Therapeutics Ireland Limited", "truncated": false}, "before_length": 35, "before_sha256": "d94d3153d193ed26567f2b4ed48df016d81c534e7c0cb1a6655a63f0083383ff", "change_kind": "content", "change_operations": [{"after_end": 2, "after_start": 0, "before_end": 3, "before_start": 0, "kind": "replace"}, {"after_end": 4, "after_start": 3, "before_end": 6, "before_start": 4, "kind": "replace"}, {"after_end": 19, "after_start": 18, "before_end": 30, "before_start": 20, "kind": "replace"}, {"after_end": 22, "after_start": 20, "before_end": 35, "before_start": 31, "kind": "replace"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 19, "chars_inserted": 6}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-a375b95e6bc0a94080798afd", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002097", "medicine_name": "Fampyra", "medicine_slug": "fampyra", "observed_at": "2026-10-12T19:15:51Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "d9fe8aaaa611a84801d6308b13685258b5248df9022536697939afdf66fc1719", "source_snapshot_id": "source-ff8e0599077f0d01044dc867", "source_updated_at": "2025-08-21", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/fampyra-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1561}
{"after": {"end": 23, "start": 0, "text": "info@euroceptpharma.com", "truncated": false}, "after_length": 23, "after_sha256": "9297cc5acdcc837f054116992765943f7907937507b2564a99ea1327a00ac0e6", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 23, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 23}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-a37eb02b57e4a4cd5257ede1", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:14Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "8b8c4cc8e6f1a21fedee4bf0743c9c03e454b50f5eaba0e3760416d7fe0a74ec", "source_snapshot_id": "source-4efe4ecf3ebf08d338a763a5", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1862}
{"after": {"end": 11, "start": 0, "text": "Vistor ehf.", "truncated": false}, "after_length": 11, "after_sha256": "7b79f0f888fc32453606a29b908677d0b6c13a510070ab26fe31e12b995d77fe", "annex": "IIIA", "before": {"end": 6, "start": 0, "text": "Vistor", "truncated": false}, "before_length": 6, "before_sha256": "880db25626eb8b4d5d7d9cc13a3d8eb1ceea5578e74cf4680a38ffc73e92fe11", "change_kind": "content", "change_operations": [{"after_end": 11, "after_start": 6, "before_end": 6, "before_start": 6, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 5}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-a3aa186920f095e70a93371d", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002702", "medicine_name": "Hexacima", "medicine_slug": "hexacima", "observed_at": "2026-10-12T19:07:04Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "44c8996457a718019c75b8322ba07a5ae7af36377b1a6f1cf4ca5a30f9b72c23", "source_snapshot_id": "source-fa766d966dea704c333b9969", "source_updated_at": "2025-09-29", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/hexacima-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 2093}
{"after": {"end": 23, "start": 0, "text": "60318 Frankfurt am Main", "truncated": false}, "after_length": 23, "after_sha256": "24c3191b5088b20c209c4387a8127297e54c776e161d305c9e57956a13b7cbbe", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 23, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 23}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-a3c9ca8aab345a80aaa0dc56", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002097", "medicine_name": "Fampyra", "medicine_slug": "fampyra", "observed_at": "2026-10-12T19:15:51Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "d9fe8aaaa611a84801d6308b13685258b5248df9022536697939afdf66fc1719", "source_snapshot_id": "source-ff8e0599077f0d01044dc867", "source_updated_at": "2025-08-21", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/fampyra-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1423}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 20, "start": 0, "text": "10 Earlsfort Terrace", "truncated": false}, "before_length": 20, "before_sha256": "22951bbf6ee77815d0c07b3af5f0a66e17d277636971c4eaff372dea65dcb193", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 20, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 20, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-a41a4b81bf74e5ed1b1c608e", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002097", "medicine_name": "Fampyra", "medicine_slug": "fampyra", "observed_at": "2026-10-12T19:15:51Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "d9fe8aaaa611a84801d6308b13685258b5248df9022536697939afdf66fc1719", "source_snapshot_id": "source-ff8e0599077f0d01044dc867", "source_updated_at": "2025-08-21", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/fampyra-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1572}
{"after": {"end": 137, "start": 0, "text": "UNE TECHNIQUE ASEPTIQUE DOIT ETRE STRICTEMENT OBSERVÉE PENDANT LA MANIPULATION DE BORTEZOMIB ACCORD CAR AUCUN CONSERVATEUR N’EST PRÉSENT.", "truncated": false}, "after_length": 137, "after_sha256": "5820a4a56ba1b9ea43b44dba1c42bae989813dd5c5efd6ee9a6b28f36851962c", "annex": "IIIA", "before": {"end": 137, "start": 0, "text": "UNE TECHNIQUE ASEPTIQUE DOIT ETRE STRICTEMENT OBSERVÉE PENDANT LA MANIPULATION DE BORTEZOMID ACCORD CAR AUCUN CONSERVATEUR N’EST PRÉSENT.", "truncated": false}, "before_length": 137, "before_sha256": "581dfbb1cdd5acffde75a0f8332b74f21628a9efdd0a21b43a4cb7c4f74e5af8", "change_kind": "content", "change_operations": [{"after_end": 92, "after_start": 91, "before_end": 92, "before_start": 91, "kind": "replace"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 1, "chars_inserted": 1}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-a44c173c9d40b913751ed3d2", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/003984", "medicine_name": "Bortezomib Accord", "medicine_slug": "bortezomib-accord", "observed_at": "2026-10-12T13:47:15Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "150a191aaf0a1e169e9d5fa2530f0eccb4e3d46509faf5ec5ee975a2e67788c4", "source_snapshot_id": "source-cba4680b7fbd2c536884abd8", "source_updated_at": "2026-03-25", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/bortezomib-accord-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 4815}
{"after": {"end": 26, "start": 0, "text": "Eckenheimer Landstraße 100", "truncated": false}, "after_length": 26, "after_sha256": "fdce1a9bd200c5ddd476c1ea5676b9ffbbea723f7353ad6fbc1fe019dcb86c07", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 26, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 26}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-a493dafd7e7636d7ada0c930", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002097", "medicine_name": "Fampyra", "medicine_slug": "fampyra", "observed_at": "2026-10-12T19:15:51Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "d9fe8aaaa611a84801d6308b13685258b5248df9022536697939afdf66fc1719", "source_snapshot_id": "source-ff8e0599077f0d01044dc867", "source_updated_at": "2025-08-21", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/fampyra-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1392}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIB", "before": {"end": 16, "start": 0, "text": "Extrovis EU Ltd.", "truncated": false}, "before_length": 16, "before_sha256": "f462ad48e7aef0bc82148ce088af1897d99ed86993128f30d506b27d3108a929", "change_kind": "unassigned", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 16, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 16, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-a49a31ba5178794d6d740206", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/006047", "medicine_name": "Lacosamide Adroiq", "medicine_slug": "lacosamide-adroiq", "observed_at": "2026-10-12T19:07:56Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "", "section_type": "unassigned", "source_provider": "European Medicines Agency", "source_sha256": "0578c53a5e1c785c4d9d4dc0dabae49dbfa89e237aa571556bee548c3f9cf4d5", "source_snapshot_id": "source-64831dec5ebf55535e19d91b", "source_updated_at": "2025-09-25", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/lacosamide-adroiq-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1888}
{"after": {"end": 22, "start": 0, "text": "Merz Therapeutics GmbH", "truncated": false}, "after_length": 22, "after_sha256": "059f049c7d0846aaadcf2573280d52110f302d4ecc7b38debd004571cd1e9d5e", "annex": "IIIA", "before": {"end": 35, "start": 0, "text": "Acorda Therapeutics Ireland Limited", "truncated": false}, "before_length": 35, "before_sha256": "d94d3153d193ed26567f2b4ed48df016d81c534e7c0cb1a6655a63f0083383ff", "change_kind": "content", "change_operations": [{"after_end": 2, "after_start": 0, "before_end": 3, "before_start": 0, "kind": "replace"}, {"after_end": 4, "after_start": 3, "before_end": 6, "before_start": 4, "kind": "replace"}, {"after_end": 19, "after_start": 18, "before_end": 30, "before_start": 20, "kind": "replace"}, {"after_end": 22, "after_start": 20, "before_end": 35, "before_start": 31, "kind": "replace"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 19, "chars_inserted": 6}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-a4a08db9c67f2f6c809df3bd", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002097", "medicine_name": "Fampyra", "medicine_slug": "fampyra", "observed_at": "2026-10-12T19:15:51Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "d9fe8aaaa611a84801d6308b13685258b5248df9022536697939afdf66fc1719", "source_snapshot_id": "source-ff8e0599077f0d01044dc867", "source_updated_at": "2025-08-21", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/fampyra-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1418}
{"after": {"end": 28, "start": 0, "text": "InfoDeutschland@dipharma.com", "truncated": false}, "after_length": 28, "after_sha256": "f5ed16f98f15b7236207edade83fdde3fb32cec02f927aaba23223b9f6077f21", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 28, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 28}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-a4a568ef030223bb6978c7d5", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:14Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "8b8c4cc8e6f1a21fedee4bf0743c9c03e454b50f5eaba0e3760416d7fe0a74ec", "source_snapshot_id": "source-4efe4ecf3ebf08d338a763a5", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1521}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 18, "start": 0, "text": "Dublin 2, D02 T380", "truncated": false}, "before_length": 18, "before_sha256": "23e6871e7960b0dadc753bc127bbea230cc8308c88b2d33704eb275a3ec1a70d", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 18, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 18, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-a4f9ac0e10a2498150a65a7c", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002097", "medicine_name": "Fampyra", "medicine_slug": "fampyra", "observed_at": "2026-10-12T19:16:07Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "a0c3ba8d58d6a43a809ecc3d142a78b10c2bd7f0b9f3a3553df2617d87daec1f", "source_snapshot_id": "source-c7a810dd21f94cd2d273f0da", "source_updated_at": "2025-08-21", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/fampyra-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1623}
{"after": {"end": 179, "start": 0, "text": "This document is the approved product information for Pheburane, with the changes since the previous procedure affecting the product information (EMEA/H/C/002500/IB/0041) tracked.", "truncated": false}, "after_length": 179, "after_sha256": "cdba6c798ff82e5eb89cea952cda620e946fc7a2927219fbafb732e481809b33", "annex": "", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "unassigned", "change_operations": [{"after_end": 179, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 179}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-a4fc1089355edd75d0173c2f", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:14Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": null, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "", "section_type": "unassigned", "source_provider": "European Medicines Agency", "source_sha256": "8b8c4cc8e6f1a21fedee4bf0743c9c03e454b50f5eaba0e3760416d7fe0a74ec", "source_snapshot_id": "source-4efe4ecf3ebf08d338a763a5", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 0}
{"after": {"end": 26, "start": 0, "text": "Eckenheimer Landstraße 100", "truncated": false}, "after_length": 26, "after_sha256": "fdce1a9bd200c5ddd476c1ea5676b9ffbbea723f7353ad6fbc1fe019dcb86c07", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 26, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 26}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-a513e95b77633d477d2b0238", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002097", "medicine_name": "Fampyra", "medicine_slug": "fampyra", "observed_at": "2026-10-12T19:16:07Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "a0c3ba8d58d6a43a809ecc3d142a78b10c2bd7f0b9f3a3553df2617d87daec1f", "source_snapshot_id": "source-c7a810dd21f94cd2d273f0da", "source_updated_at": "2025-08-21", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/fampyra-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1428}
{"after": {"end": 25, "start": 0, "text": "Eurocept International BV", "truncated": false}, "after_length": 25, "after_sha256": "b17bd89b3cf285c986a6070d0d67f5326dd5c1f08a70834c296c6c820f9e7505", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 25, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 25}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-a55721276759674d6ed7f4cf", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:19Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "77586d0bea0858214b43b86e91abc2d2711733b96959ead5ed0b5ecbd8ed888a", "source_snapshot_id": "source-85d476f9ad959cc117ca8f1f", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1840}
{"after": {"end": 23, "start": 0, "text": "info@euroceptpharma.com", "truncated": false}, "after_length": 23, "after_sha256": "9297cc5acdcc837f054116992765943f7907937507b2564a99ea1327a00ac0e6", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 23, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 23}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-a579f9662baef6cb35acec8a", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:14Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "8b8c4cc8e6f1a21fedee4bf0743c9c03e454b50f5eaba0e3760416d7fe0a74ec", "source_snapshot_id": "source-4efe4ecf3ebf08d338a763a5", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 2033}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 24, "start": 0, "text": "Τηλ: +358 (0) 3 284 8111", "truncated": false}, "before_length": 24, "before_sha256": "d6067cd3f2a7a2e958ac076aba456632e50c80f365a8e35948e7f408fe8f5396", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 24, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 24, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-a5fc63b7eda5dba25f26374e", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002066", "medicine_name": "Ikervis", "medicine_slug": "ikervis", "observed_at": "2026-10-12T13:34:16Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "ab05f9fab48768c68482390488c5b90c577e852974d4448da6ea8fe5a4eda856", "source_snapshot_id": "source-324751bde2e11edc76c2dbfe", "source_updated_at": "2026-06-23", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/ikervis-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1483}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 162, "start": 0, "text": "- if you experience unexplained muscle pain, tenderness (soreness when the muscle is pressed) or muscle weakness with or without fever while taking this medicine.", "truncated": false}, "before_length": 162, "before_sha256": "f890cf5f6db7b3cdd8b8f8c398dbb8619759e91d8e962d3a402397305c598127", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 162, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 162, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-a626001acec6df3d99f6b9fa", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/000235", "medicine_name": "Arava", "medicine_slug": "arava", "observed_at": "2026-10-12T13:27:58Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 3, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "2efff7967e2237bf8343431eef5e08b56c2441eb8a691a90c64b2635109fd697", "source_snapshot_id": "source-08b4eba1f67d2654148f41c4", "source_updated_at": "2026-09-07", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/arava-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 2656}
{"after": {"end": 23, "start": 0, "text": "Tel: +49 (0) 69 15 03 0", "truncated": false}, "after_length": 23, "after_sha256": "09683b3f43171b2266a32d9f7d44e3d62d536522dc6f42d4b47f2dda48b31833", "annex": "IIIA", "before": {"end": 23, "start": 0, "text": "Tel: +353 (0)1 231 4609", "truncated": false}, "before_length": 23, "before_sha256": "a115f11f382ef18898b9d956e48603ae236fd1846ce41e8586af99b6dabbfc4d", "change_kind": "content", "change_operations": [{"after_end": 8, "after_start": 6, "before_end": 9, "before_start": 6, "kind": "replace"}, {"after_end": 16, "after_start": 12, "before_end": 13, "before_start": 13, "kind": "insert"}, {"after_end": 18, "after_start": 17, "before_end": 14, "before_start": 14, "kind": "insert"}, {"after_end": 20, "after_start": 19, "before_end": 16, "before_start": 15, "kind": "replace"}, {"after_end": 21, "after_start": 21, "before_end": 18, "before_start": 17, "kind": "delete"}, {"after_end": 22, "after_start": 22, "before_end": 21, "before_start": 19, "kind": "delete"}, {"after_end": 23, "after_start": 23, "before_end": 23, "before_start": 22, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 8, "chars_inserted": 8}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-a626c13553b273b853739312", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002097", "medicine_name": "Fampyra", "medicine_slug": "fampyra", "observed_at": "2026-10-12T19:15:51Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "d9fe8aaaa611a84801d6308b13685258b5248df9022536697939afdf66fc1719", "source_snapshot_id": "source-ff8e0599077f0d01044dc867", "source_updated_at": "2025-08-21", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/fampyra-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1559}
{"after": {"end": 98, "start": 0, "text": "Le CHMP recommande que les termes de la/des autorisation(s) de mise sur le marché soient modifiés.", "truncated": false}, "after_length": 98, "after_sha256": "814445cd01b1f96232572044ddd66f4350cafdd933e820b4d83b946474ffc969", "annex": "IV", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 98, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 98}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-a628683ba768d69e1b2840d2", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/000554", "medicine_name": "Emselex", "medicine_slug": "emselex", "observed_at": "2026-10-12T19:12:07Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": null, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "conditions", "section_type": "conditions", "source_provider": "European Medicines Agency", "source_sha256": "9a4f1d7e260c7b80eaf397503623b63302e5945b579e9612177835e07c4ab888", "source_snapshot_id": "source-3aac7bf42b99529f25ac013b", "source_updated_at": "2025-09-15", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/emselex-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 2078}
{"after": {"end": 23, "start": 0, "text": "60318 Frankfurt am Main", "truncated": false}, "after_length": 23, "after_sha256": "24c3191b5088b20c209c4387a8127297e54c776e161d305c9e57956a13b7cbbe", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 23, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 23}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-a68ce42287600ce6ed1beb74", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002097", "medicine_name": "Fampyra", "medicine_slug": "fampyra", "observed_at": "2026-10-12T19:15:51Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "d9fe8aaaa611a84801d6308b13685258b5248df9022536697939afdf66fc1719", "source_snapshot_id": "source-ff8e0599077f0d01044dc867", "source_updated_at": "2025-08-21", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/fampyra-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1354}
{"after": {"end": 29, "start": 0, "text": "64th Km National Road Athens,", "truncated": false}, "after_length": 29, "after_sha256": "13ea56883a0ab9bffcaa1dd41d9bf3581890cd7cfc6830634cd50feb121599ea", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 29, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 29}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-a68f150edef2b2ed15e4c302", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/003984", "medicine_name": "Bortezomib Accord", "medicine_slug": "bortezomib-accord", "observed_at": "2026-10-12T13:47:15Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "150a191aaf0a1e169e9d5fa2530f0eccb4e3d46509faf5ec5ee975a2e67788c4", "source_snapshot_id": "source-cba4680b7fbd2c536884abd8", "source_updated_at": "2026-03-25", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/bortezomib-accord-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 4789}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 20, "start": 0, "text": "10 Earlsfort Terrace", "truncated": false}, "before_length": 20, "before_sha256": "22951bbf6ee77815d0c07b3af5f0a66e17d277636971c4eaff372dea65dcb193", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 20, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 20, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-a7003ffc920591433bfeb833", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002097", "medicine_name": "Fampyra", "medicine_slug": "fampyra", "observed_at": "2026-10-12T19:15:51Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "d9fe8aaaa611a84801d6308b13685258b5248df9022536697939afdf66fc1719", "source_snapshot_id": "source-ff8e0599077f0d01044dc867", "source_updated_at": "2025-08-21", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/fampyra-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1349}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 13, "start": 0, "text": "Lucane Pharma", "truncated": false}, "before_length": 13, "before_sha256": "e338afdb64acf1a6e2083a50318853589248451dd3aa707181ba02641a8521e8", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 13, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 13, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-a7076f8d7edebee2e46b2ef2", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:19Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "77586d0bea0858214b43b86e91abc2d2711733b96959ead5ed0b5ecbd8ed888a", "source_snapshot_id": "source-85d476f9ad959cc117ca8f1f", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1802}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 13, "start": 0, "text": "Lucane Pharma", "truncated": false}, "before_length": 13, "before_sha256": "e338afdb64acf1a6e2083a50318853589248451dd3aa707181ba02641a8521e8", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 13, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 13, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-a70e73fd6f5672c0341d66b3", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:14Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "8b8c4cc8e6f1a21fedee4bf0743c9c03e454b50f5eaba0e3760416d7fe0a74ec", "source_snapshot_id": "source-4efe4ecf3ebf08d338a763a5", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 2010}
{"after": {"end": 25, "start": 0, "text": "Musculoskeletal disorders", "truncated": false}, "after_length": 25, "after_sha256": "554fab09c18c12d65cee54d5caa96534b1925e5ff23a67e98a7c7c04e66bf714", "annex": "I", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 25, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": true, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 25}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-a72ec97745c8a0dcbcab774f", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/000235", "medicine_name": "Arava", "medicine_slug": "arava", "observed_at": "2026-10-12T13:27:58Z", "pipeline_version": "2.0.0", "presentation_label": "Arava 20 mg film-coated tablets", "presentation_occurrence": 2, "presentation_status": "heading_extracted_unverified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "4.4", "section_type": "warning", "source_provider": "European Medicines Agency", "source_sha256": "2efff7967e2237bf8343431eef5e08b56c2441eb8a691a90c64b2635109fd697", "source_snapshot_id": "source-08b4eba1f67d2654148f41c4", "source_updated_at": "2026-09-07", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/arava-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 747}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 18, "start": 0, "text": "Dublin 2, D02 T380", "truncated": false}, "before_length": 18, "before_sha256": "23e6871e7960b0dadc753bc127bbea230cc8308c88b2d33704eb275a3ec1a70d", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 18, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 18, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-a7e9a3367943f4d31fd60ab1", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002097", "medicine_name": "Fampyra", "medicine_slug": "fampyra", "observed_at": "2026-10-12T19:16:07Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "a0c3ba8d58d6a43a809ecc3d142a78b10c2bd7f0b9f3a3553df2617d87daec1f", "source_snapshot_id": "source-c7a810dd21f94cd2d273f0da", "source_updated_at": "2025-08-21", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/fampyra-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1376}
{"after": {"end": 23, "start": 0, "text": "dpoc.poland@organon.com", "truncated": false}, "after_length": 23, "after_sha256": "64a2356c9c563e1d59ad602a49d34aa457ffdf163dfa15c37c91becde91165f3", "annex": "IIIA", "before": {"end": 25, "start": 0, "text": "organonpolska@organon.com", "truncated": false}, "before_length": 25, "before_sha256": "25d407302ccedc28a9421e77900513d332e9ab19a438b83d152bf1baab000ba3", "change_kind": "content", "change_operations": [{"after_end": 2, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}, {"after_end": 5, "after_start": 3, "before_end": 7, "before_start": 1, "kind": "replace"}, {"after_end": 8, "after_start": 8, "before_end": 12, "before_start": 10, "kind": "delete"}, {"after_end": 11, "after_start": 9, "before_end": 13, "before_start": 13, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 8, "chars_inserted": 6}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-a7f6fe2bf26f4de07e7a16dc", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/000619", "medicine_name": "Fosavance", "medicine_slug": "fosavance", "observed_at": "2026-10-12T19:01:49Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "97e93ccf75e837b32026ca36c34d5c78008211a75d5ef225c47e7b94a0027ab2", "source_snapshot_id": "source-1ef57638e1a307f1e5437651", "source_updated_at": "2026-02-12", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/fosavance-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1265}
{"after": {"end": 132, "start": 0, "text": "There have been reports of inflammatory muscle disease and muscle breakdown (myositis and rhabdomyolysis), in patients taking Arava.", "truncated": false}, "after_length": 132, "after_sha256": "90becdd7bbf0bbe5f45ccf0044881cb69a6ac220fdad551e9ef9e14f245ee008", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 132, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 132}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-a805ec8217b70fbadeae049e", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/000235", "medicine_name": "Arava", "medicine_slug": "arava", "observed_at": "2026-10-12T13:27:58Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 3, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "2efff7967e2237bf8343431eef5e08b56c2441eb8a691a90c64b2635109fd697", "source_snapshot_id": "source-08b4eba1f67d2654148f41c4", "source_updated_at": "2026-09-07", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/arava-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 2659}
{"after": {"end": 124, "start": 0, "text": "For more information, see the European Medicines Agency’s website: https://www.ema.europa.eu/en/medicines/human/EPAR/adcirca", "truncated": false}, "after_length": 124, "after_sha256": "2474d36b3af85a3bfe383fbfa217986f75d0d14afea6808a9fe774020e7c5122", "annex": "", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "unassigned", "change_operations": [{"after_end": 124, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 124}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-a8fa5580d00754fb518af8f9", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/001021", "medicine_name": "Adcirca (previously Tadalafil Lilly)", "medicine_slug": "adcirca-previously-tadalafil-lilly", "observed_at": "2026-10-12T19:02:42Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": null, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "", "section_type": "unassigned", "source_provider": "European Medicines Agency", "source_sha256": "43438c8e53504a78747a8ff36049250fee294557f3a8b0e3acb80f71ad43ebc0", "source_snapshot_id": "source-2305a67bd1e393ee340bb8e4", "source_updated_at": "2026-01-28", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/adcirca-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 2}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 27, "start": 0, "text": "(Eurocept International BV)", "truncated": false}, "before_length": 27, "before_sha256": "e6cf9b20aaa466e53ad0d393512ca75931e13e488321e3be6f3e4f8b600970c8", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 27, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 27, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-a95a7c697710554dccbb68b1", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:19Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "77586d0bea0858214b43b86e91abc2d2711733b96959ead5ed0b5ecbd8ed888a", "source_snapshot_id": "source-85d476f9ad959cc117ca8f1f", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1996}
{"after": {"end": 25, "start": 0, "text": "Eurocept International BV", "truncated": false}, "after_length": 25, "after_sha256": "b17bd89b3cf285c986a6070d0d67f5326dd5c1f08a70834c296c6c820f9e7505", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 25, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 25}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-a97c212e2565e89204032b30", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:14Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "8b8c4cc8e6f1a21fedee4bf0743c9c03e454b50f5eaba0e3760416d7fe0a74ec", "source_snapshot_id": "source-4efe4ecf3ebf08d338a763a5", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1565}
{"after": {"end": 7, "start": 0, "text": "Germany", "truncated": false}, "after_length": 7, "after_sha256": "80db4ccdca106d37b920206331fcfe3e9e50a9e763d89b54ce3ad5ac8cf30f03", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 7, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 7}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-a97db5fa7924a7b72b953964", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002097", "medicine_name": "Fampyra", "medicine_slug": "fampyra", "observed_at": "2026-10-12T19:15:51Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "d9fe8aaaa611a84801d6308b13685258b5248df9022536697939afdf66fc1719", "source_snapshot_id": "source-ff8e0599077f0d01044dc867", "source_updated_at": "2025-08-21", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/fampyra-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 898}
{"after": {"end": 257, "start": 0, "text": "Prélever la dose requise de PHEBURANE solution buvable (voir rubrique 4.2) dans le flacon (équivalente au nombre de grammes de phénylbutyrate de sodium prescrits et selon la quantité à administrer avec le repas respectif) à l’aide de la seringue de dosage ;", "truncated": false}, "after_length": 257, "after_sha256": "fbba942b61d0177161c86c1b0a854e11db07ac6f1dbc984e84f552951527195c", "annex": "I", "before": {"end": 240, "start": 0, "text": "Prélever la dose requise de PHEBURANE (voir rubrique 4.2) dans le flacon (équivalente au nombre de grammes de phénylbutyrate de sodium prescrits et selon la quantité à administrer avec le repas respectif) à l’aide de la seringue de dosage ;", "truncated": false}, "before_length": 240, "before_sha256": "617b4ce674487f50b364316ca64c438345d0ee485b92b2631e9a448316968d12", "change_kind": "content", "change_operations": [{"after_end": 55, "after_start": 38, "before_end": 38, "before_start": 38, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 17}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-a9dbe98f6a66da87c3b2c271", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:19Z", "pipeline_version": "2.0.0", "presentation_label": "PHEBURANE 350 mg/ml solution buvable", "presentation_occurrence": 2, "presentation_status": "heading_extracted_unverified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "6.6", "section_type": "quality_presentation", "source_provider": "European Medicines Agency", "source_sha256": "77586d0bea0858214b43b86e91abc2d2711733b96959ead5ed0b5ecbd8ed888a", "source_snapshot_id": "source-85d476f9ad959cc117ca8f1f", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 654}
{"after": {"end": 23, "start": 0, "text": "info@euroceptpharma.com", "truncated": false}, "after_length": 23, "after_sha256": "9297cc5acdcc837f054116992765943f7907937507b2564a99ea1327a00ac0e6", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 23, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 23}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-a9e31e75fbe079bc68c59f45", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:19Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "77586d0bea0858214b43b86e91abc2d2711733b96959ead5ed0b5ecbd8ed888a", "source_snapshot_id": "source-85d476f9ad959cc117ca8f1f", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1455}
{"after": {"end": 122, "start": 0, "text": "Titulaire de l'Autorisation de mise sur le marché : Eli Lilly Nederland B.V., Orteliuslaan 1000, 3528 BD Utrecht, Pays-Bas", "truncated": false}, "after_length": 122, "after_sha256": "ade372096524673477bf185c16b219229849746d0f4e8be16cf963ceff153934", "annex": "III", "before": {"end": 122, "start": 0, "text": "Titulaire de l'Autorisation de mise sur le marché : Eli Lilly Nederland B.V., Papendorpseweg 83, 3528 BJ Utrecht, Pays-Bas", "truncated": false}, "before_length": 122, "before_sha256": "7d63b7a6b8d5b2c667555505f5fa293d8d6b61d71e39f5840690b997eb1f6fb5", "change_kind": "administrative", "change_operations": [{"after_end": 87, "after_start": 78, "before_end": 79, "before_start": 78, "kind": "replace"}, {"after_end": 89, "after_start": 88, "before_end": 82, "before_start": 80, "kind": "replace"}, {"after_end": 90, "after_start": 90, "before_end": 92, "before_start": 83, "kind": "delete"}, {"after_end": 95, "after_start": 91, "before_end": 95, "before_start": 93, "kind": "replace"}, {"after_end": 104, "after_start": 103, "before_end": 104, "before_start": 103, "kind": "replace"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 15, "chars_inserted": 15}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-a9e55a1f56c2c74f6cc2e6d1", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/001021", "medicine_name": "Adcirca (previously Tadalafil Lilly)", "medicine_slug": "adcirca-previously-tadalafil-lilly", "observed_at": "2026-10-12T19:02:45Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "", "section_type": "unassigned", "source_provider": "European Medicines Agency", "source_sha256": "cdbefcd6143c93e81f3c826bea8d3d01bffc55652e0f792243097df75c452721", "source_snapshot_id": "source-a1e85476de17f5a8664f7766", "source_updated_at": "2026-01-28", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/adcirca-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1920}
{"after": {"end": 23, "start": 0, "text": "Τηλ: +49 (0) 69 15 03 0", "truncated": false}, "after_length": 23, "after_sha256": "40b8b23a084b3eac3f3ba2dda37d60faaa541de50c6510ae17fd679d8490f764", "annex": "IIIA", "before": {"end": 23, "start": 0, "text": "Τηλ: +353 (0)1 231 4609", "truncated": false}, "before_length": 23, "before_sha256": "024453962d70899555df7213d15538f27fac977293417f307c134a4f3c21c4e8", "change_kind": "content", "change_operations": [{"after_end": 8, "after_start": 6, "before_end": 9, "before_start": 6, "kind": "replace"}, {"after_end": 16, "after_start": 12, "before_end": 13, "before_start": 13, "kind": "insert"}, {"after_end": 18, "after_start": 17, "before_end": 14, "before_start": 14, "kind": "insert"}, {"after_end": 20, "after_start": 19, "before_end": 16, "before_start": 15, "kind": "replace"}, {"after_end": 21, "after_start": 21, "before_end": 18, "before_start": 17, "kind": "delete"}, {"after_end": 22, "after_start": 22, "before_end": 21, "before_start": 19, "kind": "delete"}, {"after_end": 23, "after_start": 23, "before_end": 23, "before_start": 22, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 8, "chars_inserted": 8}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-aa2bac3eff95bf48d731b45b", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002097", "medicine_name": "Fampyra", "medicine_slug": "fampyra", "observed_at": "2026-10-12T19:15:51Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "d9fe8aaaa611a84801d6308b13685258b5248df9022536697939afdf66fc1719", "source_snapshot_id": "source-ff8e0599077f0d01044dc867", "source_updated_at": "2025-08-21", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/fampyra-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1605}
{"after": {"end": 5, "start": 0, "text": "Grèce", "truncated": false}, "after_length": 5, "after_sha256": "9a953a79ebdbc073046b47e64c16f1b45fce0df4f6acef8c7c40ffb97cf8997c", "annex": "II", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 5, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 5}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-aa7b1c5082d78915d2ab5027", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/003984", "medicine_name": "Bortezomib Accord", "medicine_slug": "bortezomib-accord", "observed_at": "2026-10-12T13:47:15Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "conditions", "section_type": "conditions", "source_provider": "European Medicines Agency", "source_sha256": "150a191aaf0a1e169e9d5fa2530f0eccb4e3d46509faf5ec5ee975a2e67788c4", "source_snapshot_id": "source-cba4680b7fbd2c536884abd8", "source_updated_at": "2026-03-25", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/bortezomib-accord-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 3351}
{"after": {"end": 70, "start": 0, "text": "Réactions d’hypersensibilité généralisées incluant l’œdème de Quincke*", "truncated": false}, "after_length": 70, "after_sha256": "6ea63e1e60e6f8b5de819f7146d11464728d9191d81ca8a6579aab54c47dd648", "annex": "I", "before": {"end": 16, "start": 0, "text": "Œdème de Quincke", "truncated": false}, "before_length": 16, "before_sha256": "b8d48c3260ed7fc1ddfe0761e62377846018ea8bfa63994517e465d1df19a27f", "change_kind": "content", "change_operations": [{"after_end": 54, "after_start": 0, "before_end": 1, "before_start": 0, "kind": "replace"}, {"after_end": 70, "after_start": 69, "before_end": 16, "before_start": 16, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": true, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 1, "chars_inserted": 55}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-aa83d8c258aa4e1a6994b3d6", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/000554", "medicine_name": "Emselex", "medicine_slug": "emselex", "observed_at": "2026-10-12T19:12:07Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": null, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "4.8", "section_type": "adverse_reactions", "source_provider": "European Medicines Agency", "source_sha256": "9a4f1d7e260c7b80eaf397503623b63302e5945b579e9612177835e07c4ab888", "source_snapshot_id": "source-3aac7bf42b99529f25ac013b", "source_updated_at": "2025-09-15", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/emselex-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 211}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 20, "start": 0, "text": "10 Earlsfort Terrace", "truncated": false}, "before_length": 20, "before_sha256": "22951bbf6ee77815d0c07b3af5f0a66e17d277636971c4eaff372dea65dcb193", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 20, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 20, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-aac2ee42b4a404e313da99ce", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002097", "medicine_name": "Fampyra", "medicine_slug": "fampyra", "observed_at": "2026-10-12T19:15:51Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "d9fe8aaaa611a84801d6308b13685258b5248df9022536697939afdf66fc1719", "source_snapshot_id": "source-ff8e0599077f0d01044dc867", "source_updated_at": "2025-08-21", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/fampyra-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1028}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 27, "start": 0, "text": "(Eurocept International BV)", "truncated": false}, "before_length": 27, "before_sha256": "e6cf9b20aaa466e53ad0d393512ca75931e13e488321e3be6f3e4f8b600970c8", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 27, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 27, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-ab406d835f20546403970f9f", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:19Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "77586d0bea0858214b43b86e91abc2d2711733b96959ead5ed0b5ecbd8ed888a", "source_snapshot_id": "source-85d476f9ad959cc117ca8f1f", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1957}
{"after": {"end": 23, "start": 0, "text": "60318 Frankfurt am Main", "truncated": false}, "after_length": 23, "after_sha256": "24c3191b5088b20c209c4387a8127297e54c776e161d305c9e57956a13b7cbbe", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 23, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 23}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-ab48ee7fe85325fffa217ad9", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002097", "medicine_name": "Fampyra", "medicine_slug": "fampyra", "observed_at": "2026-10-12T19:16:07Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "a0c3ba8d58d6a43a809ecc3d142a78b10c2bd7f0b9f3a3553df2617d87daec1f", "source_snapshot_id": "source-c7a810dd21f94cd2d273f0da", "source_updated_at": "2025-08-21", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/fampyra-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1038}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "II", "before": {"end": 22, "start": 0, "text": "PAION Deutschland GmbH", "truncated": false}, "before_length": 22, "before_sha256": "695a7a774aacd3b6e919ed980dbfb2ee37bbe6099af551312782cc722dbb2b31", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 22, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 22, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-ab51d18ba960311d9972d270", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/005246", "medicine_name": "Byfavo", "medicine_slug": "byfavo", "observed_at": "2026-10-12T13:28:16Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "conditions", "section_type": "conditions", "source_provider": "European Medicines Agency", "source_sha256": "61243a969f979f690fe718e414ceaeb66438c1faa31101ba25187d2f9ea662fd", "source_snapshot_id": "source-dd26eb8615d8c18bd80c1f6a", "source_updated_at": "2026-08-26", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/byfavo-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1829}
{"after": {"end": 23, "start": 0, "text": "Tel: +49 (0) 69 15 03 0", "truncated": false}, "after_length": 23, "after_sha256": "09683b3f43171b2266a32d9f7d44e3d62d536522dc6f42d4b47f2dda48b31833", "annex": "IIIA", "before": {"end": 23, "start": 0, "text": "Tel: +353 (0)1 231 4609", "truncated": false}, "before_length": 23, "before_sha256": "a115f11f382ef18898b9d956e48603ae236fd1846ce41e8586af99b6dabbfc4d", "change_kind": "content", "change_operations": [{"after_end": 8, "after_start": 6, "before_end": 9, "before_start": 6, "kind": "replace"}, {"after_end": 16, "after_start": 12, "before_end": 13, "before_start": 13, "kind": "insert"}, {"after_end": 18, "after_start": 17, "before_end": 14, "before_start": 14, "kind": "insert"}, {"after_end": 20, "after_start": 19, "before_end": 16, "before_start": 15, "kind": "replace"}, {"after_end": 21, "after_start": 21, "before_end": 18, "before_start": 17, "kind": "delete"}, {"after_end": 22, "after_start": 22, "before_end": 21, "before_start": 19, "kind": "delete"}, {"after_end": 23, "after_start": 23, "before_end": 23, "before_start": 22, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 8, "chars_inserted": 8}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-ab652bce029e4b6f563041df", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002097", "medicine_name": "Fampyra", "medicine_slug": "fampyra", "observed_at": "2026-10-12T19:15:51Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "d9fe8aaaa611a84801d6308b13685258b5248df9022536697939afdf66fc1719", "source_snapshot_id": "source-ff8e0599077f0d01044dc867", "source_updated_at": "2025-08-21", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/fampyra-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1443}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 18, "start": 0, "text": "Dublin 2, D02 T380", "truncated": false}, "before_length": 18, "before_sha256": "23e6871e7960b0dadc753bc127bbea230cc8308c88b2d33704eb275a3ec1a70d", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 18, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 18, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-ab7b46cb34b26dabd1a0828a", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002097", "medicine_name": "Fampyra", "medicine_slug": "fampyra", "observed_at": "2026-10-12T19:16:07Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "a0c3ba8d58d6a43a809ecc3d142a78b10c2bd7f0b9f3a3553df2617d87daec1f", "source_snapshot_id": "source-c7a810dd21f94cd2d273f0da", "source_updated_at": "2025-08-21", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/fampyra-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 899}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 22, "start": 0, "text": "Ierland/Irlande/Irland", "truncated": false}, "before_length": 22, "before_sha256": "f5b90d33b60e3ce9ce9b34aa380ddef8bb49ac31af7f3f716c0bee0b2c7e8497", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 22, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 22, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-ab8913098c9bbaa24edb66cc", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002097", "medicine_name": "Fampyra", "medicine_slug": "fampyra", "observed_at": "2026-10-12T19:16:07Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "a0c3ba8d58d6a43a809ecc3d142a78b10c2bd7f0b9f3a3553df2617d87daec1f", "source_snapshot_id": "source-c7a810dd21f94cd2d273f0da", "source_updated_at": "2025-08-21", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/fampyra-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1377}
{"after": {"end": 126, "start": 0, "text": "For more information, see the European Medicines Agency’s website: https://www.ema.europa.eu/en/medicines/human/epar/pheburane", "truncated": false}, "after_length": 126, "after_sha256": "d6ff20492812ce9a64a15e42614fa9a4f2a0623c3ee24ad14db2dd6d5e132e06", "annex": "", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "unassigned", "change_operations": [{"after_end": 126, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 126}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-abf57afb90cb82a789a0500e", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:14Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": null, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "", "section_type": "unassigned", "source_provider": "European Medicines Agency", "source_sha256": "8b8c4cc8e6f1a21fedee4bf0743c9c03e454b50f5eaba0e3760416d7fe0a74ec", "source_snapshot_id": "source-4efe4ecf3ebf08d338a763a5", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 2}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 13, "start": 0, "text": "Lucane Pharma", "truncated": false}, "before_length": 13, "before_sha256": "e338afdb64acf1a6e2083a50318853589248451dd3aa707181ba02641a8521e8", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 13, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 13, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-ac050c5459e718f9259935fa", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:14Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "8b8c4cc8e6f1a21fedee4bf0743c9c03e454b50f5eaba0e3760416d7fe0a74ec", "source_snapshot_id": "source-4efe4ecf3ebf08d338a763a5", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1524}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "I", "before": {"end": 25, "start": 0, "text": "Post-marketing experience", "truncated": false}, "before_length": 25, "before_sha256": "0bf5d214dc7d6f6f0451f073e7a9a7eea0190d225b8f93509ac9467e27bd17f7", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 25, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": true, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 25, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-ac2a460b0c72c8297086b39b", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/000554", "medicine_name": "Emselex", "medicine_slug": "emselex", "observed_at": "2026-10-12T19:12:04Z", "pipeline_version": "2.0.0", "presentation_label": "Emselex 15 mg prolonged-release tablets", "presentation_occurrence": 2, "presentation_status": "heading_extracted_unverified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "4.8", "section_type": "adverse_reactions", "source_provider": "European Medicines Agency", "source_sha256": "4f2565612bc728ec67b7f9c0cd5799ef2c594911c76f323aef8bf6a85adde245", "source_snapshot_id": "source-1fda25b331eb198b8b93feb3", "source_updated_at": "2025-09-15", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/emselex-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 664}
{"after": {"end": 28, "start": 0, "text": "Merz Therapeutics Nordics AB", "truncated": false}, "after_length": 28, "after_sha256": "808a08c0a7c3cad28ee90c8a6dd0178d599000f64f11d4886b61abaee3d65c15", "annex": "IIIA", "before": {"end": 35, "start": 0, "text": "Acorda Therapeutics Ireland Limited", "truncated": false}, "before_length": 35, "before_sha256": "d94d3153d193ed26567f2b4ed48df016d81c534e7c0cb1a6655a63f0083383ff", "change_kind": "content", "change_operations": [{"after_end": 2, "after_start": 0, "before_end": 3, "before_start": 0, "kind": "replace"}, {"after_end": 4, "after_start": 3, "before_end": 6, "before_start": 4, "kind": "replace"}, {"after_end": 20, "after_start": 18, "before_end": 21, "before_start": 20, "kind": "replace"}, {"after_end": 21, "after_start": 21, "before_end": 26, "before_start": 22, "kind": "delete"}, {"after_end": 25, "after_start": 22, "before_end": 27, "before_start": 27, "kind": "insert"}, {"after_end": 28, "after_start": 26, "before_end": 35, "before_start": 28, "kind": "replace"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 17, "chars_inserted": 10}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-ac331ee97dc4fc20c020be8a", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002097", "medicine_name": "Fampyra", "medicine_slug": "fampyra", "observed_at": "2026-10-12T19:16:07Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "a0c3ba8d58d6a43a809ecc3d142a78b10c2bd7f0b9f3a3553df2617d87daec1f", "source_snapshot_id": "source-c7a810dd21f94cd2d273f0da", "source_updated_at": "2025-08-21", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/fampyra-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1593}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 21, "start": 0, "text": "info@lucanepharma.com", "truncated": false}, "before_length": 21, "before_sha256": "44fd39e5fb919cb3d680fa630da23b49238fec29159c509f3622f272bb41c7c6", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 21, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 21, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-ac44c02d665b13aa5806593d", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:19Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "77586d0bea0858214b43b86e91abc2d2711733b96959ead5ed0b5ecbd8ed888a", "source_snapshot_id": "source-85d476f9ad959cc117ca8f1f", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1536}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 22, "start": 0, "text": "Tel : +31 35 528 39 57", "truncated": false}, "before_length": 22, "before_sha256": "7bb8afadf5dee15b4f4e1219e333b993040f0848bccea58b1141990fffb82aa1", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 22, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 22, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-ac997e6611eeabf6c3dd96a3", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:19Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "77586d0bea0858214b43b86e91abc2d2711733b96959ead5ed0b5ecbd8ed888a", "source_snapshot_id": "source-85d476f9ad959cc117ca8f1f", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1892}
{"after": {"end": 23, "start": 0, "text": "info@euroceptpharma.com", "truncated": false}, "after_length": 23, "after_sha256": "9297cc5acdcc837f054116992765943f7907937507b2564a99ea1327a00ac0e6", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 23, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 23}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-acc3c282a6c91b4d08fbb6ed", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:14Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "8b8c4cc8e6f1a21fedee4bf0743c9c03e454b50f5eaba0e3760416d7fe0a74ec", "source_snapshot_id": "source-4efe4ecf3ebf08d338a763a5", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1475}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 33, "start": 0, "text": "United Kingdom (Northern Ireland)", "truncated": false}, "before_length": 33, "before_sha256": "9379d82927cdb505cfb186e912177065e56a1314de3a2b914ebbb8b5fe21525a", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 33, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 33, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-acf1bc42580bf286e3c6ed51", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002702", "medicine_name": "Hexacima", "medicine_slug": "hexacima", "observed_at": "2026-10-12T19:07:06Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "b990725709f885f3f868e5da444393a40a54f89ba2f2d9b232d9c053493d1b03", "source_snapshot_id": "source-87ea40f95d82cdfb5ba074b0", "source_updated_at": "2025-09-29", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/hexacima-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 2088}
{"after": {"end": 22, "start": 0, "text": "Fréquence indéterminée", "truncated": false}, "after_length": 22, "after_sha256": "9dbca2ea64869864cf27be15cb397d59f7675843792a00e126385e734d3768e0", "annex": "I", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 22, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": true, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 22}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-acfb70cdb2ccf52bdc5cdf4f", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/000554", "medicine_name": "Emselex", "medicine_slug": "emselex", "observed_at": "2026-10-12T19:12:07Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": null, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "4.8", "section_type": "adverse_reactions", "source_provider": "European Medicines Agency", "source_sha256": "9a4f1d7e260c7b80eaf397503623b63302e5945b579e9612177835e07c4ab888", "source_snapshot_id": "source-3aac7bf42b99529f25ac013b", "source_updated_at": "2025-09-15", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/emselex-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 176}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 13, "start": 0, "text": "Lucane Pharma", "truncated": false}, "before_length": 13, "before_sha256": "e338afdb64acf1a6e2083a50318853589248451dd3aa707181ba02641a8521e8", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 13, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 13, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-ad77c7051dcad07eea13a799", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:19Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "77586d0bea0858214b43b86e91abc2d2711733b96959ead5ed0b5ecbd8ed888a", "source_snapshot_id": "source-85d476f9ad959cc117ca8f1f", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1527}
{"after": {"end": 9, "start": 0, "text": "Nederland", "truncated": false}, "after_length": 9, "after_sha256": "8a869db3fa453526573e4f2c956528743cf246af5d1b5eac4879257589776797", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 9, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 9}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-ada7c48d3f7bd6841d2a473e", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002097", "medicine_name": "Fampyra", "medicine_slug": "fampyra", "observed_at": "2026-10-12T19:15:51Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "d9fe8aaaa611a84801d6308b13685258b5248df9022536697939afdf66fc1719", "source_snapshot_id": "source-ff8e0599077f0d01044dc867", "source_updated_at": "2025-08-21", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/fampyra-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1457}
{"after": {"end": 21, "start": 0, "text": "Tel: +31 35 528 39 57", "truncated": false}, "after_length": 21, "after_sha256": "7baf6601f41e49e470f803fdd4e755a86efa38be423317c000ed79963ebdd213", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 21, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 21}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-ae11d7030c02c7cf5c13ad90", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:19Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "77586d0bea0858214b43b86e91abc2d2711733b96959ead5ed0b5ecbd8ed888a", "source_snapshot_id": "source-85d476f9ad959cc117ca8f1f", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1493}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 27, "start": 0, "text": "(Eurocept International BV)", "truncated": false}, "before_length": 27, "before_sha256": "e6cf9b20aaa466e53ad0d393512ca75931e13e488321e3be6f3e4f8b600970c8", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 27, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 27, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-ae4b2709843650a9772bccbe", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:19Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "77586d0bea0858214b43b86e91abc2d2711733b96959ead5ed0b5ecbd8ed888a", "source_snapshot_id": "source-85d476f9ad959cc117ca8f1f", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1930}
{"after": {"end": 23, "start": 0, "text": "info@euroceptpharma.com", "truncated": false}, "after_length": 23, "after_sha256": "9297cc5acdcc837f054116992765943f7907937507b2564a99ea1327a00ac0e6", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 23, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 23}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-ae5be67255e69268cb07b183", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:19Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "77586d0bea0858214b43b86e91abc2d2711733b96959ead5ed0b5ecbd8ed888a", "source_snapshot_id": "source-85d476f9ad959cc117ca8f1f", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1510}
{"after": {"end": 138, "start": 0, "text": "Le PRAC a conclu que les informations sur le produit des médicaments contenant de la darifénacine devraient être modifiées en conséquence.", "truncated": false}, "after_length": 138, "after_sha256": "9760cf0c43de730bd298ee122f2c7397a9071c71cddc40ebf28cddea5ec85a6a", "annex": "IV", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 138, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 138}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-ae71eadde300534710eeafcf", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/000554", "medicine_name": "Emselex", "medicine_slug": "emselex", "observed_at": "2026-10-12T19:12:07Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": null, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "conditions", "section_type": "conditions", "source_provider": "European Medicines Agency", "source_sha256": "9a4f1d7e260c7b80eaf397503623b63302e5945b579e9612177835e07c4ab888", "source_snapshot_id": "source-3aac7bf42b99529f25ac013b", "source_updated_at": "2025-09-15", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/emselex-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 2070}
{"after": {"end": 25, "start": 0, "text": "Eurocept International BV", "truncated": false}, "after_length": 25, "after_sha256": "b17bd89b3cf285c986a6070d0d67f5326dd5c1f08a70834c296c6c820f9e7505", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 25, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 25}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-ae7785d92549873313fd41f2", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:19Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "77586d0bea0858214b43b86e91abc2d2711733b96959ead5ed0b5ecbd8ed888a", "source_snapshot_id": "source-85d476f9ad959cc117ca8f1f", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1412}
{"after": {"end": 22, "start": 0, "text": "Merz Therapeutics GmbH", "truncated": false}, "after_length": 22, "after_sha256": "059f049c7d0846aaadcf2573280d52110f302d4ecc7b38debd004571cd1e9d5e", "annex": "IIIA", "before": {"end": 35, "start": 0, "text": "Acorda Therapeutics Ireland Limited", "truncated": false}, "before_length": 35, "before_sha256": "d94d3153d193ed26567f2b4ed48df016d81c534e7c0cb1a6655a63f0083383ff", "change_kind": "content", "change_operations": [{"after_end": 2, "after_start": 0, "before_end": 3, "before_start": 0, "kind": "replace"}, {"after_end": 4, "after_start": 3, "before_end": 6, "before_start": 4, "kind": "replace"}, {"after_end": 19, "after_start": 18, "before_end": 30, "before_start": 20, "kind": "replace"}, {"after_end": 22, "after_start": 20, "before_end": 35, "before_start": 31, "kind": "replace"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 19, "chars_inserted": 6}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-ae7833a02d649769beb9ae9a", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002097", "medicine_name": "Fampyra", "medicine_slug": "fampyra", "observed_at": "2026-10-12T19:15:51Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "d9fe8aaaa611a84801d6308b13685258b5248df9022536697939afdf66fc1719", "source_snapshot_id": "source-ff8e0599077f0d01044dc867", "source_updated_at": "2025-08-21", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/fampyra-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1027}
{"after": {"end": 22, "start": 0, "text": "IMED Poland Sp. z o.o.", "truncated": false}, "after_length": 22, "after_sha256": "b3265866c253edae29f5501eb68307d984be0f139bc8dba8b343d9b3ff61e415", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 22, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 22}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-ae95142562c9d37f95281c52", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:14Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "8b8c4cc8e6f1a21fedee4bf0743c9c03e454b50f5eaba0e3760416d7fe0a74ec", "source_snapshot_id": "source-4efe4ecf3ebf08d338a763a5", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1980}
{"after": {"end": 26, "start": 0, "text": "Tél/Tel: +31 (0) 762057088", "truncated": false}, "after_length": 26, "after_sha256": "3bc75506c55c8b7cd4fff8d2140ba08d71ae9e9c73edbd7c8810587852e9e7f9", "annex": "IIIA", "before": {"end": 27, "start": 0, "text": "Tél/Tel: +353 (0)1 231 4609", "truncated": false}, "before_length": 27, "before_sha256": "87104ca41090d27d4255b5464c46bf8c8c6fca2440bf6dae9e31ce28d2ad406a", "change_kind": "content", "change_operations": [{"after_end": 12, "after_start": 11, "before_end": 13, "before_start": 11, "kind": "replace"}, {"after_end": 16, "after_start": 16, "before_end": 18, "before_start": 17, "kind": "delete"}, {"after_end": 19, "after_start": 17, "before_end": 19, "before_start": 19, "kind": "insert"}, {"after_end": 20, "after_start": 20, "before_end": 25, "before_start": 20, "kind": "delete"}, {"after_end": 26, "after_start": 21, "before_end": 27, "before_start": 26, "kind": "replace"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 9, "chars_inserted": 8}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-aeec545c8bb14ed985802660", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002097", "medicine_name": "Fampyra", "medicine_slug": "fampyra", "observed_at": "2026-10-12T19:15:51Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "d9fe8aaaa611a84801d6308b13685258b5248df9022536697939afdf66fc1719", "source_snapshot_id": "source-ff8e0599077f0d01044dc867", "source_updated_at": "2025-08-21", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/fampyra-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1405}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 18, "start": 0, "text": "Dublin 2, D02 T380", "truncated": false}, "before_length": 18, "before_sha256": "23e6871e7960b0dadc753bc127bbea230cc8308c88b2d33704eb275a3ec1a70d", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 18, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 18, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-af01fdf3a5cf48c6c18938c4", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002097", "medicine_name": "Fampyra", "medicine_slug": "fampyra", "observed_at": "2026-10-12T19:15:51Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "d9fe8aaaa611a84801d6308b13685258b5248df9022536697939afdf66fc1719", "source_snapshot_id": "source-ff8e0599077f0d01044dc867", "source_updated_at": "2025-08-21", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/fampyra-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1410}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "III", "before": {"end": 25, "start": 0, "text": "Tel: + 353-(0) 1 661 4377", "truncated": false}, "before_length": 25, "before_sha256": "48fde288146f4033a2172164570180a8f875f4e361fcf85a8e43ff77834511cc", "change_kind": "unassigned", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 25, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 25, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-af06a99dc8129c97dda477f1", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/001021", "medicine_name": "Adcirca (previously Tadalafil Lilly)", "medicine_slug": "adcirca-previously-tadalafil-lilly", "observed_at": "2026-10-12T19:02:45Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "", "section_type": "unassigned", "source_provider": "European Medicines Agency", "source_sha256": "cdbefcd6143c93e81f3c826bea8d3d01bffc55652e0f792243097df75c452721", "source_snapshot_id": "source-a1e85476de17f5a8664f7766", "source_updated_at": "2026-01-28", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/adcirca-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 2305}
{"after": {"end": 21, "start": 0, "text": "Tel: +31 35 528 39 57", "truncated": false}, "after_length": 21, "after_sha256": "7baf6601f41e49e470f803fdd4e755a86efa38be423317c000ed79963ebdd213", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 21, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 21}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-af90c23f8b428ff186d87a2f", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:19Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "77586d0bea0858214b43b86e91abc2d2711733b96959ead5ed0b5ecbd8ed888a", "source_snapshot_id": "source-85d476f9ad959cc117ca8f1f", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1897}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 13, "start": 0, "text": "Lucane Pharma", "truncated": false}, "before_length": 13, "before_sha256": "e338afdb64acf1a6e2083a50318853589248451dd3aa707181ba02641a8521e8", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 13, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 13, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-afa5934d07ab331baebc4a21", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:14Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "8b8c4cc8e6f1a21fedee4bf0743c9c03e454b50f5eaba0e3760416d7fe0a74ec", "source_snapshot_id": "source-4efe4ecf3ebf08d338a763a5", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1570}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 20, "start": 0, "text": "10 Earlsfort Terrace", "truncated": false}, "before_length": 20, "before_sha256": "22951bbf6ee77815d0c07b3af5f0a66e17d277636971c4eaff372dea65dcb193", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 20, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 20, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-afe4572c69baae8331bdb4aa", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002097", "medicine_name": "Fampyra", "medicine_slug": "fampyra", "observed_at": "2026-10-12T19:16:07Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "a0c3ba8d58d6a43a809ecc3d142a78b10c2bd7f0b9f3a3553df2617d87daec1f", "source_snapshot_id": "source-c7a810dd21f94cd2d273f0da", "source_updated_at": "2025-08-21", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/fampyra-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1468}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 18, "start": 0, "text": "Dublin 2, D02 T380", "truncated": false}, "before_length": 18, "before_sha256": "23e6871e7960b0dadc753bc127bbea230cc8308c88b2d33704eb275a3ec1a70d", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 18, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 18, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-b0711474956c6faa7fdc43ae", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002097", "medicine_name": "Fampyra", "medicine_slug": "fampyra", "observed_at": "2026-10-12T19:15:51Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "d9fe8aaaa611a84801d6308b13685258b5248df9022536697939afdf66fc1719", "source_snapshot_id": "source-ff8e0599077f0d01044dc867", "source_updated_at": "2025-08-21", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/fampyra-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1589}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 13, "start": 0, "text": "Lucane Pharma", "truncated": false}, "before_length": 13, "before_sha256": "e338afdb64acf1a6e2083a50318853589248451dd3aa707181ba02641a8521e8", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 13, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 13, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-b082a8aeaf23fa93e923ae7a", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:14Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "8b8c4cc8e6f1a21fedee4bf0743c9c03e454b50f5eaba0e3760416d7fe0a74ec", "source_snapshot_id": "source-4efe4ecf3ebf08d338a763a5", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1857}
{"after": {"end": 156, "start": 0, "text": "The printed package leaflet of the medicinal product must state the name and address of the manufacturer responsible for the release of the concerned batch.", "truncated": false}, "after_length": 156, "after_sha256": "183c90cbf0ec43d0450fbf1ac2be9d123d464059fe683f7b42e974414cde5f1c", "annex": "II", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 156, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 156}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-b0bd747d6b6e4599d9f8802b", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/000980", "medicine_name": "Samsca", "medicine_slug": "samsca", "observed_at": "2026-10-12T13:28:23Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "conditions", "section_type": "conditions", "source_provider": "European Medicines Agency", "source_sha256": "b92d73a758b8976c4438a072d544f0d6c603112c90dfc9c084d362ce62419257", "source_snapshot_id": "source-15b8b5681aba542ec1668c0b", "source_updated_at": "2026-08-20", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/samsca-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 557}
{"after": {"end": 11, "start": 0, "text": "Németország", "truncated": false}, "after_length": 11, "after_sha256": "b5bbb24c748b70690808a17e5285ee60570c7732e995787c311f673f9c79e808", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 11, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 11}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-b107d76fa35049befd1f8809", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002097", "medicine_name": "Fampyra", "medicine_slug": "fampyra", "observed_at": "2026-10-12T19:16:07Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "a0c3ba8d58d6a43a809ecc3d142a78b10c2bd7f0b9f3a3553df2617d87daec1f", "source_snapshot_id": "source-c7a810dd21f94cd2d273f0da", "source_updated_at": "2025-08-21", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/fampyra-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1430}
{"after": {"end": 25, "start": 0, "text": "Gustav III:s Boulevard 32", "truncated": false}, "after_length": 25, "after_sha256": "bba3ec2bf3d09014ee723cdd39b8fa83a1dc3705ce0797ed375b3af7c8be027c", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 25, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 25}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-b138fa7cdc72395c71fa6e13", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002097", "medicine_name": "Fampyra", "medicine_slug": "fampyra", "observed_at": "2026-10-12T19:16:07Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "a0c3ba8d58d6a43a809ecc3d142a78b10c2bd7f0b9f3a3553df2617d87daec1f", "source_snapshot_id": "source-c7a810dd21f94cd2d273f0da", "source_updated_at": "2025-08-21", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/fampyra-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1598}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 18, "start": 0, "text": "Dublin 2, D02 T380", "truncated": false}, "before_length": 18, "before_sha256": "23e6871e7960b0dadc753bc127bbea230cc8308c88b2d33704eb275a3ec1a70d", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 18, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 18, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-b1909a297a24ac7163ec0fda", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002097", "medicine_name": "Fampyra", "medicine_slug": "fampyra", "observed_at": "2026-10-12T19:16:07Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "a0c3ba8d58d6a43a809ecc3d142a78b10c2bd7f0b9f3a3553df2617d87daec1f", "source_snapshot_id": "source-c7a810dd21f94cd2d273f0da", "source_updated_at": "2025-08-21", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/fampyra-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1444}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 21, "start": 0, "text": "Tel: + 33 153 868 750", "truncated": false}, "before_length": 21, "before_sha256": "efffe29324e968019e6e2b111904182ba06d83e76b1f29b933bed9dd8779c114", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 21, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 21, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-b1f4c3e457cd20fde798e19d", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:19Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "77586d0bea0858214b43b86e91abc2d2711733b96959ead5ed0b5ecbd8ed888a", "source_snapshot_id": "source-85d476f9ad959cc117ca8f1f", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1496}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 20, "start": 0, "text": "10 Earlsfort Terrace", "truncated": false}, "before_length": 20, "before_sha256": "22951bbf6ee77815d0c07b3af5f0a66e17d277636971c4eaff372dea65dcb193", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 20, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 20, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-b22b44b9c82ef66c101c1a25", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002097", "medicine_name": "Fampyra", "medicine_slug": "fampyra", "observed_at": "2026-10-12T19:15:51Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "d9fe8aaaa611a84801d6308b13685258b5248df9022536697939afdf66fc1719", "source_snapshot_id": "source-ff8e0599077f0d01044dc867", "source_updated_at": "2025-08-21", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/fampyra-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1389}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 18, "start": 0, "text": "Dublin 2, D02 T380", "truncated": false}, "before_length": 18, "before_sha256": "23e6871e7960b0dadc753bc127bbea230cc8308c88b2d33704eb275a3ec1a70d", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 18, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 18, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-b297b0ff2b9ce38a5a648921", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002097", "medicine_name": "Fampyra", "medicine_slug": "fampyra", "observed_at": "2026-10-12T19:16:07Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "a0c3ba8d58d6a43a809ecc3d142a78b10c2bd7f0b9f3a3553df2617d87daec1f", "source_snapshot_id": "source-c7a810dd21f94cd2d273f0da", "source_updated_at": "2025-08-21", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/fampyra-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1386}
{"after": {"end": 16, "start": 0, "text": "Extrovis EU Kft.", "truncated": false}, "after_length": 16, "after_sha256": "b9216ef80e71e17798dce313e4318f03f37328f225d30ab508b7413813a908e5", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 16, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 16}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-b2c0b32e7f431b3ebf880199", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/006047", "medicine_name": "Lacosamide Adroiq", "medicine_slug": "lacosamide-adroiq", "observed_at": "2026-10-12T19:07:59Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "cc83d966059d42856d0211a4f256b29b20d43593865704d6a9315aeb694f3c76", "source_snapshot_id": "source-896abba1d8391c918345d46b", "source_updated_at": "2025-09-25", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/lacosamide-adroiq-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1781}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 13, "start": 0, "text": "Lucane Pharma", "truncated": false}, "before_length": 13, "before_sha256": "e338afdb64acf1a6e2083a50318853589248451dd3aa707181ba02641a8521e8", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 13, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 13, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-b38938ea03e4192803456a9f", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:14Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "8b8c4cc8e6f1a21fedee4bf0743c9c03e454b50f5eaba0e3760416d7fe0a74ec", "source_snapshot_id": "source-4efe4ecf3ebf08d338a763a5", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1595}
{"after": {"end": 17, "start": 0, "text": "Tlf: +46 8 368000", "truncated": false}, "after_length": 17, "after_sha256": "f05e1f0a3ce4f37db4216310bafc5f59464b812748444615fe40c193a9c52c41", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 17, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 17}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-b3b1c6b5e7529969e4505a70", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002097", "medicine_name": "Fampyra", "medicine_slug": "fampyra", "observed_at": "2026-10-12T19:16:07Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "a0c3ba8d58d6a43a809ecc3d142a78b10c2bd7f0b9f3a3553df2617d87daec1f", "source_snapshot_id": "source-c7a810dd21f94cd2d273f0da", "source_updated_at": "2025-08-21", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/fampyra-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1601}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "III", "before": {"end": 18, "start": 0, "text": "Pátriárka utca 14.", "truncated": false}, "before_length": 18, "before_sha256": "488a80d25b682a58591b4751c4687d5b516ccd6a004748e40d4e8f1454217b07", "change_kind": "unassigned", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 18, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 18, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-b3edf16169869eb91a8e42f6", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/006047", "medicine_name": "Lacosamide Adroiq", "medicine_slug": "lacosamide-adroiq", "observed_at": "2026-10-12T19:07:56Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "", "section_type": "unassigned", "source_provider": "European Medicines Agency", "source_sha256": "0578c53a5e1c785c4d9d4dc0dabae49dbfa89e237aa571556bee548c3f9cf4d5", "source_snapshot_id": "source-64831dec5ebf55535e19d91b", "source_updated_at": "2025-09-25", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/lacosamide-adroiq-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1205}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 25, "start": 0, "text": "Tél/Tel: +31 35 528 39 57", "truncated": false}, "before_length": 25, "before_sha256": "92c714a72165e0b9b7201b868cdfaa9781cb8fddb4505d51829e1b448291e604", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 25, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 25, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-b3ff1b87d93fba236c1803c5", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:14Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "8b8c4cc8e6f1a21fedee4bf0743c9c03e454b50f5eaba0e3760416d7fe0a74ec", "source_snapshot_id": "source-4efe4ecf3ebf08d338a763a5", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1881}
{"after": {"end": 10, "start": 0, "text": "Dux pharma", "truncated": false}, "after_length": 10, "after_sha256": "dc883eef1df083eb86278145e5f12f39a539e9c6480843f1755b844cc69019ee", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 10, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 10}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-b41da41e4cb55df17461048e", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:19Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "77586d0bea0858214b43b86e91abc2d2711733b96959ead5ed0b5ecbd8ed888a", "source_snapshot_id": "source-85d476f9ad959cc117ca8f1f", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1486}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIB", "before": {"end": 16, "start": 0, "text": "Extrovis EU Ltd.", "truncated": false}, "before_length": 16, "before_sha256": "f462ad48e7aef0bc82148ce088af1897d99ed86993128f30d506b27d3108a929", "change_kind": "unassigned", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 16, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 16, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-b50d71f7f8262d46220d77da", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/006047", "medicine_name": "Lacosamide Adroiq", "medicine_slug": "lacosamide-adroiq", "observed_at": "2026-10-12T19:07:56Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "", "section_type": "unassigned", "source_provider": "European Medicines Agency", "source_sha256": "0578c53a5e1c785c4d9d4dc0dabae49dbfa89e237aa571556bee548c3f9cf4d5", "source_snapshot_id": "source-64831dec5ebf55535e19d91b", "source_updated_at": "2025-09-25", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/lacosamide-adroiq-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1904}
{"after": {"end": 23, "start": 0, "text": "60318 Frankfurt am Main", "truncated": false}, "after_length": 23, "after_sha256": "24c3191b5088b20c209c4387a8127297e54c776e161d305c9e57956a13b7cbbe", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 23, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 23}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-b55685e84e8374f281b14889", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002097", "medicine_name": "Fampyra", "medicine_slug": "fampyra", "observed_at": "2026-10-12T19:15:51Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "d9fe8aaaa611a84801d6308b13685258b5248df9022536697939afdf66fc1719", "source_snapshot_id": "source-ff8e0599077f0d01044dc867", "source_updated_at": "2025-08-21", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/fampyra-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1393}
{"after": {"end": 8, "start": 0, "text": "W12 HX57", "truncated": false}, "after_length": 8, "after_sha256": "fbe61b7957c4f976a9508e38ecbe9e357c9eb7e4d21a231b5de7c7f72f183159", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 8, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 8}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-b584cd9db8eca76dcb40b64b", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/000273", "medicine_name": "Rapamune", "medicine_slug": "rapamune", "observed_at": "2026-10-12T13:39:00Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "5ec17411e4c1a81999ea8a4a3fb0ca56fd42f205f10b55b04218801cee6c6cfa", "source_snapshot_id": "source-dda7a9536e6e3b6e820a6139", "source_updated_at": "2026-05-04", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/rapamune-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 2954}
{"after": {"end": 22, "start": 0, "text": "Tel: + 48 22 663 43 03", "truncated": false}, "after_length": 22, "after_sha256": "5345f797275d32abdc54039c15f0a4f05223d8f5424eaa63545f2efe682185e2", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 22, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 22}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-b58ada756daa15848becfb8f", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:14Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "8b8c4cc8e6f1a21fedee4bf0743c9c03e454b50f5eaba0e3760416d7fe0a74ec", "source_snapshot_id": "source-4efe4ecf3ebf08d338a763a5", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1535}
{"after": {"end": 25, "start": 0, "text": "Gustav III:s Boulevard 32", "truncated": false}, "after_length": 25, "after_sha256": "bba3ec2bf3d09014ee723cdd39b8fa83a1dc3705ce0797ed375b3af7c8be027c", "annex": "IIIA", "before": {"end": 25, "start": 0, "text": "Gustav III S Boulevard 32", "truncated": false}, "before_length": 25, "before_sha256": "6117fe99f25fb7a4848fea16fe447d9ead174e8fb74f0ec2aaad6366c885562b", "change_kind": "content", "change_operations": [{"after_end": 12, "after_start": 10, "before_end": 12, "before_start": 10, "kind": "replace"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 2, "chars_inserted": 2}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-b5b44a2844a0316ff4a54903", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002097", "medicine_name": "Fampyra", "medicine_slug": "fampyra", "observed_at": "2026-10-12T19:16:07Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "a0c3ba8d58d6a43a809ecc3d142a78b10c2bd7f0b9f3a3553df2617d87daec1f", "source_snapshot_id": "source-c7a810dd21f94cd2d273f0da", "source_updated_at": "2025-08-21", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/fampyra-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1435}
{"after": {"end": 13, "start": 0, "text": "Nieuwe Donk 9", "truncated": false}, "after_length": 13, "after_sha256": "9b03d8cf912ad0cf483871c4e8c85fde0243688b3a66c83ca9b8961156374e51", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 13, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 13}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-b5bb2d661dbfdbdc46232cff", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/000980", "medicine_name": "Samsca", "medicine_slug": "samsca", "observed_at": "2026-10-12T13:28:24Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "3080d919225c2a98f20aec84d5803b3fde6e1b64f323055c46d098625f4ad301", "source_snapshot_id": "source-e05739a15a0532954ee45dd4", "source_updated_at": "2026-08-20", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/samsca-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1259}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 14, "start": 0, "text": "Heussstraße 25", "truncated": false}, "before_length": 14, "before_sha256": "805584102a210d40b5c8e0e7014cb2d6f4194a7c2ef94da3309e0707eed85073", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 14, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 14, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-b5cb8096925b517747efa833", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/005246", "medicine_name": "Byfavo", "medicine_slug": "byfavo", "observed_at": "2026-10-12T13:28:16Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "61243a969f979f690fe718e414ceaeb66438c1faa31101ba25187d2f9ea662fd", "source_snapshot_id": "source-dd26eb8615d8c18bd80c1f6a", "source_updated_at": "2026-08-26", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/byfavo-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 2379}
{"after": {"end": 23, "start": 0, "text": "60318 Frankfurt am Main", "truncated": false}, "after_length": 23, "after_sha256": "24c3191b5088b20c209c4387a8127297e54c776e161d305c9e57956a13b7cbbe", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 23, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 23}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-b5d8cb887e8af94a935ee630", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002097", "medicine_name": "Fampyra", "medicine_slug": "fampyra", "observed_at": "2026-10-12T19:15:51Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "d9fe8aaaa611a84801d6308b13685258b5248df9022536697939afdf66fc1719", "source_snapshot_id": "source-ff8e0599077f0d01044dc867", "source_updated_at": "2025-08-21", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/fampyra-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1576}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 21, "start": 0, "text": "info@lucanepharma.com", "truncated": false}, "before_length": 21, "before_sha256": "44fd39e5fb919cb3d680fa630da23b49238fec29159c509f3622f272bb41c7c6", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 21, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 21, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-b5e32df257d9ee2e83a34d20", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:19Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "77586d0bea0858214b43b86e91abc2d2711733b96959ead5ed0b5ecbd8ed888a", "source_snapshot_id": "source-85d476f9ad959cc117ca8f1f", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1490}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 27, "start": 0, "text": "(Eurocept International BV)", "truncated": false}, "before_length": 27, "before_sha256": "e6cf9b20aaa466e53ad0d393512ca75931e13e488321e3be6f3e4f8b600970c8", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 27, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 27, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-b5f618d8fa2e110f9121496f", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:19Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "77586d0bea0858214b43b86e91abc2d2711733b96959ead5ed0b5ecbd8ed888a", "source_snapshot_id": "source-85d476f9ad959cc117ca8f1f", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1803}
{"after": {"end": 25, "start": 0, "text": "Eurocept International BV", "truncated": false}, "after_length": 25, "after_sha256": "b17bd89b3cf285c986a6070d0d67f5326dd5c1f08a70834c296c6c820f9e7505", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 25, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 25}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-b60cedc71b54d23ddcd7a8ed", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:19Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "77586d0bea0858214b43b86e91abc2d2711733b96959ead5ed0b5ecbd8ed888a", "source_snapshot_id": "source-85d476f9ad959cc117ca8f1f", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1453}
{"after": {"end": 25, "start": 0, "text": "Eurocept International BV", "truncated": false}, "after_length": 25, "after_sha256": "b17bd89b3cf285c986a6070d0d67f5326dd5c1f08a70834c296c6c820f9e7505", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 25, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 25}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-b62fd710b193293260ad2ed9", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:14Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "8b8c4cc8e6f1a21fedee4bf0743c9c03e454b50f5eaba0e3760416d7fe0a74ec", "source_snapshot_id": "source-4efe4ecf3ebf08d338a763a5", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 2070}
{"after": {"end": 96, "start": 0, "text": "Each gram of sodium phenylbutyrate contains 5.7 mg of aspartame and 124 mg (5.4 mmol) of sodium.", "truncated": false}, "after_length": 96, "after_sha256": "43fe6e048c6236b91173ad12b39e4b67c468b3e915e8f52d33322a1474177061", "annex": "I", "before": {"end": 101, "start": 0, "text": "Each gram dose of sodium phenylbutyrate contains 5.7 mg of aspartame and 124 mg (5.4 mmol) of sodium.", "truncated": false}, "before_length": 101, "before_sha256": "8c924c9c90070458f0281970a50383691716684be767439669b1f428b2c7ccd5", "change_kind": "content", "change_operations": [{"after_end": 10, "after_start": 10, "before_end": 15, "before_start": 10, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 5, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-b65636b55359f79de5c008e5", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:14Z", "pipeline_version": "2.0.0", "presentation_label": "PHEBURANE 350 mg/mL oral solution", "presentation_occurrence": 2, "presentation_status": "heading_extracted_unverified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "2", "section_type": "quality_presentation", "source_provider": "European Medicines Agency", "source_sha256": "8b8c4cc8e6f1a21fedee4bf0743c9c03e454b50f5eaba0e3760416d7fe0a74ec", "source_snapshot_id": "source-4efe4ecf3ebf08d338a763a5", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 357}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 18, "start": 0, "text": "Dublin 2, D02 T380", "truncated": false}, "before_length": 18, "before_sha256": "23e6871e7960b0dadc753bc127bbea230cc8308c88b2d33704eb275a3ec1a70d", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 18, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 18, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-b6ec9e31133756b81a53071c", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002097", "medicine_name": "Fampyra", "medicine_slug": "fampyra", "observed_at": "2026-10-12T19:15:51Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "d9fe8aaaa611a84801d6308b13685258b5248df9022536697939afdf66fc1719", "source_snapshot_id": "source-ff8e0599077f0d01044dc867", "source_updated_at": "2025-08-21", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/fampyra-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1370}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 13, "start": 0, "text": "Lucane Pharma", "truncated": false}, "before_length": 13, "before_sha256": "e338afdb64acf1a6e2083a50318853589248451dd3aa707181ba02641a8521e8", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 13, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 13, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-b70aaab07e8f0ae3e49ac484", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:19Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "77586d0bea0858214b43b86e91abc2d2711733b96959ead5ed0b5ecbd8ed888a", "source_snapshot_id": "source-85d476f9ad959cc117ca8f1f", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1907}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 16, "start": 0, "text": "Extrovis EU Ltd.", "truncated": false}, "before_length": 16, "before_sha256": "f462ad48e7aef0bc82148ce088af1897d99ed86993128f30d506b27d3108a929", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 16, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 16, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-b70e97f1b5ea311d2c93fce2", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/006047", "medicine_name": "Lacosamide Adroiq", "medicine_slug": "lacosamide-adroiq", "observed_at": "2026-10-12T19:07:59Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "cc83d966059d42856d0211a4f256b29b20d43593865704d6a9315aeb694f3c76", "source_snapshot_id": "source-896abba1d8391c918345d46b", "source_updated_at": "2025-09-25", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/lacosamide-adroiq-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1707}
{"after": {"end": 23, "start": 0, "text": "info@euroceptpharma.com", "truncated": false}, "after_length": 23, "after_sha256": "9297cc5acdcc837f054116992765943f7907937507b2564a99ea1327a00ac0e6", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 23, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 23}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-b71c95ebbc5b7bca0fd37329", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:14Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "8b8c4cc8e6f1a21fedee4bf0743c9c03e454b50f5eaba0e3760416d7fe0a74ec", "source_snapshot_id": "source-4efe4ecf3ebf08d338a763a5", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1442}
{"after": {"end": 23, "start": 0, "text": "Tel: +49 (0) 69 15 03 0", "truncated": false}, "after_length": 23, "after_sha256": "09683b3f43171b2266a32d9f7d44e3d62d536522dc6f42d4b47f2dda48b31833", "annex": "IIIA", "before": {"end": 23, "start": 0, "text": "Tel: +353 (0)1 231 4609", "truncated": false}, "before_length": 23, "before_sha256": "a115f11f382ef18898b9d956e48603ae236fd1846ce41e8586af99b6dabbfc4d", "change_kind": "content", "change_operations": [{"after_end": 8, "after_start": 6, "before_end": 9, "before_start": 6, "kind": "replace"}, {"after_end": 16, "after_start": 12, "before_end": 13, "before_start": 13, "kind": "insert"}, {"after_end": 18, "after_start": 17, "before_end": 14, "before_start": 14, "kind": "insert"}, {"after_end": 20, "after_start": 19, "before_end": 16, "before_start": 15, "kind": "replace"}, {"after_end": 21, "after_start": 21, "before_end": 18, "before_start": 17, "kind": "delete"}, {"after_end": 22, "after_start": 22, "before_end": 21, "before_start": 19, "kind": "delete"}, {"after_end": 23, "after_start": 23, "before_end": 23, "before_start": 22, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 8, "chars_inserted": 8}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-b7200db3e44aedc1483a5504", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002097", "medicine_name": "Fampyra", "medicine_slug": "fampyra", "observed_at": "2026-10-12T19:16:07Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "a0c3ba8d58d6a43a809ecc3d142a78b10c2bd7f0b9f3a3553df2617d87daec1f", "source_snapshot_id": "source-c7a810dd21f94cd2d273f0da", "source_updated_at": "2025-08-21", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/fampyra-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1546}
{"after": {"end": 21, "start": 0, "text": "Tel: +31 35 528 39 57", "truncated": false}, "after_length": 21, "after_sha256": "7baf6601f41e49e470f803fdd4e755a86efa38be423317c000ed79963ebdd213", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 21, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 21}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-b723c8572e332f6e73709e46", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:14Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "8b8c4cc8e6f1a21fedee4bf0743c9c03e454b50f5eaba0e3760416d7fe0a74ec", "source_snapshot_id": "source-4efe4ecf3ebf08d338a763a5", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1441}
{"after": {"end": 23, "start": 0, "text": "60318 Frankfurt am Main", "truncated": false}, "after_length": 23, "after_sha256": "24c3191b5088b20c209c4387a8127297e54c776e161d305c9e57956a13b7cbbe", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 23, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 23}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-b735c3ffc38abceca43f7d1c", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002097", "medicine_name": "Fampyra", "medicine_slug": "fampyra", "observed_at": "2026-10-12T19:16:07Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "a0c3ba8d58d6a43a809ecc3d142a78b10c2bd7f0b9f3a3553df2617d87daec1f", "source_snapshot_id": "source-c7a810dd21f94cd2d273f0da", "source_updated_at": "2025-08-21", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/fampyra-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1563}
{"after": {"end": 26, "start": 0, "text": "Eckenheimer Landstraße 100", "truncated": false}, "after_length": 26, "after_sha256": "fdce1a9bd200c5ddd476c1ea5676b9ffbbea723f7353ad6fbc1fe019dcb86c07", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 26, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 26}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-b75daad79cf36b74a6fb1bb3", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002097", "medicine_name": "Fampyra", "medicine_slug": "fampyra", "observed_at": "2026-10-12T19:16:07Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "a0c3ba8d58d6a43a809ecc3d142a78b10c2bd7f0b9f3a3553df2617d87daec1f", "source_snapshot_id": "source-c7a810dd21f94cd2d273f0da", "source_updated_at": "2025-08-21", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/fampyra-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1571}
{"after": {"end": 18, "start": 0, "text": "4844 CK Terheijden", "truncated": false}, "after_length": 18, "after_sha256": "e7ea1ad04b1071e360b652726acc9e8a22118603b55f58e0bd782476a7e47649", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 18, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 18}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-b799a19639ca6b029e852386", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002097", "medicine_name": "Fampyra", "medicine_slug": "fampyra", "observed_at": "2026-10-12T19:15:51Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "d9fe8aaaa611a84801d6308b13685258b5248df9022536697939afdf66fc1719", "source_snapshot_id": "source-ff8e0599077f0d01044dc867", "source_updated_at": "2025-08-21", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/fampyra-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1456}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 18, "start": 0, "text": "Dublin 2, D02 T380", "truncated": false}, "before_length": 18, "before_sha256": "23e6871e7960b0dadc753bc127bbea230cc8308c88b2d33704eb275a3ec1a70d", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 18, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 18, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-b7d861e15720524bd6d839fd", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002097", "medicine_name": "Fampyra", "medicine_slug": "fampyra", "observed_at": "2026-10-12T19:15:51Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "d9fe8aaaa611a84801d6308b13685258b5248df9022536697939afdf66fc1719", "source_snapshot_id": "source-ff8e0599077f0d01044dc867", "source_updated_at": "2025-08-21", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/fampyra-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1554}
{"after": {"end": 26, "start": 0, "text": "Eckenheimer Landstraße 100", "truncated": false}, "after_length": 26, "after_sha256": "fdce1a9bd200c5ddd476c1ea5676b9ffbbea723f7353ad6fbc1fe019dcb86c07", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 26, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 26}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-b7d95c05280ff9c4c858fdf2", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002097", "medicine_name": "Fampyra", "medicine_slug": "fampyra", "observed_at": "2026-10-12T19:15:51Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "d9fe8aaaa611a84801d6308b13685258b5248df9022536697939afdf66fc1719", "source_snapshot_id": "source-ff8e0599077f0d01044dc867", "source_updated_at": "2025-08-21", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/fampyra-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1556}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 25, "start": 0, "text": "Tél/Tel: +31 35 528 39 57", "truncated": false}, "before_length": 25, "before_sha256": "92c714a72165e0b9b7201b868cdfaa9781cb8fddb4505d51829e1b448291e604", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 25, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 25, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-b8048b21bb39423467b12d8b", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:14Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "8b8c4cc8e6f1a21fedee4bf0743c9c03e454b50f5eaba0e3760416d7fe0a74ec", "source_snapshot_id": "source-4efe4ecf3ebf08d338a763a5", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1859}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "III", "before": {"end": 33, "start": 0, "text": "United Kingdom (Northern Ireland)", "truncated": false}, "before_length": 33, "before_sha256": "9379d82927cdb505cfb186e912177065e56a1314de3a2b914ebbb8b5fe21525a", "change_kind": "unassigned", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 33, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 33, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-b81475c755bc7e3f879a07bc", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/001021", "medicine_name": "Adcirca (previously Tadalafil Lilly)", "medicine_slug": "adcirca-previously-tadalafil-lilly", "observed_at": "2026-10-12T19:02:45Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "", "section_type": "unassigned", "source_provider": "European Medicines Agency", "source_sha256": "cdbefcd6143c93e81f3c826bea8d3d01bffc55652e0f792243097df75c452721", "source_snapshot_id": "source-a1e85476de17f5a8664f7766", "source_updated_at": "2026-01-28", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/adcirca-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 2013}
{"after": {"end": 259, "start": 0, "text": "La solution avec l’arôme citron-menthe est légèrement moins épaisse que celle avec l’arôme cassis et peut conduire à l’ajout de plus de 2 gouttes. Il est recommandé de mesurer soigneusement l’arôme citron-menthe pour s’assurer qu’une seule goutte est ajoutée.", "truncated": false}, "after_length": 259, "after_sha256": "63cfab65a1b679831aab2fc223aade1975568b7890afeec91186532d5c7f97c8", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 259, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 259}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-b85bf15c94c156446277726e", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:19Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "77586d0bea0858214b43b86e91abc2d2711733b96959ead5ed0b5ecbd8ed888a", "source_snapshot_id": "source-85d476f9ad959cc117ca8f1f", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1677}
{"after": {"end": 23, "start": 0, "text": "Tel: +49 6431 285 88 30", "truncated": false}, "after_length": 23, "after_sha256": "ef2d8f53356e21d9673844a7ef23ea7b054ff18cc0092c86a4e97d96486b24a7", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 23, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 23}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-b86aaa9d1042e8b8ccbeeba0", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:19Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "77586d0bea0858214b43b86e91abc2d2711733b96959ead5ed0b5ecbd8ed888a", "source_snapshot_id": "source-85d476f9ad959cc117ca8f1f", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1888}
{"after": {"end": 23, "start": 0, "text": "info@euroceptpharma.com", "truncated": false}, "after_length": 23, "after_sha256": "9297cc5acdcc837f054116992765943f7907937507b2564a99ea1327a00ac0e6", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 23, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 23}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-b89bfd253ebb32bfdf90e070", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:14Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "8b8c4cc8e6f1a21fedee4bf0743c9c03e454b50f5eaba0e3760416d7fe0a74ec", "source_snapshot_id": "source-4efe4ecf3ebf08d338a763a5", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1954}
{"after": {"end": 22, "start": 0, "text": "Merz Therapeutics GmbH", "truncated": false}, "after_length": 22, "after_sha256": "059f049c7d0846aaadcf2573280d52110f302d4ecc7b38debd004571cd1e9d5e", "annex": "I", "before": {"end": 35, "start": 0, "text": "Acorda Therapeutics Ireland Limited", "truncated": false}, "before_length": 35, "before_sha256": "d94d3153d193ed26567f2b4ed48df016d81c534e7c0cb1a6655a63f0083383ff", "change_kind": "administrative", "change_operations": [{"after_end": 2, "after_start": 0, "before_end": 3, "before_start": 0, "kind": "replace"}, {"after_end": 4, "after_start": 3, "before_end": 6, "before_start": 4, "kind": "replace"}, {"after_end": 19, "after_start": 18, "before_end": 30, "before_start": 20, "kind": "replace"}, {"after_end": 22, "after_start": 20, "before_end": 35, "before_start": 31, "kind": "replace"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 19, "chars_inserted": 6}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-b8b1ad252e9270b0fa616914", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002097", "medicine_name": "Fampyra", "medicine_slug": "fampyra", "observed_at": "2026-10-12T19:16:07Z", "pipeline_version": "2.0.0", "presentation_label": "Fampyra 10 mg, comprimés à libération prolongée", "presentation_occurrence": 1, "presentation_status": "heading_extracted_unverified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "7", "section_type": "administrative", "source_provider": "European Medicines Agency", "source_sha256": "a0c3ba8d58d6a43a809ecc3d142a78b10c2bd7f0b9f3a3553df2617d87daec1f", "source_snapshot_id": "source-c7a810dd21f94cd2d273f0da", "source_updated_at": "2025-08-21", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/fampyra-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 679}
{"after": {"end": 25, "start": 0, "text": "Eurocept International BV", "truncated": false}, "after_length": 25, "after_sha256": "b17bd89b3cf285c986a6070d0d67f5326dd5c1f08a70834c296c6c820f9e7505", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 25, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 25}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-b8dca0aa5b5352bd3f57ee44", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:19Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "77586d0bea0858214b43b86e91abc2d2711733b96959ead5ed0b5ecbd8ed888a", "source_snapshot_id": "source-85d476f9ad959cc117ca8f1f", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1391}
{"after": {"end": 23, "start": 0, "text": "Tel: +49 6431 285 88 30", "truncated": false}, "after_length": 23, "after_sha256": "ef2d8f53356e21d9673844a7ef23ea7b054ff18cc0092c86a4e97d96486b24a7", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 23, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 23}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-b9198ec8291dd26fead940a6", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:14Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "8b8c4cc8e6f1a21fedee4bf0743c9c03e454b50f5eaba0e3760416d7fe0a74ec", "source_snapshot_id": "source-4efe4ecf3ebf08d338a763a5", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1925}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 22, "start": 0, "text": "Τηλ : +31 35 528 39 57", "truncated": false}, "before_length": 22, "before_sha256": "4fc1c78ca72f46f7b8d2c99f2eda4e151fd08c046b983b97e4033a28eff83142", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 22, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 22, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-b91daaae9a67cf97416f9354", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:19Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "77586d0bea0858214b43b86e91abc2d2711733b96959ead5ed0b5ecbd8ed888a", "source_snapshot_id": "source-85d476f9ad959cc117ca8f1f", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1883}
{"after": {"end": 9, "start": 0, "text": "Not known", "truncated": false}, "after_length": 9, "after_sha256": "117adf013b8521b57cc432f1d680aa8ca8ffe7ac83edfa7e0a5867794a6429cc", "annex": "I", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 9, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": true, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 9}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-b9399028be6bd80b4a550b31", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/000554", "medicine_name": "Emselex", "medicine_slug": "emselex", "observed_at": "2026-10-12T19:12:04Z", "pipeline_version": "2.0.0", "presentation_label": "Emselex 15 mg prolonged-release tablets", "presentation_occurrence": 2, "presentation_status": "heading_extracted_unverified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "4.8", "section_type": "adverse_reactions", "source_provider": "European Medicines Agency", "source_sha256": "4f2565612bc728ec67b7f9c0cd5799ef2c594911c76f323aef8bf6a85adde245", "source_snapshot_id": "source-1fda25b331eb198b8b93feb3", "source_updated_at": "2025-09-15", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/emselex-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 605}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 21, "start": 0, "text": "info@lucanepharma.com", "truncated": false}, "before_length": 21, "before_sha256": "44fd39e5fb919cb3d680fa630da23b49238fec29159c509f3622f272bb41c7c6", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 21, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 21, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-b9599e0bf607081ecb401bd0", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:19Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "77586d0bea0858214b43b86e91abc2d2711733b96959ead5ed0b5ecbd8ed888a", "source_snapshot_id": "source-85d476f9ad959cc117ca8f1f", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1497}
{"after": {"end": 10, "start": 0, "text": "6250 Kundl", "truncated": false}, "after_length": 10, "after_sha256": "67790cb68c49594409628724e5999d8cf300f8fd141207fdc89beccc8be3592d", "annex": "II", "before": {"end": 16, "start": 0, "text": "6336 Langkampfen", "truncated": false}, "before_length": 16, "before_sha256": "b9f18afdf777127453e8278d60cb7f5e3f22a29760be53f0595ada54a24f6ad2", "change_kind": "content", "change_operations": [{"after_end": 4, "after_start": 1, "before_end": 4, "before_start": 1, "kind": "replace"}, {"after_end": 7, "after_start": 5, "before_end": 7, "before_start": 5, "kind": "replace"}, {"after_end": 10, "after_start": 8, "before_end": 16, "before_start": 8, "kind": "replace"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 13, "chars_inserted": 7}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-b95dd9b81f74653aed81c774", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/000725", "medicine_name": "Binocrit", "medicine_slug": "binocrit", "observed_at": "2026-10-12T19:29:33Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "conditions", "section_type": "conditions", "source_provider": "European Medicines Agency", "source_sha256": "2110517cc45ca102ca5957f2578ba74090631cf709d5be3e5f6e34712f237bdb", "source_snapshot_id": "source-63ba5976f2b2d4350a9afd16", "source_updated_at": "2025-07-11", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/binocrit-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1198}
{"after": {"end": 9, "start": 0, "text": "Vokietija", "truncated": false}, "after_length": 9, "after_sha256": "209e90aca507f0b2d7b9c5fec852bd7cc9b24a75512b1389b9828d64ee5e62f5", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 9, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 9}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-b9613b0377344fb245bcda0f", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002097", "medicine_name": "Fampyra", "medicine_slug": "fampyra", "observed_at": "2026-10-12T19:15:51Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "d9fe8aaaa611a84801d6308b13685258b5248df9022536697939afdf66fc1719", "source_snapshot_id": "source-ff8e0599077f0d01044dc867", "source_updated_at": "2025-08-21", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/fampyra-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1384}
{"after": {"end": 23, "start": 0, "text": "info@euroceptpharma.com", "truncated": false}, "after_length": 23, "after_sha256": "9297cc5acdcc837f054116992765943f7907937507b2564a99ea1327a00ac0e6", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 23, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 23}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-b9bcd0421b1173e819c4f6dc", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:19Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "77586d0bea0858214b43b86e91abc2d2711733b96959ead5ed0b5ecbd8ed888a", "source_snapshot_id": "source-85d476f9ad959cc117ca8f1f", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1393}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 13, "start": 0, "text": "Lucane Pharma", "truncated": false}, "before_length": 13, "before_sha256": "e338afdb64acf1a6e2083a50318853589248451dd3aa707181ba02641a8521e8", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 13, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 13, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-ba27a9549a9c158574435b38", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:14Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "8b8c4cc8e6f1a21fedee4bf0743c9c03e454b50f5eaba0e3760416d7fe0a74ec", "source_snapshot_id": "source-4efe4ecf3ebf08d338a763a5", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 2051}
{"after": {"end": 132, "start": 0, "text": "There have been reports of inflammatory muscle disease and muscle breakdown (myositis and rhabdomyolysis), in patients taking Arava.", "truncated": false}, "after_length": 132, "after_sha256": "90becdd7bbf0bbe5f45ccf0044881cb69a6ac220fdad551e9ef9e14f245ee008", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 132, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 132}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-ba497f0bc33e9a1589d94878", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/000235", "medicine_name": "Arava", "medicine_slug": "arava", "observed_at": "2026-10-12T13:27:58Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 3, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "2efff7967e2237bf8343431eef5e08b56c2441eb8a691a90c64b2635109fd697", "source_snapshot_id": "source-08b4eba1f67d2654148f41c4", "source_updated_at": "2026-09-07", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/arava-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 3040}
{"after": {"end": 28, "start": 0, "text": "Otsuka Pharma Scandinavia AB", "truncated": false}, "after_length": 28, "after_sha256": "da6b14629ea48096b1862cba5aad936b5d470b29f653a1de638e5ea031c53c39", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 28, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 28}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-ba85846aded51ac5c269615e", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/000980", "medicine_name": "Samsca", "medicine_slug": "samsca", "observed_at": "2026-10-12T13:28:24Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "3080d919225c2a98f20aec84d5803b3fde6e1b64f323055c46d098625f4ad301", "source_snapshot_id": "source-e05739a15a0532954ee45dd4", "source_updated_at": "2026-08-20", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/samsca-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1279}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "I", "before": {"end": 18, "start": 0, "text": "Dublin 2, D02 T380", "truncated": false}, "before_length": 18, "before_sha256": "23e6871e7960b0dadc753bc127bbea230cc8308c88b2d33704eb275a3ec1a70d", "change_kind": "administrative", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 18, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 18, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-ba9334e82fa4e7d8fcb6e01d", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002097", "medicine_name": "Fampyra", "medicine_slug": "fampyra", "observed_at": "2026-10-12T19:16:07Z", "pipeline_version": "2.0.0", "presentation_label": "Fampyra 10 mg, comprimés à libération prolongée", "presentation_occurrence": 1, "presentation_status": "heading_extracted_unverified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "7", "section_type": "administrative", "source_provider": "European Medicines Agency", "source_sha256": "a0c3ba8d58d6a43a809ecc3d142a78b10c2bd7f0b9f3a3553df2617d87daec1f", "source_snapshot_id": "source-c7a810dd21f94cd2d273f0da", "source_updated_at": "2025-08-21", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/fampyra-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 681}
{"after": {"end": 30, "start": 0, "text": "Troubles musculo-squelettiques", "truncated": false}, "after_length": 30, "after_sha256": "19f3f11cced96282f29a83fb37b4e112d045fd9d5612609940e426e03f7708ab", "annex": "I", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 30, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": true, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 30}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-bae23cae4794bfac002f2ee2", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/000235", "medicine_name": "Arava", "medicine_slug": "arava", "observed_at": "2026-10-12T13:28:00Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": null, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "4.4", "section_type": "warning", "source_provider": "European Medicines Agency", "source_sha256": "98b73c5c6b1e5009c9d048f8f11257f3a8407759fd25a4c8d5ef5c611519e916", "source_snapshot_id": "source-4b7ea3b78addea82376b3432", "source_updated_at": "2026-09-07", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/arava-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 751}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 16, "start": 0, "text": "Biochemiestr. 10", "truncated": false}, "before_length": 16, "before_sha256": "81f5fd80fa6d15bedf7da13d3cb3de66938eb7c6943ab1798dd881ede2bc4804", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 16, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 16, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-bb55980fabc061514094af5d", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/000725", "medicine_name": "Binocrit", "medicine_slug": "binocrit", "observed_at": "2026-10-12T19:28:20Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "b2bb40c100cab3babee14bbe20cc7718cb73ac1bbb3971dfd487c4f10a0e6478", "source_snapshot_id": "source-b97c331d23a7a0f19aebfb61", "source_updated_at": "2025-07-11", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/binocrit-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 3448}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 25, "start": 0, "text": "Τηλ: + 358 (0) 3 284 8111", "truncated": false}, "before_length": 25, "before_sha256": "d2ab4368a6c3c7f07a280429f635d511f63583d8ab426619ec80daa220d95537", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 25, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 25, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-bb8e84de5a4a6fd7197c568e", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002066", "medicine_name": "Ikervis", "medicine_slug": "ikervis", "observed_at": "2026-10-12T13:34:10Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "7995ffe3d4b9c2e870327b45fae2f1d35ae1ab0e1e9e22b434fd9805b58a174e", "source_snapshot_id": "source-5ff0e792002ee89d9eb06e5d", "source_updated_at": "2026-06-23", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/ikervis-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1472}
{"after": {"end": 79, "start": 0, "text": "Viatris Germany GmbH, Zweigniederlassung Bad Homburg v. d. Höhe, Benzstrasse 1,", "truncated": false}, "after_length": 79, "after_sha256": "ec5d8b467f097b5f6e626a2a056336fab8904b07ad533e62379b09597067a87b", "annex": "IIIA", "before": {"end": 77, "start": 0, "text": "Mylan Germany GmbH, Zweigniederlassung Bad Homburg v. d. Höhe, Benzstrasse 1,", "truncated": false}, "before_length": 77, "before_sha256": "592354ac8c07b62540d767b349e438cbf42cff382f1d83c4853733a8264bcf56", "change_kind": "content", "change_operations": [{"after_end": 2, "after_start": 0, "before_end": 3, "before_start": 0, "kind": "replace"}, {"after_end": 7, "after_start": 3, "before_end": 5, "before_start": 4, "kind": "replace"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 4, "chars_inserted": 6}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-bbd1f0fb0c2b1585068fe46d", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/000403", "medicine_name": "Arixtra", "medicine_slug": "arixtra", "observed_at": "2026-10-12T13:38:45Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 5, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "d627c7ab3c0e2e04ec110e8a99901c16a8eb257c9c55138e1bd3875249a20bde", "source_snapshot_id": "source-1eab2dd77b34f4c6fe6e82df", "source_updated_at": "2026-05-07", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/arixtra-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 3335}
{"after": {"end": 25, "start": 0, "text": "Eurocept International BV", "truncated": false}, "after_length": 25, "after_sha256": "b17bd89b3cf285c986a6070d0d67f5326dd5c1f08a70834c296c6c820f9e7505", "annex": "IIIA", "before": {"end": 41, "start": 0, "text": "Eurocept International BV (Lucane Pharma)", "truncated": false}, "before_length": 41, "before_sha256": "d1cf3f14927b7038ed47975d2f7feb981f2ee8e6e304b86c1eb0fdc0b2419528", "change_kind": "content", "change_operations": [{"after_end": 25, "after_start": 25, "before_end": 41, "before_start": 25, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 16, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-bbfe8f6950a883162e27468b", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:19Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "77586d0bea0858214b43b86e91abc2d2711733b96959ead5ed0b5ecbd8ed888a", "source_snapshot_id": "source-85d476f9ad959cc117ca8f1f", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 860}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 8, "start": 0, "text": "Ιρλανδία", "truncated": false}, "before_length": 8, "before_sha256": "095fc3722309c3e2ff6ebfa3844425d8040e1db38d62071ba0f333f624dc0081", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 8, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 8, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-bc2ba74cb1b72ed23e434fed", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002097", "medicine_name": "Fampyra", "medicine_slug": "fampyra", "observed_at": "2026-10-12T19:15:51Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "d9fe8aaaa611a84801d6308b13685258b5248df9022536697939afdf66fc1719", "source_snapshot_id": "source-ff8e0599077f0d01044dc867", "source_updated_at": "2025-08-21", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/fampyra-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1601}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 27, "start": 0, "text": "(Eurocept International BV)", "truncated": false}, "before_length": 27, "before_sha256": "e6cf9b20aaa466e53ad0d393512ca75931e13e488321e3be6f3e4f8b600970c8", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 27, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 27, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-bc751c4160cdb640757e94d6", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:14Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "8b8c4cc8e6f1a21fedee4bf0743c9c03e454b50f5eaba0e3760416d7fe0a74ec", "source_snapshot_id": "source-4efe4ecf3ebf08d338a763a5", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1977}
{"after": {"end": 25, "start": 0, "text": "Eurocept International BV", "truncated": false}, "after_length": 25, "after_sha256": "b17bd89b3cf285c986a6070d0d67f5326dd5c1f08a70834c296c6c820f9e7505", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 25, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 25}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-bc8125d5541cc575060d348f", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:14Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "8b8c4cc8e6f1a21fedee4bf0743c9c03e454b50f5eaba0e3760416d7fe0a74ec", "source_snapshot_id": "source-4efe4ecf3ebf08d338a763a5", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1882}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 16, "start": 0, "text": "Extrovis EU Ltd.", "truncated": false}, "before_length": 16, "before_sha256": "f462ad48e7aef0bc82148ce088af1897d99ed86993128f30d506b27d3108a929", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 16, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 16, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-bcdbb3bc7bcacb62b13abe09", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/006047", "medicine_name": "Lacosamide Adroiq", "medicine_slug": "lacosamide-adroiq", "observed_at": "2026-10-12T19:07:59Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "cc83d966059d42856d0211a4f256b29b20d43593865704d6a9315aeb694f3c76", "source_snapshot_id": "source-896abba1d8391c918345d46b", "source_updated_at": "2025-09-25", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/lacosamide-adroiq-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1766}
{"after": {"end": 21, "start": 0, "text": "Tel: +31 35 528 39 57", "truncated": false}, "after_length": 21, "after_sha256": "7baf6601f41e49e470f803fdd4e755a86efa38be423317c000ed79963ebdd213", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 21, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 21}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-bcf7d83b7078ad4ba8e3a72a", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:19Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "77586d0bea0858214b43b86e91abc2d2711733b96959ead5ed0b5ecbd8ed888a", "source_snapshot_id": "source-85d476f9ad959cc117ca8f1f", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1509}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 25, "start": 0, "text": "Tel: + 353-(0) 1 661 4377", "truncated": false}, "before_length": 25, "before_sha256": "48fde288146f4033a2172164570180a8f875f4e361fcf85a8e43ff77834511cc", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 25, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 25, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-bd3646548b294212eee143f5", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/001021", "medicine_name": "Adcirca (previously Tadalafil Lilly)", "medicine_slug": "adcirca-previously-tadalafil-lilly", "observed_at": "2026-10-12T19:02:42Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "43438c8e53504a78747a8ff36049250fee294557f3a8b0e3acb80f71ad43ebc0", "source_snapshot_id": "source-2305a67bd1e393ee340bb8e4", "source_updated_at": "2026-01-28", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/adcirca-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 2332}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 13, "start": 0, "text": "Lucane Pharma", "truncated": false}, "before_length": 13, "before_sha256": "e338afdb64acf1a6e2083a50318853589248451dd3aa707181ba02641a8521e8", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 13, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 13, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-bd7c7c770d96a364eea1eef7", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:14Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "8b8c4cc8e6f1a21fedee4bf0743c9c03e454b50f5eaba0e3760416d7fe0a74ec", "source_snapshot_id": "source-4efe4ecf3ebf08d338a763a5", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1464}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIB", "before": {"end": 16, "start": 0, "text": "Extrovis EU Ltd.", "truncated": false}, "before_length": 16, "before_sha256": "f462ad48e7aef0bc82148ce088af1897d99ed86993128f30d506b27d3108a929", "change_kind": "unassigned", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 16, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 16, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-bdf99b70038470e01aa3a456", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/006047", "medicine_name": "Lacosamide Adroiq", "medicine_slug": "lacosamide-adroiq", "observed_at": "2026-10-12T19:07:56Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "", "section_type": "unassigned", "source_provider": "European Medicines Agency", "source_sha256": "0578c53a5e1c785c4d9d4dc0dabae49dbfa89e237aa571556bee548c3f9cf4d5", "source_snapshot_id": "source-64831dec5ebf55535e19d91b", "source_updated_at": "2025-09-25", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/lacosamide-adroiq-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 2036}
{"after": {"end": 23, "start": 0, "text": "60318 Frankfurt am Main", "truncated": false}, "after_length": 23, "after_sha256": "24c3191b5088b20c209c4387a8127297e54c776e161d305c9e57956a13b7cbbe", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 23, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 23}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-be0b10fd388aa4845cfa92d0", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002097", "medicine_name": "Fampyra", "medicine_slug": "fampyra", "observed_at": "2026-10-12T19:15:51Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "d9fe8aaaa611a84801d6308b13685258b5248df9022536697939afdf66fc1719", "source_snapshot_id": "source-ff8e0599077f0d01044dc867", "source_updated_at": "2025-08-21", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/fampyra-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1505}
{"after": {"end": 47, "start": 0, "text": "Musculoskeletal and connective tissue disorders", "truncated": false}, "after_length": 47, "after_sha256": "69d772c782fa9697b873fb5f9f3414bb76b587f7b06356c4c8e2da44b36fd9ea", "annex": "I", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 47, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": true, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 47}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-be174389b69f35573d845ff7", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/000554", "medicine_name": "Emselex", "medicine_slug": "emselex", "observed_at": "2026-10-12T19:12:04Z", "pipeline_version": "2.0.0", "presentation_label": "Emselex 7.5 mg prolonged-release tablets", "presentation_occurrence": 1, "presentation_status": "heading_extracted_unverified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "4.8", "section_type": "adverse_reactions", "source_provider": "European Medicines Agency", "source_sha256": "4f2565612bc728ec67b7f9c0cd5799ef2c594911c76f323aef8bf6a85adde245", "source_snapshot_id": "source-1fda25b331eb198b8b93feb3", "source_updated_at": "2025-09-15", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/emselex-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 213}
{"after": {"end": 23, "start": 0, "text": "info@euroceptpharma.com", "truncated": false}, "after_length": 23, "after_sha256": "9297cc5acdcc837f054116992765943f7907937507b2564a99ea1327a00ac0e6", "annex": "IIIA", "before": {"end": 25, "start": 0, "text": "Eurocept International BV", "truncated": false}, "before_length": 25, "before_sha256": "b17bd89b3cf285c986a6070d0d67f5326dd5c1f08a70834c296c6c820f9e7505", "change_kind": "content", "change_operations": [{"after_end": 6, "after_start": 0, "before_end": 1, "before_start": 0, "kind": "replace"}, {"after_end": 16, "after_start": 13, "before_end": 13, "before_start": 8, "kind": "replace"}, {"after_end": 18, "after_start": 17, "before_end": 15, "before_start": 14, "kind": "replace"}, {"after_end": 21, "after_start": 19, "before_end": 18, "before_start": 16, "kind": "replace"}, {"after_end": 23, "after_start": 22, "before_end": 25, "before_start": 19, "kind": "replace"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 15, "chars_inserted": 13}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-be252311b318a85fc1cccde1", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:19Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "77586d0bea0858214b43b86e91abc2d2711733b96959ead5ed0b5ecbd8ed888a", "source_snapshot_id": "source-85d476f9ad959cc117ca8f1f", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1439}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 18, "start": 0, "text": "Dublin 2, D02 T380", "truncated": false}, "before_length": 18, "before_sha256": "23e6871e7960b0dadc753bc127bbea230cc8308c88b2d33704eb275a3ec1a70d", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 18, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 18, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-be364f2f4da1b7bcc4d1dde2", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002097", "medicine_name": "Fampyra", "medicine_slug": "fampyra", "observed_at": "2026-10-12T19:16:07Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "a0c3ba8d58d6a43a809ecc3d142a78b10c2bd7f0b9f3a3553df2617d87daec1f", "source_snapshot_id": "source-c7a810dd21f94cd2d273f0da", "source_updated_at": "2025-08-21", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/fampyra-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1560}
{"after": {"end": 29, "start": 0, "text": "64th Km National Road Athens,", "truncated": false}, "after_length": 29, "after_sha256": "13ea56883a0ab9bffcaa1dd41d9bf3581890cd7cfc6830634cd50feb121599ea", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 29, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 29}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-be9a80edd1d179a7c8828714", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/003984", "medicine_name": "Bortezomib Accord", "medicine_slug": "bortezomib-accord", "observed_at": "2026-10-12T13:47:12Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "e4aac937241121e8ad1e32b40b1007fb58398035928568a7e60a65074b0efb36", "source_snapshot_id": "source-b1eaab6445cfa827e3b1481b", "source_updated_at": "2026-03-25", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/bortezomib-accord-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 4238}
{"after": {"end": 21, "start": 0, "text": "Tel: +31 35 528 39 57", "truncated": false}, "after_length": 21, "after_sha256": "7baf6601f41e49e470f803fdd4e755a86efa38be423317c000ed79963ebdd213", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 21, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 21}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-bed21bc3a79013cde58a054d", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:19Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "77586d0bea0858214b43b86e91abc2d2711733b96959ead5ed0b5ecbd8ed888a", "source_snapshot_id": "source-85d476f9ad959cc117ca8f1f", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1945}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 22, "start": 0, "text": "Tel : +31 35 528 39 57", "truncated": false}, "before_length": 22, "before_sha256": "7bb8afadf5dee15b4f4e1219e333b993040f0848bccea58b1141990fffb82aa1", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 22, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 22, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-bf1f13b34bff51383ac42cea", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:19Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "77586d0bea0858214b43b86e91abc2d2711733b96959ead5ed0b5ecbd8ed888a", "source_snapshot_id": "source-85d476f9ad959cc117ca8f1f", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1940}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 25, "start": 0, "text": "Tel: +44 (0) 208 159 3593", "truncated": false}, "before_length": 25, "before_sha256": "414e64590804cce28e6009911f9bd5a23d726e7fc95e07972af37d503d5083c8", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 25, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 25, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-bf225b5e3218cf729d82ed96", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/000619", "medicine_name": "Fosavance", "medicine_slug": "fosavance", "observed_at": "2026-10-12T19:01:48Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "37324165444dd93963c38ccfa569b0631b8d34d16c725b5a46b16dd7bb4cbbc2", "source_snapshot_id": "source-829e9ebd79c1d98e8a839547", "source_updated_at": "2026-02-12", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/fosavance-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1317}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 16, "start": 0, "text": "Extrovis EU Ltd.", "truncated": false}, "before_length": 16, "before_sha256": "f462ad48e7aef0bc82148ce088af1897d99ed86993128f30d506b27d3108a929", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 16, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 16, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-bf2772c7411c2c6908c9f2c1", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/006047", "medicine_name": "Lacosamide Adroiq", "medicine_slug": "lacosamide-adroiq", "observed_at": "2026-10-12T19:07:59Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "cc83d966059d42856d0211a4f256b29b20d43593865704d6a9315aeb694f3c76", "source_snapshot_id": "source-896abba1d8391c918345d46b", "source_updated_at": "2025-09-25", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/lacosamide-adroiq-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1728}
{"after": {"end": 81, "start": 0, "text": "Fréquence indéterminée (ne peut être estimée sur la base des données disponibles)", "truncated": false}, "after_length": 81, "after_sha256": "75ccbf7d675659d67f64d5a6b8b0887c0ca93da4861103bffd6fcb14ad37692c", "annex": "IIIA", "before": {"end": 22, "start": 0, "text": "Fréquence indéterminée", "truncated": false}, "before_length": 22, "before_sha256": "9dbca2ea64869864cf27be15cb397d59f7675843792a00e126385e734d3768e0", "change_kind": "content", "change_operations": [{"after_end": 81, "after_start": 22, "before_end": 22, "before_start": 22, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 59}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-bf3798f48d2221b9eba7f79c", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/000554", "medicine_name": "Emselex", "medicine_slug": "emselex", "observed_at": "2026-10-12T19:12:07Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": null, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "9a4f1d7e260c7b80eaf397503623b63302e5945b579e9612177835e07c4ab888", "source_snapshot_id": "source-3aac7bf42b99529f25ac013b", "source_updated_at": "2025-09-15", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/emselex-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1985}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 20, "start": 0, "text": "10 Earlsfort Terrace", "truncated": false}, "before_length": 20, "before_sha256": "22951bbf6ee77815d0c07b3af5f0a66e17d277636971c4eaff372dea65dcb193", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 20, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 20, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-bf935ff2cd1797b784bb9519", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002097", "medicine_name": "Fampyra", "medicine_slug": "fampyra", "observed_at": "2026-10-12T19:15:51Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "d9fe8aaaa611a84801d6308b13685258b5248df9022536697939afdf66fc1719", "source_snapshot_id": "source-ff8e0599077f0d01044dc867", "source_updated_at": "2025-08-21", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/fampyra-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1534}
{"after": {"end": 23, "start": 0, "text": "info@euroceptpharma.com", "truncated": false}, "after_length": 23, "after_sha256": "9297cc5acdcc837f054116992765943f7907937507b2564a99ea1327a00ac0e6", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 23, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 23}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-bf9f307b232837e6e16cc801", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:19Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "77586d0bea0858214b43b86e91abc2d2711733b96959ead5ed0b5ecbd8ed888a", "source_snapshot_id": "source-85d476f9ad959cc117ca8f1f", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1469}
{"after": {"end": 23, "start": 0, "text": "Τηλ: +49 (0) 69 15 03 0", "truncated": false}, "after_length": 23, "after_sha256": "40b8b23a084b3eac3f3ba2dda37d60faaa541de50c6510ae17fd679d8490f764", "annex": "IIIA", "before": {"end": 23, "start": 0, "text": "Τηλ: +353 (0)1 231 4609", "truncated": false}, "before_length": 23, "before_sha256": "024453962d70899555df7213d15538f27fac977293417f307c134a4f3c21c4e8", "change_kind": "content", "change_operations": [{"after_end": 8, "after_start": 6, "before_end": 9, "before_start": 6, "kind": "replace"}, {"after_end": 16, "after_start": 12, "before_end": 13, "before_start": 13, "kind": "insert"}, {"after_end": 18, "after_start": 17, "before_end": 14, "before_start": 14, "kind": "insert"}, {"after_end": 20, "after_start": 19, "before_end": 16, "before_start": 15, "kind": "replace"}, {"after_end": 21, "after_start": 21, "before_end": 18, "before_start": 17, "kind": "delete"}, {"after_end": 22, "after_start": 22, "before_end": 21, "before_start": 19, "kind": "delete"}, {"after_end": 23, "after_start": 23, "before_end": 23, "before_start": 22, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 8, "chars_inserted": 8}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-bfdc0290fb56c520a6a098d2", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002097", "medicine_name": "Fampyra", "medicine_slug": "fampyra", "observed_at": "2026-10-12T19:16:07Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "a0c3ba8d58d6a43a809ecc3d142a78b10c2bd7f0b9f3a3553df2617d87daec1f", "source_snapshot_id": "source-c7a810dd21f94cd2d273f0da", "source_updated_at": "2025-08-21", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/fampyra-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1492}
{"after": {"end": 23, "start": 0, "text": "60318 Frankfurt am Main", "truncated": false}, "after_length": 23, "after_sha256": "24c3191b5088b20c209c4387a8127297e54c776e161d305c9e57956a13b7cbbe", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 23, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 23}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-bfe10999c007b79a71034c55", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002097", "medicine_name": "Fampyra", "medicine_slug": "fampyra", "observed_at": "2026-10-12T19:15:51Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "d9fe8aaaa611a84801d6308b13685258b5248df9022536697939afdf66fc1719", "source_snapshot_id": "source-ff8e0599077f0d01044dc867", "source_updated_at": "2025-08-21", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/fampyra-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1032}
{"after": {"end": 20, "start": 0, "text": "Τηλ: +30 210 8009111", "truncated": false}, "after_length": 20, "after_sha256": "4be2eb2931a7797b144651aebec87029f222cbdda35f539f6c814b9013ffc042", "annex": "IIIA", "before": {"end": 9, "start": 0, "text": "Santen Oy", "truncated": false}, "before_length": 9, "before_sha256": "b8d3bb307d9e8fe0e3311ac213bd7de3f9df0c142a11ebd9fb9b8ec5c7ed12b6", "change_kind": "content", "change_operations": [{"after_end": 4, "after_start": 0, "before_end": 6, "before_start": 0, "kind": "replace"}, {"after_end": 20, "after_start": 5, "before_end": 9, "before_start": 7, "kind": "replace"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 8, "chars_inserted": 19}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-bff9d506237fc689dc019501", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002066", "medicine_name": "Ikervis", "medicine_slug": "ikervis", "observed_at": "2026-10-12T13:34:16Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "ab05f9fab48768c68482390488c5b90c577e852974d4448da6ea8fe5a4eda856", "source_snapshot_id": "source-324751bde2e11edc76c2dbfe", "source_updated_at": "2026-06-23", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/ikervis-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1425}
{"after": {"end": 17, "start": 0, "text": "Torokbalint, 2045", "truncated": false}, "after_length": 17, "after_sha256": "d6dbae334e70b70d590689409d24e6c0cda7d30fd5104550892da04a039d1276", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 17, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 17}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-c00919b3ca8bc184270d8c13", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/006047", "medicine_name": "Lacosamide Adroiq", "medicine_slug": "lacosamide-adroiq", "observed_at": "2026-10-12T19:07:59Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "cc83d966059d42856d0211a4f256b29b20d43593865704d6a9315aeb694f3c76", "source_snapshot_id": "source-896abba1d8391c918345d46b", "source_updated_at": "2025-09-25", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/lacosamide-adroiq-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1113}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 20, "start": 0, "text": "10 Earlsfort Terrace", "truncated": false}, "before_length": 20, "before_sha256": "22951bbf6ee77815d0c07b3af5f0a66e17d277636971c4eaff372dea65dcb193", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 20, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 20, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-c01a7a904095f19b28f13f02", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002097", "medicine_name": "Fampyra", "medicine_slug": "fampyra", "observed_at": "2026-10-12T19:16:07Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "a0c3ba8d58d6a43a809ecc3d142a78b10c2bd7f0b9f3a3553df2617d87daec1f", "source_snapshot_id": "source-c7a810dd21f94cd2d273f0da", "source_updated_at": "2025-08-21", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/fampyra-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1356}
{"after": {"end": 28, "start": 0, "text": "Depressed mood/mood altered*", "truncated": false}, "after_length": 28, "after_sha256": "66ff665807886829d149b66603b562aed7d6aa63dff022ea162b00999956ff23", "annex": "I", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 28, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": true, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 28}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-c08214988ead1cdf0b6af06b", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/000554", "medicine_name": "Emselex", "medicine_slug": "emselex", "observed_at": "2026-10-12T19:12:04Z", "pipeline_version": "2.0.0", "presentation_label": "Emselex 7.5 mg prolonged-release tablets", "presentation_occurrence": 1, "presentation_status": "heading_extracted_unverified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "4.8", "section_type": "adverse_reactions", "source_provider": "European Medicines Agency", "source_sha256": "4f2565612bc728ec67b7f9c0cd5799ef2c594911c76f323aef8bf6a85adde245", "source_snapshot_id": "source-1fda25b331eb198b8b93feb3", "source_updated_at": "2025-09-15", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/emselex-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 180}
{"after": {"end": 68, "start": 0, "text": "* observés dans le cadre de l’expérience depuis la commercialisation", "truncated": false}, "after_length": 68, "after_sha256": "6a66df38643e7ee27efd700b8bd1783e4a4f6005b15265de84f0e10132cfcb4d", "annex": "I", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 68, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": true, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 68}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-c0b8a9533e659704071be662", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/000554", "medicine_name": "Emselex", "medicine_slug": "emselex", "observed_at": "2026-10-12T19:12:07Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": null, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "4.8", "section_type": "adverse_reactions", "source_provider": "European Medicines Agency", "source_sha256": "9a4f1d7e260c7b80eaf397503623b63302e5945b579e9612177835e07c4ab888", "source_snapshot_id": "source-3aac7bf42b99529f25ac013b", "source_updated_at": "2025-09-15", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/emselex-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 230}
{"after": {"end": 14, "start": 0, "text": "Hallucination*", "truncated": false}, "after_length": 14, "after_sha256": "b5feb0253dc60e46de934da2e507a42e3fd02688dbb6bca5220b99ffc3db83b2", "annex": "I", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 14, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": true, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 14}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-c0c069760b7a670e29fc58ff", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/000554", "medicine_name": "Emselex", "medicine_slug": "emselex", "observed_at": "2026-10-12T19:12:04Z", "pipeline_version": "2.0.0", "presentation_label": "Emselex 7.5 mg prolonged-release tablets", "presentation_occurrence": 1, "presentation_status": "heading_extracted_unverified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "4.8", "section_type": "adverse_reactions", "source_provider": "European Medicines Agency", "source_sha256": "4f2565612bc728ec67b7f9c0cd5799ef2c594911c76f323aef8bf6a85adde245", "source_snapshot_id": "source-1fda25b331eb198b8b93feb3", "source_updated_at": "2025-09-15", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/emselex-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 182}
{"after": {"end": 6, "start": 0, "text": "Greece", "truncated": false}, "after_length": 6, "after_sha256": "9c93ad439373b4ee35e70ba1318055a14d2ed222f69f9e2d069689e83829833d", "annex": "II", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 6, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 6}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-c0c4f6531e489c95caf40821", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/003984", "medicine_name": "Bortezomib Accord", "medicine_slug": "bortezomib-accord", "observed_at": "2026-10-12T13:47:12Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "conditions", "section_type": "conditions", "source_provider": "European Medicines Agency", "source_sha256": "e4aac937241121e8ad1e32b40b1007fb58398035928568a7e60a65074b0efb36", "source_snapshot_id": "source-b1eaab6445cfa827e3b1481b", "source_updated_at": "2026-03-25", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/bortezomib-accord-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 3286}
{"after": {"end": 22, "start": 0, "text": "Merz Therapeutics GmbH", "truncated": false}, "after_length": 22, "after_sha256": "059f049c7d0846aaadcf2573280d52110f302d4ecc7b38debd004571cd1e9d5e", "annex": "IIIA", "before": {"end": 35, "start": 0, "text": "Acorda Therapeutics Ireland Limited", "truncated": false}, "before_length": 35, "before_sha256": "d94d3153d193ed26567f2b4ed48df016d81c534e7c0cb1a6655a63f0083383ff", "change_kind": "content", "change_operations": [{"after_end": 2, "after_start": 0, "before_end": 3, "before_start": 0, "kind": "replace"}, {"after_end": 4, "after_start": 3, "before_end": 6, "before_start": 4, "kind": "replace"}, {"after_end": 19, "after_start": 18, "before_end": 30, "before_start": 20, "kind": "replace"}, {"after_end": 22, "after_start": 20, "before_end": 35, "before_start": 31, "kind": "replace"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 19, "chars_inserted": 6}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-c0f54be1f1fb6259cb7fa5a7", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002097", "medicine_name": "Fampyra", "medicine_slug": "fampyra", "observed_at": "2026-10-12T19:16:07Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "a0c3ba8d58d6a43a809ecc3d142a78b10c2bd7f0b9f3a3553df2617d87daec1f", "source_snapshot_id": "source-c7a810dd21f94cd2d273f0da", "source_updated_at": "2025-08-21", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/fampyra-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1539}
{"after": {"end": 9, "start": 0, "text": "Vokietija", "truncated": false}, "after_length": 9, "after_sha256": "209e90aca507f0b2d7b9c5fec852bd7cc9b24a75512b1389b9828d64ee5e62f5", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 9, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 9}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-c106d10c3057ff007ebd072a", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002097", "medicine_name": "Fampyra", "medicine_slug": "fampyra", "observed_at": "2026-10-12T19:16:07Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "a0c3ba8d58d6a43a809ecc3d142a78b10c2bd7f0b9f3a3553df2617d87daec1f", "source_snapshot_id": "source-c7a810dd21f94cd2d273f0da", "source_updated_at": "2025-08-21", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/fampyra-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1390}
{"after": {"end": 28, "start": 0, "text": "InfoDeutschland@dipharma.com", "truncated": false}, "after_length": 28, "after_sha256": "f5ed16f98f15b7236207edade83fdde3fb32cec02f927aaba23223b9f6077f21", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 28, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 28}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-c10db7bd9da3118fdb905992", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:14Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "8b8c4cc8e6f1a21fedee4bf0743c9c03e454b50f5eaba0e3760416d7fe0a74ec", "source_snapshot_id": "source-4efe4ecf3ebf08d338a763a5", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1964}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "I", "before": {"end": 22, "start": 0, "text": "PAION Deutschland GmbH", "truncated": false}, "before_length": 22, "before_sha256": "695a7a774aacd3b6e919ed980dbfb2ee37bbe6099af551312782cc722dbb2b31", "change_kind": "administrative", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 22, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 22, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-c10f3c65bdaa2697a3b79d07", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/005246", "medicine_name": "Byfavo", "medicine_slug": "byfavo", "observed_at": "2026-10-12T13:28:16Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "7", "section_type": "administrative", "source_provider": "European Medicines Agency", "source_sha256": "61243a969f979f690fe718e414ceaeb66438c1faa31101ba25187d2f9ea662fd", "source_snapshot_id": "source-dd26eb8615d8c18bd80c1f6a", "source_updated_at": "2026-08-26", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/byfavo-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 2709}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 38, "start": 0, "text": "Otsuka Pharmaceutical Netherlands B.V.", "truncated": false}, "before_length": 38, "before_sha256": "2891d7989f773ce0b34a3e835488071e6ffd7e94478e61a5899dcf87bd99c38c", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 38, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 38, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-c1820d0cdd70d31630c182b2", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/000980", "medicine_name": "Samsca", "medicine_slug": "samsca", "observed_at": "2026-10-12T13:28:24Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "3080d919225c2a98f20aec84d5803b3fde6e1b64f323055c46d098625f4ad301", "source_snapshot_id": "source-e05739a15a0532954ee45dd4", "source_updated_at": "2026-08-20", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/samsca-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1268}
{"after": {"end": 9, "start": 0, "text": "Allemagne", "truncated": false}, "after_length": 9, "after_sha256": "6b58dbd6a994339b48d8446597da22402857b3409613459c7e3a293788fbe66a", "annex": "I", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "administrative", "change_operations": [{"after_end": 9, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 9}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-c18f8e597ed51b8bea16ca5b", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002097", "medicine_name": "Fampyra", "medicine_slug": "fampyra", "observed_at": "2026-10-12T19:16:07Z", "pipeline_version": "2.0.0", "presentation_label": "Fampyra 10 mg, comprimés à libération prolongée", "presentation_occurrence": 1, "presentation_status": "heading_extracted_unverified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "7", "section_type": "administrative", "source_provider": "European Medicines Agency", "source_sha256": "a0c3ba8d58d6a43a809ecc3d142a78b10c2bd7f0b9f3a3553df2617d87daec1f", "source_snapshot_id": "source-c7a810dd21f94cd2d273f0da", "source_updated_at": "2025-08-21", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/fampyra-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 686}
{"after": {"end": 25, "start": 0, "text": "Musculoskeletal disorders", "truncated": false}, "after_length": 25, "after_sha256": "554fab09c18c12d65cee54d5caa96534b1925e5ff23a67e98a7c7c04e66bf714", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 25, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 25}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-c1aa5682324bee83e289b245", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/000235", "medicine_name": "Arava", "medicine_slug": "arava", "observed_at": "2026-10-12T13:27:58Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 3, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "2efff7967e2237bf8343431eef5e08b56c2441eb8a691a90c64b2635109fd697", "source_snapshot_id": "source-08b4eba1f67d2654148f41c4", "source_updated_at": "2026-09-07", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/arava-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 2658}
{"after": {"end": 23, "start": 0, "text": "info@euroceptpharma.com", "truncated": false}, "after_length": 23, "after_sha256": "9297cc5acdcc837f054116992765943f7907937507b2564a99ea1327a00ac0e6", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 23, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 23}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-c1bfe149d23c01dbe4d52112", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:19Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "77586d0bea0858214b43b86e91abc2d2711733b96959ead5ed0b5ecbd8ed888a", "source_snapshot_id": "source-85d476f9ad959cc117ca8f1f", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1937}
{"after": {"end": 50, "start": 0, "text": "Orteliuslaan 1000, 3528 BD Utrecht The Netherlands", "truncated": false}, "after_length": 50, "after_sha256": "de386d3b3aeebba1dff0a070ffc767173cbc1fa354dbcd29dd86469dc23d8ff6", "annex": "IIIA", "before": {"end": 50, "start": 0, "text": "Papendorpseweg 83, 3528 BJ Utrecht The Netherlands", "truncated": false}, "before_length": 50, "before_sha256": "5d621ef45df9c1911e6b63f15edb513d80fad3ee63f11fe58a733f65b67cd3cd", "change_kind": "content", "change_operations": [{"after_end": 9, "after_start": 0, "before_end": 1, "before_start": 0, "kind": "replace"}, {"after_end": 11, "after_start": 10, "before_end": 4, "before_start": 2, "kind": "replace"}, {"after_end": 12, "after_start": 12, "before_end": 14, "before_start": 5, "kind": "delete"}, {"after_end": 17, "after_start": 13, "before_end": 17, "before_start": 15, "kind": "replace"}, {"after_end": 26, "after_start": 25, "before_end": 26, "before_start": 25, "kind": "replace"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 15, "chars_inserted": 15}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-c1c3fd8966710c42d24edb89", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/001021", "medicine_name": "Adcirca (previously Tadalafil Lilly)", "medicine_slug": "adcirca-previously-tadalafil-lilly", "observed_at": "2026-10-12T19:02:42Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "43438c8e53504a78747a8ff36049250fee294557f3a8b0e3acb80f71ad43ebc0", "source_snapshot_id": "source-2305a67bd1e393ee340bb8e4", "source_updated_at": "2026-01-28", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/adcirca-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1436}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 21, "start": 0, "text": "info@lucanepharma.com", "truncated": false}, "before_length": 21, "before_sha256": "44fd39e5fb919cb3d680fa630da23b49238fec29159c509f3622f272bb41c7c6", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 21, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 21, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-c24260dbec7a8322ef6f1a9c", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:19Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "77586d0bea0858214b43b86e91abc2d2711733b96959ead5ed0b5ecbd8ed888a", "source_snapshot_id": "source-85d476f9ad959cc117ca8f1f", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1973}
{"after": {"end": 7, "start": 0, "text": "Nemčija", "truncated": false}, "after_length": 7, "after_sha256": "8728a912120c7cbc7d783419a6aa9043a427c04e373baed3d52316c7b253fb79", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 7, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 7}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-c251500722591e2dc3b46be8", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002097", "medicine_name": "Fampyra", "medicine_slug": "fampyra", "observed_at": "2026-10-12T19:16:07Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "a0c3ba8d58d6a43a809ecc3d142a78b10c2bd7f0b9f3a3553df2617d87daec1f", "source_snapshot_id": "source-c7a810dd21f94cd2d273f0da", "source_updated_at": "2025-08-21", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/fampyra-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1564}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 5, "start": 0, "text": "Regus", "truncated": false}, "before_length": 5, "before_sha256": "69ef2ca82e0f736644001207ab7589688f2ada81eedc4859209d50896d65b095", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 5, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 5, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-c252151ef97861f19b874207", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002097", "medicine_name": "Fampyra", "medicine_slug": "fampyra", "observed_at": "2026-10-12T19:16:07Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "a0c3ba8d58d6a43a809ecc3d142a78b10c2bd7f0b9f3a3553df2617d87daec1f", "source_snapshot_id": "source-c7a810dd21f94cd2d273f0da", "source_updated_at": "2025-08-21", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/fampyra-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1616}
{"after": {"end": 140, "start": 0, "text": "Pour plus d’informations, voir le site web de l’Agence européenne des médicaments: https://www.ema.europa.eu/en/medicines/human/epar/Sprycel", "truncated": false}, "after_length": 140, "after_sha256": "00e5d0f288cb91234b94ed8e723e77eca4e1c2201ce05817ac532e4364e6b9a8", "annex": "", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "unassigned", "change_operations": [{"after_end": 140, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 140}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-c29eb78e91d685df80bb1f7a", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/000709", "medicine_name": "Sprycel", "medicine_slug": "sprycel", "observed_at": "2026-10-12T13:27:38Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": null, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "", "section_type": "unassigned", "source_provider": "European Medicines Agency", "source_sha256": "f19afb6c99c9f6c4da575a1ec1ad2116d41e1ee33bed1a9a3406fd820f8970ff", "source_snapshot_id": "source-753ed8ea69e2a319805bb49a", "source_updated_at": "2026-10-02", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/sprycel-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 2}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 18, "start": 0, "text": "Dublin 2, D02 T380", "truncated": false}, "before_length": 18, "before_sha256": "23e6871e7960b0dadc753bc127bbea230cc8308c88b2d33704eb275a3ec1a70d", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 18, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 18, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-c29f3af35b7b478834e33356", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002097", "medicine_name": "Fampyra", "medicine_slug": "fampyra", "observed_at": "2026-10-12T19:15:51Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "d9fe8aaaa611a84801d6308b13685258b5248df9022536697939afdf66fc1719", "source_snapshot_id": "source-ff8e0599077f0d01044dc867", "source_updated_at": "2025-08-21", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/fampyra-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1481}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "I", "before": {"end": 16, "start": 0, "text": "Extrovis EU Ltd.", "truncated": false}, "before_length": 16, "before_sha256": "f462ad48e7aef0bc82148ce088af1897d99ed86993128f30d506b27d3108a929", "change_kind": "administrative", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 16, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 16, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-c30df5fb5d771ee3d51e8e15", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/006047", "medicine_name": "Lacosamide Adroiq", "medicine_slug": "lacosamide-adroiq", "observed_at": "2026-10-12T19:07:59Z", "pipeline_version": "2.0.0", "presentation_label": "Lacosamide Adroiq 10 mg/ml solution pour perfusion", "presentation_occurrence": 1, "presentation_status": "heading_extracted_unverified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "7", "section_type": "administrative", "source_provider": "European Medicines Agency", "source_sha256": "cc83d966059d42856d0211a4f256b29b20d43593865704d6a9315aeb694f3c76", "source_snapshot_id": "source-896abba1d8391c918345d46b", "source_updated_at": "2025-09-25", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/lacosamide-adroiq-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 913}
{"after": {"end": 23, "start": 0, "text": "Tel: +49 6431 285 88 30", "truncated": false}, "after_length": 23, "after_sha256": "ef2d8f53356e21d9673844a7ef23ea7b054ff18cc0092c86a4e97d96486b24a7", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 23, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 23}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-c33b705a2be6a04019cc5b10", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:14Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "8b8c4cc8e6f1a21fedee4bf0743c9c03e454b50f5eaba0e3760416d7fe0a74ec", "source_snapshot_id": "source-4efe4ecf3ebf08d338a763a5", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1520}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "II", "before": {"end": 61, "start": 0, "text": "McDermott Laboratories Limited trading as Gerard Laboratories", "truncated": false}, "before_length": 61, "before_sha256": "f28bee890ae72cccea9b87c3be57809b0afb7f64e286de2c77b2c05b413da700", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 61, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 61, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-c351bf897fc8a5b133b89fcb", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/004025", "medicine_name": "Lopinavir/Ritonavir Viatris (previously Ritonavir Mylan)", "medicine_slug": "lopinavir-ritonavir-viatris-previously-ritonavir-mylan", "observed_at": "2026-10-12T19:14:59Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "conditions", "section_type": "conditions", "source_provider": "European Medicines Agency", "source_sha256": "d782e33ec97bc43bb54f942c83f07f89482c9a433e3846beaffe05b4a52b4b36", "source_snapshot_id": "source-ff48b23a80b98be4c15aa440", "source_updated_at": "2025-09-08", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/lopinavir-ritonavir-viatris-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1462}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 21, "start": 0, "text": "info@lucanepharma.com", "truncated": false}, "before_length": 21, "before_sha256": "44fd39e5fb919cb3d680fa630da23b49238fec29159c509f3622f272bb41c7c6", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 21, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 21, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-c3646f75df15cb8adab1bf14", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:19Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "77586d0bea0858214b43b86e91abc2d2711733b96959ead5ed0b5ecbd8ed888a", "source_snapshot_id": "source-85d476f9ad959cc117ca8f1f", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1416}
{"after": {"end": 64, "start": 0, "text": "Pfizer Service Company BV, Hermeslaan 11, 1932 Zaventem, Belgium", "truncated": false}, "after_length": 64, "after_sha256": "2d1de952e89b25ed7dca5315276a9346ff59a654b86d6d9699542cec21b0c114", "annex": "IIIA", "before": {"end": 63, "start": 0, "text": "Pfizer Service Company BV, Hoge Wei 10, Zaventem, 1930, Belgium", "truncated": false}, "before_length": 63, "before_sha256": "7c496678739b73b11084d5312a94bbb82c52b499a60b63bcf78f4b28157f91df", "change_kind": "content", "change_operations": [{"after_end": 28, "after_start": 28, "before_end": 30, "before_start": 28, "kind": "delete"}, {"after_end": 31, "after_start": 29, "before_end": 33, "before_start": 31, "kind": "replace"}, {"after_end": 37, "after_start": 32, "before_end": 35, "before_start": 34, "kind": "replace"}, {"after_end": 40, "after_start": 39, "before_end": 38, "before_start": 37, "kind": "replace"}, {"after_end": 46, "after_start": 41, "before_end": 39, "before_start": 39, "kind": "insert"}, {"after_end": 55, "after_start": 55, "before_end": 54, "before_start": 48, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 12, "chars_inserted": 13}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-c37d37afe03847f12a0322e1", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/004697", "medicine_name": "Zirabev", "medicine_slug": "zirabev", "observed_at": "2026-10-12T19:08:39Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "ef33f1350f1fcae139a251926014b13e3e973646fc918d603307fbce8dac4777", "source_snapshot_id": "source-7ce336750684e46ba3e4e54c", "source_updated_at": "2025-09-17", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/zirabev-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 3307}
{"after": {"end": 156, "start": 0, "text": "The printed package leaflet of the medicinal product must state the name and address of the manufacturer responsible for the release of the concerned batch.", "truncated": false}, "after_length": 156, "after_sha256": "183c90cbf0ec43d0450fbf1ac2be9d123d464059fe683f7b42e974414cde5f1c", "annex": "II", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 156, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 156}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-c3a0f0741da627237d157ab0", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/003984", "medicine_name": "Bortezomib Accord", "medicine_slug": "bortezomib-accord", "observed_at": "2026-10-12T13:47:12Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "conditions", "section_type": "conditions", "source_provider": "European Medicines Agency", "source_sha256": "e4aac937241121e8ad1e32b40b1007fb58398035928568a7e60a65074b0efb36", "source_snapshot_id": "source-b1eaab6445cfa827e3b1481b", "source_updated_at": "2026-03-25", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/bortezomib-accord-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 3288}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 20, "start": 0, "text": "10 Earlsfort Terrace", "truncated": false}, "before_length": 20, "before_sha256": "22951bbf6ee77815d0c07b3af5f0a66e17d277636971c4eaff372dea65dcb193", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 20, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 20, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-c3b9a57b77870d9adde209ad", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002097", "medicine_name": "Fampyra", "medicine_slug": "fampyra", "observed_at": "2026-10-12T19:15:51Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "d9fe8aaaa611a84801d6308b13685258b5248df9022536697939afdf66fc1719", "source_snapshot_id": "source-ff8e0599077f0d01044dc867", "source_updated_at": "2025-08-21", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/fampyra-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1553}
{"after": {"end": 16, "start": 0, "text": "Extrovis EU Kft.", "truncated": false}, "after_length": 16, "after_sha256": "b9216ef80e71e17798dce313e4318f03f37328f225d30ab508b7413813a908e5", "annex": "IIIB", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "unassigned", "change_operations": [{"after_end": 16, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 16}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-c3c329083bf822d95325b13c", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/006047", "medicine_name": "Lacosamide Adroiq", "medicine_slug": "lacosamide-adroiq", "observed_at": "2026-10-12T19:07:56Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "", "section_type": "unassigned", "source_provider": "European Medicines Agency", "source_sha256": "0578c53a5e1c785c4d9d4dc0dabae49dbfa89e237aa571556bee548c3f9cf4d5", "source_snapshot_id": "source-64831dec5ebf55535e19d91b", "source_updated_at": "2025-09-25", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/lacosamide-adroiq-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1968}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 21, "start": 0, "text": "info@lucanepharma.com", "truncated": false}, "before_length": 21, "before_sha256": "44fd39e5fb919cb3d680fa630da23b49238fec29159c509f3622f272bb41c7c6", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 21, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 21, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-c40530572748de2a350b36cb", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:19Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "77586d0bea0858214b43b86e91abc2d2711733b96959ead5ed0b5ecbd8ed888a", "source_snapshot_id": "source-85d476f9ad959cc117ca8f1f", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1520}
{"after": {"end": 207, "start": 0, "text": "Contact your doctor or pharmacist immediately if you experience any of the following symptoms while taking Arava: unexplained muscle pain, tenderness (soreness when the muscle is pressed) or muscle weakness.", "truncated": false}, "after_length": 207, "after_sha256": "e54adb526f1c998d8db84ee9ca0359d3dde4372f14416f24c515365e96d1c41c", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 207, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 207}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-c41a1c54e4e80fdf33ea73da", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/000235", "medicine_name": "Arava", "medicine_slug": "arava", "observed_at": "2026-10-12T13:27:58Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 3, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "2efff7967e2237bf8343431eef5e08b56c2441eb8a691a90c64b2635109fd697", "source_snapshot_id": "source-08b4eba1f67d2654148f41c4", "source_updated_at": "2026-09-07", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/arava-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 3420}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 13, "start": 0, "text": "Lucane Pharma", "truncated": false}, "before_length": 13, "before_sha256": "e338afdb64acf1a6e2083a50318853589248451dd3aa707181ba02641a8521e8", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 13, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 13, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-c4401bbe812878cc8afce84f", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:14Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "8b8c4cc8e6f1a21fedee4bf0743c9c03e454b50f5eaba0e3760416d7fe0a74ec", "source_snapshot_id": "source-4efe4ecf3ebf08d338a763a5", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1967}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 21, "start": 0, "text": "Tel: + 33 153 868 750", "truncated": false}, "before_length": 21, "before_sha256": "efffe29324e968019e6e2b111904182ba06d83e76b1f29b933bed9dd8779c114", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 21, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 21, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-c441f5f3795ece5cb39557b5", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:14Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "8b8c4cc8e6f1a21fedee4bf0743c9c03e454b50f5eaba0e3760416d7fe0a74ec", "source_snapshot_id": "source-4efe4ecf3ebf08d338a763a5", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1546}
{"after": {"end": 23, "start": 0, "text": "60318 Frankfurt am Main", "truncated": false}, "after_length": 23, "after_sha256": "24c3191b5088b20c209c4387a8127297e54c776e161d305c9e57956a13b7cbbe", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 23, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 23}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-c449d40ecde50e1d3f94bdce", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002097", "medicine_name": "Fampyra", "medicine_slug": "fampyra", "observed_at": "2026-10-12T19:15:51Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "d9fe8aaaa611a84801d6308b13685258b5248df9022536697939afdf66fc1719", "source_snapshot_id": "source-ff8e0599077f0d01044dc867", "source_updated_at": "2025-08-21", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/fampyra-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1538}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 21, "start": 0, "text": "info@lucanepharma.com", "truncated": false}, "before_length": 21, "before_sha256": "44fd39e5fb919cb3d680fa630da23b49238fec29159c509f3622f272bb41c7c6", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 21, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 21, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-c46848547aba3568eef2f415", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:19Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "77586d0bea0858214b43b86e91abc2d2711733b96959ead5ed0b5ecbd8ed888a", "source_snapshot_id": "source-85d476f9ad959cc117ca8f1f", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1396}
{"after": {"end": 16, "start": 0, "text": "Extrovis EU Kft.", "truncated": false}, "after_length": 16, "after_sha256": "b9216ef80e71e17798dce313e4318f03f37328f225d30ab508b7413813a908e5", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 16, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 16}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-c47a0701466b3ebf5c35ef7c", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/006047", "medicine_name": "Lacosamide Adroiq", "medicine_slug": "lacosamide-adroiq", "observed_at": "2026-10-12T19:07:59Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "cc83d966059d42856d0211a4f256b29b20d43593865704d6a9315aeb694f3c76", "source_snapshot_id": "source-896abba1d8391c918345d46b", "source_updated_at": "2025-09-25", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/lacosamide-adroiq-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1700}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 21, "start": 0, "text": "info@lucanepharma.com", "truncated": false}, "before_length": 21, "before_sha256": "44fd39e5fb919cb3d680fa630da23b49238fec29159c509f3622f272bb41c7c6", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 21, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 21, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-c4ccf966e4765d7ddd580fe6", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:14Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "8b8c4cc8e6f1a21fedee4bf0743c9c03e454b50f5eaba0e3760416d7fe0a74ec", "source_snapshot_id": "source-4efe4ecf3ebf08d338a763a5", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1533}
{"after": {"end": 21, "start": 0, "text": "Tel: +31 35 528 39 57", "truncated": false}, "after_length": 21, "after_sha256": "7baf6601f41e49e470f803fdd4e755a86efa38be423317c000ed79963ebdd213", "annex": "IIIA", "before": {"end": 22, "start": 0, "text": "Tel : +31 35 528 39 57", "truncated": false}, "before_length": 22, "before_sha256": "7bb8afadf5dee15b4f4e1219e333b993040f0848bccea58b1141990fffb82aa1", "change_kind": "content", "change_operations": [{"after_end": 3, "after_start": 3, "before_end": 4, "before_start": 3, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 1, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-c4fcbe4c09e12d69008fb911", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:19Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "77586d0bea0858214b43b86e91abc2d2711733b96959ead5ed0b5ecbd8ed888a", "source_snapshot_id": "source-85d476f9ad959cc117ca8f1f", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1862}
{"after": {"end": 9, "start": 0, "text": "Nederland", "truncated": false}, "after_length": 9, "after_sha256": "8a869db3fa453526573e4f2c956528743cf246af5d1b5eac4879257589776797", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 9, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 9}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-c53af1bdfe1ab8730a963b43", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002097", "medicine_name": "Fampyra", "medicine_slug": "fampyra", "observed_at": "2026-10-12T19:16:07Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "a0c3ba8d58d6a43a809ecc3d142a78b10c2bd7f0b9f3a3553df2617d87daec1f", "source_snapshot_id": "source-c7a810dd21f94cd2d273f0da", "source_updated_at": "2025-08-21", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/fampyra-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1463}
{"after": {"end": 20, "start": 0, "text": "Tel: +386 1 2355 100", "truncated": false}, "after_length": 20, "after_sha256": "08d49fea809e3878122f78a398ef6a77d2a4cf472eb2cf3d9f1450515a1ced0f", "annex": "IIIA", "before": {"end": 19, "start": 0, "text": "Tel: +386 235 51 00", "truncated": false}, "before_length": 19, "before_sha256": "fd65023f7b15127a4e3fb22b56c0b3c2e844610946d4b104bb5a61e296f3bb32", "change_kind": "content", "change_operations": [{"after_end": 12, "after_start": 10, "before_end": 10, "before_start": 10, "kind": "insert"}, {"after_end": 16, "after_start": 15, "before_end": 13, "before_start": 13, "kind": "insert"}, {"after_end": 17, "after_start": 17, "before_end": 15, "before_start": 14, "kind": "delete"}, {"after_end": 18, "after_start": 18, "before_end": 17, "before_start": 16, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 2, "chars_inserted": 3}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-c5f554354f027557059b9a5c", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002702", "medicine_name": "Hexacima", "medicine_slug": "hexacima", "observed_at": "2026-10-12T19:07:06Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "b990725709f885f3f868e5da444393a40a54f89ba2f2d9b232d9c053493d1b03", "source_snapshot_id": "source-87ea40f95d82cdfb5ba074b0", "source_updated_at": "2025-09-29", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/hexacima-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 2061}
{"after": {"end": 150, "start": 0, "text": "Des informations détaillées sur ce médicament sont disponibles sur le site internet de l'Agence européenne des médicaments : https://www.ema.europa.eu", "truncated": false}, "after_length": 150, "after_sha256": "7a57f3971964eb7bea4ed295986ca64649117ce6b1ea800c91cdf0ed4877b711", "annex": "III", "before": {"end": 150, "start": 0, "text": "Des informations détaillées sur ce médicament sont disponibles sur le site internet de l'Agence européenne des médicaments : http://www.ema.europa.eu.", "truncated": false}, "before_length": 150, "before_sha256": "6272fb3d1bf208f727e3ec8521cb6d15c24e42031d06a96b3c4d43ff5b48aa11", "change_kind": "technical", "change_operations": [{"after_end": 130, "after_start": 129, "before_end": 129, "before_start": 129, "kind": "insert"}, {"after_end": 150, "after_start": 150, "before_end": 150, "before_start": 149, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 1, "chars_inserted": 1}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-c648d9d49124a6bd617a7fd5", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/001021", "medicine_name": "Adcirca (previously Tadalafil Lilly)", "medicine_slug": "adcirca-previously-tadalafil-lilly", "observed_at": "2026-10-12T19:02:45Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "", "section_type": "unassigned", "source_provider": "European Medicines Agency", "source_sha256": "cdbefcd6143c93e81f3c826bea8d3d01bffc55652e0f792243097df75c452721", "source_snapshot_id": "source-a1e85476de17f5a8664f7766", "source_updated_at": "2026-01-28", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/adcirca-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 2020}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 21, "start": 0, "text": "Tel: + 33 153 868 750", "truncated": false}, "before_length": 21, "before_sha256": "efffe29324e968019e6e2b111904182ba06d83e76b1f29b933bed9dd8779c114", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 21, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 21, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-c6610387e55ea191790bb8dd", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:19Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "77586d0bea0858214b43b86e91abc2d2711733b96959ead5ed0b5ecbd8ed888a", "source_snapshot_id": "source-85d476f9ad959cc117ca8f1f", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1519}
{"after": {"end": 23, "start": 0, "text": "info@euroceptpharma.com", "truncated": false}, "after_length": 23, "after_sha256": "9297cc5acdcc837f054116992765943f7907937507b2564a99ea1327a00ac0e6", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 23, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 23}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-c686e48d9b706337897c61fe", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:19Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "77586d0bea0858214b43b86e91abc2d2711733b96959ead5ed0b5ecbd8ed888a", "source_snapshot_id": "source-85d476f9ad959cc117ca8f1f", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1502}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 13, "start": 0, "text": "Lucane Pharma", "truncated": false}, "before_length": 13, "before_sha256": "e338afdb64acf1a6e2083a50318853589248451dd3aa707181ba02641a8521e8", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 13, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 13, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-c6f32a6c58ecabbc36e484e0", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:14Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "8b8c4cc8e6f1a21fedee4bf0743c9c03e454b50f5eaba0e3760416d7fe0a74ec", "source_snapshot_id": "source-4efe4ecf3ebf08d338a763a5", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1563}
{"after": {"end": 20, "start": 0, "text": "Τηλ: +30 210 8009111", "truncated": false}, "after_length": 20, "after_sha256": "4be2eb2931a7797b144651aebec87029f222cbdda35f539f6c814b9013ffc042", "annex": "IIIA", "before": {"end": 9, "start": 0, "text": "Santen Oy", "truncated": false}, "before_length": 9, "before_sha256": "b8d3bb307d9e8fe0e3311ac213bd7de3f9df0c142a11ebd9fb9b8ec5c7ed12b6", "change_kind": "content", "change_operations": [{"after_end": 4, "after_start": 0, "before_end": 6, "before_start": 0, "kind": "replace"}, {"after_end": 20, "after_start": 5, "before_end": 9, "before_start": 7, "kind": "replace"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 8, "chars_inserted": 19}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-c6fc932097e2bd30e35dc8ca", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002066", "medicine_name": "Ikervis", "medicine_slug": "ikervis", "observed_at": "2026-10-12T13:34:16Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "ab05f9fab48768c68482390488c5b90c577e852974d4448da6ea8fe5a4eda856", "source_snapshot_id": "source-324751bde2e11edc76c2dbfe", "source_updated_at": "2026-06-23", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/ikervis-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1798}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 25, "start": 0, "text": "Τηλ: + 358 (0) 3 284 8111", "truncated": false}, "before_length": 25, "before_sha256": "d2ab4368a6c3c7f07a280429f635d511f63583d8ab426619ec80daa220d95537", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 25, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 25, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-c7983264a9f8d804e8e6f6d9", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002066", "medicine_name": "Ikervis", "medicine_slug": "ikervis", "observed_at": "2026-10-12T13:34:10Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "7995ffe3d4b9c2e870327b45fae2f1d35ae1ab0e1e9e22b434fd9805b58a174e", "source_snapshot_id": "source-5ff0e792002ee89d9eb06e5d", "source_updated_at": "2026-06-23", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/ikervis-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1851}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 18, "start": 0, "text": "Dublin 2, D02 T380", "truncated": false}, "before_length": 18, "before_sha256": "23e6871e7960b0dadc753bc127bbea230cc8308c88b2d33704eb275a3ec1a70d", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 18, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 18, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-c7f522c030d63f4e9d8d0f1c", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002097", "medicine_name": "Fampyra", "medicine_slug": "fampyra", "observed_at": "2026-10-12T19:16:07Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "a0c3ba8d58d6a43a809ecc3d142a78b10c2bd7f0b9f3a3553df2617d87daec1f", "source_snapshot_id": "source-c7a810dd21f94cd2d273f0da", "source_updated_at": "2025-08-21", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/fampyra-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1579}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 21, "start": 0, "text": "Tel: + 33 153 868 750", "truncated": false}, "before_length": 21, "before_sha256": "efffe29324e968019e6e2b111904182ba06d83e76b1f29b933bed9dd8779c114", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 21, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 21, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-c824d4263a018e7affc9e9ac", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:19Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "77586d0bea0858214b43b86e91abc2d2711733b96959ead5ed0b5ecbd8ed888a", "source_snapshot_id": "source-85d476f9ad959cc117ca8f1f", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1464}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 38, "start": 0, "text": "Otsuka Pharmaceutical Netherlands B.V.", "truncated": false}, "before_length": 38, "before_sha256": "2891d7989f773ce0b34a3e835488071e6ffd7e94478e61a5899dcf87bd99c38c", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 38, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 38, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-c82abbe945085b5b809eec07", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/000980", "medicine_name": "Samsca", "medicine_slug": "samsca", "observed_at": "2026-10-12T13:28:23Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "b92d73a758b8976c4438a072d544f0d6c603112c90dfc9c084d362ce62419257", "source_snapshot_id": "source-15b8b5681aba542ec1668c0b", "source_updated_at": "2026-08-20", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/samsca-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1289}
{"after": {"end": 21, "start": 0, "text": "Tel: +31 35 528 39 57", "truncated": false}, "after_length": 21, "after_sha256": "7baf6601f41e49e470f803fdd4e755a86efa38be423317c000ed79963ebdd213", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 21, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 21}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-c897101895dd876ba80908b8", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:19Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "77586d0bea0858214b43b86e91abc2d2711733b96959ead5ed0b5ecbd8ed888a", "source_snapshot_id": "source-85d476f9ad959cc117ca8f1f", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1400}
{"after": {"end": 6, "start": 0, "text": "Vācija", "truncated": false}, "after_length": 6, "after_sha256": "48b6655a9b490b23ced767bcfdf9112b44b466d83f3970463fdb7c0e9750a6a8", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 6, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 6}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-c8a27494b720365e33fa580a", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002097", "medicine_name": "Fampyra", "medicine_slug": "fampyra", "observed_at": "2026-10-12T19:16:07Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "a0c3ba8d58d6a43a809ecc3d142a78b10c2bd7f0b9f3a3553df2617d87daec1f", "source_snapshot_id": "source-c7a810dd21f94cd2d273f0da", "source_updated_at": "2025-08-21", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/fampyra-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1627}
{"after": {"end": 17, "start": 0, "text": "Torokbalint, 2045", "truncated": false}, "after_length": 17, "after_sha256": "d6dbae334e70b70d590689409d24e6c0cda7d30fd5104550892da04a039d1276", "annex": "III", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "unassigned", "change_operations": [{"after_end": 17, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 17}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-c8c2c7855c1874d58e1bbb20", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/006047", "medicine_name": "Lacosamide Adroiq", "medicine_slug": "lacosamide-adroiq", "observed_at": "2026-10-12T19:07:56Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "", "section_type": "unassigned", "source_provider": "European Medicines Agency", "source_sha256": "0578c53a5e1c785c4d9d4dc0dabae49dbfa89e237aa571556bee548c3f9cf4d5", "source_snapshot_id": "source-64831dec5ebf55535e19d91b", "source_updated_at": "2025-09-25", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/lacosamide-adroiq-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1203}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 27, "start": 0, "text": "Tél/Tel. : +31 35 528 39 57", "truncated": false}, "before_length": 27, "before_sha256": "eddad606e05a9455dde7d268d2b9f8b333c53e1b7fe89a456795afc087881b80", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 27, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 27, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-c8f15010a21b9311af1a4dd4", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:19Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "77586d0bea0858214b43b86e91abc2d2711733b96959ead5ed0b5ecbd8ed888a", "source_snapshot_id": "source-85d476f9ad959cc117ca8f1f", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1813}
{"after": {"end": 483, "start": 0, "text": "Au vu des données disponibles sur le(s) risque(s) issues de la littérature et des notifications spontanées, dont 8 cas en relation temporelle étroite, avec « de-challenge » (résolution à l’arrêt du traitement) et « re-challenge » (réapparition à la réintroduction du traitement) positifs, et dans la mesure où il existe un mécanisme d’action plausible, le PRAC estime qu’un lien de causalité entre la darifénacine et la survenue d’une confusion est au moins raisonnablement possible.", "truncated": false}, "after_length": 483, "after_sha256": "7b914094c8ba66e17886aa1e44614d31a5dedf6c88f4d754e70ac009b4d57d2c", "annex": "IV", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 483, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 483}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-c8fbfba6c4fb5a2ac59499e8", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/000554", "medicine_name": "Emselex", "medicine_slug": "emselex", "observed_at": "2026-10-12T19:12:07Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": null, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "conditions", "section_type": "conditions", "source_provider": "European Medicines Agency", "source_sha256": "9a4f1d7e260c7b80eaf397503623b63302e5945b579e9612177835e07c4ab888", "source_snapshot_id": "source-3aac7bf42b99529f25ac013b", "source_updated_at": "2025-09-15", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/emselex-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 2066}
{"after": {"end": 284, "start": 0, "text": "The overall safety profile of SPRYCEL in the paediatric Ph+ CMLCP population was similar to that of the adult population, regardless of formulation. Of the 130 SPRYCEL-treated paediatric subjects with CMLCP, 2 (1.5%) experienced adverse reactions leading to treatment discontinuation.", "truncated": false}, "after_length": 284, "after_sha256": "a93f0d5739e46329a99d92e3579a091992fe0956a0ed725e331ab4ff5a1dd901", "annex": "I", "before": {"end": 432, "start": 0, "text": "The overall safety profile of SPRYCEL in the paediatric Ph+ CMLCP population was similar to that of the adult population, regardless of formulation, with the exception of no reported pericardial effusion, pleural effusion, pulmonary oedema, or pulmonary hypertension in the paediatric population. Of the 130 SPRYCEL-treated paediatric subjects with CMLCP, 2 (1.5%) experienced adverse reactions leading to treatment discontinuation.", "truncated": false}, "before_length": 432, "before_sha256": "9c7c89bef11745b1619d0bbe79611b554ea6f08b54465c9a5ba4b901dbf51a35", "change_kind": "content", "change_operations": [{"after_end": 147, "after_start": 147, "before_end": 295, "before_start": 147, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": true, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 148, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-c904d2a98fc8fc974a6e5006", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/000709", "medicine_name": "Sprycel", "medicine_slug": "sprycel", "observed_at": "2026-10-12T13:27:33Z", "pipeline_version": "2.0.0", "presentation_label": "SPRYCEL 10 mg/mL powder for oral suspension", "presentation_occurrence": 2, "presentation_status": "heading_extracted_unverified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "4.8", "section_type": "adverse_reactions", "source_provider": "European Medicines Agency", "source_sha256": "7b2a270ca60f948a69940b5bd26552042c4c20cae01b420ad781477ba43b0fe9", "source_snapshot_id": "source-c03fb6f08190e30934edc22f", "source_updated_at": "2026-10-02", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/sprycel-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 2113}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 61, "start": 0, "text": "McDermott Laboratories Limited trading as Gerard Laboratories", "truncated": false}, "before_length": 61, "before_sha256": "f28bee890ae72cccea9b87c3be57809b0afb7f64e286de2c77b2c05b413da700", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 61, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 61, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-c9332e98db4e9ee0e291a906", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/004025", "medicine_name": "Lopinavir/Ritonavir Viatris (previously Ritonavir Mylan)", "medicine_slug": "lopinavir-ritonavir-viatris-previously-ritonavir-mylan", "observed_at": "2026-10-12T19:14:59Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "d782e33ec97bc43bb54f942c83f07f89482c9a433e3846beaffe05b4a52b4b36", "source_snapshot_id": "source-ff48b23a80b98be4c15aa440", "source_updated_at": "2025-09-08", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/lopinavir-ritonavir-viatris-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 3330}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 8, "start": 0, "text": "Irlandia", "truncated": false}, "before_length": 8, "before_sha256": "6bff01f45c592880e92a15c13630eb9cc0b59aacad2c2ad60a9e91435d5a022c", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 8, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 8, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-c9334f1e9e5ce60682bc60c2", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002097", "medicine_name": "Fampyra", "medicine_slug": "fampyra", "observed_at": "2026-10-12T19:15:51Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "d9fe8aaaa611a84801d6308b13685258b5248df9022536697939afdf66fc1719", "source_snapshot_id": "source-ff8e0599077f0d01044dc867", "source_updated_at": "2025-08-21", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/fampyra-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1503}
{"after": {"end": 22, "start": 0, "text": "Fréquence indéterminée", "truncated": false}, "after_length": 22, "after_sha256": "9dbca2ea64869864cf27be15cb397d59f7675843792a00e126385e734d3768e0", "annex": "I", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 22, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": true, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 22}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-c972c4e38c9066c121ed8d39", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/000554", "medicine_name": "Emselex", "medicine_slug": "emselex", "observed_at": "2026-10-12T19:12:07Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": null, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "4.8", "section_type": "adverse_reactions", "source_provider": "European Medicines Agency", "source_sha256": "9a4f1d7e260c7b80eaf397503623b63302e5945b579e9612177835e07c4ab888", "source_snapshot_id": "source-3aac7bf42b99529f25ac013b", "source_updated_at": "2025-09-15", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/emselex-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 601}
{"after": {"end": 23, "start": 0, "text": "info@euroceptpharma.com", "truncated": false}, "after_length": 23, "after_sha256": "9297cc5acdcc837f054116992765943f7907937507b2564a99ea1327a00ac0e6", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 23, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 23}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-c998b1719463a822bdf59e35", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:14Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "8b8c4cc8e6f1a21fedee4bf0743c9c03e454b50f5eaba0e3760416d7fe0a74ec", "source_snapshot_id": "source-4efe4ecf3ebf08d338a763a5", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1599}
{"after": {"end": 21, "start": 0, "text": "Tel: +31 35 528 39 57", "truncated": false}, "after_length": 21, "after_sha256": "7baf6601f41e49e470f803fdd4e755a86efa38be423317c000ed79963ebdd213", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 21, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 21}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-c9b8023e2e86425c9e9fecbf", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:19Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "77586d0bea0858214b43b86e91abc2d2711733b96959ead5ed0b5ecbd8ed888a", "source_snapshot_id": "source-85d476f9ad959cc117ca8f1f", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1517}
{"after": {"end": 34, "start": 0, "text": "Orteliuslaan 1000, 3528 BD Utrecht", "truncated": false}, "after_length": 34, "after_sha256": "46a90fc46ae308c2beeb35ead613fcf3ade5a51e2217a834de3fa5972dab9eec", "annex": "I", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "administrative", "change_operations": [{"after_end": 34, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 34}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-c9beca4fc30671c26fe8d996", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/001021", "medicine_name": "Adcirca (previously Tadalafil Lilly)", "medicine_slug": "adcirca-previously-tadalafil-lilly", "observed_at": "2026-10-12T19:02:42Z", "pipeline_version": "2.0.0", "presentation_label": "ADCIRCA 2 mg/mL oral suspension", "presentation_occurrence": 2, "presentation_status": "heading_extracted_unverified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "7", "section_type": "administrative", "source_provider": "European Medicines Agency", "source_sha256": "43438c8e53504a78747a8ff36049250fee294557f3a8b0e3acb80f71ad43ebc0", "source_snapshot_id": "source-2305a67bd1e393ee340bb8e4", "source_updated_at": "2026-01-28", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/adcirca-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1228}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 27, "start": 0, "text": "(Eurocept International BV)", "truncated": false}, "before_length": 27, "before_sha256": "e6cf9b20aaa466e53ad0d393512ca75931e13e488321e3be6f3e4f8b600970c8", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 27, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 27, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-c9edf9debfa2e0c315ad14d6", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:19Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "77586d0bea0858214b43b86e91abc2d2711733b96959ead5ed0b5ecbd8ed888a", "source_snapshot_id": "source-85d476f9ad959cc117ca8f1f", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1821}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIB", "before": {"end": 18, "start": 0, "text": "Pátriárka utca 14.", "truncated": false}, "before_length": 18, "before_sha256": "488a80d25b682a58591b4751c4687d5b516ccd6a004748e40d4e8f1454217b07", "change_kind": "unassigned", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 18, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 18, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-c9f0a4f4873dcc54262e0178", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/006047", "medicine_name": "Lacosamide Adroiq", "medicine_slug": "lacosamide-adroiq", "observed_at": "2026-10-12T19:07:56Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "", "section_type": "unassigned", "source_provider": "European Medicines Agency", "source_sha256": "0578c53a5e1c785c4d9d4dc0dabae49dbfa89e237aa571556bee548c3f9cf4d5", "source_snapshot_id": "source-64831dec5ebf55535e19d91b", "source_updated_at": "2025-09-25", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/lacosamide-adroiq-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1858}
{"after": {"end": 12, "start": 0, "text": "169 73 Solna", "truncated": false}, "after_length": 12, "after_sha256": "396199e813d8f79edb20275a432ef3c356a2964b18c41134b918894de8dcbb3d", "annex": "IIIA", "before": {"end": 12, "start": 0, "text": "Solna 169 73", "truncated": false}, "before_length": 12, "before_sha256": "48d3b71370d55743d8f6af2ff4ab7a798818c3958ea6d6d44d45c3a952fd50d5", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 6, "before_start": 0, "kind": "delete"}, {"after_end": 12, "after_start": 6, "before_end": 12, "before_start": 12, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 6, "chars_inserted": 6}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-ca311b93c4881f44edc11148", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002097", "medicine_name": "Fampyra", "medicine_slug": "fampyra", "observed_at": "2026-10-12T19:15:51Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "d9fe8aaaa611a84801d6308b13685258b5248df9022536697939afdf66fc1719", "source_snapshot_id": "source-ff8e0599077f0d01044dc867", "source_updated_at": "2025-08-21", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/fampyra-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1474}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 8, "start": 0, "text": "Autriche", "truncated": false}, "before_length": 8, "before_sha256": "dea55da9d453f7a5125a553d05297c736f00626d1baa09e099247c0e7937d0cf", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 8, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 8, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-ca3f0ef36d1290aee0272b98", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/000725", "medicine_name": "Binocrit", "medicine_slug": "binocrit", "observed_at": "2026-10-12T19:29:33Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "2110517cc45ca102ca5957f2578ba74090631cf709d5be3e5f6e34712f237bdb", "source_snapshot_id": "source-63ba5976f2b2d4350a9afd16", "source_updated_at": "2025-07-11", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/binocrit-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 3387}
{"after": {"end": 25, "start": 0, "text": "Eurocept International BV", "truncated": false}, "after_length": 25, "after_sha256": "b17bd89b3cf285c986a6070d0d67f5326dd5c1f08a70834c296c6c820f9e7505", "annex": "IIIA", "before": {"end": 21, "start": 0, "text": "info@lucanepharma.com", "truncated": false}, "before_length": 21, "before_sha256": "44fd39e5fb919cb3d680fa630da23b49238fec29159c509f3622f272bb41c7c6", "change_kind": "content", "change_operations": [{"after_end": 3, "after_start": 0, "before_end": 3, "before_start": 0, "kind": "replace"}, {"after_end": 4, "after_start": 4, "before_end": 7, "before_start": 4, "kind": "delete"}, {"after_end": 5, "after_start": 5, "before_end": 10, "before_start": 8, "kind": "delete"}, {"after_end": 15, "after_start": 7, "before_end": 13, "before_start": 12, "kind": "replace"}, {"after_end": 20, "after_start": 16, "before_end": 16, "before_start": 14, "kind": "replace"}, {"after_end": 25, "after_start": 21, "before_end": 21, "before_start": 17, "kind": "replace"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 15, "chars_inserted": 19}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-ca4b4bca44abbec1858c52b5", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:14Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "8b8c4cc8e6f1a21fedee4bf0743c9c03e454b50f5eaba0e3760416d7fe0a74ec", "source_snapshot_id": "source-4efe4ecf3ebf08d338a763a5", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1572}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIB", "before": {"end": 16, "start": 0, "text": "Extrovis EU Ltd.", "truncated": false}, "before_length": 16, "before_sha256": "f462ad48e7aef0bc82148ce088af1897d99ed86993128f30d506b27d3108a929", "change_kind": "unassigned", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 16, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 16, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-ca734f12b76eff211310a2d6", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/006047", "medicine_name": "Lacosamide Adroiq", "medicine_slug": "lacosamide-adroiq", "observed_at": "2026-10-12T19:07:56Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "", "section_type": "unassigned", "source_provider": "European Medicines Agency", "source_sha256": "0578c53a5e1c785c4d9d4dc0dabae49dbfa89e237aa571556bee548c3f9cf4d5", "source_snapshot_id": "source-64831dec5ebf55535e19d91b", "source_updated_at": "2025-09-25", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/lacosamide-adroiq-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1981}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 8, "start": 0, "text": "Ιρλανδία", "truncated": false}, "before_length": 8, "before_sha256": "095fc3722309c3e2ff6ebfa3844425d8040e1db38d62071ba0f333f624dc0081", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 8, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 8, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-ca8a8b573ae89631fed9a882", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002097", "medicine_name": "Fampyra", "medicine_slug": "fampyra", "observed_at": "2026-10-12T19:16:07Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "a0c3ba8d58d6a43a809ecc3d142a78b10c2bd7f0b9f3a3553df2617d87daec1f", "source_snapshot_id": "source-c7a810dd21f94cd2d273f0da", "source_updated_at": "2025-08-21", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/fampyra-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1488}
{"after": {"end": 12, "start": 0, "text": "Виатрис ЕООД", "truncated": false}, "after_length": 12, "after_sha256": "92f9a32247d19bdb1e65df1219954c43f6ad757cc355e8022e7566c35de78f1a", "annex": "IIIA", "before": {"end": 11, "start": 0, "text": "Майлан ЕООД", "truncated": false}, "before_length": 11, "before_sha256": "5770366f858d91109bdad7a5551dc97b9878455f55713851de8277df30093b62", "change_kind": "content", "change_operations": [{"after_end": 2, "after_start": 0, "before_end": 1, "before_start": 0, "kind": "replace"}, {"after_end": 7, "after_start": 3, "before_end": 6, "before_start": 2, "kind": "replace"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 5, "chars_inserted": 6}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-caa9b6e51afd33cf369c89d9", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/000403", "medicine_name": "Arixtra", "medicine_slug": "arixtra", "observed_at": "2026-10-12T13:38:45Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 5, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "d627c7ab3c0e2e04ec110e8a99901c16a8eb257c9c55138e1bd3875249a20bde", "source_snapshot_id": "source-1eab2dd77b34f4c6fe6e82df", "source_updated_at": "2026-05-07", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/arixtra-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 3760}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 15, "start": 0, "text": "2000 Szentendre", "truncated": false}, "before_length": 15, "before_sha256": "6541cfa43ac22d35453442b205116e312f60338169ddc5a705a8fe3ff3f4fcd9", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 15, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 15, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-cad3cc13de654b48d230e17f", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/006047", "medicine_name": "Lacosamide Adroiq", "medicine_slug": "lacosamide-adroiq", "observed_at": "2026-10-12T19:07:59Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "cc83d966059d42856d0211a4f256b29b20d43593865704d6a9315aeb694f3c76", "source_snapshot_id": "source-896abba1d8391c918345d46b", "source_updated_at": "2025-09-25", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/lacosamide-adroiq-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1213}
{"after": {"end": 119, "start": 0, "text": "Detailed information on this medicine is available on the European Medicines Agency web site: https://www.ema.europa.eu", "truncated": false}, "after_length": 119, "after_sha256": "0f2b81ab8009e1a279ca008eb6e21bdb2e532de63aef52b62bdac980c49555d4", "annex": "IIIA", "before": {"end": 118, "start": 0, "text": "Detailed information on this medicine is available on the European Medicines Agency web site: http://www.ema.europa.eu", "truncated": false}, "before_length": 118, "before_sha256": "d114210a3c6f4b6710e22609ee80410ff17f5efd93b30ab72728a60b65635068", "change_kind": "technical", "change_operations": [{"after_end": 99, "after_start": 98, "before_end": 98, "before_start": 98, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 1}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-caf35897640b531c19449714", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/001021", "medicine_name": "Adcirca (previously Tadalafil Lilly)", "medicine_slug": "adcirca-previously-tadalafil-lilly", "observed_at": "2026-10-12T19:02:42Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "43438c8e53504a78747a8ff36049250fee294557f3a8b0e3acb80f71ad43ebc0", "source_snapshot_id": "source-2305a67bd1e393ee340bb8e4", "source_updated_at": "2026-01-28", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/adcirca-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 2032}
{"after": {"end": 22, "start": 0, "text": "Merz Therapeutics GmbH", "truncated": false}, "after_length": 22, "after_sha256": "059f049c7d0846aaadcf2573280d52110f302d4ecc7b38debd004571cd1e9d5e", "annex": "IIIA", "before": {"end": 35, "start": 0, "text": "Acorda Therapeutics Ireland Limited", "truncated": false}, "before_length": 35, "before_sha256": "d94d3153d193ed26567f2b4ed48df016d81c534e7c0cb1a6655a63f0083383ff", "change_kind": "content", "change_operations": [{"after_end": 2, "after_start": 0, "before_end": 3, "before_start": 0, "kind": "replace"}, {"after_end": 4, "after_start": 3, "before_end": 6, "before_start": 4, "kind": "replace"}, {"after_end": 19, "after_start": 18, "before_end": 30, "before_start": 20, "kind": "replace"}, {"after_end": 22, "after_start": 20, "before_end": 35, "before_start": 31, "kind": "replace"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 19, "chars_inserted": 6}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-cb0bcbab95d616653ef8cbe2", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002097", "medicine_name": "Fampyra", "medicine_slug": "fampyra", "observed_at": "2026-10-12T19:16:07Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "a0c3ba8d58d6a43a809ecc3d142a78b10c2bd7f0b9f3a3553df2617d87daec1f", "source_snapshot_id": "source-c7a810dd21f94cd2d273f0da", "source_updated_at": "2025-08-21", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/fampyra-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1506}
{"after": {"end": 23, "start": 0, "text": "Τηλ: +49 (0) 69 15 03 0", "truncated": false}, "after_length": 23, "after_sha256": "40b8b23a084b3eac3f3ba2dda37d60faaa541de50c6510ae17fd679d8490f764", "annex": "IIIA", "before": {"end": 23, "start": 0, "text": "Τηλ: +353 (0)1 231 4609", "truncated": false}, "before_length": 23, "before_sha256": "024453962d70899555df7213d15538f27fac977293417f307c134a4f3c21c4e8", "change_kind": "content", "change_operations": [{"after_end": 8, "after_start": 6, "before_end": 9, "before_start": 6, "kind": "replace"}, {"after_end": 16, "after_start": 12, "before_end": 13, "before_start": 13, "kind": "insert"}, {"after_end": 18, "after_start": 17, "before_end": 14, "before_start": 14, "kind": "insert"}, {"after_end": 20, "after_start": 19, "before_end": 16, "before_start": 15, "kind": "replace"}, {"after_end": 21, "after_start": 21, "before_end": 18, "before_start": 17, "kind": "delete"}, {"after_end": 22, "after_start": 22, "before_end": 21, "before_start": 19, "kind": "delete"}, {"after_end": 23, "after_start": 23, "before_end": 23, "before_start": 22, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 8, "chars_inserted": 8}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-cb729a6da035a24966c48e16", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002097", "medicine_name": "Fampyra", "medicine_slug": "fampyra", "observed_at": "2026-10-12T19:15:51Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "d9fe8aaaa611a84801d6308b13685258b5248df9022536697939afdf66fc1719", "source_snapshot_id": "source-ff8e0599077f0d01044dc867", "source_updated_at": "2025-08-21", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/fampyra-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1486}
{"after": {"end": 21, "start": 0, "text": "Tel: +31 35 528 39 57", "truncated": false}, "after_length": 21, "after_sha256": "7baf6601f41e49e470f803fdd4e755a86efa38be423317c000ed79963ebdd213", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 21, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 21}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-cba407aa7cb8aea585a6e413", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:19Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "77586d0bea0858214b43b86e91abc2d2711733b96959ead5ed0b5ecbd8ed888a", "source_snapshot_id": "source-85d476f9ad959cc117ca8f1f", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1786}
{"after": {"end": 23, "start": 0, "text": "Τηλ: +49 (0) 69 15 03 0", "truncated": false}, "after_length": 23, "after_sha256": "40b8b23a084b3eac3f3ba2dda37d60faaa541de50c6510ae17fd679d8490f764", "annex": "IIIA", "before": {"end": 23, "start": 0, "text": "Τηλ: +353 (0)1 231 4609", "truncated": false}, "before_length": 23, "before_sha256": "024453962d70899555df7213d15538f27fac977293417f307c134a4f3c21c4e8", "change_kind": "content", "change_operations": [{"after_end": 8, "after_start": 6, "before_end": 9, "before_start": 6, "kind": "replace"}, {"after_end": 16, "after_start": 12, "before_end": 13, "before_start": 13, "kind": "insert"}, {"after_end": 18, "after_start": 17, "before_end": 14, "before_start": 14, "kind": "insert"}, {"after_end": 20, "after_start": 19, "before_end": 16, "before_start": 15, "kind": "replace"}, {"after_end": 21, "after_start": 21, "before_end": 18, "before_start": 17, "kind": "delete"}, {"after_end": 22, "after_start": 22, "before_end": 21, "before_start": 19, "kind": "delete"}, {"after_end": 23, "after_start": 23, "before_end": 23, "before_start": 22, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 8, "chars_inserted": 8}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-cbb812d9215f21d43f8190dc", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002097", "medicine_name": "Fampyra", "medicine_slug": "fampyra", "observed_at": "2026-10-12T19:16:07Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "a0c3ba8d58d6a43a809ecc3d142a78b10c2bd7f0b9f3a3553df2617d87daec1f", "source_snapshot_id": "source-c7a810dd21f94cd2d273f0da", "source_updated_at": "2025-08-21", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/fampyra-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1611}
{"after": {"end": 205, "start": 0, "text": "If your baby is less than 4 weeks old, talk to your doctor or pharmacist before giving them this flavour topping in particular if the baby is given other medicines that contain propylene glycol or alcohol.", "truncated": false}, "after_length": 205, "after_sha256": "3f04cdf4be5696e7a89c05d7d76e6aec341afc9e8aa6f161af680c59846bb476", "annex": "IIIA", "before": {"end": 199, "start": 0, "text": "If your baby is less than 4 weeks old, talk to your doctor or pharmacist before giving them this medicine, in particular if the baby is given other medicines that contain propylene glycol or alcohol.", "truncated": false}, "before_length": 199, "before_sha256": "b62170b5b3b036ea9b5cd69f0b30f5a76fb9c34977bff99fea9049c7075d499a", "change_kind": "content", "change_operations": [{"after_end": 109, "after_start": 97, "before_end": 102, "before_start": 97, "kind": "replace"}, {"after_end": 112, "after_start": 111, "before_end": 106, "before_start": 104, "kind": "replace"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 7, "chars_inserted": 13}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-cbced692d2e0e3dd78299ea7", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:14Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "8b8c4cc8e6f1a21fedee4bf0743c9c03e454b50f5eaba0e3760416d7fe0a74ec", "source_snapshot_id": "source-4efe4ecf3ebf08d338a763a5", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1711}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 8, "start": 0, "text": "Ιρλανδία", "truncated": false}, "before_length": 8, "before_sha256": "095fc3722309c3e2ff6ebfa3844425d8040e1db38d62071ba0f333f624dc0081", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 8, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 8, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-cbd850606ebf6da34fa9176d", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002097", "medicine_name": "Fampyra", "medicine_slug": "fampyra", "observed_at": "2026-10-12T19:16:07Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "a0c3ba8d58d6a43a809ecc3d142a78b10c2bd7f0b9f3a3553df2617d87daec1f", "source_snapshot_id": "source-c7a810dd21f94cd2d273f0da", "source_updated_at": "2025-08-21", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/fampyra-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1607}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 14, "start": 0, "text": "Irlande/Irland", "truncated": false}, "before_length": 14, "before_sha256": "b273d331b1c063fa0e68d467f1babcfdd0f9d8054c6ea3f570cdc268ea454e91", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 14, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 14, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-cc1c34ae9c581b92505a22b6", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002097", "medicine_name": "Fampyra", "medicine_slug": "fampyra", "observed_at": "2026-10-12T19:15:51Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "d9fe8aaaa611a84801d6308b13685258b5248df9022536697939afdf66fc1719", "source_snapshot_id": "source-ff8e0599077f0d01044dc867", "source_updated_at": "2025-08-21", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/fampyra-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1401}
{"after": {"end": 168, "start": 0, "text": "This document is the approved product information for Arixtra, with the changes since the previous procedure affecting the product information EMA/N/0000315081 tracked.", "truncated": false}, "after_length": 168, "after_sha256": "e08a79a761a97afb2ff2cbbc55170d797c4bcc95686b792f79b148e93991b5c6", "annex": "", "before": {"end": 151, "start": 0, "text": "This document is the approved product information for Arixtra, with the changes since the previous procedure affecting the product information tracked.", "truncated": false}, "before_length": 151, "before_sha256": "d05507ee392c9c2d98fcbb3afc8e52ae42960a099e17bcb924d26028521deb93", "change_kind": "unassigned", "change_operations": [{"after_end": 160, "after_start": 143, "before_end": 143, "before_start": 143, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 17}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-cc6c9b767c313c4804b58d00", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/000403", "medicine_name": "Arixtra", "medicine_slug": "arixtra", "observed_at": "2026-10-12T13:38:45Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": null, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "", "section_type": "unassigned", "source_provider": "European Medicines Agency", "source_sha256": "d627c7ab3c0e2e04ec110e8a99901c16a8eb257c9c55138e1bd3875249a20bde", "source_snapshot_id": "source-1eab2dd77b34f4c6fe6e82df", "source_updated_at": "2026-05-07", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/arixtra-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1}
{"after": {"end": 17, "start": 0, "text": "msdpolska@msd.com", "truncated": false}, "after_length": 17, "after_sha256": "1b250a519a0f233f4e354eb6c7114ba65293ff16c0041901602d11e2c6c3498c", "annex": "IIIA", "before": {"end": 19, "start": 0, "text": "msdpolska@merck.com", "truncated": false}, "before_length": 19, "before_sha256": "5690867ba2de57367aef5787dfb5119647492569c1acc32aee4d6aec5daced2d", "change_kind": "content", "change_operations": [{"after_end": 13, "after_start": 11, "before_end": 15, "before_start": 11, "kind": "replace"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 4, "chars_inserted": 2}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-cc7a6e71053faa69cc317780", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/000389", "medicine_name": "Invanz", "medicine_slug": "invanz", "observed_at": "2026-10-12T17:30:44Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "a9208c117495d2d6c465ba196e4dbbb3d498b27d747df3b2d0145b0549743e4b", "source_snapshot_id": "source-e56383168f778128e02c2b2e", "source_updated_at": "2025-11-21", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/invanz-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1172}
{"after": {"end": 8, "start": 0, "text": "Ġermanja", "truncated": false}, "after_length": 8, "after_sha256": "777374490a90bf7933fa93e8dff699f1180358fdd68182f9a146eb475e78a3b7", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 8, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 8}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-ccf99db9ee920b46bb1d1501", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002097", "medicine_name": "Fampyra", "medicine_slug": "fampyra", "observed_at": "2026-10-12T19:15:51Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "d9fe8aaaa611a84801d6308b13685258b5248df9022536697939afdf66fc1719", "source_snapshot_id": "source-ff8e0599077f0d01044dc867", "source_updated_at": "2025-08-21", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/fampyra-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1442}
{"after": {"end": 28, "start": 0, "text": "Otsuka Pharma Scandinavia AB", "truncated": false}, "after_length": 28, "after_sha256": "da6b14629ea48096b1862cba5aad936b5d470b29f653a1de638e5ea031c53c39", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 28, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 28}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-cd046059acf4ef8a29e6174e", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/000980", "medicine_name": "Samsca", "medicine_slug": "samsca", "observed_at": "2026-10-12T13:28:24Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "3080d919225c2a98f20aec84d5803b3fde6e1b64f323055c46d098625f4ad301", "source_snapshot_id": "source-e05739a15a0532954ee45dd4", "source_updated_at": "2026-08-20", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/samsca-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1266}
{"after": {"end": 13, "start": 0, "text": "Bredaseweg 63", "truncated": false}, "after_length": 13, "after_sha256": "a37bbd239b649e23c8960a4ab83fa25cba872a2c2e743860ae8149ff61815928", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 13, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 13}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-cd2e44a6a03295f31f338276", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002097", "medicine_name": "Fampyra", "medicine_slug": "fampyra", "observed_at": "2026-10-12T19:15:51Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "d9fe8aaaa611a84801d6308b13685258b5248df9022536697939afdf66fc1719", "source_snapshot_id": "source-ff8e0599077f0d01044dc867", "source_updated_at": "2025-08-21", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/fampyra-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1372}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 27, "start": 0, "text": "(Eurocept International BV)", "truncated": false}, "before_length": 27, "before_sha256": "e6cf9b20aaa466e53ad0d393512ca75931e13e488321e3be6f3e4f8b600970c8", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 27, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 27, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-cd514cb158eb9c80a8434f08", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:14Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "8b8c4cc8e6f1a21fedee4bf0743c9c03e454b50f5eaba0e3760416d7fe0a74ec", "source_snapshot_id": "source-4efe4ecf3ebf08d338a763a5", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1950}
{"after": {"end": 25, "start": 0, "text": "Lamia, Schimatari, 32009,", "truncated": false}, "after_length": 25, "after_sha256": "731caa8982d6c36ded24b2c0ae7f96bbe4b52b5f2fe4fdabe022c9e027a41c9e", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 25, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 25}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-cd662565fa593f825a34d7b9", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/003984", "medicine_name": "Bortezomib Accord", "medicine_slug": "bortezomib-accord", "observed_at": "2026-10-12T13:47:12Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "e4aac937241121e8ad1e32b40b1007fb58398035928568a7e60a65074b0efb36", "source_snapshot_id": "source-b1eaab6445cfa827e3b1481b", "source_updated_at": "2026-03-25", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/bortezomib-accord-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 4747}
{"after": {"end": 138, "start": 0, "text": "Pour plus d’informations, voir le site web de l’Agence européenne des médicaments: https://www.ema.europa.eu/en/medicines/human/EPAR/Arava", "truncated": false}, "after_length": 138, "after_sha256": "23404c42fdf3d056ce893a2f83a82a7cdbe1e99005991005b81d0093cf9b6f53", "annex": "", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "unassigned", "change_operations": [{"after_end": 138, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 138}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-cd79280919904b2198f3458e", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/000235", "medicine_name": "Arava", "medicine_slug": "arava", "observed_at": "2026-10-12T13:28:00Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": null, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "", "section_type": "unassigned", "source_provider": "European Medicines Agency", "source_sha256": "98b73c5c6b1e5009c9d048f8f11257f3a8407759fd25a4c8d5ef5c611519e916", "source_snapshot_id": "source-4b7ea3b78addea82376b3432", "source_updated_at": "2026-09-07", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/arava-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 2}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 21, "start": 0, "text": "Tel: +31 35 528 39 57", "truncated": false}, "before_length": 21, "before_sha256": "7baf6601f41e49e470f803fdd4e755a86efa38be423317c000ed79963ebdd213", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 21, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 21, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-cda8effb6748ac9c65295e3d", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:14Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "8b8c4cc8e6f1a21fedee4bf0743c9c03e454b50f5eaba0e3760416d7fe0a74ec", "source_snapshot_id": "source-4efe4ecf3ebf08d338a763a5", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1969}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 27, "start": 0, "text": "(Eurocept International BV)", "truncated": false}, "before_length": 27, "before_sha256": "e6cf9b20aaa466e53ad0d393512ca75931e13e488321e3be6f3e4f8b600970c8", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 27, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 27, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-cdc553d1de184cb2532fd43b", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:14Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "8b8c4cc8e6f1a21fedee4bf0743c9c03e454b50f5eaba0e3760416d7fe0a74ec", "source_snapshot_id": "source-4efe4ecf3ebf08d338a763a5", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1858}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 21, "start": 0, "text": "Tel: + 33 153 868 750", "truncated": false}, "before_length": 21, "before_sha256": "efffe29324e968019e6e2b111904182ba06d83e76b1f29b933bed9dd8779c114", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 21, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 21, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-cdcf454e9c654c7955fcabf2", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:19Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "77586d0bea0858214b43b86e91abc2d2711733b96959ead5ed0b5ecbd8ed888a", "source_snapshot_id": "source-85d476f9ad959cc117ca8f1f", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1512}
{"after": {"end": 434, "start": 0, "text": "The total daily dose should be divided into equal amounts and given with each meal or feeding (e.g. 46 times per day in small children). The granules can be directly swallowed with a drink (such as water, fruit juices, protein-free infant formulas) or sprinkled on to a spoonful of solid foods (such as mashed potatoes or apple sauce); in this case, it is important that it is taken immediately in order to preserve the taste-masking.", "truncated": false}, "after_length": 434, "after_sha256": "bfe95598557595decf56944aba6d1b59f2556f991cb22fce718006ee5519e2c2", "annex": "I", "before": {"end": 418, "start": 0, "text": "The total daily dose should be divided into equal amounts and given with each meal or feeding (e.g. 46 times per day in small children). The granules can be directly swallowed with a drink (water, fruit juices, protein-free infant formulas) or sprinkled on to a spoonful of solid foods (mashed potatoes or apple sauce); in this case, it is important that it is taken immediately in order to preserve the taste-masking.", "truncated": false}, "before_length": 418, "before_sha256": "ecd14b6d62566185b26d3272061b48a0a62028017ef166981430ba30056bcaf2", "change_kind": "content", "change_operations": [{"after_end": 198, "after_start": 190, "before_end": 190, "before_start": 190, "kind": "insert"}, {"after_end": 303, "after_start": 295, "before_end": 287, "before_start": 287, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": true, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 16}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-ce1662864388615f59765b9e", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:14Z", "pipeline_version": "2.0.0", "presentation_label": "PHEBURANE 483 mg/g granules", "presentation_occurrence": 1, "presentation_status": "heading_extracted_unverified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "4.2", "section_type": "posology", "source_provider": "European Medicines Agency", "source_sha256": "8b8c4cc8e6f1a21fedee4bf0743c9c03e454b50f5eaba0e3760416d7fe0a74ec", "source_snapshot_id": "source-4efe4ecf3ebf08d338a763a5", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 95}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 39, "start": 0, "text": "Eli Lilly and Company (Ireland) Limited", "truncated": false}, "before_length": 39, "before_sha256": "0555e8a06c0ef36afd955d945d4997f04834690c546541adf74802bac524a0e4", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 39, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 39, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-ce1780019a3471c9d5bb9ff3", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/001021", "medicine_name": "Adcirca (previously Tadalafil Lilly)", "medicine_slug": "adcirca-previously-tadalafil-lilly", "observed_at": "2026-10-12T19:02:42Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "43438c8e53504a78747a8ff36049250fee294557f3a8b0e3acb80f71ad43ebc0", "source_snapshot_id": "source-2305a67bd1e393ee340bb8e4", "source_updated_at": "2026-01-28", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/adcirca-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 2027}
{"after": {"end": 21, "start": 0, "text": "Tel: +31 35 528 39 57", "truncated": false}, "after_length": 21, "after_sha256": "7baf6601f41e49e470f803fdd4e755a86efa38be423317c000ed79963ebdd213", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 21, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 21}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-ce417e095be169b457535008", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:19Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "77586d0bea0858214b43b86e91abc2d2711733b96959ead5ed0b5ecbd8ed888a", "source_snapshot_id": "source-85d476f9ad959cc117ca8f1f", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1800}
{"after": {"end": 8, "start": 0, "text": "Германия", "truncated": false}, "after_length": 8, "after_sha256": "c2574453e3d10cfd248ec6f7ce0fcc01944f6ead4ff06b6617d5e8621ad4660f", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 8, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 8}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-ce6cb8e3fd09b0912458c7d9", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002097", "medicine_name": "Fampyra", "medicine_slug": "fampyra", "observed_at": "2026-10-12T19:16:07Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "a0c3ba8d58d6a43a809ecc3d142a78b10c2bd7f0b9f3a3553df2617d87daec1f", "source_snapshot_id": "source-c7a810dd21f94cd2d273f0da", "source_updated_at": "2025-08-21", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/fampyra-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1400}
{"after": {"end": 25, "start": 0, "text": "Eurocept International BV", "truncated": false}, "after_length": 25, "after_sha256": "b17bd89b3cf285c986a6070d0d67f5326dd5c1f08a70834c296c6c820f9e7505", "annex": "IIIA", "before": {"end": 21, "start": 0, "text": "info@lucanepharma.com", "truncated": false}, "before_length": 21, "before_sha256": "44fd39e5fb919cb3d680fa630da23b49238fec29159c509f3622f272bb41c7c6", "change_kind": "content", "change_operations": [{"after_end": 3, "after_start": 0, "before_end": 3, "before_start": 0, "kind": "replace"}, {"after_end": 4, "after_start": 4, "before_end": 7, "before_start": 4, "kind": "delete"}, {"after_end": 5, "after_start": 5, "before_end": 10, "before_start": 8, "kind": "delete"}, {"after_end": 15, "after_start": 7, "before_end": 13, "before_start": 12, "kind": "replace"}, {"after_end": 20, "after_start": 16, "before_end": 16, "before_start": 14, "kind": "replace"}, {"after_end": 25, "after_start": 21, "before_end": 21, "before_start": 17, "kind": "replace"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 15, "chars_inserted": 19}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-ce7dd7bc158b3b6d7e6bb20e", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:14Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "8b8c4cc8e6f1a21fedee4bf0743c9c03e454b50f5eaba0e3760416d7fe0a74ec", "source_snapshot_id": "source-4efe4ecf3ebf08d338a763a5", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 2045}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 20, "start": 0, "text": "10 Earlsfort Terrace", "truncated": false}, "before_length": 20, "before_sha256": "22951bbf6ee77815d0c07b3af5f0a66e17d277636971c4eaff372dea65dcb193", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 20, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 20, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-ce94600ebeced3824efb2f0a", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002097", "medicine_name": "Fampyra", "medicine_slug": "fampyra", "observed_at": "2026-10-12T19:16:07Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "a0c3ba8d58d6a43a809ecc3d142a78b10c2bd7f0b9f3a3553df2617d87daec1f", "source_snapshot_id": "source-c7a810dd21f94cd2d273f0da", "source_updated_at": "2025-08-21", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/fampyra-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1405}
{"after": {"end": 8, "start": 0, "text": "Pays-Bas", "truncated": false}, "after_length": 8, "after_sha256": "2f1d512c96e61c1e31319fc9326840a0ea9ab221bba6bbdca327b162ac12fa51", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 8, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 8}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-ceaba468bb188fd6c7db809a", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/000980", "medicine_name": "Samsca", "medicine_slug": "samsca", "observed_at": "2026-10-12T13:28:24Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "3080d919225c2a98f20aec84d5803b3fde6e1b64f323055c46d098625f4ad301", "source_snapshot_id": "source-e05739a15a0532954ee45dd4", "source_updated_at": "2026-08-20", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/samsca-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1261}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "II", "before": {"end": 14, "start": 0, "text": "Heussstraße 25", "truncated": false}, "before_length": 14, "before_sha256": "805584102a210d40b5c8e0e7014cb2d6f4194a7c2ef94da3309e0707eed85073", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 14, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 14, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-ced314f5cb6d25ebe32b569c", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/005246", "medicine_name": "Byfavo", "medicine_slug": "byfavo", "observed_at": "2026-10-12T13:28:16Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "conditions", "section_type": "conditions", "source_provider": "European Medicines Agency", "source_sha256": "61243a969f979f690fe718e414ceaeb66438c1faa31101ba25187d2f9ea662fd", "source_snapshot_id": "source-dd26eb8615d8c18bd80c1f6a", "source_updated_at": "2026-08-26", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/byfavo-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1830}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "I", "before": {"end": 437, "start": 0, "text": "Les événements suivants ont été rapportés en association avec la darifénacine depuis sa commercialisation mondiale : réactions d’hypersensibilité généralisées incluant des oedèmes de Quincke, dépression/altération de l’humeur, hallucinations. Du fait que ces événements indésirables ont été rapportés spontanément depuis la commercialisation mondiale, la fréquence de ces événements ne peut être estimée à partir des données disponibles.", "truncated": false}, "before_length": 437, "before_sha256": "910956457aa25f620772a2dfe040318739a13956ea672ab17ff6d8ce656c0e79", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 437, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": true, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 437, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-cf0a30427d16b4745155729e", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/000554", "medicine_name": "Emselex", "medicine_slug": "emselex", "observed_at": "2026-10-12T19:12:07Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": null, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "4.8", "section_type": "adverse_reactions", "source_provider": "European Medicines Agency", "source_sha256": "9a4f1d7e260c7b80eaf397503623b63302e5945b579e9612177835e07c4ab888", "source_snapshot_id": "source-3aac7bf42b99529f25ac013b", "source_updated_at": "2025-09-15", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/emselex-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 660}
{"after": {"end": 113, "start": 0, "text": "The PRAC concluded that the product information of products containing darifenacin should be amended accordingly.", "truncated": false}, "after_length": 113, "after_sha256": "6c121698019446bf0f5ac78fc6200463717c6b9b7d719b26856a1092f247f5a3", "annex": "IV", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 113, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 113}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-cf3eeddc70522e45d7292e5c", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/000554", "medicine_name": "Emselex", "medicine_slug": "emselex", "observed_at": "2026-10-12T19:12:04Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "conditions", "section_type": "conditions", "source_provider": "European Medicines Agency", "source_sha256": "4f2565612bc728ec67b7f9c0cd5799ef2c594911c76f323aef8bf6a85adde245", "source_snapshot_id": "source-1fda25b331eb198b8b93feb3", "source_updated_at": "2025-09-15", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/emselex-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 2081}
{"after": {"end": 16, "start": 0, "text": "Extrovis EU Kft.", "truncated": false}, "after_length": 16, "after_sha256": "b9216ef80e71e17798dce313e4318f03f37328f225d30ab508b7413813a908e5", "annex": "IIIB", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "unassigned", "change_operations": [{"after_end": 16, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 16}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-cf5457f58c4e3e8743b7c310", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/006047", "medicine_name": "Lacosamide Adroiq", "medicine_slug": "lacosamide-adroiq", "observed_at": "2026-10-12T19:07:56Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "", "section_type": "unassigned", "source_provider": "European Medicines Agency", "source_sha256": "0578c53a5e1c785c4d9d4dc0dabae49dbfa89e237aa571556bee548c3f9cf4d5", "source_snapshot_id": "source-64831dec5ebf55535e19d91b", "source_updated_at": "2025-09-25", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/lacosamide-adroiq-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1913}
{"after": {"end": 23, "start": 0, "text": "info@euroceptpharma.com", "truncated": false}, "after_length": 23, "after_sha256": "9297cc5acdcc837f054116992765943f7907937507b2564a99ea1327a00ac0e6", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 23, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 23}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-cf810cf386eb69a7dc731faf", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:14Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "8b8c4cc8e6f1a21fedee4bf0743c9c03e454b50f5eaba0e3760416d7fe0a74ec", "source_snapshot_id": "source-4efe4ecf3ebf08d338a763a5", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 2057}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIB", "before": {"end": 16, "start": 0, "text": "Extrovis EU Ltd.", "truncated": false}, "before_length": 16, "before_sha256": "f462ad48e7aef0bc82148ce088af1897d99ed86993128f30d506b27d3108a929", "change_kind": "unassigned", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 16, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 16, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-cf9341e72b1b5c9b204b2606", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/006047", "medicine_name": "Lacosamide Adroiq", "medicine_slug": "lacosamide-adroiq", "observed_at": "2026-10-12T19:07:56Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "", "section_type": "unassigned", "source_provider": "European Medicines Agency", "source_sha256": "0578c53a5e1c785c4d9d4dc0dabae49dbfa89e237aa571556bee548c3f9cf4d5", "source_snapshot_id": "source-64831dec5ebf55535e19d91b", "source_updated_at": "2025-09-25", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/lacosamide-adroiq-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 2020}
{"after": {"end": 23, "start": 0, "text": "60318 Frankfurt am Main", "truncated": false}, "after_length": 23, "after_sha256": "24c3191b5088b20c209c4387a8127297e54c776e161d305c9e57956a13b7cbbe", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 23, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 23}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-cfb5a69ca7dff5cb82f18178", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002097", "medicine_name": "Fampyra", "medicine_slug": "fampyra", "observed_at": "2026-10-12T19:16:07Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "a0c3ba8d58d6a43a809ecc3d142a78b10c2bd7f0b9f3a3553df2617d87daec1f", "source_snapshot_id": "source-c7a810dd21f94cd2d273f0da", "source_updated_at": "2025-08-21", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/fampyra-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1399}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 13, "start": 0, "text": "Lucane Pharma", "truncated": false}, "before_length": 13, "before_sha256": "e338afdb64acf1a6e2083a50318853589248451dd3aa707181ba02641a8521e8", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 13, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 13, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-cfcd729582dc963bd1d937cd", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:19Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "77586d0bea0858214b43b86e91abc2d2711733b96959ead5ed0b5ecbd8ed888a", "source_snapshot_id": "source-85d476f9ad959cc117ca8f1f", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1534}
{"after": {"end": 310, "start": 0, "text": "In placebo-controlled studies in adult patients, no increase in serious infections was observed with teriflunomide 14 mg (2.7%) as compared to placebo (2.2%). Serious opportunistic infections occurred in 0.2% of each group. Severe infections including sepsis, sometimes fatal have been reported post-marketing.", "truncated": false}, "after_length": 310, "after_sha256": "a0e49ed29cce19826db30b2f4a95122f0e8d33a9397424e8cc1e3d4e1eb1b8ac", "annex": "I", "before": {"end": 309, "start": 0, "text": "In placebo-controlled studies in adult patients, no increase in serious infections was observed with teriflunomide 14 mg (2.7%) as compared to placebo (2.2%). Serious opportunistic infections occurred in 0.2% of each group. Severe infections including sepsis, sometimes fatal have been reported postmarketing.", "truncated": false}, "before_length": 309, "before_sha256": "51fed73b4713eb6cc26975fb08ae81066994cbc83675d481cf33963ef9780768", "change_kind": "content", "change_operations": [{"after_end": 300, "after_start": 299, "before_end": 299, "before_start": 299, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": true, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 1}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-cfd882b531d7ca2bfd560982", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002514", "medicine_name": "Aubagio", "medicine_slug": "aubagio", "observed_at": "2026-10-12T17:28:37Z", "pipeline_version": "2.0.0", "presentation_label": "AUBAGIO 7 mg film-coated tablets AUBAGIO 14 mg film-coated tablets", "presentation_occurrence": 1, "presentation_status": "heading_extracted_unverified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "4.8", "section_type": "adverse_reactions", "source_provider": "European Medicines Agency", "source_sha256": "2583b2915ecedeb3bccc3ac6bea691e65d05f5e437bf8aa7970917b6fdeb700c", "source_snapshot_id": "source-15791f384b9e49792c9776dd", "source_updated_at": "2025-12-09", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/aubagio-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 547}
{"after": {"end": 23, "start": 0, "text": "60318 Frankfurt am Main", "truncated": false}, "after_length": 23, "after_sha256": "24c3191b5088b20c209c4387a8127297e54c776e161d305c9e57956a13b7cbbe", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 23, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 23}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-d07b712e22a30941ec4a91ae", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002097", "medicine_name": "Fampyra", "medicine_slug": "fampyra", "observed_at": "2026-10-12T19:15:51Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "d9fe8aaaa611a84801d6308b13685258b5248df9022536697939afdf66fc1719", "source_snapshot_id": "source-ff8e0599077f0d01044dc867", "source_updated_at": "2025-08-21", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/fampyra-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1413}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 7, "start": 0, "text": "Ireland", "truncated": false}, "before_length": 7, "before_sha256": "02bf1dfa9a0365a86223f0e4ac9eaa0517b06b2e9273790f719feda656a247ae", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 7, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 7, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-d08858f89efc7cecfd51d6da", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002097", "medicine_name": "Fampyra", "medicine_slug": "fampyra", "observed_at": "2026-10-12T19:15:51Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "d9fe8aaaa611a84801d6308b13685258b5248df9022536697939afdf66fc1719", "source_snapshot_id": "source-ff8e0599077f0d01044dc867", "source_updated_at": "2025-08-21", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/fampyra-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1351}
{"after": {"end": 22, "start": 0, "text": "Merz Therapeutics GmbH", "truncated": false}, "after_length": 22, "after_sha256": "059f049c7d0846aaadcf2573280d52110f302d4ecc7b38debd004571cd1e9d5e", "annex": "IIIA", "before": {"end": 35, "start": 0, "text": "Acorda Therapeutics Ireland Limited", "truncated": false}, "before_length": 35, "before_sha256": "d94d3153d193ed26567f2b4ed48df016d81c534e7c0cb1a6655a63f0083383ff", "change_kind": "content", "change_operations": [{"after_end": 2, "after_start": 0, "before_end": 3, "before_start": 0, "kind": "replace"}, {"after_end": 4, "after_start": 3, "before_end": 6, "before_start": 4, "kind": "replace"}, {"after_end": 19, "after_start": 18, "before_end": 30, "before_start": 20, "kind": "replace"}, {"after_end": 22, "after_start": 20, "before_end": 35, "before_start": 31, "kind": "replace"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 19, "chars_inserted": 6}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-d0be856f6db5af5156ca2b4f", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002097", "medicine_name": "Fampyra", "medicine_slug": "fampyra", "observed_at": "2026-10-12T19:16:07Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "a0c3ba8d58d6a43a809ecc3d142a78b10c2bd7f0b9f3a3553df2617d87daec1f", "source_snapshot_id": "source-c7a810dd21f94cd2d273f0da", "source_updated_at": "2025-08-21", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/fampyra-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1577}
{"after": {"end": 11, "start": 0, "text": "Vianex S.A.", "truncated": false}, "after_length": 11, "after_sha256": "5aa05543f23c771ae6d358a0283a8ebc791ceaed5f1fb141cf038e2e49a6ac7b", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 11, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 11}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-d121b9105ddc85fcabf74342", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002066", "medicine_name": "Ikervis", "medicine_slug": "ikervis", "observed_at": "2026-10-12T13:34:16Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "ab05f9fab48768c68482390488c5b90c577e852974d4448da6ea8fe5a4eda856", "source_snapshot_id": "source-324751bde2e11edc76c2dbfe", "source_updated_at": "2026-06-23", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/ikervis-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1481}
{"after": {"end": 89, "start": 0, "text": "Confusion, humeur dépressive/altération de l’humeur, hallucinations, spasmes musculaires.", "truncated": false}, "after_length": 89, "after_sha256": "5304f2a1844257c299518ee93e48e17acc2ec82123701078c0bc6b89a57eb756", "annex": "IIIA", "before": {"end": 57, "start": 0, "text": "Humeur dépressive/altération de l’humeur, hallucinations.", "truncated": false}, "before_length": 57, "before_sha256": "542fe37d57d34ac2c05d3e25aeab6c112fb589a5da4e0cff3946e4cef96a4797", "change_kind": "content", "change_operations": [{"after_end": 12, "after_start": 0, "before_end": 1, "before_start": 0, "kind": "replace"}, {"after_end": 87, "after_start": 66, "before_end": 55, "before_start": 55, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 1, "chars_inserted": 33}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-d18f2a6732578148d7639175", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/000554", "medicine_name": "Emselex", "medicine_slug": "emselex", "observed_at": "2026-10-12T19:12:07Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": null, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "9a4f1d7e260c7b80eaf397503623b63302e5945b579e9612177835e07c4ab888", "source_snapshot_id": "source-3aac7bf42b99529f25ac013b", "source_updated_at": "2025-09-15", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/emselex-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1986}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 25, "start": 0, "text": "Tel: +44 (0) 800 035 2525", "truncated": false}, "before_length": 25, "before_sha256": "84fbcd82ef02323a82bdadb0119979f04bfbc916f52f9d1dc35ed28128dd714d", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 25, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 25, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-d19cd4c2ea5ba58ba1e455ac", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002702", "medicine_name": "Hexacima", "medicine_slug": "hexacima", "observed_at": "2026-10-12T19:07:04Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "44c8996457a718019c75b8322ba07a5ae7af36377b1a6f1cf4ca5a30f9b72c23", "source_snapshot_id": "source-fa766d966dea704c333b9969", "source_updated_at": "2025-09-29", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/hexacima-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1703}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 27, "start": 0, "text": "(Eurocept International BV)", "truncated": false}, "before_length": 27, "before_sha256": "e6cf9b20aaa466e53ad0d393512ca75931e13e488321e3be6f3e4f8b600970c8", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 27, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 27, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-d25ddf11a55192e2867ab2bd", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:19Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "77586d0bea0858214b43b86e91abc2d2711733b96959ead5ed0b5ecbd8ed888a", "source_snapshot_id": "source-85d476f9ad959cc117ca8f1f", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1891}
{"after": {"end": 25, "start": 0, "text": "Musculoskeletal disorders", "truncated": false}, "after_length": 25, "after_sha256": "554fab09c18c12d65cee54d5caa96534b1925e5ff23a67e98a7c7c04e66bf714", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 25, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 25}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-d27555f733d1289a02c079fd", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/000235", "medicine_name": "Arava", "medicine_slug": "arava", "observed_at": "2026-10-12T13:27:58Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 3, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "2efff7967e2237bf8343431eef5e08b56c2441eb8a691a90c64b2635109fd697", "source_snapshot_id": "source-08b4eba1f67d2654148f41c4", "source_updated_at": "2026-09-07", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/arava-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 3417}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "I", "before": {"end": 18, "start": 0, "text": "Dublin 2, D02 T380", "truncated": false}, "before_length": 18, "before_sha256": "23e6871e7960b0dadc753bc127bbea230cc8308c88b2d33704eb275a3ec1a70d", "change_kind": "administrative", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 18, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 18, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-d27d5e4e6447623eab5b4ad8", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002097", "medicine_name": "Fampyra", "medicine_slug": "fampyra", "observed_at": "2026-10-12T19:15:51Z", "pipeline_version": "2.0.0", "presentation_label": "Fampyra 10 mg prolonged-release tablets", "presentation_occurrence": 1, "presentation_status": "heading_extracted_unverified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "7", "section_type": "administrative", "source_provider": "European Medicines Agency", "source_sha256": "d9fe8aaaa611a84801d6308b13685258b5248df9022536697939afdf66fc1719", "source_snapshot_id": "source-ff8e0599077f0d01044dc867", "source_updated_at": "2025-08-21", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/fampyra-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 684}
{"after": {"end": 11, "start": 0, "text": "Vianex S.A.", "truncated": false}, "after_length": 11, "after_sha256": "5aa05543f23c771ae6d358a0283a8ebc791ceaed5f1fb141cf038e2e49a6ac7b", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 11, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 11}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-d29d5a1c1e8beab55ca98b61", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002066", "medicine_name": "Ikervis", "medicine_slug": "ikervis", "observed_at": "2026-10-12T13:34:10Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "7995ffe3d4b9c2e870327b45fae2f1d35ae1ab0e1e9e22b434fd9805b58a174e", "source_snapshot_id": "source-5ff0e792002ee89d9eb06e5d", "source_updated_at": "2026-06-23", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/ikervis-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1470}
{"after": {"end": 25, "start": 0, "text": "Eurocept International BV", "truncated": false}, "after_length": 25, "after_sha256": "b17bd89b3cf285c986a6070d0d67f5326dd5c1f08a70834c296c6c820f9e7505", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 25, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 25}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-d2eef2761d9234ae119ded5d", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:19Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "77586d0bea0858214b43b86e91abc2d2711733b96959ead5ed0b5ecbd8ed888a", "source_snapshot_id": "source-85d476f9ad959cc117ca8f1f", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1926}
{"after": {"end": 25, "start": 0, "text": "Eurocept International BV", "truncated": false}, "after_length": 25, "after_sha256": "b17bd89b3cf285c986a6070d0d67f5326dd5c1f08a70834c296c6c820f9e7505", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 25, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 25}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-d2f097d5a1fe99d32ddcbcd7", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:19Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "77586d0bea0858214b43b86e91abc2d2711733b96959ead5ed0b5ecbd8ed888a", "source_snapshot_id": "source-85d476f9ad959cc117ca8f1f", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1516}
{"after": {"end": 23, "start": 0, "text": "info@euroceptpharma.com", "truncated": false}, "after_length": 23, "after_sha256": "9297cc5acdcc837f054116992765943f7907937507b2564a99ea1327a00ac0e6", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 23, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 23}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-d32677bf8439bfa5e3233d24", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:14Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "8b8c4cc8e6f1a21fedee4bf0743c9c03e454b50f5eaba0e3760416d7fe0a74ec", "source_snapshot_id": "source-4efe4ecf3ebf08d338a763a5", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1454}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 7, "start": 0, "text": "Ireland", "truncated": false}, "before_length": 7, "before_sha256": "02bf1dfa9a0365a86223f0e4ac9eaa0517b06b2e9273790f719feda656a247ae", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 7, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 7, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-d354f04b4416b862f5fe8d3b", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/004025", "medicine_name": "Lopinavir/Ritonavir Viatris (previously Ritonavir Mylan)", "medicine_slug": "lopinavir-ritonavir-viatris-previously-ritonavir-mylan", "observed_at": "2026-10-12T19:12:46Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "3e30663f02732816ed8779d7a929d500c824ae15aeaee9144ca6eef11900e273", "source_snapshot_id": "source-c58e019b5bec1fb24569e83e", "source_updated_at": "2025-09-08", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/lopinavir-ritonavir-viatris-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 2968}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 7, "start": 0, "text": "Ireland", "truncated": false}, "before_length": 7, "before_sha256": "02bf1dfa9a0365a86223f0e4ac9eaa0517b06b2e9273790f719feda656a247ae", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 7, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 7, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-d35ce7305edc76b22369111d", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002097", "medicine_name": "Fampyra", "medicine_slug": "fampyra", "observed_at": "2026-10-12T19:15:51Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "d9fe8aaaa611a84801d6308b13685258b5248df9022536697939afdf66fc1719", "source_snapshot_id": "source-ff8e0599077f0d01044dc867", "source_updated_at": "2025-08-21", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/fampyra-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1030}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 21, "start": 0, "text": "Τηλ: + 33 153 868 750", "truncated": false}, "before_length": 21, "before_sha256": "e4516e3adf69ae4bf8e517fd63976d7665183bba6c244e35e8cd4567dd8fb0e5", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 21, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 21, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-d376d4265497b8e43b8977b4", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:19Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "77586d0bea0858214b43b86e91abc2d2711733b96959ead5ed0b5ecbd8ed888a", "source_snapshot_id": "source-85d476f9ad959cc117ca8f1f", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1547}
{"after": {"end": 23, "start": 0, "text": "Tel: +49 (0) 69 15 03 0", "truncated": false}, "after_length": 23, "after_sha256": "09683b3f43171b2266a32d9f7d44e3d62d536522dc6f42d4b47f2dda48b31833", "annex": "IIIA", "before": {"end": 23, "start": 0, "text": "Tel: +353 (0)1 231 4609", "truncated": false}, "before_length": 23, "before_sha256": "a115f11f382ef18898b9d956e48603ae236fd1846ce41e8586af99b6dabbfc4d", "change_kind": "content", "change_operations": [{"after_end": 8, "after_start": 6, "before_end": 9, "before_start": 6, "kind": "replace"}, {"after_end": 16, "after_start": 12, "before_end": 13, "before_start": 13, "kind": "insert"}, {"after_end": 18, "after_start": 17, "before_end": 14, "before_start": 14, "kind": "insert"}, {"after_end": 20, "after_start": 19, "before_end": 16, "before_start": 15, "kind": "replace"}, {"after_end": 21, "after_start": 21, "before_end": 18, "before_start": 17, "kind": "delete"}, {"after_end": 22, "after_start": 22, "before_end": 21, "before_start": 19, "kind": "delete"}, {"after_end": 23, "after_start": 23, "before_end": 23, "before_start": 22, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 8, "chars_inserted": 8}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-d37d9ba91cc389139c040e04", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002097", "medicine_name": "Fampyra", "medicine_slug": "fampyra", "observed_at": "2026-10-12T19:15:51Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "d9fe8aaaa611a84801d6308b13685258b5248df9022536697939afdf66fc1719", "source_snapshot_id": "source-ff8e0599077f0d01044dc867", "source_updated_at": "2025-08-21", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/fampyra-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1622}
{"after": {"end": 238, "start": 0, "text": "Ce document constitue les informations sur le produit approuvées pour Arava, les modifications apportées depuis la procédure précédente qui ont une incidence sur les informations sur le produit (EMA/VR/0000309158) étant mises en évidence.", "truncated": false}, "after_length": 238, "after_sha256": "85e311937332f7c7a4c80c42b83ccafe3ed378b499a627be433bed95784e6e44", "annex": "", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "unassigned", "change_operations": [{"after_end": 238, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 238}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-d3a558764a9ecacd2f6388d5", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/000235", "medicine_name": "Arava", "medicine_slug": "arava", "observed_at": "2026-10-12T13:28:00Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": null, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "", "section_type": "unassigned", "source_provider": "European Medicines Agency", "source_sha256": "98b73c5c6b1e5009c9d048f8f11257f3a8407759fd25a4c8d5ef5c611519e916", "source_snapshot_id": "source-4b7ea3b78addea82376b3432", "source_updated_at": "2026-09-07", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/arava-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 0}
{"after": {"end": 20, "start": 0, "text": "Pays-Bas/Niederlande", "truncated": false}, "after_length": 20, "after_sha256": "3ec90945e96bc0329608c9d655b3faf37a91ae94f1c8b5c2223902ae05d9db34", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 20, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 20}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-d3ab746dca4a90a02df5acf3", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002097", "medicine_name": "Fampyra", "medicine_slug": "fampyra", "observed_at": "2026-10-12T19:15:51Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "d9fe8aaaa611a84801d6308b13685258b5248df9022536697939afdf66fc1719", "source_snapshot_id": "source-ff8e0599077f0d01044dc867", "source_updated_at": "2025-08-21", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/fampyra-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1404}
{"after": {"end": 25, "start": 0, "text": "Lamia, Schimatari, 32009,", "truncated": false}, "after_length": 25, "after_sha256": "731caa8982d6c36ded24b2c0ae7f96bbe4b52b5f2fe4fdabe022c9e027a41c9e", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 25, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 25}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-d3ba13431815b12b67d43082", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/003984", "medicine_name": "Bortezomib Accord", "medicine_slug": "bortezomib-accord", "observed_at": "2026-10-12T13:47:15Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "150a191aaf0a1e169e9d5fa2530f0eccb4e3d46509faf5ec5ee975a2e67788c4", "source_snapshot_id": "source-cba4680b7fbd2c536884abd8", "source_updated_at": "2026-03-25", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/bortezomib-accord-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 4790}
{"after": {"end": 16, "start": 0, "text": "imed@imed.com.pl", "truncated": false}, "after_length": 16, "after_sha256": "ea84c1c4a48b3783f0be9b72cd284be4ace13bfe979d55d22fedbadbb0b4aff0", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 16, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 16}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-d3da3e0f93a3b2baf6c57959", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:14Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "8b8c4cc8e6f1a21fedee4bf0743c9c03e454b50f5eaba0e3760416d7fe0a74ec", "source_snapshot_id": "source-4efe4ecf3ebf08d338a763a5", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1982}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 22, "start": 0, "text": "Tel : +31 35 528 39 57", "truncated": false}, "before_length": 22, "before_sha256": "7bb8afadf5dee15b4f4e1219e333b993040f0848bccea58b1141990fffb82aa1", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 22, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 22, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-d3f790ab837452846825c44b", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:19Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "77586d0bea0858214b43b86e91abc2d2711733b96959ead5ed0b5ecbd8ed888a", "source_snapshot_id": "source-85d476f9ad959cc117ca8f1f", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1972}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 22, "start": 0, "text": "Τηλ : +31 35 528 39 57", "truncated": false}, "before_length": 22, "before_sha256": "4fc1c78ca72f46f7b8d2c99f2eda4e151fd08c046b983b97e4033a28eff83142", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 22, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 22, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-d40c3be95306ed4b4c023c9f", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:19Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "77586d0bea0858214b43b86e91abc2d2711733b96959ead5ed0b5ecbd8ed888a", "source_snapshot_id": "source-85d476f9ad959cc117ca8f1f", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1997}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 21, "start": 0, "text": "Tel: + 33 153 868 750", "truncated": false}, "before_length": 21, "before_sha256": "efffe29324e968019e6e2b111904182ba06d83e76b1f29b933bed9dd8779c114", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 21, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 21, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-d433f1a2c5698c8148e8c420", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:14Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "8b8c4cc8e6f1a21fedee4bf0743c9c03e454b50f5eaba0e3760416d7fe0a74ec", "source_snapshot_id": "source-4efe4ecf3ebf08d338a763a5", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1483}
{"after": {"end": 61, "start": 0, "text": "When using the pack without toppings, swirl gently and drink.", "truncated": false}, "after_length": 61, "after_sha256": "7fdc1bc6a225d2fea171126c577148f958459f150e82f40c510921829db512b1", "annex": "IIIA", "before": {"end": 60, "start": 0, "text": "When using the pack without toppings, swirl gently and drink", "truncated": false}, "before_length": 60, "before_sha256": "bed372e42b0a5b1402db4c72f971efd44f0525cb6a256d7a33ba106d505e6f21", "change_kind": "content", "change_operations": [{"after_end": 61, "after_start": 60, "before_end": 60, "before_start": 60, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 1}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-d47d243f47ea639392b0dc90", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:14Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "8b8c4cc8e6f1a21fedee4bf0743c9c03e454b50f5eaba0e3760416d7fe0a74ec", "source_snapshot_id": "source-4efe4ecf3ebf08d338a763a5", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1748}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIB", "before": {"end": 16, "start": 0, "text": "Extrovis EU Ltd.", "truncated": false}, "before_length": 16, "before_sha256": "f462ad48e7aef0bc82148ce088af1897d99ed86993128f30d506b27d3108a929", "change_kind": "unassigned", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 16, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 16, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-d47dcb52d95c7c958aa3aebb", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/006047", "medicine_name": "Lacosamide Adroiq", "medicine_slug": "lacosamide-adroiq", "observed_at": "2026-10-12T19:07:56Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "", "section_type": "unassigned", "source_provider": "European Medicines Agency", "source_sha256": "0578c53a5e1c785c4d9d4dc0dabae49dbfa89e237aa571556bee548c3f9cf4d5", "source_snapshot_id": "source-64831dec5ebf55535e19d91b", "source_updated_at": "2025-09-25", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/lacosamide-adroiq-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 2004}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 18, "start": 0, "text": "Dublin 2, D02 T380", "truncated": false}, "before_length": 18, "before_sha256": "23e6871e7960b0dadc753bc127bbea230cc8308c88b2d33704eb275a3ec1a70d", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 18, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 18, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-d48b91236511af08e6e6df9a", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002097", "medicine_name": "Fampyra", "medicine_slug": "fampyra", "observed_at": "2026-10-12T19:15:51Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "d9fe8aaaa611a84801d6308b13685258b5248df9022536697939afdf66fc1719", "source_snapshot_id": "source-ff8e0599077f0d01044dc867", "source_updated_at": "2025-08-21", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/fampyra-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1535}
{"after": {"end": 16, "start": 0, "text": "Extrovis EU Kft.", "truncated": false}, "after_length": 16, "after_sha256": "b9216ef80e71e17798dce313e4318f03f37328f225d30ab508b7413813a908e5", "annex": "IIIB", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "unassigned", "change_operations": [{"after_end": 16, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 16}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-d503bc6ef18f06b9a792609b", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/006047", "medicine_name": "Lacosamide Adroiq", "medicine_slug": "lacosamide-adroiq", "observed_at": "2026-10-12T19:07:56Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "", "section_type": "unassigned", "source_provider": "European Medicines Agency", "source_sha256": "0578c53a5e1c785c4d9d4dc0dabae49dbfa89e237aa571556bee548c3f9cf4d5", "source_snapshot_id": "source-64831dec5ebf55535e19d91b", "source_updated_at": "2025-09-25", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/lacosamide-adroiq-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 2031}
{"after": {"end": 16, "start": 0, "text": "Extrovis EU Kft.", "truncated": false}, "after_length": 16, "after_sha256": "b9216ef80e71e17798dce313e4318f03f37328f225d30ab508b7413813a908e5", "annex": "III", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "unassigned", "change_operations": [{"after_end": 16, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 16}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-d53359ef199308cfc50cb8f6", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/006047", "medicine_name": "Lacosamide Adroiq", "medicine_slug": "lacosamide-adroiq", "observed_at": "2026-10-12T19:07:56Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "", "section_type": "unassigned", "source_provider": "European Medicines Agency", "source_sha256": "0578c53a5e1c785c4d9d4dc0dabae49dbfa89e237aa571556bee548c3f9cf4d5", "source_snapshot_id": "source-64831dec5ebf55535e19d91b", "source_updated_at": "2025-09-25", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/lacosamide-adroiq-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1346}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "II", "before": {"end": 4, "start": 0, "text": "1930", "truncated": false}, "before_length": 4, "before_sha256": "70fa656aa0391eb9ef7bbc9c7e6771ec09e7d5d7ab1fcbbde2480d21263ee79a", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 4, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 4, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-d55ed066f8106a2a1e2611dd", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/004697", "medicine_name": "Zirabev", "medicine_slug": "zirabev", "observed_at": "2026-10-12T19:08:42Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "conditions", "section_type": "conditions", "source_provider": "European Medicines Agency", "source_sha256": "845774ee3d135dcbab2d035e014eb75d076ae724c8a5ea323882196493b05d44", "source_snapshot_id": "source-58a9ecf053a0ab93bbcc0173", "source_updated_at": "2025-09-17", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/zirabev-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 2514}
{"after": {"end": 18, "start": 0, "text": "4844 CK Terheijden", "truncated": false}, "after_length": 18, "after_sha256": "e7ea1ad04b1071e360b652726acc9e8a22118603b55f58e0bd782476a7e47649", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 18, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 18}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-d59572bb12abdb46f995db46", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002097", "medicine_name": "Fampyra", "medicine_slug": "fampyra", "observed_at": "2026-10-12T19:16:07Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "a0c3ba8d58d6a43a809ecc3d142a78b10c2bd7f0b9f3a3553df2617d87daec1f", "source_snapshot_id": "source-c7a810dd21f94cd2d273f0da", "source_updated_at": "2025-08-21", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/fampyra-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1462}
{"after": {"end": 23, "start": 0, "text": "Tel: +49 (0) 69 15 03 0", "truncated": false}, "after_length": 23, "after_sha256": "09683b3f43171b2266a32d9f7d44e3d62d536522dc6f42d4b47f2dda48b31833", "annex": "IIIA", "before": {"end": 23, "start": 0, "text": "Tel: +353 (0)1 231 4609", "truncated": false}, "before_length": 23, "before_sha256": "a115f11f382ef18898b9d956e48603ae236fd1846ce41e8586af99b6dabbfc4d", "change_kind": "content", "change_operations": [{"after_end": 8, "after_start": 6, "before_end": 9, "before_start": 6, "kind": "replace"}, {"after_end": 16, "after_start": 12, "before_end": 13, "before_start": 13, "kind": "insert"}, {"after_end": 18, "after_start": 17, "before_end": 14, "before_start": 14, "kind": "insert"}, {"after_end": 20, "after_start": 19, "before_end": 16, "before_start": 15, "kind": "replace"}, {"after_end": 21, "after_start": 21, "before_end": 18, "before_start": 17, "kind": "delete"}, {"after_end": 22, "after_start": 22, "before_end": 21, "before_start": 19, "kind": "delete"}, {"after_end": 23, "after_start": 23, "before_end": 23, "before_start": 22, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 8, "chars_inserted": 8}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-d5a4658eb28ca17a4dadac9d", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002097", "medicine_name": "Fampyra", "medicine_slug": "fampyra", "observed_at": "2026-10-12T19:16:07Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "a0c3ba8d58d6a43a809ecc3d142a78b10c2bd7f0b9f3a3553df2617d87daec1f", "source_snapshot_id": "source-c7a810dd21f94cd2d273f0da", "source_updated_at": "2025-08-21", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/fampyra-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1391}
{"after": {"end": 25, "start": 0, "text": "Eurocept International BV", "truncated": false}, "after_length": 25, "after_sha256": "b17bd89b3cf285c986a6070d0d67f5326dd5c1f08a70834c296c6c820f9e7505", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 25, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 25}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-d5aae9959a929536bd4540f3", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:19Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "77586d0bea0858214b43b86e91abc2d2711733b96959ead5ed0b5ecbd8ed888a", "source_snapshot_id": "source-85d476f9ad959cc117ca8f1f", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1405}
{"after": {"end": 22, "start": 0, "text": "Merz Therapeutics GmbH", "truncated": false}, "after_length": 22, "after_sha256": "059f049c7d0846aaadcf2573280d52110f302d4ecc7b38debd004571cd1e9d5e", "annex": "IIIA", "before": {"end": 35, "start": 0, "text": "Acorda Therapeutics Ireland Limited", "truncated": false}, "before_length": 35, "before_sha256": "d94d3153d193ed26567f2b4ed48df016d81c534e7c0cb1a6655a63f0083383ff", "change_kind": "content", "change_operations": [{"after_end": 2, "after_start": 0, "before_end": 3, "before_start": 0, "kind": "replace"}, {"after_end": 4, "after_start": 3, "before_end": 6, "before_start": 4, "kind": "replace"}, {"after_end": 19, "after_start": 18, "before_end": 30, "before_start": 20, "kind": "replace"}, {"after_end": 22, "after_start": 20, "before_end": 35, "before_start": 31, "kind": "replace"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 19, "chars_inserted": 6}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-d611d19dbf67eaa70c4495ac", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002097", "medicine_name": "Fampyra", "medicine_slug": "fampyra", "observed_at": "2026-10-12T19:15:51Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "d9fe8aaaa611a84801d6308b13685258b5248df9022536697939afdf66fc1719", "source_snapshot_id": "source-ff8e0599077f0d01044dc867", "source_updated_at": "2025-08-21", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/fampyra-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1479}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 5, "start": 0, "text": "Irska", "truncated": false}, "before_length": 5, "before_sha256": "cdf0cd77f332e6161d4630ec3fed3ecf30c6b67caf2a1d2468282a1045c12636", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 5, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 5, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-d619b56448d5a7aa1ef13230", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002097", "medicine_name": "Fampyra", "medicine_slug": "fampyra", "observed_at": "2026-10-12T19:15:51Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "d9fe8aaaa611a84801d6308b13685258b5248df9022536697939afdf66fc1719", "source_snapshot_id": "source-ff8e0599077f0d01044dc867", "source_updated_at": "2025-08-21", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/fampyra-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1555}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 21, "start": 0, "text": "info@lucanepharma.com", "truncated": false}, "before_length": 21, "before_sha256": "44fd39e5fb919cb3d680fa630da23b49238fec29159c509f3622f272bb41c7c6", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 21, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 21, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-d6203f337ad68579b653adda", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:19Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "77586d0bea0858214b43b86e91abc2d2711733b96959ead5ed0b5ecbd8ed888a", "source_snapshot_id": "source-85d476f9ad959cc117ca8f1f", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1823}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 20, "start": 0, "text": "10 Earlsfort Terrace", "truncated": false}, "before_length": 20, "before_sha256": "22951bbf6ee77815d0c07b3af5f0a66e17d277636971c4eaff372dea65dcb193", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 20, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 20, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-d627d412782c4ccaba25ee5c", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002097", "medicine_name": "Fampyra", "medicine_slug": "fampyra", "observed_at": "2026-10-12T19:16:07Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "a0c3ba8d58d6a43a809ecc3d142a78b10c2bd7f0b9f3a3553df2617d87daec1f", "source_snapshot_id": "source-c7a810dd21f94cd2d273f0da", "source_updated_at": "2025-08-21", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/fampyra-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1622}
{"after": {"end": 14, "start": 0, "text": "Hallucination*", "truncated": false}, "after_length": 14, "after_sha256": "b5feb0253dc60e46de934da2e507a42e3fd02688dbb6bca5220b99ffc3db83b2", "annex": "I", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 14, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": true, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 14}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-d64d8ef72182ec697536fb6a", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/000554", "medicine_name": "Emselex", "medicine_slug": "emselex", "observed_at": "2026-10-12T19:12:04Z", "pipeline_version": "2.0.0", "presentation_label": "Emselex 15 mg prolonged-release tablets", "presentation_occurrence": 2, "presentation_status": "heading_extracted_unverified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "4.8", "section_type": "adverse_reactions", "source_provider": "European Medicines Agency", "source_sha256": "4f2565612bc728ec67b7f9c0cd5799ef2c594911c76f323aef8bf6a85adde245", "source_snapshot_id": "source-1fda25b331eb198b8b93feb3", "source_updated_at": "2025-09-15", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/emselex-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 606}
{"after": {"end": 25, "start": 0, "text": "Eurocept International BV", "truncated": false}, "after_length": 25, "after_sha256": "b17bd89b3cf285c986a6070d0d67f5326dd5c1f08a70834c296c6c820f9e7505", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 25, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 25}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-d65ee477da2d1f6acb987c26", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:14Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "8b8c4cc8e6f1a21fedee4bf0743c9c03e454b50f5eaba0e3760416d7fe0a74ec", "source_snapshot_id": "source-4efe4ecf3ebf08d338a763a5", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1597}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 18, "start": 0, "text": "Dublin 2, D02 T380", "truncated": false}, "before_length": 18, "before_sha256": "23e6871e7960b0dadc753bc127bbea230cc8308c88b2d33704eb275a3ec1a70d", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 18, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 18, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-d665ed201d6a1c64ca30efe4", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002097", "medicine_name": "Fampyra", "medicine_slug": "fampyra", "observed_at": "2026-10-12T19:15:51Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "d9fe8aaaa611a84801d6308b13685258b5248df9022536697939afdf66fc1719", "source_snapshot_id": "source-ff8e0599077f0d01044dc867", "source_updated_at": "2025-08-21", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/fampyra-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1463}
{"after": {"end": 26, "start": 0, "text": "Tél/Tel: +31 (0) 762057088", "truncated": false}, "after_length": 26, "after_sha256": "3bc75506c55c8b7cd4fff8d2140ba08d71ae9e9c73edbd7c8810587852e9e7f9", "annex": "IIIA", "before": {"end": 27, "start": 0, "text": "Tél/Tel: +353 (0)1 231 4609", "truncated": false}, "before_length": 27, "before_sha256": "87104ca41090d27d4255b5464c46bf8c8c6fca2440bf6dae9e31ce28d2ad406a", "change_kind": "content", "change_operations": [{"after_end": 12, "after_start": 11, "before_end": 13, "before_start": 11, "kind": "replace"}, {"after_end": 16, "after_start": 16, "before_end": 18, "before_start": 17, "kind": "delete"}, {"after_end": 19, "after_start": 17, "before_end": 19, "before_start": 19, "kind": "insert"}, {"after_end": 20, "after_start": 20, "before_end": 25, "before_start": 20, "kind": "delete"}, {"after_end": 26, "after_start": 21, "before_end": 27, "before_start": 26, "kind": "replace"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 9, "chars_inserted": 8}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-d684dbffdc6777d9b409de5b", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002097", "medicine_name": "Fampyra", "medicine_slug": "fampyra", "observed_at": "2026-10-12T19:15:51Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "d9fe8aaaa611a84801d6308b13685258b5248df9022536697939afdf66fc1719", "source_snapshot_id": "source-ff8e0599077f0d01044dc867", "source_updated_at": "2025-08-21", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/fampyra-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1375}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 33, "start": 0, "text": "United Kingdom (Northern Ireland)", "truncated": false}, "before_length": 33, "before_sha256": "9379d82927cdb505cfb186e912177065e56a1314de3a2b914ebbb8b5fe21525a", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 33, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 33, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-d687444961c7a2019c304e7c", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002702", "medicine_name": "Hexacima", "medicine_slug": "hexacima", "observed_at": "2026-10-12T19:07:04Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "44c8996457a718019c75b8322ba07a5ae7af36377b1a6f1cf4ca5a30f9b72c23", "source_snapshot_id": "source-fa766d966dea704c333b9969", "source_updated_at": "2025-09-29", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/hexacima-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1701}
{"after": {"end": 23, "start": 0, "text": "info@euroceptpharma.com", "truncated": false}, "after_length": 23, "after_sha256": "9297cc5acdcc837f054116992765943f7907937507b2564a99ea1327a00ac0e6", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 23, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 23}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-d696fdf82df3ccfd26464ac7", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:19Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "77586d0bea0858214b43b86e91abc2d2711733b96959ead5ed0b5ecbd8ed888a", "source_snapshot_id": "source-85d476f9ad959cc117ca8f1f", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1828}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 16, "start": 0, "text": "Extrovis EU Ltd.", "truncated": false}, "before_length": 16, "before_sha256": "f462ad48e7aef0bc82148ce088af1897d99ed86993128f30d506b27d3108a929", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 16, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 16, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-d6bc95b92be200521fea5e16", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/006047", "medicine_name": "Lacosamide Adroiq", "medicine_slug": "lacosamide-adroiq", "observed_at": "2026-10-12T19:07:59Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "cc83d966059d42856d0211a4f256b29b20d43593865704d6a9315aeb694f3c76", "source_snapshot_id": "source-896abba1d8391c918345d46b", "source_updated_at": "2025-09-25", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/lacosamide-adroiq-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1211}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 16, "start": 0, "text": "6336 Langkampfen", "truncated": false}, "before_length": 16, "before_sha256": "b9f18afdf777127453e8278d60cb7f5e3f22a29760be53f0595ada54a24f6ad2", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 16, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 16, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-d6f09adb114d48f4d34b4ad4", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/000725", "medicine_name": "Binocrit", "medicine_slug": "binocrit", "observed_at": "2026-10-12T19:29:33Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "2110517cc45ca102ca5957f2578ba74090631cf709d5be3e5f6e34712f237bdb", "source_snapshot_id": "source-63ba5976f2b2d4350a9afd16", "source_updated_at": "2025-07-11", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/binocrit-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 3386}
{"after": {"end": 5, "start": 0, "text": "Grèce", "truncated": false}, "after_length": 5, "after_sha256": "9a953a79ebdbc073046b47e64c16f1b45fce0df4f6acef8c7c40ffb97cf8997c", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 5, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 5}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-d718d290c4bbf95349f438c5", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/003984", "medicine_name": "Bortezomib Accord", "medicine_slug": "bortezomib-accord", "observed_at": "2026-10-12T13:47:15Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "150a191aaf0a1e169e9d5fa2530f0eccb4e3d46509faf5ec5ee975a2e67788c4", "source_snapshot_id": "source-cba4680b7fbd2c536884abd8", "source_updated_at": "2026-03-25", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/bortezomib-accord-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 4791}
{"after": {"end": 26, "start": 0, "text": "Tél/Tel: +31 (0) 762057088", "truncated": false}, "after_length": 26, "after_sha256": "3bc75506c55c8b7cd4fff8d2140ba08d71ae9e9c73edbd7c8810587852e9e7f9", "annex": "IIIA", "before": {"end": 27, "start": 0, "text": "Tél/Tel: +353 (0)1 231 4609", "truncated": false}, "before_length": 27, "before_sha256": "87104ca41090d27d4255b5464c46bf8c8c6fca2440bf6dae9e31ce28d2ad406a", "change_kind": "content", "change_operations": [{"after_end": 12, "after_start": 11, "before_end": 13, "before_start": 11, "kind": "replace"}, {"after_end": 16, "after_start": 16, "before_end": 18, "before_start": 17, "kind": "delete"}, {"after_end": 19, "after_start": 17, "before_end": 19, "before_start": 19, "kind": "insert"}, {"after_end": 20, "after_start": 20, "before_end": 25, "before_start": 20, "kind": "delete"}, {"after_end": 26, "after_start": 21, "before_end": 27, "before_start": 26, "kind": "replace"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 9, "chars_inserted": 8}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-d72ad16ebf06a6b3520ede08", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002097", "medicine_name": "Fampyra", "medicine_slug": "fampyra", "observed_at": "2026-10-12T19:16:07Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "a0c3ba8d58d6a43a809ecc3d142a78b10c2bd7f0b9f3a3553df2617d87daec1f", "source_snapshot_id": "source-c7a810dd21f94cd2d273f0da", "source_updated_at": "2025-08-21", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/fampyra-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1411}
{"after": {"end": 22, "start": 0, "text": "Fréquence indéterminée", "truncated": false}, "after_length": 22, "after_sha256": "9dbca2ea64869864cf27be15cb397d59f7675843792a00e126385e734d3768e0", "annex": "I", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 22, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": true, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 22}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-d733d4af5e2778575e5ce47b", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/000554", "medicine_name": "Emselex", "medicine_slug": "emselex", "observed_at": "2026-10-12T19:12:07Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": null, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "4.8", "section_type": "adverse_reactions", "source_provider": "European Medicines Agency", "source_sha256": "9a4f1d7e260c7b80eaf397503623b63302e5945b579e9612177835e07c4ab888", "source_snapshot_id": "source-3aac7bf42b99529f25ac013b", "source_updated_at": "2025-09-15", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/emselex-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 213}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIB", "before": {"end": 16, "start": 0, "text": "Extrovis EU Ltd.", "truncated": false}, "before_length": 16, "before_sha256": "f462ad48e7aef0bc82148ce088af1897d99ed86993128f30d506b27d3108a929", "change_kind": "unassigned", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 16, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 16, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-d76949920297facdf1d191a3", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/006047", "medicine_name": "Lacosamide Adroiq", "medicine_slug": "lacosamide-adroiq", "observed_at": "2026-10-12T19:07:56Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "", "section_type": "unassigned", "source_provider": "European Medicines Agency", "source_sha256": "0578c53a5e1c785c4d9d4dc0dabae49dbfa89e237aa571556bee548c3f9cf4d5", "source_snapshot_id": "source-64831dec5ebf55535e19d91b", "source_updated_at": "2025-09-25", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/lacosamide-adroiq-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1857}
{"after": {"end": 23, "start": 0, "text": "Tel: +49 (0) 69 15 03 0", "truncated": false}, "after_length": 23, "after_sha256": "09683b3f43171b2266a32d9f7d44e3d62d536522dc6f42d4b47f2dda48b31833", "annex": "IIIA", "before": {"end": 23, "start": 0, "text": "Tel: +353 (0)1 231 4609", "truncated": false}, "before_length": 23, "before_sha256": "a115f11f382ef18898b9d956e48603ae236fd1846ce41e8586af99b6dabbfc4d", "change_kind": "content", "change_operations": [{"after_end": 8, "after_start": 6, "before_end": 9, "before_start": 6, "kind": "replace"}, {"after_end": 16, "after_start": 12, "before_end": 13, "before_start": 13, "kind": "insert"}, {"after_end": 18, "after_start": 17, "before_end": 14, "before_start": 14, "kind": "insert"}, {"after_end": 20, "after_start": 19, "before_end": 16, "before_start": 15, "kind": "replace"}, {"after_end": 21, "after_start": 21, "before_end": 18, "before_start": 17, "kind": "delete"}, {"after_end": 22, "after_start": 22, "before_end": 21, "before_start": 19, "kind": "delete"}, {"after_end": 23, "after_start": 23, "before_end": 23, "before_start": 22, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 8, "chars_inserted": 8}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-d7815b808d0b5c68f19f4deb", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002097", "medicine_name": "Fampyra", "medicine_slug": "fampyra", "observed_at": "2026-10-12T19:15:51Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "d9fe8aaaa611a84801d6308b13685258b5248df9022536697939afdf66fc1719", "source_snapshot_id": "source-ff8e0599077f0d01044dc867", "source_updated_at": "2025-08-21", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/fampyra-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1578}
{"after": {"end": 644, "start": 0, "text": "Myositis and /or rhabdomyolysis have been reported in patients treated with leflunomide, frequently in combination with other immunosuppressive drugs. Clinical symptoms may include unexplained muscle pain, tenderness or muscle weakness. Patients should be informed about the signs and symptoms associated with myositis and rhabdomyolysis and advised to seek medical attention immediately if such symptoms occur during leflunomide treatment. Monitor the patients for elevation of CK levels if clinically indicated. If patients develop any of these conditions, leflunomide must be discontinued and a washout procedure initiated (see section 4.4).", "truncated": false}, "after_length": 644, "after_sha256": "54416fa80b2720b6142b9cb375a3b6e04c26b8a363a88b57c6bfcd4d9d1e672b", "annex": "I", "before": {"end": 135, "start": 0, "text": "Myopathy muscle injury has with leflunomide treatment. Follow-up with patients periodically for muscle pain and weakness. as necessary.", "truncated": false}, "before_length": 135, "before_sha256": "a9c5aa43249002e83964883b90965cb0316721089889783990eedc99707d282f", "change_kind": "content", "change_operations": [{"after_end": 54, "after_start": 3, "before_end": 3, "before_start": 3, "kind": "insert"}, {"after_end": 74, "after_start": 57, "before_end": 6, "before_start": 6, "kind": "insert"}, {"after_end": 98, "after_start": 75, "before_end": 7, "before_start": 7, "kind": "insert"}, {"after_end": 192, "after_start": 99, "before_end": 8, "before_start": 8, "kind": "insert"}, {"after_end": 202, "after_start": 200, "before_end": 16, "before_start": 16, "kind": "insert"}, {"after_end": 221, "after_start": 204, "before_end": 19, "before_start": 18, "kind": "replace"}, {"after_end": 260, "after_start": 222, "before_end": 20, "before_start": 20, "kind": "insert"}, {"after_end": 286, "after_start": 261, "before_end": 21, "before_start": 21, "kind": "insert"}, {"after_end": 293, "after_start": 287, "before_end": 22, "before_start": 22, "kind": "insert"}, {"after_end": 294, "after_start": 294, "before_end": 24, "before_start": 23, "kind": "delete"}, {"after_end": 304, "after_start": 296, "before_end": 26, "before_start": 26, "kind": "insert"}, {"after_end": 417, "after_start": 309, "before_end": 31, "before_start": 31, "kind": "insert"}, {"after_end": 442, "after_start": 441, "before_end": 56, "before_start": 55, "kind": "replace"}, {"after_end": 444, "after_start": 443, "before_end": 66, "before_start": 57, "kind": "replace"}, {"after_end": 450, "after_start": 446, "before_end": 68, "before_start": 68, "kind": "insert"}, {"after_end": 452, "after_start": 451, "before_end": 69, "before_start": 69, "kind": "insert"}, {"after_end": 466, "after_start": 462, "before_end": 80, "before_start": 79, "kind": "replace"}, {"after_end": 472, "after_start": 467, "before_end": 82, "before_start": 81, "kind": "replace"}, {"after_end": 496, "after_start": 474, "before_end": 85, "before_start": 84, "kind": "replace"}, {"after_end": 515, "after_start": 503, "before_end": 92, "before_start": 92, "kind": "insert"}, {"after_end": 531, "after_start": 516, "before_end": 93, "before_start": 93, "kind": "insert"}, {"after_end": 570, "after_start": 532, "before_end": 95, "before_start": 94, "kind": "replace"}, {"after_end": 577, "after_start": 574, "before_end": 101, "before_start": 99, "kind": "replace"}, {"after_end": 586, "after_start": 579, "before_end": 105, "before_start": 103, "kind": "replace"}, {"after_end": 591, "after_start": 588, "before_end": 107, "before_start": 107, "kind": "insert"}, {"after_end": 598, "after_start": 596, "before_end": 112, "before_start": 112, "kind": "insert"}, {"after_end": 599, "after_start": 599, "before_end": 122, "before_start": 113, "kind": "delete"}, {"after_end": 605, "after_start": 601, "before_end": 124, "before_start": 124, "kind": "insert"}, {"after_end": 617, "after_start": 606, "before_end": 125, "before_start": 125, "kind": "insert"}, {"after_end": 632, "after_start": 618, "before_end": 126, "before_start": 126, "kind": "insert"}, {"after_end": 643, "after_start": 634, "before_end": 134, "before_start": 128, "kind": "replace"}], "classification_method": "documentary_rules_v2", "clinical_candidate": true, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 35, "chars_inserted": 544}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-d7886dc5ba37dad81b77c246", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/000235", "medicine_name": "Arava", "medicine_slug": "arava", "observed_at": "2026-10-12T13:27:58Z", "pipeline_version": "2.0.0", "presentation_label": "Arava 10 mg film-coated tablets", "presentation_occurrence": 1, "presentation_status": "heading_extracted_unverified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "4.4", "section_type": "warning", "source_provider": "European Medicines Agency", "source_sha256": "2efff7967e2237bf8343431eef5e08b56c2441eb8a691a90c64b2635109fd697", "source_snapshot_id": "source-08b4eba1f67d2654148f41c4", "source_updated_at": "2026-09-07", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/arava-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 184}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIB", "before": {"end": 33, "start": 0, "text": "United Kingdom (Northern Ireland)", "truncated": false}, "before_length": 33, "before_sha256": "9379d82927cdb505cfb186e912177065e56a1314de3a2b914ebbb8b5fe21525a", "change_kind": "unassigned", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 33, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 33, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-d82b7d69bf54c3d7cb387180", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/006047", "medicine_name": "Lacosamide Adroiq", "medicine_slug": "lacosamide-adroiq", "observed_at": "2026-10-12T19:07:56Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "", "section_type": "unassigned", "source_provider": "European Medicines Agency", "source_sha256": "0578c53a5e1c785c4d9d4dc0dabae49dbfa89e237aa571556bee548c3f9cf4d5", "source_snapshot_id": "source-64831dec5ebf55535e19d91b", "source_updated_at": "2025-09-25", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/lacosamide-adroiq-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 2035}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 21, "start": 0, "text": "Tel: +31 35 528 39 57", "truncated": false}, "before_length": 21, "before_sha256": "7baf6601f41e49e470f803fdd4e755a86efa38be423317c000ed79963ebdd213", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 21, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 21, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-d842ef8719106ffb15d3bb18", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:14Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "8b8c4cc8e6f1a21fedee4bf0743c9c03e454b50f5eaba0e3760416d7fe0a74ec", "source_snapshot_id": "source-4efe4ecf3ebf08d338a763a5", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 2002}
{"after": {"end": 17, "start": 0, "text": "Tlf: +46 8 368000", "truncated": false}, "after_length": 17, "after_sha256": "f05e1f0a3ce4f37db4216310bafc5f59464b812748444615fe40c193a9c52c41", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 17, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 17}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-d8edc21f851d72172ad3a818", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002097", "medicine_name": "Fampyra", "medicine_slug": "fampyra", "observed_at": "2026-10-12T19:15:51Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "d9fe8aaaa611a84801d6308b13685258b5248df9022536697939afdf66fc1719", "source_snapshot_id": "source-ff8e0599077f0d01044dc867", "source_updated_at": "2025-08-21", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/fampyra-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1595}
{"after": {"end": 25, "start": 0, "text": "Eurocept International BV", "truncated": false}, "after_length": 25, "after_sha256": "b17bd89b3cf285c986a6070d0d67f5326dd5c1f08a70834c296c6c820f9e7505", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 25, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 25}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-d902c130b9f2f4445b31ebaf", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:14Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "8b8c4cc8e6f1a21fedee4bf0743c9c03e454b50f5eaba0e3760416d7fe0a74ec", "source_snapshot_id": "source-4efe4ecf3ebf08d338a763a5", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1484}
{"after": {"end": 464, "start": 0, "text": "Au vu des données disponibles sur le(s) risque(s) issues de la littérature et des notifications spontanées, dont 2 cas avec « de-challenge » positif, « re-challenge » positif et délai d’apparition compatible, 5 cas avec délai d’apparition compatible et « de-challenge » positif et 13 autres cas en relation temporelle étroite, le PRAC estime qu’un lien de causalité entre la darifénacine et la survenue de spasmes musculaires est au moins raisonnablement possible.", "truncated": false}, "after_length": 464, "after_sha256": "cfda82e3dd8ecb1a3c09d9b2c16525c63234ce54bd8fd08745cd2b7ffd556fd3", "annex": "IV", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 464, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 464}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-d971cd3df4e4decf502dd696", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/000554", "medicine_name": "Emselex", "medicine_slug": "emselex", "observed_at": "2026-10-12T19:12:07Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": null, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "conditions", "section_type": "conditions", "source_provider": "European Medicines Agency", "source_sha256": "9a4f1d7e260c7b80eaf397503623b63302e5945b579e9612177835e07c4ab888", "source_snapshot_id": "source-3aac7bf42b99529f25ac013b", "source_updated_at": "2025-09-15", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/emselex-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 2068}
{"after": {"end": 810, "start": 0, "text": "Des cas de myosite et/ou de rhabdomyolyse ont été rapportés chez des patients traités par le léflunomide, souvent en association avec d'autres médicaments immunosuppresseurs. Les symptômes cliniques peuvent inclure des douleurs musculaires inexpliquées, une sensibilité ou une faiblesse musculaire. Les patients doivent être informés des signes et des symptômes associés à la myosite et à la rhabdomyolyse et ils doivent consulter immédiatement un médecin si de tels symptômes surviennent au cours du traitement par le léflunomide. L’élévation des taux de créatine kinase doit être surveillée chez les patients selon leur situation clinique. Si les patients développent l'une de ces manifestations, le léflunomide doit être arrêté et une procédure d'élimination accélérée doit être initiée (voir rubrique 4.4).", "truncated": false}, "after_length": 810, "after_sha256": "cc10a5be2b707546b777c939543f700115911fa1a843b097c61bccdf668a3cf8", "annex": "I", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 810, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": true, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 810}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-da328b42efa8e454210e52fb", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/000235", "medicine_name": "Arava", "medicine_slug": "arava", "observed_at": "2026-10-12T13:28:00Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": null, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "4.4", "section_type": "warning", "source_provider": "European Medicines Agency", "source_sha256": "98b73c5c6b1e5009c9d048f8f11257f3a8407759fd25a4c8d5ef5c611519e916", "source_snapshot_id": "source-4b7ea3b78addea82376b3432", "source_updated_at": "2026-09-07", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/arava-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 177}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 8, "start": 0, "text": "Írország", "truncated": false}, "before_length": 8, "before_sha256": "17626bbbdd692796fd93bdfc39a5853f3960883d102671585b9599a86d5b229b", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 8, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 8, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-da49a3ec389c6179476dd393", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002097", "medicine_name": "Fampyra", "medicine_slug": "fampyra", "observed_at": "2026-10-12T19:16:07Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "a0c3ba8d58d6a43a809ecc3d142a78b10c2bd7f0b9f3a3553df2617d87daec1f", "source_snapshot_id": "source-c7a810dd21f94cd2d273f0da", "source_updated_at": "2025-08-21", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/fampyra-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1427}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 27, "start": 0, "text": "(Eurocept International BV)", "truncated": false}, "before_length": 27, "before_sha256": "e6cf9b20aaa466e53ad0d393512ca75931e13e488321e3be6f3e4f8b600970c8", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 27, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 27, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-da4fa72466976978a9ba9dab", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:14Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "8b8c4cc8e6f1a21fedee4bf0743c9c03e454b50f5eaba0e3760416d7fe0a74ec", "source_snapshot_id": "source-4efe4ecf3ebf08d338a763a5", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 2052}
{"after": {"end": 23, "start": 0, "text": "info@euroceptpharma.com", "truncated": false}, "after_length": 23, "after_sha256": "9297cc5acdcc837f054116992765943f7907937507b2564a99ea1327a00ac0e6", "annex": "IIIA", "before": {"end": 13, "start": 0, "text": "Lucane Pharma", "truncated": false}, "before_length": 13, "before_sha256": "e338afdb64acf1a6e2083a50318853589248451dd3aa707181ba02641a8521e8", "change_kind": "content", "change_operations": [{"after_end": 6, "after_start": 0, "before_end": 1, "before_start": 0, "kind": "replace"}, {"after_end": 9, "after_start": 7, "before_end": 2, "before_start": 2, "kind": "insert"}, {"after_end": 10, "after_start": 10, "before_end": 5, "before_start": 3, "kind": "delete"}, {"after_end": 14, "after_start": 11, "before_end": 8, "before_start": 6, "kind": "replace"}, {"after_end": 23, "after_start": 19, "before_end": 13, "before_start": 13, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 5, "chars_inserted": 15}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-da5533ca0f1f6acb5442c897", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:19Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "77586d0bea0858214b43b86e91abc2d2711733b96959ead5ed0b5ecbd8ed888a", "source_snapshot_id": "source-85d476f9ad959cc117ca8f1f", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1381}
{"after": {"end": 134, "start": 0, "text": "Detailed information on this medicinal product is available on the website of the European Medicines Agency https://www.ema.europa.eu.", "truncated": false}, "after_length": 134, "after_sha256": "9f2a855337f11701b0cd4191c51820fa5a70b201b2e0721ba6acd34544486f89", "annex": "I", "before": {"end": 133, "start": 0, "text": "Detailed information on this medicinal product is available on the website of the European Medicines Agency http://www.ema.europa.eu.", "truncated": false}, "before_length": 133, "before_sha256": "eabdb61a543e11ee016c5c43ada549964199ddf9e287a2eb3256e15d4a87fe4a", "change_kind": "technical", "change_operations": [{"after_end": 113, "after_start": 112, "before_end": 112, "before_start": 112, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 1}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-da5c4ac3e604bb4810179151", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/001021", "medicine_name": "Adcirca (previously Tadalafil Lilly)", "medicine_slug": "adcirca-previously-tadalafil-lilly", "observed_at": "2026-10-12T19:02:42Z", "pipeline_version": "2.0.0", "presentation_label": "ADCIRCA 20 mg film-coated tablets", "presentation_occurrence": 1, "presentation_status": "heading_extracted_unverified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "10", "section_type": "administrative", "source_provider": "European Medicines Agency", "source_sha256": "43438c8e53504a78747a8ff36049250fee294557f3a8b0e3acb80f71ad43ebc0", "source_snapshot_id": "source-2305a67bd1e393ee340bb8e4", "source_updated_at": "2026-01-28", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/adcirca-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 632}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 22, "start": 0, "text": "Teл.: +31 35 528 39 57", "truncated": false}, "before_length": 22, "before_sha256": "48ea1f01d1f8b280a575b1ed256b0fcaa8b12dad56a82e5f7c422885f8c352c8", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 22, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 22, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-da5f110c765d4f24406037e0", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:14Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "8b8c4cc8e6f1a21fedee4bf0743c9c03e454b50f5eaba0e3760416d7fe0a74ec", "source_snapshot_id": "source-4efe4ecf3ebf08d338a763a5", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1873}
{"after": {"end": 28, "start": 0, "text": "InfoDeutschland@dipharma.com", "truncated": false}, "after_length": 28, "after_sha256": "f5ed16f98f15b7236207edade83fdde3fb32cec02f927aaba23223b9f6077f21", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 28, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 28}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-dacf4bb566e7903d82f55b22", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:19Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "77586d0bea0858214b43b86e91abc2d2711733b96959ead5ed0b5ecbd8ed888a", "source_snapshot_id": "source-85d476f9ad959cc117ca8f1f", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1431}
{"after": {"end": 26, "start": 0, "text": "Dipharma Arzneimittel GmbH", "truncated": false}, "after_length": 26, "after_sha256": "d8cb257047b7439a3be44a22f3227e45df27054340bbfa9cd6525bbf1d237add", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 26, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 26}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-dae6d20b050b0226a750998c", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:14Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "8b8c4cc8e6f1a21fedee4bf0743c9c03e454b50f5eaba0e3760416d7fe0a74ec", "source_snapshot_id": "source-4efe4ecf3ebf08d338a763a5", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1519}
{"after": {"end": 25, "start": 0, "text": "Eurocept International BV", "truncated": false}, "after_length": 25, "after_sha256": "b17bd89b3cf285c986a6070d0d67f5326dd5c1f08a70834c296c6c820f9e7505", "annex": "IIIA", "before": {"end": 21, "start": 0, "text": "info@lucanepharma.com", "truncated": false}, "before_length": 21, "before_sha256": "44fd39e5fb919cb3d680fa630da23b49238fec29159c509f3622f272bb41c7c6", "change_kind": "content", "change_operations": [{"after_end": 3, "after_start": 0, "before_end": 3, "before_start": 0, "kind": "replace"}, {"after_end": 4, "after_start": 4, "before_end": 7, "before_start": 4, "kind": "delete"}, {"after_end": 5, "after_start": 5, "before_end": 10, "before_start": 8, "kind": "delete"}, {"after_end": 15, "after_start": 7, "before_end": 13, "before_start": 12, "kind": "replace"}, {"after_end": 20, "after_start": 16, "before_end": 16, "before_start": 14, "kind": "replace"}, {"after_end": 25, "after_start": 21, "before_end": 21, "before_start": 17, "kind": "replace"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 15, "chars_inserted": 19}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-daee7c345df9263f266baad3", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:14Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "8b8c4cc8e6f1a21fedee4bf0743c9c03e454b50f5eaba0e3760416d7fe0a74ec", "source_snapshot_id": "source-4efe4ecf3ebf08d338a763a5", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1440}
{"after": {"end": 41, "start": 0, "text": "Humeur dépressive/altération de l’humeur*", "truncated": false}, "after_length": 41, "after_sha256": "dd5c3e4accf22b1df1479bc3e64bb39bdc164eb5a426916bd455e1de8bd49ab4", "annex": "I", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 41, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": true, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 41}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-db1ee7a48d5f58738cf49e87", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/000554", "medicine_name": "Emselex", "medicine_slug": "emselex", "observed_at": "2026-10-12T19:12:07Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": null, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "4.8", "section_type": "adverse_reactions", "source_provider": "European Medicines Agency", "source_sha256": "9a4f1d7e260c7b80eaf397503623b63302e5945b579e9612177835e07c4ab888", "source_snapshot_id": "source-3aac7bf42b99529f25ac013b", "source_updated_at": "2025-09-15", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/emselex-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 179}
{"after": {"end": 23, "start": 0, "text": "info@euroceptpharma.com", "truncated": false}, "after_length": 23, "after_sha256": "9297cc5acdcc837f054116992765943f7907937507b2564a99ea1327a00ac0e6", "annex": "IIIA", "before": {"end": 13, "start": 0, "text": "Lucane Pharma", "truncated": false}, "before_length": 13, "before_sha256": "e338afdb64acf1a6e2083a50318853589248451dd3aa707181ba02641a8521e8", "change_kind": "content", "change_operations": [{"after_end": 6, "after_start": 0, "before_end": 1, "before_start": 0, "kind": "replace"}, {"after_end": 9, "after_start": 7, "before_end": 2, "before_start": 2, "kind": "insert"}, {"after_end": 10, "after_start": 10, "before_end": 5, "before_start": 3, "kind": "delete"}, {"after_end": 14, "after_start": 11, "before_end": 8, "before_start": 6, "kind": "replace"}, {"after_end": 23, "after_start": 19, "before_end": 13, "before_start": 13, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 5, "chars_inserted": 15}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-db6131da67134630cfa37ce0", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:19Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "77586d0bea0858214b43b86e91abc2d2711733b96959ead5ed0b5ecbd8ed888a", "source_snapshot_id": "source-85d476f9ad959cc117ca8f1f", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1425}
{"after": {"end": 16, "start": 0, "text": "Extrovis EU Kft.", "truncated": false}, "after_length": 16, "after_sha256": "b9216ef80e71e17798dce313e4318f03f37328f225d30ab508b7413813a908e5", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 16, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 16}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-db9301cb6c733cbcbc5d4d34", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/006047", "medicine_name": "Lacosamide Adroiq", "medicine_slug": "lacosamide-adroiq", "observed_at": "2026-10-12T19:07:59Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "cc83d966059d42856d0211a4f256b29b20d43593865704d6a9315aeb694f3c76", "source_snapshot_id": "source-896abba1d8391c918345d46b", "source_updated_at": "2025-09-25", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/lacosamide-adroiq-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1706}
{"after": {"end": 25, "start": 0, "text": "Gustav III:s Boulevard 32", "truncated": false}, "after_length": 25, "after_sha256": "bba3ec2bf3d09014ee723cdd39b8fa83a1dc3705ce0797ed375b3af7c8be027c", "annex": "IIIA", "before": {"end": 25, "start": 0, "text": "Gustav III S Boulevard 32", "truncated": false}, "before_length": 25, "before_sha256": "6117fe99f25fb7a4848fea16fe447d9ead174e8fb74f0ec2aaad6366c885562b", "change_kind": "content", "change_operations": [{"after_end": 12, "after_start": 10, "before_end": 12, "before_start": 10, "kind": "replace"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 2, "chars_inserted": 2}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-dc3934c1f07405557bfbe914", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002097", "medicine_name": "Fampyra", "medicine_slug": "fampyra", "observed_at": "2026-10-12T19:15:51Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "d9fe8aaaa611a84801d6308b13685258b5248df9022536697939afdf66fc1719", "source_snapshot_id": "source-ff8e0599077f0d01044dc867", "source_updated_at": "2025-08-21", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/fampyra-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1472}
{"after": {"end": 17, "start": 0, "text": "Torokbalint, 2045", "truncated": false}, "after_length": 17, "after_sha256": "d6dbae334e70b70d590689409d24e6c0cda7d30fd5104550892da04a039d1276", "annex": "I", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "administrative", "change_operations": [{"after_end": 17, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 17}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-dc47a5b5522e9e4b1193f625", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/006047", "medicine_name": "Lacosamide Adroiq", "medicine_slug": "lacosamide-adroiq", "observed_at": "2026-10-12T19:07:56Z", "pipeline_version": "2.0.0", "presentation_label": "Lacosamide Adroiq 10 mg/ml solution for infusion", "presentation_occurrence": 1, "presentation_status": "heading_extracted_unverified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "7", "section_type": "administrative", "source_provider": "European Medicines Agency", "source_sha256": "0578c53a5e1c785c4d9d4dc0dabae49dbfa89e237aa571556bee548c3f9cf4d5", "source_snapshot_id": "source-64831dec5ebf55535e19d91b", "source_updated_at": "2025-09-25", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/lacosamide-adroiq-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 921}
{"after": {"end": 12, "start": 0, "text": "169 73 Solna", "truncated": false}, "after_length": 12, "after_sha256": "396199e813d8f79edb20275a432ef3c356a2964b18c41134b918894de8dcbb3d", "annex": "IIIA", "before": {"end": 12, "start": 0, "text": "Solna 169 73", "truncated": false}, "before_length": 12, "before_sha256": "48d3b71370d55743d8f6af2ff4ab7a798818c3958ea6d6d44d45c3a952fd50d5", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 6, "before_start": 0, "kind": "delete"}, {"after_end": 12, "after_start": 6, "before_end": 12, "before_start": 12, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 6, "chars_inserted": 6}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-dc619ff26fe88780462c984f", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002097", "medicine_name": "Fampyra", "medicine_slug": "fampyra", "observed_at": "2026-10-12T19:15:51Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "d9fe8aaaa611a84801d6308b13685258b5248df9022536697939afdf66fc1719", "source_snapshot_id": "source-ff8e0599077f0d01044dc867", "source_updated_at": "2025-08-21", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/fampyra-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1431}
{"after": {"end": 23, "start": 0, "text": "60318 Frankfurt am Main", "truncated": false}, "after_length": 23, "after_sha256": "24c3191b5088b20c209c4387a8127297e54c776e161d305c9e57956a13b7cbbe", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 23, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 23}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-dc8116b0ac0e81629ccd8361", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002097", "medicine_name": "Fampyra", "medicine_slug": "fampyra", "observed_at": "2026-10-12T19:16:07Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "a0c3ba8d58d6a43a809ecc3d142a78b10c2bd7f0b9f3a3553df2617d87daec1f", "source_snapshot_id": "source-c7a810dd21f94cd2d273f0da", "source_updated_at": "2025-08-21", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/fampyra-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1472}
{"after": {"end": 21, "start": 0, "text": "Tel: +31 35 528 39 57", "truncated": false}, "after_length": 21, "after_sha256": "7baf6601f41e49e470f803fdd4e755a86efa38be423317c000ed79963ebdd213", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 21, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 21}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-dcd42cbbbec9829946d99964", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:19Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "77586d0bea0858214b43b86e91abc2d2711733b96959ead5ed0b5ecbd8ed888a", "source_snapshot_id": "source-85d476f9ad959cc117ca8f1f", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1406}
{"after": {"end": 26, "start": 0, "text": "Eckenheimer Landstraße 100", "truncated": false}, "after_length": 26, "after_sha256": "fdce1a9bd200c5ddd476c1ea5676b9ffbbea723f7353ad6fbc1fe019dcb86c07", "annex": "IIIA", "before": {"end": 25, "start": 0, "text": "Tél. : +353 (0)1 231 4609", "truncated": false}, "before_length": 25, "before_sha256": "7559b60efac10cd9095a91d00c551b436a807ad1176cc4f0e8d980243453fbd9", "change_kind": "content", "change_operations": [{"after_end": 11, "after_start": 0, "before_end": 4, "before_start": 0, "kind": "replace"}, {"after_end": 22, "after_start": 12, "before_end": 6, "before_start": 5, "kind": "replace"}, {"after_end": 24, "after_start": 23, "before_end": 13, "before_start": 7, "kind": "replace"}, {"after_end": 25, "after_start": 25, "before_end": 23, "before_start": 14, "kind": "delete"}, {"after_end": 26, "after_start": 26, "before_end": 25, "before_start": 24, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 21, "chars_inserted": 22}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-dd049f3b739513fc51ccad22", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002097", "medicine_name": "Fampyra", "medicine_slug": "fampyra", "observed_at": "2026-10-12T19:16:07Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "a0c3ba8d58d6a43a809ecc3d142a78b10c2bd7f0b9f3a3553df2617d87daec1f", "source_snapshot_id": "source-c7a810dd21f94cd2d273f0da", "source_updated_at": "2025-08-21", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/fampyra-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1359}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 16, "start": 0, "text": "6336 Langkampfen", "truncated": false}, "before_length": 16, "before_sha256": "b9f18afdf777127453e8278d60cb7f5e3f22a29760be53f0595ada54a24f6ad2", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 16, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 16, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-dd060fc0c308521a241cbe5f", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/000725", "medicine_name": "Binocrit", "medicine_slug": "binocrit", "observed_at": "2026-10-12T19:28:20Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "b2bb40c100cab3babee14bbe20cc7718cb73ac1bbb3971dfd487c4f10a0e6478", "source_snapshot_id": "source-b97c331d23a7a0f19aebfb61", "source_updated_at": "2025-07-11", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/binocrit-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 3449}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 5, "start": 0, "text": "Irsko", "truncated": false}, "before_length": 5, "before_sha256": "9ec7bc95bee4f9b389ce7195514d6c61521a21ed76102c902803086caf1a3bc9", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 5, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 5, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-dd257ef129a8bc823eef60a8", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002097", "medicine_name": "Fampyra", "medicine_slug": "fampyra", "observed_at": "2026-10-12T19:16:07Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "a0c3ba8d58d6a43a809ecc3d142a78b10c2bd7f0b9f3a3553df2617d87daec1f", "source_snapshot_id": "source-c7a810dd21f94cd2d273f0da", "source_updated_at": "2025-08-21", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/fampyra-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1417}
{"after": {"end": 16, "start": 0, "text": "imed@imed.com.pl", "truncated": false}, "after_length": 16, "after_sha256": "ea84c1c4a48b3783f0be9b72cd284be4ace13bfe979d55d22fedbadbb0b4aff0", "annex": "IIIA", "before": {"end": 13, "start": 0, "text": "Lucane Pharma", "truncated": false}, "before_length": 13, "before_sha256": "e338afdb64acf1a6e2083a50318853589248451dd3aa707181ba02641a8521e8", "change_kind": "content", "change_operations": [{"after_end": 10, "after_start": 0, "before_end": 2, "before_start": 0, "kind": "replace"}, {"after_end": 12, "after_start": 11, "before_end": 11, "before_start": 3, "kind": "replace"}, {"after_end": 16, "after_start": 13, "before_end": 13, "before_start": 12, "kind": "replace"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 11, "chars_inserted": 14}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-dd3b685a2aabb0d79351af93", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:19Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "77586d0bea0858214b43b86e91abc2d2711733b96959ead5ed0b5ecbd8ed888a", "source_snapshot_id": "source-85d476f9ad959cc117ca8f1f", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1477}
{"after": {"end": 30, "start": 0, "text": "Troubles musculo-squelettiques", "truncated": false}, "after_length": 30, "after_sha256": "19f3f11cced96282f29a83fb37b4e112d045fd9d5612609940e426e03f7708ab", "annex": "I", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 30, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": true, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 30}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-dd42c18bf392db7334222e45", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/000235", "medicine_name": "Arava", "medicine_slug": "arava", "observed_at": "2026-10-12T13:28:00Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": null, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "4.4", "section_type": "warning", "source_provider": "European Medicines Agency", "source_sha256": "98b73c5c6b1e5009c9d048f8f11257f3a8407759fd25a4c8d5ef5c611519e916", "source_snapshot_id": "source-4b7ea3b78addea82376b3432", "source_updated_at": "2026-09-07", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/arava-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1326}
{"after": {"end": 28, "start": 0, "text": "InfoDeutschland@dipharma.com", "truncated": false}, "after_length": 28, "after_sha256": "f5ed16f98f15b7236207edade83fdde3fb32cec02f927aaba23223b9f6077f21", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 28, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 28}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-ddb4c0920cf8959a46dfbea2", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:14Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "8b8c4cc8e6f1a21fedee4bf0743c9c03e454b50f5eaba0e3760416d7fe0a74ec", "source_snapshot_id": "source-4efe4ecf3ebf08d338a763a5", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1928}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 27, "start": 0, "text": "Organon Pharma (UK) Limited", "truncated": false}, "before_length": 27, "before_sha256": "c8c04efa9dcf216d0ea3d041a3d87291ade3325e118bd7735bab989bbb69d521", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 27, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 27, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-ddc3effff4ca9fbfb7ff2710", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/000619", "medicine_name": "Fosavance", "medicine_slug": "fosavance", "observed_at": "2026-10-12T19:01:49Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "97e93ccf75e837b32026ca36c34d5c78008211a75d5ef225c47e7b94a0027ab2", "source_snapshot_id": "source-1ef57638e1a307f1e5437651", "source_updated_at": "2026-02-12", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/fosavance-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1330}
{"after": {"end": 29, "start": 0, "text": "Tél/Tel: +46 (0) 8 545 286 60", "truncated": false}, "after_length": 29, "after_sha256": "672d350e486dbb33717dc4c2744825e72dd0b3f703f12d852ec53e65d676b58d", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 29, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 29}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-de239a54b49741419d4f357c", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/000980", "medicine_name": "Samsca", "medicine_slug": "samsca", "observed_at": "2026-10-12T13:28:23Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "b92d73a758b8976c4438a072d544f0d6c603112c90dfc9c084d362ce62419257", "source_snapshot_id": "source-15b8b5681aba542ec1668c0b", "source_updated_at": "2026-08-20", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/samsca-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1288}
{"after": {"end": 284, "start": 0, "text": "The overall safety profile of SPRYCEL in the paediatric Ph+ CMLCP population was similar to that of the adult population, regardless of formulation. Of the 130 SPRYCEL-treated paediatric subjects with CMLCP, 2 (1.5%) experienced adverse reactions leading to treatment discontinuation.", "truncated": false}, "after_length": 284, "after_sha256": "a93f0d5739e46329a99d92e3579a091992fe0956a0ed725e331ab4ff5a1dd901", "annex": "I", "before": {"end": 432, "start": 0, "text": "The overall safety profile of SPRYCEL in the paediatric Ph+ CMLCP population was similar to that of the adult population, regardless of formulation, with the exception of no reported pericardial effusion, pleural effusion, pulmonary oedema, or pulmonary hypertension in the paediatric population. Of the 130 SPRYCEL-treated paediatric subjects with CMLCP, 2 (1.5%) experienced adverse reactions leading to treatment discontinuation.", "truncated": false}, "before_length": 432, "before_sha256": "9c7c89bef11745b1619d0bbe79611b554ea6f08b54465c9a5ba4b901dbf51a35", "change_kind": "content", "change_operations": [{"after_end": 147, "after_start": 147, "before_end": 295, "before_start": 147, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": true, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 148, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-de30662e0204b504f3347411", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/000709", "medicine_name": "Sprycel", "medicine_slug": "sprycel", "observed_at": "2026-10-12T13:27:33Z", "pipeline_version": "2.0.0", "presentation_label": "SPRYCEL 20 mg filmcoated tablets SPRYCEL 50 mg filmcoated tablets SPRYCEL 70 mg filmcoated tablets SPRYCEL 80 mg filmcoated tablets SPRYCEL 100 mg filmcoated tablets SPRYCEL 140 mg filmcoated tablets", "presentation_occurrence": 1, "presentation_status": "heading_extracted_unverified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "4.8", "section_type": "adverse_reactions", "source_provider": "European Medicines Agency", "source_sha256": "7b2a270ca60f948a69940b5bd26552042c4c20cae01b420ad781477ba43b0fe9", "source_snapshot_id": "source-c03fb6f08190e30934edc22f", "source_updated_at": "2026-10-02", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/sprycel-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 400}
{"after": {"end": 25, "start": 0, "text": "Eurocept International BV", "truncated": false}, "after_length": 25, "after_sha256": "b17bd89b3cf285c986a6070d0d67f5326dd5c1f08a70834c296c6c820f9e7505", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 25, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 25}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-de3bad6baec597a7067ce007", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:19Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "77586d0bea0858214b43b86e91abc2d2711733b96959ead5ed0b5ecbd8ed888a", "source_snapshot_id": "source-85d476f9ad959cc117ca8f1f", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1967}
{"after": {"end": 21, "start": 0, "text": "Tel: +31 35 528 39 57", "truncated": false}, "after_length": 21, "after_sha256": "7baf6601f41e49e470f803fdd4e755a86efa38be423317c000ed79963ebdd213", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 21, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 21}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-de4727f96ce09e16d6848943", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:14Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "8b8c4cc8e6f1a21fedee4bf0743c9c03e454b50f5eaba0e3760416d7fe0a74ec", "source_snapshot_id": "source-4efe4ecf3ebf08d338a763a5", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 2032}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 5, "start": 0, "text": "Regus", "truncated": false}, "before_length": 5, "before_sha256": "69ef2ca82e0f736644001207ab7589688f2ada81eedc4859209d50896d65b095", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 5, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 5, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-de5d8b315769c7545cbf14b7", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002097", "medicine_name": "Fampyra", "medicine_slug": "fampyra", "observed_at": "2026-10-12T19:15:51Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "d9fe8aaaa611a84801d6308b13685258b5248df9022536697939afdf66fc1719", "source_snapshot_id": "source-ff8e0599077f0d01044dc867", "source_updated_at": "2025-08-21", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/fampyra-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1473}
{"after": {"end": 22, "start": 0, "text": "Merz Therapeutics GmbH", "truncated": false}, "after_length": 22, "after_sha256": "059f049c7d0846aaadcf2573280d52110f302d4ecc7b38debd004571cd1e9d5e", "annex": "IIIA", "before": {"end": 35, "start": 0, "text": "Acorda Therapeutics Ireland Limited", "truncated": false}, "before_length": 35, "before_sha256": "d94d3153d193ed26567f2b4ed48df016d81c534e7c0cb1a6655a63f0083383ff", "change_kind": "content", "change_operations": [{"after_end": 2, "after_start": 0, "before_end": 3, "before_start": 0, "kind": "replace"}, {"after_end": 4, "after_start": 3, "before_end": 6, "before_start": 4, "kind": "replace"}, {"after_end": 19, "after_start": 18, "before_end": 30, "before_start": 20, "kind": "replace"}, {"after_end": 22, "after_start": 20, "before_end": 35, "before_start": 31, "kind": "replace"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 19, "chars_inserted": 6}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-dec6ace1e307359578ee14b0", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002097", "medicine_name": "Fampyra", "medicine_slug": "fampyra", "observed_at": "2026-10-12T19:15:51Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "d9fe8aaaa611a84801d6308b13685258b5248df9022536697939afdf66fc1719", "source_snapshot_id": "source-ff8e0599077f0d01044dc867", "source_updated_at": "2025-08-21", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/fampyra-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1571}
{"after": {"end": 109, "start": 0, "text": "Marketing Authorisation Holder: Eli Lilly Nederland B.V., Orteliuslaan 1000, 3528 BD Utrecht, The Netherlands", "truncated": false}, "after_length": 109, "after_sha256": "60a228fbf1ec2f19e615c9b676c9dff75b4935be8aadcdbe4902c014b861d939", "annex": "IIIA", "before": {"end": 109, "start": 0, "text": "Marketing Authorisation Holder: Eli Lilly Nederland B.V., Papendorpseweg 83, 3528 BJ Utrecht, The Netherlands", "truncated": false}, "before_length": 109, "before_sha256": "500ff14606beaa924e6e2a258711fcdf39978fdda94be513851db6b0a3356ccd", "change_kind": "administrative", "change_operations": [{"after_end": 67, "after_start": 58, "before_end": 59, "before_start": 58, "kind": "replace"}, {"after_end": 69, "after_start": 68, "before_end": 62, "before_start": 60, "kind": "replace"}, {"after_end": 70, "after_start": 70, "before_end": 72, "before_start": 63, "kind": "delete"}, {"after_end": 75, "after_start": 71, "before_end": 75, "before_start": 73, "kind": "replace"}, {"after_end": 84, "after_start": 83, "before_end": 84, "before_start": 83, "kind": "replace"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 15, "chars_inserted": 15}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-ded15b71298e1df67135b844", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/001021", "medicine_name": "Adcirca (previously Tadalafil Lilly)", "medicine_slug": "adcirca-previously-tadalafil-lilly", "observed_at": "2026-10-12T19:02:42Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "43438c8e53504a78747a8ff36049250fee294557f3a8b0e3acb80f71ad43ebc0", "source_snapshot_id": "source-2305a67bd1e393ee340bb8e4", "source_updated_at": "2026-01-28", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/adcirca-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 2221}
{"after": {"end": 25, "start": 0, "text": "Eurocept International BV", "truncated": false}, "after_length": 25, "after_sha256": "b17bd89b3cf285c986a6070d0d67f5326dd5c1f08a70834c296c6c820f9e7505", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 25, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 25}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-dedb5e2d8a62ebe50f17e194", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:14Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "8b8c4cc8e6f1a21fedee4bf0743c9c03e454b50f5eaba0e3760416d7fe0a74ec", "source_snapshot_id": "source-4efe4ecf3ebf08d338a763a5", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1526}
{"after": {"end": 21, "start": 0, "text": "Tel: +31 35 528 39 57", "truncated": false}, "after_length": 21, "after_sha256": "7baf6601f41e49e470f803fdd4e755a86efa38be423317c000ed79963ebdd213", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 21, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 21}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-df0b18c62cba8fec581c4ccb", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:19Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "77586d0bea0858214b43b86e91abc2d2711733b96959ead5ed0b5ecbd8ed888a", "source_snapshot_id": "source-85d476f9ad959cc117ca8f1f", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1936}
{"after": {"end": 333, "start": 0, "text": "Le profil général de tolérance de SPRYCEL dans la population pédiatrique atteinte de LMC Ph+ PC était similaire à celui de la population adulte, indépendamment de la formulation. Parmi les 130 sujets pédiatriques atteints de LMC PC traités par SPRYCEL, 2 (1,5 %) ont présenté des effets indésirables entraînant l’arrêt du traitement.", "truncated": false}, "after_length": 333, "after_sha256": "68755e2845726297f06d0075f534ad99061e27d0e5fe90f22406927735b118d2", "annex": "I", "before": {"end": 505, "start": 0, "text": "Le profil général de tolérance de SPRYCEL dans la population pédiatrique atteinte de LMC Ph+ PC était similaire à celui de la population adulte, indépendamment de la formulation, à l’exception de l’absence de cas rapporté d’épanchement péricardique, d’épanchement pleural, d’œdème pulmonaire ou hypertension pulmonaire dans la population pédiatrique. Parmi les 130 sujets pédiatriques atteints de LMC PC traités par SPRYCEL, 2 (1,5 %) ont présenté des effets indésirables entraînant l’arrêt du traitement.", "truncated": false}, "before_length": 505, "before_sha256": "cebe88c4ef21c9d6fe12ec355784573c5e8d19d697b4eda5f3af2c815393eb2e", "change_kind": "content", "change_operations": [{"after_end": 177, "after_start": 177, "before_end": 349, "before_start": 177, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": true, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 172, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-df5021edb5ce036e3f5cf41c", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/000709", "medicine_name": "Sprycel", "medicine_slug": "sprycel", "observed_at": "2026-10-12T13:27:38Z", "pipeline_version": "2.0.0", "presentation_label": "SPRYCEL 20 mg comprimés pelliculés SPRYCEL 50 mg comprimés pelliculés SPRYCEL 70 mg comprimés pelliculés SPRYCEL 80 mg comprimés pelliculés SPRYCEL 100 mg comprimés pelliculés SPRYCEL 140 mg comprimés pelliculés", "presentation_occurrence": 1, "presentation_status": "heading_extracted_unverified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "4.8", "section_type": "adverse_reactions", "source_provider": "European Medicines Agency", "source_sha256": "f19afb6c99c9f6c4da575a1ec1ad2116d41e1ee33bed1a9a3406fd820f8970ff", "source_snapshot_id": "source-753ed8ea69e2a319805bb49a", "source_updated_at": "2026-10-02", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/sprycel-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 394}
{"after": {"end": 16, "start": 0, "text": "Extrovis EU Kft.", "truncated": false}, "after_length": 16, "after_sha256": "b9216ef80e71e17798dce313e4318f03f37328f225d30ab508b7413813a908e5", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 16, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 16}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-dfb828e0c2a0d085d8d53e38", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/006047", "medicine_name": "Lacosamide Adroiq", "medicine_slug": "lacosamide-adroiq", "observed_at": "2026-10-12T19:07:59Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "cc83d966059d42856d0211a4f256b29b20d43593865704d6a9315aeb694f3c76", "source_snapshot_id": "source-896abba1d8391c918345d46b", "source_updated_at": "2025-09-25", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/lacosamide-adroiq-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1716}
{"after": {"end": 12, "start": 0, "text": "169 73 Solna", "truncated": false}, "after_length": 12, "after_sha256": "396199e813d8f79edb20275a432ef3c356a2964b18c41134b918894de8dcbb3d", "annex": "IIIA", "before": {"end": 12, "start": 0, "text": "Solna 169 73", "truncated": false}, "before_length": 12, "before_sha256": "48d3b71370d55743d8f6af2ff4ab7a798818c3958ea6d6d44d45c3a952fd50d5", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 6, "before_start": 0, "kind": "delete"}, {"after_end": 12, "after_start": 6, "before_end": 12, "before_start": 12, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 6, "chars_inserted": 6}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-e0096e4deee2550e596fe8f9", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002097", "medicine_name": "Fampyra", "medicine_slug": "fampyra", "observed_at": "2026-10-12T19:16:07Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "a0c3ba8d58d6a43a809ecc3d142a78b10c2bd7f0b9f3a3553df2617d87daec1f", "source_snapshot_id": "source-c7a810dd21f94cd2d273f0da", "source_updated_at": "2025-08-21", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/fampyra-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1480}
{"after": {"end": 23, "start": 0, "text": "info@euroceptpharma.com", "truncated": false}, "after_length": 23, "after_sha256": "9297cc5acdcc837f054116992765943f7907937507b2564a99ea1327a00ac0e6", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 23, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 23}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-e0296a5d088cb94fd1e04a16", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:14Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "8b8c4cc8e6f1a21fedee4bf0743c9c03e454b50f5eaba0e3760416d7fe0a74ec", "source_snapshot_id": "source-4efe4ecf3ebf08d338a763a5", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 2072}
{"after": {"end": 23, "start": 0, "text": "60318 Frankfurt am Main", "truncated": false}, "after_length": 23, "after_sha256": "24c3191b5088b20c209c4387a8127297e54c776e161d305c9e57956a13b7cbbe", "annex": "IIIA", "before": {"end": 15, "start": 0, "text": "60318 Frankfurt", "truncated": false}, "before_length": 15, "before_sha256": "e51a2d4338d09f9fbc6ab0ad5d0a6dc6efd90f583e365f4764dd86681442d5b4", "change_kind": "content", "change_operations": [{"after_end": 23, "after_start": 15, "before_end": 15, "before_start": 15, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 8}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-e03047702a891d8ed4aa00b3", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002097", "medicine_name": "Fampyra", "medicine_slug": "fampyra", "observed_at": "2026-10-12T19:16:07Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "a0c3ba8d58d6a43a809ecc3d142a78b10c2bd7f0b9f3a3553df2617d87daec1f", "source_snapshot_id": "source-c7a810dd21f94cd2d273f0da", "source_updated_at": "2025-08-21", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/fampyra-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1454}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 27, "start": 0, "text": "Puh/Tel: +353 (0)1 231 4609", "truncated": false}, "before_length": 27, "before_sha256": "f946a5d376a72faf3c642bb86119f2a062037954a86623b94a3726bfe30ae694", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 27, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 27, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-e066cb8a8a5911712c01fd86", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002097", "medicine_name": "Fampyra", "medicine_slug": "fampyra", "observed_at": "2026-10-12T19:16:07Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "a0c3ba8d58d6a43a809ecc3d142a78b10c2bd7f0b9f3a3553df2617d87daec1f", "source_snapshot_id": "source-c7a810dd21f94cd2d273f0da", "source_updated_at": "2025-08-21", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/fampyra-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1597}
{"after": {"end": 22, "start": 0, "text": "Merz Therapeutics GmbH", "truncated": false}, "after_length": 22, "after_sha256": "059f049c7d0846aaadcf2573280d52110f302d4ecc7b38debd004571cd1e9d5e", "annex": "IIIA", "before": {"end": 35, "start": 0, "text": "Acorda Therapeutics Ireland Limited", "truncated": false}, "before_length": 35, "before_sha256": "d94d3153d193ed26567f2b4ed48df016d81c534e7c0cb1a6655a63f0083383ff", "change_kind": "content", "change_operations": [{"after_end": 2, "after_start": 0, "before_end": 3, "before_start": 0, "kind": "replace"}, {"after_end": 4, "after_start": 3, "before_end": 6, "before_start": 4, "kind": "replace"}, {"after_end": 19, "after_start": 18, "before_end": 30, "before_start": 20, "kind": "replace"}, {"after_end": 22, "after_start": 20, "before_end": 35, "before_start": 31, "kind": "replace"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 19, "chars_inserted": 6}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-e073618d30ba48e7463d538a", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002097", "medicine_name": "Fampyra", "medicine_slug": "fampyra", "observed_at": "2026-10-12T19:16:07Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "a0c3ba8d58d6a43a809ecc3d142a78b10c2bd7f0b9f3a3553df2617d87daec1f", "source_snapshot_id": "source-c7a810dd21f94cd2d273f0da", "source_updated_at": "2025-08-21", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/fampyra-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1442}
{"after": {"end": 20, "start": 0, "text": "Tel: +386 1 2355 100", "truncated": false}, "after_length": 20, "after_sha256": "08d49fea809e3878122f78a398ef6a77d2a4cf472eb2cf3d9f1450515a1ced0f", "annex": "IIIA", "before": {"end": 19, "start": 0, "text": "Tel: +386 235 51 00", "truncated": false}, "before_length": 19, "before_sha256": "fd65023f7b15127a4e3fb22b56c0b3c2e844610946d4b104bb5a61e296f3bb32", "change_kind": "content", "change_operations": [{"after_end": 12, "after_start": 10, "before_end": 10, "before_start": 10, "kind": "insert"}, {"after_end": 16, "after_start": 15, "before_end": 13, "before_start": 13, "kind": "insert"}, {"after_end": 17, "after_start": 17, "before_end": 15, "before_start": 14, "kind": "delete"}, {"after_end": 18, "after_start": 18, "before_end": 17, "before_start": 16, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 2, "chars_inserted": 3}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-e07babbfa376e35e02a0a444", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002702", "medicine_name": "Hexacima", "medicine_slug": "hexacima", "observed_at": "2026-10-12T19:07:06Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "b990725709f885f3f868e5da444393a40a54f89ba2f2d9b232d9c053493d1b03", "source_snapshot_id": "source-87ea40f95d82cdfb5ba074b0", "source_updated_at": "2025-09-29", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/hexacima-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1659}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 21, "start": 0, "text": "info@lucanepharma.com", "truncated": false}, "before_length": 21, "before_sha256": "44fd39e5fb919cb3d680fa630da23b49238fec29159c509f3622f272bb41c7c6", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 21, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 21, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-e083dab3c7ad8ef0ec69419b", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:19Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "77586d0bea0858214b43b86e91abc2d2711733b96959ead5ed0b5ecbd8ed888a", "source_snapshot_id": "source-85d476f9ad959cc117ca8f1f", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1410}
{"after": {"end": 499, "start": 0, "text": "if you are taking medicines that strongly decrease the activity of some liver enzymes such as ciclosporin (a medicine used in transplantation to prevent organ rejection or for other conditions, e.g. rheumatoid arthritis or atopic dermatitis), verapamil (a medicine used to lower blood pressure, to correct heart rhythm or to treat angina pectoris), antifungal medicines (e.g. ketoconazole and itraconazole) and some antiviral medicines (e.g. ritonavir) – see paragraph “Other medicines and Emselex”.", "truncated": false}, "after_length": 499, "after_sha256": "10ef34598d39153c23a6459dfdc1095cd1be00e82fdde7d6077b324a39fa5fef", "annex": "IIIA", "before": {"end": 498, "start": 0, "text": "if you are taking medicines that strongly decrease the activity of some liver enzymes such as ciclosporin (a medicine used in transplantation to prevent organ rejection or for other conditions, e.g. rheumatoid arthritis or atopic dermatitis), verapamil (a medicine used to lower blood pressure, to correct heart rhythm or to treat angina pectoris), antifungal medicines (e.g. ketoconazole and itraconazole) and some antiviral medicines (e.g. ritonavir) see paragraph “Other medicines and Emselex”).", "truncated": false}, "before_length": 498, "before_sha256": "335c4b033be1448fb159df385b855b398b84ee98b9c6755e8da6b2f9cd3ce17e", "change_kind": "content", "change_operations": [{"after_end": 455, "after_start": 453, "before_end": 453, "before_start": 453, "kind": "insert"}, {"after_end": 498, "after_start": 498, "before_end": 497, "before_start": 496, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 1, "chars_inserted": 2}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-e084898fcb07bc428937d6c3", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/000554", "medicine_name": "Emselex", "medicine_slug": "emselex", "observed_at": "2026-10-12T19:12:04Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "4f2565612bc728ec67b7f9c0cd5799ef2c594911c76f323aef8bf6a85adde245", "source_snapshot_id": "source-1fda25b331eb198b8b93feb3", "source_updated_at": "2025-09-15", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/emselex-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1717}
{"after": {"end": 25, "start": 0, "text": "Eurocept International BV", "truncated": false}, "after_length": 25, "after_sha256": "b17bd89b3cf285c986a6070d0d67f5326dd5c1f08a70834c296c6c820f9e7505", "annex": "IIIA", "before": {"end": 41, "start": 0, "text": "Eurocept International BV (Lucane Pharma)", "truncated": false}, "before_length": 41, "before_sha256": "d1cf3f14927b7038ed47975d2f7feb981f2ee8e6e304b86c1eb0fdc0b2419528", "change_kind": "content", "change_operations": [{"after_end": 25, "after_start": 25, "before_end": 41, "before_start": 25, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 16, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-e0add0cca137d3e9462daa76", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:14Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "8b8c4cc8e6f1a21fedee4bf0743c9c03e454b50f5eaba0e3760416d7fe0a74ec", "source_snapshot_id": "source-4efe4ecf3ebf08d338a763a5", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 908}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 25, "start": 0, "text": "Tél/Tel: +31 35 528 39 57", "truncated": false}, "before_length": 25, "before_sha256": "92c714a72165e0b9b7201b868cdfaa9781cb8fddb4505d51829e1b448291e604", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 25, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 25, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-e0cd8e417cf204844d0f9c11", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:14Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "8b8c4cc8e6f1a21fedee4bf0743c9c03e454b50f5eaba0e3760416d7fe0a74ec", "source_snapshot_id": "source-4efe4ecf3ebf08d338a763a5", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1890}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 20, "start": 0, "text": "10 Earlsfort Terrace", "truncated": false}, "before_length": 20, "before_sha256": "22951bbf6ee77815d0c07b3af5f0a66e17d277636971c4eaff372dea65dcb193", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 20, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 20, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-e11250e2892410bbb3368afa", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002097", "medicine_name": "Fampyra", "medicine_slug": "fampyra", "observed_at": "2026-10-12T19:15:51Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "d9fe8aaaa611a84801d6308b13685258b5248df9022536697939afdf66fc1719", "source_snapshot_id": "source-ff8e0599077f0d01044dc867", "source_updated_at": "2025-08-21", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/fampyra-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1419}
{"after": {"end": 13, "start": 0, "text": "Nieuwe Donk 9", "truncated": false}, "after_length": 13, "after_sha256": "9b03d8cf912ad0cf483871c4e8c85fde0243688b3a66c83ca9b8961156374e51", "annex": "II", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 13, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 13}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-e123a92cbc225bc096df99bb", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/000980", "medicine_name": "Samsca", "medicine_slug": "samsca", "observed_at": "2026-10-12T13:28:24Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "conditions", "section_type": "conditions", "source_provider": "European Medicines Agency", "source_sha256": "3080d919225c2a98f20aec84d5803b3fde6e1b64f323055c46d098625f4ad301", "source_snapshot_id": "source-e05739a15a0532954ee45dd4", "source_updated_at": "2026-08-20", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/samsca-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 551}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 13, "start": 0, "text": "Lucane Pharma", "truncated": false}, "before_length": 13, "before_sha256": "e338afdb64acf1a6e2083a50318853589248451dd3aa707181ba02641a8521e8", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 13, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 13, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-e130edd338705b1908c319dd", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:19Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "77586d0bea0858214b43b86e91abc2d2711733b96959ead5ed0b5ecbd8ed888a", "source_snapshot_id": "source-85d476f9ad959cc117ca8f1f", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1938}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 7, "start": 0, "text": "Irlande", "truncated": false}, "before_length": 7, "before_sha256": "a8cdfff5dbbda1b070a2acb339b6f0aa20b6230d9b5500c9ce066eaa89bc9a64", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 7, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 7, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-e157815c5137a235aa4d80a1", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002097", "medicine_name": "Fampyra", "medicine_slug": "fampyra", "observed_at": "2026-10-12T19:16:07Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "a0c3ba8d58d6a43a809ecc3d142a78b10c2bd7f0b9f3a3553df2617d87daec1f", "source_snapshot_id": "source-c7a810dd21f94cd2d273f0da", "source_updated_at": "2025-08-21", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/fampyra-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1036}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "I", "before": {"end": 25, "start": 0, "text": "Post-marketing experience", "truncated": false}, "before_length": 25, "before_sha256": "0bf5d214dc7d6f6f0451f073e7a9a7eea0190d225b8f93509ac9467e27bd17f7", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 25, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": true, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 25, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-e231c12deb7d8ad90c855eee", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/000554", "medicine_name": "Emselex", "medicine_slug": "emselex", "observed_at": "2026-10-12T19:12:04Z", "pipeline_version": "2.0.0", "presentation_label": "Emselex 7.5 mg prolonged-release tablets", "presentation_occurrence": 1, "presentation_status": "heading_extracted_unverified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "4.8", "section_type": "adverse_reactions", "source_provider": "European Medicines Agency", "source_sha256": "4f2565612bc728ec67b7f9c0cd5799ef2c594911c76f323aef8bf6a85adde245", "source_snapshot_id": "source-1fda25b331eb198b8b93feb3", "source_updated_at": "2025-09-15", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/emselex-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 240}
{"after": {"end": 26, "start": 0, "text": "Eckenheimer Landstraße 100", "truncated": false}, "after_length": 26, "after_sha256": "fdce1a9bd200c5ddd476c1ea5676b9ffbbea723f7353ad6fbc1fe019dcb86c07", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 26, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 26}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-e23d363fc20ec1c06e655dc9", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002097", "medicine_name": "Fampyra", "medicine_slug": "fampyra", "observed_at": "2026-10-12T19:15:51Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "d9fe8aaaa611a84801d6308b13685258b5248df9022536697939afdf66fc1719", "source_snapshot_id": "source-ff8e0599077f0d01044dc867", "source_updated_at": "2025-08-21", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/fampyra-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1031}
{"after": {"end": 22, "start": 0, "text": "Tel: + 48 22 663 43 03", "truncated": false}, "after_length": 22, "after_sha256": "5345f797275d32abdc54039c15f0a4f05223d8f5424eaa63545f2efe682185e2", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 22, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 22}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-e2600687f08fda456be27cdf", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:19Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "77586d0bea0858214b43b86e91abc2d2711733b96959ead5ed0b5ecbd8ed888a", "source_snapshot_id": "source-85d476f9ad959cc117ca8f1f", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1905}
{"after": {"end": 22, "start": 0, "text": "Merz Therapeutics GmbH", "truncated": false}, "after_length": 22, "after_sha256": "059f049c7d0846aaadcf2573280d52110f302d4ecc7b38debd004571cd1e9d5e", "annex": "IIIA", "before": {"end": 35, "start": 0, "text": "Acorda Therapeutics Ireland Limited", "truncated": false}, "before_length": 35, "before_sha256": "d94d3153d193ed26567f2b4ed48df016d81c534e7c0cb1a6655a63f0083383ff", "change_kind": "content", "change_operations": [{"after_end": 2, "after_start": 0, "before_end": 3, "before_start": 0, "kind": "replace"}, {"after_end": 4, "after_start": 3, "before_end": 6, "before_start": 4, "kind": "replace"}, {"after_end": 19, "after_start": 18, "before_end": 30, "before_start": 20, "kind": "replace"}, {"after_end": 22, "after_start": 20, "before_end": 35, "before_start": 31, "kind": "replace"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 19, "chars_inserted": 6}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-e2645920da09808cf242990a", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002097", "medicine_name": "Fampyra", "medicine_slug": "fampyra", "observed_at": "2026-10-12T19:15:51Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "d9fe8aaaa611a84801d6308b13685258b5248df9022536697939afdf66fc1719", "source_snapshot_id": "source-ff8e0599077f0d01044dc867", "source_updated_at": "2025-08-21", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/fampyra-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1388}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 16, "start": 0, "text": "Extrovis EU Ltd.", "truncated": false}, "before_length": 16, "before_sha256": "f462ad48e7aef0bc82148ce088af1897d99ed86993128f30d506b27d3108a929", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 16, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 16, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-e2ab922396561609dac4cbdf", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/006047", "medicine_name": "Lacosamide Adroiq", "medicine_slug": "lacosamide-adroiq", "observed_at": "2026-10-12T19:07:59Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "cc83d966059d42856d0211a4f256b29b20d43593865704d6a9315aeb694f3c76", "source_snapshot_id": "source-896abba1d8391c918345d46b", "source_updated_at": "2025-09-25", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/lacosamide-adroiq-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1793}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 13, "start": 0, "text": "Lucane Pharma", "truncated": false}, "before_length": 13, "before_sha256": "e338afdb64acf1a6e2083a50318853589248451dd3aa707181ba02641a8521e8", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 13, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 13, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-e2ba847b7684e4bbe05d3904", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:19Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "77586d0bea0858214b43b86e91abc2d2711733b96959ead5ed0b5ecbd8ed888a", "source_snapshot_id": "source-85d476f9ad959cc117ca8f1f", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1456}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 7, "start": 0, "text": "Ireland", "truncated": false}, "before_length": 7, "before_sha256": "02bf1dfa9a0365a86223f0e4ac9eaa0517b06b2e9273790f719feda656a247ae", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 7, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 7, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-e2f0e05a424c1b1c20125e0b", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002097", "medicine_name": "Fampyra", "medicine_slug": "fampyra", "observed_at": "2026-10-12T19:15:51Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "d9fe8aaaa611a84801d6308b13685258b5248df9022536697939afdf66fc1719", "source_snapshot_id": "source-ff8e0599077f0d01044dc867", "source_updated_at": "2025-08-21", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/fampyra-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 895}
{"after": {"end": 144, "start": 0, "text": "if you will have or have had recent major surgery, or if you still have an unhealed wound following surgery as AUBAGIO may impair wound healing.", "truncated": false}, "after_length": 144, "after_sha256": "bcb190c66c3bfaa83538081942a1f029477973f4229434027f82c4c8f75de5c1", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 144, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 144}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-e3d638f31425f6e85a6b015e", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002514", "medicine_name": "Aubagio", "medicine_slug": "aubagio", "observed_at": "2026-10-12T17:28:37Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "2583b2915ecedeb3bccc3ac6bea691e65d05f5e437bf8aa7970917b6fdeb700c", "source_snapshot_id": "source-15791f384b9e49792c9776dd", "source_updated_at": "2025-12-09", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/aubagio-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1734}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 30, "start": 0, "text": "Tél/Tel : +31 (0) 20 85 46 555", "truncated": false}, "before_length": 30, "before_sha256": "bd7d9bc432496d186f6adce35d66f3f28fab643149eb4da4eb943905cea371d6", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 30, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 30, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-e3e66e0b797bddea40792747", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/000980", "medicine_name": "Samsca", "medicine_slug": "samsca", "observed_at": "2026-10-12T13:28:24Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "3080d919225c2a98f20aec84d5803b3fde6e1b64f323055c46d098625f4ad301", "source_snapshot_id": "source-e05739a15a0532954ee45dd4", "source_updated_at": "2026-08-20", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/samsca-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1269}
{"after": {"end": 13, "start": 0, "text": "Nieuwe Donk 9", "truncated": false}, "after_length": 13, "after_sha256": "9b03d8cf912ad0cf483871c4e8c85fde0243688b3a66c83ca9b8961156374e51", "annex": "II", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 13, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 13}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-e45a60af6bfec86d8763fccf", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/000980", "medicine_name": "Samsca", "medicine_slug": "samsca", "observed_at": "2026-10-12T13:28:23Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "conditions", "section_type": "conditions", "source_provider": "European Medicines Agency", "source_sha256": "b92d73a758b8976c4438a072d544f0d6c603112c90dfc9c084d362ce62419257", "source_snapshot_id": "source-15b8b5681aba542ec1668c0b", "source_updated_at": "2026-08-20", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/samsca-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 553}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 27, "start": 0, "text": "(Eurocept International BV)", "truncated": false}, "before_length": 27, "before_sha256": "e6cf9b20aaa466e53ad0d393512ca75931e13e488321e3be6f3e4f8b600970c8", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 27, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 27, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-e4bbfdc087169f8e860b1275", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:14Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "8b8c4cc8e6f1a21fedee4bf0743c9c03e454b50f5eaba0e3760416d7fe0a74ec", "source_snapshot_id": "source-4efe4ecf3ebf08d338a763a5", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 2067}
{"after": {"end": 31, "start": 0, "text": "Τηλ: 800 00 673 (+357 22866700)", "truncated": false}, "after_length": 31, "after_sha256": "a59db243531a957e81cf49732ba35a306387a53ff3e1a49f426d23388b2868d8", "annex": "IIIA", "before": {"end": 32, "start": 0, "text": "Τηλ.: 800 00 673 (+357 22866700)", "truncated": false}, "before_length": 32, "before_sha256": "6899ad477cba5f04d4e1237dc94a908a8c321135efda6b48a0963782b4bb0bdd", "change_kind": "content", "change_operations": [{"after_end": 3, "after_start": 3, "before_end": 4, "before_start": 3, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 1, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-e522496797739948bfd34ca5", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/000389", "medicine_name": "Invanz", "medicine_slug": "invanz", "observed_at": "2026-10-12T17:30:44Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "a9208c117495d2d6c465ba196e4dbbb3d498b27d747df3b2d0145b0549743e4b", "source_snapshot_id": "source-e56383168f778128e02c2b2e", "source_updated_at": "2025-11-21", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/invanz-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1224}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 20, "start": 0, "text": "10 Earlsfort Terrace", "truncated": false}, "before_length": 20, "before_sha256": "22951bbf6ee77815d0c07b3af5f0a66e17d277636971c4eaff372dea65dcb193", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 20, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 20, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-e5638387fe59f844f80c6fbd", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002097", "medicine_name": "Fampyra", "medicine_slug": "fampyra", "observed_at": "2026-10-12T19:15:51Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "d9fe8aaaa611a84801d6308b13685258b5248df9022536697939afdf66fc1719", "source_snapshot_id": "source-ff8e0599077f0d01044dc867", "source_updated_at": "2025-08-21", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/fampyra-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1599}
{"after": {"end": 21, "start": 0, "text": "Tel: +31 35 528 39 57", "truncated": false}, "after_length": 21, "after_sha256": "7baf6601f41e49e470f803fdd4e755a86efa38be423317c000ed79963ebdd213", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 21, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 21}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-e596afd5d4bf9d8f1338e821", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:14Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "8b8c4cc8e6f1a21fedee4bf0743c9c03e454b50f5eaba0e3760416d7fe0a74ec", "source_snapshot_id": "source-4efe4ecf3ebf08d338a763a5", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1875}
{"after": {"end": 12, "start": 0, "text": "169 73 Solna", "truncated": false}, "after_length": 12, "after_sha256": "396199e813d8f79edb20275a432ef3c356a2964b18c41134b918894de8dcbb3d", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 12, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 12}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-e5c469747e2c27df93282ca7", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002097", "medicine_name": "Fampyra", "medicine_slug": "fampyra", "observed_at": "2026-10-12T19:16:07Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "a0c3ba8d58d6a43a809ecc3d142a78b10c2bd7f0b9f3a3553df2617d87daec1f", "source_snapshot_id": "source-c7a810dd21f94cd2d273f0da", "source_updated_at": "2025-08-21", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/fampyra-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1599}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 5, "start": 0, "text": "Írsko", "truncated": false}, "before_length": 5, "before_sha256": "f94349a2269c5b8a87adcdc639846023eb0a54b3cd323637a78d9c7d5a8feb5e", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 5, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 5, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-e614c7596b6f26b78374e101", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002097", "medicine_name": "Fampyra", "medicine_slug": "fampyra", "observed_at": "2026-10-12T19:16:07Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "a0c3ba8d58d6a43a809ecc3d142a78b10c2bd7f0b9f3a3553df2617d87daec1f", "source_snapshot_id": "source-c7a810dd21f94cd2d273f0da", "source_updated_at": "2025-08-21", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/fampyra-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1580}
{"after": {"end": 22, "start": 0, "text": "Merz Therapeutics GmbH", "truncated": false}, "after_length": 22, "after_sha256": "059f049c7d0846aaadcf2573280d52110f302d4ecc7b38debd004571cd1e9d5e", "annex": "IIIA", "before": {"end": 35, "start": 0, "text": "Acorda Therapeutics Ireland Limited", "truncated": false}, "before_length": 35, "before_sha256": "d94d3153d193ed26567f2b4ed48df016d81c534e7c0cb1a6655a63f0083383ff", "change_kind": "content", "change_operations": [{"after_end": 2, "after_start": 0, "before_end": 3, "before_start": 0, "kind": "replace"}, {"after_end": 4, "after_start": 3, "before_end": 6, "before_start": 4, "kind": "replace"}, {"after_end": 19, "after_start": 18, "before_end": 30, "before_start": 20, "kind": "replace"}, {"after_end": 22, "after_start": 20, "before_end": 35, "before_start": 31, "kind": "replace"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 19, "chars_inserted": 6}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-e621567199f9dd994d9fc7b1", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002097", "medicine_name": "Fampyra", "medicine_slug": "fampyra", "observed_at": "2026-10-12T19:15:51Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "d9fe8aaaa611a84801d6308b13685258b5248df9022536697939afdf66fc1719", "source_snapshot_id": "source-ff8e0599077f0d01044dc867", "source_updated_at": "2025-08-21", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/fampyra-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1082}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 18, "start": 0, "text": "Dublin 2, D02 T380", "truncated": false}, "before_length": 18, "before_sha256": "23e6871e7960b0dadc753bc127bbea230cc8308c88b2d33704eb275a3ec1a70d", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 18, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 18, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-e6368e6f7e8d4f512e9e232d", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002097", "medicine_name": "Fampyra", "medicine_slug": "fampyra", "observed_at": "2026-10-12T19:16:07Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "a0c3ba8d58d6a43a809ecc3d142a78b10c2bd7f0b9f3a3553df2617d87daec1f", "source_snapshot_id": "source-c7a810dd21f94cd2d273f0da", "source_updated_at": "2025-08-21", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/fampyra-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1606}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 14, "start": 0, "text": "Irlanti/Irland", "truncated": false}, "before_length": 14, "before_sha256": "f8843fba35e81866fa6c37940ee500a77f509d98b1c78410796638d567548f02", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 14, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 14, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-e64a02c35d475896180f7066", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002097", "medicine_name": "Fampyra", "medicine_slug": "fampyra", "observed_at": "2026-10-12T19:15:51Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "d9fe8aaaa611a84801d6308b13685258b5248df9022536697939afdf66fc1719", "source_snapshot_id": "source-ff8e0599077f0d01044dc867", "source_updated_at": "2025-08-21", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/fampyra-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1590}
{"after": {"end": 30, "start": 0, "text": "Merz Therapeutics Benelux B.V.", "truncated": false}, "after_length": 30, "after_sha256": "7c5530f091b2eaff46486c1452be442d4a9c6f4c46924db34e94c6cdb089882e", "annex": "IIIA", "before": {"end": 35, "start": 0, "text": "Acorda Therapeutics Ireland Limited", "truncated": false}, "before_length": 35, "before_sha256": "d94d3153d193ed26567f2b4ed48df016d81c534e7c0cb1a6655a63f0083383ff", "change_kind": "content", "change_operations": [{"after_end": 2, "after_start": 0, "before_end": 3, "before_start": 0, "kind": "replace"}, {"after_end": 4, "after_start": 3, "before_end": 6, "before_start": 4, "kind": "replace"}, {"after_end": 21, "after_start": 18, "before_end": 22, "before_start": 20, "kind": "replace"}, {"after_end": 25, "after_start": 23, "before_end": 27, "before_start": 24, "kind": "replace"}, {"after_end": 30, "after_start": 26, "before_end": 35, "before_start": 28, "kind": "replace"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 17, "chars_inserted": 12}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-e64fb5ea06d1f7f45323035b", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002097", "medicine_name": "Fampyra", "medicine_slug": "fampyra", "observed_at": "2026-10-12T19:15:51Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "d9fe8aaaa611a84801d6308b13685258b5248df9022536697939afdf66fc1719", "source_snapshot_id": "source-ff8e0599077f0d01044dc867", "source_updated_at": "2025-08-21", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/fampyra-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1398}
{"after": {"end": 16, "start": 0, "text": "Extrovis EU Kft.", "truncated": false}, "after_length": 16, "after_sha256": "b9216ef80e71e17798dce313e4318f03f37328f225d30ab508b7413813a908e5", "annex": "IIIB", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "unassigned", "change_operations": [{"after_end": 16, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 16}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-e664baa8b18fb9c4df1e6184", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/006047", "medicine_name": "Lacosamide Adroiq", "medicine_slug": "lacosamide-adroiq", "observed_at": "2026-10-12T19:07:56Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "", "section_type": "unassigned", "source_provider": "European Medicines Agency", "source_sha256": "0578c53a5e1c785c4d9d4dc0dabae49dbfa89e237aa571556bee548c3f9cf4d5", "source_snapshot_id": "source-64831dec5ebf55535e19d91b", "source_updated_at": "2025-09-25", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/lacosamide-adroiq-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1980}
{"after": {"end": 26, "start": 0, "text": "Dipharma Arzneimittel GmbH", "truncated": false}, "after_length": 26, "after_sha256": "d8cb257047b7439a3be44a22f3227e45df27054340bbfa9cd6525bbf1d237add", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 26, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 26}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-e6e89bf8b3339176e33f4133", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:19Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "77586d0bea0858214b43b86e91abc2d2711733b96959ead5ed0b5ecbd8ed888a", "source_snapshot_id": "source-85d476f9ad959cc117ca8f1f", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1850}
{"after": {"end": 7, "start": 0, "text": "Germany", "truncated": false}, "after_length": 7, "after_sha256": "80db4ccdca106d37b920206331fcfe3e9e50a9e763d89b54ce3ad5ac8cf30f03", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 7, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 7}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-e6ee8908b5ac23852e2d70cd", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002097", "medicine_name": "Fampyra", "medicine_slug": "fampyra", "observed_at": "2026-10-12T19:15:51Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "d9fe8aaaa611a84801d6308b13685258b5248df9022536697939afdf66fc1719", "source_snapshot_id": "source-ff8e0599077f0d01044dc867", "source_updated_at": "2025-08-21", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/fampyra-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1033}
{"after": {"end": 9, "start": 0, "text": "Allemagne", "truncated": false}, "after_length": 9, "after_sha256": "6b58dbd6a994339b48d8446597da22402857b3409613459c7e3a293788fbe66a", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 9, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 9}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-e703bdfe8689a480d5a8ee4f", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002097", "medicine_name": "Fampyra", "medicine_slug": "fampyra", "observed_at": "2026-10-12T19:16:07Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "a0c3ba8d58d6a43a809ecc3d142a78b10c2bd7f0b9f3a3553df2617d87daec1f", "source_snapshot_id": "source-c7a810dd21f94cd2d273f0da", "source_updated_at": "2025-08-21", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/fampyra-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1361}
{"after": {"end": 23, "start": 0, "text": "60318 Frankfurt am Main", "truncated": false}, "after_length": 23, "after_sha256": "24c3191b5088b20c209c4387a8127297e54c776e161d305c9e57956a13b7cbbe", "annex": "I", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "administrative", "change_operations": [{"after_end": 23, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 23}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-e721c10f749ad22b754ce9f6", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002097", "medicine_name": "Fampyra", "medicine_slug": "fampyra", "observed_at": "2026-10-12T19:15:51Z", "pipeline_version": "2.0.0", "presentation_label": "Fampyra 10 mg prolonged-release tablets", "presentation_occurrence": 1, "presentation_status": "heading_extracted_unverified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "7", "section_type": "administrative", "source_provider": "European Medicines Agency", "source_sha256": "d9fe8aaaa611a84801d6308b13685258b5248df9022536697939afdf66fc1719", "source_snapshot_id": "source-ff8e0599077f0d01044dc867", "source_updated_at": "2025-08-21", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/fampyra-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 688}
{"after": {"end": 23, "start": 0, "text": "info@euroceptpharma.com", "truncated": false}, "after_length": 23, "after_sha256": "9297cc5acdcc837f054116992765943f7907937507b2564a99ea1327a00ac0e6", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 23, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 23}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-e735bc470175931bcdea3ae8", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:14Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "8b8c4cc8e6f1a21fedee4bf0743c9c03e454b50f5eaba0e3760416d7fe0a74ec", "source_snapshot_id": "source-4efe4ecf3ebf08d338a763a5", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1902}
{"after": {"end": 30, "start": 0, "text": "Nederland/Pays-Bas/Niederlande", "truncated": false}, "after_length": 30, "after_sha256": "531c576490cac7295a5202182f4a0efb0dc7a4acfd97f71ab0f5a345dd36c11a", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 30, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 30}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-e74dc3e513c13597520bb667", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002097", "medicine_name": "Fampyra", "medicine_slug": "fampyra", "observed_at": "2026-10-12T19:16:07Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "a0c3ba8d58d6a43a809ecc3d142a78b10c2bd7f0b9f3a3553df2617d87daec1f", "source_snapshot_id": "source-c7a810dd21f94cd2d273f0da", "source_updated_at": "2025-08-21", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/fampyra-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1380}
{"after": {"end": 26, "start": 0, "text": "Eckenheimer Landstraße 100", "truncated": false}, "after_length": 26, "after_sha256": "fdce1a9bd200c5ddd476c1ea5676b9ffbbea723f7353ad6fbc1fe019dcb86c07", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 26, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 26}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-e7506dd0bd947624d953c51d", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002097", "medicine_name": "Fampyra", "medicine_slug": "fampyra", "observed_at": "2026-10-12T19:16:07Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "a0c3ba8d58d6a43a809ecc3d142a78b10c2bd7f0b9f3a3553df2617d87daec1f", "source_snapshot_id": "source-c7a810dd21f94cd2d273f0da", "source_updated_at": "2025-08-21", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/fampyra-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1562}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 38, "start": 0, "text": "sanofi-aventis Ireland Ltd. T/A SANOFI", "truncated": false}, "before_length": 38, "before_sha256": "dad9251ce581d41bcfcb8818c11a57a8d3490b978d09cf04cfd9162a081c8d28", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 38, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 38, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-e75afa71c858a354a7dc6f38", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002702", "medicine_name": "Hexacima", "medicine_slug": "hexacima", "observed_at": "2026-10-12T19:07:06Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "b990725709f885f3f868e5da444393a40a54f89ba2f2d9b232d9c053493d1b03", "source_snapshot_id": "source-87ea40f95d82cdfb5ba074b0", "source_updated_at": "2025-09-29", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/hexacima-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1686}
{"after": {"end": 20, "start": 0, "text": "Tel: +386 1 2355 100", "truncated": false}, "after_length": 20, "after_sha256": "08d49fea809e3878122f78a398ef6a77d2a4cf472eb2cf3d9f1450515a1ced0f", "annex": "IIIA", "before": {"end": 19, "start": 0, "text": "Tel: +386 235 51 00", "truncated": false}, "before_length": 19, "before_sha256": "fd65023f7b15127a4e3fb22b56c0b3c2e844610946d4b104bb5a61e296f3bb32", "change_kind": "content", "change_operations": [{"after_end": 12, "after_start": 10, "before_end": 10, "before_start": 10, "kind": "insert"}, {"after_end": 16, "after_start": 15, "before_end": 13, "before_start": 13, "kind": "insert"}, {"after_end": 17, "after_start": 17, "before_end": 15, "before_start": 14, "kind": "delete"}, {"after_end": 18, "after_start": 18, "before_end": 17, "before_start": 16, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 2, "chars_inserted": 3}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-e7722f3a421f540f3f53bd98", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002702", "medicine_name": "Hexacima", "medicine_slug": "hexacima", "observed_at": "2026-10-12T19:07:04Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "44c8996457a718019c75b8322ba07a5ae7af36377b1a6f1cf4ca5a30f9b72c23", "source_snapshot_id": "source-fa766d966dea704c333b9969", "source_updated_at": "2025-09-29", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/hexacima-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 2090}
{"after": {"end": 16, "start": 0, "text": "Extrovis EU Kft.", "truncated": false}, "after_length": 16, "after_sha256": "b9216ef80e71e17798dce313e4318f03f37328f225d30ab508b7413813a908e5", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 16, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 16}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-e7a253b43d36e577757769b2", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/006047", "medicine_name": "Lacosamide Adroiq", "medicine_slug": "lacosamide-adroiq", "observed_at": "2026-10-12T19:07:59Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "cc83d966059d42856d0211a4f256b29b20d43593865704d6a9315aeb694f3c76", "source_snapshot_id": "source-896abba1d8391c918345d46b", "source_updated_at": "2025-09-25", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/lacosamide-adroiq-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1855}
{"after": {"end": 22, "start": 0, "text": "Tel: +31 (0) 762057088", "truncated": false}, "after_length": 22, "after_sha256": "c454b0c9bb138a63ac3390284b6a75f5d68e39351b0aff35e8f0847a98b3625d", "annex": "IIIA", "before": {"end": 23, "start": 0, "text": "Tel: +353 (0)1 231 4609", "truncated": false}, "before_length": 23, "before_sha256": "a115f11f382ef18898b9d956e48603ae236fd1846ce41e8586af99b6dabbfc4d", "change_kind": "content", "change_operations": [{"after_end": 8, "after_start": 7, "before_end": 9, "before_start": 7, "kind": "replace"}, {"after_end": 12, "after_start": 12, "before_end": 14, "before_start": 13, "kind": "delete"}, {"after_end": 15, "after_start": 13, "before_end": 15, "before_start": 15, "kind": "insert"}, {"after_end": 16, "after_start": 16, "before_end": 21, "before_start": 16, "kind": "delete"}, {"after_end": 22, "after_start": 17, "before_end": 23, "before_start": 22, "kind": "replace"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 9, "chars_inserted": 8}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-e7b160bd2e4b8738892a7a59", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002097", "medicine_name": "Fampyra", "medicine_slug": "fampyra", "observed_at": "2026-10-12T19:16:07Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "a0c3ba8d58d6a43a809ecc3d142a78b10c2bd7f0b9f3a3553df2617d87daec1f", "source_snapshot_id": "source-c7a810dd21f94cd2d273f0da", "source_updated_at": "2025-08-21", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/fampyra-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1464}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 27, "start": 0, "text": "(Eurocept International BV)", "truncated": false}, "before_length": 27, "before_sha256": "e6cf9b20aaa466e53ad0d393512ca75931e13e488321e3be6f3e4f8b600970c8", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 27, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 27, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-e7c06205c535f479a1e44e6d", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:19Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "77586d0bea0858214b43b86e91abc2d2711733b96959ead5ed0b5ecbd8ed888a", "source_snapshot_id": "source-85d476f9ad959cc117ca8f1f", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1855}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "I", "before": {"end": 20, "start": 0, "text": "10 Earlsfort Terrace", "truncated": false}, "before_length": 20, "before_sha256": "22951bbf6ee77815d0c07b3af5f0a66e17d277636971c4eaff372dea65dcb193", "change_kind": "administrative", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 20, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 20, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-e879cb24eb38ae9a972b7e31", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002097", "medicine_name": "Fampyra", "medicine_slug": "fampyra", "observed_at": "2026-10-12T19:16:07Z", "pipeline_version": "2.0.0", "presentation_label": "Fampyra 10 mg, comprimés à libération prolongée", "presentation_occurrence": 1, "presentation_status": "heading_extracted_unverified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "7", "section_type": "administrative", "source_provider": "European Medicines Agency", "source_sha256": "a0c3ba8d58d6a43a809ecc3d142a78b10c2bd7f0b9f3a3553df2617d87daec1f", "source_snapshot_id": "source-c7a810dd21f94cd2d273f0da", "source_updated_at": "2025-08-21", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/fampyra-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 680}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 18, "start": 0, "text": "Dublin 2, D02 T380", "truncated": false}, "before_length": 18, "before_sha256": "23e6871e7960b0dadc753bc127bbea230cc8308c88b2d33704eb275a3ec1a70d", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 18, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 18, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-e8914e130469b133cf86ad30", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002097", "medicine_name": "Fampyra", "medicine_slug": "fampyra", "observed_at": "2026-10-12T19:16:07Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "a0c3ba8d58d6a43a809ecc3d142a78b10c2bd7f0b9f3a3553df2617d87daec1f", "source_snapshot_id": "source-c7a810dd21f94cd2d273f0da", "source_updated_at": "2025-08-21", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/fampyra-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1396}
{"after": {"end": 23, "start": 0, "text": "info@euroceptpharma.com", "truncated": false}, "after_length": 23, "after_sha256": "9297cc5acdcc837f054116992765943f7907937507b2564a99ea1327a00ac0e6", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 23, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 23}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-e8935a2d7748454b87143da5", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:14Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "8b8c4cc8e6f1a21fedee4bf0743c9c03e454b50f5eaba0e3760416d7fe0a74ec", "source_snapshot_id": "source-4efe4ecf3ebf08d338a763a5", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1468}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 21, "start": 0, "text": "Tel: + 33 153 868 750", "truncated": false}, "before_length": 21, "before_sha256": "efffe29324e968019e6e2b111904182ba06d83e76b1f29b933bed9dd8779c114", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 21, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 21, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-e89db60f780a37d055901825", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:14Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "8b8c4cc8e6f1a21fedee4bf0743c9c03e454b50f5eaba0e3760416d7fe0a74ec", "source_snapshot_id": "source-4efe4ecf3ebf08d338a763a5", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1532}
{"after": {"end": 23, "start": 0, "text": "info@euroceptpharma.com", "truncated": false}, "after_length": 23, "after_sha256": "9297cc5acdcc837f054116992765943f7907937507b2564a99ea1327a00ac0e6", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 23, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 23}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-e95ae351ad9c1388ccad831b", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:19Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "77586d0bea0858214b43b86e91abc2d2711733b96959ead5ed0b5ecbd8ed888a", "source_snapshot_id": "source-85d476f9ad959cc117ca8f1f", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1842}
{"after": {"end": 26, "start": 0, "text": "Eckenheimer Landstraße 100", "truncated": false}, "after_length": 26, "after_sha256": "fdce1a9bd200c5ddd476c1ea5676b9ffbbea723f7353ad6fbc1fe019dcb86c07", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 26, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 26}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-e972dad79b66c43c3359ac97", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002097", "medicine_name": "Fampyra", "medicine_slug": "fampyra", "observed_at": "2026-10-12T19:16:07Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "a0c3ba8d58d6a43a809ecc3d142a78b10c2bd7f0b9f3a3553df2617d87daec1f", "source_snapshot_id": "source-c7a810dd21f94cd2d273f0da", "source_updated_at": "2025-08-21", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/fampyra-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1037}
{"after": {"end": 18, "start": 0, "text": "Tel: +39 800081631", "truncated": false}, "after_length": 18, "after_sha256": "e9fce0d94f9041280e35646ab57e254fcbe728cc284affbb3960407773c3578b", "annex": "IIIA", "before": {"end": 20, "start": 0, "text": "Tel: +39-02-38598801", "truncated": false}, "before_length": 20, "before_sha256": "b6360c0dfd7fea5b5771d4a018fb270c0d84f69f9d874f189292e2bdbb54fd10", "change_kind": "content", "change_operations": [{"after_end": 9, "after_start": 8, "before_end": 17, "before_start": 8, "kind": "replace"}, {"after_end": 17, "after_start": 11, "before_end": 19, "before_start": 19, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 9, "chars_inserted": 7}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-e97e708130bd4cb3bef2de58", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/006047", "medicine_name": "Lacosamide Adroiq", "medicine_slug": "lacosamide-adroiq", "observed_at": "2026-10-12T19:07:59Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "cc83d966059d42856d0211a4f256b29b20d43593865704d6a9315aeb694f3c76", "source_snapshot_id": "source-896abba1d8391c918345d46b", "source_updated_at": "2025-09-25", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/lacosamide-adroiq-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1834}
{"after": {"end": 21, "start": 0, "text": "Tel: +31 35 528 39 57", "truncated": false}, "after_length": 21, "after_sha256": "7baf6601f41e49e470f803fdd4e755a86efa38be423317c000ed79963ebdd213", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 21, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 21}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-ea345e8a3391c667981a127c", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:14Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "8b8c4cc8e6f1a21fedee4bf0743c9c03e454b50f5eaba0e3760416d7fe0a74ec", "source_snapshot_id": "source-4efe4ecf3ebf08d338a763a5", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1566}
{"after": {"end": 123, "start": 0, "text": "For more information, see the European Medicines Agency’s website: https://www.ema.europa.eu/en/medicines/human/epar/Byfavo", "truncated": false}, "after_length": 123, "after_sha256": "046df1412e740f74be5a5262443d755298e7fcccbe8b2146cac818f85edc5f6a", "annex": "", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "unassigned", "change_operations": [{"after_end": 123, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 123}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-ea34b4f279f448d5f2df707d", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/005246", "medicine_name": "Byfavo", "medicine_slug": "byfavo", "observed_at": "2026-10-12T13:28:14Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": null, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "", "section_type": "unassigned", "source_provider": "European Medicines Agency", "source_sha256": "92a178ceb705631219efa40b1d0da73ebe6dfa866bc1b24d7e4dab9ded8a6861", "source_snapshot_id": "source-d485be5d9060fd557be910b2", "source_updated_at": "2026-08-26", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/byfavo-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 2}
{"after": {"end": 25, "start": 0, "text": "Eurocept International BV", "truncated": false}, "after_length": 25, "after_sha256": "b17bd89b3cf285c986a6070d0d67f5326dd5c1f08a70834c296c6c820f9e7505", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 25, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 25}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-ead1d7c1126a1af827f23a28", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:14Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "8b8c4cc8e6f1a21fedee4bf0743c9c03e454b50f5eaba0e3760416d7fe0a74ec", "source_snapshot_id": "source-4efe4ecf3ebf08d338a763a5", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1466}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 18, "start": 0, "text": "Dublin 2, D02 T380", "truncated": false}, "before_length": 18, "before_sha256": "23e6871e7960b0dadc753bc127bbea230cc8308c88b2d33704eb275a3ec1a70d", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 18, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 18, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-eb05b76f98fbad8baaee8502", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002097", "medicine_name": "Fampyra", "medicine_slug": "fampyra", "observed_at": "2026-10-12T19:15:51Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "d9fe8aaaa611a84801d6308b13685258b5248df9022536697939afdf66fc1719", "source_snapshot_id": "source-ff8e0599077f0d01044dc867", "source_updated_at": "2025-08-21", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/fampyra-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1380}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 21, "start": 0, "text": "info@lucanepharma.com", "truncated": false}, "before_length": 21, "before_sha256": "44fd39e5fb919cb3d680fa630da23b49238fec29159c509f3622f272bb41c7c6", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 21, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 21, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-eb0cbcd6ca0a06e7864db56e", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:19Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "77586d0bea0858214b43b86e91abc2d2711733b96959ead5ed0b5ecbd8ed888a", "source_snapshot_id": "source-85d476f9ad959cc117ca8f1f", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1982}
{"after": {"end": 23, "start": 0, "text": "60318 Frankfurt am Main", "truncated": false}, "after_length": 23, "after_sha256": "24c3191b5088b20c209c4387a8127297e54c776e161d305c9e57956a13b7cbbe", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 23, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 23}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-eb137ab6579b4ccdc4aff29a", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002097", "medicine_name": "Fampyra", "medicine_slug": "fampyra", "observed_at": "2026-10-12T19:16:07Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "a0c3ba8d58d6a43a809ecc3d142a78b10c2bd7f0b9f3a3553df2617d87daec1f", "source_snapshot_id": "source-c7a810dd21f94cd2d273f0da", "source_updated_at": "2025-08-21", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/fampyra-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1626}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 27, "start": 0, "text": "(Eurocept International BV)", "truncated": false}, "before_length": 27, "before_sha256": "e6cf9b20aaa466e53ad0d393512ca75931e13e488321e3be6f3e4f8b600970c8", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 27, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 27, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-eb3cd326d73934aa68a9f6c1", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:19Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "77586d0bea0858214b43b86e91abc2d2711733b96959ead5ed0b5ecbd8ed888a", "source_snapshot_id": "source-85d476f9ad959cc117ca8f1f", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1939}
{"after": {"end": 220, "start": 0, "text": "Si votre bébé est âgé de moins de 4 semaines, consultez votre médecin ou votre pharmacien avant de lui donner cet arôme, en particulier si le bébé reçoit d’autres médicaments contenant du propylène glycol ou de l’alcool.", "truncated": false}, "after_length": 220, "after_sha256": "82d965d7f3933904d2d63d21dea860afc36b53ccacc19115813b6d341af8ee25", "annex": "I", "before": {"end": 224, "start": 0, "text": "Si votre bébé est âgé de moins de 4 semaines, consultez votre médecin ou votre pharmacien avant de lui donner ce médicament, en particulier si le bébé reçoit d’autres médicaments contenant du propylène glycol ou de l’alcool.", "truncated": false}, "before_length": 224, "before_sha256": "4da4000b63141de5814a102ec1a2df16618663fa4660b111ee9514bcbe2003b7", "change_kind": "content", "change_operations": [{"after_end": 113, "after_start": 112, "before_end": 112, "before_start": 112, "kind": "insert"}, {"after_end": 114, "after_start": 114, "before_end": 118, "before_start": 113, "kind": "delete"}, {"after_end": 117, "after_start": 115, "before_end": 119, "before_start": 119, "kind": "insert"}, {"after_end": 119, "after_start": 119, "before_end": 123, "before_start": 121, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": true, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 7, "chars_inserted": 3}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-eb5abd3a5049ae55a9c5ded1", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:19Z", "pipeline_version": "2.0.0", "presentation_label": "PHEBURANE 350 mg/ml solution buvable", "presentation_occurrence": 2, "presentation_status": "heading_extracted_unverified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "4.4", "section_type": "warning", "source_provider": "European Medicines Agency", "source_sha256": "77586d0bea0858214b43b86e91abc2d2711733b96959ead5ed0b5ecbd8ed888a", "source_snapshot_id": "source-85d476f9ad959cc117ca8f1f", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 433}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 24, "start": 0, "text": "Τηλ: +358 (0) 3 284 8111", "truncated": false}, "before_length": 24, "before_sha256": "d6067cd3f2a7a2e958ac076aba456632e50c80f365a8e35948e7f408fe8f5396", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 24, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 24, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-ebabd881ae16620c7d5f6e78", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002066", "medicine_name": "Ikervis", "medicine_slug": "ikervis", "observed_at": "2026-10-12T13:34:16Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "ab05f9fab48768c68482390488c5b90c577e852974d4448da6ea8fe5a4eda856", "source_snapshot_id": "source-324751bde2e11edc76c2dbfe", "source_updated_at": "2026-06-23", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/ikervis-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1426}
{"after": {"end": 20, "start": 0, "text": "Pays-Bas/Niederlande", "truncated": false}, "after_length": 20, "after_sha256": "3ec90945e96bc0329608c9d655b3faf37a91ae94f1c8b5c2223902ae05d9db34", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 20, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 20}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-ebc5885b25ba727f804f3084", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002097", "medicine_name": "Fampyra", "medicine_slug": "fampyra", "observed_at": "2026-10-12T19:16:07Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "a0c3ba8d58d6a43a809ecc3d142a78b10c2bd7f0b9f3a3553df2617d87daec1f", "source_snapshot_id": "source-c7a810dd21f94cd2d273f0da", "source_updated_at": "2025-08-21", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/fampyra-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1410}
{"after": {"end": 8, "start": 0, "text": "Njemačka", "truncated": false}, "after_length": 8, "after_sha256": "d86d75a0350345bd2fc6c8bca77b927decba49ece60e02b51c592d8d5cd55dd8", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 8, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 8}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-ebe2f76040de4fbda28335d7", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002097", "medicine_name": "Fampyra", "medicine_slug": "fampyra", "observed_at": "2026-10-12T19:16:07Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "a0c3ba8d58d6a43a809ecc3d142a78b10c2bd7f0b9f3a3553df2617d87daec1f", "source_snapshot_id": "source-c7a810dd21f94cd2d273f0da", "source_updated_at": "2025-08-21", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/fampyra-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1535}
{"after": {"end": 153, "start": 0, "text": "Des cas de maladies musculaires inflammatoires et de dégradation musculaire (myosite et rhabdomyolyse) ont été rapportés chez des patients prenant Arava.", "truncated": false}, "after_length": 153, "after_sha256": "bf44af41f5e86d44b1efb868b810995f7e8139f5f6be57cd1a49b92c73815dce", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 153, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 153}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-ec5fa264812bc5f727d8e79d", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/000235", "medicine_name": "Arava", "medicine_slug": "arava", "observed_at": "2026-10-12T13:28:00Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": null, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "98b73c5c6b1e5009c9d048f8f11257f3a8407759fd25a4c8d5ef5c611519e916", "source_snapshot_id": "source-4b7ea3b78addea82376b3432", "source_updated_at": "2026-09-07", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/arava-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 2701}
{"after": {"end": 30, "start": 0, "text": "Merz Therapeutics Benelux B.V.", "truncated": false}, "after_length": 30, "after_sha256": "7c5530f091b2eaff46486c1452be442d4a9c6f4c46924db34e94c6cdb089882e", "annex": "IIIA", "before": {"end": 35, "start": 0, "text": "Acorda Therapeutics Ireland Limited", "truncated": false}, "before_length": 35, "before_sha256": "d94d3153d193ed26567f2b4ed48df016d81c534e7c0cb1a6655a63f0083383ff", "change_kind": "content", "change_operations": [{"after_end": 2, "after_start": 0, "before_end": 3, "before_start": 0, "kind": "replace"}, {"after_end": 4, "after_start": 3, "before_end": 6, "before_start": 4, "kind": "replace"}, {"after_end": 21, "after_start": 18, "before_end": 22, "before_start": 20, "kind": "replace"}, {"after_end": 25, "after_start": 23, "before_end": 27, "before_start": 24, "kind": "replace"}, {"after_end": 30, "after_start": 26, "before_end": 35, "before_start": 28, "kind": "replace"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 17, "chars_inserted": 12}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-ec6fde1706b7b70a32fc3993", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002097", "medicine_name": "Fampyra", "medicine_slug": "fampyra", "observed_at": "2026-10-12T19:15:51Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "d9fe8aaaa611a84801d6308b13685258b5248df9022536697939afdf66fc1719", "source_snapshot_id": "source-ff8e0599077f0d01044dc867", "source_updated_at": "2025-08-21", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/fampyra-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1368}
{"after": {"end": 27, "start": 0, "text": "CPO Pharmaceuticals Limited", "truncated": false}, "after_length": 27, "after_sha256": "94b644443752e2cb52916b23f8141fbd44c47055b3416af333e12ac18e101b87", "annex": "IIIA", "before": {"end": 23, "start": 0, "text": "GPA Pharmaceuticals Ltd", "truncated": false}, "before_length": 23, "before_sha256": "ece7127e303c91e9501d2cedd822476265aae86acb9f96ef1553ab3a6954afe1", "change_kind": "content", "change_operations": [{"after_end": 1, "after_start": 0, "before_end": 1, "before_start": 0, "kind": "replace"}, {"after_end": 3, "after_start": 2, "before_end": 3, "before_start": 2, "kind": "replace"}, {"after_end": 24, "after_start": 21, "before_end": 21, "before_start": 21, "kind": "insert"}, {"after_end": 26, "after_start": 25, "before_end": 22, "before_start": 22, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 2, "chars_inserted": 6}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-ec86f5921e531d35111737f5", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/004025", "medicine_name": "Lopinavir/Ritonavir Viatris (previously Ritonavir Mylan)", "medicine_slug": "lopinavir-ritonavir-viatris-previously-ritonavir-mylan", "observed_at": "2026-10-12T19:14:59Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "d782e33ec97bc43bb54f942c83f07f89482c9a433e3846beaffe05b4a52b4b36", "source_snapshot_id": "source-ff48b23a80b98be4c15aa440", "source_updated_at": "2025-09-08", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/lopinavir-ritonavir-viatris-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 3440}
{"after": {"end": 9, "start": 0, "text": "Not known", "truncated": false}, "after_length": 9, "after_sha256": "117adf013b8521b57cc432f1d680aa8ca8ffe7ac83edfa7e0a5867794a6429cc", "annex": "I", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 9, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": true, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 9}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-ec8d5ab8f34950372f23eae6", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/000554", "medicine_name": "Emselex", "medicine_slug": "emselex", "observed_at": "2026-10-12T19:12:04Z", "pipeline_version": "2.0.0", "presentation_label": "Emselex 15 mg prolonged-release tablets", "presentation_occurrence": 2, "presentation_status": "heading_extracted_unverified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "4.8", "section_type": "adverse_reactions", "source_provider": "European Medicines Agency", "source_sha256": "4f2565612bc728ec67b7f9c0cd5799ef2c594911c76f323aef8bf6a85adde245", "source_snapshot_id": "source-1fda25b331eb198b8b93feb3", "source_updated_at": "2025-09-15", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/emselex-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 638}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 33, "start": 0, "text": "United Kingdom (Northern Ireland)", "truncated": false}, "before_length": 33, "before_sha256": "9379d82927cdb505cfb186e912177065e56a1314de3a2b914ebbb8b5fe21525a", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 33, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 33, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-eccceda27b4dae71804f2b42", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002702", "medicine_name": "Hexacima", "medicine_slug": "hexacima", "observed_at": "2026-10-12T19:07:06Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "b990725709f885f3f868e5da444393a40a54f89ba2f2d9b232d9c053493d1b03", "source_snapshot_id": "source-87ea40f95d82cdfb5ba074b0", "source_updated_at": "2025-09-29", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/hexacima-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1685}
{"after": {"end": 239, "start": 0, "text": "Ce document constitue les informations sur le produit approuvées pour Byfavo, les modifications apportées depuis la procédure précédente qui ont une incidence sur les informations sur le produit (EMA/VR/0000348950) étant mises en évidence.", "truncated": false}, "after_length": 239, "after_sha256": "5a1399af27a4c44f358fd30b1191175a6a1b977ea1a3dd43f137639e4daeab82", "annex": "", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "unassigned", "change_operations": [{"after_end": 239, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 239}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-ece318eabf36d1f20ae6a508", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/005246", "medicine_name": "Byfavo", "medicine_slug": "byfavo", "observed_at": "2026-10-12T13:28:16Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": null, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "", "section_type": "unassigned", "source_provider": "European Medicines Agency", "source_sha256": "61243a969f979f690fe718e414ceaeb66438c1faa31101ba25187d2f9ea662fd", "source_snapshot_id": "source-dd26eb8615d8c18bd80c1f6a", "source_updated_at": "2026-08-26", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/byfavo-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 0}
{"after": {"end": 16, "start": 0, "text": "Extrovis EU Kft.", "truncated": false}, "after_length": 16, "after_sha256": "b9216ef80e71e17798dce313e4318f03f37328f225d30ab508b7413813a908e5", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 16, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 16}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-ed08043c70f2810cf49adf48", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/006047", "medicine_name": "Lacosamide Adroiq", "medicine_slug": "lacosamide-adroiq", "observed_at": "2026-10-12T19:07:59Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "cc83d966059d42856d0211a4f256b29b20d43593865704d6a9315aeb694f3c76", "source_snapshot_id": "source-896abba1d8391c918345d46b", "source_updated_at": "2025-09-25", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/lacosamide-adroiq-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1722}
{"after": {"end": 21, "start": 0, "text": "Tel: +31 35 528 39 57", "truncated": false}, "after_length": 21, "after_sha256": "7baf6601f41e49e470f803fdd4e755a86efa38be423317c000ed79963ebdd213", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 21, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 21}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-ed642a2f28aab7ebd0f65b6d", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:14Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "8b8c4cc8e6f1a21fedee4bf0743c9c03e454b50f5eaba0e3760416d7fe0a74ec", "source_snapshot_id": "source-4efe4ecf3ebf08d338a763a5", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1598}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 6, "start": 0, "text": "Írland", "truncated": false}, "before_length": 6, "before_sha256": "79e1686a0077421a1a954c9396db299b5732be9336ce03f0071f7749fcd800a0", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 6, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 6, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-ed69c0592c0646b302bc17f9", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002097", "medicine_name": "Fampyra", "medicine_slug": "fampyra", "observed_at": "2026-10-12T19:15:51Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "d9fe8aaaa611a84801d6308b13685258b5248df9022536697939afdf66fc1719", "source_snapshot_id": "source-ff8e0599077f0d01044dc867", "source_updated_at": "2025-08-21", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/fampyra-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1564}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 20, "start": 0, "text": "10 Earlsfort Terrace", "truncated": false}, "before_length": 20, "before_sha256": "22951bbf6ee77815d0c07b3af5f0a66e17d277636971c4eaff372dea65dcb193", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 20, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 20, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-eded3093165924a25b3e737d", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002097", "medicine_name": "Fampyra", "medicine_slug": "fampyra", "observed_at": "2026-10-12T19:15:51Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "d9fe8aaaa611a84801d6308b13685258b5248df9022536697939afdf66fc1719", "source_snapshot_id": "source-ff8e0599077f0d01044dc867", "source_updated_at": "2025-08-21", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/fampyra-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1452}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "I", "before": {"end": 18, "start": 0, "text": "Pátriárka utca 14.", "truncated": false}, "before_length": 18, "before_sha256": "488a80d25b682a58591b4751c4687d5b516ccd6a004748e40d4e8f1454217b07", "change_kind": "administrative", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 18, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 18, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-ee3213a117616f3809b3daca", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/006047", "medicine_name": "Lacosamide Adroiq", "medicine_slug": "lacosamide-adroiq", "observed_at": "2026-10-12T19:07:56Z", "pipeline_version": "2.0.0", "presentation_label": "Lacosamide Adroiq 10 mg/ml solution for infusion", "presentation_occurrence": 1, "presentation_status": "heading_extracted_unverified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "7", "section_type": "administrative", "source_provider": "European Medicines Agency", "source_sha256": "0578c53a5e1c785c4d9d4dc0dabae49dbfa89e237aa571556bee548c3f9cf4d5", "source_snapshot_id": "source-64831dec5ebf55535e19d91b", "source_updated_at": "2025-09-25", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/lacosamide-adroiq-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 923}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 11, "start": 0, "text": "Sandoz GmbH", "truncated": false}, "before_length": 11, "before_sha256": "503d20ac6cfe17be906a08dea4551c3c95b04eb3306e0f2392e0ef4f74d9fb03", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 11, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 11, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-ee40c3fd00ea8b4d28ac8ff9", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/000725", "medicine_name": "Binocrit", "medicine_slug": "binocrit", "observed_at": "2026-10-12T19:28:20Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "b2bb40c100cab3babee14bbe20cc7718cb73ac1bbb3971dfd487c4f10a0e6478", "source_snapshot_id": "source-b97c331d23a7a0f19aebfb61", "source_updated_at": "2025-07-11", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/binocrit-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 3447}
{"after": {"end": 7, "start": 0, "text": "Nemčija", "truncated": false}, "after_length": 7, "after_sha256": "8728a912120c7cbc7d783419a6aa9043a427c04e373baed3d52316c7b253fb79", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 7, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 7}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-ee51d8ae873cd013464aaf45", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002097", "medicine_name": "Fampyra", "medicine_slug": "fampyra", "observed_at": "2026-10-12T19:15:51Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "d9fe8aaaa611a84801d6308b13685258b5248df9022536697939afdf66fc1719", "source_snapshot_id": "source-ff8e0599077f0d01044dc867", "source_updated_at": "2025-08-21", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/fampyra-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1558}
{"after": {"end": 29, "start": 0, "text": "64th Km National Road Athens,", "truncated": false}, "after_length": 29, "after_sha256": "13ea56883a0ab9bffcaa1dd41d9bf3581890cd7cfc6830634cd50feb121599ea", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 29, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 29}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-ee52c6e5d03db2f4cca47162", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/003984", "medicine_name": "Bortezomib Accord", "medicine_slug": "bortezomib-accord", "observed_at": "2026-10-12T13:47:15Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "150a191aaf0a1e169e9d5fa2530f0eccb4e3d46509faf5ec5ee975a2e67788c4", "source_snapshot_id": "source-cba4680b7fbd2c536884abd8", "source_updated_at": "2026-03-25", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/bortezomib-accord-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 4297}
{"after": {"end": 26, "start": 0, "text": "Dipharma Arzneimittel GmbH", "truncated": false}, "after_length": 26, "after_sha256": "d8cb257047b7439a3be44a22f3227e45df27054340bbfa9cd6525bbf1d237add", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 26, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 26}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-ee5c7a6c93052b1d6ceac889", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:14Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "8b8c4cc8e6f1a21fedee4bf0743c9c03e454b50f5eaba0e3760416d7fe0a74ec", "source_snapshot_id": "source-4efe4ecf3ebf08d338a763a5", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1962}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 18, "start": 0, "text": "Dublin 2, D02 T380", "truncated": false}, "before_length": 18, "before_sha256": "23e6871e7960b0dadc753bc127bbea230cc8308c88b2d33704eb275a3ec1a70d", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 18, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 18, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-ee7e10b786ff386c5d30e3dc", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002097", "medicine_name": "Fampyra", "medicine_slug": "fampyra", "observed_at": "2026-10-12T19:16:07Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "a0c3ba8d58d6a43a809ecc3d142a78b10c2bd7f0b9f3a3553df2617d87daec1f", "source_snapshot_id": "source-c7a810dd21f94cd2d273f0da", "source_updated_at": "2025-08-21", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/fampyra-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1357}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 33, "start": 0, "text": "United Kingdom (Northern Ireland)", "truncated": false}, "before_length": 33, "before_sha256": "9379d82927cdb505cfb186e912177065e56a1314de3a2b914ebbb8b5fe21525a", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 33, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 33, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-ee926946d0dd79761814dab2", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/000619", "medicine_name": "Fosavance", "medicine_slug": "fosavance", "observed_at": "2026-10-12T19:01:48Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "37324165444dd93963c38ccfa569b0631b8d34d16c725b5a46b16dd7bb4cbbc2", "source_snapshot_id": "source-829e9ebd79c1d98e8a839547", "source_updated_at": "2026-02-12", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/fosavance-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1315}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 20, "start": 0, "text": "10 Earlsfort Terrace", "truncated": false}, "before_length": 20, "before_sha256": "22951bbf6ee77815d0c07b3af5f0a66e17d277636971c4eaff372dea65dcb193", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 20, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 20, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-ee9fdec6b0c875996df2870b", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002097", "medicine_name": "Fampyra", "medicine_slug": "fampyra", "observed_at": "2026-10-12T19:16:07Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "a0c3ba8d58d6a43a809ecc3d142a78b10c2bd7f0b9f3a3553df2617d87daec1f", "source_snapshot_id": "source-c7a810dd21f94cd2d273f0da", "source_updated_at": "2025-08-21", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/fampyra-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1559}
{"after": {"end": 22, "start": 0, "text": "Merz Therapeutics GmbH", "truncated": false}, "after_length": 22, "after_sha256": "059f049c7d0846aaadcf2573280d52110f302d4ecc7b38debd004571cd1e9d5e", "annex": "IIIA", "before": {"end": 35, "start": 0, "text": "Acorda Therapeutics Ireland Limited", "truncated": false}, "before_length": 35, "before_sha256": "d94d3153d193ed26567f2b4ed48df016d81c534e7c0cb1a6655a63f0083383ff", "change_kind": "content", "change_operations": [{"after_end": 2, "after_start": 0, "before_end": 3, "before_start": 0, "kind": "replace"}, {"after_end": 4, "after_start": 3, "before_end": 6, "before_start": 4, "kind": "replace"}, {"after_end": 19, "after_start": 18, "before_end": 30, "before_start": 20, "kind": "replace"}, {"after_end": 22, "after_start": 20, "before_end": 35, "before_start": 31, "kind": "replace"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 19, "chars_inserted": 6}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-eeb69e7f6e6255a5e3ed97da", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002097", "medicine_name": "Fampyra", "medicine_slug": "fampyra", "observed_at": "2026-10-12T19:16:07Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "a0c3ba8d58d6a43a809ecc3d142a78b10c2bd7f0b9f3a3553df2617d87daec1f", "source_snapshot_id": "source-c7a810dd21f94cd2d273f0da", "source_updated_at": "2025-08-21", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/fampyra-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1424}
{"after": {"end": 23, "start": 0, "text": "info@euroceptpharma.com", "truncated": false}, "after_length": 23, "after_sha256": "9297cc5acdcc837f054116992765943f7907937507b2564a99ea1327a00ac0e6", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 23, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 23}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-eec4ac10bc66b10d4f8e189d", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:19Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "77586d0bea0858214b43b86e91abc2d2711733b96959ead5ed0b5ecbd8ed888a", "source_snapshot_id": "source-85d476f9ad959cc117ca8f1f", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1801}
{"after": {"end": 23, "start": 0, "text": "60318 Frankfurt am Main", "truncated": false}, "after_length": 23, "after_sha256": "24c3191b5088b20c209c4387a8127297e54c776e161d305c9e57956a13b7cbbe", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 23, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 23}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-ef72f0dc812c1feeb3b4848c", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002097", "medicine_name": "Fampyra", "medicine_slug": "fampyra", "observed_at": "2026-10-12T19:15:51Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "d9fe8aaaa611a84801d6308b13685258b5248df9022536697939afdf66fc1719", "source_snapshot_id": "source-ff8e0599077f0d01044dc867", "source_updated_at": "2025-08-21", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/fampyra-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1484}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 13, "start": 0, "text": "Lucane Pharma", "truncated": false}, "before_length": 13, "before_sha256": "e338afdb64acf1a6e2083a50318853589248451dd3aa707181ba02641a8521e8", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 13, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 13, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-efbe37f7164045faa0e84dec", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:14Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "8b8c4cc8e6f1a21fedee4bf0743c9c03e454b50f5eaba0e3760416d7fe0a74ec", "source_snapshot_id": "source-4efe4ecf3ebf08d338a763a5", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1949}
{"after": {"end": 16, "start": 0, "text": "Extrovis EU Kft.", "truncated": false}, "after_length": 16, "after_sha256": "b9216ef80e71e17798dce313e4318f03f37328f225d30ab508b7413813a908e5", "annex": "I", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "administrative", "change_operations": [{"after_end": 16, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 16}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-efd10037f8066019dbb991aa", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/006047", "medicine_name": "Lacosamide Adroiq", "medicine_slug": "lacosamide-adroiq", "observed_at": "2026-10-12T19:07:59Z", "pipeline_version": "2.0.0", "presentation_label": "Lacosamide Adroiq 10 mg/ml solution pour perfusion", "presentation_occurrence": 1, "presentation_status": "heading_extracted_unverified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "7", "section_type": "administrative", "source_provider": "European Medicines Agency", "source_sha256": "cc83d966059d42856d0211a4f256b29b20d43593865704d6a9315aeb694f3c76", "source_snapshot_id": "source-896abba1d8391c918345d46b", "source_updated_at": "2025-09-25", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/lacosamide-adroiq-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 910}
{"after": {"end": 25, "start": 0, "text": "Musculoskeletal disorders", "truncated": false}, "after_length": 25, "after_sha256": "554fab09c18c12d65cee54d5caa96534b1925e5ff23a67e98a7c7c04e66bf714", "annex": "I", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 25, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": true, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 25}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-f01a4950458c194ed28bf730", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/000235", "medicine_name": "Arava", "medicine_slug": "arava", "observed_at": "2026-10-12T13:27:58Z", "pipeline_version": "2.0.0", "presentation_label": "Arava 100 mg film-coated tablets", "presentation_occurrence": 3, "presentation_status": "heading_extracted_unverified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "4.4", "section_type": "warning", "source_provider": "European Medicines Agency", "source_sha256": "2efff7967e2237bf8343431eef5e08b56c2441eb8a691a90c64b2635109fd697", "source_snapshot_id": "source-08b4eba1f67d2654148f41c4", "source_updated_at": "2026-09-07", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/arava-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1308}
{"after": {"end": 21, "start": 0, "text": "Teл.: +40 21 528 0290", "truncated": false}, "after_length": 21, "after_sha256": "ec107d1625029392f60daf4b58132a83529ea43f1b9ebdf646436a843f24ad5b", "annex": "IIIA", "before": {"end": 26, "start": 0, "text": "Teл.: +359 (0) 888 755 393", "truncated": false}, "before_length": 26, "before_sha256": "25d34bfa98e800128c16111612beebc119b20f0c6456910d298344a0c0ffe050", "change_kind": "content", "change_operations": [{"after_end": 13, "after_start": 7, "before_end": 8, "before_start": 7, "kind": "replace"}, {"after_end": 15, "after_start": 14, "before_end": 17, "before_start": 9, "kind": "replace"}, {"after_end": 19, "after_start": 17, "before_end": 24, "before_start": 19, "kind": "replace"}, {"after_end": 21, "after_start": 20, "before_end": 26, "before_start": 25, "kind": "replace"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 15, "chars_inserted": 10}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-f01ae7420651aba4eb3afcf6", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002066", "medicine_name": "Ikervis", "medicine_slug": "ikervis", "observed_at": "2026-10-12T13:34:10Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "7995ffe3d4b9c2e870327b45fae2f1d35ae1ab0e1e9e22b434fd9805b58a174e", "source_snapshot_id": "source-5ff0e792002ee89d9eb06e5d", "source_updated_at": "2026-06-23", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/ikervis-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1375}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 21, "start": 0, "text": "Tel: + 33 153 868 750", "truncated": false}, "before_length": 21, "before_sha256": "efffe29324e968019e6e2b111904182ba06d83e76b1f29b933bed9dd8779c114", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 21, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 21, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-f0534c0d15374ec82c1ce234", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:14Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "8b8c4cc8e6f1a21fedee4bf0743c9c03e454b50f5eaba0e3760416d7fe0a74ec", "source_snapshot_id": "source-4efe4ecf3ebf08d338a763a5", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1589}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 22, "start": 0, "text": "Tel : +31 35 528 39 57", "truncated": false}, "before_length": 22, "before_sha256": "7bb8afadf5dee15b4f4e1219e333b993040f0848bccea58b1141990fffb82aa1", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 22, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 22, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-f057a225a4a8f541fce83d99", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:19Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "77586d0bea0858214b43b86e91abc2d2711733b96959ead5ed0b5ecbd8ed888a", "source_snapshot_id": "source-85d476f9ad959cc117ca8f1f", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1958}
{"after": {"end": 16, "start": 0, "text": "Extrovis EU Kft.", "truncated": false}, "after_length": 16, "after_sha256": "b9216ef80e71e17798dce313e4318f03f37328f225d30ab508b7413813a908e5", "annex": "IIIB", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "unassigned", "change_operations": [{"after_end": 16, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 16}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-f07ba57e0830fe2acbfdc4cf", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/006047", "medicine_name": "Lacosamide Adroiq", "medicine_slug": "lacosamide-adroiq", "observed_at": "2026-10-12T19:07:56Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "", "section_type": "unassigned", "source_provider": "European Medicines Agency", "source_sha256": "0578c53a5e1c785c4d9d4dc0dabae49dbfa89e237aa571556bee548c3f9cf4d5", "source_snapshot_id": "source-64831dec5ebf55535e19d91b", "source_updated_at": "2025-09-25", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/lacosamide-adroiq-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1882}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 21, "start": 0, "text": "Tel: +31 35 528 39 57", "truncated": false}, "before_length": 21, "before_sha256": "7baf6601f41e49e470f803fdd4e755a86efa38be423317c000ed79963ebdd213", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 21, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 21, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-f0a584d0638b3c29c624af59", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:14Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "8b8c4cc8e6f1a21fedee4bf0743c9c03e454b50f5eaba0e3760416d7fe0a74ec", "source_snapshot_id": "source-4efe4ecf3ebf08d338a763a5", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 2021}
{"after": {"end": 21, "start": 0, "text": "Tel: +31 35 528 39 57", "truncated": false}, "after_length": 21, "after_sha256": "7baf6601f41e49e470f803fdd4e755a86efa38be423317c000ed79963ebdd213", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 21, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 21}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-f0c8379779a33b6990070cd5", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:19Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "77586d0bea0858214b43b86e91abc2d2711733b96959ead5ed0b5ecbd8ed888a", "source_snapshot_id": "source-85d476f9ad959cc117ca8f1f", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1501}
{"after": {"end": 26, "start": 0, "text": "Eckenheimer Landstraße 100", "truncated": false}, "after_length": 26, "after_sha256": "fdce1a9bd200c5ddd476c1ea5676b9ffbbea723f7353ad6fbc1fe019dcb86c07", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 26, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 26}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-f0d9770bb759ea27c0156cdd", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002097", "medicine_name": "Fampyra", "medicine_slug": "fampyra", "observed_at": "2026-10-12T19:15:51Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "d9fe8aaaa611a84801d6308b13685258b5248df9022536697939afdf66fc1719", "source_snapshot_id": "source-ff8e0599077f0d01044dc867", "source_updated_at": "2025-08-21", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/fampyra-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1504}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "I", "before": {"end": 16, "start": 0, "text": "2000, Szentendre", "truncated": false}, "before_length": 16, "before_sha256": "e7eec80782064f78f9518825c15b4c5b91e88a8bf75f429cef005c9630048901", "change_kind": "administrative", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 16, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 16, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-f12b787731c0fb2dfa2fb6d6", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/006047", "medicine_name": "Lacosamide Adroiq", "medicine_slug": "lacosamide-adroiq", "observed_at": "2026-10-12T19:07:56Z", "pipeline_version": "2.0.0", "presentation_label": "Lacosamide Adroiq 10 mg/ml solution for infusion", "presentation_occurrence": 1, "presentation_status": "heading_extracted_unverified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "7", "section_type": "administrative", "source_provider": "European Medicines Agency", "source_sha256": "0578c53a5e1c785c4d9d4dc0dabae49dbfa89e237aa571556bee548c3f9cf4d5", "source_snapshot_id": "source-64831dec5ebf55535e19d91b", "source_updated_at": "2025-09-25", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/lacosamide-adroiq-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 924}
{"after": {"end": 21, "start": 0, "text": "Tel: +31 35 528 39 57", "truncated": false}, "after_length": 21, "after_sha256": "7baf6601f41e49e470f803fdd4e755a86efa38be423317c000ed79963ebdd213", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 21, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 21}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-f17381079d119d139cc467c2", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:14Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "8b8c4cc8e6f1a21fedee4bf0743c9c03e454b50f5eaba0e3760416d7fe0a74ec", "source_snapshot_id": "source-4efe4ecf3ebf08d338a763a5", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 2023}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 27, "start": 0, "text": "(Eurocept International BV)", "truncated": false}, "before_length": 27, "before_sha256": "e6cf9b20aaa466e53ad0d393512ca75931e13e488321e3be6f3e4f8b600970c8", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 27, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 27, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-f1b03a31ac94da7bad78b4e7", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:14Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "8b8c4cc8e6f1a21fedee4bf0743c9c03e454b50f5eaba0e3760416d7fe0a74ec", "source_snapshot_id": "source-4efe4ecf3ebf08d338a763a5", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1992}
{"after": {"end": 20, "start": 0, "text": "Τηλ: +30 210 8009111", "truncated": false}, "after_length": 20, "after_sha256": "4be2eb2931a7797b144651aebec87029f222cbdda35f539f6c814b9013ffc042", "annex": "IIIA", "before": {"end": 9, "start": 0, "text": "Santen Oy", "truncated": false}, "before_length": 9, "before_sha256": "b8d3bb307d9e8fe0e3311ac213bd7de3f9df0c142a11ebd9fb9b8ec5c7ed12b6", "change_kind": "content", "change_operations": [{"after_end": 4, "after_start": 0, "before_end": 6, "before_start": 0, "kind": "replace"}, {"after_end": 20, "after_start": 5, "before_end": 9, "before_start": 7, "kind": "replace"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 8, "chars_inserted": 19}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-f21e2e4a00ade4c74ef54dbf", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002066", "medicine_name": "Ikervis", "medicine_slug": "ikervis", "observed_at": "2026-10-12T13:34:10Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "7995ffe3d4b9c2e870327b45fae2f1d35ae1ab0e1e9e22b434fd9805b58a174e", "source_snapshot_id": "source-5ff0e792002ee89d9eb06e5d", "source_updated_at": "2026-06-23", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/ikervis-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1414}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "II", "before": {"end": 7, "start": 0, "text": "Ireland", "truncated": false}, "before_length": 7, "before_sha256": "02bf1dfa9a0365a86223f0e4ac9eaa0517b06b2e9273790f719feda656a247ae", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 7, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 7, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-f23c915afed08a5ad916290c", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/004025", "medicine_name": "Lopinavir/Ritonavir Viatris (previously Ritonavir Mylan)", "medicine_slug": "lopinavir-ritonavir-viatris-previously-ritonavir-mylan", "observed_at": "2026-10-12T19:12:46Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "conditions", "section_type": "conditions", "source_provider": "European Medicines Agency", "source_sha256": "3e30663f02732816ed8779d7a929d500c824ae15aeaee9144ca6eef11900e273", "source_snapshot_id": "source-c58e019b5bec1fb24569e83e", "source_updated_at": "2025-09-08", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/lopinavir-ritonavir-viatris-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1470}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 38, "start": 0, "text": "Otsuka Pharmaceutical Netherlands B.V.", "truncated": false}, "before_length": 38, "before_sha256": "2891d7989f773ce0b34a3e835488071e6ffd7e94478e61a5899dcf87bd99c38c", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 38, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 38, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-f28e127f2381732c300b09d7", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/000980", "medicine_name": "Samsca", "medicine_slug": "samsca", "observed_at": "2026-10-12T13:28:23Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "b92d73a758b8976c4438a072d544f0d6c603112c90dfc9c084d362ce62419257", "source_snapshot_id": "source-15b8b5681aba542ec1668c0b", "source_updated_at": "2026-08-20", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/samsca-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1276}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 13, "start": 0, "text": "Lucane Pharma", "truncated": false}, "before_length": 13, "before_sha256": "e338afdb64acf1a6e2083a50318853589248451dd3aa707181ba02641a8521e8", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 13, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 13, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-f2fe3868168d0a36fb9e736e", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:14Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "8b8c4cc8e6f1a21fedee4bf0743c9c03e454b50f5eaba0e3760416d7fe0a74ec", "source_snapshot_id": "source-4efe4ecf3ebf08d338a763a5", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1958}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 56, "start": 0, "text": "35/36 Baldoyle Industrial Estate, Grange Road, Dublin 13", "truncated": false}, "before_length": 56, "before_sha256": "f0fa66e07d117c6c91c11210809d32b098e6ea28fc318be9df3a372f6c002a1a", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 56, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 56, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-f30bbed3ac09830fa464248d", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/004025", "medicine_name": "Lopinavir/Ritonavir Viatris (previously Ritonavir Mylan)", "medicine_slug": "lopinavir-ritonavir-viatris-previously-ritonavir-mylan", "observed_at": "2026-10-12T19:14:59Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "d782e33ec97bc43bb54f942c83f07f89482c9a433e3846beaffe05b4a52b4b36", "source_snapshot_id": "source-ff48b23a80b98be4c15aa440", "source_updated_at": "2025-09-08", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/lopinavir-ritonavir-viatris-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 3331}
{"after": {"end": 105, "start": 0, "text": "CONCLUSIONS SCIENTIFIQUES ET MOTIFS DE LA MODIFICATION DES TERMES DES AUTORISATIONS DE MISE SUR LE MARCHÉ", "truncated": false}, "after_length": 105, "after_sha256": "986a5a8167262a2e1b34885d8bf0d8f1d06f2dd4da8ab0f4d7bedc4081ef8b90", "annex": "IV", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 105, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 105}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-f333f1410093017b9aad52f5", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/000554", "medicine_name": "Emselex", "medicine_slug": "emselex", "observed_at": "2026-10-12T19:12:07Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": null, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "conditions", "section_type": "conditions", "source_provider": "European Medicines Agency", "source_sha256": "9a4f1d7e260c7b80eaf397503623b63302e5945b579e9612177835e07c4ab888", "source_snapshot_id": "source-3aac7bf42b99529f25ac013b", "source_updated_at": "2025-09-15", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/emselex-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 2060}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 21, "start": 0, "text": "info@lucanepharma.com", "truncated": false}, "before_length": 21, "before_sha256": "44fd39e5fb919cb3d680fa630da23b49238fec29159c509f3622f272bb41c7c6", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 21, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 21, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-f483b812795de8bda3a1f39c", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:19Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "77586d0bea0858214b43b86e91abc2d2711733b96959ead5ed0b5ecbd8ed888a", "source_snapshot_id": "source-85d476f9ad959cc117ca8f1f", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1513}
{"after": {"end": 23, "start": 0, "text": "info@euroceptpharma.com", "truncated": false}, "after_length": 23, "after_sha256": "9297cc5acdcc837f054116992765943f7907937507b2564a99ea1327a00ac0e6", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 23, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 23}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-f5233d671c73b27870d190dc", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:14Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "8b8c4cc8e6f1a21fedee4bf0743c9c03e454b50f5eaba0e3760416d7fe0a74ec", "source_snapshot_id": "source-4efe4ecf3ebf08d338a763a5", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1513}
{"after": {"end": 11, "start": 0, "text": "Vianex S.A.", "truncated": false}, "after_length": 11, "after_sha256": "5aa05543f23c771ae6d358a0283a8ebc791ceaed5f1fb141cf038e2e49a6ac7b", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 11, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 11}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-f5876125ec088db3f0ad8710", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002066", "medicine_name": "Ikervis", "medicine_slug": "ikervis", "observed_at": "2026-10-12T13:34:16Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "ab05f9fab48768c68482390488c5b90c577e852974d4448da6ea8fe5a4eda856", "source_snapshot_id": "source-324751bde2e11edc76c2dbfe", "source_updated_at": "2026-06-23", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/ikervis-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1424}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 22, "start": 0, "text": "Teл.: + 33 153 868 750", "truncated": false}, "before_length": 22, "before_sha256": "120524751a9a5afbd671d2280e37714c4f0f7472b699b4fcfa1461decd998217", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 22, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 22, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-f59678ee9033a2be84d267cc", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:14Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "8b8c4cc8e6f1a21fedee4bf0743c9c03e454b50f5eaba0e3760416d7fe0a74ec", "source_snapshot_id": "source-4efe4ecf3ebf08d338a763a5", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1451}
{"after": {"end": 34, "start": 0, "text": "Orteliuslaan 1000, 3528 BD Utrecht", "truncated": false}, "after_length": 34, "after_sha256": "46a90fc46ae308c2beeb35ead613fcf3ade5a51e2217a834de3fa5972dab9eec", "annex": "III", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "unassigned", "change_operations": [{"after_end": 34, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 34}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-f5ba5d1fffee0b312448eda5", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/001021", "medicine_name": "Adcirca (previously Tadalafil Lilly)", "medicine_slug": "adcirca-previously-tadalafil-lilly", "observed_at": "2026-10-12T19:02:45Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "", "section_type": "unassigned", "source_provider": "European Medicines Agency", "source_sha256": "cdbefcd6143c93e81f3c826bea8d3d01bffc55652e0f792243097df75c452721", "source_snapshot_id": "source-a1e85476de17f5a8664f7766", "source_updated_at": "2026-01-28", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/adcirca-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1445}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 7, "start": 0, "text": "Irlanda", "truncated": false}, "before_length": 7, "before_sha256": "b62093ae50b42c09bf9083f92f576b6b687195082e19705b63f1aed7277898a5", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 7, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 7, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-f5c756e3b63416735965b0c9", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002097", "medicine_name": "Fampyra", "medicine_slug": "fampyra", "observed_at": "2026-10-12T19:15:51Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "d9fe8aaaa611a84801d6308b13685258b5248df9022536697939afdf66fc1719", "source_snapshot_id": "source-ff8e0599077f0d01044dc867", "source_updated_at": "2025-08-21", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/fampyra-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1536}
{"after": {"end": 8, "start": 0, "text": "W12 HX57", "truncated": false}, "after_length": 8, "after_sha256": "fbe61b7957c4f976a9508e38ecbe9e357c9eb7e4d21a231b5de7c7f72f183159", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 8, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 8}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-f5e14ad2aa45d882ba70125d", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/000273", "medicine_name": "Rapamune", "medicine_slug": "rapamune", "observed_at": "2026-10-12T13:39:02Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": null, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "1bc6ada5e7d1ea7efaa7d7335dea3defceb38c76db5469ed0119010981160699", "source_snapshot_id": "source-2864bce7b25be5450f0e0ac7", "source_updated_at": "2026-05-04", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/rapamune-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 2951}
{"after": {"end": 23, "start": 0, "text": "60318 Frankfurt am Main", "truncated": false}, "after_length": 23, "after_sha256": "24c3191b5088b20c209c4387a8127297e54c776e161d305c9e57956a13b7cbbe", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 23, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 23}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-f62087809c565b00ce00b2c9", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002097", "medicine_name": "Fampyra", "medicine_slug": "fampyra", "observed_at": "2026-10-12T19:16:07Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "a0c3ba8d58d6a43a809ecc3d142a78b10c2bd7f0b9f3a3553df2617d87daec1f", "source_snapshot_id": "source-c7a810dd21f94cd2d273f0da", "source_updated_at": "2025-08-21", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/fampyra-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1572}
{"after": {"end": 13, "start": 0, "text": "Hermeslaan 11", "truncated": false}, "after_length": 13, "after_sha256": "6426889eacea87c88f1e0405aad54515d8a889ca0f1b2ab39e2039040651e7d3", "annex": "II", "before": {"end": 11, "start": 0, "text": "Hoge Wei 10", "truncated": false}, "before_length": 11, "before_sha256": "ba5c0cab58e83e9dc6ec41e55e6acc00077e1be63c8a1ed970723221f2f12ba4", "change_kind": "content", "change_operations": [{"after_end": 1, "after_start": 1, "before_end": 3, "before_start": 1, "kind": "delete"}, {"after_end": 4, "after_start": 2, "before_end": 6, "before_start": 4, "kind": "replace"}, {"after_end": 10, "after_start": 5, "before_end": 8, "before_start": 7, "kind": "replace"}, {"after_end": 13, "after_start": 12, "before_end": 11, "before_start": 10, "kind": "replace"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 6, "chars_inserted": 8}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-f649ff54f7550a78d7d7a10f", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/004697", "medicine_name": "Zirabev", "medicine_slug": "zirabev", "observed_at": "2026-10-12T19:08:42Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "conditions", "section_type": "conditions", "source_provider": "European Medicines Agency", "source_sha256": "845774ee3d135dcbab2d035e014eb75d076ae724c8a5ea323882196493b05d44", "source_snapshot_id": "source-58a9ecf053a0ab93bbcc0173", "source_updated_at": "2025-09-17", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/zirabev-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 2512}
{"after": {"end": 21, "start": 0, "text": "Tel: +31 35 528 39 57", "truncated": false}, "after_length": 21, "after_sha256": "7baf6601f41e49e470f803fdd4e755a86efa38be423317c000ed79963ebdd213", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 21, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 21}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-f65bfa5ac42d50cb28fb10bf", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:19Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "77586d0bea0858214b43b86e91abc2d2711733b96959ead5ed0b5ecbd8ed888a", "source_snapshot_id": "source-85d476f9ad959cc117ca8f1f", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1968}
{"after": {"end": 22, "start": 0, "text": "Merz Therapeutics GmbH", "truncated": false}, "after_length": 22, "after_sha256": "059f049c7d0846aaadcf2573280d52110f302d4ecc7b38debd004571cd1e9d5e", "annex": "IIIA", "before": {"end": 35, "start": 0, "text": "Acorda Therapeutics Ireland Limited", "truncated": false}, "before_length": 35, "before_sha256": "d94d3153d193ed26567f2b4ed48df016d81c534e7c0cb1a6655a63f0083383ff", "change_kind": "content", "change_operations": [{"after_end": 2, "after_start": 0, "before_end": 3, "before_start": 0, "kind": "replace"}, {"after_end": 4, "after_start": 3, "before_end": 6, "before_start": 4, "kind": "replace"}, {"after_end": 19, "after_start": 18, "before_end": 30, "before_start": 20, "kind": "replace"}, {"after_end": 22, "after_start": 20, "before_end": 35, "before_start": 31, "kind": "replace"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 19, "chars_inserted": 6}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-f666ff8f9737e3d6934a2893", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002097", "medicine_name": "Fampyra", "medicine_slug": "fampyra", "observed_at": "2026-10-12T19:16:07Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "a0c3ba8d58d6a43a809ecc3d142a78b10c2bd7f0b9f3a3553df2617d87daec1f", "source_snapshot_id": "source-c7a810dd21f94cd2d273f0da", "source_updated_at": "2025-08-21", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/fampyra-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1355}
{"after": {"end": 17, "start": 0, "text": "Torokbalint, 2045", "truncated": false}, "after_length": 17, "after_sha256": "d6dbae334e70b70d590689409d24e6c0cda7d30fd5104550892da04a039d1276", "annex": "IIIB", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "unassigned", "change_operations": [{"after_end": 17, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 17}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-f6eb75e2dc80c0f9cf9c1586", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/006047", "medicine_name": "Lacosamide Adroiq", "medicine_slug": "lacosamide-adroiq", "observed_at": "2026-10-12T19:07:56Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "", "section_type": "unassigned", "source_provider": "European Medicines Agency", "source_sha256": "0578c53a5e1c785c4d9d4dc0dabae49dbfa89e237aa571556bee548c3f9cf4d5", "source_snapshot_id": "source-64831dec5ebf55535e19d91b", "source_updated_at": "2025-09-25", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/lacosamide-adroiq-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1856}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 5, "start": 0, "text": "Regus", "truncated": false}, "before_length": 5, "before_sha256": "69ef2ca82e0f736644001207ab7589688f2ada81eedc4859209d50896d65b095", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 5, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 5, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-f7156fae8e73e61e40abeec3", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002097", "medicine_name": "Fampyra", "medicine_slug": "fampyra", "observed_at": "2026-10-12T19:16:07Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "a0c3ba8d58d6a43a809ecc3d142a78b10c2bd7f0b9f3a3553df2617d87daec1f", "source_snapshot_id": "source-c7a810dd21f94cd2d273f0da", "source_updated_at": "2025-08-21", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/fampyra-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1479}
{"after": {"end": 18, "start": 0, "text": "Raktarvarosi Ut 9,", "truncated": false}, "after_length": 18, "after_sha256": "71dd279084ba9f87e79f1095d3565620050fda91d248303c2e19c46598fb0c2b", "annex": "III", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "unassigned", "change_operations": [{"after_end": 18, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 18}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-f71b13bd18d2793bb92dc850", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/006047", "medicine_name": "Lacosamide Adroiq", "medicine_slug": "lacosamide-adroiq", "observed_at": "2026-10-12T19:07:56Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "", "section_type": "unassigned", "source_provider": "European Medicines Agency", "source_sha256": "0578c53a5e1c785c4d9d4dc0dabae49dbfa89e237aa571556bee548c3f9cf4d5", "source_snapshot_id": "source-64831dec5ebf55535e19d91b", "source_updated_at": "2025-09-25", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/lacosamide-adroiq-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1347}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 22, "start": 0, "text": "Tel : +31 35 528 39 57", "truncated": false}, "before_length": 22, "before_sha256": "7bb8afadf5dee15b4f4e1219e333b993040f0848bccea58b1141990fffb82aa1", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 22, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 22, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-f72174a8f506e177a48d1698", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:19Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "77586d0bea0858214b43b86e91abc2d2711733b96959ead5ed0b5ecbd8ed888a", "source_snapshot_id": "source-85d476f9ad959cc117ca8f1f", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1949}
{"after": {"end": 21, "start": 0, "text": "Tel: +31 35 528 39 57", "truncated": false}, "after_length": 21, "after_sha256": "7baf6601f41e49e470f803fdd4e755a86efa38be423317c000ed79963ebdd213", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 21, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 21}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-f73750020e613fcfbd16245f", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:14Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "8b8c4cc8e6f1a21fedee4bf0743c9c03e454b50f5eaba0e3760416d7fe0a74ec", "source_snapshot_id": "source-4efe4ecf3ebf08d338a763a5", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1559}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 9, "start": 0, "text": "L-Irlanda", "truncated": false}, "before_length": 9, "before_sha256": "5eb0ac67738a7e0d70fbddb7744faafd60a4efdf5e93e46fca1bc519d14e757b", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 9, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 9, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-f76cd0a0a770a1af8fe4cda4", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002097", "medicine_name": "Fampyra", "medicine_slug": "fampyra", "observed_at": "2026-10-12T19:16:07Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "a0c3ba8d58d6a43a809ecc3d142a78b10c2bd7f0b9f3a3553df2617d87daec1f", "source_snapshot_id": "source-c7a810dd21f94cd2d273f0da", "source_updated_at": "2025-08-21", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/fampyra-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1445}
{"after": {"end": 23, "start": 0, "text": "info@euroceptpharma.com", "truncated": false}, "after_length": 23, "after_sha256": "9297cc5acdcc837f054116992765943f7907937507b2564a99ea1327a00ac0e6", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 23, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 23}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-f7869f73ffab714e3f4530fe", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:14Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "8b8c4cc8e6f1a21fedee4bf0743c9c03e454b50f5eaba0e3760416d7fe0a74ec", "source_snapshot_id": "source-4efe4ecf3ebf08d338a763a5", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1461}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 16, "start": 0, "text": "Extrovis EU Ltd.", "truncated": false}, "before_length": 16, "before_sha256": "f462ad48e7aef0bc82148ce088af1897d99ed86993128f30d506b27d3108a929", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 16, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 16, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-f7ae324bed22bef01d30c183", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/006047", "medicine_name": "Lacosamide Adroiq", "medicine_slug": "lacosamide-adroiq", "observed_at": "2026-10-12T19:07:59Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "cc83d966059d42856d0211a4f256b29b20d43593865704d6a9315aeb694f3c76", "source_snapshot_id": "source-896abba1d8391c918345d46b", "source_updated_at": "2025-09-25", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/lacosamide-adroiq-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1799}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 12, "start": 0, "text": "52078 Aachen", "truncated": false}, "before_length": 12, "before_sha256": "1475580660011b5e5dfa9a59bc8bd0d29441e95b38b37c8e74cd2bb2e32158de", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 12, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 12, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-f7d3ddd7a37042ac1b363393", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/005246", "medicine_name": "Byfavo", "medicine_slug": "byfavo", "observed_at": "2026-10-12T13:28:14Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "92a178ceb705631219efa40b1d0da73ebe6dfa866bc1b24d7e4dab9ded8a6861", "source_snapshot_id": "source-d485be5d9060fd557be910b2", "source_updated_at": "2026-08-26", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/byfavo-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 2293}
{"after": {"end": 18, "start": 0, "text": "Raktarvarosi Ut 9,", "truncated": false}, "after_length": 18, "after_sha256": "71dd279084ba9f87e79f1095d3565620050fda91d248303c2e19c46598fb0c2b", "annex": "IIIB", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "unassigned", "change_operations": [{"after_end": 18, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 18}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-f7f33533499fa4c89b09dc2f", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/006047", "medicine_name": "Lacosamide Adroiq", "medicine_slug": "lacosamide-adroiq", "observed_at": "2026-10-12T19:07:56Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "", "section_type": "unassigned", "source_provider": "European Medicines Agency", "source_sha256": "0578c53a5e1c785c4d9d4dc0dabae49dbfa89e237aa571556bee548c3f9cf4d5", "source_snapshot_id": "source-64831dec5ebf55535e19d91b", "source_updated_at": "2025-09-25", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/lacosamide-adroiq-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1855}
{"after": {"end": 23, "start": 0, "text": "info@euroceptpharma.com", "truncated": false}, "after_length": 23, "after_sha256": "9297cc5acdcc837f054116992765943f7907937507b2564a99ea1327a00ac0e6", "annex": "IIIA", "before": {"end": 13, "start": 0, "text": "Lucane Pharma", "truncated": false}, "before_length": 13, "before_sha256": "e338afdb64acf1a6e2083a50318853589248451dd3aa707181ba02641a8521e8", "change_kind": "content", "change_operations": [{"after_end": 6, "after_start": 0, "before_end": 1, "before_start": 0, "kind": "replace"}, {"after_end": 9, "after_start": 7, "before_end": 2, "before_start": 2, "kind": "insert"}, {"after_end": 10, "after_start": 10, "before_end": 5, "before_start": 3, "kind": "delete"}, {"after_end": 14, "after_start": 11, "before_end": 8, "before_start": 6, "kind": "replace"}, {"after_end": 23, "after_start": 19, "before_end": 13, "before_start": 13, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 5, "chars_inserted": 15}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-f8332e02f20f7bee17cc4de5", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:19Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "77586d0bea0858214b43b86e91abc2d2711733b96959ead5ed0b5ecbd8ed888a", "source_snapshot_id": "source-85d476f9ad959cc117ca8f1f", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1518}
{"after": {"end": 12, "start": 0, "text": "169 73 Solna", "truncated": false}, "after_length": 12, "after_sha256": "396199e813d8f79edb20275a432ef3c356a2964b18c41134b918894de8dcbb3d", "annex": "IIIA", "before": {"end": 12, "start": 0, "text": "Solna 169 73", "truncated": false}, "before_length": 12, "before_sha256": "48d3b71370d55743d8f6af2ff4ab7a798818c3958ea6d6d44d45c3a952fd50d5", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 6, "before_start": 0, "kind": "delete"}, {"after_end": 12, "after_start": 6, "before_end": 12, "before_start": 12, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 6, "chars_inserted": 6}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-f8ae15f269986d8f6a99e04e", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002097", "medicine_name": "Fampyra", "medicine_slug": "fampyra", "observed_at": "2026-10-12T19:15:51Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "d9fe8aaaa611a84801d6308b13685258b5248df9022536697939afdf66fc1719", "source_snapshot_id": "source-ff8e0599077f0d01044dc867", "source_updated_at": "2025-08-21", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/fampyra-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1611}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 21, "start": 0, "text": "info@lucanepharma.com", "truncated": false}, "before_length": 21, "before_sha256": "44fd39e5fb919cb3d680fa630da23b49238fec29159c509f3622f272bb41c7c6", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 21, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 21, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-f8d249a8e3ba7ce4424b2e17", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:19Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "77586d0bea0858214b43b86e91abc2d2711733b96959ead5ed0b5ecbd8ed888a", "source_snapshot_id": "source-85d476f9ad959cc117ca8f1f", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1814}
{"after": {"end": 99, "start": 0, "text": "SCIENTIFIC CONCLUSIONS AND GROUNDS FOR THE VARIATION TO THE TERMS OF THE MARKETING AUTHORISATION(S)", "truncated": false}, "after_length": 99, "after_sha256": "4d43e1a4109e8a776bcf1a5f90e9a1bc3b91d0b8306edf4d773e154de56fdd42", "annex": "IV", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 99, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 99}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-f8dd9f4a7f88e876193cda1b", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/000554", "medicine_name": "Emselex", "medicine_slug": "emselex", "observed_at": "2026-10-12T19:12:04Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "conditions", "section_type": "conditions", "source_provider": "European Medicines Agency", "source_sha256": "4f2565612bc728ec67b7f9c0cd5799ef2c594911c76f323aef8bf6a85adde245", "source_snapshot_id": "source-1fda25b331eb198b8b93feb3", "source_updated_at": "2025-09-15", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/emselex-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 2063}
{"after": {"end": 48, "start": 0, "text": "2. What you need to know before you take Emselex", "truncated": false}, "after_length": 48, "after_sha256": "cd7909d2814876a4507ab9d0def9c1f7d3d258ceec9455bbcf6f77a3abaa319c", "annex": "IIIA", "before": {"end": 47, "start": 0, "text": "2. What you need to know before you use Emselex", "truncated": false}, "before_length": 47, "before_sha256": "15dc5bf56b0b45784c5d74e7681e029e0853bad642e43708d601907e112e2b35", "change_kind": "content", "change_operations": [{"after_end": 39, "after_start": 36, "before_end": 38, "before_start": 36, "kind": "replace"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 2, "chars_inserted": 3}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-f8ed4e2894156c9612db2058", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/000554", "medicine_name": "Emselex", "medicine_slug": "emselex", "observed_at": "2026-10-12T19:12:04Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "4f2565612bc728ec67b7f9c0cd5799ef2c594911c76f323aef8bf6a85adde245", "source_snapshot_id": "source-1fda25b331eb198b8b93feb3", "source_updated_at": "2025-09-15", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/emselex-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1887}
{"after": {"end": 15, "start": 0, "text": "Hallucinations*", "truncated": false}, "after_length": 15, "after_sha256": "e03d7497659f0976d952b2cf81a1f0c187edccdbb092664ea8649d30f7c62311", "annex": "I", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 15, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": true, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 15}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-f8f81ee2899f344de8e562c1", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/000554", "medicine_name": "Emselex", "medicine_slug": "emselex", "observed_at": "2026-10-12T19:12:07Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": null, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "4.8", "section_type": "adverse_reactions", "source_provider": "European Medicines Agency", "source_sha256": "9a4f1d7e260c7b80eaf397503623b63302e5945b579e9612177835e07c4ab888", "source_snapshot_id": "source-3aac7bf42b99529f25ac013b", "source_updated_at": "2025-09-15", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/emselex-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 602}
{"after": {"end": 26, "start": 0, "text": "Eckenheimer Landstraße 100", "truncated": false}, "after_length": 26, "after_sha256": "fdce1a9bd200c5ddd476c1ea5676b9ffbbea723f7353ad6fbc1fe019dcb86c07", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 26, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 26}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-f90ce7f872fb79ee0cef3f8b", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002097", "medicine_name": "Fampyra", "medicine_slug": "fampyra", "observed_at": "2026-10-12T19:16:07Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "a0c3ba8d58d6a43a809ecc3d142a78b10c2bd7f0b9f3a3553df2617d87daec1f", "source_snapshot_id": "source-c7a810dd21f94cd2d273f0da", "source_updated_at": "2025-08-21", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/fampyra-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1446}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 25, "start": 0, "text": "Τηλ: + 358 (0) 3 284 8111", "truncated": false}, "before_length": 25, "before_sha256": "d2ab4368a6c3c7f07a280429f635d511f63583d8ab426619ec80daa220d95537", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 25, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 25, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-f97b4e95a8c0b71b85c147f0", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002066", "medicine_name": "Ikervis", "medicine_slug": "ikervis", "observed_at": "2026-10-12T13:34:10Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "7995ffe3d4b9c2e870327b45fae2f1d35ae1ab0e1e9e22b434fd9805b58a174e", "source_snapshot_id": "source-5ff0e792002ee89d9eb06e5d", "source_updated_at": "2026-06-23", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/ikervis-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1794}
{"after": {"end": 246, "start": 0, "text": "Contactez immédiatement votre médecin ou votre pharmacien si vous ressentez l'un des symptômes suivants pendant votre traitement par Arava : douleurs musculaires inexpliquées, sensibilité (douleur à la pression du muscle) ou faiblesse musculaire.", "truncated": false}, "after_length": 246, "after_sha256": "46d67b9fd5b140e533e3a7770bea1ef3e421bd3a192d785a859402c0b3ca1fc6", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 246, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 246}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-f9acfc8fa8fcff4978f1e61b", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/000235", "medicine_name": "Arava", "medicine_slug": "arava", "observed_at": "2026-10-12T13:28:00Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": null, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "98b73c5c6b1e5009c9d048f8f11257f3a8407759fd25a4c8d5ef5c611519e916", "source_snapshot_id": "source-4b7ea3b78addea82376b3432", "source_updated_at": "2026-09-07", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/arava-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 3465}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "II", "before": {"end": 7, "start": 0, "text": "Germany", "truncated": false}, "before_length": 7, "before_sha256": "80db4ccdca106d37b920206331fcfe3e9e50a9e763d89b54ce3ad5ac8cf30f03", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 7, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 7, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-f9bb38cf87d7fb198d69897a", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/005246", "medicine_name": "Byfavo", "medicine_slug": "byfavo", "observed_at": "2026-10-12T13:28:14Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "conditions", "section_type": "conditions", "source_provider": "European Medicines Agency", "source_sha256": "92a178ceb705631219efa40b1d0da73ebe6dfa866bc1b24d7e4dab9ded8a6861", "source_snapshot_id": "source-d485be5d9060fd557be910b2", "source_updated_at": "2026-08-26", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/byfavo-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1745}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "III", "before": {"end": 18, "start": 0, "text": "Pátriárka utca 14.", "truncated": false}, "before_length": 18, "before_sha256": "488a80d25b682a58591b4751c4687d5b516ccd6a004748e40d4e8f1454217b07", "change_kind": "unassigned", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 18, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 18, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-f9bfdc6cf1e64d7a632a3449", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/006047", "medicine_name": "Lacosamide Adroiq", "medicine_slug": "lacosamide-adroiq", "observed_at": "2026-10-12T19:07:56Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "", "section_type": "unassigned", "source_provider": "European Medicines Agency", "source_sha256": "0578c53a5e1c785c4d9d4dc0dabae49dbfa89e237aa571556bee548c3f9cf4d5", "source_snapshot_id": "source-64831dec5ebf55535e19d91b", "source_updated_at": "2025-09-25", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/lacosamide-adroiq-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1350}
{"after": {"end": 30, "start": 0, "text": "Troubles musculo-squelettiques", "truncated": false}, "after_length": 30, "after_sha256": "19f3f11cced96282f29a83fb37b4e112d045fd9d5612609940e426e03f7708ab", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 30, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 30}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-f9d651d91858e69c86fdaa24", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/000235", "medicine_name": "Arava", "medicine_slug": "arava", "observed_at": "2026-10-12T13:28:00Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": null, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "98b73c5c6b1e5009c9d048f8f11257f3a8407759fd25a4c8d5ef5c611519e916", "source_snapshot_id": "source-4b7ea3b78addea82376b3432", "source_updated_at": "2026-09-07", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/arava-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 2700}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 13, "start": 0, "text": "Lucane Pharma", "truncated": false}, "before_length": 13, "before_sha256": "e338afdb64acf1a6e2083a50318853589248451dd3aa707181ba02641a8521e8", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 13, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 13, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-fa4fa41a76d02b878962e000", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:14Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "8b8c4cc8e6f1a21fedee4bf0743c9c03e454b50f5eaba0e3760416d7fe0a74ec", "source_snapshot_id": "source-4efe4ecf3ebf08d338a763a5", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1897}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 27, "start": 0, "text": "(Eurocept International BV)", "truncated": false}, "before_length": 27, "before_sha256": "e6cf9b20aaa466e53ad0d393512ca75931e13e488321e3be6f3e4f8b600970c8", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 27, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 27, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-fa7b7a7ae0c3789f42e41689", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:19Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "77586d0bea0858214b43b86e91abc2d2711733b96959ead5ed0b5ecbd8ed888a", "source_snapshot_id": "source-85d476f9ad959cc117ca8f1f", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1789}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 21, "start": 0, "text": "Tel: + 33 153 868 750", "truncated": false}, "before_length": 21, "before_sha256": "efffe29324e968019e6e2b111904182ba06d83e76b1f29b933bed9dd8779c114", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 21, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 21, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-fa9e99b3589371dd3fa8094e", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:14Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "8b8c4cc8e6f1a21fedee4bf0743c9c03e454b50f5eaba0e3760416d7fe0a74ec", "source_snapshot_id": "source-4efe4ecf3ebf08d338a763a5", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1564}
{"after": {"end": 18, "start": 0, "text": "Raktarvarosi Ut 9,", "truncated": false}, "after_length": 18, "after_sha256": "71dd279084ba9f87e79f1095d3565620050fda91d248303c2e19c46598fb0c2b", "annex": "I", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "administrative", "change_operations": [{"after_end": 18, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 18}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-fb56540c8b87863fb84972eb", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/006047", "medicine_name": "Lacosamide Adroiq", "medicine_slug": "lacosamide-adroiq", "observed_at": "2026-10-12T19:07:59Z", "pipeline_version": "2.0.0", "presentation_label": "Lacosamide Adroiq 10 mg/ml solution pour perfusion", "presentation_occurrence": 1, "presentation_status": "heading_extracted_unverified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "7", "section_type": "administrative", "source_provider": "European Medicines Agency", "source_sha256": "cc83d966059d42856d0211a4f256b29b20d43593865704d6a9315aeb694f3c76", "source_snapshot_id": "source-896abba1d8391c918345d46b", "source_updated_at": "2025-09-25", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/lacosamide-adroiq-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 911}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 13, "start": 0, "text": "Lucane Pharma", "truncated": false}, "before_length": 13, "before_sha256": "e338afdb64acf1a6e2083a50318853589248451dd3aa707181ba02641a8521e8", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 13, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 13, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-fb6318ac1bc0bd903fb0d316", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:19Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "77586d0bea0858214b43b86e91abc2d2711733b96959ead5ed0b5ecbd8ed888a", "source_snapshot_id": "source-85d476f9ad959cc117ca8f1f", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1844}
{"after": {"end": 21, "start": 0, "text": "Tel: +31 35 528 39 57", "truncated": false}, "after_length": 21, "after_sha256": "7baf6601f41e49e470f803fdd4e755a86efa38be423317c000ed79963ebdd213", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 21, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 21}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-fb98c1b43f6a3b2fa4b45848", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:19Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "77586d0bea0858214b43b86e91abc2d2711733b96959ead5ed0b5ecbd8ed888a", "source_snapshot_id": "source-85d476f9ad959cc117ca8f1f", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1841}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 21, "start": 0, "text": "Tel: +31 35 528 39 57", "truncated": false}, "before_length": 21, "before_sha256": "7baf6601f41e49e470f803fdd4e755a86efa38be423317c000ed79963ebdd213", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 21, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 21, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-fbafa95452a6171fa6020825", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:14Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "8b8c4cc8e6f1a21fedee4bf0743c9c03e454b50f5eaba0e3760416d7fe0a74ec", "source_snapshot_id": "source-4efe4ecf3ebf08d338a763a5", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 2053}
{"after": {"end": 25, "start": 0, "text": "Tél: +33 (0)1 80 46 40 40", "truncated": false}, "after_length": 25, "after_sha256": "8039903c80fe171d38545fabfbccd20dc939429edfd9799a4e988d97cb003cb2", "annex": "IIIA", "before": {"end": 26, "start": 0, "text": "Tél: +33 (0) 1 80 46 40 40", "truncated": false}, "before_length": 26, "before_sha256": "9165b7fabd359af3bf21b3258ba90f79772314768215cc1ac6b105c0363dc727", "change_kind": "content", "change_operations": [{"after_end": 12, "after_start": 12, "before_end": 13, "before_start": 12, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 1, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-fbb0e4771ed42dc28e5dabe9", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/000389", "medicine_name": "Invanz", "medicine_slug": "invanz", "observed_at": "2026-10-12T17:30:44Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "a9208c117495d2d6c465ba196e4dbbb3d498b27d747df3b2d0145b0549743e4b", "source_snapshot_id": "source-e56383168f778128e02c2b2e", "source_updated_at": "2025-11-21", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/invanz-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1176}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 21, "start": 0, "text": "info@lucanepharma.com", "truncated": false}, "before_length": 21, "before_sha256": "44fd39e5fb919cb3d680fa630da23b49238fec29159c509f3622f272bb41c7c6", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 21, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 21, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-fbb2b9363099d8d2b3e64b21", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:14Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "8b8c4cc8e6f1a21fedee4bf0743c9c03e454b50f5eaba0e3760416d7fe0a74ec", "source_snapshot_id": "source-4efe4ecf3ebf08d338a763a5", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 2054}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 16, "start": 0, "text": "Extrovis EU Ltd.", "truncated": false}, "before_length": 16, "before_sha256": "f462ad48e7aef0bc82148ce088af1897d99ed86993128f30d506b27d3108a929", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 16, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 16, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-fbd53f04c09555dce229196d", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/006047", "medicine_name": "Lacosamide Adroiq", "medicine_slug": "lacosamide-adroiq", "observed_at": "2026-10-12T19:07:59Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "cc83d966059d42856d0211a4f256b29b20d43593865704d6a9315aeb694f3c76", "source_snapshot_id": "source-896abba1d8391c918345d46b", "source_updated_at": "2025-09-25", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/lacosamide-adroiq-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1717}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 21, "start": 0, "text": "Tel: + 33 153 868 750", "truncated": false}, "before_length": 21, "before_sha256": "efffe29324e968019e6e2b111904182ba06d83e76b1f29b933bed9dd8779c114", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 21, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 21, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-fc2fc4e08d8d201354a64d4c", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:14Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "8b8c4cc8e6f1a21fedee4bf0743c9c03e454b50f5eaba0e3760416d7fe0a74ec", "source_snapshot_id": "source-4efe4ecf3ebf08d338a763a5", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1472}
{"after": {"end": 267, "start": 0, "text": "The required dose of PHEBURANE oral solution (see section 4.2) should be taken from the bottle (equivalent to the number of grams sodium phenylbutyrate as prescribed and according to the amount to be given with the respective meal) with the use of the dosing syringe;", "truncated": false}, "after_length": 267, "after_sha256": "e0f80aa01a0448d135a8993c1aafce82a280c51523ec11ff4175986d1b7fbecb", "annex": "I", "before": {"end": 253, "start": 0, "text": "The required dose of PHEBURANE (see section 4.2) should be taken from the bottle (equivalent to the number of grams sodium phenylbutyrate as prescribed and according to the amount to be given with the respective meal) with the use of the dosing syringe;", "truncated": false}, "before_length": 253, "before_sha256": "838a377e042636ce70c27b40f9200b93f8d560164d17a914be4dab4d66068090", "change_kind": "content", "change_operations": [{"after_end": 45, "after_start": 31, "before_end": 31, "before_start": 31, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 14}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-fc315faacdd0ac76f73693ab", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:14Z", "pipeline_version": "2.0.0", "presentation_label": "PHEBURANE 350 mg/mL oral solution", "presentation_occurrence": 2, "presentation_status": "heading_extracted_unverified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "6.6", "section_type": "quality_presentation", "source_provider": "European Medicines Agency", "source_sha256": "8b8c4cc8e6f1a21fedee4bf0743c9c03e454b50f5eaba0e3760416d7fe0a74ec", "source_snapshot_id": "source-4efe4ecf3ebf08d338a763a5", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 683}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 20, "start": 0, "text": "10 Earlsfort Terrace", "truncated": false}, "before_length": 20, "before_sha256": "22951bbf6ee77815d0c07b3af5f0a66e17d277636971c4eaff372dea65dcb193", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 20, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 20, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-fc443e1bd3b095e43fdad0c7", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002097", "medicine_name": "Fampyra", "medicine_slug": "fampyra", "observed_at": "2026-10-12T19:15:51Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "d9fe8aaaa611a84801d6308b13685258b5248df9022536697939afdf66fc1719", "source_snapshot_id": "source-ff8e0599077f0d01044dc867", "source_updated_at": "2025-08-21", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/fampyra-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1480}
{"after": {"end": 22, "start": 0, "text": "Scientific conclusions", "truncated": false}, "after_length": 22, "after_sha256": "48a176450b72da083aae0c461d4b9485bc052767229342ad7b9f3b91fb4b3641", "annex": "IV", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 22, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 22}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-fc97e28ff2d919ab3d7cdc10", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/000554", "medicine_name": "Emselex", "medicine_slug": "emselex", "observed_at": "2026-10-12T19:12:04Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "conditions", "section_type": "conditions", "source_provider": "European Medicines Agency", "source_sha256": "4f2565612bc728ec67b7f9c0cd5799ef2c594911c76f323aef8bf6a85adde245", "source_snapshot_id": "source-1fda25b331eb198b8b93feb3", "source_updated_at": "2025-09-15", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/emselex-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 2073}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 12, "start": 0, "text": "52078 Aachen", "truncated": false}, "before_length": 12, "before_sha256": "1475580660011b5e5dfa9a59bc8bd0d29441e95b38b37c8e74cd2bb2e32158de", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 12, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 12, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-fcaa168ddb397b887c013695", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/005246", "medicine_name": "Byfavo", "medicine_slug": "byfavo", "observed_at": "2026-10-12T13:28:16Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "61243a969f979f690fe718e414ceaeb66438c1faa31101ba25187d2f9ea662fd", "source_snapshot_id": "source-dd26eb8615d8c18bd80c1f6a", "source_updated_at": "2026-08-26", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/byfavo-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 2380}
{"after": {"end": 24, "start": 0, "text": "Teл.: +49 (0) 69 15 03 0", "truncated": false}, "after_length": 24, "after_sha256": "920fc0f7a659b3b50c2a6a85a5d47a1509a5f33c7f539f20a7fa2b0b956e96af", "annex": "IIIA", "before": {"end": 24, "start": 0, "text": "Teл.: +353 (0)1 231 4609", "truncated": false}, "before_length": 24, "before_sha256": "67b46938ef79870beff219e6d0952c45314aa461a4b12e308a32545acb979c47", "change_kind": "content", "change_operations": [{"after_end": 9, "after_start": 7, "before_end": 10, "before_start": 7, "kind": "replace"}, {"after_end": 17, "after_start": 13, "before_end": 14, "before_start": 14, "kind": "insert"}, {"after_end": 19, "after_start": 18, "before_end": 15, "before_start": 15, "kind": "insert"}, {"after_end": 21, "after_start": 20, "before_end": 17, "before_start": 16, "kind": "replace"}, {"after_end": 22, "after_start": 22, "before_end": 19, "before_start": 18, "kind": "delete"}, {"after_end": 23, "after_start": 23, "before_end": 22, "before_start": 20, "kind": "delete"}, {"after_end": 24, "after_start": 24, "before_end": 24, "before_start": 23, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 8, "chars_inserted": 8}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-fcabc84cf35cfb0d56cc2b79", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002097", "medicine_name": "Fampyra", "medicine_slug": "fampyra", "observed_at": "2026-10-12T19:15:51Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "d9fe8aaaa611a84801d6308b13685258b5248df9022536697939afdf66fc1719", "source_snapshot_id": "source-ff8e0599077f0d01044dc867", "source_updated_at": "2025-08-21", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/fampyra-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1395}
{"after": {"end": 7, "start": 0, "text": "Sverige", "truncated": false}, "after_length": 7, "after_sha256": "3a7d70b4edb982a403e97d77681309e5fb1032b12d727aa1e92b145b069b9aa4", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 7, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 7}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-fccd81eec1c7c7225f866672", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/002097", "medicine_name": "Fampyra", "medicine_slug": "fampyra", "observed_at": "2026-10-12T19:16:07Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "a0c3ba8d58d6a43a809ecc3d142a78b10c2bd7f0b9f3a3553df2617d87daec1f", "source_snapshot_id": "source-c7a810dd21f94cd2d273f0da", "source_updated_at": "2025-08-21", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/fampyra-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1600}
{"after": {"end": 60, "start": 0, "text": "Generalised hypersensitivity reactions including angioedema*", "truncated": false}, "after_length": 60, "after_sha256": "e3396d35bd3fb07037a8790b0cb7dfa0628aa99dd8644fbeca4326956de79649", "annex": "I", "before": {"end": 10, "start": 0, "text": "Angioedema", "truncated": false}, "before_length": 10, "before_sha256": "99d2f164d6af2bac1f3a337d3c06922d938ea4591240fe12d89d638459724b03", "change_kind": "content", "change_operations": [{"after_end": 50, "after_start": 0, "before_end": 1, "before_start": 0, "kind": "replace"}, {"after_end": 60, "after_start": 59, "before_end": 10, "before_start": 10, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": true, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 1, "chars_inserted": 51}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-fcd93d1686464452944ff00d", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/000554", "medicine_name": "Emselex", "medicine_slug": "emselex", "observed_at": "2026-10-12T19:12:04Z", "pipeline_version": "2.0.0", "presentation_label": "Emselex 15 mg prolonged-release tablets", "presentation_occurrence": 2, "presentation_status": "heading_extracted_unverified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "4.8", "section_type": "adverse_reactions", "source_provider": "European Medicines Agency", "source_sha256": "4f2565612bc728ec67b7f9c0cd5799ef2c594911c76f323aef8bf6a85adde245", "source_snapshot_id": "source-1fda25b331eb198b8b93feb3", "source_updated_at": "2025-09-15", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/emselex-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 636}
{"after": {"end": 24, "start": 0, "text": "Sími: +49 (0) 69 15 03 0", "truncated": false}, "after_length": 24, "after_sha256": "24af20366ad81c2ae102bbb5532b3b16b7c41b0e4064781db9eed9cacd582723", "annex": "IIIA", "before": {"end": 24, "start": 0, "text": "Sími: +353 (0)1 231 4609", "truncated": false}, "before_length": 24, "before_sha256": "8572127f763bac954beb7dd6f8ef40964e7478c186731008b7840e2d0bb05099", "change_kind": "content", "change_operations": [{"after_end": 9, "after_start": 7, "before_end": 10, "before_start": 7, "kind": "replace"}, {"after_end": 17, "after_start": 13, "before_end": 14, "before_start": 14, "kind": "insert"}, {"after_end": 19, "after_start": 18, "before_end": 15, "before_start": 15, "kind": "insert"}, {"after_end": 21, "after_start": 20, "before_end": 17, "before_start": 16, "kind": "replace"}, {"after_end": 22, "after_start": 22, "before_end": 19, "before_start": 18, "kind": "delete"}, {"after_end": 23, "after_start": 23, "before_end": 22, "before_start": 20, "kind": "delete"}, {"after_end": 24, "after_start": 24, "before_end": 24, "before_start": 23, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 8, "chars_inserted": 8}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-fcec6b6685a812cd1cd9fbc9", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002097", "medicine_name": "Fampyra", "medicine_slug": "fampyra", "observed_at": "2026-10-12T19:15:51Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "d9fe8aaaa611a84801d6308b13685258b5248df9022536697939afdf66fc1719", "source_snapshot_id": "source-ff8e0599077f0d01044dc867", "source_updated_at": "2025-08-21", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/fampyra-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1568}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 20, "start": 0, "text": "10 Earlsfort Terrace", "truncated": false}, "before_length": 20, "before_sha256": "22951bbf6ee77815d0c07b3af5f0a66e17d277636971c4eaff372dea65dcb193", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 20, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 20, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-fd1a97ca4d5477e77cd7fd5a", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002097", "medicine_name": "Fampyra", "medicine_slug": "fampyra", "observed_at": "2026-10-12T19:15:51Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "d9fe8aaaa611a84801d6308b13685258b5248df9022536697939afdf66fc1719", "source_snapshot_id": "source-ff8e0599077f0d01044dc867", "source_updated_at": "2025-08-21", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/fampyra-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1588}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 21, "start": 0, "text": "Tel: + 33 153 868 750", "truncated": false}, "before_length": 21, "before_sha256": "efffe29324e968019e6e2b111904182ba06d83e76b1f29b933bed9dd8779c114", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 21, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 21, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-fd584a442ced7f81c94b6219", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002500", "medicine_name": "Pheburane", "medicine_slug": "pheburane", "observed_at": "2026-10-12T13:29:14Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "8b8c4cc8e6f1a21fedee4bf0743c9c03e454b50f5eaba0e3760416d7fe0a74ec", "source_snapshot_id": "source-4efe4ecf3ebf08d338a763a5", "source_updated_at": "2026-08-17", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/pheburane-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1525}
{"after": {"end": 17, "start": 0, "text": "Torokbalint, 2045", "truncated": false}, "after_length": 17, "after_sha256": "d6dbae334e70b70d590689409d24e6c0cda7d30fd5104550892da04a039d1276", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 17, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 17}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-fd6b62719707d749a36c09b7", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/006047", "medicine_name": "Lacosamide Adroiq", "medicine_slug": "lacosamide-adroiq", "observed_at": "2026-10-12T19:07:59Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "cc83d966059d42856d0211a4f256b29b20d43593865704d6a9315aeb694f3c76", "source_snapshot_id": "source-896abba1d8391c918345d46b", "source_updated_at": "2025-09-25", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/lacosamide-adroiq-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1678}
{"after": {"end": 13, "start": 0, "text": "1932 Zaventem", "truncated": false}, "after_length": 13, "after_sha256": "cffe4475a5de91da7a3a6363a4d41ccfd1405766d95ae182d89bf39b29686221", "annex": "II", "before": {"end": 8, "start": 0, "text": "Zaventem", "truncated": false}, "before_length": 8, "before_sha256": "c4b5ae40e486a4f873f1e130ba599e7937f63dfb26a98371397efc8b5c430f14", "change_kind": "content", "change_operations": [{"after_end": 5, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 5}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-fd879075e7faee4025d80a77", "language": "fr", "medical_validation": false, "medicine_id": "EMEA/H/C/004697", "medicine_name": "Zirabev", "medicine_slug": "zirabev", "observed_at": "2026-10-12T19:08:42Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "conditions", "section_type": "conditions", "source_provider": "European Medicines Agency", "source_sha256": "845774ee3d135dcbab2d035e014eb75d076ae724c8a5ea323882196493b05d44", "source_snapshot_id": "source-58a9ecf053a0ab93bbcc0173", "source_updated_at": "2025-09-17", "source_url": "https://www.ema.europa.eu/fr/documents/product-information-tracked-changes/zirabev-epar-product-information-tracked-changes_fr.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 2513}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "I", "before": {"end": 14, "start": 0, "text": "Heussstraße 25", "truncated": false}, "before_length": 14, "before_sha256": "805584102a210d40b5c8e0e7014cb2d6f4194a7c2ef94da3309e0707eed85073", "change_kind": "administrative", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 14, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 14, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-fdc80ef2e01a3b39c3bb1e15", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/005246", "medicine_name": "Byfavo", "medicine_slug": "byfavo", "observed_at": "2026-10-12T13:28:14Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 2, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "7", "section_type": "administrative", "source_provider": "European Medicines Agency", "source_sha256": "92a178ceb705631219efa40b1d0da73ebe6dfa866bc1b24d7e4dab9ded8a6861", "source_snapshot_id": "source-d485be5d9060fd557be910b2", "source_updated_at": "2026-08-26", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/byfavo-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 2622}
{"after": {"end": 0, "start": 0, "text": "", "truncated": false}, "after_length": 0, "after_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "annex": "IIIA", "before": {"end": 18, "start": 0, "text": "Dublin 2, D02 T380", "truncated": false}, "before_length": 18, "before_sha256": "23e6871e7960b0dadc753bc127bbea230cc8308c88b2d33704eb275a3ec1a70d", "change_kind": "content", "change_operations": [{"after_end": 0, "after_start": 0, "before_end": 18, "before_start": 0, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 18, "chars_inserted": 0}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-fe35a6c226b582937dc2850b", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002097", "medicine_name": "Fampyra", "medicine_slug": "fampyra", "observed_at": "2026-10-12T19:15:51Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "d9fe8aaaa611a84801d6308b13685258b5248df9022536697939afdf66fc1719", "source_snapshot_id": "source-ff8e0599077f0d01044dc867", "source_updated_at": "2025-08-21", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/fampyra-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1453}
{"after": {"end": 22, "start": 0, "text": "Merz Therapeutics GmbH", "truncated": false}, "after_length": 22, "after_sha256": "059f049c7d0846aaadcf2573280d52110f302d4ecc7b38debd004571cd1e9d5e", "annex": "IIIA", "before": {"end": 35, "start": 0, "text": "Acorda Therapeutics Ireland Limited", "truncated": false}, "before_length": 35, "before_sha256": "d94d3153d193ed26567f2b4ed48df016d81c534e7c0cb1a6655a63f0083383ff", "change_kind": "content", "change_operations": [{"after_end": 2, "after_start": 0, "before_end": 3, "before_start": 0, "kind": "replace"}, {"after_end": 4, "after_start": 3, "before_end": 6, "before_start": 4, "kind": "replace"}, {"after_end": 19, "after_start": 18, "before_end": 30, "before_start": 20, "kind": "replace"}, {"after_end": 22, "after_start": 20, "before_end": 35, "before_start": 31, "kind": "replace"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 19, "chars_inserted": 6}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-fe8576fdc1725e4575d706eb", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002097", "medicine_name": "Fampyra", "medicine_slug": "fampyra", "observed_at": "2026-10-12T19:15:51Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "d9fe8aaaa611a84801d6308b13685258b5248df9022536697939afdf66fc1719", "source_snapshot_id": "source-ff8e0599077f0d01044dc867", "source_updated_at": "2025-08-21", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/fampyra-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1408}
{"after": {"end": 26, "start": 0, "text": "Eckenheimer Landstraße 100", "truncated": false}, "after_length": 26, "after_sha256": "fdce1a9bd200c5ddd476c1ea5676b9ffbbea723f7353ad6fbc1fe019dcb86c07", "annex": "IIIA", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "content", "change_operations": [{"after_end": 26, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 26}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-feb0928b5e46c735995df757", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002097", "medicine_name": "Fampyra", "medicine_slug": "fampyra", "observed_at": "2026-10-12T19:15:51Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "d9fe8aaaa611a84801d6308b13685258b5248df9022536697939afdf66fc1719", "source_snapshot_id": "source-ff8e0599077f0d01044dc867", "source_updated_at": "2025-08-21", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/fampyra-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1382}
{"after": {"end": 16, "start": 0, "text": "Extrovis EU Kft.", "truncated": false}, "after_length": 16, "after_sha256": "b9216ef80e71e17798dce313e4318f03f37328f225d30ab508b7413813a908e5", "annex": "IIIB", "before": {"end": 0, "start": 0, "text": "", "truncated": false}, "before_length": 0, "before_sha256": "e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855", "change_kind": "unassigned", "change_operations": [{"after_end": 16, "after_start": 0, "before_end": 0, "before_start": 0, "kind": "insert"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 0, "chars_inserted": 16}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-ff5f1042ca0a5fdb0223fd8b", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/006047", "medicine_name": "Lacosamide Adroiq", "medicine_slug": "lacosamide-adroiq", "observed_at": "2026-10-12T19:07:56Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "", "section_type": "unassigned", "source_provider": "European Medicines Agency", "source_sha256": "0578c53a5e1c785c4d9d4dc0dabae49dbfa89e237aa571556bee548c3f9cf4d5", "source_snapshot_id": "source-64831dec5ebf55535e19d91b", "source_updated_at": "2025-09-25", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/lacosamide-adroiq-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1957}
{"after": {"end": 23, "start": 0, "text": "Tel: +49 (0) 69 15 03 0", "truncated": false}, "after_length": 23, "after_sha256": "09683b3f43171b2266a32d9f7d44e3d62d536522dc6f42d4b47f2dda48b31833", "annex": "IIIA", "before": {"end": 23, "start": 0, "text": "Tel: +353 (0)1 231 4609", "truncated": false}, "before_length": 23, "before_sha256": "a115f11f382ef18898b9d956e48603ae236fd1846ce41e8586af99b6dabbfc4d", "change_kind": "content", "change_operations": [{"after_end": 8, "after_start": 6, "before_end": 9, "before_start": 6, "kind": "replace"}, {"after_end": 16, "after_start": 12, "before_end": 13, "before_start": 13, "kind": "insert"}, {"after_end": 18, "after_start": 17, "before_end": 14, "before_start": 14, "kind": "insert"}, {"after_end": 20, "after_start": 19, "before_end": 16, "before_start": 15, "kind": "replace"}, {"after_end": 21, "after_start": 21, "before_end": 18, "before_start": 17, "kind": "delete"}, {"after_end": 22, "after_start": 22, "before_end": 21, "before_start": 19, "kind": "delete"}, {"after_end": 23, "after_start": 23, "before_end": 23, "before_start": 22, "kind": "delete"}], "classification_method": "documentary_rules_v2", "clinical_candidate": false, "comparison_basis": "word_tracked_revisions", "derivation_provider": "Medyx", "display_covers_all_edits": true, "edit_alignment_method": "string_sequence_alignment_trimmed_v2", "edit_counts": {"chars_deleted": 8, "chars_inserted": 8}, "extraction_scope": "word/document.xml paragraphs, including table paragraphs", "id": "change-ff9cba526374045bedd1aabe", "language": "en", "medical_validation": false, "medicine_id": "EMEA/H/C/002097", "medicine_name": "Fampyra", "medicine_slug": "fampyra", "observed_at": "2026-10-12T19:15:51Z", "pipeline_version": "2.0.0", "presentation_label": "", "presentation_occurrence": 1, "presentation_status": "not_identified", "review": {"label": null, "medical_relevance": null, "reviewed_at": null, "reviewer_id": null, "state": "pending"}, "section_code": "labelling", "section_type": "labelling", "source_provider": "European Medicines Agency", "source_sha256": "d9fe8aaaa611a84801d6308b13685258b5248df9022536697939afdf66fc1719", "source_snapshot_id": "source-ff8e0599077f0d01044dc867", "source_updated_at": "2025-08-21", "source_url": "https://www.ema.europa.eu/en/documents/product-information-tracked-changes/fampyra-epar-product-information-tracked-changes_en.docx", "text_normalization": "Tabs, line breaks and whitespace runs become one space; outer whitespace is trimmed.", "word_paragraph_index": 1468}